

Table of Contents

Welcome by the EAU Secretary General	2
Welcome by the EAU Congress President	3
EAU patrons and contributors	4
Synopsis	6
General	
Floorplans congress venue	17
General information	20
Speakers' guidelines	24
Social programme	25
Excursions	26
About Paris	28
Congress hotel listing	31
Programme Wednesday, 5 April	35
Programme Thursday, 6 April	89
Programme Friday, 7 April	175
Programme Saturday, 8 April	263
ESU Courses and Hands-on training sessions	
ESU courses	271
ESU/ESUT hands-on laparoscopy courses	308
Hands-on training sessions	312
EAU Section meetings	315
European Society of Residents in Urology (ESRU) Programme	335
European Association of Urology Nurses (EAUN) Programme	337
About EAU	
EAU Membership	343
EAU Offices	344
European Urology Accredited Medical Education Programme	346
Continuing Medical Education - Accreditation points national urological associations	347
Historical overview EAU Congresses	348
Indexes	
DVD library	350
List of abstract authors and presenters	380
List of abstracts sorted by topic	408
List of sessions sorted by topic	411
List of speakers (not abstracts)	412

Welcome to Paris



Prof. Pierre Teillac
EAU Secretary General

Dear Colleagues,

Bienvenue à Paris!

It is a tremendous honour and pleasure to welcome you to my home city for the 21st Annual EAU Congress from 5-8 April 2006. It is 10 years since the EAU Congress was held in Paris and in that interim period the EAU has grown into a multi-faceted professionally renowned organisation. The 21st Annual EAU Congress will provide a platform for you to interact with your colleagues, will stimulate and create an exchange of ideas and will be personally rewarding.

As professionals in the field of urology we are constantly striving to increase our knowledge and with this in mind the EAU Scientific Committee have compiled an exciting and varied programme. The high-quality scientific programme will open new perspectives on issues related to treatment and patient care. The plenary sessions and core symposia will indeed provide you with a full update on the most important aspects and latest achievements in urology.

The Congress will also serve the educational mission of the EAU through a variety of courses and hands-on training sessions organised by the European School of Urology (ESU). The Congress will be fully accredited by the EU-ACME (European Urology - Accredited Continuing Medical Education).

To coincide with the scientific programme, an extensive commercial exhibition will be held where companies and suppliers will exhibit their newest innovations. Your participation in this Congress will also be an opportunity for you to discover, or rediscover, Paris – City of Light. Paris is a city of art and theatre, of The Eiffel Tower and Notre Dame, of the Champs Elysées and the Canal St-Martin, of nightclubs and the Moulin Rouge - never a dull moment in this historic, romantic and bustling city.

I look forward to welcoming old friends and meeting new ones in what promises to be a successful and memorable Congress!





Prof. Laurent Boccon-Gibod
President 21st Annual EAU Congress

Dear colleagues,

It is a great pleasure for me to welcome you to Paris for the 21st Annual EAU Congress.

The Annual EAU Congress is one of the most important events of our association and it is only with the dedication of many people that a medical congress of this magnitude and diversity can be realised.

This programme book is the result of the commitment of the EAU Scientific Office together with all those people who have directly contributed or who are taking part in the programme. The aims of the programme are twofold:

Firstly, the plenary and sub-plenary sessions will deliver up-to-date scientific information to delegates engaged in clinical practice, providing a full update on the latest developments in the field of urology which clearly indicates what can be achieved or utilised and what remains debatable.

Secondly, the abstract sessions are a platform to foster scientific exchanges and discussions between clinician-researchers, based on recently concluded work or work in progress.

The plenary and sub-plenary programme is the culmination of the hard work of the EAU Scientific Office under the guidance of Professor F. Hamdy. Leafing through the programme book, you will find that 'no (urological) stone has been left unturned' and that the majority of the questions of the day will be addressed, if not answered.

One of the measures of a successful congress is through its scientific submissions and these are the direct result of your personal energetic input. The Paris Congress sets a new record for abstract submissions with more than 3.200 abstracts being submitted. You can be assured that reviewers and members of the EAU Scientific Office have done their best to compile a marvelous programme, the only regret being that they were unable to accept more papers due to time and space constraints.

I wish you an excellent 2006 EAU Congress in Paris.



EAU Patrons and Contributors

The European Association of Urology respectfully acknowledges the EAU Corporate Sponsors and all other sponsors for providing educational grants and services to the 21st Annual EAU Congress

EAU Platinum Corporate sponsors


ASTELLAS
BOEHRINGER INGELHEIM GMBH/ELI LILLY & COMPANY
GLAXOSMITHKLINE
LILLY ICOS LLC
MSD
NOVARTIS PHARMA AG/NOVARTIS ONCOLOGY
PFIZER INC
PIERRE FABRE MÉDICAMENT
SANOFI-AVENTIS

EAU Gold Corporate sponsors

BAYER HEALTHCARE AG
BOEHRINGER INGELHEIM GMBH
IPSEN
KARL STORZ GMBH & CO.KG
SANOFI PASTEUR

Congress Contributors

ABBOTT MOLECULAR
ASTRAZENECA
BOSTON SCIENTIFIC
EDAP
GEN-PROBE INCORPORATED
LUMENIS GMBH
STEBA BIOTECH/NEGMA
UCB PHARMA



Wednesday, 5 April

	Level 1		Level 2				Level 3	
	eURO Auditorium	Room Ternes	Room Blue	Room Maillot	Room 242	Room 251	Room 252	Room Bordeaux
08.00	08.30-12.30 EAU Section meeting	08.30-12.30 EAU Section meeting	08.30-12.30 EAU Section meeting		08.30-12.30 EAU Section meeting		08.30-12.30 EAU Section meeting	08.30-13.45 EAU Section meeting
09.00	ESOU	ESFU	ESGURS		ESNU		ESUI	ESUT
10.00	Uro-oncological surgery: Tricks and techniques	Update on female urology	Reconstructive surgery of the pelvis		Introducing the second European masterclass on Botulinum toxin for the overactive bladder		Innovative imaging in and around urology	What's new in uro-technology?
11.00	EORTC GU-group From clinical trials to patient care							
12.00	page 316	page 315	page 322		page 328		page 330	
13.00	12.45-14.15 Video Session 1 Surgical anatomy in laparoscopic radical prostatectomy	12.45-14.15 Poster Session 1 Sexual function and dysfunction: Basic research	12.45-14.15 Oral Session 1 Urothelial tumours: Management of infiltrative/ advanced tumours I	12.45-14.15 Poster Session 2 Kidney tumours: Basic research	12.45-14.15 Poster Session 3 Research and drug therapy for stone disease	12.45-14.15 Poster Session 4 Urothelial tumours: Basic research I	12.45-14.15 Poster Session 5 Basic research developments in female urology	page 334
14.00	V1-V6 page 38	9-23 page 40	1-8 page 39	24-38 page 42	39-53 page 44	54-68 page 46	69-83 page 48	
15.00	14.30-16.00 Video Session 2 Advances in laparoscopic pelvic surgery	14.30-16.00 Poster Session 10 Ejaculatory dysfunction: Basic and clinical research	14.30-16.00 Oral Session 2 Urological reconstruction I	14.30-16.00 Poster Session 11 Kidney tumours: Diagnosis and staging I	14.30-16.00 Poster Session 12 Update on ureteroscopy and stents	14.30-16.00 Poster Session 13 Urothelial tumours: Basic research II	14.30-16.00 Poster Session 14 Non-neurogenic voiding dysfunction: The bladder factor	14.30-16.00 Oral Session 3 Prostate cancer stem cells
	V7-V12 page 58	161-175 page 62	145-151 page 59	176-190 page 64	191-205 page 66	206-220 page 68	221-235 page 70	153-160 page 61
16.00	16.15-17.45 Symposium Managing the LUTS/BPH patient: The impact of nocturia	16.15-17.45 Symposium Helping couples stay connected - new paradigms in ED management	16.15-17.45 Symposium Advancing the management of OAB: New data, new directions	16.15-17.45 Symposium Vascular-targeted photodynamic therapy with Tookad (VTP) for the treatment of localised prostate cancer				16.15-17.45 Symposium Prostate cancer prevention: A relevant therapeutic target for patients with BPH
17.00	ASTELLAS/BOEHRINGER INGELHEIM page 80	BAYER HEALTHCARE AG page 81	PFIZER INC page 82	STEBA BIOTECH/NEGMA page 85				MSD page 83
18.00	18.15-21.00							
19.00	Opening Ceremony & Welcome Cocktail							
20.00	page 88							
21.00								

Room Havana	Room 341	Room 342	Level 3 Room 343	Room 351	Room 353	Room 352	Room Concorde 1	Level 4 Room Concorde 2	Room Concorde 3	
08.30-12.30 EAU Section meeting ESIU Difficult infections in urology <i>page 324</i>	08.30-12.30 EAU Section meeting ESUP Morphological changes in prostate tissue following the various forms of treatment <i>page 333</i>		08.30-12.30 EAU Section meeting ESTU Controversies in immunosuppression and hot topics in renal transplantation <i>page 320</i>	08.30-12.30 EAU Section meeting ESUR '...omics in urological disease' <i>page 332</i>	08.30-12.30 EAU Section meeting ESAU What's new in andrology? An old head on young shoulders <i>page 318</i>		08.30-12.00 EAU/CAU joint Session <i>page 35</i>		08.30-12.30 EAU Section meeting eULIS Difficult cases of urolithiasis: Medical and surgical solutions <i>page 326</i>	08.00 09.00 10.00 11.00 12.00
12.45-14.15 Poster Session 6 Urethral strictures 85-99 <i>page 50</i>		12.30-18.00 13th ESRU Meeting					12.45-14.15 Poster Session 7 Prostate cancer: High throughput target discovery and validation 100-114 <i>page 52</i>	12.45-14.15 Poster Session 8 Laparoscopic radical prostatectomy and robotic surgery I 115-129 <i>page 54</i>	12.45-14.15 Poster Session 9 Metastatic prostate cancer: Skeletal issues 130-144 <i>page 56</i>	13.00 14.00
14.30-16.00 Poster Session 15 Penile disorders and carcinoma of the penis 236-250 <i>page 72</i>							14.30-16.00 Poster Session 16 Testis tumours 251-265 <i>page 74</i>	14.30-16.00 Poster Session 17 Laparoscopic radical prostatectomy and robotic surgery II 266-280 <i>page 76</i>	14.30-16.00 Poster Session 18 Hormone refractory prostate cancer 281-295 <i>page 78</i>	15.00
16.15-17.45 Symposium BPH patient of the 3rd millennium PIERRE FABRE MÉDICAMENT <i>page 84</i>							16.15-17.45 Symposium Progress in medical management of RCC: The expanding role of the urologist PFIZER INC <i>page 87</i>	16.15-17.45 Symposium Skeletal preservation in prostate cancer: The changing role of the urologist NOVARTIS ONCOLOGY <i>page 86</i>		16.00 17.00
										18.00 19.00 20.00 21.00

Thursday, 6 April, Morning

	Level 1 eURO Auditorium	Room Ternes	Room Blue	Level 2 Room Maillot	Room 252	Level 3 Room Bordeaux
07.00	PLENARY SESSION 1					
	07.30-08.00 Highlight session 1					
08.00	08.00-08.05 Award session 1 Matula Award Thesis Award					
	08.05-08.20 State-of-the-art lecture European Urology is your journal: A plan for the future					
	08.20-08.40 American Urological Association (AUA) lecture A novel virus associated with genetic susceptibility to prostate cancer					
09.00	08.40-09.20 Breaking news Anti-angiogenic therapy in renal cancer; the role of the urologist					
	09.20-09.40 State-of-the-art lecture New indications for IPDES					
10.00	09.40-10.20 Round table discussion The management of renal stone disease in 2006					
	10.20-10.40 State-of-the-art lecture Serum proteomics in urological cancer					
	10.40-11.00 Società Italiana di Urologia (SIU) lecture The bladder detrusor - an innocent victim of the prostate <i>from page 89</i>					
	SUB-PLENARY SESSION 2	SUB-PLENARY SESSION 3	SUB-PLENARY SESSION 5	SUB-PLENARY SESSION 4	SUB-PLENARY SESSION 1	SUB-PLENARY SESSION 7
11.00	11.00-11.30 State-of-the-art lecture Laparoscopic training for urological surgeons	11.00-11.30 State-of-the-art lecture Tissue engineering for the lower urinary tract	11.00-11.30 State-of-the-art lecture The management of premature ejaculation	11.00-11.30 ESPU lecture Management of upper urinary tract lithiasis in children	11.00-11.15 ESIU Section highlights	11.00-11.20 State-of-the-art lecture Is there still a place for open stone surgery?
					11.15-11.30 ESNU Section highlights	
	11.30-12.00 State-of-the-art lecture The objective evaluation of functional results following the treatment of localised prostate cancer	11.30-12.00 State-of-the-art lecture The role of laser prostatectomy in BPH	11.30-12.00 State-of-the-art lecture Optimising semen analysis	11.30-12.00 State-of-the-art lecture The management of vesico-ureteric reflux in childhood	11.30-11.45 ESUI Section highlights	11.20-12.00 Drugs in urology: Current controversies Zoledronic acid and protection of the skeleton in prostate cancer
	11.45-12.00 EULIS Section highlights					
	<i>page 94</i>	<i>page 95</i>	<i>page 97</i>	<i>page 96</i>	<i>page 93</i>	<i>page 99</i>
12.00						

Thursday, 6 April, Morning

Room Havana	Room 341	Room 342a	Room 342b	Level 3 Room 343	Room 351	Room 353	Room 352a	Room 352b
-------------	----------	-----------	-----------	------------------	----------	----------	-----------	-----------

07.00

08.00

	09.00-12.00	09.00-12.00	09.00-12.00	09.00-12.00	09.00-12.00	09.00-11.00			09.00
	ESU Course 1	ESU Course 2	ESU Course 3	ESU Course 4	ESU Course 5	ESU Course 6	10.00-12.30	10.00-12.00	10.00
	Paediatric urology for the adult urologist: A practical update	Prostate cancer - screening, diagnosis and staging	Evaluation and management of female pelvic floor disorders	Update on benign penile and scrotal disorders	Lower urinary tract dysfunction and urodynamics	Laparoscopy for beginners	ESU/ESUT Hands-on Course 1 Laparoscopy	Hands-on Training Session Endourology masterclass training course	
						page 276			
SUB-PLENARY SESSION 6									
11.00-11.40 Original presentations selected from submitted abstracts									11.00
11.40-12.00 State-of-the-art lecture The future of academic medicine: Five scenarios to 2025									
page 98	page 271	page 272	page 273	page 274	page 275			BOSTON SCIENTIFIC page 312	
							KARL STORZ GMBH & CO.KG page 308		12.00

Thursday, 6 April, Afternoon

	Level 1		Level 2					Level 3	
	eURO Auditorium	Room Ternes	Room Blue	Room Maillot	Room 242	Room 251	Room 252	Room Bordeaux	Room Havana
12.00	12.15-13.45 Video Session 3	12.15-13.45 Poster Session 19	12.15-13.45 Oral Session 4	12.15-13.45 Poster Session 20	12.15-13.45 Poster Session 21	12.15-13.45 Poster Session 22	12.15-13.45 Poster Session 23	12.15-13.45 Oral Session 5	12.15-13.45 Poster Session 24
13.00	Laparoscopic surgery in renal cell carcinoma V13-V18 <i>page 100</i>	Erectile dysfunction: Epidemiology and clinical research 312-326 <i>page 104</i>	Testis tumours: Diagnosis and management 296-303 <i>page 101</i>	Kidney tumours: Diagnosis and staging II 327-341 <i>page 106</i>	Endourology for stones 342-356 <i>page 108</i>	Urothelial tumours: Basic research III 357-371 <i>page 110</i>	Non-neurogenic voiding dysfunction: Overactive bladder 372-386 <i>page 112</i>	Pathological staging prostate cancer 304-311 <i>page 102</i>	BPH: Basic research 387-401 <i>page 114</i>
14.00	14.00-15.30 Video Session 4	14.00-15.30 Poster Session 28	14.00-15.30 Oral Session 6	14.00-15.30 Poster Session 29	14.00-15.30 Poster Session 30	14.00-15.30 Poster Session 31	14.00-15.30 Poster Session 32	14.00-15.30 Oral Session 7	14.00-15.30 Poster Session 33
15.00	Open versus laparoscopic radical prostatectomy, the debate? V19-V24 <i>page 122</i>	Erectile dysfunction: Treatment 463-477 <i>page 126</i>	Kidney tumours: Laparoscopic treatment 447-454 <i>page 123</i>	Infections of the genito-urinary tract 478-492 <i>page 128</i>	Refinements on PCNL 493-507 <i>page 130</i>	Adrenals and clinical kidney transplantation 508-522 <i>page 132</i>	Non-neurogenic voiding dysfunction: Urinary incontinence 523-537 <i>page 134</i>	Bladder cancer: Diagnosis and staging I 455-462 <i>page 124</i>	BPH: Evaluation 538-552 <i>page 136</i>
16.00	15.45-17.15 Video Session 5	15.45-17.15 Poster Session 37	15.45-17.15 Oral Session 8	15.45-17.15 Poster Session 38	15.45-17.15 Poster Session 39	15.45-17.15 Poster Session 40	15.45-17.15 Poster Session 41	15.45-17.15 Oral Session 9	15.45-17.15 Poster Session 42
17.00	Surgical approaches to incontinence V25-V30 <i>page 144</i>	Sexual dysfunction: Medical treatment/miscellaneous 615-629 <i>page 148</i>	History of urology 598-606 <i>page 145</i>	Kidney tumours: Nephron sparing treatment 630-644 <i>page 150</i>	An appraisal of ESWL 645-659 <i>page 152</i>	Urothelial tumours: Management of superficial tumours 660-674 <i>page 154</i>	Clinical practice in female urology 675-689 <i>page 156</i>	Prostate cancer: Impact of lymphnode dissection 607-614 <i>page 146</i>	BPH: Medical therapy 690-704 <i>page 158</i>
18.00	17.30-19.00 Symposium	17.30-19.00 Symposium	17.30-19.00 Symposium	17.30-19.00 Symposium				17.30-19.00 Symposium	17.30-19.00 Symposium
	Initial treatment response and sexual function: Two keys to understanding and managing of LUTS/BPH SANOFI-AVENTIS <i>page 166</i>	Differentiating OAB treatments - critical factors for the older patient NOVARTIS PHARMA AG <i>page 167</i>	Urgency in OAB: Patient outcomes or clinical outcomes? ASTELLAS <i>page 172</i>	Optimising the urologist's use of testosterone IPSEN <i>page 171</i>				The evolution of patient treatment: Beyond ED efficacy LILLY ICOS LLC <i>page 168</i>	Ablatherm-HIFU for prostate cancer: A 10 year European experience EDAP <i>page 170</i>
19.00									19.00-19.45 EAU General Assembly <i>page 174</i>
20.00									

Thursday, 6 April, Afternoon

Room 341	Room 342a	Room 342b	Level 3 Room 343	Room 351	Room 353	Room 352a	Room Concorde 1	Level 4 Room Concorde 2	Room Concorde 3	
12.30-15.30	12.30-15.30	12.30-15.30	12.30-14.30	12.30-14.30	12.30-14.30		12.15-13.45	12.15-13.45	12.15-13.45	12.00
ESU Course 7	ESU Course 8	ESU Course 9	ESU Course 10	ESU Course 11	ESU Course 12		Poster Session 25	Poster Session 26	Poster Session 27	
Retropubic radical prostatectomy- tips, tricks and pitfalls	Chronic pelvic pain syndromes (CPPS) with special focus on chronic prostatitis (CP) and painful bladder syndrome / interstitial cystitis (PBS/IC)	Renal cell carcinoma- surgical aspects	Management and outcome in invasive and locally advanced bladder cancer	Minimally invasive treatment for localised prostate cancer	Advanced course on laparoscopic prostatectomy		Control of prostate cancer cell growth	Localised prostate cancer: Surgical results	Non surgical treatment of prostate cancer: Contemporary issues	13.00
<i>page 277</i>	<i>page 278</i>	<i>page 279</i>	<i>page 280</i>	<i>page 281</i>	<i>page 282</i>		402-416 <i>page 116</i>	417-431 <i>page 118</i>	432-446 <i>page 120</i>	
						14.00-16.30	14.00-15.30	14.00-15.30	14.00-15.30	14.00
						ESU/ESUT Hands-on Course 2	Poster Session 34	Poster Session 35	Poster Session 36	
						Laparoscopy	Novel targets for diagnosis and therapy of prostate cancer	Prostate cancer: Genetics and chemo-prevention	Prostate cancer: Radiotherapy and brachytherapy	15.00
			15.00-17.00	15.00-17.00	15.00-17.00		553-567 <i>page 138</i>	568-582 <i>page 140</i>	583-597 <i>page 142</i>	
			ESU Course 13	ESU Course 14	ESU Course 15					
			Interventional therapies for BPH	The infertile couple- urological aspects	Advanced course on laparoscopic cystectomy	KARL STORZ GMBH & CO.KG	Prostate cancer: Biopsy issues I	Management of high risk and advanced prostate cancer	Prostate cancer: Staging / imaging	16.00
			<i>page 284</i>	<i>page 285</i>	<i>page 286</i>	<i>page 309</i>	705-719 <i>page 160</i>	720-734 <i>page 162</i>	735-749 <i>page 164</i>	
										17.00
							17.30-19.00	17.30-19.00		
							Symposium	Symposium		
							Clinical experience of Duloxetine in women with Stress Urinary Incontinence (SUI) symptoms	Facing the current challenges in BPH		18.00
							BOEHRINGER INGELHEIM GMBH/ ELI LILLY <i>page 173</i>	GLAXOSMITH-KLINE <i>page 169</i>		

19.00

20.00

Friday, 7 April, Morning

	Level 1		Level 2				Level 3
	eURO Auditorium	Room Ternes	Room Blue	Room Maillot	Room 242	Room 252	Room Bordeaux
07.00	PLENARY SESSION 2						
08.00	07.45-08.15 Highlight session 2 ----- 08.15-08.20 Award session 2 ----- 08.20-08.55 Debate The management of bladder cancer in the elderly ----- 08.55-09.15 State-of-the-art lecture Current status of HIFU and cryotherapy in prostate cancer ----- 09.15-09.35 Société Internationale d'Urologie (SIU) lecture CT urography in the evaluation and management of urological malignancies ----- 09.35-09.55 Urological Association of Asia (UAA) lecture Prostate cancer incidence in Korea ----- 09.55-10.40 Round table discussion New approaches in the treatment of overactive bladder ----- 10.40-11.00 State-of-the-art lecture Testosterone supplementation in ageing male ----- <i>from page 175</i>						
09.00					09.00-11.00 ESU Course 34 Multi Media course ----- <i>page 307</i>		
10.00							
11.00	SUB-PLENARY SESSION 9 ----- 11.00-11.30 State-of-the-art lecture Update on the management of mixed urinary incontinence ----- 11.30-12.00 State-of-the-art lecture The management of failed surgery for female stress incontinence ----- <i>page 179</i>	SUB-PLENARY SESSION 10 ----- 11.00-11.40 State-of-the-art lecture Dose escalation in brachy and radio therapy for prostate cancer ----- 11.40-12.00 State-of-the-art lecture Management of stage I testis cancer ----- <i>page 180</i>	SUB-PLENARY SESSION 11 ----- 11.00-11.20 State-of-the-art lecture Modern management of priapism ----- 11.20-11.40 State-of-the-art lecture Managing ED in the cardiac patient ----- 11.40-12.00 State-of-the-art lecture Prevention of ED following radical prostatectomy ----- <i>page 181</i>	SUB-PLENARY SESSION 13 ----- 11.00-12.00 Seminar Malignant bone disease in prostate cancer ----- <i>page 183</i>	SUB-PLENARY SESSION 8 ----- 11.00-11.15 ESFU Section highlights ----- 11.15-11.30 ESUR Section highlights ----- 11.30-11.45 ESTU Section highlights ----- 11.45-12.00 ESGURS Section highlights ----- <i>page 178</i>	SUB-PLENARY SESSION 14 ----- 11.00-11.20 State-of-the-art lecture Basic and clinical research in reproductive medicine at Osaka University ----- 11.20-12.00 Drugs in urology: Current controversies Bicalutamide as monotherapy in the management of prostate cancer ----- <i>page 184</i>	
12.00							

Friday, 7 April, Morning

Room Havana	Room 341	Room 342a	Room 342b	Level 3 Room 343	Room 351	Room 353	Room 352a	Room 352b
-------------	----------	-----------	-----------	------------------	----------	----------	-----------	-----------

07.00

08.00

	09.00-12.00 ESU Course 16 Advanced course on urethral stricture surgery	09.00-12.00 ESU Course 17 Diagnosis and management of superficial bladder cancer	09.00-12.00 ESU Course 18 Advanced prostate cancer - new perspectives	09.00-12.00 ESU Course 19 Update on stone disease	09.00-12.00 ESU Course 20 Radical cystectomy and orthotopic bladder substitution - surgical tricks and management of complications	09.00-12.00 ESU Course 21 Vaginal surgery for urologists		09.00-10.00 Hands-on Training Session Holmium Laser Workshop LUMENIS page 313	09.00
							10.00-12.00 ESU/ESUT Hands-on Course 3 Laparoscopy		10.00
SUB-PLENARY SESSION 12 11.00-12.00 Debate Is surveillance an option for renal cancer? page 182								11.00-12.00 Hands-on Training Session Holmium Laser Workshop KARL STORZ GMBH & CO.KG page 310 LUMENIS page 313	11.00

12.00

Friday, 7 April, Afternoon

	Level 1		Level 2					Room 253	Level 3		
	eURO Auditorium	Room Ternes	Room Blue	Room Maillot	Room 242	Room 251	Room 252		Room Bordeaux	Room Havana	Room 341
12.00	12.15-13.45 Video Session 6 page 186	12.15-13.45 Poster Session 46 page 190	12.15-13.45 Oral Session 10 page 187	12.15-13.45 Poster Session 47 page 192	12.15-13.45 Poster Session 48 page 194	12.15-13.45 Poster Session 49 page 196	12.15-13.45 Poster Session 50 page 198	12.30-14.00 European HIFU Club EDAP page 185	12.15-13.45 Oral Session 11 page 188	12.15-13.45 Poster Session 51 page 200	12.30-14.30 ESU Course 22 page 295
13.00	Endoscopic and robotic surgery V31-V36 page 186	Male infertility 766-780 page 190	Kidney transplantation: Basic research 750-757 page 187	Kidney tumour treatment: Alternative to surgery/metastasis 781-795 page 192	Neuro-urology: Sensory mechanisms 796-810 page 194	Bladder cancer: Diagnosis and staging II 811-825 page 196	Diagnostic aspects in female urology 826-839 page 198		Prostate cancer: Surgery T3/ advanced disease 758-765 page 188	BPH: New techniques I 841-855 page 200	Penile and testicular cancer
14.00	14.00-15.30 Video Session 7 Laparoscopic surgery: Difficult cases V37-V42 page 208	14.00-15.30 Poster Session 55 Bladder cancer: Diagnosis and staging III 917-931 page 212	14.00-15.30 Oral Session 12 Prostatitis and prosta-todynia 901-908 page 209	14.00-15.30 Poster Session 56 Kidney tumours: Laparoscopy/ follow up 932-946 page 214	14.00-15.30 Poster Session 57 Neuro-urology: Neuro-modulation, urodynamics and bowel function 947-961 page 216	14.00-15.30 Poster Session 58 Paediatrics I 962-976 page 218	14.00-15.30 Poster Session 59 Female urology: Which sling? 977-991 page 220		14.00-15.30 Oral Session 13 Prostate cancer: Hormonal treatment 909-916 page 210	14.00-15.30 Poster Session 60 BPH: New techniques II 992-1006 page 222	
15.00											15.00-17.00 ESU Course 28 page 301
16.00	15.45-17.15 Video Session 8 Video award session page 230	15.45-17.15 Poster Session 64 Urothelial tumours: Management of infiltrative/ advanced tumours II 1068-1082 page 236	15.45-17.15 Oral Session 14 Kidney tumours: Systemic treatment 1052-1059 page 232	15.45-17.15 Poster Session 65 Stones miscellaneous 1083-1097 page 238	15.45-17.15 Poster Session 66 Neuro-urology: The detrusor and the urethra 1098-1112 page 240	15.45-17.15 Poster Session 67 Paediatrics II 1113-1127 page 242	15.45-17.15 Poster Session 68 Management of the complications of surgery in female urology 1128-1142 page 244		15.45-17.15 Oral Session 15 Prostate cancer: Intermittent hormonal treatment 1060-1067 page 234	15.45-17.15 Poster Session 69 BPH: Intervention therapy 1143-1157 page 246	Ultrasound for the urologist - TRUS and TRUS guided biopsies
17.00											
18.00	17.30-19.00 Symposium Targeting patient and partner satisfaction: Insights into the functional and emotional benefits of Viagra® PFIZER INC page 256	17.30-19.00 Symposium Frontiers in prostate cancer: Advancing our ability towards improved cancer detection GEN-PROBE INC. page 254	17.30-19.00 Symposium Improving management of prostate cancer: Are all LHRH agonists equal? ASTELLAS page 255	17.30-19.00 Symposium OAB: What matters to the patient? UCB PHARMA page 259					17.30-19.00 Symposium Prostate cancer: Optimising treatment strategy to meet our patients' needs SANOFI-AVENTIS page 260	17.30-19.00 Symposium Molecular diagnostics in bladder cancer management: The UroVysion experience ABBOTT MOLECULAR page 258	
19.00											

Friday, 7 April, Afternoon


Room 342a	Room 342b	Room 343	Level 3 Room 351	Room 353	Room 352a	Room 352b	Room Concorde 1	Level 4 Room Concorde 2	Room Concorde 3	
12.30-14.30	12.30-14.30	12.30-14.30	12.30-14.30	12.30-14.30			12.15-13.45	12.15-13.45	12.15-13.45	12.00
ESU Course 23	ESU Course 24	ESU Course 25	ESU Course 26	ESU Course 27			Poster Session 52	Poster Session 53	Poster Session 54	
Urological management of renal failure and renal transplantation - treatment of urological complications	How to do a clinical trial	Office management of male sexual dysfunction	Update on neurourology	Advanced course on laparoscopic nephrectomy			Prostate cancer: Diagnosis PSA	Prostate cancer: Staging	Urogenital trauma	13.00
<i>page 296</i>	<i>page 297</i>	<i>page 298</i>	<i>page 299</i>	<i>page 300</i>			856-870 <i>page 202</i>	871-885 <i>page 204</i>	886-900 <i>page 206</i>	
					14.00-16.30	14.00-15.00	14.00-15.30	14.00-15.30	14.00-15.30	14.00
					ESU/ESUT Hands-on Course 4	Hands-on Training Session	Poster Session 61	Poster Session 62	Poster Session 63	
					Laparoscopy	Holmium Laser Workshop LUMENIS <i>page 313</i>	Prostate cancer: PSA and novel markers	Prostate cancer: Treatment evaluation	Urological reconstruction II	
							1007-1021 <i>page 224</i>	1022-1036 <i>page 226</i>	1037-1051 <i>page 228</i>	15.00
15.00-17.00	15.00-17.00	15.00-17.00	15.00-17.00	15.00-17.00			15.45-17.15	15.45-17.15	15.45-17.15	16.00
ESU Course 29	ESU Course 30	ESU Course 31	ESU Course 32	ESU Course 33			Poster Session 70	Poster Session 71	Poster Session 72	
How to write a paper for publication	Upper urinary tract trauma	Ageing male	The molecular basis of prostate cancer; science in practice	Advanced course on upper tract laparoscopic (UPJ and adrenal)	KARL STORZ GMBH & CO.KG <i>page 311</i>	Hands-on Training Session	Prostate cancer: Biopsy issues II	Prostate cancer: Screening/early detection	Prostate cancer: Surgical results	
<i>page 302</i>	<i>page 303</i>	<i>page 304</i>	<i>page 305</i>	<i>page 306</i>		Holmium Laser Workshop LUMENIS <i>page 313</i>				
							1158-1172 <i>page 248</i>	1173-1187 <i>page 250</i>	1188-1202 <i>page 252</i>	17.00
							17.30-19.00	17.30-19.00		
							Symposium	Symposium		
							Targeted agents in the management of RCC: The role of the urologist	Exploring the limits of 5 α -reductase inhibitors in prostate cancer prevention, detection and treatment		18.00
							BAYER HEALTHCARE PHARMACEUTICALS <i>page 261</i>	GLAXOSMITH-KLINE <i>page 257</i>		

19.00


Saturday, 8 April

	Level 1		Level 2		
	eURO Auditorium	Room Ternes	Room Blue	Room 243	Room 252
07.00	SUB-PLENARY SESSION 16 07.45-08.15 State-of-the-art lecture Nomograms in prostate cancer	SUB-PLENARY SESSION 17 07.45-08.15 State-of-the-art lecture Small renal tumors: Pre- and post operative evaluation	SUB-PLENARY SESSION 19 07.45-08.15 State-of-the-art lecture The long term outcome of medical treatment for BPH	SUB-PLENARY SESSION 18 07.45-08.15 State-of-the-art lecture The evolution of urological training in Europe	SUB-PLENARY SESSION 15 07.45-08.00 ESUT Section highlights
08.00	08.15-08.45 State-of-the-art lecture Imaging strategies in prostate cancer <i>page 264</i>	08.15-08.45 Urological Research Society lecture Management of BCG failures in superficial bladder cancer <i>page 265</i>	08.15-08.45 State-of-the-art lecture How to handle high-risk infections in urology <i>page 267</i>	08.15-08.45 EUSP Session <i>page 266</i>	08.00-08.15 EORTC-GU Section highlights 08.15-08.30 ESOU Section highlights 08.30-08.45 ESAU Section highlights <i>page 263</i>
09.00	PLENARY SESSION 3 08.45-09.10 Award session 3 09.10-09.25 State-of-the-art lecture History of urology in France 09.25 - 09.45 EAU Guidelines What's new in 2006?				
10.00	09.45 - 10.05 State-of-the-art lecture The dilemma of over-detection and overtreatment of prostate cancer 10.05 -10.40 Round table discussion Radical prostatectomy: To do or not to do 10.40 - 11.00 State-of-the-art lecture The role of PSA kinetics in the management of prostate cancer				
11.00	11.00 - 11.35 Round table discussion The optimal management of the patient with hormone resistant prostate cancer				
12.00	11.35 - 13.00 Souvenir session from the EAU Scientific Committee <i>from page 268</i>				
13.00					

Level A (-1)




Level 0




Floorplans Palais des Congrès

Level 1




Colour explanation	
■ Session rooms	■ Catering
■ Exhibition area	Emergency exits
■ Press areas	Elevators/stairs/escalators


Level 2



Level 3



Level 4



General Information

Abstract book

The abstract book is a special supplement of European Urology. It was sent to all EAU members prior to the congress and the abstracts are available for EAU members through the EAU website. The abstract book is also included in the congress bag. Additional copies can be purchased at the Cashier Desk (on level 3) during the congress. An abstract CD will be provided to all congress delegates.

Abstract CD's are sponsored by [SANOFI-AVENTIS](#)

Accessibility Palais des Congrès

The 21st Annual EAU Congress will take place at the Palais des Congrès in Paris. The Palais des Congrès is easily accessible by public transportation (Metro line 1: Porte Maillot).

Palais des Congrès

2, Place de la Porte Maillot

75017 PARIS

P +33 (0)1 40 68 25 55

F +33 (0)1 40 68 27 40

W www.palais-congres-paris.fr

Air France and airport info

Air France has been appointed as the official airline carrier for the 21st Annual EAU Congress and is offering special congress fares to all congress participants. Air France offers a



comprehensive global route network linking many major cities to Paris.

Airport Paris: Roissy Charles de Gaulle

Roissy Charles de Gaulle Airport is located 23 kilometres North-East of Paris and is the city's largest airport. The airport is served by taxi, Air France shuttle service, TGV and RER trains.

The Air France shuttle service runs a bus service between 05:50 and 23:00 hrs. Buses run every ten minutes from the airport to the Palais des Congrès. The journey takes approximately 40 minutes.

The rapid RER train service links Roissy Charles de Gaulle Airport with central Paris. The trains run every 15 minutes (eight minutes in peak periods); the journey takes approximately 35 minutes.

Useful phone numbers

Paris Roissy Charles de Gaulle Airport +33 (0)1 48 62 22 80

Air France +33 (0)8 20 82 08 20

Taxi services G7 +33 (0)1 47 39 47 39

Badges

The badge classification is as follows:

Red : Congress delegate EAU member

Grey : Congress delegate non-EAU member

Green : Exhibitor

Blue : Health care professional (nurse)

Orange : Press

White : Accompanying person

Yellow : Organising staff

Pink : Special registration

Bank and exchange

The national currency in France is the euro (€). Banking hours in Paris are generally from 10.00 to 17.00 hrs. on Monday to Friday. Some branches are open on Saturday.

Automatic cash machines can be found in most commercial centres. The nearest automatic cash machine is located on level A of the Palais des Congrès. It accepts most international credit cards (Visa, Mastercard, Amex) and operates 24 hours a day, seven days a week.

Business Centre

A business centre is available at the Hotel Concorde Lafayette.

Car park

There is an underground car park directly under the Palais des Congrès. The car park has direct access to the Palais des Congrès.

Currency exchange

Currency exchange can be carried out at all bank branches and post offices. Exchange offices ("Bureau de change") can also be found in large department stores, railway stations, airports and close to tourist sites.

Please note: Although the exchange rate is fixed, commission rates are not. These must be clearly displayed.

An exchange office is located on level 0 of the Palais des Congrès and is open from Monday to Saturday from 09.00 to 20.00 hrs.

Cellular phones

Cellular phones must be switched off during all sessions.

Certificate of Attendance

A Certificate of Attendance for the 21st Annual EAU Congress is included in the congress bags. A list of CME accreditation points granted by various national urological societies and the European Board of Urology is available in the programme book as well as on the congress website.

Climate and weather conditions

Paris has an intermediate climate with cold winters and hot summers. In April the weather is usually pleasant with an average temperature of 16°C. It is however recommended to bring a raincoat and sweater.

Cloakroom/Luggage

The cloakroom is located on the ground level (level 0) and is at participants' disposal during congress hours. Please be sure to collect all personal effects at the end of the day.

Congress bags

Each delegate receives a voucher for a congress bag which includes a programme book, abstract book and exhibition guide.

The congress bags are sponsored by **ASTELLAS**

Congress hours

Wednesday, 5 April	08.30 – 21.00
Thursday, 6 April	07.30 – 19.00
Friday, 7 April	07.45 – 19.00
Saturday, 8 April	07.45 – 13.00

Contacts

Congress Manager

Ms. Patricia de Bont
(p.debont@congressconsultants.com)

Exhibition Manager

Ms. Henriët Wieringa (h.wieringa@congressconsultants.com)

Sponsoring

Mrs. Jacqueline Roelofswaard (j.roelofswaard@uroweb.org)

Scientific programme

Ms. Silvia de Bruin (s.debruin@congressconsultants.com)

Registrations

Ms. Marije Koops (m.koops@congressconsultants.com)

ESU courses

Mrs. Jacobijn Sedelaar (esu@uroweb.org)

All other information

info@congressconsultants.com

Daily Congress Newsletter

Daily congress newsletters will be provided on the first 3 congress days.

EAU Cyber Corner

The EAU Cyber Corner, included in the EAU Booth (booth PA27 on level 1), is at your disposal to check the EAU website: www.uroweb.org.

Supported by an unrestricted educational grant from **ASTELLAS**

EAU Digital Video Library

The EAU digital video library, included in the EAU Booth (booth PA27 on level 1), is operational during exhibition hours. A wide choice of videos from the European Association of Urology including the videos presented in Paris and at past EAU Congresses can be viewed on request on individual monitors. The prize winning videos will be on continuous display. All videos can be copied to DVD, a service that is provided free of charge for all congress delegates.

Supported by an unrestricted educational grant from **ASTELLAS**

EAU Education office (European School of Urology)

The European School of Urology, working with European faculties, aims to provide high quality international urology educational courses. The ESU has a special booth on level 3 with extensive information on the activities of the European School of Urology (ESU).



Registration for the courses can be made on-line through: www.euparis2006.org.

All congress delegates will receive an ESU Course CD.

Check page 271 for the extensive course programme.

ESU Course CD's are sponsored by **NOVARTIS PHARMA AG**



Fees ESU and ESU-ESUT courses (for congress registered participants only):

C = 2 hrs. C = 3 hrs.

Fees excluding VAT

Non-EAU member	€ 40	€ 60
EAU members, residents	€ 25	€ 40

C = Course

Registration fee for ESU courses will be waived for all ESRU-EAU junior members and EAU junior members (max. 10 free registrations are granted per course based on a first come, first served basis).

General Information

EAU Square

The EAU square in the exhibition area (booth PA27 on level 1) consists of the EAU Cyber Corner, the EAU Booth, the EBU Corner, the EAU Digital Video Library and the EAU Historical Exhibition. The EAU Booth provides information on membership status and membership benefits. Non-members are invited to visit the EAU Booth to inquire about the many advantages for EAU members and to apply for EAU membership.

European Board of Urology (EBU) info desk

For information about the activities of the EBU, such as the annual examinations in urology, in-service assessment, accreditation of residency training programmes in urology within Europe, please visit the EBU corner at the EAU square (booth PA27 on level 1).

EU-ACME info desk

Information about the EU-ACME programme, your acquired CME credit points and membership cards can be obtained at the EU-ACME corner at the EAU square (booth PA27 on level 1).

Electricity

The electricity in France runs on 220 volts and the frequency is 50 Hz. Wall outlets take plugs with two male contact pins. A plug adaptor should be taken along if incompatible electronic gadgets are used.

European Urology

European Urology, the journal of the EAU, has been a respected urological forum for over 20 years, and today is read by more than 9,000 urologists across the globe. With an impact factor of 2.651 the journal has become one of the world's leading medical periodicals.

To meet today's new challenges, we have introduced an innovative range of developments that will ensure European Urology continues to provide the best clinical guidance, research and education for urologists across Europe and the world.

See the new European Urology for yourself - visit either the European Urology or EAU booth at the exhibition.

Exhibition

An extensive technical exhibition, involving technical equipment manufacturers, pharmaceutical companies and scientific publishers, will be held jointly with the congress on levels 1 to 3 of the Palais des Congrès.

Exhibition hours

Wednesday, 5 April	10.00 – 21.00 hrs. Level 1 10.00 – 18.30 hrs. Levels 2 & 3
Thursday, 6 April	09.00 – 17.45 hrs.
Friday, 7 April	09.00 – 17.45 hrs.
Saturday, 8 April	09.00 – 13.30 hrs.

First aid

There is a medical unit present for first aid on Level 1 (room 315 on level 3). In case of an emergency contact a security guard immediately.

Future meetings area

Posters and other documentation on future meetings can be displayed in the "Future Meetings Area" on level 1. It is strictly forbidden to put up promotional material at any other location in the building.

Hospitality suites: Special Latin-American and Asian Suites

During the 21st Annual EAU Congress there will be special hospitality suites to welcome congress delegates from the Latin-American and Asian countries. You can find the suites at level 2 (room 231 & room 233).

Commercial hospitality suites

American Medical Systems	Room 127 - Level 1
Astellas Pharma	Room 125 - Level 1
Astrazeneca	Room 111 - Level 1
Cook	Room 135 - Level 1
Kyowa Hakko	Room 104 - Level 1
Pfizer Inc	Room 212 - Level 2

Hotel accommodation

The EAU has contracted the company "Colloquium" in Paris to deal with the housing for congress participants. Colloquium staff will be available for queries at the hotel desk in the registration area.

Insurance

The organisers do not accept responsibility for any personal damage. Participants are strongly recommended to arrange their own personal insurance.

Internet corners

There are two internet corners on level 2 and level 3 of the Palais des Congrès. Delegates can use the computers free of charge.

Language

All presentations during the congress will be conducted in English, the official language of the EAU. There will be no translation provided, only during the EAU/CAU session and the EAUN Meeting.

Local time

From the end of March until the end of October, French time goes from GMT+1 to GMT+2 (GMT = Greenwich Meridian Time).

Lost and found

Found items should be returned to the Information Desk on level 0. Should you unfortunately happen to lose something, please report to this desk for assistance.

Messages

Messages can be left and collected at the Information Desk on level 0. Please regularly consult the monitors at various points in the congress centre to see whether any message has been left for you.

Phone numbers

SAMU (medical emergencies)	15
Police emergency	17
Fire service emergency	18
European emergency line	112

Photo service

Photos taken by the official EAU photographer during the congress and the official social events can be purchased during and after the congress through the congress website: www.eauparis2006.org.

Poster Builder Service

The EAU offered a Poster Builder Service that enabled you to create your poster for the 21st Annual EAU Congress on-line. Your posters are ready for pick-up at the Speakers Service Centre in Paris (room 241 on level 2).

Press centre

Journalists can obtain free registration to the Congress at the Press registration Desk in the registration area on level 3. All media operators must show their credentials (press card dated 2006 and original assignment letter).

All press are invited to report to the EAU Press Centre (room 362 on level 3) to obtain the assistance and information they require. Internet access, fax machine, printer and photocopier are provided.

Restaurants

In France you will find a variety of restaurants, from the simple, small, intimate ones to famous, gourmet restaurants, along with brasseries, inns and tea rooms. The majority of restaurants serve food between 12.00 – 15.00 hrs and 19.00 – 23.00 hrs.

Shopping

Paris is one of the fashion capitals of the world. Go window-shopping at the great couturiers, along the Avenue Montaigne, the Faubourg Saint-Honoré, the Place de la Madeleine, the Saint-Sulpice quarter or Sèvres-Babylone, between the Rues de Grenelle, du Cherche-Midi and des Saints-Pères.

The department stores Printemps, Galeries Lafayette, Bon Marché, Samaritaine or BHV are Parisian institutions. They provide numerous brand names and offer every sort of merchandise. For bargain hunters, two large flea markets are held outside central Paris: Porte de Vanves and Porte de Saint-Ouen (the largest).

Another Parisian speciality is the booksellers with their stalls located along the banks of the Seine around the Saint-Michel quarter. Paris has many and varied markets in every quarter including bird markets, organic and food markets and also the flower market which is located on the Ile de la Cité.



Smoking policy

Smoking is prohibited inside the congress centre.

Tourist Information

Tourist information will be available at the Paris Info Desk in the registration area on level 3. Excursions can be booked on-line through the congress website: www.eauparis2006.org.

Transportation

Congress delegates receive a transportation pass that is valid on all public transport within the City of Paris. Also a plan of the public transport is available at the transportation desk.

Speakers' Guidelines

Speakers Service Centre – Room 241/Level 2

Only digital presentations will be accepted during the congress and all presentations should be handed in at the Speakers Service Centre at least two hours prior to the start of the session.

Opening hours

Tuesday, 4 April	14.00 – 19.30 hrs.
Wednesday, 5 April	06.30 – 20.00 hrs.
Thursday, 6 April	06.00 – 19.30 hrs.
Friday, 7 April	06.00 – 19.30 hrs.
Saturday, 8 April	06.00 – 13.30 hrs.

If you are a chair person

Locate your session room in time. Please be in your session room at least 15 minutes prior to the start of the session.

We remind you that:

- Speakers should strictly observe timing.
- Discussants should not speak without permission and must first clearly state their name, institution and country of origin.

If you are a speaker in an oral session

Locate your session room in time. Please turn in PowerPoint presentations at the Speaker Service Centre in room 241 on level 2 at least two hours prior to the start of your session. Failure to do so could result in presentations not being available for projection when required. Facilities are provided for PowerPoint presentations only. Please be in your session room no later than 15 minutes prior to the start of the session. Do remember that time allotted to speakers in oral sessions is 9 minutes (including 2 minutes for discussion). Follow the chairs' instructions, in particular those regarding the timing of your lecture.

If you are presenting a poster

Posters must be put up in the room 15 minutes prior to the start of the session. The poster boards are numbered and your poster should be mounted on the board which corresponds with your abstract number. Pushpins are available in the session room. Please remove your poster immediately at the end of the session. PowerPoint presentations are not allowed during poster sessions. The PDF of your poster, supplied by yourself prior to the congress, will be projected during discussion of your abstract. In case you forgot to submit the PDF prior to the congress, you can still do this up to 2 hours prior to your session at the Speaker Service Center in room 241 on level 2.

Disclose links to the industry

The EAU Scientific Committee request that you disclose to the audience any links you may have with the industry related to the topic of your lecture at the beginning of your session. A link can be; being a member of an advisory board or having a consultancy agreement with a specific company.

Presentation training centre

At this year's EAU Congress, as in previous years, you can take advantage of working with speaking consultant Mr. Paul Casella (Iowa, US) to help improve your presentation and delivery skills. The one-on-one half hour sessions are free of charge and are available to all speakers. As these sessions have proved to be very popular in the past, please make your appointment at the Speaker Service Centre in room 241 on level 2; you can sign up for an appointment from Wednesday 5 April to Saturday 8 April. The presentation trainings are held in a room next to the Speaker Service Centre.



Social Programme

Opening Ceremony and Welcome Cocktail

The EAU Opening Ceremony contains entertaining shows and special award presentations. The Ceremony will be followed by a Welcome Cocktail where you will have a taste of the famous French cuisine. The Ceremony and Welcome Cocktail will take place at the Palais des Congrès.

Opening Ceremony

Date Wednesday, 5 April 2006
Time 18.15 – 19.30 hrs.
Location eURO Auditorium
Costs Included in the registration fee

Welcome Cocktail

Date Wednesday, 5 April 2006
Time 19.30 – 21.00 hrs.
Location Palais des Congrès, Exhibition area Level 1
Costs Included in the registration fee

Nurses Dance Evening

For all nurses attending the 7th Meeting of the European Association of Urology Nurses (EAUN), organised in conjunction with the 21st Annual EAU Congress, a special evening has been organised which will give the opportunity to meet and socialise with colleagues in the field. As in previous years an enjoyable evening of music and dancing is guaranteed. Non nursing delegates may also attend this evening at their own expense.

Date Thursday, 6 April 2006
Time 20.00 – 01.00 hrs.
Location Private Club - Les Planches
40 rue du Colisée
75008 PARIS
Costs Included in the registration fee for healthcare professionals; other delegates have free access and only need to pay their drinks.
Transport Participants are to use their transport passes to go by metro to the venue (line 1: Franklin Roosevelt or line 9: Franklin Roosevelt or St. Philippe du Roule)

Sponsored by **HOLLISTER EUROPE LTD.**

EAU Evening

Located in an old wine storage facility along the banks of the river Seine this year's EAU Evening will take place at 'Les Pavillons de Bercy', an enchanting museum with old games and carrousels. This large collection of authentic fairground objects and carrousels provides an insight into the world of fairground arts from the 9th century.

Take a stroll through 'Le Theatre du Merveilleux' where the wonders of the magic lantern will enchant and impress. This extraordinary room has been inspired by fairy tales from around the globe.

A celebration of the world of carnivals and operas can be experienced in the Venetian Room where you will be charmed by the Italian atmosphere. During this passage through the last centuries you can enjoy the many different dinner buffets and the chance to compete with your friends and colleagues at all the authentic French games.

Tickets for the EAU evening can be purchased at the special desk in the registration area.



Date Friday, 7 April 2006
Time 20.00 – 23.30 hrs.
Location Les Pavillons de Bercy, 53, Avenue des Terroirs de France, 75012 Paris, France
Costs € 50,- for all registered delegates
€ 100,- for exhibitors and non-delegates
Fees excluding 19,6% VAT
Transport Participants are to use their transport passes to go by metro to the venue (line 14: Cour St. Emillion)
Dress Code Casual (ladies, please be aware that there are several cobble stoned areas)

Excursions



Tour E2 Orsay Museum

Date: Thursday, 6 April 2006
Time: 09.00 - 12.30 hrs.
Price: € 51,- per person

The transformation of the Orsay train station into a museum respects the original architectural design. This museum is dedicated to all forms of artistic expression: painting, sculpture and photography of the 1848-1914 period.

The era of impressionist painters is particularly well represented with the masterpieces of Manet, Monet, Renoir and Degas to name but a few.

Tour E3 Versailles and Trianons

Date: Thursday, 6 April 2006
Time: 09.00 - 17.30 hrs.
Price: € 146,- per person

This estate is often considered the most outstanding chateau in the world. Built during the reign of Louis XIV the Sun King, it is testimony to the splendor of French classicism and the power of one single man. The visit to the royal apartments traces this lavish chapter in the history of France. Visit the hall of mirrors where the 'Treaty of Versailles' was signed and not to be missed are the splendid apartments of Marie Antoinette. After lunch the afternoon will be devoted to visiting the Trianons and the Hameau de la Reine.

Tour E4 Louvre Museum

Date: Friday 7, April 2006
Time: 09.00 - 12.30 hrs.
Price: € 54,- per person

The Louvre is the largest museum in the world and the quality and sheer variety of its contents make it a must see on your visit to Paris. It plays host to an enormous collection of paintings, drawings, antiques sculptures, furniture, coins and jewellery. Next to the well known masterpieces such as the Mona Lisa and the Venus de Milo extensive art collections are displayed throughout the many galleries.



Tour E1 Paris City Tour

Date: Wednesday, 5 April 2006
Time: 14.00 - 17.30 hrs.
Price: € 41,- per person

This tour is especially designed for those who wish to discover the essentials of Paris including the Opéra, Place de la Concorde, Champs-Élysées, Arc de Triomphe, Eiffel Tower, the Invalides, Latin Quarter and the beautiful cathedral Notre Dame.





Tour E5 Fontainebleau and Vaux-Le-Vicomte


Date: Friday, 7 April 2006
Time: 08.30 - 17.30 hrs.
Price: € 146,- per person

Used by the kings of France from the 12th century, the medieval royal hunting lodge of Fontainebleau, standing at the heart of a vast forest in the Ile-de-France, was transformed, enlarged and embellished in the 16th century by François I, who wanted to create a 'New Rome'. Surrounded by an immense park, the Italianate palace combines Renaissance and French artistic traditions. North of Fontainebleau stands the majestic Vaux-Le-Vicomte castle. The castle was built in 1656 by finance wizard Fouquet, who employed the most famous artists of the period including Le Vau, Le Brun, and Le Nôtre. Vaux-Le-Vicomte today stands as a tribute to the extraordinary genius of Fouquet.

Tour E6 Conciergerie, Sainte-Chappelle and Notre-Dame

Date: Saturday, 8 April 2006
Time: 09.00 - 12.30 hrs.
Price: € 64,- per person

The Conciergerie, a fortress like building on the Ile-de-la-Cité built by Philippe the Fair (1284-1314) now makes up much of the Palais de Justice



complex. Its history as a place of imprisonment, torture, and death is significant. Among its more famous prisoners were Marie Antoinette, Charlotte Corday, Danton, and Chénier. Marie Antoinette's cell is now a chapel to her memory, and includes her crucifix, and two life portraits.

Just a few metres away stands the magnificent Sainte Chapelle. Built in the French Gothic style, it sits in the heart of Paris, on the Ile de la Cité just west of Notre Dame. King Louis IX

(Saint Louis) had it built to house the precious holy relics that he purchased from the Emperor of Constantinople. Not far from here lies the Notre-Dame. Dating back to the 13th century it is a masterpiece of Gothic art in Western Europe. Its stained glass and huge interior are stunning artistic experiences of mystical dimension.

**Excursions
can be booked through:
www.eauparis2006.org**

About Paris

City Overview

For some, Paris represents a city of romance, for others, the French capital is a sparkling mix of writers and artists. While the first visit to the French capital may surprise, it is unlikely to disappoint. On all sorts of levels – historical, architectural, cultural – this is a fascinating city.

The River Seine splits the city into the Rive Droite (Right Bank) north of the river and the Rive Gauche (Left Bank) south of the river. Paris is just 10km by 11km, and is easily explored on foot or via the efficient transport system. Orientation is simplified by the 20 arrondissements (1st to 20th, in French 1er to 20e), spiralling outwards from the central Ile de la Cité to Porte de Montreuil on the eastern edge of the city.

The life of the modern city began about 250BC when a Celtic tribe called the Parisii established a fishing settlement Lutétia, on the Ile de la Cité. The Romans were later drawn to this strategic location, a natural crossroads between Germany and Spain, and took control in 52BC. The first King of France Hugues Capet, ruled from Paris in AD987. Despite English rule between 1420 and 1436, a series of French kings brought about the centralisation of France, with Paris at its cultural, political and economic heart.

The history of Paris can be uncovered throughout its distinctive districts. Hilly Montmartre, with its village atmosphere, was where the Paris Commune began in 1871; the Marais evokes medieval Paris, its winding streets a sharp contrast to the wide, orderly Haussmann boulevards, devised by Napoleon III. These grand 19th-century avenues still dominate the city. The grands travaux (large projects) of Président Mitterrand added the Grande Arche de la Défense, the ultra-modern Opéra de la Bastille, the impressive Institut du Monde Arabe, and constructed a glass pyramid in the central courtyard of the Louvre.

Nightlife

When planning an evening out in Paris, it is more important to decide where to go than what to do. The Champs-Élysées and Trocadéro areas are full of tourists and overpriced nightspots, but may be worth considering. Pigalle, it is the seedy neighbourhood of Paris but home to some good music venues including the Moulin Rouge cabaret, where the can-can is still performed. Montmartre is heaving in summer but the views over Paris from Sacré-Coeur are unbeatable. Bastille is buzzing with bars and clubs but is a bit too hectic for some. The best area for an evening's café-hopping is the Marais district, closely followed by the increasingly fashionable Oberkampf, which suits a younger crowd.

Restaurants

Dining in Paris is an adventure for the most experienced palette. French food is served in restaurants, bistros, tea salons, cafes and wine bars. Apart from the huge variety of French cuisine, there are a multitude of international restaurants to choose from. Foods range from rich French dishes to simple local cuisine. Almost every chef brings the cuisine of his birth to his menu.

You can dine in Paris at any time day or night, particularly in the many cafes, brasseries and bistros. Good food can be found everywhere in the city; however, the Left Bank including St-Germain-des-Près and the Latin Quarter have the most restaurants. Many well-known cafes are located in Montparnasse including the splendidly preserved 1920s cafes Le Select and La Rontaine. The more expensive restaurants are located around the Invalides and Palais de Chaillot.

The eating diversity of Paris is great. The long tradition of regional cuisine can be experienced and enjoyed in many of the bistros. Dress code is generally informal unless you choose to dine at a three-star restaurant where the dress code tend to be more formal. Table reservations are recommended to avoid waiting. Bon appetite!

Shopping

The Parisian fashion ideal is elegant. Trends may come and go but Paris is always at the fashion forefront and there are few cities where you can find so many top-quality designers.

The exclusive designer shops are in the 8th arrondissement, in the golden triangle formed by Avenue des Champs-Élysées, Avenue Montaigne and Rue François 1st and along Rue du Faubourg St-Honoré. A typically Parisian shopping experience can be had at the main department stores on Boulevard Haussmann, – Les Galeries Lafayette and Au Printemps.

Métro Temple or République take the bargain shopper to the cheapest department store in the city, Tati, 172 rue du Temple, 3rd. Cut-price designer gear can be snapped up at the Mouton à Cinq Pattes, 8 rue St-Placide, 6th.

Those who enjoy intimate, friendly boutiques should head for the Marais district, in the 4th. Rue des Francs-Bourgeois in the gay quarter sells designer kitsch, while the winding rue des Rosiers in the Jewish quarter has plenty of young designers whose works are displayed at L'Eclaireur. This area is at its busiest on Sunday, with many shops closed on Saturday due to the Jewish sabbath.

The Carrousel du Louvre, under the glass pyramid in the Louvre courtyard, is a good place for tasteful gifts but shoppers determined to take home plastic Eiffel Towers should head for rue de Rivoli, home to tourist kitsch.

Most shops are open Monday to Saturday 0900/1000-1900/2000 and close between about 1200 and 1430 for lunch. Sales tax is 19.6%, as standard, although it varies widely between what are regarded as essential items and luxury goods. Non-EU visitors can get a tax deduction on purchases, from a certain amount, in any one establishment by obtaining a form at the relevant shop and presenting it to customs on departure.

Key Attractions

Tour Eiffel

The Eiffel Tower literally towers over the Champ de Mars in the smart 7th arrondissement. The top (third) floor offers a sweeping panorama of Paris. From directly underneath there is a fascinating view of the delicate ironwork of Gustave Eiffel, who was commissioned to build the tower for the Exposition Universelle in 1889, the centenary of the French Revolution.

Champ de Mars, 7th

Website: www.tour-eiffel.fr

Transport: Métro Bir-Hakeim; RER Champ de Mars-Tour Eiffel.

Cathédrale de Notre-Dame

The Notre-Dame Cathedral is located on the Ile-de-la-Cité, Bishop Maurice de Sully began construction in 1163 to outshine the new abbey at St-Denis; work was completed in 1345. The result is a Gothic masterpiece, with three stunning rose windows. Visitors can climb the 387 spiral steps to the top of the 75m (246ft) north tower. The views over the River Seine and the city centre are well worth the effort. There is also a Treasury with various liturgical objects on display.

6 Place du Parvis-Notre-Dame, 4th

E-mail: info@cathedraledeparis.com

Website: www.cathedraledeparis.com

Transport: Métro Cité; RER St-Michel-Notre-Dame.

Sacré-Coeur

A long, wide series of steps lead to the snowy-white-domed Sacré-Coeur that dominates Montmartre. A mishmash of styles, the Catholic church was built between 1870 and 1919 to atone for the 'sins' of the Commune. The interior is bright with neo-Byzantine mosaics and the domed tower offers a spectacular view over Paris. The crypt contains an interesting collection of religious relics and a slide show on the construction of the Basilica.

Pavris du Sacré-Coeur, 18th

Website: www.sacre.coeur-montmartre.com

Transport: Métro Abbesses or Anvers.

Musée National du Louvre

The Louvre first opened to the public in 1793 following the Revolution, a showcase of the art treasures of the kings of France. The museum comprises of three wings on four floors: Richelieu (along rue de Rivoli), Sully (around Cour Carrée) and Denon (along the River Seine). The vast permanent collection includes Greek, Etruscan, Roman, Egyptian and Oriental antiquities, French, Spanish, Italian and northern European sculpture and 19th-century objets d'art. The painting collection is the strongest, with French, Italian, Dutch, German, Flemish and Spanish masterpieces from the



mid-13th to the mid-19th centuries. Most famed French works include David's Coronation of Napoléon, Ingres' The Turkish Bath, Géricault's depiction of disaster, The Raft of the Medusa and Delacroix's ode to revolution, Liberty Leading the People. The Mona Lisa, in a bulletproof case, has since 2004 been housed in its own room.

Excavations have exposed traces of the medieval Louvre, which are on display together with the history of the Louvre under the Cour Carrée in the entresol level in the Sully wing.

Cour Napoléon, 1st

E-mail: info@louvrefr

Website: www.louvrefr

Transport: Métro Palais Royal-Musée du Louvre.

About Paris

Musée Rodin

Auguste Rodin (1840-1917) lived and worked in this 18th-century *hôtel particulier*. Now the Rodin Museum, his sculptures are displayed both in the interior and the gardens. Indoors, *The Kiss* portrays eternal passion frozen in white marble, while *The Hand of God* gives life to creamy white, half-formed figures. Works of Rodin's mistress and pupil, Camille Claudel and paintings by Van Gogh, Monet, Renoir and Rodin himself, are also on display. The gardens are graced by the monumental bronze *The Thinker*, whose godly physique contrasts sharply with the decrepitude of the writhing figures of *The Gates of Hell* and the controversial final portrait of Balzac, once described as 'a block that disgraces its author and French Art'.

77 rue de Varenne, 7th

Website: www.musee-rodin.fr

Transport: Métro Varenne.

Musée d'Orsay

The strength of this large museum, housed in a former train station by the River Seine, lies in its collection of Impressionist and Post-Impressionist art. The collection, covering the decisive 1848-1914 period, is arranged chronologically, beginning on the ground floor, jumping to the third, then descending to the middle level. Among the most famous works are Manet's *Déjeuner sur l'Herbe*, rejected from the Salon of 1863; five of Monet's paintings of Rouen Cathedral and the recently acquired realist work, *L'Origine du Monde* by Gustave Courbet, whose graphic depiction of the female sex continues to shock.

Entrances are at 1 rue de la Légion d'Honneur and 1 rue de Bellechasse, 7th

Website: www.musee-orsay.fr

Transport: Métro Solférino; RER Musée d'Orsay.

Musée National Picasso

Paris-based Pablo Picasso (1881-1973) owned most of this collection, the largest worldwide, housed in a 17th-century mansion in the Marais. All phases of his art are represented, with preparatory sketches and paintings covering the Blue Period, Rose Period, Cubism, Classicism, Surrealism and sculptures ranging from a huge plaster head to a small cat. Memorable works include the Blue Period self-portrait *Paolo as Harlequin*, the surreal *Nude in an Armchair* and poignant paintings of Marie-Thérèse. Photographs are displayed alongside the works they inspired and African masks with Picasso's 'primitive' wood carvings. There is also a glimpse of the artist's personal taste in paintings, with his Matisse and Cézanne paintings displayed.

Hôtel Salé, 5 rue de Thorigny, 3rd

Transport: Métro Chemin Vert or St-Paul.

Centre Georges Pompidou

Considered outrageous in 1977, the Pompidou Centre, designed by Piano and Rogers, has become part of the Parisian landscape, primary coloured tubes and all. Although not yet thirty years old, the building has already been revamped and extended to cope with the huge numbers visiting its expanding collection of contemporary art and its multimedia library. It re-opened on the first day of the new millennium, the main focus being the 20th-century collection of the Musée National d'Art Moderne (MNAM).

Place Georges Pompidou, 4th

E-mail: info@cnac-gp.fr

Website: www.centrepompidou.fr

Transport: Métro Hôtel de Ville or Rambuteau;
RER Châtelet-Les Halles.



Congress Hotels

BALMORAL

6, rue du Général Lanzerac
75017 Paris
Phone: +33 1 43 80 30 50
Fax: +33 1 43 80 51 56
www.hotel-balmoral.com
Métro Charles de Gaulle-Etoile line 1

CALIFORNIA

16, rue de Berri
75008 Paris
Phone: +33 1 43 59 93 00
Fax: +33 1 44 95 96 44
www.hotel-california-paris.com
Métro Goerge V line 1

CHATEAU FRONTENAC

54, avenue Pierre Charon
75008 Paris
Phone: +33 1 53 23 13 13
Fax: +33 1 53 23 13 01
www.groupefrontenac.com
Métro Georges V line 1

CHEVERNY

7, Villa Berthier
75017 Paris
Phone: +33 1 43 80 46 42
Fax: +33 1 47 63 26 62
www.parishotelcheverny.com
Métro Porte de Champerret line 3

CLARIDGE

74, avenue des Champs-Élysées
75008 Paris
Phone: +33 1 44 13 33 33
Fax: +33 1 42 25 04 88
www.claridge-paris.com
Métro Georges V line 1

CLARION SAINT JAMES

202, rue de Rivoli
75001 Paris
Phone: +33 1 44 58 43 00
Fax: +33 1 44 58 43 01
www.clarion-st-james.com
Métro Tuileries line 1

CONCORDE LA FAYETTE

3, place du Général Koenig
75017 Paris
Phone: +33 1 40 68 50 68
Fax: +33 1 40 68 51 78
www.concorde-lafayette.com
Métro Porte Maillot line 1

CONCORDE SAINT-LAZARE

108, rue Saint-Lazare
75008 Paris
Phone: +33 1 40 08 44 44
Fax: +33 1 40 08 43 03
www.concordestlazare-paris.com
Métro Saint-Lazare line 6

ETOILE PEREIRE

146, boulevard Pereire
75017 Paris
Phone: +33 1 42 67 60 00
Fax: +33 1 42 67 02 90
www.etoilepereire.com
10 minutes walking or Métro Pereire line 3

FERTEL ETOILE

4, rue des Acacias
75017 Paris
Phone: +33 1 47 66 77 75
Fax: +33 1 47 66 47 90
www.fertelhotels.com
Métro Argentine line 1

FERTEL MAILLOT

269, boulevard Péreire
75017 Paris
Phone: +33 1 44 09 92 92
Fax: +33 1 44 09 94 94
www.fertelhotels.com
Métro Porte Maillot line 1

FLORIDE ETOILE

14, rue St Didier
75116 Paris
Phone: +33 1 47 27 23 36
Fax: +33 1 47 27 82 87
www.floride-paris-hotel.com
Métro Boissière line 6

FRANKLIN ROOSEVELT

18, rue Clément Marot
75008 Paris
Phone: +33 1 53 57 49 50
Fax: +33 1 53 57 49 59
www.hroosevelt.com
Métro Franklin D. Roosevelt line 1

GARDEN ELYSEES

12, rue St Didier
75116 Paris
Phone: +33 1 47 55 01 11
Fax: +33 1 47 27 79 24
www.paris-hotel-gardenelysees.com
Métro Boissière line 6

HILTON ARC DE TRIOMPHE

57, rue Courcelles
75008 Paris
Phone: +33 1 43 80 31 90
Fax: +33 1 58 36 67 77
www.arcdetriompheparis.hilton.com
Métro Courcelles line 2

HILTON SUFFREN

18, avenue de Suffren
75015 Paris
Phone: +33 1 44 38 56 00
Fax: +33 1 44 38 56 10
<http://www.hilton-paris.com/>
Métro Bir-Hakeim line 6



Congress Hotels

HOTEL AMPERE

102, avenue de Villiers
75017 Paris
Phone: +33 1 44 29 17 17
Fax: +33 1 44 29 16 50
www.hotelampere.com
Métro Pereire line 3

HOTEL DU LOUVRE

Place André Malraux
75001 Paris
Phone: +33 1 44 53 38 88
Fax: +33 1 44 58 38 01
www.hoteldulouvre.com
Métro Palais Royal line 1

HOTEL VERNET

25, rue Vernet
75008 PARIS
Phone: +33 1 44 31 98 00
Fax: +33 1 44 31 85 69
http://www.hotelvernet.com
Métro Charles de Gaulle-Etoile line 1

IBIS PARIS LA DEFENSE CENTRE

4, boulevard de Neuilly
La Defense 1 Pont de Neuilly
92081 Paris La Défense Centre
Phone: +33 1 41 97 40 40
Fax: +33 1 41 97 40 50
www.accorhotels.com
Métro Esplanade de la Défense line 1

IBIS PORTE DE CLICHY

163 bis, avenue de Clichy
75017 Paris
Phone: +33 1 40 25 20 00
Fax: +33 1 40 25 26 00
www.accorhotels.com
Métro Porte de Clichy line 13

MAGELLAN

17, rue Jean Baptiste Dumas
75017 Paris
Phone: +33 1 45 72 44 51
Fax: +33 1 40 68 90 36
www.MAGELLAN-HOTEL.COM
10 minutes walking or Métro Pereire
line 3

MERCURE LA DEFENSE 5

18-30, rue Baudin
Place Charras
92400 Courbevoie
Phone: +33 1 49 04 75 00
Fax: +33 1 47 68 83 32
www.mercure.com
Métro Grande Arche La Défense line 1

MERCURE LA DEFENSE ESPLANADE

35, Cours Michelet La Défense 10
92060 Paris La Défense
Phone: +33 1 47 73 90 90
Fax: +33 1 47 76 44 36
www.mercure.com
Métro Grande Arche La Défense line 1

MERCURE LA DEFENSE PARC

17/20, Esplanade Charles de Gaulle
Rue des Trois Fontanot
92000 Nanterre
Phone: +33 1 46 69 68 00
Fax: +33 1 47 25 46 24
www.mercure.com
Métro Grande Arche La défense line 1

MERCURE NEUILLY

199, avenue Charles de Gaulle /
1 avenue de Madrid
92200 Neuilly-sur-Seine
Phone: +33 1 47 47 14 67
Fax: +33 1 47 47 97 42
www.hotel-paris-neuilly.com
Métro Pont de Neuilly line 1

MERCURE TOUR EIFFEL SUFFREN

20, rue Jean Rey
75737 Paris Cedex 15
Phone: +33 1 45 78 50 00
Fax: +33 1 45 78 42 42
www.accorhotels.com
Métro Bir Hakeim line 6

MERCURE WAGRAM ARC DE TRIOMPHE

3, rue Brey
75017 Paris
Phone: +33 1 56 68 00 01
Fax: +33 1 56 68 00 02
www.accorhotels.com
Métro Charles de Gaulle Etoile line 6



MERIDIEN ETOILE

51, boulevard Gouvion-St-Cyr
75017 Paris
Phone: +33 1 40 55 34 34
Fax: +33 1 40 55 31 31
www.lemeridien.fr
Métro Porte Maillot line 1

MERIDIEN MONTPARNASSE

19, rue du Commandant René
Mouchotte
75014 Paris
Phone: +33 1 44 36 44 36
Fax: +33 1 44 36 49 00
www.montparnasse.lemeridien.com
Métro Montparnasse line 4

NEUILLY PARK

23, rue Madeleine Michélin
92200 Neuilly sur Seine
Phone: +33 1 46 40 11 15
Fax: +33 1 46 40 14 78
www.hotelneuilypark.com/
Métro Sablons line 1

NOVOTEL LA DEFENSE

2, boulevard De Neuilly
92081 La Défense
Phone: +33 1 41 45 23 23
Fax: +33 1 41 45 23 24
www.novotel.com
Métro La Défense line 1

NOVOTEL TOUR EIFFEL

61, quai de Grenelle
75015 Paris
Phone: +33 1 40 58 20 00
Fax: +33 1 40 58 24 44
www.accorhotels.com
Métro Bir-Hakeim line 6

PERGOLESE BW

3, rue Pergolèse
75116 Paris
Phone: +33 1 53 64 04 04
Fax: +33 1 53 64 04 40
www.bestwestern.fr
Métro Argentine line 1

QUALITY HOTEL ASTOR

37, rue Pierre Demours
75017 Paris
Phone: +33 1 47 64 67 67
Fax: +33 1 40 53 91 34
www.astor-hotel.com
Métro Charles-De-Gaule Etoile line 1

RADISSON SAS

33, avenue Edouard Vaillant
92100 Boulogne
Phone: +33 1 46 08 85 00
Fax: +33 1 46 08 85 01
www.boulogne.radissonsas.com
Métro Porte de Saint Cloud line 9

ROCHESTER CHAMPS-ELYSEES

92, rue La Boétie
75008 Paris
Phone: +33 1 56 69 69 00
Fax: +33 1 56 69 69 00
www.paris-hotel-rochester.com
Métro Franklin D. Roosevelt line 1

SOFITEL ARC DE TRIOMPHE

15, rue Beaujon
75008 Paris
Phone: +33 1 53 89 50 50
Fax: +33 1 53 89 50 51
www.sofitel.com
Métro Charles de Gaulle- Etoile line 1

SOFITEL LA DEFENSE CENTRE

34, cours Michelet
92060 Paris La Défense Cedex
Phone: +33 1 47 76 72 16
Fax: +33 1 47 76 72 20
www.sofitel.com
Métro La Défense line 1

SOFITEL LA DEFENSE GRANDE ARCHE

11, avenue de l'arche Défense 6
92081 Paris La Défense
Phone: +33 1 47 17 50 76
Fax: +33 1 47 17 50 77
www.sofitel.com
Métro La Défense line 1

SOFITEL LE FAUBOURG

15, rue Boissy d'Anglas
75008 Paris
Phone: +33 1 44 94 14 14
Fax: +33 1 44 94 14 28
www.sofitel.com
Métro Concorde line 8

SPLENDID ETOILE

1, avenue Carnot
75017 Paris
Phone: +33 1 45 72 72 00
Fax: +33 1 45 72 72 01
www.paris-hotel-splendid.com
Métro Charles-de-Gaulle line 1

VILLA MAILLOT

143, avenue Malakoff
75116 Paris
Phone: +33 1 53 64 52 52
Fax: +33 1 45 00 60 61
www.lavillaimailot.fr
Métro Porte Maillot line 1

WARWICK CHAMPS ELYSEES

5, rue de Berri
75008 Paris
Phone: +33 1 45 63 14 11
Fax: +33 1 45 63 75 81
www.warwickparis.com
Métro Georges V line 1





Special session


08:30 - 12:00

Joint Session of the European Association of Urology (EAU) and the Confederaçion Americana de Urologia (CAU)

Room **Concorde 1 Level 4**

Chair: C. Llorente, Madrid (ES)

08:30 - 08:50	EAU: Patient selection for radical prostatectomy G. Aus, Göteborg (SE)	con1-5-1410
08:50 - 09:10	CAU: CT-PET scan identification of cerebral nuclei involved in normal sexual response H. Davila Barrios, Caracas (VE)	con1-5-1420
09:10 - 09:30	EAU: Functional and oncological results of LRP J-U. Stolzenburg, Leipzig (DE)	con1-5-1430
09:30 - 09:50	CAU: Transobturator approach: More than a surgical technique P. Palma, Campiñas (BR)	con1-5-1440
09:50 - 10:10	EAU: Treatment of metastatic prostate cancer T.M. De Reijke, Amsterdam (NL)	con1-5-1450
10:10 - 10:30	CAU: Laparoscopic repair of recto-urinary fistulae R. Sotelo Noguera, Caracas (VE)	con1-5-1460
10:30 - 10:50	EAU: Treatment of neurogenic bladder dysfunction J.L. Ruiz-Cerdá, Valencia (ES)	con1-5-1470
10:50 - 11:10	CAU: Laparoscopic simple prostatectomy for BPH R. Sotelo Noguera, Caracas (VE)	con1-5-1480
11:10 - 11:30	EAU: Chemotherapy for invasive bladder cancer J.A. Witjes, Nijmegen (NL)	con1-5-1490
11:30 - 12:00	Questions	



Session of the International Society for the Study of Aging Male (ISSAM)

09:30 - 11:00

Testosterone and male aging in urological practice

Room 352a/b Level 3

Chairs: G.H.J. Mickisch, Bremen (DE)
B. Lunenfeld, Tel Aviv (IL)

09:30 - 09:33	Introduction G.H.J. Mickisch, Bremen (DE)	352-5-1500
09:33 - 09:51	Incidence, prevalence and diagnosis of late-onset hypogonadism B. Lunenfeld, Tel Aviv (IL)	352-5-1510
09:51 - 10:09	What are the risks and what is the clinical relevance of (late-onset) hypogonadism? H. Behre, Halle (DE)	352-5-1520
10:09 - 10:27	Is there a role for testosterone treatment in daily urological practice? F. Montorsi, Milan (IT)	352-5-1530
10:27 - 10:45	Is testosterone needed for penile erection? A. Yassin, Hamburg (DE)	352-5-1540
10:45 - 10:57	Questions and answers	352-5-1550
10:57 - 11:00	Concluding remarks by chairs	352-5-1560

Aims and objectives

The change in endocrine profiles over a lifespan and the decline of peripheral testosterone affecting a significant percentage of the aging male population is undoubtedly a recognised reality. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the developed world. The symposium is designed to provide a brief overview of the incidence and prevalence of late-onset hypogonadism (LOH). Based on the ISSAM/ISA /EAU recommendations on diagnosis and management of LOH, an attempt will be made to define LOH and to answer the principal questions of whether older hypogonadal men will benefit from testosterone treatment, what risks are associated with such intervention and whether there is a role for testosterone treatment in daily urological practice.

Abstract Session

12:45 - 14:15

Surgical anatomy in laparoscopic radical prostatectomy

eURO Auditorium Level 1

Video Session 1

Chairs: *I.J. De Jong, Groningen (NL)*
R. Gaston, Bordeaux (FR)

All presentations are 14 minutes in length

- V1 Anatomical features and dissection of the accessory pudendal arteries during laparoscopic radical prostatectomy** eURO-5-1660
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, X. Taccoen, C. Deruelle, L. Doucet, A. Volant, O. Cussenot (Brest, Paris, France)
- V2 Laparoscopic radical prostatectomy, preservation of accessory pudendal arteries** eURO-5-1670
L. Martínez-Piñeiro, J.R. Cansino, F. Cáceres, A. Tabernerero, J. Cisneros, J.J. De La Peña (Madrid, Spain)
- V3 Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy** eURO-5-1680
F. Secin, N. Karanikolas, J.I. Martinez Salamanca, F. Bianco, K. Touijer, B. Guilloneau (New York, United States of America)
- V4 Neurovascular bundle dissection: Interfascial, extrafascial and full resection techniques** eURO-5-1690
F. Secin, A.J. Stephenson, N. Karanikolas, Z. Dotan, K. Touijer, B. Guilloneau (New York, United States of America)
- V5 Description of the surgical anatomy of the fascias surrounding the prostate during laparoscopic radical prostatectomy** eURO-5-1700
G. Fournier, A. Valeri, A. Rammal, V. Joulin, D. John, X. Taccoen, C. Deruelle, L. Doucet, A. Volant, O. Cussenot (Brest, Paris, France)
- V6 How to prevent iatrogenic capsular incision during laparoscopic nerve-sparing radical prostatectomy** eURO-5-1710
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, C. Deruelle, L. Cormier, X. Taccoen, L. Doucet, A. Volant (Brest, Nancy, France)

Abstract Session

12:45 - 14:15

Urothelial tumours: Management of infiltrative/ advanced tumours I

Room **Blue** Level 2

Oral Session 1

Chairs: *M.A. Kuczyk, Tübingen (DE)*

G.N. Thalmann, Berne (CH)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

M.A. Kuczyk, Tübingen (DE)

blue-5-1720

- 1 Comparative study for oncological outcome following laparoscopic nephroureterectomy or standard nephroureterectomy for upper urinary tract transitional cell carcinoma**
D. Manabe, T. Saika, S. Ebara, S. Uehara, A. Nagai, R. Fujita, S. Irie, D. Yamada, T. Tsushima, Y. Nasu, H. Kumon (Okayama, Kure, Kanonji, Japan)
blue-5-1730
 - 2 Laparoscopic radical cystectomy: Review of 100 cases**
R. Gaston, S. Barmoshe, A. Pansadoro, E. Lufuma, C. Mugnier, J.L. Hoepffner, T. Piechaud (Bordeaux, France; Brussels, Belgium)
blue-5-1740
 - 3 Prognostic risk factors for survival following adjuvant chemotherapy for locally advanced urothelial bladder cancer**
D. Pfister, C. Ohlmann, E. Özgür, U. Engelmann, A. Heidenreich (Cologne, Germany)
blue-5-1750
 - 4 Recurrence of transitional cell carcinoma of the bladder after radical cystectomy: Therapy and outcome**
J. Gschwend, G.J. Bartsch, M. Straub, R. Kuefer, R. Hautmann, B. Volkmer (Ulm, Germany)
blue-5-1760
 - 5 Early versus late cystectomy for T1G3 transitional cell carcinoma (TCC) of the bladder**
B. Volkmer, R. Hautmann, J. Gschwend (Ulm, Germany)
blue-5-1770
 - 6 Time to cystectomy - its influence on overall survival**
P. Cathcart, J. Armitage, M. Emberton (London, United Kingdom)
blue-5-1780
 - 7 Survival following cystectomy for primary muscle invasive bladder transitional cell carcinoma versus invasion on top of superficial disease**
B. Ali-el-Dein, M. Abdel-Latif, A. Mosbah, A. Shaaban, A. Nabeeh, E.I. Ibrahiem, H.A. El-Kappany (Mansoura, Egypt)
blue-5-1790
 - 8 Is orthotopic neobladder replacement a good derivation solution in morbid obesity patients after cystectomy for cancer?**
F. Thibault, T. Leuret, L. Yonneau, J. Herve, S. Elard, J.E. Poulain, P.M. Lugagne, F. Saporta, J.L. Orsoni, M. Butreau, H. Botto (Suresnes, France)
blue-5-1800
- Summary**
G.N. Thalmann, Berne (CH) blue-5-1810

Poster Session 1

Chairs: P. Hedlund, Lund (SE)
S. Ückert, Hanover (DE)

Study for 30 min. Interactive discussion for 60 min.

- 9 **The mechanisms for diminished erectile function in an animal model of binge cocaine use**
M. Kendirci, L. Pradhan, L. Trost, S. Chandra, K.C. Agrawal, W.J.G. Hellstrom (New Orleans, United States of America)
- 10 **Effects of hypertension and captopril-treatment on sexual functions in female rats**
A. Giralardi, P. Nedergaard, K.E. Andersson, E. Kristensen, P. Hedlund (Copenhagen, Denmark; Lund, Sweden)
- 11 **Androgens regulate smooth muscle contractility of human cavernous arteries and corpus cavernosum by non-genomic mechanisms**
E. Waldkirch, S. Ückert, D. Schultheiss, M. Sohn, U. Jonas, C.G. Stief, K.E. Andersson, P. Hedlund (Hanover, Frankfurt, Munich, Germany; Lund, Sweden)
- 12 **Plasma concentration of asymmetric dimethylarginine (ADMA) in relation to erectile dysfunction in patients with and without coronary artery disease**
K. Rokkas, C. Vlachopoulos, N. Ioakeimidis, C. Vassiliadi, K. Aznaouridis, M. Toutouza, A. Askitis, C. Stefanadis (Athens, Greece)
- 13 **Down-regulation of angiogenic factors and their downstream target molecules affect the deterioration of erectile function in a rat model of hypercholesterolaemia**
D. Seong, J. Ryu, S. Yoon, H. Shin, S.U. Song, S. Piao, L.W. Zhang, J. Han, J. Suh (Incheon, South Korea)
- 14 **Distribution of rho-kinase-related proteins and effects of Y27632 in human cavernous arteries**
E. Waldkirch, S. Ückert, M. Sohn, U. Jonas, C.G. Stief, K.E. Andersson, P. Hedlund (Hanover, Frankfurt, Munich, Germany; Lund, Sweden)
- 15 **The feasibility of ex vivo expanded marrow stromal cells (stem cells) genetically modified with eNOS for improving erectile function in diabetic rats**
M. Kendirci, W. Deng, T.J. Bivalacqua, P.J. Kadowitz, W.J.G. Hellstrom (New Orleans, Baltimore, United States of America)
- 16 **Transplantation of non-haematopoietic adult bone marrow stem cells isolated by the p75 nerve growth factor into the penis promotes recovery of erectile function in a rat model of cavernous nerve injury**
M. Kendirci, J.L. Spees, L. Trost, M.J. Whitney, D.J. Prockop, W.J.G. Hellstrom (New Orleans, United States of America)
- 17 **Non-invasive monitoring the transplanted human mesenchymal stem cells in the penis using molecular magnetic resonance image**
Y.S. Song, K.H. Lee, Y.H. Park, J.H. Kim, D.H. Choi, J.H. Won (Seoul, South Korea)

- 18 **Structural and molecular analysis of erectile nerve repair**
F. May, K. Matiasek, C. Arndt, T. Maurer, A. Lehmer, M. Vroemen, A. Blesch, N. Weidner, B. Gansbacher, R. Hartung, D. Sauer, M. Apprich (Munich, Germany; San Diego, United States of America)
- 19 **Differences between BMP-2 and TGF- β 1 stimulation of fibroblast cultures from the plaque of Peyronie's disease**
S.M. Haag, E.W. Hauck, C. Szardening-kirchner, T. Diemer, O. Eickelberg, W. Weidner (Giessen, Germany)
- 20 **The effect of epimedium brevicornum maxim extract on clitoral intracavernous pressure in the rabbit**
K. Chen, J. Chiu, L.S. Chang (Taipei, Taiwan)
- 21 **Different tissue cell turnover in the rat penis during aging: A comparative study**
C. Costa, N. Tomada, P. Vendeira, H. Almeida, J. Santos, D. Magalhães (Porto, Portugal)
- 22 **Significance of the nitric oxide (NO) pathway in the control of human vaginal tissue: A functional and immunohistochemical study**
S. Ückert, K. Richter, V. Nüser, K. Albrecht, F. Scheller, U. Jonas, G. Wolf (Hanover, Magdeburg, Germany)
- 23 **Therapeutic prospects for PEDF and its peptides in nerve regeneration on cultured major pelvic and spinal cord ganglia**
T. Nelius, S. Filleur, F. Reiher, E.P. Allhoff, O. Volpert (Magdeburg, Germany; Chicago, United States of America)

Poster Session 2

Chairs: *E. Oosterwijk, Nijmegen (NL)*
D.G. Rohde, Darmstadt (DE)

Study for 30 min. Interactive discussion for 60 min.

- 24 **PTEN independent activation of the PKB/AKT pathway in renal cell cancer and inactivation of P27kip by phosphorylation at T157**
J. Hennenlotter, [A.S. Merseburger](#), P.A. Ohneseit, P. Simon, A. Stenzl, M. Kuczyk (Tübingen, Germany)
- 25 **Correlation of p16INK4 expression in renal cell carcinoma with clinicopathological parameters**
S.O. Ikuero, M.A. Kuczyk, R. Von Wasielewski, O.B. Shittu, U. Jonas, S. Machtens, [J. Serth](#) (Ibadan, Nigeria; Tübingen, Hanover, Germany)
- 26 **Fruits and vegetables and renal cell carcinoma: Findings from the European prospective investigation into cancer and nutrition (EPIC)**
[S. Weikert](#), H. Boeing, K. Miller, F. Buechner, B. Ljungberg, N. Allen, T. Norat (Berlin, Nuthetal, Germany; Bilthoven, The Netherlands; Umea, Sweden; Oxford, United Kingdom; Lyon, France)
- 27 **The development of tumour specific immunity induced by cryosurgery in murine renal cell carcinoma animal model**
[S.H. Kang](#), J.H. Bae, K.S. Shim, H.S. Park, D.G. Moon, J.J. Kim, D.K. Yoon, J. Cheon (Seoul, South Korea)
- 28 **VEGF pathway is involved in antitumour and antiangiogenic effect of arginine deiminase on renal cell carcinoma**
[C. Yoon](#), D. Yoon, Y. Shim, E. Kim, K. Chae, J. Lee, C. Kim, N. Won, B. Min, D. Yoon (Seoul, Chungju, South Korea)
- 29 **Decreased p27kip protein expression as determined by tissue microarray analysis (TMA) predicts the clinical prognosis of renal cell cancer patients**
[M. Kuczyk](#), [J. Serth](#), M. Mengel, E. Von Der Heyde, [A.S. Merseburger](#), J. Hennenlotter, A. Stenzl, U. Jonas (Tübingen, Hanover, Germany)
- 30 **Quest for the adult human renal stem cell-isolation and characterisation of a stem cell enriched side population using Hoechst dye efflux method**
[S. Addla](#), C. Hart, V. Ramani, M. Brown, N. Clarke (Manchester, United Kingdom)
- 31 **Nucleostemin mRNA is expressed in both normal and malignant renal tissues**
[X. Fang](#), Y. Fan, Z. Liu, S. Zhao, P. Ekman, D. Xu (Jinan, China; Stockholm, Sweden)
- 32 **BFGF expression in renal cell cancer: Correlation with clinical and histological features by tissue microarray analysis and measurement of serum levels**
M. Horstmann, [A.S. Merseburger](#), E. Von Der Heyde, [J. Serth](#), G. Wegener, M. Mengel, G. Feil, J. Hennenlotter, K-D. Sievert, A. Stenzl, [M. Kuczyk](#) (Tübingen, Hanover, Germany)

- 33 **Activation combined biomarkers PI3K and p-Akt is associated with reduced survival in renal cell carcinoma**
J. Hennenlotter, A.S. Merseburger, U. Kühns, M. Horstmann, A. Stenzl, M. Kuczyk (Tübingen, Germany)
- 34 **Curcumin sensitises tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis through CCAAT/enhancer-binding protein homologous protein independent DR5 up-regulation**
D.G. Kim, H.I. Lee, I.R. Cho, H.C. Jung, J.S. Park, K.S. Lee (Gyeongju, Goyang, Daegu, South Korea)
- 35 **Correlation of RAS association family 1A gene expression in renal cell carcinoma with pathological parameters and survival of patients**
H. Tezval, M.A. Kuczyk, U. Jonas, S. Machtens, J. Serth (Hanover, Tübingen, Germany)
- 36 **A renal cancer (RENCA) vaccine inhibits tumour growth in the murine RENCA model**
C. Doehn, N. Esser, H. Pauels, D. Jocham, J. Drevs (Lübeck, Freiburg, Gronau, Germany)
- 37 **Prognostic significance of intratumoural DNA content heterogeneity on multiple fresh samples of renal cell carcinoma: A follow-up study on 132 patients**
E. Leonardi, L.G. Luciani, C. Divan, F. Coccarelli, A. Reich, P. Dalla Palma, G. Malossini (Trento, Italy)
- 38 **Quantitative analysis of RAS association family 1a gene (RASSF1A) promoter methylation in renal cell carcinoma, peritumoural and normal renal parenchyma**
I. Peters, T. Eilers, M.A. Kuczyk, J. Hennenlötter, K. Albrecht, N. Wilke, S. Machtens, U. Jonas, J. Serth (Hanover, Tübingen, Germany)

Poster Session 3

Chairs: T. Esen, Istanbul (TR)
A. Patel, London (GB)

Study for 30 min. Interactive discussion for 60 min.

- 39 Relaxant effect of drotaverine (No-Spa®) in human isolated ureteral rings**
S. Palea, P. Robineau, P. Rischmann, P. Lluel (Toulouse, Paris, France)
- 40 The effect of xanthine oxidase inhibitors on com crystal-renal epithelial cell interaction**
K. Nagatsuma, H. Asakura, S. Matsuzaki, M. Murai (Tokyo, Japan)
- 41 In vitro effects of PDE-5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle**
C. Gratzke, B. Schlenker, S. Uckert, G. Kedia, F. Scheller, O. Reich, A. Becker, C. Stief (Munich, Hanover, Germany)
- 42 Calcium oxalate monohydrate crystals inhibit the expression of heat shock protein 25 in canine renal distal tubule cells**
A. Patel, S. Choong, W. Robertson, J. Hothersall (London, United Kingdom)
- 44 Impact of ascorbic acid on cystine stone formation - evaluation in the animal model**
S. Sagi, Y. Cao, A. Haecker, M.S. Michel, P. Alken, T. Knoll (Mannheim, Germany)
- 45 A new in vitro model for cystinuria type 1 by RNAi transfection**
S. Sagi, Y. Cao, A. Haecker, P. Alken, M.S. Michel, T. Knoll (Mannheim, Germany)
- 46 Use of the ureteric pressure transducer catheter to monitor the human ureteric response to smooth muscle relaxant drugs in vivo**
K. Davenport, A. Timoney, F. Keeley (Bristol, United Kingdom)
- 47 Does sildenafil citrate reverse shock wave induced renal trauma in rabbit model?**
A. Simsir, B. Turna, O. Nazli, N. Cikili (Izmir, Turkey)
- 48 Double-blind, placebo controlled comparison of therapeutic effect of morphine and ketoprofen in monotherapy and in association varus desmopressin for acute renal colic: About 120 patients**
S. Ben Rhouma, S. Sallami, I. Bensalah, M. Chelif, G.H. Hafsia, Y. Nouria, A. Horchani (Tunis Jabbari, Tunis, Tunisia)
- 49 Prospective long-term follow-up of patients with asymptomatic lower pole caliceal stones**
K. Inci, A. Sahin, E. Islamoglu, E. Ozden, M. Bakkaloglu, H. Ozen (Ankara, Turkey)
- 50 What is the role of corticosteroid therapy in the management of distal ureteral stones in emergency?**
F. Porpiglia, D. Vaccino, M. Billia, G. Ghignone, J. Renard, F. Musso, S. Grande, C. Scoffone, R.M. Scarpa (Orbassano, Torino, Italy)

- 51 Doxazosin for the management of distal ureteral stones**
E. Liatsikos, [T. Voudoukis](#), P. Katsakiori, K. Asimakopoulos, A. Athanasopoulos, P. Perimenis, J. Stolzenburg (Patras, Greece; Leipzig, Germany)
- 52 Is daily diuresis risk factor for calcium oxalate stone formation?**
[D. Milenkovic-petronic](#), A. Vuksanovic, N. Lalic, C. Tulic, M. Kozomara, S. Dragicevic (Belgrade, Serbia and Montenegro)
- 53 The influence of diet on urinary cystine excretion**
[R. Siener](#), A. Hesse (Bonn, Germany)

Poster Session 4

Chairs: S. Machtens, Hanover (DE)
O. Nativ, Haifa (IL)

Study for 30 min. Interactive discussion for 60 min.

- 54 **Can histone deacetylase inhibitors (HDACI) delay epithelial cancers progression? - epidemiological evaluation of cancer prevalence in patients treated with valproic acid (VPA)**
M. Cohen, R. Rodriguez, Y. Mecz, A. Stein, G. Rennert (Haifa, Israel; Baltimore, United States of America)
- 55 **Targeting novel nuclear receptors with histone deacetylase inhibitor combination therapy in bladder cancer**
S.A. Abedin, A. Veerakumarasivam, J. Kelly, D.E. Neal, I. Mills, M. Campbell (Birmingham, Cambridge, United Kingdom)
- 56 **Superficial urothelial bladder tumours: Identification of a set of gene candidates to distinguish pTa and pT1 stages**
F. Descotes, M. Decaussin, C. Grenot, J.L. Campos Fernandes, J. Andre, M. Devonec, P. Paparel, P.P. Binguier, P. Perrin, A. Ruffion (Pierre Bénite, Lyon, France)
- 57 **A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder**
D. Yates, I. Rehman, S. Cross, M. Meuth, F. Hamdy, J.W. Catto (Sheffield, United Kingdom)
- 58 **Novel pro-apoptotic genes regularly methylated and associated with recurrence in superficial and muscle-invasive bladder cancer**
F. Christoph, S. Weikert, C. Kempkensteffen, H. Krause, K. Miller (Berlin, Germany)
- 59 **Genetic and epigenetic mechanism of development and progression of bladder cancer**
W.C. Moon, T.H. Kim, B.S. Shim, Y.S. Kim, C.H. Noh, M.R. Oh (Seoul, South Korea)
- 60 **Exploration of key genes modulating sensitivity against epidermal growth factor receptor tyrosine kinase inhibitor (GEFITINIB) in human bladder cancer cell lines**
R. Inoue, H. Matsuyama, S. Yano, Y. Yamamoto, C. Ohmi, S. Sakano, N. Iizuka, K. Naito (Ube, Japan)
- 61 **Competing risks nomogram predicting the probability of bladder cancer recurrence after cystectomy can reliably distinguish between those destined to recur and those who may die of other causes before recurrence**
K.F. Chun, A. Briganti, S.F. Shariat, G. Palapattu, Y. Lotan, C. Rogers, P. Bastian, A. Gilad, A. Gupta, A. Vazina, M. Nielson, A. Sagalowsky, S. Lerner, M. Schoenberg, P.I. Karakiewicz (Montreal, Canada; Dallas, Baltimore, Houston, United States of America)
- 62 **Improvement of anti-angiogenic and anti-tumourigenic efficacy of thrombospondin-1 by PPAR ligands in bladder cancer**
T. Nelius, H. Huang, S. Filleur, S. Campbell, E.P. Allhoff, O. Volpert (Magdeburg, Germany; Chicago, United States of America)

- 63 Multitarget gene inhibition by synthetic nucleic acids in bladder cancer cells**
Y. Burmeister, K. Kraemer, S. Fuessele, M. Kotsch, A. Meye, O.W. Hakenberg, M.P. Wirth (Dresden, Germany)
- 64 Proteomics urine samples analysis of healthy versus transitional cell carcinoma patients utilising surface enhanced laser desorption ionisation time of flight mass spectrometry**
M. Mullerad, H.J. Issaq, A. Kravtsov, D. Prieto, B. Luke, T.D. Veenstra, E. Issaq, O. Nativ (Haifa, Israel; Frederick, United States of America)
- 66 Targeting bladder tumour cells in vivo and in the urine by a peptide identified using phage display**
E.S. Yoo, B. Lee, T.G. Kwon, S.K. Chung, B.W. Kim, D.Y. Kim, C.H. Park, Y.K. Park (Daegu, South Korea)
- 67 The in vivo activation of the fas death receptor pathway in transitional cell carcinoma of the bladder following treatment with mitomycin-C**
H.F. O' Kane, C. Watson, P. Hyland, R. Johnston, K. Williamson (Belfast, United Kingdom)
- 68 Multidetector CT urography in the evaluation of the urinary tract**
A. Tsili, C. Tsampoulas, D. Giannakis, P. Tzoumis, D. Dristiliaris, N. Sofikitis, S. Efremidis (Ioannina, Greece)

Poster Session 5

Chairs: *K-E. Andersson, Lund (SE)*
H. Bruschini, Sao Paulo (BR)

Study for 30 min. Interactive discussion for 60 min.

- 69 **Improvement of urethral closure pressures after application of myoblasts depends on the number of injected cells**
M. Mitterberger, G. Klima, H. Fritsch, G.M. Pinggera, G. Bartsch, H. Strasser (Innsbruck, Austria)
- 70 **Transurethral ultrasound guided stem cell therapy of urinary incontinence**
H. Strasser, R. Marksteiner, E. Margreiter, M. Mitterberger, G.M. Pinggera, F. Frauscher, S. Hering, G. Bartsch (Innsbruck, Austria)
- 71 **Normal female sphincter macro- and microanatomy: Studies including fetal histology and intraurethral ultrasound**
P. Rehder, A. Weinseisen, J. Neyer, L. Pallwein, F. Frauscher, G. Pinggera, G. Bartsch, C. Gozzi (Innsbruck, Austria)
- 72 **Urinary glycosaminoglycan excretion in postmenopausal women with and without hormone replacement therapy**
J. Brollo, M. Maroclo, F. Sampaio, L. Cardoso (Rio De Janeiro, Brazil)
- 73 **Second messenger pathways following detrusor M3 receptor stimulation**
D. Daly, R. Chess-Williams, C. Chapple (Sheffield, United Kingdom)
- 74 **Abolition by estrogen of neuronal nitric oxide synthase smooth muscle relaxation in the female mice urethra**
X. Gamé, F. Praddaude, J.L. Arnal, G. Escourrou, I. Tack, J. Allard, P. Rischmann, J.L. Ader, J.P. Sarramon, B. Malavaud (Toulouse, France)
- 75 **Glycosaminoglycans behaviour following protamine induced cystitis in rats**
R. Soler, H. Bruschini, J.C. Truzzi, M.T. Alves, K.R. Leite, N.O. Camara, A. Mendes, J.R. Martins, L.G. Pimentel, H. Nader, M. Srougi, V. Ortiz (Sao Paulo, Brazil)
- 76 **Excretion of urinary glycosaminoglycans during normal pregnancy and puerperium in young women**
M. Maroclo, C. Cabral, S. Pereira, F. Sampaio, L. Cardoso (Rio De Janeiro, Brazil)
- 77 **Composition of urothelial extracellular matrix in normal young men and women**
M. Maroclo, C. Cabral, F. Sampaio, L. Cardoso (Rio de Janeiro, Brazil)
- 78 **The effect of expressions of vasoactive intestinal polypeptide and nicotinamide adenine dinucleotide phosphate diaphorase in the anterior vaginal wall on female urinary incontinence and sexual function**
W. Lee, J.I. Kim, J.Z. Lee, M.K. Chung (Busan, South Korea)
- 79 **The evaluation of ultrasound estimated bladder weight in female overactive bladder**
G. Canepa, M. Garaventa, G. Capponi, F. Campodonico, M. Maffezzini (Genoa, Italy)

- 80 **Intraurethral circumferential sphincter surface EMG: The tool to diagnose intrinsic sphincter deficiency?**
J. Heesakkers, R. Gerretsen (Nijmegen, The Netherlands)
- 81 **Effects of magnetic stimulation in the treatment of pelvic floor dysfunction**
P.J. Voorham - Van Der Zalm, R.C.M. Pelger, A.M. Stiggelbout, H.W. Elzevier, G.A.B. Lycklama A Nijeholt (Leiden, The Netherlands)
- 82 **Three-dimensional transurethral ultrasound: Measurement of dynamic activity of rhabdosphincter and urethra in women**
M. Mitterberger, G.M. Pinggera, A. Klauser, F. Frauscher, G. Bartsch, H. Strasser (Innsbruck, Austria)
- 83 **A call for a severity classification in urinary incontinence – insights from the PURE study**
B. Monz, E. Chartier-Kastler, A. Wagg, G. Samsioe, M. Espuna Pons, C. Hampel, D. Quail, C. Chinn, S. Hunskaar (Ingelheim, Mainz, Germany; Paris, France; London, Surrey, United Kingdom; Lund, Sweden; Barcelona, Spain; Bergen, Norway)

Poster Session 6

Chairs: *M.M. Fisch, Hamburg (DE)*
S.J. Hosseini, Tehran (IR)

Study for 30 min. Interactive discussion for 60 min.

- 85 Urethral ultrasound value in internal urethrotomy**
V. Cauni, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)
- 86 Urethral gray-scale and colour doppler sonography in the diagnostic evaluation of anterior urethral strictures**
A.E. Pelzer, J. Bektic, A.P. Berger, L. Pallwein, T. Akkad, G. Bartsch, W. Horninger (Innsbruck, Austria)
- 87 Buccal patch urethroplasty in men with recurrent urethral strictures**
A. O'Riordan, R. Pickard (Newcastle upon Tyne, United Kingdom)
- 88 Lingual mucosa as an alternative graft for urethroplasty**
A. Simonato, A. Gregori, A. Lissiani, P. Traverso, C. Ambruosi, A. Romagnoli, G. Carmignani (Genoa, Milan, Trieste, Italy)
- 89 Ventral oral mucosal graft (OMG) urethroplasty with spongioplasty by a ventral sagittal urethrotomy for bulbar urethral stricture**
M. Abdus Salam (Dhaka, Bangladesh)
- 90 Buccal mucosa dorsal inlay graft – a new single stage approach for reconstruction of recurrent strictures of the fossa navicularis**
S. Kamp, T. Knoll, A. Haecker, J.K. Badawi, M. Hatzinger, P. Alken (Mannheim, Germany)
- 91 Bulbar urethral stricture repair with buccal mucosa graft**
M. Titta, G. Benedetto, S. Durante, G. Abatangelo, F. Nigro, P. Ferrarese, E. Scremin, L. Cavaretta, A. Tasca (Vicenza, Italy)
- 92 Tissue-engineered buccal mucosa – preliminary results in substitution urethroplasty**
S. Bhargava, S. MacNeil, C.R. Chapple (Sheffield, United Kingdom)
- 93 Genital skin grafts as dorsal onlay for urethral reconstruction**
C. Gozzi, G. Pinggera, A. Pelzer, J. Bektic, G. Bartsch, P. Rehder (Innsbruck, Igls/ Innsbruck, Austria)
- 94 Small intestinal submucosa (SIS) in the treatment of bulbar urethral strictures**
R. Fiala, A. Vidlar, M. Grepl, V. Student, K. Belej, R. Vrtal (Olomouc, Czech Republic)
- 95 Could peritoneum share in solving problems of deficient and/or strictured anterior urethra?**
F.E. Moossa, M. Azooz, K. Farag (Cairo, Egypt)
- 96 Dorsally placed spiral penile flaps versus free grafts for repair of long bulb penile strictures**
A. Abuzeid, A. Abdel Hafez, M. Saleem, A. Badawy, A. Abdel Wahab, M. Ali (Sohag, Egypt)

- 97 **A new option for urethral reconstruction with multilayered urothelium established from bladder washings**
U. Nagele, S. Maurer, G. Feil, C. Bock, J. Krug, K.D. Sievert, A. Stenzl (Tübingen, Germany)
- 98 **Transplantation of organ-specific acellular matrix for urethral reconstruction in humans**
L. Ribeiro-Filho, Á. Sarkis, A. Mitre, P.E. Guimaraes, A. Osaki, H. Shiina, M. Igawa, R. Dahiya, E. Tanagho, M. Srougi (São Paulo, Brazil; Izumo, Japan; San Francisco, United States of America)
- 99 **Management of traumatic posterior urethral stricture – results of a randomised study**
S. Ravichandran, T. Nambirajan, G. Athmalingham (Chennai, India)

Poster Session 7

Chairs: Z. Culig, Innsbruck (AT)
H.Y. Leung, Newcastle upon Tyne (GB)

Study for 30 min. Interactive discussion for 60 min.

- 100 The effect of tissue ischaemia on gene expression in prostate cancer**
T. Schlomm, O. Hellwinkel, E. Näkel, H.K.F. Chun, J. Walz, C. Eichelberg, A. Haese, M. Graefen, H. Sültmann, H. Huland (Hamburg, Heidelberg, Germany)
- 101 The impact of internal standards in mass spectrometry used for pattern analysis of prostate cancer serum**
I. Feuerstein, A.E. Pelzer, C. Fuchsberger, K. Kofler, M. Rainer, H. Klocker, G. Bartsch, G.K. Bonn (Innsbruck, Austria)
- 102 Influence of blood sampling on protein profiling and pattern analysis using maldi mass spectrometry**
A.E. Pelzer, I. Feuerstein, C. Fuchsberger, K. Kofler, W. Horninger, G. Bartsch, G.K. Bonn, H. Klocker (Innsbruck, Austria)
- 103 Analysis of cDNA expression profiles of prostate carcinoma applying a neural network**
R. Kuefer, J. Gschwend, R. Hautmann, A. Chinnaiyan, M. Rubin, H. Kestler (Ulm, Germany; Boston, United States of America)
- 104 Comparative analysis of fibroblast growth factor receptors expression in clinical prostate cancer using tissue microarray**
K. Sahadevan, S. Darby, M. Mathers, C. Robson, H. Leung, V. Gnanapragasam (Newcastle Upon Tyne, United Kingdom)
- 105 Protein profiling with whole prostatic tissues by MALDI**
I. Feuerstein, C. Fuchsberger, K. Kofler, W. Horninger, H. Klocker, G. Bartsch, G.B. Bonn, A.E. Pelzer (Innsbruck, Austria)
- 106 Progression risk assessment in prostate cancer using a novel bioinformatics based genetic model**
B. Wullich, V. Jung, J. Rahnenführer, N. Beerenwinkel, M. Müller, W. Schulz, J. Kamradt, M. Stoeckle (Homburg/Saar, Saarbrücken, Düsseldorf, Germany)
- 107 Genomic characterization of 10 prostate cancer cell lines by microarray based comparative genomic hybridization (arrayCGH)**
J. Kamradt, V. Jung, B. Walker, M. Stöckle, P. Meltzer, B. Wullich (Homburg, Homburg Saar, Germany; Bethesda, United States of America)
- 108 Gene expression analysis of hormone-refractory prostate cancer in transurethral resection samples**
P. Albers, O. Stoss, M. Werther, D. Zielinsky, N. Jost, J. Rüschoff, T. Henkel (Kassel, Germany)
- 109 Comparison of genomic alterations of disseminated tumour cells and the primary tumour from prostate carcinoma patients**
K. Bluemke, C. Karzek, U. Bilkenroth, H. Taubert, A. Melchior, H. Heynemann, P. Fornara (Halle, Germany)

- 110** **Quantitative multigene expression profiling of primary prostate cancer**
A. Meye, U. Schmidt, S. Fuessel, R. Koch, G. Baretton, M. Froehner, M. Wirth (Dresden, Germany)
- 111** **Expression of receptor and non receptor tyrosine kinases in prostate cancer**
P.J. Bastian, S. Kummer, L.C. Heukamp, S.C. Müller, V.R. Alexander (Bonn, Germany)
- 112** **Comparative genomic hybridization (CGH) and spectral karyotyping (SKY) analysis of LNCAP. sublines**
G.N. Thalmann, J. Philips, A. Afonso, L. Chung (Berne, Switzerland; New York, Atlanta, United States of America)
- 113** **Tissue microarray analyses of multiple biomarkers as candidate prognostic indicators for predicting relapse following radical prostatectomy**
J. Nariculam, A. Freeman, M. Feneley, J. Masters (London, United Kingdom)
- 114** **Methylation profile of N33, HIC, GSTP1 and CDKN2 at different stages of prostate carcinogenesis**
B. Alekseev, P. Shegai, T. Kekeeva, M. Nemtsova, D. Zaletaev, I. Rusakov (Moscow, Russia)

Abstract Session

12:45 - 14:15

Laparoscopic radical prostatectomy and robotic surgery I

Room **Concorde 2 Level 4**

Poster Session 8

Chairs: *S. Deger, Berlin (DE)*

T. Sulser, Basel (CH)

Study for 30 min. Interactive discussion for 60 min.

- 115 An animal model for heat distribution around endoshears coagulation devices - applications for laparoscopic nerve sparing surgery**
R. Katz, Y. Danai, O. Gofrit, E. Peleg, D. Adler, D. Pode (Jerusalem, Israel)
- 116 Anatomical retrograde laparoscopic prostatectomy improves post operative erections without increasing of surgical margins: A comparative study**
M. Colombel, F. Mege Lechevallier, J.M. Marechal, L. Poissonnier, F.J. Murat, E. Pricaz, A. Gelet, M. Xavier (Lyon, France)
- 117 From standard laparoscopic to robotic extraperitoneal prostatectomy: Evolution in 350 cases**
H. John, N. Engel, C. Brugnolaro, M. Muentener, R. Strebel, D.M. Schmid, D. Hauri, P. Jaeger (Zurich, Switzerland)
- 118 The significance of positive surgical margins ≤ 1 mm after laparoscopic radical prostatectomy**
X. Cathelineau, J. Harmon, F. Rozet, E. Barret, G. Vallancien (Paris, France)
- 119 Performance and functional outcome of endoscopic extraperitoneal radical prostatectomy in relation to obesity - an assessment of 500 patients**
E. Liatsikos, S. Mühlstädt, R. Rabenalt, M. Do, L.C. Horn, M.C. Truss, J. Stoljenburg (Rio - Patras, Greece; Leipzig, Dortmund, Germany)
- 120 Extraperitoneal robot assisted radical prostatectomy-outcome in >400 patients**
J. Joseph, J. Boczko, D. Golijanin, I. Vicente, M. Mathe, E. Erturk, H. Patel (Rochester, United States of America; London, United Kingdom)
- 121 The radius surgical system - a new device for laparoscopic radical prostatectomy?**
T. Frede, A. Hammady, J. Klein, D. Teber, G. Buess, J. Rassweiler (Müllheim, Heilbronn, Tübingen, Germany)
- 122 Comparison of laparoscopic radical prostatectomy with and without previous trans urethral prostate resection**
Y. Ménard, G. Guichard, A. Hoznek, A. De La Taille, R. Yiu, D. Vordos, Y. Allory, C.C. Abbou, L. Salomon (Creteil, France)
- 123 The arrival of microrobots in urologic surgery**
J. Joseph, D. Oleynik, M. Rentschler, J. Boczko, H. Patel (Rochester, Omaha, United States of America; London, United Kingdom)
- 124 Radical prostatectomy: Morbidity of the robotic versus the laparoscopic approach**
F. Rozet, G. Braud, X. Cathelineau, E. Barret, J. Harmon, D. Almeida, G. Vallancien (Paris, France)

- 125** **The outcome of laparoscopic extraperitoneal radical prostatectomy in patients with high body mass index, prior pelvic surgery, and large prostate size**
A. Rodriguez, D. Buethe, J. Pow-Sang (Tampa, United States of America)
- 126** **Laparoscopic radical prostatectomy: The impact of obesity**
J. Ooi, T. Gianduzzo, C. Chang, D. Moon, R. Singh, N. Patil, C. Eden (Basingstoke, United Kingdom)
- 127** **Restoration of posterior aspects of striated sphincter shortens time to continence in video laparoradical prostatectomy. A prospective randomised trial**
B. Rocco, S. Stener, A. Bozzola, S. Galli, A. Gregori, F. Scieri, A. Scaburri, M.C. Paoletti, F. Gaboardi (Milan, Firenze, Italy)
- 128** **Modular training for residents with no prior experience with open pelvic surgery in endoscopic extra-peritoneal radical prostatectomy**
R. Rabenalt, J. Stolzenburg, M. Do, L.C. Horn, S. Bhanot, C. Anderson, E. Liatsikos (Leipzig, Germany; London, United Kingdom; Patras, Greece)
- 129** **Impact of previous abdominal surgery, on the feasibility and morbidity of transperitoneal laparoscopic radical prostatectomy**
G. Fournier, C. Deruelle, A. Rammal, V. Joulin, X. Taccoen, A. Valeri (Brest, France)

Abstract Session

12:45 - 14:15

Metastatic prostate cancer: Skeletal issues

Room **Concorde 3 Level 4**

Poster Session 9

Chairs: *J.B. Anderson, Sheffield (GB)*
R.C.M. Pelger, Leiden (NL)

Study for 30 min. Interactive discussion for 60 min.

- 130 Predictors of clinical outcome in patients with prostate cancer and bone metastases: Prognostic significance of fractures and bone markers**
F. Saad, R.E. Coleman, R. Cook, J.E. Brown, M. Smith, Y. Hei, Y. Chen (Montreal, Waterloo, Canada; Sheffield, United Kingdom; Boston, East Hanover, United States of America)
- 131 The role of daily calcium intake on bone mineral density in patients with prostate cancer under androgen suppression**
J. Planas, C. Salvador, A. Orsola, J.M. Abascal, H. Trilla, L. Cecchini, C.X. Raventós, J. Morote (Barcelona, Spain)
- 132 Comparison of serum bone turnover markers and pain scores in bone metastases due to hormone refractory prostate cancer (HRPCa): Effects of combined and repeated zoledronic acid and docetaxel-based chemotherapy**
A. Hegele, H.G. Wahl, A.J. Schrader, S. Sevinc, L. Koliva, R. Hofmann, P. Olbert (Marburg, Germany)
- 133 Changes in bone mineral density in prostate cancer patients under androgen suppression during the first two years of treatment**
E. Trilla, J.M. Abascal, J. Planas, A. Orsola, L. Cecchini, C.X. Raventós, J. Morote, G. Encabo (Barcelona, Spain)
- 134 Prevalence of osteoporosis in prostate cancer patients under androgen suppression**
J. Planas, J.M. Abascal, A. Orsola, E. Trilla, C.X. Raventós, L. Cecchini, G. Encabo, J. Morote (Barcelona, Spain)
- 135 Persistence and compliance (adherence) with oral bisphosphonates in prostate cancer patients**
A. Hoer, H. Gothe, V. Barghout, G. Schiffforst, B. Hauessler (Berlin, Germany; Florham Park, United States of America)
- 136 Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?**
V. Wadhwa, J. Rosser, N. Parr (Upton, Wirral, United Kingdom)
- 137 Bone turnover parameters ICTP and PINP are promising serum markers for diagnosis and therapy monitoring of bone metastases in prostate cancer patients**
G. Feil, S. Feyerabend, A.G. Anastasiadis, C. Bock, A. Stenzl (Tübingen, Germany)
- 138 The use of incadronate disodium injection for bone metastases of prostate cancer**
P. Espina, A. Uy (Quezon City, Philippines)
- 139 Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer**
R. Casey, W. Love, C. Mendoza, D. Reymond, M. Zarenda (Oakville, Dorval, Mississauga, Canada)

- 141** **Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases**
F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian (Montreal, Canada; Tucson, Long Beach, United States of America; Victoria, Australia)
- 142** **Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer**
V. Depuy, K. Anstrom, L. Castel, K. Schulman, F. Saad, V. Barghout, K. Weinfurt (Durham, Chapel Hill, Florham Park, United States of America; Montreal, Canada)
- 143** **Efficacy of radiotherapy in pain and spinal cord compression syndrome treatment from bone metastases in prostate cancer patients with low performance status and life expectancy**
P. Milecki, Z. Kwias (Poznan, Poland)
- 144** **Chronic pulmonary disease is an independent prognostic factor for advanced prostate cancer**
C.W. Jeong, S.K. Hong, H. Jeong, C. Kwak, E. Lee, S.E. Lee (Seoul, Seongnam, Gyeonggi, South Korea)

Wednesday, 5 April - EAU Programme

Abstract Session

14:30 - 16:00

Advances in laparoscopic pelvic surgery

eURO Auditorium Level 1

Video Session 2

Chairs: A. Alcaraz, Barcelona (ES)
H. Baumert, Paris (FR)

All presentations are 14 minutes in length

- | | | |
|------------|--|-------------|
| V7 | Laparoscopic partial cystectomy for bladder müllerianosis
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy) | eURO-5-1820 |
| V8 | Laparoscopic radical cystectomy in female
F. Gaboardi, A. Bozzola, S. Galli, A. Gregori, F. Scieri, S. Stener, B. Rocco (Milan, Italy) | eURO-5-1830 |
| V9 | Laparoscopic radical cystectomy with neobladder acc. to Studer
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy) | eURO-5-1840 |
| V10 | Laparoscopic radical cystectomy with bladder replacement
L. Cecchini, A. Orsola, C. Raventos, E. Trilla, J. Planas, C. Salvador, J. Morote (Barcelona, Spain) | eURO-5-1850 |
| V11 | Transvesical laparoscopic diverticulectomy
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy) | eURO-5-1860 |
| V12 | Endoscopic lymphadenectomy for penile carcinoma
R. Sotelo, A.J. García, R. Sánchez Salas, O. Carmona, R. Dubois, F. Cornejo, M. Mariano, G. Neiva, A. Finelli (Caracas, Venezuela; Quito, Ecuador; Porto Alegre, Goiania, Brazil; Toronto, Canada) | eURO-5-1870 |

Abstract Session

14:30 - 16:00

Urological reconstruction I

Room **Blue** Level 2

Oral Session 2

Chairs: *J.E. Gschwend, Ulm (DE)*
A.R. Mundy, London (GB)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

J.E. Gschwend, Ulm (DE) blue-5-1880

145 **In vitro prevascularisation of biological matrices with human bladder microvascular endothelial cells can be stimulated by bone marrow mesenchymal progenitor cells** blue-5-1890
G. Ram-Liebig, M. Haase, G. Baretton, M.P. Wirth (Dresden, Germany)

147 **Intraligineous N-butyl-2-cyanoacrylate (histoacryl)** blue-5-1910
F.E. Moossa, M. Azooz, K. Farag, H. Khattab, H. Azooz (Cairo, Egypt)

148 **Utility of an everting sheath to dilate urethral strictures** blue-5-1920
C. Adam, P. Weidlich, R. Horvath, R. Sroka, C. Stief (Munich, Germany)

149 **Biocompatibility of new bioactive biodegradable urethral stents** blue-5-1930
A. Kotsar, T. Isotalo, I. Uurto, J. Mikkonen, M. Kellomäki, M. Talja, T.L.J. Tammela (Tampere, Lahti, Finland)

150 **Endosew: The new laparoscopic sewing-machine** blue-5-1940
B. Brehmer, C. Moll, G. Jakse (Aachen, Germany)

151 **Determining the optimal frequency of skill labs for training and skill retention on endoscopic suturing** blue-5-1950
G. De Win, B. Van Cleynenbreugel, D. De Ridder, M. Miserez (Leuven, Belgium)

Summary

A.R. Mundy, London (GB) blue-5-1960



Abstract Session

14:30 - 16:00

Prostate cancer stem cells

Room Bordeaux Level 3

Oral Session 3

Chairs: M. Cecchini, Berne (CH)

N.J. Maitland, York (GB)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

N.J. Maitland, York (GB)

bord-5-1980

- 153 The human androgen receptor gene is a primary target of the Wnt signalling pathway** bord-5-1990
R. Buttyan, X. Yang, D. Bemis, M. Benson, F. Vacherot, S. Terry, A. De La Taille (New York, United States of America; Creteil, France)
- 154 Detection of mutations in genes of the Wnt signalling pathway in prostate cancer using laser microdissection and whole genome amplification** bord-5-2000
G. Yardy, S. Brewster, W. Bodmer (Oxford, United Kingdom)
- 155 Cyclin A1 binds to androgen receptor and regulates the tumour invasion in cooperation with VEGF and beta-catenin** bord-5-2010
B. Wegiel, A. Bjartell, J. Persson (Malmö, Sweden)
- 156 Noggin blocks osteosclerosis in prostate cancer bone metastasis** bord-5-2020
R. Schwaninger, C.A. Rentsch, A. Wetterwald, I. Klima, G. Van Der Pluijm, R. Van Bezooijen, C.W. Löwik, U.E. Studer, G.N. Thalmann, M.G. Cecchini (Berne, Switzerland; Leiden, The Netherlands)
- 157 BMP7 has a potential role in prostate carcinogenesis and inhibits prostate cancer metastases in vivo** bord-5-2030
C.A. Rentsch, J. Buijs, G. Van Der Horst, P. Van Overveld, A. Wetterwald, R. Schwaninger, N. Henriquez, P. Ten Dyke, F. Borovecki, G.N. Thalmann, R. Pelger, S. Vukicevic, M.G. Cecchini, C. Löwik, G. Van Der Pluijm (Berne, Switzerland; Leiden, The Netherlands; Zagreb, Croatia)
- 158 EZH2 gene is amplified in late-stage prostate cancers** bord-5-2040
T. Tammela, O. Saramäki, P. Martikainen, R. Vessella, T. Visakorpi (Tampere, Finland; Seattle, United States of America)
- 159 Enrichment of the prostate side population: The quest for the prostate epithelial stem cell** bord-5-2050
J. Samuel, C. Hart, P. Gilmore, R. Bhatt, V. Ramani, M. Brown, N. Clarke (Manchester, United Kingdom)
- 160 In vitro differentiation of human prostate progenitor cells** bord-5-2060
J. Hansson, N. Vashchenko, A. Bjartell, V. Gadaleanu, P-A. Abrahamsson (Malmö, Sweden)
- Summary**
M. Cecchini, Berne (CH) bord-5-2070

Poster Session 10

Chairs: *D. Ralph, London (GB)*
M. Waldinger, The Hague (NL)

Study for 30 min. Interactive discussion for 60 min.

- 161** Location and nature of the innervation of the ejaculatory complex: Histological and immunohistochemical studies with 3D reconstruction
I. Karam, *S. Droupy*, G. Benoît, J.F. Uhl, I. Abd-alsamad, V. Delmas (Le Kremlin Bicêtre, Paris, Creteil, France)
- 162** Distribution of androgen receptors in spinal neurons innervating the seminal vesicle in male rat
Q.S. Xue, C. Xu, E.D. Yaici, F. Giuliano, L. Cayzergues, G. Benoît, S. Droupy (Le Kremlin Bicêtre, France)
- 163** Pharmacological stimulation of brain dopamine D3 receptors induced ejaculation in anaesthetised rats
P. Clément, J. Bernabé, L. Alexandre, *F. Giuliano* (Gif-sur-Yvette, Garches, France)
- 164** Dopamine D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in anesthetized rats
P. Clément, J. Bernabé, H. Kia, L. Alexandre, P. Denys, *F. Giuliano* (Gif-sur-Yvette, Garches, France)
- 165** An overview of the sexual assessment monitor (SAM), designed to calculate ejaculatory latency time (ELT)
M. Wyllie, W. Dinsmore, M. Thomas, J. Wyllie, C. Novak (London, United Kingdom; Belfast, Ireland)
- 166** Psychometric validation of a sexual quality of life measure for men – SQOL (M): Validation in men with premature ejaculation
L. Abraham, *T. Symonds*, M.F. Morris (Sandwich, United Kingdom)
- 167** Determinants of ejaculatory dysfunction in a community-based longitudinal study
M. Gan, M. Smit, G. Dohle, A. Bohnen, R. Bosch (Rotterdam, Utrecht, The Netherlands)
- 168** Latency time in men with and without premature ejaculation: Data from five European countries
F. Giuliano, D. Patrick, E. Polverejan, C. Jamieson, D. Gagnon (Garches, France; Seattle, Raritan, Mountain View, United States of America)
- 169** Premature ejaculation: Results from a European observational study
F. Giuliano, D. Patrick, H. Porst, G. La Pera, M. Rothman, R. Hashmonay, S. Merchant (Paris, France; Seattle, Raritan, United States of America; Bonn, Germany; Rome, Italy)
- 170** How does a man's premature ejaculation impact on his partner's sexual satisfaction?
K. May, L. Abraham, *T. Symonds*, M. Martin, D. Wild (Sandwich, Oxford, United Kingdom; Seattle, United States of America)
- 171** Premature ejaculation: The female perspective
D. Patrick, *F. Giuliano*, J. Dean, A. Kokoszka, *G. La Pera*, P. McNulty, S. Merchant, M. Rothman (Seattle, Raritan, United States of America; Paris, France; Devon, United Kingdom; Warsaw, Poland; Rome, Italy)

- 172** **Prospective, randomised, double-blind study with tadalafil and slow-release fluoxetine in premature ejaculation**
R. Mattos, A.M. Lucon, M. Srougi (São Paulo, Brazil)
- 173** **Dapoxetine pharmacokinetics and tolerability in hypertensive men**
N. Modi, M. Dresser, B. Wang, S. Gupta (Mountain View, United States of America)
- 174** **Long-term safety and tolerability of dapoxetine for the treatment of men with premature ejaculation**
R. Shabsigh, G. Broderick, M. Miloslavsky, S. Bull, A. Nilsson-Neijber (New York, Jacksonville, Mountain View, Raritan, United States of America)
- 175** **To what extent is heroin used to relieve premature ejaculation and other sexual disorders?**
G. La Pera, A. Carderi, Z. Marianantoni, F. Peris, M. Lentini, F. Taggi (Rome, Italy)

Poster Session 11

Chairs: *D. Jacqmin, Strasbourg (FR)*
I.C. Sinescu, Bucharest (RO)

Study for 30 min. Interactive discussion for 60 min.

- 176 Perioperative and renal venous VEGF-levels: Prognostic relevance in patients with renal cell carcinoma**
T. Klatte, M. Böhm, E.P. Allhoff (Magdeburg, Mittenaar, Germany)
- 177 The nuclear Furhman grade: A European multicentre study for the determination of the optimal grading system in terms of prognosis**
N. Rioux-Leclercq, E. Leray, P. Fergelot, A. Mejean, A. Valeri, V. Ficarra, W. Artibani, L. Cindolo, A. De La Taille, L. Salomon, C.C. Abbou, J. Tostain, D. Chautard, L. Schips, R. Zigeuner, B. Lobel, F. Guille, J. Patard (Rennes, Paris, Brest, Creteil, St. Etienne, Angers, France; Verona, Benevento, Italy; Graz, Austria)
- 178 Multicolour FISH on fine-needle biopsies for confirmation of diagnosis**
A. Chyrhai, O. Reichelt, J. Sanjmyatav, H. Wunderlich, J. Schubert, K. Junker (Jena, Germany)
- 179 Imaging of renal cell carcinoma and prostate cancer using refractory index radiology**
C. Yoon, D. Yoon, D. Sung, J. Lee, A. Kim, C. Oh, J. Je, S. Seol, Y. Hwu, G. Margaritondo, D. Yoon (Seoul, Pohang, South Korea; Taipei, Taiwan; Lausanne, Switzerland)
- 180 Prognostic value of the urinary collecting system invasion in renal cell carcinoma**
J.J. Patard, N. Rioux-leclercq, L. Cindolo, V. Ficarra, K. Bensalah, A. De La Taille, L. Salomon, C.C. Abbou, J. Tostain, B. Lobel, F. Guille (Rennes, Creteil, St Etienne, France; Benevento, Verona, Italy)
- 181 The usefulness of F-18 deoxyglucose positron emission tomography (FDG-PET) for re-staging renal cell cancer patients when a solitary metastasis or an isolated renal fossa recurrence is suspected**
I. Iborra, E. Solsona, J. Ricós, J. Monrós, R. Dumont, J. Rubio, J. Casanova, A. Collado, F. Ortega (Valencia, Spain)
- 183 The effect of competing mortality on the risk of cancer-specific survival in kidney cancer**
D.J. Lewinshtein, A. Briganti, K.F. Chun, F. Guille, B. Lobel, J.J. Patard, V. Ficarra, W. Artibani, L. Cindolo, J. Tostain, C. Abbou, D. Chopin, A. De La Taille, P. Perrotte, P.I. Karakiewicz (Montreal, Canada; Rennes, Saint Etienne, Creteil, France; Verona, Naples, Italy)
- 184 Prognosis and clinical characteristics according to the histologic subtypes in renal cell carcinoma**
C.W. Jeong, K.T. Kim, C. Kwak, S.E. Lee (Seoul, Seongnam Gyeonggi, South Korea)
- 185 Diagnostic evaluation of small renal masses: Value of contrast-enhanced ultrasound in comparison to multi-detector helical computed tomography**
L. Pallwein, E. Pallwein, S. Matthias, R. Peschel, G. Bartsch, F. Fauscher (Innsbruck, Austria)
- 187 Prognostic factors of survival in papillary renal cell carcinomas (PRCC)**
P. Gontero, G. Ceratti, S. Guglielmetti, E. Kocjancic, G. Marchioro, S. Crivellaro, G. Maso, A. Andorno, G. Valente, D. Bonvini, F. Faggiano, B. Frea (Novara, Italy)

- 188** **Prognostic significance of the 2002 TNM classification of renal carcinoma in pT2 and pT3a stages**
D. García Rojo, E. Vicente, A. Prera, C. Abad, N. Hannaoui, J.A. Peña, J.L. González, M.A. Cabezuelo, J. Prats (Sabadell, Spain)
- 189** **Follow-up of complex cystic lesions of the kidney Bosniak type II/IIIF**
P. Weibl, I. Lutter, J. Breza (Bratislava, Slovakia)
- 190** **How can we avoid unnecessary renal surgery in oncocytoma patients?**
O. Reichelt, M. Gajda, A. Chyrai, H. Wunderlich, K. Junker, J. Schubert (Jena, Germany)

Abstract Session

14:30 - 16:00

Update on ureteroscopy and stents

Room 242 Level 2

Poster Session 12

Chairs: H. Danuser, Luzern (CH)
M. Gallucci, Rome (IT)

Study for 30 min. Interactive discussion for 60 min.

- 191 Nature and characteristics of double J stent encrustations**
O. Traxer, M. Daudon, B. Dore, J. Amiel, H. Hadjadj, P. Conort, E. Lechevallier, P. Meria, C. Saussine (Paris, Poitiers, Nice, Marseille, Strasbourg, France)
- 192 Thermo-expandable ureteric stent in the management of complex refractory benign ureteric strictures: Long term efficacy and risk factors associated with complications**
G. Lee, S. Longhorn, M. Kellett, C. Allen, D. Rickards, S. Choong, T. Philp (London, United Kingdom)
- 193 Ureteral double-J stents: Subjective and objective evaluation of morbidity and quality of life in 64 patients**
C. Milesi, E. Panicucci, F. Carlino, F. Manassero, G. Giannarini, C. Selli (Pisa, Italy)
- 194 Biocompatibility of polymeric materials employed in the manufacture of endourological catheters. Histological changes in an animal model**
J. Vallejo, F.J. Burgos, I. Castillon, E. Rios, A. Linares, E. Redondo, A. Paez (Madrid, Spain)
- 195 Risk of collateral damage of endourological tools**
P. Honeck, G. Wendt Nordahl, A. Häcker, P. Alken, T. Knoll (Mannheim, Germany)
- 197 Which flexible ureterorenoscopes are the best?**
J. Deturmeny, S. Larre, Y. Rouach, P. Rivière, A. Girshovich, K. Jamali, P. Sebe, B. Gattegno, O. Traxer (Paris, France)
- 198 Is pneumatic ureteroscopic lithotripsy superior to extracorporeal shock wave lithotripsy in the treatment of large upper ureteral stones?**
B. Gunlusoy, M. Arslan, T. Degirmenci, N. Nergiz, S. Minareci, A.R. Ayder (Izmir, Turkey)
- 199 Laser endoureterotomy: Long term results and prediction of the outcome**
A. Shoma, R. Faisal, O. Mansour, H. El Kappany (Mansoura, Egypt)
- 200 Impact of hydronephrosis, stone size, location and composition on the efficacy of holmium: YAG laser ureterorenoscopy**
C. Seitz, M. Remzi, E. Tanovic, M. Lozinskiy, M. Waldert, H. Fajkovic, G. Kramer, M. Marberger (Vienna, Austria)
- 201 Endoscopic management of impassable ureteric strictures: 8 Year experience**
G. Lee, S. Longhorn, M. Kellett, C. Allen, D. Rickards, S. Choong, T. Philp (London, United Kingdom)
- 202 Adverse events and re-admissions after ambulatory urological surgery**
A. Paez Borda, E. Redondo, A. Linares, E. Ríos, I. Castillón, J. Vallejo, J. Sáenz (Madrid, Spain)

- 203 Post-operative pain after flexible ureterorenoscopy using simple gravity for irrigation or automated, electronically, controlled irrigation systems**
O. Traxer, Z. Abourjeily, A. Thevenin, E. Marret, B. Gattegno, P. Thibault (Paris, France)
- 204 Flexible ureteroscopy in upper urinary calculi: Indications and results**
A. Hochmuth, V. Zimmermanns, P. Liske, S. Lahme (Pforzheim, Germany)
- 205 In vitro study of irrigation flow and pressure in 3 new generation of flexible ureteroscopes by using pneumatic cuff and automated devices**
F. Thibault, P. Sèbe, L. Niang, M.A. Lakmichi, B. Gattegno, P. Thibault, O. Traxer (Paris, France)

Poster Session 13

Chairs: P. Gontero, Novara (IT)
M.J. Ribal Caparros, Barcelona (ES)

Study for 30 min. Interactive discussion for 60 min.

- 206 Evaluation of the prenyltransferase inhibitor AZD3409 in pre-clinical models of urothelial carcinoma**
J.L. Dominguez-Escrig, B.R. Davies, H.Y. Leung, T.C. Stephens, D.E. Neal, J.D. Kelly (Newcastle upon Tyne, Macclesfield, Cambridge, United Kingdom)
- 207 Thiothymidine combined with raltitrexed and UVA as a potential therapy for bladder cancer**
S. Pridgeon, G.A. Taylor, H.Y. Leung, P. Karran, A.V. Boddy (Newcastle upon Tyne, London, United Kingdom)
- 208 Genome-wide expression analysis after demethylation in p53 wildtype and mutated bladder and renal cell carcinoma cell lines**
F. Christoph, D. Lenze, B. Hirsch, M. Hummel, H. Krause, K. Miller (Berlin, Germany)
- 209 Matrix metalloproteinase-9 expression helps predict response to intravesical therapy in CIS of bladder**
J. Cherian, A. Vodovnik, T. Shah, R. Puri, P. Loadman, R. Phillips (Manchester, Halifax, Bradford, United Kingdom)
- 210 Molecular profiling of bladder cancer by cDNA microarrays**
M.J. Ribal, M. Burset, L. Mengual, E. Ars, F. Algaba, H. Villavicencio, A. Alcaraz (Barcelona, Spain)
- 211 The knockdown of multidrug resistance protein 1 gene activity by RNA interference in bladder cell line**
Y. Takihana, H. Zakoji, T. Nomura, T. Tsuchida, M. Fukasawa, I. Araki, M. Takeda (Yamanashi, Japan)
- 212 Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair-wise tissue proteomic and immunohistochemical analysis**
J. Tolson, V. Gnau, H. Dihazi, J. Hennenlotter, A.S. Merseburger, A. Beck, G. Müller, T. Flad, C.A. Müller, M. Kuczyk (Tübingen, Göttingen, Germany)
- 213 Dicoumarol potentiates cisplatin-induced apoptosis mediated by C-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines**
J. Watanabe, H. Nishiyama, Y. Matsui, H. Kawanishi, M. Ito, T. Kamoto, O. Ogawa (Kyoto, Japan)
- 214 Effectivity and availability of an intravesical antisense approach in a bladder cancer model**
C.E. Blietz, I. Kausch, B. Kynast, C. Doehn, D. Jocham (Lübeck, Leipzig, Germany)
- 215 Fluorescent-in-situ-hybridization (FISH) for detection of recurrent transitional cell carcinoma of the bladder**
M. Marin, L. Mengual, F. Algaba, Y. Arce, M. Burset, M.J. Ribal, E. Ars, L. Izquierdo, H. Villavicencio, A. Alcaraz (Barcelona, Spain)
- 216 Is high resolution array-based comparative genomic hybridisation able to pick up germline genomic aberrations in hereditary bladder cancer?**
L.A. Kiemeny, R.P. Kuiper, R. Pfundt, S. Van Reijmersdal, M.P. Schoenberg, K.A. Aben, M.F. Niermeijer,

- J. Witjes, E.F. Schoenmakers (Nijmegen, The Netherlands; Baltimore, United States of America)
- 217 Bcl-2 and Bcl-xL antisense oligonucleotides enhance cytotoxicity of gemcitabine in bladder cancer cell lines**
A. Becker, C. Bolenz, A. Schaaf, L. Trojan, Y. Cao, P. Alken, M.S. Michel (Mannheim, Germany)
- 218 Low frequency of chromosomal alterations in CGH analysis in low-risk papillary bladder tumours with FGFR3 mutations**
K. Junker, E. Zwarthoff, J. Van Oers, I. Kania, J. Schubert, A. Hartmann (Jena, Regensburg, Germany; Rotterdam, The Netherlands)
- 219 Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder**
A. Yurakh, D. Ramos, S. Calabuig Fariñas, J.A. López Guerrero, J. Rubio, E. Solsona, A. Vozianov, A. Pellin, A. Llombart Bosch (Kyiv, Ukraine; Valencia, Spain)
- 220 Microarray analyses in bladder cancer cells: Inhibition of hTERT expression down-regulates EGFR**
K. Kraemer, U. Schmidt, S. Fuessel, A. Herr, O.W. Hakenberg, A. Meyer, M.P. Wirth (Dresden, Germany)

Poster Session 14

Chairs: *K.P. Jünemann, Kiel (DE)*
M. Lazzeri, Firenze (IT)

Study for 30 min. Interactive discussion for 60 min.

- 221 **Cellular characterization of detrusor smooth muscle cadherin**
K.A.J. Kuijpers, J.P.F.A. Heesakkers, J.A. Schalken (Nijmegen, The Netherlands)
- 222 **Cumene hydroperoxide, an agent inducing lipid peroxidation, causes muscarinic receptor damage in the urinary bladder**
R. De Jongh, G. Van Koeveringe, M. Dambros, G.R. Haenen, P. Van Kerrebroeck (Maastricht, The Netherlands)
- 223 **A new approach for functional treatment of urinary incontinence with mesenchymal stem cells in a rat model**
G. Feil, A.M. Boehmler, S. Maurer, R. Zimmermann, J. Krug, R. Moehle, C. Bock, G. Seitz, A. Stenzl, K.D. Sievert (Tübingen, Germany)
- 224 **Experimental evidence of the effect of the inhibition of phosphodiesterase type 4 by rolipram in conscious rat with bladder outlet obstruction**
V. Julia-Guilloteau, K. Mevel, S. Oger, J. Bernabe, P. Denys, L. Alexandre, F. Giuliano (Gif Sur Yvette, Garches, France)
- 225 **Influence of the inhibition of cyclic nucleotide phosphodiesterase type 4 on human detrusor smooth muscle contractions**
S. Oger, D. Behr-Roussel, J. Bernabe, P. Denys, E. Camperat, T. Lebret, F. Giuliano (Gif Sur Yvette, Garches, Paris, Suresnes, France)
- 226 **Is the urothelium derived inhibitory factor the same substance as the endothelium derived hyperpolarising factor?**
R. Cross, C.R. Chapple, R. Chess-Williams (Sheffield, United Kingdom)
- 227 **The role of interleukin-6 on the contractile responses of rat urinary bladder**
S.C. Myung, M.Y. Lee, M.K. Lee, S.H. Ahn, T.H. Kim, S.C. Kim (Seoul, South Korea)
- 228 **Beta-adrenoceptor agonists effectively relax rat bladder irrespective of contractile stimulus**
M. Michel, C. Sand (Amsterdam, The Netherlands; Essen, Germany)
- 229 **Histologic features in the urinary bladder wall affected from neurogenic overactivity – a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A**
E. Compérat, A. Reitz, A. Delcourt, F. Capron, P. Denys, E. Chartier-Kastler (Paris, France)
- 230 **Persistent detrusor instability after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder**
M. Mitterberger, G.M. Pinggera, K. Kofler, F. Frauscher, L. Pallwein, H. Gradl, G. Bartsch, H. Strasser (Innsbruck, Austria)

- 232** **Effects of estrogen on the function and the expression of Rho-kinase in rat bladder**
S.K. Hong, J.H. Yang, J.H. Ku, K.J. Park, S.W. Kim, J.S. Paick (Sunnam, Seoul, South Korea)
- 233** **Neonatal diethylstilbestrol treatment and surgical bladder outlet obstruction differentially affect the composition of the rat vesical extracellular matrix**
C. Cabral, F. Sampaio, L. Cardoso (Rio de Janeiro, Brazil)
- 235** **Correlation between CT and urodynamic findings of patients after cerebrovascular accidents (CVA)**
A. Abdel Hafez, D. Rohmann, R. Toepper, S. Kemény, J. Noth, G. Jakse (Sohag, Egypt; Aachen, Germany)

Poster Session 15

Chairs: S. Minhas, London (GB)
A. Salonia, Milan (IT)

Study for 30 min. Interactive discussion for 60 min.

- 236 Significant alterations of transforming growth factor- and tumour necrosis factor- in patients with Peyronie's disease compared to healthy controls**
M. Praetorius, R. Zimmermann, C. Bock, S. Corvin, W. Sturm, G. Feil, A. Stenzl (Tübingen, Germany)
- 237 Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD) - first results of a prospective, randomised, placebo-controlled, single-blind study**
G. Hatzichristodoulou, C. Meisner, P. Liske, A. Stenzl, S. Lahme (Pforzheim, Tübingen, Germany)
- 238 The effect of transdermal electromotive administration (EMDA) of verapamil on the serum levels of metalloproteinase - 1 (MMP1) and their inhibitors (TIMPs) in Peyronie's disease**
C. Tsalikis, A. Lekas, G. Doumanis, S. Tsalavoutas, G. Koritsiadis, V. Politis, C. Mitsios, S. Koritsiadis (Piraeus, Athens, Greece)
- 239 Tunica albuginea free graft for corporoplasty in the baboon: A comparison between 6 months and 1 year effects**
R. Seyam, A. Mokhtar, M. Chishti, M. Ahmed, W. Mourad, A. Al-agha, R. El-sayed, K. Hanash (Riyadh, Saudi Arabia)
- 240 Single centre experience with Mondor's disease: Clinical presentation, therapy and outcome**
G. Pinggera, K. Tosun, L. Pallwein, M. Mitterberger, J. Bektic, P. Rehder, C. Gozzi, H. Strasser, G. Bartsch (Innsbruck, Austria)
- 241 Urogenital involvement in the Klippel-Trenaunay-Weber syndrome - treatment options and results**
F. Vicentini, F.T. Denes, C.M. Gomes, J.L.B. Mesquita, F.A.Q. Silva, M. Srougi (Sao Paulo, Brazil)
- 242 Iatrogenic trapped penis: One stage repair**
M. Djordjevic, S. Perovic, S. Sansalone (Belgrade, Serbia and Montenegro)
- 243 Value of 18F-FDG-PET/CT in staging penile cancer**
M. Seitz, B. Scher, E. Hungerhuber, P. Schneede, C. Gratzke, O. Reich, C. Stief, B. Schlenker (Munich, Germany)
- 244 Comparison of diagnostic radiological modalities in predicting inguinal lymph node involvement in penile cancer**
O. Kayes, C. Allen, D. Ralph, S. Minhas (Harrow, London, United Kingdom)
- 245 Nomogram predictive of pathological inguinal lymph node**
V. Ficarra, W. Artibani, S. Cosciani Cunico, G. Anselmo, F. Zattoni, M. Kattan (Verona, Brescia, Treviso, Udine, Italy; Cleveland, United States of America)

- 246 Penile carcinoma managed in a UK supra-regional referral centre: Lessons learned**
P. Hadway, C.M. Corbishley, M. Perry, N.A. Watkin (London, United Kingdom)
- 247 Size of metastasis in the sentinel node predicts additional nodal involvement in penile carcinoma**
B. Kroon, O. Nieweg, H. Van Boven, S. Horenblas (Amsterdam, The Netherlands)
- 248 Penectomy with simultaneous compared to deferred bilateral inguinal lymph node dissection (ILND) for squamous carcinoma of the penis – evaluation of surgical complications**
C. Heyns, P. Theron (Tygerberg, South Africa)
- 249 Penile cancer – histopathological subtypes and predictors of outcome in a UK series**
O. Kayes, S. Minhas, P. Kumar, A. Freeman, N. Christopher, D. Ralph (Harrow, London, United Kingdom)
- 250 Metastatic risk of T1 penile carcinoma: Has it been underestimated?**
C.M. Naumann, C. Van Der Horst, C. Seif, M. Hamann, S.H. Hautmann, P.M. Braun, B. Volkmer, R. Hautmann, K.P. Jünemann (Kiel, Ulm, Germany)

Poster Session 16

Chairs: *B. Lobel, Rennes (FR)*
G. Pizzocaro, Milan (IT)

Study for 30 min. Interactive discussion for 60 min.

- 251 Hypothesis for a correlation of genetic variants of the insulin-like factor 3 gene with the development of testicular cancer**
A. Sylakos, D. Baltogiannis, I. Miyagawa, F. Dimitriadis, D. Giannakis, N. Sofikitis (Ioannina, Greece; Yonago, Japan)
- 252 Examination of cell-death, cell-cycle, repair and stress**
H. Schmelz, M. Port, E.W. Hauck, W. Weidner, C. Sparwasser, M. Abend (Ulm, Munich, Giessen, Germany)
- 253 Promotor methylation and corresponding m-RNA expression of the putative tumour suppressor gene testisin in testicular germ cell tumours (TGCT)**
C. Kempkensteffen, F. Christoph, S. Weikert, H. Krause, M. Schrader, K. Miller (Berlin, Germany)
- 254 Expression of the p63 and notch signalling systems in the testicular germ cell tumour**
T. Hayashi, S. Yoshida, R. Ohno, N. Ishii, T. Terao, T. Yamada (Kawagoe, Saitama, Japan)
- 255 Frequent epigenetic inactivation of the p53 target gene APAF-1 and distinct methylation profile in seminomatous and nonseminomatous germ cell tumours**
F. Christoph, C. Kempkensteffen, S. Weikert, H. Krause, M. Schrader, K. Miller (Berlin, Germany)
- 256 Expression of oestrogen and luteinising hormone receptor in testis cancer**
A. Giwercman, N. Dizelyi, A. Bjartell, Å. Lundwall, V. Gadaleanu, K. Teerds (Malmö, Sweden; Utrecht, The Netherlands)
- 257 Incidence of germ cell tumours during follow-up of testicular microlithiasis**
M.A. Van Leeuwen, S. Nadorp, J.L.H.R. Bosch, M.T.W.T. Lock (Utrecht, The Netherlands)
- 258 Surveillance of testicular microlithiasis? Results of an UK based national questionnaire survey**
S. Ravichandran, R. Smith, P. Conford, M. Fordham (Liverpool, United Kingdom)
- 259 Incidental ultrasound findings in a great population of sub-fertile patients: Our experience and description of a paradoxical oncological disease**
I. Gattuccio, F. Montalto, F. Zangara, M. Parrinello, G. Savoca, L. Salame, C. Gagliardo, F. Gattuccio (Palermo, Italy)
- 260 Outcome analysis of 16 cases of bilateral germ-cell tumours**
V. Matveev, M. Volkova, D. Roschin (Moscow, Russia)
- 261 Bilateral testicular germ cell tumours in Turkey: Long term results and risk factors in 27 patients**
B. Akdogan, T. Divrik, S. Dogan, T. Tombul, F. Zorlu, C. Tasar, H. Ozen (Ankara, Izmir, Turkey)

- 262 Tumourectomy for the treatment of Leydig cell tumours of the testis**
S. Droupy, H. Mawlawi, V. Izard, E. Fabre, Y. Hammoudi, P. Eschwege, L. Cayzergues, S. Ferlicot, G. Benoît (Le Kremlin Bicêtre, France)
- 263 Feasibility of bilateral nerve-sparing laparoscopic retroperitoneal lymph node dissection**
H. Steiner, T. Müller, T. Akkad, R. Neururer, G. Bartsch, R. Peschel (Innsbruck, Austria)
- 264 Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in patients with metastatic testicular carcinoma**
S. Corvin, R. Maldonado, D. Schilling, A. Anastasiadis, A. Stenzl (Tübingen, Germany)
- 265 Intrathoracic germ cell tumours: Treatment results and long-term follow-up**
M. Volkova, A. Tjulandin, B. Polotskiy, B. Ahmedov, V. Matveev (Moscow, Russia)

Poster Session 17

Chairs: X. Cathelineau, Paris (FR)
J-U. Stolzenburg, Leipzig (DE)

Study for 30 min. Interactive discussion for 60 min.

- 267 Functional and oncological outcome of interfascial nerve-sparing laparoscopic radical prostatectomy**
J. Rassweiler, M. Hruza, C. Stock, A.S. Gözen, D. Teber (Heilbronn, Germany)
- 268 Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer**
F. Secin, A. Serio, F. Bianco, N. Karanikolas, K. Touijer, B. Guillonnet (New York, United States of America)
- 269 Incidence and risk factors of symptomatic deep venous thrombosis in prostate cancer patients undergoing laparoscopic radical prostatectomy**
F. Secin, C.C. Abbou, I. Gill, G. Fournier, T. Piéchaud, C. Schullman, I. Turk, G. Janetschek, N. Karanikolas, A. Serio, A. Vickers, K. Touijer, B. Guillonnet (New York, Cleveland, Burlington, United States of America; Creteil, Brest, Bordeaux, France; Brussels, Belgium; Linz, Austria)
- 270 5-year biochemical progression free and cancer specific survival following laparoscopic radical prostatectomy**
F. Rozet, G. Braud, X. Cathelineau, E. Barret, J. Harmon, D. Almeida, G. Vallancien (Paris, France)
- 271 Value of frozen sections during nerve-sparing laparoscopic radical prostatectomy**
R. Naspro, G. Guazzoni, M. Freschi, A. Cestari, A. Salonia, N. Buffi, F. Montorsi, P. Rigatti (Milan, Italy)
- 272 Evaluation of sexual activity after laparoscopic radical prostatectomy**
A. Mombet, N. Cathala, F. Giuliano, D. Prapotnich, X. Cathelineau, F. Rozet, E. Barret, G. Vallancien (Paris, France)
- 273 Endoscopic extraperitoneal radical prostatectomy – experience with 900 procedures**
J. Stolzenburg, R. Rabenalt, M. Do, M. Burchardt, S. Bhanot, L.C. Horn, M.C. Truss, E. Liatsikos (Leipzig, Hanover, Dortmund, Germany; London, United Kingdom; Patras, Greece)
- 274 The importance of video documented laparoscopic radical prostatectomy for improvement of positive surgical margin rate in organ confined prostate cancer**
T. Erdogru, D. Teber, R. Marrero, A. Hammady, T. Frede, J. Rassweiler (Antalya, Turkey; Heilbronn, Germany)
- 275 A simple affordable homemade laparoscopic model for narrowing the learning curve of urological trainees-skill acquisition using two key laparoscopic radical prostatectomy steps**
S.S. Kommu, F.H. Mumtaz (London, United Kingdom)
- 276 Endoscopic extraperitoneal radical prostatectomy in the elderly: Comparison of clinical outcomes and short-term oncological results between younger and older men**
V. Poulakis, R. De Vries, D. Wolfgang, U. Witzsch, E. Becht (Frankfurt am Main, Germany)

- 277 Modified transperitoneal approach for laparoscopic radical prostatectomy**
A. Häcker, A. Al-Bodour, N. Albquami, S. Jeschke, P. Prammer, K. Leeb, G. Janetschek (Mannheim, Germany; Linz, Austria)
- 278 Impact of a multidisciplinary continuous quality improvement programme on the positive surgical margin rate after laparoscopic radical prostatectomy**
K. Touijer, K. Kuroiwa, A. Vickers, V. Reuter, H. Hricak, P. Scardino, B. Guillonneau (New York, United States of America)
- 279 The effect of prior bladder outlet surgery on laparoscopic radical prostatectomy**
A. Richards, J. Ooi, I. Laczko, D. Moon, C. Eden (Basingstoke, United Kingdom)
- 280 Urethovesical anastomosis during endoscopic extraperitoneal radical prostatectomy: A prospective comparison between the single-knot running and interrupted technique**
V. Poulakis, R. De Vries, W. Dillenburg, U. Witzsch, E. Becht (Frankfurt am Main, Germany)
- 266 Is it worth revisiting laparoscopic 3D visualisation? A validated assessment**
H.R. Patel, J. Joseph (London, United Kingdom; Rochester, United States of America)

Poster Session 18

Chairs: *N.W. Clarke, Manchester (GB)*
C.N. Sternberg, Rome (IT)

Study for 30 min. Interactive discussion for 60 min.

- 281** **Molecular triggered therapy in hormone-refractory prostate cancer**
C. Ohlmann, E. Özgür, U. Engelmann, A. Heidenreich (Cologne, Germany)
- 282** **Somatostatin receptor scintigraphy for neuroendocrine pattern in patients with hormone-refractory prostate cancer: Preliminary experience**
F. Manassero, P. Erba, P. Lazzeri, S. Evangelisti, G. Mariani, C. Selli (Pisa, Italy)
- 283** **Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and somatostatin analogue versus LHRH analogue with dexamethasone in hormone refractory prostate cancer patients**
F. Calais Da Silva junior, F. Calais Da Silva, T. Oliver, F. Gonçalves (Lisbon, Portugal; London, United Kingdom; Bratislava, Slovakia)
- 284** **Randomised controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs zoledronate in patients with androgen ablation refractory prostate cancer**
M. Koutsilieris, C. Mitsiades, J. Bogdanos, D. Karamanolakis, C. Milathianakis, A. Sourla, T. Dimopoulos (Athens, Piraeous, Thessaloniki, Greece; Boston, United States of America)
- 285** **Increase of circulating chromogranin A in patients with hormone refractory prostate cancer**
D. Hirano, S. Minei, S. Sugimoto, K. Yamaguchi, T. Yoshikawa, T. Yoshida (Tokyo, Japan)
- 286** **Serum chromogranin A and chemotherapy in hormone-resistant prostate cancer**
L. Guy, A. Cabrespine, J.B. Bay, E. Khenifar, F. Kwiatkowski, P. Chollet, J. Boiteux (Clermont-Ferrand, Vichy, France)
- 287** **Randomised study of docetaxel (D) and dexamethasone (Dx) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)**
T. Nelius, T. Klatte, F. Reiher, R. Yap, E.P. Allhoff (Magdeburg, Germany; Chicago, United States of America)
- 288** **A phase II clinical study of high-dose Calcitriol plus Docetaxel and Zoledronic acid in hormone-refractory prostate cancer (HRPC)**
M. Bulbul, A. Shamseddine, J. Makarem, Z. Abdel Khalik, A. Taher, N. El-Saghir, R. Khawli, K. Hemadeh (Beirut, Lebanon)
- 289** **Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy**
C. Ohlmann, E. Özgür, S. Wille, U. Engelmann, A. Heidenreich (Cologne, Germany)

- 290 Docetaxel, vinorelbine and zoledronic acid as first line treatment in patients with hormone refractory prostate cancer**
G. Di Lorenzo, R. Autorino, G. Napodano, S. Perdonà, M. De Laurentiis, G. Canello, **V. Altieri**, M. d'Armiento, A.R. Bianco, S. De Placido (Napoli, Naples, Italy)
- 291 Phase II study of intravenous vinorelbine plus hormone therapy in hormone-refractory prostate cancer**
F. Calais Da Silva Junior, F.E. Calais Da Silva (Lisbon, Portugal)
- 293 Low-dose oral chemotherapy for hormone refractory prostate carcinoma (HRPC). Estramustine phosphate versus estramustine phosphate and etoposide. A randomised phase II study of GSTU foundation**
V. Serretta, G. Morgia, V. Altieri, A. Siragusa, M. Motta, F. Orestano, M. Napoli, G. De Grande, A. Galuffo, D. Melloni, C. Pavone, M. Pavone Macaluso, R. Allegro, All Members of GSTU (Palermo, Sassari, Napoli, Caltagirone (CT), Catania, Trapani, Siracusa, Sicilia, Calabria, Campania, Molise, Puglia, Basilicata, Italy)
- 294 Phase I study with an immunomodulated autologous cell vaccine for locally advanced prostate cancer**
M. Berger, J.L. Horst, F. Kreutz, **M. Pimentel**, R.L. Müller, W.J. Koff (Porto Alegre, Brazil)
- 295 Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Clinical results of a phase I clinical trial**
O. Hakenberg, S. Fuessel, A. Meye, M. Schmitz, S. Zastrow, K. Richter, P. Rieber (Dresden, Germany)

Wednesday, 5 April - EAU Programme

Symposium

16:15 - 17:45

Managing the LUTS/BPH patient: The impact of nocturia

eURO Auditorium Level 1

Chair: P.E. Van Kerrebroeck, Maastricht (NL)

Introduction

P.E. Van Kerrebroeck, Maastricht (NL)

eURO-5-2080

Nocturia: Does it also affect the partner?

N. Stanley, Guildford, Surrey (GB)

eURO-5-2090

Measuring nocturia and its effects on quality of life and quality of sleep

E. Chartier-Kastler, Paris (FR)

eURO-5-2100

Controlling the impact of nocturia: Initial data

M.J. Speakman, Taunton, Somerset (GB)

eURO-5-2110

Discussion and take home messages

P.E. Van Kerrebroeck, Maastricht (NL)

eURO-5-2120

Aims and objectives

Nocturia is one of the most bothersome symptoms for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Consequently, impaired sleep due to frequent nocturnal awakenings and/or difficulty in falling asleep again may result in a reduction in the hours of undisturbed sleep (HUS), i.e. the time between falling asleep and first awakening to void. This may impair quality of life (QoL) and, in the long term, increase morbidity and mortality. Treatment for LUTS/BPH should therefore relieve LUTS both during the day and night. During the symposium, the need for new instruments to measure nocturia, as well as the impact of nocturia on QoL and HUS, will be reviewed. In addition, data on the effect of the new formulation of tamsulosin, the oral controlled-absorption system (OCAS), on nocturia will be discussed.

Symposium

16:15 - 17:45

Helping couples stay connected - new paradigms in ED management

Room **Ternes Level 1**

Chair: *I. Saenz De Tejada, Madrid (ES)*

Welcome and introduction

I. Saenz de Tejada, Madrid (ES) tern-5-2130

Sexual ecology: The partner perspective

A. Graziottin, Milan (IT) tern-5-2140

Is timing everything?

I. Saenz de Tejada, Madrid (ES) tern-5-2150

Sexual satisfaction for couples

B. Cuzin, Lyon (FR) tern-5-2160

Maria and ED: A case discussion

B. Cuzin, Lyon (FR) tern-5-2170

A. Graziottin, Milan (IT) tern-5-2180

Conclusion

I. Saenz De Tejada, Madrid (ES) tern-5-2190

Aims and objectives

At the end of this session, participants will be able to:

- Recognise the importance of the partner and the relationship in treating men with erectile dysfunction (ED)
- Understand the unique biochemical profile of Levitra®
- Understand how ED relates to the quality of life (QoL) of the patient and partner
- Improve communication skills in treating ED.

This symposium will focus on couples with ED and the impact that ED has on their relationship. Research on the female partner of a man with ED elucidates the important effect that ED has on her sexual experience and how successful treatment of the man's ED improves the experience of both the man and his partner. Our understanding of the sexual ecology of men with ED and their partners helps to put clinical data and treatment decisions into perspective. There is now an extensive body of knowledge about ED that focuses primarily on functionality and improvement of erections, but still too little attention has been given to female partners of men with ED. We will discuss clinical data from a trial that tested the hypothesis that by treating male ED subjects with vardenafil, their female partner's sexual QoL also shows meaningful improvement. In addition, an overview of new clinical data on Levitra® will be provided.

EAU Programme, 5 April

Wednesday, 5 April - EAU Programme

Symposium

16:15 - 17:45

Advancing the management of OAB: New data, new directions

Room **Blue Level 2**

Chair: C.R. Chapple, Sheffield (GB)

Opening remarks

C.R. Chapple, Sheffield (GB)

blue-5-2200

The impact of LUTS: Multi-national results from the EPIC study

I. Milsom, Goteborg (SE)

blue-5-2210

New data: Do the findings dispel the questions about the treatment of OAB in men?

S.A. Kaplan, New York (US)

blue-5-2220

Outcomes in OAB treatment: Patient perception - a key to success

W. Artibani, Padua (IT)

blue-5-2230

Questions and answers/Closing remarks

C.R. Chapple, Sheffield (GB)

blue-5-2240

Aims and objectives

Overactive bladder (OAB) is often perceived as a condition that affects primarily women. However, there is increasing evidence that OAB is equally prevalent in men and women. New data from the Overactive Bladder (OAB): Epidemiology, Risk Factors, Comorbidities, and Bother (Impact on Quality of Life, Productivity, Depression, and Sexuality study [EPIC]) study—released at this symposium—document the high prevalence of lower urinary tract symptoms (LUTS) in men. Urgency and frequency, with or without urgency incontinence, are part of the LUTS complex and are highly prevalent in men. Yet, men are less likely than women to be diagnosed and therefore less likely to be prescribed an antimuscarinic agent. Men are predominately managed with use of α -blockers, and, despite this treatment, many continue to have persistent, bothersome symptoms. The evidence supporting the advancement of the management of men with LUTS and OAB symptoms will be reviewed. These data demonstrate the need for a shift in the treatment paradigm for men with LUTS. Further, data from the IMprovement in Patients: Assessing Symptomatic Control With Tolterodine (IMPACT) trial suggest that management of OAB in men and women can be further advanced by focusing on the most bothersome symptoms as a treatment end point and a driver of patient satisfaction. The new data presented in this symposium will provide physicians with new insight into the prevalence and bothersomeness of OAB, as well as diagnosis and treatment of this condition in men and women.

Symposium

16:15 - 17:45

Prostate cancer prevention: A relevant therapeutic target for patients with BPH

Room **Bordeaux** Level 3

Chair: M. Marberger, Vienna (AT)

Welcome and introduction

M. Marberger, Vienna (AT)

bord-5-2250

PCPT revisited

S. Lippman, Houston (US)

bord-5-2260

Consequences of screening for prostate cancer: New insights from PCPT

A. Joyce, Leeds (UK)

bord-5-2270

Chemoprevention of prostate cancer in the urological patient

M. Marberger, Vienna (AT)

bord-5-2280

Panel discussion, questions and answers

bord-5-2285

Conclusion

M. Marberger, Vienna (AT)

bord-5-2290

Aims and objectives

The purpose of this symposium is to update participants on NEW aspects from the Prostate Cancer Prevention Trial (PCPT) for prostate cancer prevention and its implications for the management of patients with benign prostatic hyperplasia (BPH). We will examine the use of prostate-specific antigen as a predictive marker in BPH, and as a diagnostic strategy for the detection of prostate cancer in the urologist's practice. In addition, clinicians will be provided with up-to-date information on the latest evidence from the PCPT, the relationship of the PCPT outcomes to BPH, and the role of finasteride in the management of patients with BPH who are concerned about or at risk of prostate cancer.

Wednesday, 5 April - EAU Programme

Symposium

16:15 - 17:45

BPH patient of the third millennium

Room **Havana** Level 3

Chair: M.P. Wirth, Dresden (DE)

Introduction

M.P. Wirth, Dresden (DE)

hava-5-2300

Is there a role for watchful waiting?

P-A. Abrahamsson, Malmö (SE)

hava-5-2310

LUTS/BPH sexual impact on female partner: CHOQ project

P. Perrin, Lyon (FR)

hava-5-2320

Evaluation of treatment impact on male sexual function

A.R. Zlotta, Brussels (BE)

hava-5-2330

Discussion

Conclusion

M.P. Wirth, Dresden (DE)

hava-5-2340

Aims and objectives

The aim in this symposium is to present the evolution of benign prostatic hyperplasia (BPH) management regarding today's patient and to discuss the approach in the management of BPH.

Is there a role for watchful waiting? (P-A. Abrahamsson, Malmo)

To evaluate what leads to the decision to treat a patient (symptoms, risk, age) and to try to answer the question as to which patients need no treatment.

Sexual impact on female partner: CHOQ project (P. Perrin, Lyon)

Today's patient must be seen as a whole considering his everyday life including his relationship with his female partner. The CHOQ project presents the impact of BPH on the female partner.

Evaluation of treatment impact on male sexual function (A. Zlotta, Brussels)

As people live longer, men today want to enjoy their life, including their sexual life, as long as possible. Drugs available for the medical treatment of BPH have a negative impact on sexual function. How should patients be counselled regarding medical and surgical treatment in this respect?

Symposium

16:15 - 17:45

Vascular-targeted photodynamic therapy with Tookad (VTP) for the treatment of localised prostate cancer

Room **Maillot Level 2**

Chair: F.M.J. Debruyne, Nijmegen (NL)

Introduction

F.M.J. Debruyne, Nijmegen (NL)

mail-5-2350

VTP with Tookad for the focal treatment of prostate cancer

P. Scardino, New York (US)

mail-5-2360

Results of phase I/II trials with Tookad for the treatment of prostate cancer after radiation therapy

J. Trachtenberg, Toronto (CA)

mail-5-2370

Vascular-targeted photodynamic therapy using Tookad: A clinical study in early prostate cancer

C. Moore, London (GB)

mail-5-2380

Conclusion

F.M.J. Debruyne, Nijmegen (NL)

mail-5-2390

Aims and objectives

Photodynamic therapy (PDT) is a therapeutic modality that enables the destruction of a target tissue by administration of a light-sensitive photosensitiser and the local application of monochromatic light, in the presence of oxygen. Steba Biotech and Negma, in collaboration with the Weizmann Institute of Science, are developing the new-generation photosensitiser Tookad (WST09), a bacteriochlorophyll derivative with the unique characteristics of distribution within the vascular network, better penetration into tissues and rapid clearance without skin phototoxicity. Since PDT with Tookad causes tissue necrosis via vascular damage, this procedure is known as "vascular-targeted photodynamic therapy" (VTP). The symposium organised by Steba Biotech and Negma at EAU 2006 will discuss the use of VTP with Tookad in cancer treatment. Several internationally renowned speakers will present recent results from trials of Tookad given to patients with recurring localised prostate cancer and as a first-line treatment.

Wednesday, 5 April - EAU Programme

Symposium

16:15 - 17:45

Skeletal preservation in prostate cancer: The changing role of the urologist

Room **Concorde 2 Level 4**

Chair: N.W. Clarke, Manchester (GB)

Welcome and introduction

N. Clarke, Manchester (GB)

con2-5-2400

Diagnosis and prevention of bone loss in patients with prostate cancer

M. Colombel, Lyon (FR)

con2-5-2410

New clinical tools for urologists: Case studies and best practice

J. Eastham, New York (US)

con2-5-2420

New research findings on bisphosphonates: Survival, pain, and antitumor effects

F. Saad, Montreal (CA)

con2-5-2430

Focusing bisphosphonate treatment in prostate cancer

N. Clarke, Manchester (GB)

con2-5-2440

Questions to the panel and audience feedback

Conclusion

N. Clarke, Manchester (GB)

con2-5-2450

Aims and objectives

1. Encourage urologists to actively screen and treat bone metastases in patients with prostate cancer.
2. Discuss the increased risks of fractures for patients receiving androgen deprivation therapy and the impact of bisphosphonates on reducing bone resorption.
3. Highlight the impact of bisphosphonate therapy on improving pain and quality of life in patients with metastatic prostate cancer.
4. Describe the activities of bisphosphonates that may affect tumour growth and survival.

Symposium

16:15 - 17:45

Progress in medical management of renal cell carcinoma (RCC): The expanding role of the urologist

Room **Concorde 1 Level 4**

Chair: D. Jacqmin, Strasbourg (FR)

Introduction

D. Jacqmin, Strasbourg (FR)

con1-5-2460

Signal transduction inhibitors: The benefits of multi-targeting

P. De Mulder, Nijmegen (NL)

con1-5-2470

New perspectives in the treatment of RCC

O. Rixe, Paris (FR)

con1-5-2480

Rationale for study of multi-targeted Tyrosine kinase inhibitors in the adjuvant and neo-adjuvant setting

D. Jacqmin, Strasbourg (FR)

con1-5-2490

Conclusion

D. Jacqmin, Strasbourg (FR)

con1-5-2500

Aims and objectives

Highlight and review the benefits of multi-targeted therapies. Review disease background, pathophysiology and current management techniques in renal cell carcinoma (RCC). Provide critical information on new therapies to treat RCC. Present the rationale of multi-targeted tyrosine kinase inhibitors in the neo-adjuvant and adjuvant settings

Wednesday, 5 April - EAU Programme

18:15 - 21:00

EAU Opening Ceremony and Welcome Cocktail

eURO Auditorium Level 1

18:15 - 19:30

Welcome address

eURO-5-2510

L. Boccon-Gibod, Paris (FR), EAU Congress President

Opening address

eURO-5-2520

P. Teillac, Paris (FR), EAU Secretary General

Short Opening Show

eURO-5-2530

Announcement of the new honorary EAU members

eURO-5-2540

Citation by P. Teillac, Paris (FR)

Honorary members: G. Bartsch, Innsbruck (AT)

Presentation Willy Gregoir Medal

eURO-5-2550

Citation by P. Teillac, Paris (FR)

Presented to: A. Borkowski, Warsaw (PL)

The EAU is proud to present the Willy Gregoir Medal to an important senior urologist who contributed in an extraordinary way to the development of urology in Europe

Presentation Frans Debruyne Lifetime Achievement Award

eURO-5-2560

Citation by P. Teillac, Paris (FR)

Presented to: C. Schulman, Brussels (BE)

The EAU wish both to honour and acknowledge the important and long-standing contributions by a distinguished colleague to the activities and development of this association

EAU-AUA International Academic Exchange Programme – the European Tour

eURO-5-2570

Recognition of the participants:

Senior advisor:

J. William McRoberts, Kentucky (US)

Fellows:

S. Chang, Vanderbilt University Medical Centres, Nashville (US)

P. Dahm, Duke University, Durham (US)

S. Jackman, University of Pittsburgh, Pittsburgh (US)

Congress Opening Show

eURO-5-2580

KIMERA - *Fable and imaginery created as reality*

Sergi Buka combines the ancient and universal language of Chinese shadows with the modernity of the projections of video, using magic as a conductive thread to surprise the audience.

19:30 - 21:00

Welcome Cocktail in the exhibition area on level 1

Plenary session

07:30 - 11:00

Plenary session 1

eURO Auditorium Level 1

Chairs: C.R. Chapple, Sheffield (GB)
P. Teillac, Paris (FR)

07:30 - 08:00

Highlight session 1

Oncology

S. Hautmann, Kiel (DE)

eURO-6-0000

Functional urology

F. Carboni, Novara (IT)

eURO-6-0010

Stone disease

O.W. Hakenberg, Dresden (DE)

eURO-6-0020

08:00 - 08:05

Award session 1

EAU Crystal Matula Award 2006

Supported by an unrestricted educational grant from LABORIE MEDICAL TECHNOLOGIES

eURO-6-0030

EAU Thesis Award 2005

Supported by an unrestricted educational grant from SANOFI-AVENTIS

eURO-6-0040

08:05 - 08:20

State-of-the-art lecture **European Urology is your journal: A plan for the future**

Speaker: F. Montorsi, Milan (IT)

eURO-6-0050

Aims and objectives

This lecture is aimed at illustrating in detail the new format of European Urology, the official journal of the European Association of Urology. Following 30 years of invaluable leadership of Prof. Claude Schulman, currently editor emeritus of the journal, Prof. Francesco Montorsi from Milan has taken over and guided European Urology through a number of major changes. New features in European Urology will include: new cover and new layout of articles, new table of contents with take-home messages for each article, extended editorial authored by major experts, review articles, original articles, case study of the month to be published in part on the front cover of the journal, "open to debate" and "interviews sections" involving internationally known opinion leaders, "words of wisdom" section devoted to surveying the urological literature, resident's corner devoted to highlighting the best work from residents, top downloads of articles, previews of future articles. High quality copy-editing will be applied to every accepted paper. First round of peer review is completed in 14 days. Following acceptance, articles will be available online in 14 days. The editorial board of European Urology has been completely renovated. Join this European Urology session to know more about "your platinum" journal.

08:20 - 08:40 **American Urological Association (AUA) lecture *A novel virus associated with genetic susceptibility to prostate cancer***

Speaker: E.A. Klein, Cleveland (US)

eURO-6-0060

Aims and objectives

While the etiology of prostate cancer is unknown, it is clear that both genetics and environment play a role in its origin and evolution. Guided by epidemiologic observations and genome-wide scans, genetic linkage studies have recently identified a number of susceptibility genes for the development of prostate cancer. In addition, histologic and molecular studies suggest an important role for intraprostatic inflammation in tumor initiation and progression. This review highlights recent scientific and clinical evidence, including the isolation and characterization of a new viral pathogen, suggesting a convergence between genetic susceptibility, predisposition to infection, and impaired cellular defense mechanisms against oxidative stress in the genesis of prostate cancer, and presents an integrated model synthesizing these genetic, molecular, and cell biological events. The potential implications for development of effective prevention strategies are also discussed.

08:40 - 09:20 **Breaking news session *Anti-angiogenic therapy in renal cancer; the role of the urologist***

Chair: P.F.A. Mulders, Nijmegen (NL)

Introduction renal cell carcinoma and anti-angiogenic therapy

P.F.A. Mulders, Nijmegen (NL)

eURO-6-0070

Prognostication and patient selection

J.J. Patard, Rennes (FR)

eURO-6-0080

Results of clinical studies and future perspectives

A. Belldegrun, Los Angeles (US)

eURO-6-0090

Aims and objectives

Within a breaking news session the EAU attendance will be informed on the implementation of new targeted therapy with proven efficacy in renal cell carcinoma (RCC). These new small molecules inhibit angiogenesis and a significant impact on disease control and survival. Knowledge on current treatment and selection of RCC patients for systemic treatments will be presented. Moreover the important role of the urologist in these new treatment modalities will be explained.

09:20 - 09:40 **State-of-the-art lecture *New indications for IPDE 5***

Speaker: P. Hedlund, Lund (SE)

eURO-6-0100

09:40 - 10:20 **Round table discussion** **The management of renal stone disease in 2006**

Chair: P. Van Cangh, Brussels (BE)

Panel: P.J. Conort, Paris (FR)

 F. Keeley, Bristol (GB)

 N. Vodopija, Slovenj Gradec (SI)

eURO-6-0110

eURO-6-0120

eURO-6-0130

Aims and objectives

There is an increasing tendency to consider that the major problems related to stone disease and its management are largely resolved. This is reflected by a trend to reduce the time devoted to urolithiasis at contemporary urological congresses, and the decreasing number of publications on the topic in modern literature. A closer look however reveals a less than optimistic reality. Complete stone-free rates remain unacceptably low, recurrences are high, and complications and re-treatment rates are probably under-reported, or more importantly, considered inevitable.

This round table is clinically oriented. Commonly encountered scenarios will be presented involving problematic renal and ureteral calculi. The panel of experts will provide delegates with the most recent information on indications and rationale for treatment selection, helping the practising urologist to address the simple but difficult issue of: "When and how to intervene" and more importantly "When not to interfere".

10:20 - 10:40 **State-of-the-art lecture** **Serum proteomics in urological cancer**

Speaker: U.H. Stenman, Helsinki (FI)

eURO-6-0140

Aims and objectives

Proteomics is a promising approach for identification of new tumour markers. Mass spectrometric (MS) techniques for detection of proteins have evolved dramatically and are increasingly applied to the identification of new biomarkers. So far methods based on matrix-assisted laser desorption and ionisation (MALDI or SELDI) have mainly been used to study protein and peptide profiles associated with cancer and several promising reports have been published. However, the results have not been reproducible and really useful new markers remain to be detected. This can be explained by over-optimistic expectations regarding the sensitivity and resolution of the methods used. All known tumour markers occur at concentrations that are about one millionth-fold lower than those of the major serum proteins. With the MS techniques used, only abundant proteins are detectable. New studies using more sophisticated techniques have therefore been initiated. Other promising approaches are to use pre-fractionation of the sample before MS analysis and to study other body fluids, e.g. urine, and tissue extracts. Although we are still waiting for a breakthrough, it is most likely that proteomics will provide us with new tools to diagnose urological cancer.

10:40 - 11:00 **Società Italiana di Urologia (SIU) lecture** **The bladder detrusor - an innocent victim of the prostate**


Speaker: V. Mirone, Naples (IT)

eURO-6-0150

Aims and objectives

Morpho-functional alterations of the bladder detrusor are one of the most important, if not the main, mechanism through which benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS). Data is now available in the literature showing how infravesical obstruction causes enlargement and wall thickening of the detrusor muscle. This morphological change can cause irreversible damage if a critical threshold is not surpassed. It has also been demonstrated that this modification is not only due to muscle cell hypertrophy, but also to collagen neo-deposition, which severely alters bladder wall architecture and structure. The increase in collagen content correlates with the presence and severity of LUTS in BPH patients, and tends to correlate with the presence of detrusor overactivity. Being irreversible, collagen neo-deposition possibly plays a role in

the persistence of symptoms after obstruction-reliever procedures, described in as many as 30% of men with BPH. Based upon this new discovery of pathogenesis of LUTS in “prostatic patients”, the natural history of BPH should be updated.



Sub-plenary session

11:00 - 12:00

Sub-plenary session 1

Room 252 Level 2

Moderator: U. Jonas, Hanover (DE)

11:00 - 11:15

Section highlights of the European Society of Infection in Urology (ESIU)

Speaker: M.C. Bishop, Nottingham (GB)

252-6-0160

11:15 - 11:30

Section highlights of the European Society of Neurourology (ESNU)

Speaker: D.J.M.K. De Ridder, Leuven (BE)

252-6-0170

11:30 - 11:45

Section highlights of the European Society for Urological Imaging (ESUI)

Speaker: H. Wijkstra, Amsterdam (NL)

252-6-0180

11:45 - 12:00

Section highlights by the eUrolithiasis Society (EULIS)

Speaker: P.N. Rao, Manchester (GB)

252-6-0190

Thursday, 6 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 2

eURO Auditorium Level 1

Moderator: C. Llorente, Madrid (ES)

11:00 - 11:30

State-of-the-art lecture **Laparoscopic training for urological surgeons**

Speaker: C.C. Abbou, Creteil (FR)

eURO-6-0200

Aims and objectives

Most of the well- standardised open techniques are switching to minimal invasive procedures. The laparoscopic approach has proven its value in this matter. Due to the steep learning curve, methods of training have been developed worldwide in which two parameters must be considered: the laparoscopic skills of the surgeon and knowledge of the technique. Daily practice on the pelvitrainer is a crucial and unavoidable step in achieving laparoscopic skills, particularly in terms of becoming familiar with the handling of instruments and dissection and suturing techniques. Nowadays, each training programme has its own well-defined method. In the near future, virtual training with the modality of simulation will be used for practice, as well as for evaluating the skills of a trainee. To gain knowledge of a particular technique, self-study by reading books, watching videos, attending live surgery in an operating room and assisting a skilled expert will lead to an understanding of the different steps involved. At the end, it will give the trainee the opportunity to be self-confident with the technique and to fulfil a laparoscopic procedure advised by the expert. The tips and tricks given by an expert will help the trainee to shorten his learning curve. For this purpose, a standardised and reproducible technique is necessary and even obligatory. Developments of all these ideas will be addressed during the session.

11:30 - 12:00

State-of-the-art lecture **The objective evaluation of functional results following the treatment of localised prostate cancer**

Speaker: G. Vallancien, Paris (FR)

eURO-6-0210

Aims and objectives

A great disparity exists in the literature regarding the reporting of functional outcomes following radical prostatectomy. Although validated questionnaires are used, many variables still exist in the evaluation of erectile dysfunction and incontinence that render the comparison of outcomes impossible.

A query was conducted encompassing the literature from January, 2000 to October, 2005.

98 papers were available for analysis. Variability was seen in study design. Twenty-seven percent of articles stated that a single surgeon performed all operations. Two surgeons were said to have performed all operations in 6.25%, and three surgeons in 3.12% of studies. Multiple surgeons (four or greater) contributed in 22.9% of articles, and in 40.6% of papers this statistic was not stated. The party responsible for the collection of data was stated in 25% of papers. Of these papers, direct physician involvement in the collection occurred in 8.3%, research assistants were the primary collectors in 5.2%, and an independent third party was responsible 11.4% of papers. The timing of survey also varied greatly. In articles pertaining to erectile dysfunction, an average of 69% potent men postoperatively was calculated (range 6-100%). For incontinence, an average of 95.3% was calculated (range 42-100%). The patient's preoperative status was given in 31.6% of papers pertaining to ED while 18.3% of papers relating to incontinence made this information available. 7.5% of papers reported on ejaculatory or orgasm satisfaction.

Conclusions : Many variables exist when evaluating the functional outcomes following radical prostatectomy. Differences in methodology, scores and statistics data do not allow to get the truth. In order to better evaluate the functional outcomes of radical prostatectomy, a unified approach is essential.

Sub-plenary session

11:00 - 12:00

Sub-plenary session 3

Room **Ternes Level 1**

Moderator: C.R. Chapple, Sheffield (GB)

11:00 - 11:30

State-of-the-art lecture **Tissue engineering for the lower urinary tract**

Speaker: K-D. Sievert, Tübingen (DE)

tern-6-0220

Aims and objectives

Clinical "state-of-the-art" tissue engineering (TE) solutions for urological reconstruction currently means acellular xenograft matrices. Certain materials have been introduced with a proclaimed success rate as free transplants; however, the clinical outcome has been disappointing as there are long study follow-ups for most materials and indications. With continued research, the approach has been taken to understand the mixed outcome of these materials. In addition, cell expansion and tissue regeneration has progressed with the first successful clinical application in treating urinary stress incontinence. To understand the place of TE in reconstructive urology, it is important to pinpoint which goals have been reached in the laboratory and to address future requirements to solve the outstanding issues. By articulating these possibilities, TE can be successfully brought into the clinic to conform to general medical principles.

11:30 - 12:00

State-of-the-art lecture **The role of laser prostatectomy in BPH**

Speaker: D. Jocham, Lübeck (DE)

tern-6-0230

Aims and objectives

Holmium laser enucleation of the prostate (HoLEP) combined with mechanical morcellation represents the latest refinement of holmium:YAG surgical treatment for benign prostatic hyperplasia (BPH). The efficiency and reliability of the HoLEP technique as an alternative to transurethral resection of the prostate (TURP) and open prostatectomy have been verified by numerous prospectively randomised studies. Photoselective vaporisation of the prostate (PVP) utilises high-power (80W). Potassium-titanyl-phosphate (KTP) laser represents the latest evolutionary development in laser prostatectomy. The latest results of studies comparing TURP and laser technology have proven that both laser techniques (HoLEP and PVP) are safe and efficacious with durable results. As yet, there are no studies comparing the efficiency and safety of the HoLEP and PVP techniques. Although there is a lack of long-term results, the short-term results suggest that both techniques are equal in efficiency and are superior with respect to safety compared to TURP.

Thursday, 6 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 4

Room **Maillot Level 2**

Moderator: G.A. Bogaert, Leuven (BE)

11:00 - 11:30

ESPU lecture **Management of upper urinary tract lithiasis in children**

Speaker: H.B. Lottmann, Paris (FR)

mail-6-0240

Aims and objectives

Particularities in the management of urolithiasis in the paediatric age group mainly concern the very young age group, particularly infants. Apart from this very young age group, treatment options for older children are very similar to that of adults and the patient can be managed in most urolithiasis treating centres. Because of its efficiency, and its low morbidity, ESWL should always be considered as the first treatment option; other treatment modalities (i.e. percutaneous nephrolithotomy, ureteroscopy, laparoscopy or open surgery) are discussed when ESWL is a poor indication, or has failed or is not available.

11:30 - 12:00

State-of-the-art lecture **The management of vesico-ureteric reflux in childhood**

Speaker: E. Jaureguizar, Madrid (ES)

mail-6-0250

Aims and objectives

Vesico-ureteric reflux (VUR) remains one of the most controversial issues in paediatric urology. Evidence-based medicine has shown that many of the old theories of VUR were based on opinion rather than on evidence. Pertinent questions are:

- Is reflux alone harmful or must it be associated with urinary tract infections to produce damage?
- Are VUR-related renal lesions acquired or congenital?
- Does bladder dysfunction have a role in VUR? Our ability to use modern imaging techniques to follow the development of VUR from the fetal period onwards has changed our understanding of the problem. The remaining controversial questions are:
 - Whether reflux should be treated?
 - And if so, when should that happen? As with many other aspects of life, there are no clear answers in medicine, and in fact, valid answers may be mutually exclusive. However, we shall still be able to present some clear conclusions on how to manage VUR at the beginning of the 21st century.

Sub-plenary session

11:00 - 12:00

Sub-plenary session 5

Room **Blue Level 2**

Moderator: I. Eardley, Leeds (GB)

11:00 - 11:30

State-of-the-art lecture **The management of premature ejaculation**

Speaker: S. Droupy, Le Kremlin Bicêtre (FR)

blue-6-0260

Aims and objectives

The recent increase in research with regard to premature ejaculation has generated a significant number of new informations looking at the diagnosis, definition and management of this condition. A number of behavioural and psycho-relational approaches have been proposed to treat premature ejaculation. Effective psychosexual treatment combines multiple strategies such as physiological relaxation, pubococcygeal muscle training, cognitive and behavioral pacing strategies, and the involvement of the partner in the therapy. Taking advantage of the ejaculation-delaying effects of selective serotonin reuptake inhibitors (SSRIs) increases the treatment options available to prescribers and patients. A recent meta-analysis of daily treatment studies with SSRIs and clomipramine demonstrated comparable efficacy of clomipramine with sertraline and fluoxetine in delaying ejaculation, whereas the efficacy of paroxetine was greater. New acute treatment interventions with short half-lives SSRIs are under investigation.

11:30 - 12:00

State-of-the-art lecture **Optimising semen analysis**

Speaker: W. Weidner, Giessen (DE)

blue-6-0270

Aims and objectives

Approximately 15% of couples are unable to conceive a child after 1 year of regular unprotected intercourse. In up to 50%, a male factor is involved, which is usually defined by abnormal semen analysis. Precise normal values have not been accepted worldwide for semen parameters. In Europe, the reference values given by the WHO are considered to be the "gold standard".

- Standardised tests of semen are based on the WHO reference values. Varying time of sexual abstinence and lack of standardisation may contribute to significant different results.
- Concerning morphology, the use of strict criteria indicates that cut-off values for normality are substantially lower than those proposed by the WHO.
- Estimating motility, the introduction of objective, computer-aided sperm assessment may improve accuracy. Limitations of these techniques will be addressed.
- Identification of leucocytes is necessary for the diagnosis of male accessory gland infections and prostatitis. Today, the techniques and cut-off points are under debate.
- Specialised tests, e.g. antisperm antibodies, specialised test of sperm function and the measurement of seminal plasma parameters may have an indication in selected patients. The indications are presented.

Finally, the relation between semen quality and fertility is discussed against the background of the new literature published in the century of intracytoplasmic sperm injection (ICSI).

Thursday, 6 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 6

Room **Havana** Level 3

Moderator: H. Van Poppel, Leuven (BE)

11:00 - 11:40

Original presentations selected from submitted abstracts

Predicting recurrence and progression in stage Ta-T1 bladder cancer patients using EORTC risk tables

R. Sylvester, Brussels (BE)

[hava-6-0280](#)

Which patients with T₀₋₄ N₀ M₀ prostate cancer not suitable for local treatment with curative intent do not need immediate treatment in EORTC trial 30891?

L. Collette, Brussels (BE)

[hava-6-0290](#)

11:40 - 12:00

State-of-the-art lecture **The future of academic medicine: Five scenarios to 2025**

Speaker: J. Clark, London (GB)

[hava-6-0300](#)

Aims and objectives

Two of the greatest challenges facing academic medicine in the 21st century are its relationship with stakeholders and bridging the translational gap.

- Will fostering deeper collaboration with health care partners (including the pharmaceutical industry) threaten or save academic medicine?
- How best can academic medicine better engage with its chief “customers”: patients, general and specialist practitioners, and policy makers?

Scenario building provides an opportunity to think outside the box. We have considered current global instabilities and future drivers of change to create five scenarios of how academic medicine might look in 2025. These generate possibilities for what strategic decisions need to be taken today. The aims of this seminar are to introduce five future scenarios for academic medicine, discuss the similarities and differences between them, debate their relative merits, and identify decisions that must be taken now to ensure the most desirable future.

Sub-plenary session

11:00 - 12:00

Sub-plenary session 7

Room **Bordeaux Level 3**

Moderator: G.N. Thalmann, Berne (CH)

11:00 - 11:20

State-of-the-art lecture *Is there still a place for open stone surgery?*

Speaker: J.J.M.C.H. De La Rosette, Amsterdam (NL)

bord-6-0310

11:20 - 12:00

Drugs in urology: Current controversies *Zoledronic acid and protection of the skeleton in prostate cancer*

The evidence

Y. Hei (Novartis US)

bord-6-0320

The urologist's view

C.C. Schulman, Brussels (BE)

bord-6-0330

M.P. Wirth, Dresden (DE)

bord-6-0340

Debate: The way forward and questions from the audience

bord-6-0350

Y. Hei (Novartis US)

C.C. Schulman, Brussels (BE)

M.P. Wirth, Dresden (DE)

Thursday, 6 April - EAU Programme

Abstract Session

12:15 - 13:45

Laparoscopic surgery in renal cell carcinoma

eURO Auditorium Level 1

Video Session 3

Chairs: *R. Bollens, Brussels (BE)*
H.G. Van Der Poel, Amsterdam (NL)

All presentations are 14 minutes in length

- V13** **Laparoscopic partial nephrectomy with clamping of the renal parenchyma** eURO-6-0360
A. Manunta, K. Bensalah, S. Vincendeau, G. Verhoest, N. Rioux-leclercq, B. Lobel, F. Guillé, J.J. Patard (Rennes, France)
- V14** **Laparoscopic partial nephrectomy for RCC in warm ischaemia** eURO-6-0370
A. Häcker, K. Leeb, N. Albquami, A. Al Badour, S. Jeschke, G. Janetschek (Mannheim, Germany; Linz, Austria)
- V15** **Laparoscopic upper pole heminephroureterectomy in complete duplication of the ureter** eURO-6-0380
P. Casale, M. Simone, R. Marzano, C. Casarosa, G. Pomara, F. Francesca (Pisa, Italy)
- V16** **Tachosil® is an effective haemostatic aid during laparoscopic partial nephrectomy in a porcine model** eURO-6-0390
D. Murphy, R. Puri, P. Rimington, A. Rane (London, Bradford, Eastbourne, Redhill, United Kingdom)
- V17** **A refined technique of laparoscopic nephroureterectomy** eURO-6-0400
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)
- V18** **Laparoscopic removal of local recurrence of renal cell carcinoma (RCC)** eURO-6-0410
A. Tsivian, S. Benjamin, A. Kheifets, A.A. Sidi (Holon, Israel)

Abstract Session

12:15 - 13:45

Testis tumours: Diagnosis and management

Room Blue Level 2

Oral Session 4

Chairs: P. Albers, Kassel (DE)
F.M.J. Debruyne, Nijmegen (NL)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

- P. Albers, Kassel (DE) blue-6-0420
- 296 **Real-time elastography for evaluation of testicular masses: Initial experience** blue-6-0430
L. Pallwein, H. Steiner, T. Akkad, G. Bartsch, F. Frauscher (Innsbruck, Austria)
- 297 **MR imaging in the histological characterisation of testicular tumours** blue-6-0440
A. Tsili, C. Tsampoulas, X. Giannakopoulos, A. Silakos, E. Arkoumani, N. Sofikitis, S. Efremidis (Ioannina, Greece)
- 298 **Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumours; is shift to risk adapted policy justified?** blue-6-0450
R.T. Divrik, B. Akdogan, H. Ozen, F. Zorlu (Izmir, Ankara, Turkey)
- 299 **Management of bilateral testicular germ cell tumours – experience of the German testicular cancer study group (GTCSG)** blue-6-0460
A. Heidenreich, P. Albers, S. Krege (Cologne, Kassel, Essen, Germany)
- 300 **Post chemotherapy retroperitoneal lymph node dissection – is full bilateral resection always necessary?** blue-6-0470
H. Steiner, R. Peschel, T. Müller, T. Akkad, C. Gozzi, G. Bartsch (Innsbruck, Austria)
- 301 **The value of post chemotherapy surgery in the management of patients harbouring liver metastases from germ cell tumours** blue-6-0480
J. Hartmann, O. Rick, K. Öchsle, T. Gauler, P. Schöffski, J. Schleicher, F. Mayer, R. Teichmann, L. Kanz, C. Bokemeyer, M. Kuczyk (Tübingen, Berlin, Essen, Hanover, Hamburg, Germany)
- 302 **Open versus laparoscopic retroperitoneal lymph node dissection in clinical stage I nonseminomatous germ cell tumour: A comparative study of quality of life and reconvalescence** blue-6-0490
V. Poulakis, W. Dillenburger, K. Skriapas, R. De Vries, U. Witzsch, E. Becht (Frankfurt am Main, Germany)
- 303 **Organ sparing surgery in small testicular tumours does not lead to development of anti-sperm antibodies** blue-6-0500
H. Steiner, T. Müller, T. Akkad, C. Gozzi, M. Neyer, G. Bartsch (Innsbruck, Austria)
- Summary**
F.M.J. Debruyne, Nijmegen (NL) blue-6-0510

Oral Session 5

Chairs: L. Egevad, Stockholm (SE)
H. Patel, London (GB)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

L. Egevad, Stockholm (SE) bord-6-0520

304 Detailed analysis of histopathological parameters and PCA3 test results bord-6-0530

M. Van Gils, D. Hessels, C. Hulsbergen-Van De Kaa, F. Witjes, B. Knipscheer, C. Jansen, P. Peelen, O. Van Hooij, S. Jannink, S. Hanssen, P. Mulders, J. Schalken (Nijmegen, The Netherlands)

305 Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7 bord-6-0540

C. Mian, F. Marziani, M. Lodde, E. Comploj, S. Palermo, L. Lusuardi, M. Mian (Bolzano, Italy)

306 Adverse pathological findings in patients with needle biopsy Gleason score 6 prostate cancer with a PSA level of 2-4ng/ml and 4-10ng/ml following radical prostatectomy bord-6-0550

J. Bektic, A.E. Pelzer, A.P. Berger, G. Bartsch, W. Horninger (Innsbruck, Austria)

307 Anterior and posterior T1c prostate cancer, clinical and histopathological characteristics of 202 cases bord-6-0560

S. Arbeláez Arango, F. Aguiló Lúcia, E. Condom Mundó, J. Suarez Novo, F. Vigués Juliá, J. Muñoz Seguí, N. Serrallach Mila (Barcelona, Spain)

308 Grade inflation in prostate cancer throughout 20 consecutive years of radical prostatectomy at the same institution. Is there a real upward shift in grade? bord-6-0570

A. Salonia, G. Zanni, M. Scavini, M. Freschi, F. Montorsi, L.F. Da Pozzo, V. Scattoni, R. Bertini, G. Guazzoni, P. Karakiewicz, P. Rigatti (Milan, Italy; Montreal, Canada)

309 Competitive evaluation of the 1992 and 2002 pathologic T3 substages in prediction of biochemical recurrence after radical prostatectomy bord-6-0580

T. Steuber, A. Erbersdobler, A. Haese, T. Schlomm, M. Graefen, H. Huland, P. Karakiewicz (Hamburg, Germany; Montreal, Canada)

310 Intraoperative pathological staging of prostate cancer during radical retropubic prostatectomy bord-6-0590

S. Lacquaniti, P. De Giuli, P.P. Fasolo, E. Conti, N. Dogliani, G. Sebastiani, R. Mandras, L. Puccetti, G. Fasolis (Alba, Italy)

311 **Determination of preoperative PSA and Gleason score from punch biopsy alone is limited in the prediction of lymph node metastasis in prostate carcinoma patients** bord-6-0600
M. Musch, V. Klevecka, U. Roggenbuck, S. Stoerkel, D. Kroepfl (Essen, Wuppertal, Germany)

Summary

H. Patel, London (GB)

bord-6-0610



Poster Session 19

Chairs: *I. Moncada-Iribarren, Madrid (ES)*
V. Mirone, Naples (IT)

Study for 30 min. Interactive discussion for 60 min.

- 312** **Erectile dysfunction predictor for acute myocardial infarction and stroke**
B.W.V. Schouten, A.M. Bohnen, J.L.H. Bosch, J.W. Deckers, R.M.D. Bernsen, S. Thomas (Rotterdam, Utrecht, The Netherlands)
- 313** **Erectile dysfunction as a predictive factor of coronary artery disease: A prospective study**
F. Dubosq, T. Lebret, A. Guiomord, C. Tainturier, J.C. Bousquet, H. Botto (Suresnes, Paris, France)
- 314** **A cross sectional study of the effects of vascular disease on corporal oxygen saturation (StO₂) in the flaccid and erect penis**
P. Padmanabhan, S. Telegrafi, A. Mccullough (New York, United States of America)
- 315** **Male sexual dysfunction after stroke: Correlation between brain lesion and sexual function**
J. Hyun, S.C. Gam, J.H. Chong, O. Kwon, K. Moon (Jinju, Daegu, South Korea)
- 316** **Vascular risk factors and erectile dysfunction in healthy men**
A. Ponholzer, C. Temml, M. Marszalek, K. Mock, M. Rauchenwald, S. Madersbacher (Vienna, Austria)
- 317** **The effect of vardenafil (Levitra) on endothelial function of cavernous and brachial arteries in patients with erectile dysfunction**
E. Mazo, S. Gamidov, V. Iremashvili (Moscow, Russia)
- 318** **Endothelial function of brachial and cavernous arteries in patients with erectile dysfunction**
S. Gamidov, E. Mazo, V. Iremashvili (Moscow, Russia)
- 319** **Erectile dysfunction in patients suffering from adrenal tumours**
J. Stefancik, B. Trebaticky, J. Dubravicky, J. Brutenic, J. Breza (Bratislava, Slovakia)
- 320** **Thoughts and views on erectile dysfunction in the 50+ population in Belgium**
H. Claes, H. Van Poppel (Leuven, Belgium)
- 321** **The impact of discussions between men with erectile dysfunction (ED) and their doctors on continuation of PDE5 inhibitor treatment: Subset analysis of men with ED from the multinational men's attitudes to life events and sexuality (MALES) phase II study**
W.A. Fisher, R. Rosen, I. Eardley, M. Sand (Ontario, Canada; Piscataway, Westhaven, Connecticut, United States of America; Leeds, United Kingdom)
- 322** **Female partners' attitudes are associated with treatment seeking for erectile dysfunction (ED) in men with ED**
W.A. Fisher, R. Rosen, I. Eardley, M. Sand (Ontario, Canada; Piscataway, Westhaven, Connecticut, United States of America; Leeds, United Kingdom)

- 323** **Clinimetric properties of LISAT-8 questionnaire as a screening tool for erectile dysfunction**
I. Moncada-Iribarren, J. Rejas, E.M. Martinez, C. Fernandez Micheltorena (Madrid, Spain)
- 324** **Daytime penile tumescence testing during midazolam induced sleep after the nocturnal sleep deprivation at the previous night**
Y.S. Song, K.H. Lee, K.J. Kim, Y.H. Park (Seoul, South Korea)
- 325** **Erectile functions and nocturnal penile tumescence and rigidity monitoring in men with lower urinary tract symptoms**
T. Jakubczyk, P. Kryst, K. Pych, B. Dybowski, R. Hanecki, A. Gugala, A. Borkowski (Warsaw, Poland)
- 326** **Apolipoprotein E knockout mice as a new model of hypercholesterolaemia and atherosclerosis-associated erectile dysfunction**
D. Behr-Roussel, B. Darblade, A. Oudot, S. Compagnie, J. Bernabé, L. Alexandre, F. Giuliano (Gif Sur Yvette, Garches, France)

Poster Session 20

Chairs: *B. Ljungberg, Umeå (SE)*
J.J. Patard, Rennes (FR)

Study for 30 min. Interactive discussion for 60 min.

- 327 Association between tumour necrosis and usual prognostic parameters in renal cell carcinoma**
N. Rioux-Leclercq, P. Fergelot, K. Bensalah, B. Lobel, F. Guille, A. Manunta, S. Vincendeau, **J. Patard** (Rennes, France)
- 328 Diagnostic and evolutive patterns of renal cell carcinoma in adults 40 years or less: Comparative study versus older patients**
X. Taccoen, **A. Valeri**, J. Descotes, V. Morin, E. Stindel, L. Doucet, F. Bocqueraz, C. Coulange, J. Rambeaud, G. Fournier, A. Mejean (Brest, Grenoble, Marseille, Paris, France)
- 329 Histopathology of renal tumours of 4 cm or less: A Korean multi-institutional study**
S.J. Hong, Y.D. Choi, H.K. Lim, S.J. Kim, B.H. Chung, D.H. Seong, C.I. Kim, **S.I. Kim**, S.H. Cheon, J.S. Cho, Y.S. Song, Y.S. Kim, I.R. Cho, D.H. Lee, K.H. Song, H.S. Kim (Seoul, Suwon, Incheon, Daegu, Ulsan, Anyang, Goyang, Daejeon, Chungju, South Korea)
- 330 Renal cancer and kidney tuberculosis**
E. Kulchavenya (Novosibirsk, Russia)
- 331 Renal tumours in young patients (20-40 years): Analysis of 120 tumours and comparison of presentation and outcome with older patients**
S. Siemer, J. Lehmann, F. Becker, B. Wullich, M. Stöckle (Homburg/Saar, Germany)
- 332 Long-term outcome of patients with papillary renal cell carcinoma**
F.H. Hartmann, U. Ramp, F.R. Moltzahn, I. Wolff, R. Ackermann, M. Grimm (Düsseldorf, Germany)
- 333 Risk classification of renal cell carcinoma - NARA Oncology Research Group Experience**
M. Tanaka, K. Fujimoto, H. Kondo, Y. Chihara, N. Tanaka, M. Tanaka, Y. Hirao (Kashihara, Japan)
- 334 Hsp27 expression in primary and metastatic renal cell carcinoma**
R. Zigeuner, N. Droschl, V. Tauber, P. Rehak, C. Langner (Graz, Austria)
- 335 Renal cell carcinoma in the Netherlands: Difference in stage presentation in the last decade**
I. Kümmerlin, F. Ten Kate, H. Wijkstra, J. De La Rosette, P. Laguna (Amsterdam, The Netherlands)
- 336 Retrospective prognostic value of nodal and distant metastases in renal cell carcinoma**
E. Leray, P. Fergelot, N. Rioux-Leclercq, K. Bensalah, A. Valeri, A. Mejean, V. Ficarra, W. Artibani, L. Cindolo, A. De La Taille, L. Salomon, J. Tostain, D. Chautard, L. Schips, R. Zigeuner, C.C. Abbou, B. Lobel, F. Guille, E. Lechevallier, J. Descottes, A. Manunta, S. Vincendeau, **J.J. Patard** (Rennes, Brest, Paris, Creteil, St Etienne, Angers, Marseille, Grenoble, France; Verona, Benevente, Italy; Graz, Austria)

- 337 Survival and prognostic classification of patients with metastatic kidney cancer of bone**
Y. Toyoda, N. Shinohara, T. Harabayashi, T. Abe, T. Akino, A. Sazawa, K. Nonomura (Sapporo, Japan)
- 338 External validation of the Mayo Clinic sign score to predict cancer-specific survival using a European series of conventional renal cell carcinoma**
V. Ficarra, C. Lohse, G. Novara, A. Galfano, S. Cavalleri, G. Martignoni, W. Artibani (Verona, Italy; Rochester, United States of America)
- 339 Renal tumours between 3 and 4cm show significantly more aggressive parameters than tumours equal or less than 3cm. An analysis of 287 renal tumours ≤ 4 cm**
M. Remzi, H.C. Klingler, M. Öszoy, M. Susani, M. Waldert, C. Seitz, E. Tanovic, M. Dobrovits, J. Schmidbauer, M. Marberger (Vienna, Austria)
- 340 Analysis of clinical-pathological features and survival for patients under the age of 40 with renal cortical tumours**
M. Ordonez, M. Snyder, A. Iasonos, F. Secin, P. Russo, B. Guillonneau, K. Touijer (New York, United States of America)
- 341 Congenital renal arteriovenous malformation: Diagnostic clues and methods**
D.G. Lee, J.S. Huh, S.H. Jeon, S.J. Lee (Seoul, Cheju, South Korea)

Poster Session 21

Chairs: *F. Keeley, Bristol (GB)*
J-G. Valdivia Uria, Zaragoza (ES)

Study for 30 min. Interactive discussion for 60 min.

- 342 Predictors of pain during outpatient flexible cystoscopy**
S.S. Kommu, R.S. Surange, M. Gupta, S.D. Chowdhury, N.K. Sharma (London, Oldham, United Kingdom)
- 343 A prospective audit of flexible ureterorenoscopy and holmium laser lithotripsy for the treatment of intrarenal calculi**
J. Henderson, L. Ajayi, K. Thomas, P. Dasgupta, R. Tiptaft, J. Glass (London, United Kingdom)
- 344 Ureteroscopic retrieval of migrated stents under local anaesthesia**
K. Livadas, A. Skolarikos, I. Varkarakis, D. Chalikopoulos, E. Karagiotis, G. Alivizatos, A. Bisas (Athens, Greece)
- 345 Flexible ureteroscopy in the treatment of renal stones**
L.G. Luciani, G. De Giorgi, M. Zanin, F. Zattoni (Trento, Udine, Italy)
- 346 Influence of stone retrieval devices on deflection-ability of double bending flexible ureteroscopes**
V. Zimmermanns, P. Liske, S. Lahme (Pforzheim, Germany)
- 347 Pig kidney: Anatomical relationships between the renal venous arrangement and the kidney collecting system - applied study for urological research and surgical training**
L. Favorito, H. Bagefi Filho, M.A. Pereira-Sampaio, F. Sampaio (Rio de Janeiro, Brazil)
- 348 Ex vivo training model for percutaneous renal surgery**
W.L. Strohmaier, A. Giese (Coburg, Germany)
- 349 Percutaneous nephrolithotripsy (PCNL) in supine position: Our experience**
A. Frattini, P. Salsi, S. Ferretti, M. Ciuffreda, P. Cortellini (Parma, Italy)
- 350 Percutaneous nephrolithotomy in the supine position**
I. Camargo, G. Ibarluzea, M. Gamarra, J.A. Gallego, A. Astobieta, J.J. Aurtenetxe, A. Bildosola, I. Gurtubay, A. Jorge, N. Prieto (Bilbao, Spain)
- 351 Miniperc? No, thank you**
G. Giusti, M. Seveso, G. Taverna, A. Piccinelli, A. Benetti, L. Pasini, P. Graziotti (Milan, Italy)
- 352 Detection of residual stones after percutaneous nephrolithotomy: Role of non-enhanced spiral computed tomography**
Y. Osman, N. El-tabey, H. Refai, A. Elnahas, A. Shoma, I. Eraky, M. Kenawy, H. El-Kapany (Mansoura, Egypt)
- 353 Is percutaneous nephrolithotomy a safe and effective procedure for treatment of renal stones in children?**
F. Dal Moro, A. Capizzi, W. Rigamonti, M. Cosentino, A. Cisternino, T. Prayer Galetti, W. Artibani (Padua, Italy)

- 354** **Intraoperative complications in PCNL. Observations of a teaching centre after more than 1800 procedures**
F. Miclea, M. Botoca, P. Boiborean, V. Bucuras, I. Herman, A. Cumpanas, D. Tigaran (Timisoara, Romania)
- 355** **The effect of previous ipsilateral open stone surgery on percutaneous nephrolithotomy**
T. Erdogru, A. Danisman, A. Sanli, O. Kutlu, M. Ucar, M. Baykara (Antalya, Turkey)
- 356** **Management of residual renal stone fragments after percutaneous nephrolithotomy: About 63 patients**
S. Sallami, M. Cheliff, I. Bensalah, G. Hafsia, S. Ben Rhouma, Y. Nouira, A. Horchani (Tunis, Tunisia)

Poster Session 22

Chairs: *O.W. Hakenberg, Dresden (DE)*
L.N. Türkeri, Istanbul (TR)

Study for 30 min. Interactive discussion for 60 min.

- 357** Inhibitory effect of vitamin E on cigarette smoke induced oxidative damage to transitional cell epithelium in a rat model
F.F. ÖnoI, Y. Temiz, M. Yüksel, F. Eren, L. Türkeri (Istanbul, Turkey)
- 358** Tissue inhibitor of metalloproteinase-2 (TIMP-2) expression assessed by real time RT-PCR assay in peripheral blood is a marker of metastatic disease in bladder cancer
C. Pascual-Mateo, A. Ferruelo, M. Lujan, J.M. Garcia, A. Berenguer, J.C. Angulo (Getafe, Spain)
- 359** Triptolide (PG490)-mediated sensitisation of urothelial cancer cells to cisplatin induced apoptosis
Y. Matsui, J. Watanabe, H. Nishiyama, H. Kawanishi, M. Ito, T. Takahashi, T. Kamoto, O. Ogawa (Kyoto, Japan)
- 360** Cigarette smoking, professional exposition, Ki-67, p53, mitotic index and bladder cancer prognosis: A case-control clinical study
G. Casetta, A. Zitella, A. Greco, A. Tizzani (Torino, Italy)
- 361** Peptabody-EGF: A novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells
C. Kündig, O. Fattah, S. Rotman, S. Cloutier, L. Felber, C. Gygi, P. Jichlinski, H.J. Leisinger, P. De Witte, G. Thalman, J.P. Mach, D. Deperthes (Epalinges, Lausanne, Berne, Switzerland; Leuven, Belgium)
- 362** Initial experience with evaluation of bladder tumour growth in the nude rat using a newly developed mini-endoscope: A new orthotopic transitional cell cancer model
C. Bolenz, Y. Cao, M. Wenzel, M. Fernandez, L. Trojan, P. Alken, M.S. Michel (Mannheim, Germany)
- 363** In vitro study of epirubicin and ciprofloxacin induced apoptosis in human urothelial cancer cell lines
D. Engeler, E. Scandella, H. Schmid, B. Ludewig (St. Gallen, Switzerland)
- 364** Microsatellite instability and mutation analysis of candidate genes in urothelial cell
P. Mongiat Artus, C. Miquel, M. Van Der Aa, O. Buhard, R. Hamelin, H. Soliman, C. Bangma, A. Janin, P. Teillac, T. Van Der Kwast, F. Praz (Paris, Villejuif, France; Rotterdam, The Netherlands)
- 365** Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma
M. Rouprêt, G. Fromont, G. Cancel-Tassin, A. Azzouzi, J.W. Catto, F.C. Hamdy, G. Vallancien, F. Richard, O. Cussenot (Paris, Angers, France; Sheffield, United Kingdom)
- 366** Urinary survivin is a biomarker for the diagnosis of invasive bladder cancer
J.L. Campos-Fernandes, F. Descotes, M. Decaussin, J. André, P. Paparel, D. Collin-chavagnac, R.C. Boisson, P. Perrin, M. Devonec, A. Ruffion (Pierre Bénite, Lyon, France)

- 367 DNA methylation alterations in bladder cancer**
A. Neuhausen, A.R. Florl, M. Grimm, W.A. Schulz (Düsseldorf, Germany)
- 368 Genetic profiling of urothelial carcinomas of the upper urinary tract**
K. Junker, B. Jentsch, R. Stöhr, M. Burger, A. Hartmann, J. Schubert (Jena, Regensburg, Germany)
- 369 Single-nucleotide polymorphism of ninjurin gene is associated with higher risk for human bladder cancer progression**
A. Sarkis, L. Ribeiro-filho, P.E. Guimaraes, J. Pontes Junior, I. Amorin Da Silva, V. Sa, H. Shiina, R. Dahiya, M. Srougi (Sao Paulo, Brazil; San Francisco, United States of America)
- 370 20q13 gain is associated with chromosomal instability in transitional cell carcinomas of the upper urinary tract**
J. Akao, H. Matsuyama, Y. Yamamoto, K. Nagao, C. Ohmi, S. Sakano, K. Naito (Ube, Japan)
- 371 Application of Paclitaxel-Eluting metal mesh stents within the pig ureter: An experimental study**
E. Liatsikos, T. Voudoukis, D. Karnabatidis, N. Christeas, G. Kagadis, N. Flaris, C. Scopa, P. Perimenis, K. Filos, G. Nikiforidis, J. Stoljenburg, D. Siablis (Patras, Greece; Leipzig, Germany)

Poster Session 23

Chairs: *J. Heesakkers, Nijmegen (NL)*

P. Radziszewski, Warsaw (PL)

Study for 30 min. Interactive discussion for 60 min.

- 372 Prevalence of overactive bladder syndrome: European results from the EPIC study**
D. Irwin, I. Milsom, K. Reilly, S. Hunskaar, Z. Kopp, S. Herschorn, C. Kelleher, C. Hampel, W. Artibani, P. Abrams (Chapel Hill, New York, United States of America; Goteborg, Sweden; Bergen, Norway; Toronto, Canada; London, Bristol, United Kingdom; Mainz, Germany; Padova, Italy)
- 373 Prevalence of incontinence and overactive bladder: European results from the EPIC study**
K. Reilly, I. Milsom, D. Irwin, S. Hunskaar, Z. Kopp, S. Herschorn, C. Kelleher, C. Hampel, W. Artibani, P. Abrams (New York, Chapel Hill, United States of America; Goteborg, Sweden; Bergen, Norway; Toronto, Canada; London, Bristol, United Kingdom; Mainz, Germany; Padova, Italy)
- 374 Epidemiological study of risk factors for urinary incontinence and overactive bladder in a primary care population**
J.M. Mendive, S. Armengol (Barcelona, Spain)
- 375 Tolterodine extended release (TER) for overactive bladder (OAB): Improvement in objective symptoms is correlated with reductions in symptom bother and improvement in health-related quality of life**
M. Brodsky, D.B. Glasser, K.S. Coyne, Z. Jumadilova, M. Carlsson (New York, Bethesda, United States of America)
- 376 Symptom-specific efficacy of tolterodine extended release in primary care patients with overactive bladder**
D.B. Glasser, V. Elinoff, T. Bavendam, M. Carlsson, N. Eyland, R.G. Roberts (New York, Endwell, Madison, United States of America)
- 377 Differential effects of the antimuscarinic agents darifenacin and extended-release oxybutynin on recent memory in older subjects**
G. Kay, T. Crook, L. Rebeda, R. Lima (Washington, Fort Lauderdale, East Hanover, United States of America)
- 378 Long-term treatment of overactive bladder with darifenacin in older patients: Analysis of responder rates in a 2-year, open-label extension study**
F. Haab, S. Hill, K. Lheritier, F.T. Kawakami, M. Gittelman (Paris, France; Blackburn, United Kingdom; Basel, Switzerland; Aventura, United States of America)
- 379 Fesoterodine in non-neurogenic voiding dysfunction - results on efficacy and safety in a phase 3 trial**
C. Chapple, P. Van Kerrebroeck, A. Tubaro, R. Millard (Sheffield, United Kingdom; Maastricht, The Netherlands; Rome, Italy; Randwick, Australia)
- 380 The STAR study: Analysis of symptom severity and treatment response in overactive bladder**
C. Chapple, R. Fiala, L. Gorilovsky, I. Mincik, S. Pasechnikov, D. Pushkar, M. Wright, J. Bolodeoku (Sheffield, Staines, United Kingdom; Oloumouc, Czech Republic; Moscow, Russia; Presov, Slovakia; Kyiv, Ukraine)

- 381 Botulinum toxin-A is safe and effective in the treatment of patients with overactive bladder and idiopathic detrusor overactivity: Results from a randomised, double blind, placebo controlled trial**
A. Sahai, S. Khan, P. Dasgupta (London, United Kingdom)
- 382 Experience including long-term results of 150 cases treated with Botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics**
D.M. Schmid, P. Saueremann, M. Werner, D. Perucchini, R. Strebel, M. Muntener, N. Blick, P. Jaeger, D. Hauri, B. Schurch (Zurich, Switzerland)
- 383 Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study**
A. Giannantoni, E. Costantini, S.M. Di Stasi, M.C. Tascini, F. Santaniello, M. Del Zingaro, M. Porena (Perugia, Rome, Italy)
- 384 Botulinum toxin B is not an effective treatment of the refractory overactive bladder**
H. Graham, A. Watkins, K. Wareham, S. Emery, D. Jones, M. Lucas (Swansea, Llantrisant, United Kingdom)
- 385 Surgical reinterventions following InterStim® sacral nerve modulation implant – 11 years experience**
J. Gajewski (Halifax, Canada)
- 386 Nocturia and overactive bladder: Do they have similar aetiology?**
K.A. Tikkinen, T. Tammela, A. Auvinen (Tampere, Finland)

Poster Session 24

Chairs: *F.K. Habib, Edinburgh (GB)*

T. Prayer-Galetti, Padua (IT)

Study for 30 min. Interactive discussion for 60 min.

- 387 Benign prostatic hyperplasia may be an epigenetic disease**
T.H. Kim, W.C. Moon, M.R. Oh, T.H. Uhm, C.H. Noh (Seoul, South Korea)
- 388 Prostate hypertrophy induced by testosterone: Effect of oxybutynin in an experimental model of overactive bladder in conscious rats**
V. Julia-guilloteau, K. Mevel, A. Oudot, J. Bernabé, P. Denys, E. Chartier-Kastler, L. Alexandre, F. Giuliano (Gif Sur Yvette, Garches, Paris, France)
- 389 Benign prostatic hyperplasia specimens derived from patients after urinary retention show significantly more prostate glands with upregulation of HLA-DR and loss of CD38 than those derived from patients without urinary retention**
G. Kramer, M. Dieter, K. Hrachowitz, C. Seitz, M. Marberger (Vienna, Austria)
- 390 Are muscarinic receptors of the prostate having significant role in the pathophysiology of bladder outlet obstruction? Phase 1 (in vitro-) study**
M. Abdel-Khalek, A. Nabieh, E. Ibrahim (Mansoura, Egypt)
- 391 Expression of proinflammatory interleukin-17B,-C,-E and their receptors in prostatic tissue**
K. Hrachowitz, G. Kramer, G. Steiner, M. Marberger (Vienna, Austria)
- 392 Changes of calcium-activated potassium channel expressions in rat bladder and ureter after relieving partial bladder outlet obstruction**
D. Kim, E.K. Yang, J.W. Kim (Daegu, South Korea)
- 393 Insulin, estrogen and lean body mass - three risk factors for the development of benign prostatic hyperplasia**
J. Hammarsten, J.E. Damber, O. Johnell, T. Knutson, Ö. Ljunggren, C. Ohlsson, R. Pecker, D. Mellström (Borås, Göteborg, Malmö, Uppsala, Sweden)
- 394 Morphometric analysis of the prostate demonstrates the importance of the loco-regional morphology to the mechanical characteristics of the gland**
S. Leung, S. Phipps, J. Yang, R. Rueben, F. Habib, A. McNeill (Edinburgh, United Kingdom)
- 395 The effects of the ATP - sensitive potassium channel opener, cromakalim, on the contractile activity of human and pig prostates**
H. Akino, C.R. Chapple, R. Chess-Williams (Sheffield, United Kingdom)
- 396 Alfuzosin reverses bladder hypertrophy induced by bladder outlet obstruction in rats**
P. Lluel, M. Méen, S. Palea (Toulouse, France)

- 397 Nitric oxide donors reverse the tension induced by endothelin-1 of isolated human prostate tissue and stimulate the production of cyclic GMP**
G. Kedia, M. Truss, T. Chigogidze, L. Managadze, U. Jonas, S. Ückert (Hanover, Dortmund, Germany; Tbilisi, Georgia)
- 398 The expression pattern of TNF receptors family on the prostate epithelial from BPH patients after the α -1 antagonist treatment. An in vitro assay**
T. Drewa, Z. Wolski, B. Misterek, R. Debski, Z. Skok (Bydgoszcz, Poland)
- 399 Effects of nitric oxide synthases on overactive bladder after relief of bladder outlet obstruction in rats**
H. Kim, M. Choo, J.C. Kim, S.M. So (Daejeon, Seoul, South Korea)
- 400 Analysis of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia**
F. Sampaio, M. Babinski, M. Chagas, F. Carrerete, W. Costa (Rio de Janeiro, Brazil)
- 401 BPH: Histological aspects of adenoma mononuclear cell infiltration**
F. Manzarbeitia, R. Vela Navarrete, J.L. Sarasa, J.V. García Cardoso, C. González Enguita (Madrid, Spain)

Poster Session 25

Chairs: *A. Meye, Dresden (DE)*
R.W.G. Watson, Dublin (IE)

Study for 30 min. Interactive discussion for 60 min.

- 402** Mutations of epidermal growth factor receptor in hormone sensitive and refractory prostate cancers
Y.D. Choi, N.H. Cho, K. Park, J.S. Lee (Seoul, South Korea)
- 403** Role of promyelocytic leukaemia zinc finger (PLZF) and pre-B-cell leukaemia transcription factor (PBX1) in androgen-independent prostate cancer cell growth
T. Kikugawa, S. Higashiyama, N. Tanji, M. Yokoyama (Toon, Japan)
- 404** Abnormal ERK5 expression is associated with metastatic, androgen-independent human prostate cancer and stimulates proliferation, migration, invasion and MMP-1, -2 and -9 expression
S. McCracken, M. Mathers, J. Edwards, C. Robson, P. Cohen, H. Leung (Newcastle upon Tyne, Glasgow, Dundee, United Kingdom)
- 405** Rheb, a novel small G-protein of Ras superfamily, is associated with proliferation in human prostate cancer cell lines
T. Kobayashi, T. Inoue, Y. Shimizu, T. Segawa, T. Kamoto, E. Nakamura, O. Ogawa (Kyoto, Japan)
- 406** Differential regulation of the A-type cyclins in response to interleukin-6 treatment is mediated by PI3k-Akt and map kinase pathways in LnCaP prostate cancer cell line
B. Wegiel, J. Persson, Z. Culig, A. Bjartell (Malmö, Sweden; Innsbruck, Austria)
- 407** Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells
T. Shin, H. Sumiyoshi, N. Matsuo, F. Sato, H. Mimata, H. Yoshioka (Yufu-shi, Oita, Japan)
- 408** Osteoprotegerin derived from tumour cells or from bone marrow cell types differs in its activity as a survival factor for prostate cancer
N. Cross, E. Waterman, N. Jokonya, I. Holen, F. Hamdy, C. Eaton (Sheffield, United Kingdom)
- 409** Functional analyzes of C13orf19 in prostate cell lines
D. Kunze, U. Schmidt, S. Fuessel, U. Stelzl, A. Meye, M.P. Wirth (Dresden, Berlin, Germany)
- 410** Grade-specific characterization of VEGF and Cox-2 expression in benign prostatic hyperplasia and prostate cancer: Switch of angiogenic factor expression in high-grade carcinomas
K. Gyftopoulos, K. Vourda, E. Papadaki, P. Perimenis, G. Sakellaropoulos, I. Varakis (Patras, Greece)
- 411** Extracellular matrix dermatopontin modulates prostate cell growth in vivo
T. Takeuchi, M. Suzuki, J. Kumagai, M. Sakai, T. Kitamura (Tokyo, Japan)

- 412** **Hormone treatment alters expression of RNaseL and oligoadenylate synthetases in hormone sensitive prostate cell lines**
J. Kamradt, H. Cunliffe, [B. Wullich](#), M. Stöckle, P. Meltzer (Homburg/Saar, Germany; Bethesda, United States of America)
- 413** **Androgen regulated human homeobox gene OTEX is expressed in androgen dependent LNCaP cells and down-regulated in the pure androgen independent prostate cancer**
[K.C. Chen](#), C. Peng, H. Hsieh-Li (Taipei, Taiwan)
- 414** **Characterization for the molecular signalling pathway through with androgen deprivation upregulated Akt phosphorylation in LNCaP prostate cancer cells**
R. Buttyan, X. Yang, D. Bemis, M. Benson, F. Vacherot, S. Terry, [A. De La Taille](#) (New York, United States of America; Creteil, France)
- 415** **Human prostate fibroblasts of different zonal origin induce LNCaP cell proliferation, androgen-independence and bone metastasis**
[G.N. Thalmann](#), H. Rhee, R. Sikes, S. Pathak, H. Zhau, U.E. Studer, L. Chung (Berne, Switzerland; Atlanta, Delaware, Houston, United States of America)
- 416** **Drug-specific modulation of 11C-cholin uptake in human prostate cancer cell lines**
[U. Treiber](#), S. Müller, K. Holzapfel, C. Seidl, H.J. Wester, A. Lehmer, A.L. Grosu, M. Schwaiger, H. Van Randenborgh, R. Paul, N. Zantl, R. Hartung, R. Senekowitsch Schmidtke (Munich, Germany)

Poster Session 26

Chairs: *F. Recker, Aarau (CH)*
P. Wiklund, Stockholm (SE)

Study for 30 min. Interactive discussion for 60 min.

- 417** Intra-cavernosal saline infusion decreases intraoperative blood loss during radical retropubic prostatectomy by using the gate structure of the Santorini plexus
K. Stav, F. Zacci, M. Bahar, A. Lindner, A. Zisman (Zeriffin, Israel)
- 418** Significance of variation in the shapes of prostatic apex and dorsal vein complex observed on preoperative magnetic resonance imaging (MRI) in performing radical retropubic prostatectomy (RRP)
S.K. Hong, I.H. Chang, Y.J. Kim, M.C. Gil, S.B. Lee, J.S. Jeong, H. Jeong, C. Kwak, J.B. Lee, S. Byun, S.E. Lee (Sungnam, Incheon, Koyang, Seoul, South Korea)
- 419** Long term survival after prostatectomy
M. Colombel, M. Xavier, M.L. Florence, M. Jean Marie (Lyon, France)
- 420** Radical prostatectomy in Austria: A nation-wide analysis of 16.524 cases
S. Madersbacher, M. Willinger, M. Rauchenwald (Vienna, Austria)
- 421** Influence of the extent of positive margins on biochemical recurrence after radical prostatectomy
C. Llorente, J.M. De La Morena, D. Martin, C. Capitan, P. Dominguez, M. Alvarez, M. Sanchez (Madrid, Spain)
- 422** Prognostic factors of recurrence following radical prostatectomy for clinically localised prostate cancer. Evaluation of the prostate glandular non-malignant margins
C. Allepuz, A. Borque, M. Allúe, J. Alfaro, M.J. Gil, P. Gil, A. Servera, C. Rioja, L. Rioja (Zaragoza, Spain)
- 423** The effect of surgical volume on failure free survival after radical prostatectomy in the province of Quebec
E. Antebi, S. Benayoun, A. Ramirez, P. Perrotte, M. McCormack, F. Benard, L. Valiquette, F. Saad, P.I. Karakiewicz (Montreal, Canada)
- 424** Ratio of urine loss (UL) to micturation volume (MV) on the first day after catheter removal predicts recover of
D. Teber, M. Ates, A.S. Goetzen, M. Hruza, J. Rassweiler (Heilbronn, Germany)
- 425** Outcome after radical prostatectomy in young men with or without a family history of prostate cancer
M. Rouprêt, G. Fromont, M. Bitker, B. Gattegno, F. Richard, G. Vallancien, O. Cussenot (Paris, France)
- 426** European study on radical prostatectomy (ESRPE)-part I: Surgical and oncological results and changes 1993-2004
B. Djavan, B. Rocco, V. Ravery, P. Hammerer, A. Zlotta, M. Brausi, A. Kaisary, I. Romics, T. Anagnostou, P. Dobronski, M. Marberger (Vienna, Austria; Milan, Italy; Paris, France; Braunschweig, Germany; Brussels, Belgium; London, United Kingdom; Budapest, Hungary; Athens, Greece; Warsaw, Poland)
- 427** European study on radical prostatectomy (ESRPE)-part II: Functional results and changes 1993-2004
B. Djavan, B. Rocco, V. Ravery, P. Hammerer, A. Zlotta, M. Brausi, A. Kaisary, I. Romics, T. Anagnostou,

P. Dobronski, M. Marberger (Vienna, Austria; Milan, Italy; Paris, France; Braunschweig, Germany; Brussels, Belgium; London, United Kingdom; Budapest, Hungary; Athens, Greece; Warsaw, Poland)

428 Anterograde radical retropubic prostatectomy for cure clinically localised prostate cancer: Oncological outcome in a 17-year series

L. Masieri, S. Serni, A. Lapini, A. Minervini, G. Nesi, M. Carloni, G. Vignolini, M. Carini (Florence, Italy)

429 Does surgical manipulation of tumour accelerate cancer dissemination: A prospective longitudinal study of radical prostatectomised cancer patients

P. Eschwège, S. Moutereau, Z. Aboujeili, S. Droupy, Y. Hammoudi, G. Benoit, P. Blanchet, R. Douard, M. Conti, S. Loric (Le Kremlin Bicêtre, Creteil, Paris, France; Pointe A Pitre, Guadeloupe)

430 The use of a morbidity score after radical prostatectomy

M. Hruza, M. Schulze, S. Subotic, C. Stock, D. Teber, J.J. Rassweiler (Heilbronn, Germany)

431 Prevalence and prognostic significance of a tertiary Gleason pattern in radical prostatectomy specimens among a consecutive cohort of 3147 prostate cancer patients

T. Steuber, A. Brieger, A. Erbersdobler, S. Ahyai, T. Schlomm, H. Huland (Hamburg, Germany)


Poster Session 27

Chairs: *D. Dearnaley, Sutton (GB)*

V. Ravery, Paris (FR)

Study for 30 min. Interactive discussion for 60 min.

- 432 Immediate external beam radiation therapy (EBRT) after radical prostatectomy (RP): Long-term influence on QoL, urinary and rectal symptoms**
B. Tombal, B. Debie, A. Feyaerts, R. Opsomer, F.X. Wese, P. Scaillet, P. Van Cangh (Brussels, Belgium)
- 433 A clinical evaluation of the optical characteristics of the prostate in men with prostate cancer**
C. Moore, C.A. Mosse, I. Hoh, H. Payne, C. Allen, S.G. Bown, M. Emberton (London, United Kingdom)
- 434 Vascular-targeted photodynamic therapy in organ confined prostate cancer – report of a novel photosensitiser**
C. Moore, I. Hoh, C.A. Mosse, C. Allen, A. Freeman, S.G. Bown, M. Emberton (London, United Kingdom)
- 435 Match pair analysis HDR brachytherapy vs. thermoradiotherapy using interstitial thermoseeds**
S. Deger, T. Schink, D. Böhmer, K. Taymoorian, J. Roigas, V. Budach, S. Loening (Berlin, Germany)
- 436 Thermotherapy using magnetic nanoparticles in patients with locally recurrent prostate cancer: Initial results of a phase I study**
M. Johannsen, U. Gneveckow, P. Wust, K. Taymoorian, B. Thiesen, N. Waldöfner, S. Deger, R. Scholz, A. Feussner, S.A. Loening, A. Jordan (Berlin, Germany)
- 437 Feasibility of cyberknife for the treatment of localised prostate cancer: Preliminary results**
K. Park, K.H. Kim, M.K. Jo, C. Lee, C.G. Cho (Seoul, South Korea)
- 438 High intensity focussed ultrasound treatment for prostate cancer: Is the internet a good source of patient information?**
S. Patel, S. Kommu, M. Hotston, R. Persad (Bristol, United Kingdom)
- 439 10 years high intensity focused ultrasound (HIFU) as local treatment of prostate cancer: Profile of side effects**
S. Thueroff, K. Knauer, C. Chaussy (Munich, Germany)
- 440 Salvage therapy using high intensity focused ultrasound for local recurrence of prostate cancer after radiation therapy**
S. Mallick, A. Dufour, Y. Fouques, H. Bensadoun (Caen, France)
- 441 Prostate cancer control with transrectal HIFU in 124 patients: Seven-years actuarial results**
A. Gelet, J. Chapelon, F. Murat, L. Curiel, R. Bouvier, O. Rouviere, X. Martin (Lyon, France)
- 442 10 years application of high intensity focused ultrasound (HIFU) in prostate cancer (PCa)**
C. Chaussy, S. Thueroff, K. Knauer (Munich, Germany)

- 
- 443 Salvage HIFU for radiorecurrent prostate cancer: Factors influencing the outcome**
F. Murat, J. Chapelon, L. Poissonnier, R. Bouvier, L. Curiel, X. Martin, A. Gelet (Lyon, France)
- 444 High intensity focused ultrasound (HIFU) in prostate cancer**
V. Zizzi, A. Callea, R. Piccinni, A. Cafarelli, D. Sblendorio, B. Berardi, A. Tempesta, F. Gala, A. Traficante (Bari, Italy)
- 445 Prostate cryosurgery: Not all the freezing probes are the same**
S. Ahmed, J. Davies (Guildford, United Kingdom)
- 446 Cryoablation of prostate cancer using 17 gauge cryoneedles technology 4 year European experience**
U. Witzsch, W. Dillenburg, V. Poulakis, E. Becht (Frankfurt, Germany)

Thursday, 6 April - EAU Programme

Abstract Session

14:00 - 15:30

Open versus laparoscopic radical prostatectomy, the debate?

eURO Auditorium Level 1

Video Session 4

Chairs: M.C. Truss, Dortmund (DE)

M. Zerbib, Paris (FR)

All presentations are 14 minutes in length

- | | | |
|-----|---|-------------|
| V19 | Urachal-sparing laparoscopic radical prostatectomy
F. Secin, F. Bianco, N. Karanikolas, K. Touijer, B. Guillonnet (New York, United States of America) | eURO-6-0620 |
| V20 | Open retropubic nerve-sparing radical prostatectomy – how I do it
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland) | eURO-6-0630 |
| V21 | Selective dissection of the apex during radical prostatectomy allows better tumour control and continence
J. Walz, M. Graefen, A. Haese, H. Heinzer, H. Huland (Hamburg, Germany) | eURO-6-0640 |
| V22 | Nerve-sparing radical prostatectomy - the surgeons view through the Varioscope® M5
R. Goetschl, N. Schmeller (Salzburg, Austria) | eURO-6-0650 |
| V23 | The radical perineal prostatectomy with simultaneous extended pelvic lymphadenectomy via the same incision
J. Beier, H. Keller (Hof, Germany) | eURO-6-0660 |
| V24 | Laparoscopic radical prostatectomy. Differences between the inter-fascial and intra-fascial technique
L. Martínez-Piñero, J.R. Cansino, C. Sanchez, A. Taberero, J. Cisneros, J. De La Peña (Madrid, Spain) | eURO-6-0670 |

Abstract Session

14:00 - 15:30

Kidney tumours: Laparoscopic treatment

Room Blue Level 2

Oral Session 6

Chairs: M. Jewett, Toronto (CA)
V. Pansadoro, Rome (IT)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

V. Pansadoro, Rome (IT) blue-6-0680

447 Morbidity and clinical outcome of nephron sparing surgery in relation to tumour size and indication blue-6-0690

J.J. Patard, M. Crepel, A.J. Pantuck, J.S. Lam, L. Bellec, M. Soulie, B. Albouy, C. Pfister, D. Lopes, L. Salomon, A. De La Taille, C.C. Abbou, J. Bernhard, J. Ferriere, B. Lacroix, J. Tostain, M. Colombel, X. Martin, B. Lobel, F. Guille, R.A. Figlin, A.S. Belldegrun (Rennes, Toulouse, Rouen, Creteil, Bordeaux, St Etienne, Lyon, France; Los Angeles, United States of America)

448 A cost analysis of laparoscopic versus open radical nephrectomy in the management of solid renal tumours - the experience of a tertiary United Kingdom referral centre blue-6-0710

S.S. Kommu, E. Siddiqui, S. Patel, M.P. Wright, F.H. Mumtaz, R.A. Persad (Surrey, Bristol, London, United Kingdom)

449 Effect of obesity on the result of laparoscopic nephrectomy blue-6-0720

T.H. Oh, D.S. Ryu, J.C. Woo, C.H. Chong (Masan, Busan, South Korea)

450 Laparoscopic transperitoneal nephrectomy using a remote-controlled robotic surgical system (Da Vinci®). 40 cases blue-6-0730

J. Hubert, F. Leclers, F. Kotaiche, B. Feuillu, E. Mourey, L. Cormier, R. Kipper (Nancy, France)

451 Can warm ischaemia of more than 30 minutes, during laparoscopic nephron sparing surgery, cause damage of renal parenchyma: Prospective study and preliminary results blue-6-0740

F. Porpiglia, F. Musso, C. Terrone, J. Renard, S. Grande, M. Poggio, R.M. Scarpa (Orbassano, Italy)

452 Photodynamic detection as a new tool to assess resection status in laparoscopic nephron-sparing surgery for renal cell carcinoma blue-6-0750

C. Kuemmel, K. Fehst, H. Gerullis, G. Popken (Berlin, Germany)

453 Laparoscopic partial nephrectomy, single centre experience with 80 cases - outcomes and lessons learned blue-6-0760

A. Nadu, N. Kitrey, M. Laufer, E. Friedman, J. Ramon (Ramat Gan, Israel)

454 Laparoscopic partial nephrectomy: A multi-institutional Italian survey blue-6-0770

A. Celia, G. Guazzoni, V. Pansadoro, V. Disanto, F. Porpiglia, C. Milani, G. Breda (Bassano del Grappa (VI), Milan, Rome, Acqua Viva Delle Fonti, Torino, Padua, Bassano del Grappa, Italy)

Summary

M. Jewett, Toronto (CA) blue-6-0780

Abstract Session

14:00 - 15:30

Bladder cancer: Diagnosis and staging I

Room **Bordeaux Level 3**

Oral Session 7

Chairs: P. Graziotti, Rozzano (IT)
J. Rubio Briones, Valencia (ES)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

J. Rubio Briones, Valencia (ES) bord-6-0790

455 Discrepancy between clinical and pathologic stage: Impact on prognosis following radical cystectomy bord-6-0800

S. Shariat, G. Palapattu, P. Karakiewicz, G. Amiel, A. Gupta, C. Rogers, A. Vazina, P. Bastian, M. Schoenberg, S. Lerner, A. Sagalowsky, Y. Lotan (Dallas, Baltimore, Montreal, Houston, United States of America)

456 Biological significance of squamous and glandular differentiation in urothelial cell carcinoma of the upper urinary tract bord-6-0830

R. Zigeuner, G. Hutterer, T. Chromecki, P. Rehak, C. Langner (Graz, Austria)

457 Tumour necrosis as prognostic indicator in urothelial carcinoma of the upper urinary tract bord-6-0840

C. Langner, G. Hutterer, T. Chromecki, S. Leibl, P. Rehak, R. Zigeuner (Graz, Austria)

458 Is the new two-tiered WHO/ISUP grading system superior to the traditional three-tiered grading system in predicting outcome of patients with upper urinary tract urothelial carcinoma? bord-6-0860

C. Langner, G. Hutterer, T. Chromecki, P. Rehak, R. Zigeuner (Graz, Austria)

459 Review pathology in a diagnostic bladder cancer trial: The impact of patient risk category bord-6-0870

J.A. Witjes, P.M.J. Moonen, A.G. Van Der Heijden (Nijmegen, The Netherlands)

460 Initial diagnosis of bladder cancer using a point-of-care assay bord-6-0880

H. Barton Grossman, NMP22 Clinical Investigation Group (Houston, United States of America)

461 Gene-expression profiles predict nodal metastasis and survival in patients undergoing radical cystectomy bord-6-0890

F. Liedberg, S. Gudjonsson, M. Höglund, D. Lindgren, W. Månsson (Lund, Sweden)

462 Comparison of urinary cytology and fluorescence-in-situ hybridisation assay (FISH) for the detection of urothelial bladder carcinoma bord-6-0900

O. Hakenberg, U. Schmidt, N. Berdjis, A. Meye, F. Wawroschek, A. Baldauf, S. Zastrow, M. Wirth (Dresden, Germany)

Summary

P. Graziotti, Rozzano (IT) bord-6-0910



Poster Session 28

Chairs: A. Martin-Morales, Malaga (ES)
E. Wespes, Charleroi (BE)

Study for 30 min. Interactive discussion for 60 min.

- 463 Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction**
J. Kaufman, J. Dietrich (Aurora, Mountain View, United States of America)
- 464 Hemodynamic effects of co-administration of avanafil and glyceryl trinitrate**
A. Nehra, D. Swearingen, J. Dietrich, C. Peterson (Rochester, Phoenix, Mountain View, United States of America)
- 465 Efficacy and safety of tadalafil 2.5 mg and 5 mg administered once a day in men with diabetes mellitus and erectile dysfunction**
G. Brock, J. Buvat, M. Gambla, D. Hatzichristou, D. Lording, L. Rose, E. Rubio Auriolles, G. Spera, S.Y. Liang, L. Frumkin (London, Canada; Lille, France; Columbus, OH, Bothell, WA, United States of America; Thessaloniki, Greece; Malvern, Australia; Münster, Germany; Delagación Tlalpan, Mexico; Rome, Italy)
- 466 Treatment with sildenafil improves self-esteem in patients with erectile dysfunction. A double-blind, placebo controlled study using the SEAR (self-esteem and relationship) questionnaire**
I. Moncada-Iribarren, J. Koskimaki, L. Rodriguez-Vela, S. Jimenez, J. Chaves (Madrid, Zaragoza, Spain; Tampere, Finland)
- 467 Erectile dysfunction drug (phosphodiesterase-5 inhibitors) associated with nonarteritic anterior ischemic optic neuropathy (NAION)**
C. Calvet, K. Martin, H. Farghal, M. Molimard, N. Moore, R. Ballanger (Bordeaux, France)
- 468 Comparison of clinical efficacy and preference of three different PDE5 inhibitors for the patients with erectile dysfunction**
Y. Changhee, S. Seoung Hun, H. Bumsik, T.Y. Ahn (Seoul, South Korea)
- 469 Timing of sexual intercourse in erectile dysfunction (ED) patients treated with the three available PDE5 inhibitors**
F. Giuliano, E. Vicaud, Y. Jeanpetit, E. Lavallée (Garches, Paris, France)
- 470 Microvascular arterial bypass surgery: Assessment of long-term outcome**
G.V. Fantini, C. Panzer, R. Munarriz, I. Goldstein (Milan, Italy; Boston, United States of America)
- 471 Results of a phase I hMaxi-K gene transfer trial for erectile dysfunction**
A. Melman, N. Bar-Chama, A. Mccullough, K. Davies, G. Christ (Bronx, New York, Winston Salem, United States of America)
- 472 There is no significant difference between on-demand PDE5-I vs. PDE5-I as rehabilitative treatment in patients treated by bilateral nerve-sparing radical retropubic prostatectomy**
F. Montorsi, A. Salonia, A. Gallina, G. Zanni, A. Saccà, F. Dehò, A. Briganti, M. Ghezzi, L. Barbieri, E. Farina,

- J. Schuit Simon, P. Rigatti (Milan, Italy; Rotterdam, The Netherlands)
- 473** **Nightly low dose sildenafil improves recovery of erectile function after nerve-sparing radical prostatectomy**
A. Bannowsky, S. Hautmann, B. Wefer, H. Schulze, C. Van Der Horst, C. Seif, P.M. Braun, K-P. Jünemann (Kiel, Germany)
- 474** **Severe dropout rate from the treatment for erectile dysfunction in non-counselled patients who underwent bilateral nerve sparing radical retropubic prostatectomy**
A. Salonia, A. Gallina, G. Zanni, A. Saccà, S.J. Schuit, L. Barbieri, A. Briganti, E. Farina, P. Rigatti, F. Montorsi (Milan, Milan, Italy; Rotterdam, The Netherlands)
- 475** **Age difference between patient and partner is a predictive factor of potency rate following radical prostatectomy**
A. Descazeaud, M. Peyromaure, B. Debre, T. Flam (Paris, France)
- 476** **The real-life safety and efficacy of vardenafil (REALISE): Subgroup analysis of patients with radical prostatectomy**
H. Van Ahlen, J. Zumbé, K. Stauch, H. Landen (Osnabrück, Leverkusen, Germany)
- 477** **Sexual rehabilitation after radical retropubic prostatectomy: A randomised prospective study on vacuum device + sildenafil vs. alprostadil + sildenafil**
A. Zucchi, L. Mearini, E. Costantini, A. Giannatoni, F. Fioretti, M. Porena (Perugia, Italy)

Poster Session 29

Chairs: *T.E. Bjerklund Johansen, Porsgrunn (NO)*
T. Hanus, Prague (CZ)

Study for 30 min. Interactive discussion for 60 min.

- 478** **Multicentre study on diagnosis of sexually transmitted disease by using oligonucleotide microarray (STD DNA chip)**
W.C. Moon, T.H. Kim, M.R. Oh, C.H. Noh, J.H. Cho (Seoul, South Korea)
- 479** **Protective effects of hyaluronic acid in rats with cyclophosphamide induced cystitis**
S. Lee, J.W. Yi, J. Huh, S.H. Jeon, J.I. Kim (Seoul, Jeju, South Korea)
- 480** **Assessment of immunological response to chlamydia infection in male infertility**
G. Pinggera, G. Walder, K. Tosun, J. Bektic, P. Rehder, R. Herwig, M. Mitterberger, H. Strasser, G. Bartsch (Innsbruck, Austria)
- 481** **MRI in colo-vesical fistula**
S. Ravichandran, S. Matanhelia, M. Dobson (Preston, United Kingdom)
- 482** **Relationship between ciprofloxacin-resistant E coli and complicated urinary tract infection**
K. Ohjung, L. Changug, S. Bongmo (Seoul, South Korea)
- 483** **E Coli resistance in community and hospital acquired urinary tract infections**
B. Lobel, V. Bouygues, A. Valot, O. Gaillot, A. Manunta, K. Bensalah, J.J. Patard, S. Vincendeau, F. Guillé (Rennes, Paris, France)
- 484** **Microbiologic colonization of ileal neobladders**
C. Braun, G. Bartsch, R. Marre, R. Hautmann, B. Volkmer (Ulm, Germany)
- 485** **Long-term effects of antibiotic-coated Foley catheter on bacterial bio film formations and the analysis of auto inducer gene expression related quorum sensing mechanism**
J.Y. Lee, J.S. Koh, K.R. Peck, H.T. Jung, S.S. Lee, S. Song (Pucheon-si, Kyonggi-do, Seoul, Daejeon-si, Suwon-si, South Korea)
- 486** **Heparin coating as a preventive strategy to control catheter-associated urinary tract infections**
P. Tenke, B. Kovács (Budapest, Hungary)
- 487** **A randomised double-blinded placebo controlled cross over trial assessing the effect of cranberry juice intake on mucus production and symptomatic urinary tract infections in patients transposed intestinal segments into the urinary bladder**
G. Nabi, B. Somani, T. Hasan, J. Norrie, J. N'dow (Aberdeen, Newcastle, United Kingdom)
- 488** **Trimethoprim-sulfamethoxazol – first-line treatment for urinary tract infection by methicillin-resistant staphylococcus aureus?**
A. Strauß, S. Seseke, T. Seiler, F. Seseke, R. Ringert (Göttingen, Germany)

- 489 Plasma concentrations, urinary excretion and bactericidal activity of Ciprofloxacin XR (1,000mg) versus Levofloxacin (500mg) in healthy volunteers receiving a single oral dose**
F. Wagenlehner, M. Kinzig-schippers, U. Tischmeyer, C. Wagenlehner, F. Sörgel, W. Weidner, K.G. Naber (Straubing, Nürnberg-Heroldsberg, Giessen, Germany)
- 490 Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis**
B.S. Park, J.S. Huh, S.H. Jeon, S.J. Lee, J.I. Kim, S.G. Chang (Seoul, Jeju, South Korea)
- 491 Urinary tract infection and risk factors after urodynamic studies in female stress urinary incontinence**
J.H. Choe, J.W. Kim, W.T. Kim, J.S. Lee, J.T. Seo (Seoul, South Korea)
- 492 The prevalence of TB in 82 hematospermic patients**
S.A. Mahmoudi (Esfahan, Iran)

Poster Session 30

Chairs: *M. Grabe, Malmö (SE)*

X. Martin, Lyon (FR)

Study for 30 min. Interactive discussion for 60 min.

- 493** A prospective randomised trial comparing 16-slice three-dimensional computed tomographic urography vs intravenous urogram for planning percutaneous renal stone surgery
K. Ghani, M. Lynch, B. John, U. Patel, K. Anson (London, United Kingdom)
- 494** Predictors of perioperative course and clinical outcome in patients undergoing PCNL for extensive stone disease. Results from 3 centres in Germany and Malaysia
P. Olbert, W.S. Leong, M.L. Liong, A. Hegele, A.J. Schrader, R. Hofmann (Marburg, Germany; Penang, Malaysia)
- 495** Colonic perforation during percutaneous nephrolithotomy: Study of risk factors
A. El-Nahas, A. Shokeir, A. El-Assmy, A. Shoma, I. Eraky, M. El-Kenawy, H. El-Kappany (Mansora, Egypt)
- 496** The impact of commonly encountered medical disorders on the outcome and complication rates of percutaneous nephrolithotomy
A. Muslumanoglu, A. Tefekli, F. Altunrende, M. Akcay, M. Baykal, Y. Berberoglu (Istanbul, Turkey)
- 497** Routine placement of a nephrostomy tube after percutaneous nephrolithotomy is unnecessary
Z. Zaman, S. Kommu, N. Watkin, C. Jones, P. Boyd, E. North (North Cheam, United Kingdom)
- 498** Planning percutaneous renal stone surgery: Differences between 16-slice three-dimensional computed tomographic urography and intravenous urography
K. Ghani, M. Lynch, B. John, U. Patel, K. Anson (London, United Kingdom)
- 499** Percutaneous suprapubic cyst lithotripsy under local anesthesia
E. Aravantinos, V. Tzortzis, A. Karatzas, I. Mitsogiannis, G. Moutzouris, M. Melekos (Larissa, Greece)
- 500** The learning curve in PCNL. Do individual skills prevails over experience?
M.R. Botoca, P. Boiborean, V. Bucuras, I. Herman, R. Minciu, D. Claiici, G. Pupca, A. Cumpanas, M. Burdan, E. Ghita, F. Miclea (Timisoara, Romania)
- 501** Management of pelvic stones larger than 20 mm: Laparoscopic transperitoneal pyelolithotomy or percutaneous nephrolithotomy?
P. Meria, S. Milcent, F. Desgrandchamps, F. Dubosq, P. Mongiat Artus, J.M. Duclos, P. Teillac (Paris, Rheims, France)
- 502** Number of renal calix punctures and blood loss during percutaneous nephrolithotripsy. Is there a correlation?
S. Ferretti, P. Salsi, A. Frattini, U. Maestroni, L. Astesana, P. Cortellini (Parma, Italy)

- 503 Supracostal approach for percutaneous renal surgery**
S. Giannakopoulos, T. Pantazis, D. Antoniou, C. Kalaitzis, A. Triantafyllidis, S. Touloupidis (Alexandroupolis, Greece)
- 504 Minimal invasive PCNL in patients with renal pelvic and calyceal stones - enhanced experience in 164 patients**
V. Zimmermanns, P. Liske, S. Lahme (Pforzheim, Germany)
- 505 Percutaneous treatment of large upper tract stones after urinary diversion**
A. El-Nahas, I. Eraky, A. El-Assmy, A. Shoma, M. Abdel-Latif, H. Abol-Enein, A. Shaaban, H. El-Kappany (Mansora, Egypt)
- 506 Endourological treatment of pyelogenic cyst**
F. Nigro, P. Ferrarese, G. Abatangelo, M. Titta, E. Scremin, A. Tasca (Venice, Italy)
- 507 Comparison of outcomes in percutaneous nephrolithotomy requiring single or multiple access tracts**
N. Hegarty, B. Chung, A. Monish, M. Desai (Cleveland, United States of America)

Poster Session 31

Chairs: *B.C. Knipscheer, Nijmegen (NL)*
E. Lechevallier, Marseille (FR)

Study for 30 min. Interactive discussion for 60 min.

- 508 Transperitoneal laparoscopic adrenalectomy: The platinum standard for the treatment of adrenal surgical pathologies**
A. Cestari, G. Guazzoni, A. Centemero, M. Riva, A. Losa, R. Naspro, T. Maga, P. Rigatti (Milan, Italy)
- 509 Long term follow up of adrenocortical carcinoma patients treated with adjuvant low dose mitotane (o,p'-DDD)**
M. Mullerad, G. Dickstein, C. Shechner, G. Meyer, B. Moskovitz, O. Nativ (Haifa, Israel)
- 510 Laparoscopic surgery for pheochromocytoma**
N. Knezevic, M.M. Bernat, T. Roncevic, T. Hudolin, I. Krhen, Z. Marekovic, N. Goreta, J. Pasini (Zagreb, Croatia)
- 511 Adrenalectomy for pheochromocytoma: Laparoscopy versus open**
E.S. Yoo, S.K. Chung, B.W. Kim, Y.K. Park, G.T. Sung, T.H. Oh, H.C. Jung, T.G. Kwon (Daegu, Busan, Masan, South Korea)
- 512 Adrenal metastases in adult patients with parenchymatous renal cancer**
S. Voinea, I. Sinescu, M. Harza, C. Gingu, B. Serbanescu, V. Cerempei, E. Dudu, C. Baston, R. Lazar, C. Pavel (Bucharest, Romania)
- 513 Laparoscopic transperitoneal adrenalectomy in 130 patients**
J. Luptak, J. Vseticka, M. Vraný, J. Svihra, B. Elias, R. Tomaskin, J. Kliment (Martin, Slovakia; Jablonec N. Nisou, Czech Republic)
- 514 Total bilateral adrenalectomy - retrospective study for 10 years**
B. Serbanescu, I. Sinescu, M. Harza, S. Voinea, E. Dudu, A. Iordache, I. Manea (Bucharest, Romania)
- 515 Simultaneous bilateral laparoscopic adrenalectomy**
N. Knezevic, M.M. Bernat, T. Hudolin, H. Miskic, I. Krhen, E. Stajduhar, V. Bekavac, Z. Marekovic, J. Pasini (Zagreb, Croatia)
- 516 Over 15 years of kidney transplantation from non-heart beating donors**
H. Amano, H. Ishida, N. Miyamoto, N. Tokumoto, K. Tanabe, H. Toma (Shinjuku-ku, Tokyo, Japan)
- 517 A multicentre prospective randomised living donor (LIDO) trial: Laparoscopic versus minimally invasive open donor nephrectomy**
B. Knipscheer, N. Kok, D. Pilzecker, I. Dooper, J. Yzermans, P. Mulders (Nijmegen, Rotterdam, The Netherlands)
- 518 Hand-assisted laparoscopic donor nephrectomy versus open donor nephrectomy: Recovery of glomerular filtration rate**
T.G. Kwon, E. Yoo, S.K. Chung, Y.K. Park, C.H. Park, D.Y. Kim, H.C. Jung, B.W. Kim (Daegu, South Korea)

- 519 Laparoscopic donor nephrectomy: Outcome in vascular challenging cases**
H. Abouel Fettouh (Agouza-Cairo, Egypt)
- 520 Complete robotic-assistance during laparoscopic live donor nephrectomies: An initial evaluation of 28 procedures at a single site**
J. Hubert, E. Renoult, E. Mourey, L. Frimat, B. Feuillu, L. Cormier, A. Coissard, M. Kessler (Vandoeuvre les Nancy, France)
- 521 The role of renal autotransplantation in complex urological reconstruction**
F.J. Burgos, J. Pascual, R. Marcen, J. Saenz, A. Linares, L. Lopez Fando, A. Paez, J. Ortuño (Madrid, Spain)
- 522 Renal transplant recipients are at high risk for locally advanced and metastatic prostate cancer**
F. Kleinclauss, L. Salomon, Y. Neuzillet, M. Gigante, F. Iborra, J. Petit, L. Cormier, E. Lechevallier (Besançon, Creteil, Marseille, Nice, Montpellier, Amiens, Nancy, France)

Poster Session 32

Chairs: P. Dinis Oliveira, Porto (PT)
C. Saussine, Strasbourg (FR)

Study for 30 min. Interactive discussion for 60 min.

- 523 The transobturator tape (TOT) for male urinary incontinence: Mechanism of action according to dynamic MRI imaging and first clinical results**
P. Rehder, J. Bektic, L. Pallwein, G. Bartsch, C. Gozzi (Innsbruck, Austria)
- 524 Principles of anatomy and histology for male transobturator tape (TOT) suspension for the treatment of post-prostatectomy urinary incontinence**
P. Rehder, A. Lunacek, G. Bartsch, C. Gozzi (Innsbruck, Austria)
- 525 Male perineal sling for stress urinary incontinence : Mid-term results for the first 50 treated patients**
H. Fassi-Fehri, A. Cherasse, F. Murat, M. Colombel, X. Martin, X. Gelet (Lyons, France)
- 526 Artificial urinary sphincter and in-vance male sling in the treatment of post-prostatectomy incontinence: A comparison study**
S. Herschorn, M. Liu (Toronto, Canada)
- 527 Proact versus male sling: Preliminary data of a retrospective study**
S. Crivellaro, A. Singla, N. Aggarwal, B. Frea, E. Kocjancic (Novara, Italy; Detroit, United States of America)
- 528 Results of the French multicentric prospective study for treatment of stress urinary incontinence with ProACT balloons after prostate surgery**
T. Le Bret, F. Cour, J. Benchetrit, P. Grise, J. Bernstein, V. Delaporte, E. Chartier-Kastler, H. Botto, P. Costa (Suresnes, Paris, Montauban, Rouen, Muret, Marseille, Nîmes, France)
- 529 Single centre Austrian study evaluating the adjustable continence therapy (Pro ACT™) for male post prostatectomy stress urinary incontinence - last 17 months follow up**
O. Schlarp, W.A. Huebner (Korneuburg, Austria)
- 530 Post prostatectomy incontinence: Duloxetine and rehabilitation versus rehabilitation alone**
G. Del Popolo, M.T. Filocamo, V. Li Marzi, M. Marzocco, E. Dattolo, A. Tosto, D. Villari, G. Nicita (Florence, Italy)
- 531 Prospective randomised study of duloxetine versus anticholinergics versus pelvic floor training alone following radical prostatectomy: Impact on timing and magnitude of recovery of continence**
S. Marihart, M. Brausi, B. Rocco, R. Herwig, T. Anagnostou, A. Kaisary, M. Marberger, M. Chancellor, B. Djavan (Vienna, Austria; Milan, Italy; Athens, Greece; London, United Kingdom; Houston, United States of America)
- 532 A new artificial urinary sphincter with conditional occlusion for stress urinary incontinence - long term clinical results**
S. Knight, J. Susser, T. Greenwell, A. Mundy, M. Craggs (London, United Kingdom)

- 533 Voiding chart data to study lower urinary tract function non-invasively: Critical review of the parameter “voiding frequency”**
S. De Wachter, J.J. Wyndaele (Edegem, Belgium)
- 534 Tables for predicting post prostatectomy incontinence (PPI)**
S. Wille, C. Ohlmann, A. Heidenreich, R. Hofmann, U. Engelmann (Cologne, Marburg, Germany)
- 535 Randomised sham-controlled evaluation of functional continuous magnetic stimulation with pelvic floor muscle training in patients with urinary incontinence**
T. Yamanishi, T. Suzuki, K. Yasuda, S. Kitahara, K. Yoshida (Tochigi, Saitama, Japan)
- 536 Tolterodine extended release (ER) for overactive bladder (OAB): Correlations among improvements in objective symptoms, patient perception of bladder condition (PPBC), and health-related quality of life (HRQL)**
P. Van Kerrebroeck, K.S. Coyne, Z. Kopp, M. Brodsky, J.T. Wang (Maastricht, The Netherlands; Bethesda, New York, United States of America)
- 537 Prevalence of lower urinary tract symptoms (LUTS) in men: European results from the EPIC study**
D. Irwin, I. Milsom, K. Reilly, S. Hunskaar, Z. Kopp, S. Herschorn, C. Kelleher, C. Hampel, W. Artibani, P. Abrams (Chapel Hill, New York, United States of America; Goteborg, Sweden; Bergen, Norway; Toronto, Canada; London, Bristol, United Kingdom; Mainz, Germany; Padova, Italy)
- 84 The use of spiral MDCT (multi detector computed tomography) scan in proACT (adjustable continence therapy) implant failures**
A. Giammò, G. Bodo, S. Castellano, M.P. Bertapelle, A. Borrè, R. Carone (Torino, Italy)

Poster Session 33

Chairs: G.J. Alivizatos, Athens (GR)
F. Desgrandchamps, Paris (FR)

Study for 30 min. Interactive discussion for 60 min.

- 538** LUTS significantly affect quality of life measured with the fact questionnaire
J.E. Batista Miranda, Y. Pardo-Cladellas, B. Molinuevo (Barcelona, Spain)
- 539** All components of ejaculation are impaired in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
J.M. Fitzpatrick, R.C. Rosen (Dublin, Ireland; Piscataway, United States of America)
- 540** A simple case definition of clinical Benign Prostatic Hyperplasia, based on International Prostate Symptom Score, predicts general practitioner consultation rates
E.T. Kok, R. Jonkheijm, J. Gouweloos, F.P.M.J. Groeneveld, S. Thomas, A.M. Bohnen, J.L.H. Bosch (Rotterdam, Utrecht, The Netherlands)
- 541** Management of benign prostatic hyperplasia by French urologists: The Duo study
R.O. Fourcade, M.C. Picot, A.F. Gaudin, N. Texier, A. Slama (Auxerre, Montpellier, Marly Le Roi, Paris, France)
- 542** Longitudinal changes in international prostate symptom score in community-dwelling men: 6.53 year follow-up data from the Krimpen study
R. Bosch, F. Groeneveld, A. Bohnen (Utrecht, Rotterdam, The Netherlands)
- 543** Has the decline in surgical treatment for benign prostatic hyperplasia resulted in an increase in the incidence of acute urinary retention?
P. Cathcart, J. Armitage, J. Van Der Meulen, M. Emberton (London, United Kingdom)
- 544** Relapse in acute urinary retention following its first occurrence
P. Cathcart, J. Armitage, J. Van Der Meulen, M. Emberton (London, United Kingdom)
- 545** Basic fibroblast's growth factor (bFGF) as prognostic risk factor of progression of LUTS/BPH
R. Boroyan, I. Aghajanyan, G. Shahbazyan (Yerevan, Armenia)
- 546** Perfusion of the prostate before and after transurethral resection of the prostate
M. Mitterberger, G.M. Pinggera, L. Pallwein, H. Gradl, F. Ferauscher, G. Bartsch, H. Strasser (Innsbruck, Austria)
- 547** Association of obesity and benign prostatic enlargement: A case-control study in China
L. Xie, Y. Bai, X. Zheng, X. Zhang, K. Yao, L. Xu (Hangzhou, China)
- 548** Benign prostate hyperplasia: Must bothersomeness of symptoms be privileged?
P. Perrin, N. Marionneau, M. Cucherat, C. Taïeb (Pierre Bénite, Boulogne Billancourt, Lyon, France)
- 549** Benign prostate hyperplasia: Relation between IPSS, SPI and quality of life IPSS item scores
P. Perrin, M. Cucherat, N. Marionneau, A. Ruffion, C. Taïeb (Pierre Bénite, Lyon, Boulogne Billancourt, France)

- 550 Actigraphy: A new method to assess the impact of nocturia on the bed partner**
R. Meadows, N. Stanley, S. Venn, J. Hislop, J. Dawson, K. McDonald, S. Arber (Guildford, United Kingdom)
- 551 Predictive factors of daily activities related to LUTS**
N. Marionneau, P. Perrin, C. Taïeb (Boulogne Billancourt, Lyon, France)
- 552 Lower urinary tract symptoms: Local ischemia assessed by sonographic findings and correlated to impaired quality of life**
G. Pinggera, M. Mitterberger, L. Pallwein, F. Frauscher, P. Rehder, R. Herwig, C. Gozzi, G. Bartsch, H. Strasser (Innsbruck, Austria)

Poster Session 34

Chairs: *A. Bjartell, New York (US)*
P. Mongiat-Artus, Paris (FR)

Study for 30 min. Interactive discussion for 60 min.

- 553** Epidermal growth factor receptor family members (EGFR and Her2) are prognostic markers and potential therapeutic targets in prostate cancer
T. Schlomm, T. Steuber, A. Haese, H. Isbarn, A. Erbersdobler, R. Simon, M. Graefen, G. Sauter, H. Huland (Hamburg, Germany)
- 554** Peroxisome proliferator activator-receptor- is a new target in the treatment of human prostate cancer
T. Hayama, M. Matsuyama, K. Tsuchida, Y. Takemoto, T. Nakatani, R. Yoshimura (Osaka, Japan)
- 555** Superior anti-tumour immune response of dendritic cells fused with prostate cancer cells compared with tumour lysate-pulsed dendritic cells
S.B. Lee, S.Y. Jun, C. Yoo, J. Park, J.Y. Park, H.S. Kim, C.S. Kim (Seoul, Kangneung, Chungnam, South Korea)
- 556** Enhanced efficacy of radiation sensitivity by controlled gene delivery of PTEN expression vector conjugated with cationised gelatin in prostate cancer cells
A. Tomioka, S. Takada, M. Tanaka, Y. Hirao (Kashihara, Japan)
- 557** Effects of a new oncolytic adenovirus (Xvir03) in human prostate cancer cell lines and in xenograft mouse model
U. Treiber, K. Mantwill, N. Köhler Vargas, A. Bernshausen, P.S. Holm, H. Van Randenborgh, R. Paul, N. Zantl, R. Hartung, B. Gänsbacher (Munich, Germany)
- 558** Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-CoA racemase (AMACR) in prostate cancer
I. Honma, T. Torigoe, Y. Hirohashi, H. Kitamura, E. Sato, A. Takahashi, N. Masumori, N. Itoh, N. Sato, T. Tsukamoto (Sapporo, Japan)
- 559** Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Immunological results of a phase 1 clinical trial
S. Fuessel, M. Schmitz, K. Richter, A. Meye, S. Zastrow, C. Linné, O.W. Hakenberg, E.P. Rieber, M.P. Wirth (Dresden, Germany)
- 560** Quantitative RT-PCR analysis of steroid hormone receptor gene expression in laser microdissected prostate cancer specimens
T. Walton, G. Li, T. Mc Culloch, R. Seth, D. Powe, M. Bishop, R. Rees (Nottingham, United Kingdom)
- 561** Human kallikrein 2 (hK2) inhibitors suppress tumour growth of prostate cancer xenografts in nude mice
C. Kündig, S. Cloutier, S. Aellen, L. Felber, J. Chagas, C. Gygi, P. Jichlinski, H.J. Leisinger, E. Diamandis, D. Deperthes (Epalinges, Lausanne, Switzerland; Mogi Das Cruzes, Brazil; Toronto, Canada)

- 562 The occurrence of prostate specific antigen - IgM immune complexes (IC) as novel serum biomarker for prostate cancer**
L. Beneduce, T. Prayer-Galetti, M. Grimani Giustinian, A. Gallotta, S. Fracalanza, G. Betto, W. Artibani, F. Pagano (Venezia, Padua, Italy)
- 563 Assessment of a cleaved product of E-cadherin as a serum biomarker with predictive value for prostate cancer**
R. Kuefer, M. Hofer, B. Volkmer, J. Gschwend, R. Hautmann, M. Rubin, D. Mark (Ulm, Germany; Boston, Ann Arbor, United States of America)
- 564 Human lymphocytes response to the challenging dose as a predictive assay**
Z. Dobrowolski, A. Wasilewska, W. Lipczyński, B. Dobrowolska, L. Michalski, P. Jakubik, A. Strach, A. Panek (Cracow, Poland)
- 565 The role of determination of androgen receptors in the management of patients with locally advanced and metastatic prostate cancer**
A. Muradian, A. Avoyan, T. Sarkissyan, G. Khachatryan, A. Martirosyan, G. Yernkyan (Yerevan, Armenia)
- 566 A potential tumour suppressive role for the novel prostate basal cell marker TSC-22 in prostate cancer**
C.A. Rentsch, M. Germann, A. Wetterwald, R. Schwaninger, M. Voller, V. Rotter, M. Oren, J. Schalken, U.E. Studer, G.N. Thalman, M.G. Cecchini (Berne, Switzerland; Nijmegen, The Netherlands; Rehovot, Israel)
- 567 Pim-1 enhances androgen responses at castrate DHT levels in prostate cancer cell lines**
M. Nawijn, H. Van Der Poel (Amsterdam, The Netherlands)

Poster Session 35

Chairs: *O. Cussenot, Paris (FR)*
L.A. Kiemeny, Nijmegen (NL)

Study for 30 min. Interactive discussion for 60 min.

- 568 Segregation analysis of 1546 Finnish pedigrees**
S. Pakkanen, A. Baffoe-Bonnie, M. Matikainen, P. Koivisto, T. Tammela, O. Liang, B. Joan, J. Schleutker (Tampereen Yliopisto, Tampere, Finland; Philadelphia, Bethesda, United States of America)
- 569 The impact of clinical features on linkage to prostate cancer predisposition in German prostate cancer families**
K. Herkommer, C. Martin, C. Maier, W. Vogel, R.E. Hautmann, T. Paiss, J. Hoegel (Ulm, Germany)
- 570 Expression of hormone-/carcinogen-metabolising enzymes in the prostate: Clues into peripheral-zone susceptibility?**
N. Ragavan, R. Hewitt, A.C. Hindley, C.M. Nicholson, S.S. Matanhelia, F.L. Martin (Preston, Lancaster, United Kingdom)
- 571 An observational study of cancers among female partners of UK-resident prostate cancer patients**
N. Ragavan, P. Grover, S.P. Balasubramanian, A.C. Hindley, S.S. Matanhelia, F.L. Martin (Preston, Sutton, Sheffield, Lancaster, United Kingdom)
- 572 Clinical significance of PL polymorphism of the glycoprotein 3 gene in prostate cancer**
O. Loran, A. Itkes, A. Serilogin, Jr (Moscow, Russia)
- 573 CAG repeat shortening – an explanation for the development of androgen-independent prostate cancer**
R.P. Manecksha, A. Perry, H. Varadaraj, B. Loftus, M.P. Lawler, T.H. Lynch (Dublin, Ireland)
- 574 Androgens and prostate cancer risk: A prospective study**
S. Wirén, U. Stenman, G. Hallmans, P. Stattin (Umeå, Sweden; Helsinki, Finland)
- 575 Differences in distribution of polymorphisms in genes regulating androgen activity between prostate cancer low-risk Inuit men and high-risk Scandinavians**
Y. Giwercman, C. Giwercman, A. Giwercman, H.S. Pedersen, G. Toft, J.P. Bonde (Malmö, Sweden; Nuuk, Greenland; Aarhus, Denmark)
- 576 Chemoprevention of human prostate cancer (PCa) by oral administration of green tea catechins (GTCs) in high grade pin (HGPIN) subjects: A preliminary report from a 1 year proof of principle study**
S. Bettuzzi, M. Brausi, F. Rizzi, G. Castagnetti, G. Peracchia, S. Astancolle, A. Corti (Parma, Modena, Italy)
- 577 Omega-3 poly-unsaturated fatty acids inhibit omega-6 poly-unsaturated fatty acid directed metastasis towards human bone marrow stroma**
M. Brown, C. Hart, E. Gazi, N. Clarke (Manchester, United Kingdom)

- 578 Bioavailability of isoflavones in the human prostate**
N. Védrine, L. Guy, C. Manach, C. Rémésy, J. Boiteux (Clermont-Ferrand, France)
- 579 A low-carbohydrate, high-fat diet inhibits proliferation of prostate cancer in vivo**
L. Klotz, N. Fleshner, V. Venkateswaran (Toronto, Canada)
- 580 Differences in serum concentrations of vitamin E, C, A, lycopene, carotenoids, macro- and microelements, products of lipid peroxidation in various prostate lesions**
Y. Alyaev, E. Severin, V. Spirichev, E. Zezerov, A. Vinarov, A. Amosov, G. Barashkov, N. Beketova, O. Pereverzeva, E. Bezrukov, D. Butnaru, P. Shestiperov (Moscow, Russia)
- 581 Green tea (EGCG) and prostate cancer: A new sphingosine kinase inhibitor?**
N. Doumerc, E. Bonhoure, A. Dayon, P. Rischmann, B. Malavaud, O. Cuvillier (Toulouse, France)
- 582 Modification of proliferation, apoptosis and androgen receptor expression of LNCaP cells by diet polyphenols**
A. Ferruelo, J. Angulo, C. Pascual-mateo, I. Romero, M. Lujan, A. Berenguer (Getafe, Spain)

Poster Session 36

Chairs: T.M. De Reijke, Amsterdam (NL)
F. Pina, Matosinhos (PT)

Study for 30 min. Interactive discussion for 60 min.

- 583 External beam radiotherapy outcomes in septa- and octogenarians**
T. Lebeau, P. Perrotte, J. Bahary, F. Saad, P.I. Karakiewicz (Montreal, Canada)
- 584 Intensity-modulated radiotherapy (IMRT) for prostate cancer at Ghent University Hospital (GUH): First report on late toxicity**
V. Fonteyne, L. Vakaet, G. Villeirs, W. Oosterlinck, L. Denoyette, W. De Neve, G. De Meerleer (Ghent, Belgium)
- 585 Migration or not migration of intraprostatic fiducial gold seed markers during conformal external beam radiation therapy of prostate carcinoma**
F. Munoz, A. Guarneri, O. Sedigh, P. Ciammella, U. Ferrando, C. Fiandra, R. Ragona, F. Liberale, U. Ricardi (Torino, Italy)
- 586 Quality of life in patients submitted to external beam radiotherapy as adjuvant treatment after radical prostatectomy. Preliminary results**
A. Salonia, C. Cozzarini, L.F. Da Pozzo, F. Fazio, V. Scattoni, A. Briganti, L. Bua, P. Rigatti, F. Montorsi (Milan, Italy)
- 587 Late severe complications (G3-4 RTOG) of 3D conformal adjuvant radiotherapy for prostate kc after radical retropubic prostatectomy**
J. Nohra, E. Huyghe, M. Soulie, M. Khedis, P. Rischmann, B. Malavaud, P. Pierre (Toulouse, France)
- 588 Acute urinary morbidity during conformal radiotherapy for prostate cancer**
H. Burden, S. Evans, R. Persad (Bristol, United Kingdom)
- 589 External beam radiotherapy and high dose rate brachytherapy for the treatment of localised prostate cancer. Karolinska experience**
G. Cohn Cedermark, K.M. Kälkner, T. Wahlgren, M. Ryberg, E. Castellanos, R. Zimmerman, J. Nilsson, M. Lundell, S. Lewitt, M. Hellström, S. Nilsson (Stockholm, Sweden)
- 590 Prophylactic median lobe resection / bladder neck incision in obstructed patients prior to iodine seed brachytherapy for localised prostate cancer**
M. Simms, P. Royce, R. Snow, J. Millar (Melbourne, Australia)
- 591 Is a large prostate a contraindication to permanent prostate brachytherapy?**
P. Acher, R. Popert, S. Morris, J. Nichol, L. Potters, R. Beaney (London, United Kingdom; New York, United States of America)
- 592 HDR - brachytherapy in prostate cancer long-term outcome**
S.H. Stübinger, S. Hautmann, C. Horst, K. Overmoyer, O. Erdt, P. Braun, K.P. Jünemann (Kiel, Germany)

- 593** **Oncological outcome and treatment related toxicity in patients with localised prostate cancer following HDR-IR-192 brachytherapy combined with external beam radiotherapy**
F. Jansen, M. Wildhagen, W. Kirkels, P. Jansen, C. Bangma, B. Chaplin (Rotterdam, The Netherlands)
- 594** **Long-term erectile function after LDR-brachytherapy with iodine-125 for the treatment of localised prostate cancers**
S. Machtens, R. Baumann, J.H. Karstens, B. Bastian, J. Hagemann, J. Serth, U. Jonas (Hanover, Germany)
- 595** **Acute toxicity in low risk prostate cancer treated with low dose (125) I brachytherapy: Prospective analysis**
A. Rodríguez, M.Í. Cabeza, F. Villacampa, S. De La Rosa, O. Leiva, P. Fernandez, A. Lopez, E. Lanzós (Madrid, Spain)
- 596** **Side effects after 16 years of brachytherapy for localised prostate carcinoma**
S. Hautmann, S.H. Stübinger, A. Bannowsky, K. Overmoyer, O. Erdt, M. Danilevicius, C. Van Der Horst, P.M. Braun, K.P. Jünemann (Kiel, Germany)
- 597** **Long term health related quality of life after state of the art radical treatment for early prostate cancer: Brachytherapy and laparoscopic radical prostatectomy outcome data with 18 month follow-up**
A. Henderson, P. Sooriakumaran, S. Khaksar, C. Eden, S. Langley, R. Laing (Guildford, Basingstoke, United Kingdom)

Abstract Session

15:45 - 17:15

Surgical approaches to incontinence

eURO Auditorium Level 1

Video Session 5

Chairs: *B. Bemelmans, Amsterdam (NL)*

P.A. Geavlete, Bucharest (RO)

All presentations are 14 minutes in length

- | | | |
|------------|--|-------------|
| V25 | Combined obturator - pre-pubic cystocele and incontinence repair: Rationale and technique
<i>P. Palma, C. Riccetto, M. Dambros, R. De Fraga, N. Rodrigues Netto Jr. (Campinas, Brazil)</i> | eURO-6-0920 |
| V26 | A new surgical technique for implantation of a permanent electro stimulation system for treatment of female overactive bladder and interstitial cystitis
<i>I. Nissenkorn, R. De Jong, P. Radziszewski, M. Cervigni, M. Parsons, L. Cardozo, B. Farnsworth, J. Nordling (Tel-Aviv, Israel; Cape Town, South Africa; Warsaw, Poland; Rome, Italy; London, United Kingdom; Sydney, Australia; Herlev, Denmark)</i> | eURO-6-0930 |
| V27 | Bulbourethral sling with invance device for the treatment of post-prostatectomy incontinence
<i>I. Morra, R. Tarabuzzi, F. Porpiglia, M. Cossu, M. Billia, J. Renard, R.M. Scarpa (Torino, Italy)</i> | eURO-6-0940 |
| V28 | Laparoscopic sacral colpopexy using a double polyester mesh
<i>J.P. Giolitto (Rheims, France)</i> | eURO-6-0950 |
| V29 | Simultaneous implantation of the artificial urinary sphincter and inflatable penile prosthesis
<i>L. Jones (San Antonio, United States of America)</i> | eURO-6-0960 |
| V30 | Dorsal graft urethroplasty for urethral stricture in the female
<i>A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)</i> | eURO-6-0970 |

Abstract Session

15:45 - 17:15

History of urology

Room **Blue** Level 2

Oral Session 8

Chairs: A. Jardin, Paris (FR)
D. Schultheiss, Giessen (DE)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

- D. Schultheiss, Giessen (DE) blue-6-0980
- 598 History of condoms: An interesting journey of the “rubber”** blue-6-0990
A. Omar, A. Rao, O. Karim, H. Motiwala (Slough, United Kingdom)
- 599 Androgyne: An universal phenomena** blue-6-1000
J.J. Mattelaer (Kortrijk, Belgium)
- 600 Urogenital tract diseases from the scope of medieval Armenian doctors** blue-6-1010
R. Badalyan, S. Vardanyan, H. Yenokyan, I. Aghajanyan (Yerevan, Armenia)
- 601 The origins of scientific treatment for venereal diseases** blue-6-1020
E. Poulakou-Rebelakou, C. Tsiamis, C. Alamanis, A. Rempelakos (Athens, Greece)
- 602 The urethral catheter - a passage through history** blue-6-1030
A. Khan, A. Thwaini, A. Mampitya, A. Rao, I. Shergill, J. Barua (Harold Wood, United Kingdom)
- 603 Wolfgang Amadeus Mozart. The death of a genius** blue-6-1040
M. Hatzinger, A. Haecker, J.K. Badawi, S. Kamp, P. Alken (Mannheim, Germany)
- 604 The moment of ‘enlightment’** blue-6-1050
R. Pelger (Leiden, The Netherlands)
- 605 Moulages in urology, a forgotten topic** blue-6-1060
F.H. Moll, M. Frank, J. Leissner (Cologne, Germany)
- 606 Sir Peter Freyer – a distinguished Irish doctor** blue-6-1070
J.P. O’Donoghue, J.G. Noble (Oxford, United Kingdom)
- Summary** blue-6-1080
A. Jardin, Paris (FR)

Oral Session 9

Chair: C.C. Abbou, Creteil (FR)
A. Heidenreich, Cologne (DE)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

A. Heidenreich, Cologne (DE) bord-6-1090

- 607 Extended lymphadenectomy should be performed in patients with PSA \geq 6, biopsy Gleason score 7-10 and stage T2 or higher prostate cancer** bord-6-1100
A. Briganti, K.F. Chun, F. Montorsi, V. Scattoni, L. Da Pozzo, A. Salonia, F. Deho, E. Farina, B. Aldo, A. Gallina, R. Colombo, R. Bertini, L. Barbieri, L. Valiquette, P. Rigatti, P.I. Karakiewicz (Montreal, Milan, Italy; Montreal, Canada)
- 608 Defining the ideal number of nodes to remove at pelvic lymphadenectomy for prostate cancer: Validation of a nomogram for intermediate- to high risk patients** bord-6-1120
A. Briganti, R. Heuer, K.H.F. Chun, H. Isbarn, G. Salomon, G. Tinn, O. Von Nordenflycht, A. Haese, H. Heinzer, M. Graefen, H. Huland, P.I. Karakiewicz (Milan, Italy; Hamburg, Germany; Montreal, Canada)
- 609 Laparoscopic extended pelvic lymphnode dissection for prostate cancer: Description of the surgical technique and first results** bord-6-1130
A. Häcker, S. Jeschke, N. Albqami, A. Al-Bodour, P. Prammer, K. Leeb, G. Janetschek (Mannheim, Germany; Linz, Austria)
- 610 Can extended lymphnode dissection improve prognosis?** bord-6-1140
D. Echte, E. Mueller, D. Frohneberg (Essen, Karlsruhe, Germany)
- 611 Complications of pelvic lymphadenectomy in a consecutive series of 1000 patients undergoing radical prostatectomy between 1993 and 2004** bord-6-1150
M. Musch, V. Klevecka, U. Roggenbuck, D. Kroepfl (Essen, Germany)
- 612 Node positive prostate cancer is not always a systemic disease and benefits from radical prostatectomy, extended pelvic lymphadenectomy and adjuvant radiotherapy** bord-6-1160
L. Da Pozzo, C. Cozzarini, B. Mazzocoli, G.V. Fantini, N. Suardi, F. Montorsi, R. Bertini, A. Salonia, A. Bolognesi, F. Fazio, P. Rigatti (Milan, Italy)
- 613 Pelvic lymphnode dissection (PLND) can safely be spared in adequately selected low risk patients without affecting cure rates of patients undergoing radical retropubic prostatectomy (RRP)** bord-6-1170
A. Haese, T. Steuber, M. Graefen, J. Walz, T. Schlomm, C. Eichelberg (Hamburg, Germany)

614 **Number of sentinel lymphnodes (SLN) of the prostate localised outside the areas of “limited” versus “extended” pelvic node dissection**
A. Mattei, F. Fuechsel, S. Warncke, S. Z'brun, T. Krause, U.E. Studer (Berne, Switzerland)

bord-6-1180

Summary

C.C. Abbou, Creteil (FR)

bord-6-1190



Poster Session 37

Chairs: *E.A. Austoni, Milan (IT)*
I. Saenz De Tejada, Madrid (ES)

Study for 30 min. Interactive discussion for 60 min.

- 615** Are body mass index or waist/hip-ratio independent risk factors for erectile dysfunction or lower urinary tract symptoms?
A. Ponholzer, C. Temml, M. Marszalek, K. Mock, M. Rauchenwald, S. Madersbacher (Vienna, Austria)
- 616** Moderate or severe erectile dysfunction is associated with severe coronary artery disease among chest pain patients
S. Hirsimäki, J. Koskimäki, P. Kuukasjärvi, J. Laurikka, H. Huhtala, A. Kaipia (Tampere, Finland)
- 617** The correlation of erectile dysfunction and intima-media thickness of common carotid arteries
S. Kwon, K. Moon, J. Kim, T. Park, J. Hyun (Daegu, Jinju, South Korea)
- 618** Is there a change in female genital sensation during sexual arousal?
I. Gruenwald, I. Gertman, L. Loewenstein, Y. Vardi (Haifa, Israel)
- 619** Vardenafil improves satisfaction in couples affected by erectile dysfunction previously untreated with PDE5 inhibitors
D. Edwards, G. Hackett, O. Collins, J. Curram (Gloucestershire, Birmingham, Newbury, Berkshire, United Kingdom)
- 620** Improvement in erection quality is associated with treatment satisfaction and improved self-esteem, confidence, and sexual relationship satisfaction
V. Stecher, S. Collins, C. Feiner, D. Lording, M. Gillman (New York, United States of America; Malvern, Victoria, Queensland, Australia)
- 621** Influence of sildenafil on lower urinary tract symptoms
H.S. Chang, C.H. Park, C.I. Kim, K.S. Kim, D.G. Kim, Y.J. Seo, T.G. Kwon, D.Y. Kim, H.C. Jung (Daegu, Gyeongju, South Korea)
- 622** Patient expectations for treatment outcomes when initiating tadalafil treatment for erectile dysfunction: Results from the Detect study
S. Arver, T. Eliasson, P. Perimenis, A. Bitton, K. Giannitsas, M. Belger, H. Schmitt (Stockholm, Sweden; Patras, Athens, Greece; Geneva, Switzerland; Erl Wood, United Kingdom; Brussels, Belgium)
- 623** A prospective evaluation of long-term therapy with tadalafil and penile haemodynamics at colour Doppler ultrasound
A. Mofferdin, M.C. Sighinolfi, S. De Stefani, S. Micali, G. Peluso, G. Bianchi (Modena, Italy)
- 624** Penile rehabilitation and recovery penile length following radical prostatectomy. 5 years' follow-up
O. Sedigh, M. Paradiso, A. Abbona, G.L. Milan, U. Ferrando, G. Pasquale (Torino, Italy)

- 625 Early rehabilitation and nerve-sparing cystectomy. Is there any value?**
E. Hekal, M. El-Bahnasawy, A. Mesbah, A. Shaaban (Mansoura, Egypt)
- 626 Sildenafil in the treatment of post-radical cystectomy erectile dysfunction in 100 patients**
T. Syed Ahmed, M. El-bahnasawy, E. Ibrahiem, E. El-sobky, N. El-tabei, M. Bazeed (Sharjah, United Arab Emirates; Mansoura, Egypt)
- 627 Tadalafil in men with erectile dysfunction and spinal cord injury**
F. Giuliano, A. Sanchez Ramos, D. Loechner Ernst, G. Del Popolo, Y. Zhao, J. Casariego (Le Kremlin Bicetre, France; Toledo, Madrid, Spain; Murnau, Germany; Florence, Italy; Indianapolis, United States of America)
- 628 Efficacy of sildenafil 100 mg on demand in patients undergoing bilateral nerve-sparing radical prostatectomy is based on precise predicting factors**
F. Montorsi, G. Zanni, A. Salonia, A. Gallina, A. Briganti, L. Barbieri, F. Dehò, N. Suardi, F. Fabbri, E. Farina, P. Rigatti (Milan, Italy)
- 629 Young men with erectile dysfunction: Too young to be true?**
R. Casella, L. Ronci, T. Sulser, K. Lehmann (Biel, Basel, Baden, Switzerland)

Abstract Session

15:45 - 17:15

Kidney tumours: Nephron sparing treatment

Room **Maillot Level 2**

Poster Session 38

Chairs: *V. Ficarra, Verona (IT)*
I. Romics, Budapest (HU)

Study for 30 min. Interactive discussion for 60 min.

- 630 Kidney tumour resection with use of tachosil as haemostatic treatment**
H. Van Poppel, S. Siemer, S. Lahme, S. Altziebler, S. Machtens, W. Strohmaier, H.W. Wechsel, P. Goebell, N. Schmeller, R. Oberneder, J.U. Stolzenburg, H. Becker, W. Lüftenecker, V. Tetens, S. Joniau (Leuven, Belgium; Homburg/Saar, Tübingen, Hanover, Coburg, Wilhelmshaven, Essen, Planegg, Leipzig, Hamburg, Germany; Graz, Salzburg, Wien, Austria; Roskilde, Denmark)
- 631 A novel method of renal parenchymal suturing with the absorbable clips during laparoscopic partial nephrectomy in a porcine model**
Z. Hidenori, N. Teruhisa, A. Isao, T. Takayuki, M. Yuki, K. Hideki, N. Munehiro, N. Hiroshi, S. Nobuharu, F. Mizuya, T. Yoshio, T. Masayuki (Yamanashi, Japan)
- 632 Surgical evaluation of parenchymal clamping during conservative surgery for renal tumours**
A. Mejean, M.O. Timsit, E. Fontaine, N. Thiounn, B. Dufour (Paris, France)
- 633 Laparoscopic partial nephrectomy for renal cell tumours in warm ischaemia**
H. Meixl, J. Wakonig, K. Jeschke (Klagenfurt, Austria)
- 634 Open partial nephrectomy with selective renal parenchymal control: A new reliable clamp**
J. Nohra, E. Huyghe, E. El Khoury, M. Khedis, M. Soulie, D. Roux, P. Plante (Toulouse, France)
- 635 Longer-term outcome of non-ischaeic partial nephrectomy using microwave tissue coagulator**
K. Fujimoto, M. Tanaka, M. Tanaka, Y. Hirao (Kashihara, Japan)
- 636 Partial nephrectomy for centrally located tumours**
N. Kleinmann, A. Nadu, Y. Mor, J. Ramon (Ramat Gan, Israel)
- 637 'Bench' surgery with autotransplantation for hilar kidney tumours: A nephron-sparing alternative in patients with a solitary kidney**
J. Boormans, W. Marchand, J. Ijzermans, G. Mikisch, P. Verhagen (Rotterdam, The Netherlands; Bremen, Germany)
- 638 Prospective study of safety margins in partial nephrectomy: Intra-operative assessment and contribution of frozen sections**
M.O. Timsit, J.P. Bazin, N. Thiounn, E. Fontaine, Y. Chretien, B. Dufour, A. Mejean (Paris, France)
- 639 A national survey on the practice of nephron-sparing surgery in France**
J. Patard, B. Albouy, D. Lopes, A. De La Taille, L. Salomon, M. Crepel, B. Lobel, F. Guille, L. Bellec, M. Soulie, J. Bernhard, J. Ferriere, B. Lacroix, J. Tostain, C. Pfister, M. Colombel (Rennes, Rouen, Creteil, Toulouse, Bordeaux, St Etienne, Lyon, France)

- 640 Nephron-sparing surgery: Experience in 159 consecutive cases**
S. Joniau, H. Van Poppel (Leuven, Belgium)
- 641 Progression and long-term survival after simple enucleation for the elective treatment of pT1a renal cell carcinoma (RCC): Our experience over 25 years**
A. Lapini, A. Minervini, S. Serni, L. Masieri, F. Nelli, G. Giubilei, N. Tosi, M. Carini (Florence, Italy)
- 642 Enucleoresection for renal cell carcinoma: Prognostic factors and long-term results in pathological T1-stage patients**
R. Bertini, M. Roscigno, C. Cozzarini, M. Sangalli, A. Pasta, B. Mazzoccoli, D. Angiolilli, L. Da Pozzo, R. Colombo, A. Bocciardi, P. Rigatti (Milan, Italy)
- 643 Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: Progression and long-term survival**
A. Minervini, S. Serni, A. Lapini, L. Masieri, M. Carloni, L. Manoni, F. Lanzi, M. Carini (Florence, Italy)
- 644 30 Years' experience in nephron-sparing surgery: Long-term survival and comparison of results after elective and imperative surgery**
F. Becker, S. Siemer, M. Hack, A. Tzavaras, C. Pönicke, M. Stöckle (Homburg, Germany)

Poster Session 39

Chairs: *P. Alken, Mannheim (DE)*
H-G. Tiselius, Stockholm (SE)

Study for 30 min. Interactive discussion for 60 min.

- 645** The role of volume and attenuation value histogram of urinary stone on non-contrast helical CT as the predictor of fragility by shock wave lithotripsy
S. Yoshida, T. Hayashi, A. Yoshinaga, R. Ohno, N. Ishii, T. Terao, T. Watanabe, T. Okada, H. Osada, N. Honda, T. Yamada (Saitama, Japan)
- 646** Use of double-J stents prior to extracorporeal shock wave lithotripsy: A prospective study assessing symptoms and complications
A.A. Karama Musa (Aden, Yemen)
- 647** Semen changes after extracorporeal shock wave lithotripsy for distal ureteral stones
M.A. Sayed (Assiut, Egypt)
- 648** Ureteric calculi treated with increased shock wave energy
J. Bikhchandani, P. Zammit, N. Bafaloukas, C. Cannaby, S. Albanis, N. Buchholz (London, United Kingdom)
- 649** Effectiveness of successive shock wave lithotripsy for renal and ureteral stones after failed initial treatment
H. Hegazy, A. Elabbady (Alexandria, Egypt)
- 650** Predictors of clinical significance of residual fragments after ESWL for renal stones
A. El-Nahas, A. El-Assmy, K. Madbouly, K. Sheir (Mansora, Egypt)
- 651** Right and left lower calyceal stones: Is there any difference in terms of renal anatomical features affecting stone clearance after extracorporeal shock wave lithotripsy?
C. Acar, B. Küpeli, S. Gürocak, I. Bozkirli (Ankara, Turkey)
- 652** Effects of extracorporeal shock wave lithotripsy on endovascular aortic stentgrafts
J. Birzele, D. Mayer, R. Winkler, M. Lachat, H. John (Zurich, Dübendorf, Switzerland)
- 653** Comparison of success rate of ESWL technique according to the position of stone in different parts of ureter
M. Rastegari, S. Shakeri, H. Khishdoost (Shiraz, Iran)
- 654** Extracorporeal shock wave lithotripsy success based on body mass index
G. Mokhtari (Rasht, Iran)
- 655** Predictors of success after extracorporeal shock wave lithotripsy (ESWL) for renal calculi between 20-30mm: A multivariate analysis model
A. El-Assmy, A. El-Nahas, M. Abo-Elghar, I. Eraky, M. El-Kenawy, K. Sheir (Mansoura, Egypt)

- 656 Can we predict the success of shockwave lithotripsy by stone density measured with computerised tomography?**
M.R. Goren, U. Bilgilişoy, C. Ozer, M.I. Tekin, L. Peskircioglu, H. Ozkardes (Ankara, Turkey)
- 657 Impact of lower pole renal anatomy on stone clearance after shock wave lithotripsy in children**
B. Turna, O. Nazli, A. Simsir, G. Ustun, E. Apaydin (Izmir, Turkey)
- 658 Treatment of renal stones in children: A comparison between percutaneous nephrolithotomy**
A. Shokeir, K. Sheir, A. El-Assmy, A. El-Nahas, W. Easa, H. El-Kappany (Mansoura, Egypt)
- 659 Tamsulosin improves clearance of renal stones larger than 10mm after ESWL**
G.L. Gravina, A.M. Costa, P. Ronchi, G. Galatioto Paradiso, G. Pace, L. Gualà, O. Martella, G. Simoncini, G. Ranieri, G. Angelozzi, M. Coscione, C. Vicentini (L'Aquila, Italy)

Poster Session 40

Chairs: T. Le Bret, Suresnes (FR)
J. Palou Redorta, Barcelona (ES)

Study for 30 min. Interactive discussion for 60 min.

- 660 Testing of chemosensitivity in patients with transitional cancer of the bladder**
M. Büttner, W. Strohmaier, H. Heidecke (Coburg, Luckenwalde, Germany)
- 661 Retinoblastoma protein expression is a predictor of response to BCG and interferon- treatment for superficial bladder cancer**
E. Chiong, T.P. Thamboo, M. Teh, Y.H. Chan, K. Esuvaranathan (Singapore, Singapore)
- 662 Intravesical pemetrexed: Potential and toxicity in a pre-clinical pig study**
K. Hendricksen, P.M.J. Moonen, A.G. Van Der Heijden, J. Molkenboer-Kuennen, C.A. Hulsbergen-Van De Kaa, J.A. Witjes (Nijmegen, The Netherlands)
- 663 Comparison of the 1973 and 1998 grading systems for superficial papillary bladder cancer**
B. Van Rhijn, B. Ooms, A. Jöbssis, T. Van Der Kwast (Rotterdam, Den Haag, The Netherlands; Toronto, Canada)
- 664 Phase II marker lesion study with intravesical instillation of eoquin™ in superficial bladder cancer, toxicity and marker response - the final results**
A.G. Van Der Heijden, P.M. Moonen, E.B. Cornel, H. Vergunst, T.M. De Reijke, E. Van Boven, E.J. Barten, R. Puri, S. Chawla, G. Lenaz, J.A. Witjes (Nijmegen, Hengelo, Amsterdam, Boxmeer, Arnhem, The Netherlands; Bradford, United Kingdom; Irvine, CA, United States of America)
- 665 Complications of BCG intravesical treatment for superficial bladder tumours - 21 years' follow-up**
D.A. Georgescu, P. Geavlete, I. Arabagiu, D. Soroiu (Bucharest, Romania)
- 666 Metachronous upper urinary tract tumours after superficial bladder tumours**
D.A. Georgescu, P. Geavlete, G. Nita, S. Aghamiri (Bucharest, Romania)
- 667 Effects of simultaneous transurethral resection of the prostate and solitary bladder tumours smaller than three centimetres on oncological results**
O. Ugurlu, U. Gonulalan, O. Adsan, M. Kosan, V. Oztekin, M. Cetinkaya (Ankara, Turkey)
- 668 The use of local anaesthesia with N-DO™ injector (thysion™) for TUR of small bladder tumours (BT) and bladder mapping: Preliminary results and cost-effectiveness analysis**
M. Brausi, M. Gavioli, G. Peracchia, G. De Luca, M. Viola, G. Simonini, G. Verrini (Modena, Modena-Carpi, Italy)
- 669 Value of second TURBT in grade 3 stage T1 transitional cell carcinoma of the bladder**
B. Ali-el-Dein, M. Badran, R. Abu-Eideh, A. Nabeeh, E. Ibrahim (Mansoura, Egypt)

- 670 Prognostic significance of absence of proper muscle in the resected specimen of primary T1G3 bladder cancer**
J. Park, C. Song, J.B. Kim, J. Hong, C. Kim, H. Ahn (Seoul, South Korea)
- 671 Optimised postoperative administration of intravesical Mitomycin C**
T. Müller, T. Akkad, C. Gozzi, R. Ramoner, M. Mitterberger, G. Bartsch, H. Steiner (Innsbruck, Austria)
- 672 Efficacy of managing small recurrent bladder tumours by diathermy using the CVF 4 Olympus flexible cystoscope under local anaesthesia in day surgery unit**
P. Chandrasekar, G. Walkay, J. Calleary, R. Samman, J. Virdi, B. Potluri (Harlow, United Kingdom)
- 673 Long-term follow-up of a randomised trial comparing sequential Bacillus Calmette-Guèrin and electro-motive mitomycin-C with Bacillus Calmette-Guèrin alone in high-risk superficial bladder cancer**
S.M. Di Stasi, A. Giannantoni, A. Giurioli, G. Vespasiani, G. Zampa, L. Storti, F. Attisani, A. De Carolis, M. Valenti, R.L. Stephen (Rome, Perugia, Brindisi, L'Aquila, Medolla, Italy)
- 674 Early versus delayed cystectomy for superficial bladder transitional cell carcinoma: A retrospective study**
B. Ali-el-Dein, M. Abdel-Latif, A. Mosbah, A.A. Shaaban, A. Nabeeh, E.I. Ibrahiem, H.A. El-Kappany (Mansoura, Egypt)

Poster Session 41

Chairs: *W. Artibani, Padua (IT)*
M. Spinelli, Milan (IT)

Study for 30 min. Interactive discussion for 60 min.

- 675** Quality of life in patients with symptoms of overactive bladder and refractory idiopathic detrusor over activity following intradetrusor injections of botulinum toxin type A: Results from a randomised, double blind, placebo-controlled trial
A. Sahai, S. Khan, P. Dasgupta (London, United Kingdom)
- 676** Evaluation of pelvic implants in preventing recurrence of anterior vaginal wall prolapse: Randomised multicentre study
E. Kocjancic, P. Pifarotti, F. Magatti, F. Bernasconi, D. Riva, B. Frea, M. Meschia (Novara, Milan, Como, Desio, Cantù, Magenta, Italy)
- 677** Prospective, open, randomised trial of tension-free vaginal tape and colposuspension as treatment for stress incontinence, 3-years' follow-up: Preliminary 6-month and 1-year results
M. Tellez Martinez- Fornes, C. Fernandez, F. Gimeno Albo (Madrid, Spain)
- 678** Short-term efficacy of high-supervisory-intensity group pelvic floor training versus unsupervised, home training in female stress urinary incontinence: A randomised pilot study
E. Konstantinidou, A. Apostolidis, N. Kondelidis, Z. Tsimtsiou, D. Hatzichristou, E. Ioannides (Thessaloniki, Greece)
- 679** Assessment of pelvic neuropathic lesions in female stress urinary incontinence
G. Pinggera, R. Spranger, P. Rehder, K. Tosun, M. Mitterberger, H. Strasser, G. Bartsch (Innsbruck, Austria)
- 680** Cizolirtine citrate, an effective treatment for urinary incontinence secondary to overactive bladder
J. Všeticka, J. Schraml, I. Pavlik, J. Zátura, T. Semeradt, M. Abadías (Jablonec N. Nisou, Ústí Nad Labem, Prague, Olomouc, Rakovník, Czech Republic; Barcelona, Spain)
- 681** Laparoscopic promontofixation: Results at 4.5 years
C. Mugnier, A. Pansadoro, S. Barmoshe, J.L. Hoepffner, T. Piechaud, R. Gaston (Bordeaux, Rome, France; Brussels, Belgium)
- 682** Successful treatment of vesico-vaginal fistula through the abdominal approach: A 24-year experience
M. Mancini, R. Boscolo Berto, F. Gottardo, F. Dal Moro, F. Pagano, W. Artibani (Padua, Italy)
- 683** Analysis of long-term pelvic floor electrostimulation therapy for interstitial cystitis
M. Parsons, P. De Jong, P. Radziszewski, D. Peter, A. Borkowski, M. Cervigni, L. Cardozo, B. Farnsworth, J. Nordling, J. Groen, J.L.H. Bosch, C. Chapple, H. O'Connell, R. Anna, I. Nissenkorn (Edgbaston, Birmingham, London, Sheffield, United Kingdom; Cape-town, South Africa; Warsaw, Poland; Rome, Italy; Sydney, Melbourne, Australia; Herlev, Denmark; Rotterdam, Utrecht, The Netherlands; Tel Aviv, Israel)

- 684** **Reproducibility of a minimally invasive intradetrusor injection technique to treat detrusor overactivity with botulinum toxin**
A. Sahai, V. Kalsi, S. Khan, C. Fowler (London, United Kingdom)
- 685** **Italian single-centre evaluation of adjustable continence therapy for the treatment of female stress urinary incontinence: 4 Year follow-up**
E. Kocjancic, S. Crivellaro, S. Ranzoni, D. Bonvini, B. Frea (Novara, Italy)
- 686** **Use of Ho: YAG laser in the treatment of patients with recurrent and interstitial cystitis**
A. Zaitcev, D. Pushkar, V. Diyakov, I. Galchikov (Moscow, Russia)
- 687** **Predictive value of female voiding (outflow obstruction and detrusor contraction-) nomograms is insufficient**
P. Rosier, L. De Kort, R. Bosch (Utrecht, The Netherlands)
- 688** **Electrical stimulation and behavioural treatment in female patients with mild overactive bladder syndrome, clinical results**
G. Palleschi, A. Pastore, G. Bova, E. Shehi, S. Mariani, A. Tubaro, A. Carbone (Latina, Italy)
- 689** **How useful is uroflowmetry in females?**
S. Al-hayek, M. Belal, P. Abrams (Bristol, United Kingdom)

Poster Session 42

Chairs: *R. Berges, Cologne (DE)*

B. Djavan, Vienna (AT)

Study for 30 min. Interactive discussion for 60 min.

- 690 Alfuzosin 10mg once daily prevents BPH overall clinical progression but not acute urinary retention occurrence: Results of a 2-year placebo-controlled study**
C. Roehrborn (Dallas, United States of America)
- 691 The relationship between testosterone levels and measures of sexual dysfunction: Baseline data from dutasteride studies involving a total of 12,464 subjects**
M. Marberger, C. Roehrborn, R. Rittmaster, T. Wilson (Vienna, Austria; Dallas, Research Triangle Park, United States of America)
- 692 Baseline data from the Combination of Avodart™ and Tamsulosin (CombAT) trial: Relationships between body mass index (BMI) and LUTS/BPH measures**
C. Roehrborn, C. Schulman, P. Arrosagarai, A. Duggan, K. Major-Walker, B. Morrill (Dallas, Research Triangle Park, United States of America; Brussels, Belgium; Guipúzcoa, Spain; Greenford, United Kingdom)
- 693 Racial differences in baseline characteristics in the Combination of Avodart™ and Tamsulosin (CombAT) trial**
F. Montorsi, R. Damião, M. Chung, A. Duggan, K. Major-Walker, B. Morrill (Milan, Italy; Rio De Janeiro, Brazil; Busan, South Korea; Greenford, United Kingdom; Research Triangle Park, United States of America)
- 694 Management of acute urinary retention in France: Cross-sectional survey in 2635 men with BPH**
F. Desgrandchamps, F. De La Taille, J. Doublet (Paris, Creteil, France)
- 695 Management of patients suffering from moderate to severe benign prostatic hyperplasia: Real-life practice of French urologists (the Duo study)**
R.O. Fourcade, M.C. Picot, A. Gaudin, N. Texier, A. Slama (Auxerre, Montpellier, Marly Le Roi, Paris, France)
- 696 The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH)**
K. Mc Vary, C. Roehrborn, J. Kaminetsky, S. Auerbach, B. Wachs, J. Young, A. Esler, G. Sides, B. Denes (Chicago, Dallas, New York, Newport Beach, Long Beach, Laguna Woods, Bothell, Indianapolis, United States of America)
- 697 Impact of baseline variables on the risk of LUTS progression, AUR and BPH-related surgery: Results of a 2-year placebo-controlled study with alfuzosin 10mg once daily**
C. Roehrborn (Dallas, United States of America)
- 698 Alfuzosin 10mg once daily administered for 3 years is associated with a low incidence of LUTS/BPH progression events**
M. Emberton, A. Alcaraz, H. Matzkin, M. Elhilali, R. Hartung, N. Harving, J. Van Moorselaar (London, United Kingdom; Barcelona, Spain; Tel Aviv, Israel; Montreal, Canada; Munich, Germany; Aalborg, Denmark; Amsterdam, The Netherlands)

- 699** **Combination of an α -blocker, alfuzosin and a PDE5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms and sexual dysfunction**
S.A. Kaplan, R. Gonzalez, J. Ogiste, A.E. Te (New York, United States of America)
- 700** **Treatment of LUTS in men with a novel aromatase inhibitor finrozole**
T.L. Tammela, A. Nilson, T. Streng, K. Vaahtera, R. Lammintausta, R. Santti (Tampere, Turku, Finland)
- 701** **Medical management of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/ BPH): Differences between urologists and primary care physicians (PCPs)**
J.T. Wei, J. Nuckolls, M. Miner, R.C. Rosen, C.G. Roehrborn (Ann Arbor, Michigan, Roanoke, Virginia, Swansea, Massachusetts, Piscataway, New Jersey, Dallas, Texas, United States of America)
- 702** **Demographic and clinical parameters associated with use of medical therapy at enrolment to the BPH registry & patient survey**
C.G. Roehrborn, J.T. Wei, S.E. Althof, L.S. Marks, D.J. Pasta, A.D. Seftel (Dallas, Texas, Ann Arbor, Michigan, Cleveland, Ohio, Los Angeles, California, San Francisco, California, United States of America)
- 703** **Stromal nodules and vessel wall thickening are pathological features of BPH associated with failure of α -blocker therapy**
R.D. Smith, M.A. Tran-dang, B. Khoubehi, R. Witherow, J. Vale, A. Patel, M. Walker (London, United Kingdom)
- 704** **Self-management for men with uncomplicated lower urinary tract symptoms: A randomised controlled trial**
C. Brown, T. Yap, D. Cromwell, J. Coe, L. Rixon, S. Newman, J. Van Der Meulen, T. Mundy, M. Emberton (London, United Kingdom)

Poster Session 43

Chairs: *J. Breza, Bratislava (SK)*
T. Loch, Flensburg (DE)

Study for 30 min. Interactive discussion for 60 min.

- 705 Prostate biopsy using different applications of Lidocaine**
R. Szlauer, P. Meissner, A. Gnad, R. Goetschl, N.T. Schmeller, [K. Fink](#) (Salzburg, Austria)
- 706 The effect of the patient's anxiety and periprostatic anaesthesia on pain control during transrectal prostate needle biopsy**
U. Tekdogan, [A. Tuncel](#), V. Nalcacioglu, C. Kisa, Y. Aslan, A. Atan (Ankara, Turkey)
- 707 A randomised, single-blind, parallel-group study to assess the efficacy of analgesia protocols for transrectal ultrasonographically guided prostate biopsy**
[K. Moysidis](#), M. Kantziou, O. Kerasidou, E. Thomaidou, A. Giakoumelos, K. Hatzimouratidis, D. Hatzichristou (Thessaloniki, Greece)
- 708 Prostate biopsy in middle Europe: Results of a survey about indication, patient preparation and biopsy technique**
[K.G. Fink](#), H. Schmid, L. Paras, N.T. Schmeller (Salzburg, Austria; St. Gallen, Switzerland)
- 709 MRI-guided prostate biopsy in a routine setting: First results in individuals with elevated PSA levels and negative TRUS-biopsy**
[A.G. Anastasiadis](#), M.P. Lichy, H.P. Schlemmer, U. Nagele, J. Hennenlotter, A.S. Merseburger, M.A. Kuczyk, S. Corvin, C.D. Claussen, A. Stenzl (Tübingen, Germany)
- 710 Prostate biopsy directed on the basis of 3-dimensional proton MR spectroscopic imaging findings in patients with prior negative biopsy**
[R. Schiavina](#), C. Testa, B. Corti, R. Lodi, E. Brunocilla, S. Concetti, A. Franceschelli, E. Salizzoni, B. Barbiroli, G. Martorana (Bologna, Italy)
- 711 Comparison of contrast enhanced targeted repeat biopsy in patients with low PSA (2 to 4 ng/ml) and low prostate volume versus 10 core laterally based biopsy strategy**
C. Wiunig, J. Pointner, S. Obwexer, R. Meyer-venter, M. Remzi, F. Frauscher, [A. Reissigl](#) (Bregenz, Vienna, Innsbruck, Austria)
- 712 The effect of TRUSG guided prostate biopsy on the uroflowmetry parameters**
[K. Ozer](#), K. Bal, F. Sengul, Y. Ozdamar, A. Bolukbası (Izmir, Turkey)
- 713 Prognosis factors to predict seminal vesicle invasion in patients diagnosed by systematic ten core biopsies**
[F. Gomez Veiga](#), A. Barbagelata, S. Pertega, J. Ponce, E. Romero, J. Janeiro, P. Casas, L. Castelo, E. Rosado, M. Gonzalez Martin (La Coruña, Spain)
- 714 Value of longitudinal total PSA slope in predicting repeat prostate biopsy outcome**
O. Celhay, A. De La Taille, L. Salomon, C.C. Abbou, B. Doré, [J. Irani](#) (Poitiers, Creteil, France)

- 715 Risk of non significant prostate cancer in prostate cancer patients diagnosed by an extended prostate needle biopsy procedure and treated by radical prostatectomy**
[A. De La Taille](#), L. Salomon, G. Guichard, S. Beley, H. Faucon, Y. Allory, J. Patard, D. Vordos, A. Hoznek, C. Abbou (Creteil, France)
- 716 Variation of biopsy prostate cancer detection rate among individual investigators**
[S. Ahyai](#), T. Steuber, J. Walz, K.H. Chun, T. Schlomm, A. Haese, P. Karakiewicz, H. Huland, M. Graefen (Hamburg, Germany; Montreal, Canada)
- 717 Systematic, standardised pathological examination of the prostate in radical cystoprostatectomy specimens raises the detection rate of prostatic carcinoma**
[E. Fridman](#), J. Kopolovic, Y. Mor, M. Laufer, J. Ramon (Tel-Hashomer, Israel)
- 718 Role of antimicrobial treatment in patients with elevated PSA and normal digital rectal examination**
[V. Serretta](#), A. Galuffo, A. Catanese, R. Allegro, R. Ascoli, D. Melloni, F. Aragona, C. Pavone, M. Pavone Macaluso (Palermo, Italy)
- 719 Migration of cancer features in clinically localised prostate cancer treated with radical prostatectomy over a 12 year period**
[H. Augustin](#), M. Auپرich, P. Stummvoll, K. Lipsky, K. Pummer, P. Petritsch (Graz, Austria)

Poster Session 44

Chairs: *P.D. Abel, Southall (GB)*
C.C. Schulman, Brussels (BE)

Study for 30 min. Interactive discussion for 60 min.

- 720 Serum il-6 more than 4 pg/ml in prostate cancer (PC) patients is an independent prognostic factor of PC death**
F. Pina, G. Figueiredo, N. Lunet, L. Saraiva, P. Silva, F. Cruz, B. Henrique (Matosinhos, Porto, Portugal)
- 721 PSA doubling time as predictor of objective progression and death in patients with T0-4 N0-2 M0 prostate cancer not suitable for local definitive treatment on watchful waiting (EORTC 30891)**
L. Collette, U.E. Studer, P. Whelan, W. Albrecht, J. Casselman, T.M. De Reijke, D. Hauri, W. Loidl, S. Isorna, S.K. Sundaram, M. Debois (Brussels, Oostende, Belgium; Berne, Zurich, Switzerland; Leeds, Wakefield, United Kingdom; Vienna, Linz, Austria; Amsterdam, The Netherlands; Las Palmas, Spain)
- 722 Comparative analysis of post-treatment biochemical outcomes of localised prostate cancer in a Japanese population: What is the best approach for high-risk patients?**
T. Kamoto, T Mizowaki, M Mitsumori, M Hiraoka, T. Kobayashi, Y. Shimizu, T. Inoue, T. Segawa, E. Nakamura, O. Ogawa (Kyoto, Japan)
- 723 PSA and ALP as survival predictors for patients with metastatic prostate cancer**
D. Robinson, G. Sandblom, R. Johansson, E. Varenhorst, P.O. Hedlund (Linköping, Uppsala, Umeå, Stockholm, Sweden)
- 724 What does brachytherapy treat? Histopathological analysis of 49 cases after radical prostatectomy for T1c prostate cancer**
S. Arbeláez Arango, F. Aguiló Lúcia, E. Condom Mundó, J. Suarez Novo, N. Camps, N. Serrallach Mila (Barcelona, Spain)
- 725 Poor overall survival in men treated with definitive radiotherapy without evidence of disease relapse – are we treating too many men with radiotherapy?**
I. Stikarovska, P. Perrotte, F. Saad, M. McCormack, P.I. Karakiewicz (Montreal, Canada)
- 726 Non-metastatic hormone-refractory prostate cancer (HRPC): Is any place for conformal radiotherapy in management?**
P. Milecki, P. Milecki, P. Martenka, Z. Kwias, A. Antczak (Poznan, Poland)
- 727 Metastatic disease rates after radical prostatectomy and radiotherapy in screen-detected prostate cancer**
S. Roemeling, M.J. Roobol, C. Gosselaar, C.G. Franken-Raab, T.H. Van Der Kwast, F.H. Schröder (Rotterdam, The Netherlands; Toronto, Canada)
- 728 Radical retropubic prostatectomy versus external beam radiotherapy for localised prostate cancer: An interim report of a multicentre, prospective, phase III randomised study**
S.M. Di Stasi, A. Giannantoni, G. Virgili, L. Storti, F. Attisani, A. De Carolis, G. Zampa, E.A. Jannini, M. Valenti, G. Vespasiani (Rome, Perugia, L'Aquila, Italy)

- 729** **Impact of pathological review of radical prostatectomy specimens on prognosis and predicted benefit from immediate post-operative irradiation for high risk patients (EORTC 22911)**
[T. Van Der Kwast](#), M. Bolla, H. Van Poppel, K. Vekemans, P. Van Cangh, F. Schroder, T. De Reijke, L. Da Pozzo, J. Bosset, L. Collette (Toronto, Canada; Grenoble, Besancon, France; Leuven, Hasselt, Brussels, Belgium; Rotterdam, Amsterdam, The Netherlands; Milan, Italy)
- 730** **Morbidity after long-term androgen deprivation – a matched pair comparison to radical prostatectomy and external beam irradiation**
[S. Madersbacher](#), A. Henning, G. Struhal, A. Ponholzer (Vienna, Austria)
- 731** **Effect of zoledronic acid on bone metabolism in prostate cancer (T3NxMo) patients on the androgen deprivation**
[Y. Alaev](#), [A. Vinarov](#), Y. Demidko, E. Bezrukov, D. Butnaru (Moscow, Russia)
- 732** **Percutaneous nephrostomy insertion for patients with ureteric obstruction caused by prostate cancer**
[J. Nariculam](#), D. Murphy, N. Sellars, S. Gwyther, M. Swinn (Redhill, United Kingdom)
- 733** **To do or not to do: Nephrostomy in obstructive malignant uropathy. Does hormone status matter and can we predict who may benefit?**
[M. Harris](#), M. Speakman (Taunton, United Kingdom)
- 734** **Does perineural invasion result in early bone metastases in prostate cancer?**
[R. Thurairaja](#), R. Persad, J. McFarlane, R. Iles, A. Bahl (Bristol, Bath, London, United Kingdom)

Poster Session 45

Chairs: *A. De La Taille, Creteil (FR)*
M. Graefen, Hamburg (DE)

Study for 30 min. Interactive discussion for 60 min.

- 735 Staging of unilateral clinical T3a prostate cancer: Digital rectal examination or transrectal ultrasound?**
C. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel (Leuven, Belgium)
- 736 Transrectal ultrasound in preoperative staging of prostate cancer – a single-centre study in 300 patients**
A. Bannowsky, D. Osmonov, B. Wefer, S.H. Stübinger, S. Hautmann, K. Bothe, C.M. Naumann, U. Mehnert, P.M. Braun, K-P. Jünemann (Kiel, Germany)
- 737 A comparison of prostate cancer staging performance of gray-scale transrectal ultrasound with T2-weighted 3 tesla MRI using a body array and endorectal coil**
S. Heijmink, J. Fütterer, H. Van Moerkerk, H. Langenhuijsen, C. Hulsbergen-V.D. Kaa, B. Knipscheer, F. Witjes, J. Barentsz (Nijmegen, The Netherlands)
- 738 Diagnostic accuracy of magnetic resonance imaging with endorectal coil (ER-MRI) in staging early prostate cancer (EPC) before radical prostatectomy (RP)**
A.B. Porcaro, F. Migliorini, C. Monaco, M. Balzarro, S. Montemezzi, A. Borsato, G. Gortenuiti, R. Pianon, M. Longo, C. Ghimenton, M. Romano, L. Comunale (Verona, Italy)
- 739 Is there a role for magnetic resonance imaging (MRI) in the management of T1c carcinoma prostate?**
H. Qazi, R. Manikandan, J. Philip, R. Mistry, G. Lamb, P. Cornford, A. Woolfenden, K. Parsons (Liverpool, United Kingdom)
- 740 Wash-in rate on the basis of dynamic contrast-enhanced MR imaging: Usefulness for prostate cancer detection and localisation**
S.B. Lee, J.K. Kim, J. Park, C. Yoo, H.S. Kim, J.Y. Park, H. Ahn, C.S. Kim (Seoul, Daejeon, Kangneung, South Korea)
- 741 11C-choline PET/TC for tumour localisation of primary prostate cancer: Comparison with 3-dimensional proton MR spectroscopic imaging using radical prostatectomy specimen as standard of reference**
R. Schiavina, M. Farsad, C. Testa, A. Bertaccini, F. Manferrari, M. Garofalo, B. Barbiroli, R. Lodi, A. D'errico-grigioni, G. Martorana (Bologna, Italy)
- 742 11C-choline PET and PET/CT in patients with suspected prostate cancer - is there a clinical relevance?**
M. Seitz, B. Scher, C. Gratzke, B. Schlenker, O. Reich, C. Stief (Munich, Germany)
- 743 Prostate carcinoma: Sentinel-lymph-node mapping by 3D-fusion-scintigraphy combined with intra-operative gamma-probing increases sensitivity in detecting lymph node metastases**
D. Schilling, R. Maldonado, I. Hund, B. Amend, G. Gakis, R. Bares, A. Stenzl, S. Corvin (Tübingen, Germany)

- 744 Sentinel node technique and lymphatic drainage in prostate cancer: Results of a study on 110 patients**
G. Marchioro, G. Monesi, P. Gontero, M. Sala, S. Zaramella, E. Kocjancic, F. Fontana, S. Ranzoni, M. Rudoni, E. Inglese, B. Frea (Novara, Italy)
- 745 Comparison of 18-fluor cholin PET CT and laparoscopic radioisotope-guided sentinel lymph node dissection for detection of pelvic lymph node metastases in patients with clinically localised prostate cancer**
G. Janetschek, A. Häcker, S. Jeschke, S. Ziegerhofer, S. Sega, K. Leeb, W. Langsteger (Linz, Austria; Mannheim, Germany)
- 746 Detection of sentinel lymph nodes in prostate cancer patients**
I. Rusakov, B. Alekseev, K. Nyushko, G. Frank, E. Belova, N. Vorobyev, V. Polyakov, A. Kalpinskiy (Moscow, Russia)
- 747 Preliminary results of the radiofrequency ultrasonic signal processing in prostate cancer detection**
A. Bertaccini, A. Franceschelli, E. Brunocilla, F. Manferrari, R. Schiavina, D. Marchiori, S. Granchi, E. Biagi, L. Masotti, G. Martorana (Bologna, Florence, Italy)
- 748 Tissue resonance interaction method (TRIMprobtm) for non invasive diagnosis of prostate cancer: A multi-centre clinical evaluation**
L. Da Pozzo, B. Mazzocoli, P. Rigatti, F. Manferrari, G. Martorana, F. Pietropaolo, E. Belgrano, D. Prezioso, T. Lotti, D. Villari, G. Nicita, C. Vedruccio (Milan, Bologna, Trieste, Naples, Florence, La Spezia, Italy)
- 749 Using prostate-specific antigen (PSA) and amino-terminal propeptide of type 1 procollagen (P1NP) with axial skeletal magnetic resonance imaging (MRI) enhances prediction and detection of early bone metastases in prostate cancer**
R. Thurairaja, J. Mcfarlane, R. Greenwood, R. Iles, R. Persad (Bristol, Bath, London, United Kingdom)

Symposium

17:30 - 19:00

Initial treatment response and sexual function: Two keys to understanding and managing of LUTS/BPH

eURO Auditorium Level 1

Chair: C.G. Roehrborn, Dallas (US)

Introduction

C.G. Roehrborn, Dallas (US)

eURO-6-1200

Sexuality in BPH patients: Why and how to evaluate it?

R.C. Rosen, Piscataway (US)

eURO-6-1210

Baseline characteristics of the BPH patients: Is it possible to define clear cut offs?

C.G. Roehrborn, Dallas (US)

eURO-6-1220

Initial response to the medical treatment: A pragmatic approach of the BPH management

M. Emberton, London (GB)

eURO-6-1230

Conclusion

C.G. Roehrborn, Dallas (US)

eURO-6-1240

Aims and objectives

Lower urinary tract symptoms (LUTS) associated with BPH is an increasingly prevalent condition in ageing men, which significantly affects their daily life and particularly their sexual function. Although BPH is not a life-threatening condition, some men with LUTS have a progressive disease that is defined mainly by a deterioration in symptoms, and in rare cases by acute urinary retention and/or BPH-related surgery. Identification of these patients who are at risk of unfavourable outcomes is important to optimise their management. Beside the baseline variables, such as severe LUTS, high post-void residual volume, enlarged prostate and high prostate-specific antigen, there is increasing evidence that treatment response is also a crucial predictor of serious outcomes. Furthermore, sexuality is an important aspect of quality of life in the ageing male. As there is a link between LUTS severity and sexual dysfunction and because treatment options for BPH management have different impacts on sexuality, the sexual dimension has to be taken into account when considering a patient's expectations and choice of treatment.

Symposium

17:30 - 19:00

Differentiating OAB treatments - critical factors for the older patient

Room **Ternes Level 1**

Chair: A. Wein, Philadelphia (US)

Introduction - OAB and the older patient

A. Wein, Philadelphia (US)

tern-6-1250

OAB treatment in older patients - key safety considerations

G. Kay, Washington (US)

tern-6-1260

Darifenacin - a review of urodynamics, efficacy, tolerability and 2-year data

P. Abrams, Bristol (GB)

tern-6-1270

Patient-perceived outcomes of OAB treatment

C. Kelleher, London (GB)

tern-6-1280

Questions and answers

tern-6-1290

Conclusion

A. Wein, Philadelphia (US)

tern-6-1300

Aims and objectives

In this symposium we will consider strategies to optimise our management of overactive bladder (OAB), particularly with respect to older patients, who constitute a large proportion of patients with OAB. We will review key issues affecting the management of OAB in older patients, and discuss how to refine OAB treatment to achieve the best outcomes in this patient group. The symposium will also include an overview of the latest clinical data on darifenacin, a muscarinic M3 selective receptor antagonist developed for the treatment of OAB.

Thursday, 6 April - EAU Programme

Symposium

17:30 - 19:00

The evolution of patient treatment: Beyond ED efficacy

Room **Bordeaux Level 3**

Chair: I. Eardley, Leeds (GB)

Welcome and opening remarks

I. Eardley, Leeds (GB)

[bord-6-1310](#)

A comparative trial of sildenafil citrate and tadalafil: Efficacy, preference and reasons for preference

I. Eardley, Leeds (GB)

[bord-6-1320](#)

The reconditioning endothelium concept: A step forward in treatment of erectile dysfunction with PDE5 inhibitors

P. Montorsi, Milan (IT)

[bord-6-1330](#)

PDE5 inhibitor dosing regimens for the treatment of ED: Review of the data

W. Hellstrom, New Orleans (US)

[bord-6-1340](#)

BPH: The rationale for treatment with PDE5 inhibitors

M.P. O'Leary, Boston (US)

[bord-6-1350](#)

Panel discussion

[bord-6-1360](#)

Questions and closing remarks

I. Eardley, Leeds (GB)

[bord-6-1370](#)

Aims and objectives

The Lilly ICOS Symposium at the EAU 2006 is entitled "The evolution of patient treatment: beyond ED efficacy". The symposium faculty looks forward to updating health care providers with the current efficacy and safety data on the use of tadalafil in the treatment of erectile dysfunction (ED) both on demand and chronically. This update will include results from the first head-to-head study comparing efficacy, safety, and patient preference between phosphodiesterase 5 (PDE5) inhibitors. Additionally, there is a growing body of evidence that PDE5 inhibitors may have therapeutic benefits beyond ED. The symposium will address the potential use of PDE5 inhibitors in reconditioning the endothelium, and in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).

Symposium

17:30 - 19:00

Facing the current challenges in BPH

Room **Concorde 2 Level 4**

Chair: P. Teillac, Paris (FR)

Introduction

P. Teillac, Paris (FR) con2-6-1380

Current and future clinical practice in Europe - what is really happening?

B. Djavan, Vienna (AT) con2-6-1390

What are the views of patients and urologists on BPH and its management?

R. Harkaway, Moorestown (US) con2-6-1400

What are the data on BPH treatment from everyday practice?

F. Desgrandchamps, Paris (FR) con2-6-1410

How do new data from clinical trials allow us to optimise the assessment and treatment of BPH patients?

V. Mirone, Naples (IT) con2-6-1420

Discussion

con2-6-1430

Conclusion

P. Teillac, Paris (FR) con2-6-1440

Aims and objectives

Published data on the consequences and complications of the disease BPH has changed so that BPH is now considered to be a progressive disease. This new understanding has been reflected in the latest edition of the EAU BPH guidelines and this symposium will discuss how this new perspective has altered real-life clinical practice. The main focus of the symposium will be to present the latest data in BPH, how the concept of the disease has evolved and how this may impact on management. A key theme for discussion will be patient preference; new evidence will be presented including attitudes to treatment and which treatment for which patient. Discussion will be included on how this latest data impacts on critical assessments and treatment recommendations.

Symposium

17:30 - 19:00

Ablatherm-HIFU for prostate cancer: A 10-year European experience

Room **Havana** Level **3**

Chair: K. Miller, Berlin (DE)

Introduction

K. Miller, Berlin (DE)

[hava-6-1450](#)

High intensity focused ultrasound - physical principles and future promise

G. Ter Haar, Sutton (GB)

[hava-6-1460](#)

Efficacy results and safety of high intensity focused ultrasound for the treatment of localised prostate cancer: 10 Years experience

S. Thüroff, Munich (DE)

[hava-6-1470](#)

Salvage high intensity focused ultrasound for prostate cancer local relapse after radiation beam therapy

F.J. Murat, Lyon (FR)

[hava-6-1480](#)

Open questions on the role of HIFU as a low side effects option in the treatment of localised prostate cancer: "A medical oncologist point of view"

U. Tirelli, Aviano (IT)

[hava-6-1490](#)

Conclusion

K. Miller, Berlin (DE)

[hava-6-1500](#)

Aims and objectives

Mini invasive techniques are increasingly used in modern medicine and are received with enthusiasm by patients. With 10 years European data Ablatherm HIFU is now recognised by urology and considered as a standard routine treatment for localised PCa. As a result, the number of centres with access to Ablatherm HIFU increased at a very fast pace. With in excess of 100 centres in Europe and 10000 patients treated so far Ablatherm HIFU is well positioned to become one of the alternatives of choice for curing PCa while preserving quality of life. During this symposium the physics of Focused Ultrasound will be explained and the first 10 years results will be reported. This symposium will demonstrate why according to physical principle, HIFU is the best solution to combine Efficacy and Accuracy thus preserving quality of life for certain indications. An exhaustive report on 10 years experience with Ablatherm HIFU will give an objective picture of the situation.

Symposium

17:30 - 19:00

Optimising the urologist's use of testosterone

Room **Maillot Level 2**

Chair: F. Montorsi, Milan (IT)

Introduction: Are we really using testosterone the way we should?

F. Montorsi, Milan (IT)

mail-6-1510

Highlighting EAU official recommendations on LOH

W. Weidner, Giessen (DE)

mail-6-1520

Testosterone substitution in LOH: A risk/benefit analysis

A. Allona Almagro, Madrid (ES)

mail-6-1530

Testosterone and PDE5 inhibitors: Legitimate companions?

C. Stief, Munich (DE)

mail-6-1540

Roadmap to testosterone substitution in clinical practice - a US perspective

A. Dobs, Baltimore (US)

mail-6-1550

Conclusion

F. Montorsi, Milan (IT)

mail-6-1560

Aims and objectives

Testosterone substitution is an effective form of managing late-onset hypogonadism (LOH). As a therapeutic tool, testosterone is sometimes overlooked as a prime source of treatment. The symposium will discuss the means by which testosterone substitution can assist the urologist's management of LOH. During the session, a risk/benefit analysis, as well as recently published recommendations will be reviewed, offering a strong basis for the optimal standard of care. The use of testosterone substitution will also be discussed in combination with PDE5-inhibitors and erectile dysfunction. Furthermore, information on new treatment options will be explored and experts in the field will discuss their own experience in clinical practice with testosterone substitution.

Thursday, 6 April - EAU Programme

Symposium

17:30 - 19:00

Urgency in OAB: Patient outcomes or clinical outcomes?

Room **Blue Level 2**

Chair: F. Haab, Paris (FR)

Introduction

F. Haab, Paris (FR)

blue-6-1570

Putting patient or physician requirements first?

M. Espuna Pons, Barcelona (ES)

blue-6-1580

Review of new evidence - a clinical perspective

D. Robinson, London (GB)

blue-6-1590

Review of real-life evidence- a more relevant perspective?

D.J.M.K. De Ridder, Leuven (BE)

blue-6-1600

Panel discussion

blue-6-1610

Conclusion

F. Haab, Paris (FR)

blue-6-1620

Aims and objectives

To review what really bothers the OAB patient the most

To review the latest clinical data, focussing on patient outcomes

To define effective patient management for the future

Symposium

17:30 - 19:00

Clinical experience of duloxetine in women with stress urinary incontinence (SUI) symptoms

Room **Concorde 1 Level 4**

Chair: J.R. Shah, London (GB)

Introduction

J.R. Shah, London (GB)

con1-6-1620

Portrait of an SUI patient: Bridging the gap between patient and physicians' perspectives

S. Hunskaar, Bergen (NO)

con1-6-1630

How well is clinical practice supported by efficacy data?

K.P. Jünemann, Kiel (DE)

con1-6-1640

The use of SNRI in urology: Safety in practice

A. Smith, Manchester (GB)

con1-6-1650

Take home messages

J.R. Shah, London (GB)

con1-6-1660

Aims and objectives

The differential diagnosis of (predominant) stress urinary incontinence (SUI) and urge urinary incontinence (UUI), and the subsequent treatment of SUI in clinical practice remains a challenge. During this symposium, the impact of the different types of UI on patient's quality of life and how these types of UI can be identified and recognised in clinical practice will be discussed. It will also be reviewed which treatments are effective in women with pure or predominant SUI (according to evidence-based medicine), and how these treatments fit into clinical practice. Finally, the application of serotonin noradrenaline reuptake inhibitors, such as duloxetine, in the treatment of women with pure or predominant SUI symptoms in clinical practice will be addressed from efficacy and safety points of view.

Thursday, 6 April - EAU Programme

19:00 - 19:45

EAU General Assembly

Room Havana Level 3

- | | | |
|----------|---|-----------------------------|
| 1 | Welcome by the EAU Secretary General
P. Teillac, Paris (FR) | hava-6-1670 |
| 2 | Approval minutes General Assembly, 16 March 2005, Istanbul, Turkey | hava-6-1680 |
| 3 | General report by the Secretary General
P. Teillac, Paris (FR) | hava-6-1690 |
| 4 | Report by the EAU Treasurer and Audit Committee
M.P. Wirth, Dresden (DE) | hava-6-1700 |
| 5 | Specific reports on the EAU Offices by the EAU Executive
• EAU Foundation for Urological Research | hava-6-1710 |
| 6 | Future congresses
Presentation of the 22nd EAU Annual Congress in Berlin, 21-24 March 2007 | hava-6-1720 |
| 7 | Report by the Secretary General on the EAU Membership & Nomination Office
• Approval new EAU members
• Approval new Honorary members | hava-6-1730 |
| 8 | Other items
P. Teillac, Paris (FR) | hava-6-1740 |

Plenary session

07:45 - 11:00

Plenary session 2

eURO Auditorium Level 1

Chairs: P-A. Abrahamsson, Malmö (SE)
F. Hamdy, Sheffield (GB)

07:45 - 08:15

Highlight session 2

Oncology

B. Tombal, Brussels (BE)

eURO-7-0000

Prostate cancer - prostate disease

J.B. Anderson, Sheffield (GB)

eURO-7-0010

Andrology

A. Salonia, Milan (IT)

eURO-7-0020

08:15 - 08:20

Award session 2

Hans Marberger prize for the best European paper published on endoscopy in urology in the year 2005

eURO-7-0030

Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG

08:20 - 08:55

Debate The management of bladder cancer in the elderly

Chair: M.P. Wirth, Dresden (DE)

Introduction

eURO-7-0040

Panel: M. Brausi, Modena (IT)

eURO-7-0050

P. Whelan, Leeds (GB)

eURO-7-0060

Conclusion

eURO-7-0070

Aims and objectives

Radical cystectomy with urinary diversion and chemotherapy has traditionally been reserved for less elderly patients. There is evidence in the literature that older patients have a poorer outcome after radical cystectomy not because of their age but because of more advanced tumour stages and less aggressive treatment, e.g. adjuvant chemotherapy. While the risks of surgery and anaesthesia remain, modern surgical and perioperative management has considerably facilitated the management of radical cystectomy patients. Of great importance is postoperative pain management and its implications for bowel function. It will be discussed whether today there is still an age limit for radical cystectomy. The importance of comorbidity and its influences on complications and outcome will be another topic. The panellists will also discuss whether patients for whom a cure is surgically possible should be offered this option regardless of age and whether there is an age limit for chemotherapeutic strategies.

08:55 - 09:15 **State-of-the-art lecture** **Current status of HIFU and cryotherapy in prostate cancer**

Speaker: G. Aus, Göteborg (SE)

eURO-7-0080

Aims and objectives

The current trend in Europe is for an increasing number of men to be diagnosed with early-stage prostate cancer. Surgery and radiation therapies in any form are the standard options offered to these men when treatment with curative intent is an option. High-intensity focussed ultrasound (HIFU) and cryotherapy have been available for several years but have not yet found widespread clinical use. Both methods have been continuously developed and today's therapies have little resemblance to those used a decade ago. The aim of the presentation is to present modern HIFU and cryotherapy and to try to evaluate their potential use in everyday clinical practice.

09:15 - 09:35 **Société Internationale d'Urologie (SIU) lecture** **CT urography in the evaluation and management of urological malignancies**

Speaker: J. Ramon, Ramat-Gan (IL)

eURO-7-0090

Aims and objectives

CT urography (CTU) is a relatively new non-invasive multi-phase scan of the urinary tract. The multidetector CT (MDCT) scanners that have developed dramatically in recent years have enabled rapid, thin-section imaging with high resolution and multiple reconstruction possibilities. Urologists accept coronal and sagittal 2D- and 3D- reconstructions more easily than conventional axial CT images. CTU images simulate the well-known images of an excretory urography (IVP), but are able to reveal much more information on the renal parenchyma and other abdominal structures. The ability of the multi-phase CTU to differentiate calculi from a blood clot or an enhancing tumour is a major advantage over IVP. In the past several years, CTU has become a primary investigational tool for haematuria and other urological problems. It is being used as a problem-solving test for equivocal results from ultrasound, IVP, conventional CT and cystoscopy examinations. Several imaging protocols for CTU are currently used, and different reconstruction methods are applied. In the 3D volume rendering reconstruction, all tissues excluding the urinary tract (including bones) are deleted and a movie including 360 views of the urinary system is generated. Images that could not be shown by any of the previously used imaging modalities are generated and reveal anatomical information on the structure of the urinary system.

09:35 - 09:55 **Urological Association of Asia (UAA) lecture** **Prostate cancer incidence in Korea**

Speaker: K.H. Lee, Koyang (KR)

eURO-7-0100

Aims and objectives

The incidence of prostate cancer in Asia including Korea is much lower than that of Western countries, but it is very rapidly increasing in Korea. The aim of this lecture is to present descriptive epidemiological data of the incidence of prostate cancer and to explore the possible causes of a rapidly rising incidence of prostate cancer in Korea. In addition, this lecture reports on the collective results of a multicentre prospective study in Korea: Cancer detection rates by prostate needle biopsy in accordance with prostate-specific antigen (PSA), number of biopsy cores, age, and the clinical usefulness of % free PSA for reducing unnecessary prostate biopsy in patients with an intermediate PSA level. This research will eventually contribute to early detection of prostate cancer.

09:55 - 10:40

Round table discussion [New approaches in the treatment of overactive bladder](#)

Chair: P. Abrams, Bristol (GB)

Introduction

eURO-7-0110

Panel:

K-E. Andersson, Lund (SE)

eURO-7-0120

D. Castro Diaz, Santa Cruz De Tenerife (ES)

eURO-7-0130

E. Chartier-Kastler, Paris (FR)

eURO-7-0140

Conclusion

eURO-7-0150

Aims and objectives

- To review our knowledge of the Pathogenesis of OAB symptoms: targeting the afferent nerves?
- To differentiate OAB from other conditions such as painful bladder syndrome, in order to effectively target treatment.
- How to choose the autotmuscarinic treatment of choice.
- Defining the place of intra vesical therapies such as botulinum toxin
- To understand the role of nerve stimulation and neuromodulation
- To create an algorithm of care in OAB

10:40 - 11:00

State-of-the-art lecture [Testosterone supplementation in the ageing male](#)

Speaker: C.C. Schulman, Brussels (BE)

eURO-7-0160

Aims and objectives

The various aspects of hormonal supplementation in men will be considered. Potential benefits and risks remain controversial due to a lack of evidence based long-term studies. Special attention will be focused on testosterone and the prostate. On the other hand, the risks of androgen deprivation therapy for prostate cancer will be outlined with specific reference to the increased risk of cardiovascular side effects and mortality.

Friday, 7 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 8

Room 252 Level 2

Moderator: U. Jonas, Hanover (DE)

11:00 - 11:15

Section highlights of the European Society of Female Urology (ESFU)

Speaker: E. Costantini, Perugia (IT)

252-7-0170

11:15 - 11:30

Section highlights of the European Society of Urological Research (ESUR)

Speaker: E. Oosterwijk, Nijmegen (NL)

252-7-0180

11:30 - 11:45

Section highlights of the European Society of Transplantation Urology (ESTU)

Speaker: M. Giessing, Berlin (DE)

252-7-0190

11:45 - 12:00

Section highlights of the European Society of Genito-Urinary Reconstructive Surgeons (ESGURS)

Speaker: S. Perovic, Belgrade (CS)

252-7-0200

Sub-plenary session

11:00 - 12:00

Sub-plenary session 9

eURO Auditorium Level 1

Moderator: F.R. Cruz, Porto (PT)

11:00 - 11:30

State-of-the-art lecture [Update on the management of mixed urinary incontinence](#)

Speaker: W. Artibani, Padua (IT)

eURO-7-0210

11:30 - 12:00

State-of-the-art lecture [The management of failed surgery for female stress incontinence](#)

Speaker: J.R. Shah, London (GB)

eURO-7-0220

Aims and objectives

The majority of females with stress incontinence can expect success rates from minimally invasive surgery of approximately 90%. However, those that fail to benefit from surgery are both distressed and difficult to treat. Once a “tape” is in place, can we repeat this type of surgery if the outcome is not successful? What should we do to investigate our patients when failure or complications have arisen? There is no doubt some form of investigation in patients with failed surgery is clearly necessary. Video-urodynamics form the mainstay of investigation and should be used for those patients with complex symptoms and incontinence in order to judge the best form of treatment. Surgical options are limited for the patient with failed surgery and much depends upon age, mobility, manual dexterity and the patient’s desires. Although each surgeon has his/her own preference when surgery fails, we should be able to develop a framework to help our failed patients that will help to reduce suffering with the opportunity for greatest success.

Friday, 7 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 10

Room **Ternes Level 1**

Moderator: A.R. Zlotta, Brussels (BE)

11:00 - 11:40

State-of-the-art lecture **Dose escalation in brachy and radiotherapy for prostate cancer**

Radiotherapy: D. Dearnaley, Sutton (GB)

[tern-7-0230](#)

Brachytherapy: S. Machtens, Hanover (DE)

[tern-7-0240](#)

Aims and objectives

Permanent interstitial brachytherapy by the use of implantable seeds has become a widely accepted therapeutic modality in patients with localised prostate cancer. The application of iodine-125 or palladium-103 seeds has resulted in the most conformal way to irradiate prostate cancer so far available. The long-term outcome in regard to tumour control has been determined by the dose that is delivered to the prostate. As the prescription dose for iodine-125 implants has been limited to 140-145 Gy in the past, most recent investigations have proved a prescription dose of 160 Gy to be more effective in regard to tumour control without increasing therapy-dependent morbidity. Technical advances in seed application ensure a safe and effective application of sources and a good correlation between intra-operative and postoperative dosimetry.

11:40 - 12:00

State-of-the-art lecture **Management of stage I testis cancer**

Speaker: P. Albers, Kassel (DE)

[tern-7-0250](#)

Aims and objectives

During the last 5 years, several important trials including randomised phase III trials have been published concerning the optimal treatment of stage I seminoma and non-seminoma patients. Consecutively, the consensus recommendations regarding diagnosis and treatment of testicular cancer have changed (see updated EAU Guidelines on Testicular Cancer, European Urology, December 2005). In comparison to about 10 years ago, many patients with non-seminoma can now be sufficiently treated with a thorough surveillance strategy. Surgery and chemotherapy remain options for patients at high risk of recurrence or unwilling to undergo surveillance. Comparable changes have been proposed for the treatment of seminoma patients. Most patients will not experience a recurrence with a carefully selected surveillance protocol. This talk will summarise the most important changes in the treatment recommendations for seminoma as well as non-seminoma clinical stage I patients.

Sub-plenary session

11:00 - 12:00

Sub-plenary session 11

Room **Blue Level 2**

Moderator: P. Dobronski, Warsaw (PL)

11:00 - 11:20 State-of-the-art lecture **Modern management of priapism**

Speaker: A. Kadioglu, Istanbul (TR)

blue-7-0260

Aims and objectives

The term “priapism” is named after the Greek god Priapus. Priapism is a pathological condition of penile erection that persists beyond or is unrelated to sexual stimulation. Priapism can be classified as ischaemic or non-ischaemic depending on the status of penile arterial flow. It is a true urological emergency requiring a prompt and accurate diagnosis and treatment. Treatments may have a benefit in relieving the unwanted erection and associated pain, but they have little documented benefit in terms of potency preservation. For this reason, urologists should know how to manage this urgent condition. Eventually, pathophysiology and management of priapism with the current data obtained from basic science and clinical researches will be discussed.

11:20 - 11:40 State-of-the-art lecture **Managing erectile dysfunction in the cardiac patient**

Speaker: P. Montorsi, Milan (IT)

blue-7-0270

Aims and objectives

To evaluate cardiac patients who have erectile dysfunction (ED) and need to be treated with phosphodiesterase 5 (PDE-5) inhibitors. Objectives: Sexual activity carries a modestly increased relative risk of acute coronary infarction in normal subjects and patients with established coronary artery disease (CAD). The risk is confined in the 2 h-interval following sexual intercourse and is greatly reduced by regular exercise. Since ED often coexists with CAD, it is of paramount importance to investigate fully CAD patients with ED, regardless of whether they have or have not had cardiovascular symptoms. The exercise stress test is a useful, readily available and reproducible non-invasive tool to test patient coronary reserve during exercise. According to this, a risk score (low-, intermediate- and high-risk category) is able to stratify those patients who can be treated immediately with PDE-5 inhibitors and those who require additional tests and therapy before the administration of this highly effective class of drugs for ED. The overall cardiovascular safety of PDE-5 inhibitors is well documented.

11:40 - 12:00 State-of-the-art lecture **Prevention of erectile dysfunction following radical prostatectomy**

Speaker: K.P. Jünemann, Kiel (DE)

blue-7-0280

Friday, 7 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 12

Room **Havana Level 3**

Moderator: C. Selli, Pisa (IT)

Debate **Is surveillance an option for renal cancer?**

Chair: P. Matthews, Cardiff (GB)

Introduction

[hava-7-0290](#)

Pro: M. Jewett, Toronto (CA)

[hava-7-0300](#)

Con: M. Stöckle, Homburg/Saar (DE)

[hava-7-0310](#)

Conclusion

[hava-7-0320](#)

Aims and objectives

The incidence of renal cancer is increasing while the mortality has remained stable. One possible explanation for this is the increasing number of small renal masses (2cms or less) that are being diagnosed using modern more sensitive imaging. It is likely that these masses are renal cancers although they may grow very slowly and cause no harm to the patient. The advent on new minimally invasive technologies such as cryotherapy, RF ablation and HIFU has increased the pressure on clinicians to treat these lesions. Do they all need treating or is there a case for surveillance?

This aim of this session is to explore the arguments for and against conservative non-operative management of the patient with a small renal mass.



Sub-plenary session

11:00 - 12:00

Sub-plenary session 13

Room **Maillot Level 2**

Moderator: F. Hamdy, Sheffield (GB)

Seminar **Malignant bone disease in prostate cancer**

Mechanisms of malignant bone disease

G. Van Der Pluijm, Leiden (NL)

mail-7-0330

Monitoring the skeleton

R.E. Coleman, Sheffield (GB)

mail-7-0340

Current therapies and novel targets

B. Tombal, Brussels (BE)

mail-7-0350

Aims and objectives

- 1.To explain the importance of increased bone resorption in the pathophysiology of metastatic bone disease from prostate cancer and outline how bone markers can be used to predict the likelihood of skeletal morbidity.
- 2.To outline the rationale for bisphosphonate therapy in advanced prostate cancer and present an overview of the clinical trial results with bone specific treatments.
- 3.To describe the effects of prostate cancer treatments on normal bone and outline the appropriate strategies for evaluation and treatment.

Friday, 7 April - EAU Programme

Sub-plenary session

11:00 - 12:00

Sub-plenary session 14

Room **Bordeaux** Level 3

Moderator: F.M.J. Debruyne, Nijmegen (NL)

11:00 - 11:20

State-of-the-art lecture **Basic and clinical research in reproductive medicine at Osaka University**

Speaker: A. Okuyama, Osaka (JP)

bord-7-0360

Aims and objectives

Since 1928 our department has been composed of five basic/clinical research groups: oncology; urodynamics; endourology; kidney transplant and male reproduction/andrology. The department has 30 faculty urologists inclusive of PhD students. In this lecture, I will introduce recent research achievements in reproductive medicine including: Transplantation of spermatogonial stem cells isolated from leukemic mice restored fertility without inducing leukemia (J. Clin. Inv. 2005). Prediction of successful outcome of microdissection TESE in men with idiopathic nonobstructive azoospermia (J. Urol. 2004). Comparative study on evaluation methods for serum free testosterone level for PADAM diagnosis (Int. J. Imp. Res. 2005). Brain proceedings and audio visual sexual stimuli inducing penile erection: A positron emission tomography study (J. Urol. 2006 in press)

11:20 - 12:00

Drugs in urology: **Current controversies Bicalutamide as monotherapy in the management of prostate cancer**

The evidence

T. Morris (AstraZeneca GB)

bord-7-0370

D. Newling (AstraZeneca GB)

bord-7-0380

The urologist's view

P-A. Abrahamsson, Malmö (SE)

bord-7-0390

P. Teillac, Paris (FR)

bord-7-0400

Debate: The way forward and questions from the audience

bord-7-0410

P-A. Abrahamsson, Malmö (SE)

T. Morris (AstraZeneca GB)

D. Newling (AstraZeneca GB)

P. Teillac, Paris (FR)

Special Session

12:30 - 14:00

European HIFU Club

Room 253 Level 2

Chair: W. Artibani, Padua (IT)

Introduction 253-7-0411
W. Artibani, Padua (IT)

What the integrated imaging has changed? 253-7-0412
S. Thuroff, Munich (DE)

Discussion and questions

Ideas and solutions for preserving patient's potency and continence after HIFU treatment 253-7-0413
W. Wieland, Regensburg (DE)

Discussion and questions

Tips and tricks for treating with HIFU, prostates greater than 35g. 253-7-0414
G. Pasticier, Bordeaux (FR), P. Conort, Paris (FR)

Discussion and questions

The learning curve with HIFU technique: What is easy, what is difficult? 253-7-0415
S. Brown, Stockport (UK)

Discussion and questions

HIFU history: From the beginning and after 1300 patients in Lyon. Past, present and future 253-7-0416
A. Gelet, Lyon (FR)

Discussion and questions

What are the patients asking for? What do we want to tell them? 253-7-0417
W. Artibani, Padua (IT)

Discussion and questions

Conclusion 253-7-0418
W. Artibani, Padua (IT)

Friday, 7 April - EAU Programme

Abstract Session

12:15 - 13:45

Endoscopic and robotic surgery

eURO Auditorium Level 1

Video Session 6

Chairs: *I.J. De Jong, Groningen (NL)*
P.A. Geavlete, Bucharest (RO)

All presentations are 14 minutes in length

- | | | |
|------------|---|-------------|
| V31 | Ureteroscopic laser approach in recurrent ureteropelvic junction stenosis
<i>V. Mirciulescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)</i> | eURO-7-0420 |
| V32 | One day stay for robotic pyeloplasty
<i>D. Murphy, S. Khan, B. Challacombe, J. Olsburgh, P. Dasgupta (London, United Kingdom)</i> | eURO-7-0430 |
| V33 | The thulium laser vaporesction of the prostate
<i>R. Goetschl, N. Schmeller (Salzburg, Austria)</i> | eURO-7-0440 |
| V34 | Magnetic resonance image-guided robot for prostate brachytherapy
<i>M. Muntener, H. Bagga, A. Patriciu, D. Mazilu, D. Petrisor, N. Patel, L. Kavoussi, D. Stoianovici (Baltimore, United States of America)</i> | eURO-7-0450 |
| V35 | Retrograde flexible ureteroscopic approach in symptomatic caliceal calculi
<i>D.R. Multescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)</i> | eURO-7-0460 |
| V36 | Extending the application of tubeless percutaneous nephrolithotomy (PNL)
<i>M. Sofer, I. Kaver, J. Ben Chaim, A. Friedman, E. Metlitzky, H. Matzkin (Tel-Aviv, Israel)</i> | eURO-7-0470 |

Abstract Session

12:15 - 13:45

Kidney transplantation: Basic research

Room Blue Level 2

Oral Session 10

Chairs: J. Burgos Revilla, Madrid (ES)
G. Nicita, Florence (IT)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

- J. Burgos Revilla, Madrid (ES) blue-7-0480
- 750** **Ischaemic preconditioning of the rat kidney prior to subsequent ischaemia reduces fibrosis and alpha-smooth muscle actin expression after 15 days of reperfusion** blue-7-0490
M. Timsit, R. Gadet, B. McGregor, H. Ben-Abdennebi, B. Rambaud, J. Steghens, M. Laville, X. Martin, M. Colombel, L. Badet (Paris, Lyon, France; Monastir, Tunisia)
- 751** **Effect of simvastatin in apolipoprotein deficient (apo E^{-/-}) mice with surgically induced chronic renal failure** blue-7-0500
O. Ivanovski, D. Szumilak, T. Nguyen-Khoa, N. Mothu, B. Lacour, T. B. Drüeke, Z. A. Massy (Skopje, Macedonia; Paris, Amiens, France)
- 752** **Regeneration of kidney tissue through the transplantation of embryonic renal cell in rat** blue-7-0510
H.S. Ahn, S.S. Kim, C.Y. Choi, J.H. Han, M.H. Park, K.W. Song, Y.S. Kim, J.B. Choi, H.L. Lee, H.J. Kim, J.K. Park, B.S. Kim, K.J. Joo, C.H. Kwon, H.J. Park (Seoul, Suwon, Cheongju, Cheonan, Jeonju, South Korea)
- 753** **Role of endothelial cells in solid organ transplantation: Technique and first results from a transgenic mouse model** blue-7-0520
D. Engeler, P. Krebs, B. Bolinger, H. Schmid, B. Ludewig (St. Gallen, Switzerland)
- 754** **Microchimerism and renal transplantation: Doubt still persists** blue-7-0530
G. Pourmand, B. Nikbin, A. Saraji, A. Mehraei, S. Moosavi, A.R. Abedi (Tehran, Iran)
- 755** **Preconditioning in renal transplantation depends on the manipulation of anti-apoptotic proteins** blue-7-0540
P. Daly, D. Healy, K. O'Connor, N. Docherty, C. Taylor, J. Fitzpatrick, W. Watson (Dublin, Ireland)
- 756** **The ultrastructure of arteriosclerosis in patients with endstage renal disease** blue-7-0550
D. Rohrmann, G. Schlieper, A. Mahnken, J. Mayer, M. Ketteler, G. Jakse, J. Floege (Aachen, Germany)
- 757** **A new method for standardised diagnosis following renal transplantation: Contrast enhanced ultrasound** blue-7-0560
M. Giessing, T. Fischer, S. Deger, J. Roigas, A. Wille, S.A. Loening (Berlin, Germany)
- Summary**
G. Nicita, Florence (IT) blue-7-0570

Oral Session 11

Chairs: G. Ahlgren, Malmö (SE)
H. Van Poppel, Leuven (BE)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

H. Van Poppel, Leuven (BE)

bord-7-0580

- 758** **Is radical prostatectomy a useful method for the clinically localised prostate cancers with Gleason score 8 or greater?** bord-7-0590

S. Bedir, M. Kilciler, F. Erdemir, Y. Ozgok, S. Goktas, A.F. Peker (Ankara, Turkey)

- 759** **Radical prostatectomy after neo-adjuvant hormonal therapy until PSA-nadir in initially unresectable prostate cancer** bord-7-0600

M. Hack, U. Zwergel, F. Becker, C. Pönicke, J. Lehmann, M. Stöckle (Homburg, Germany)

- 760** **PCa with PSA >20 - is there a chance of cure?** bord-7-0610

M. Spahn, P. Bader, M. Woehr, D. Frohneberg (Karlsruhe, Germany)

- 761** **Treatment of clinical stage T3 prostate cancer: A surgical disease?** bord-7-0620

S. Joniau, A. Van Baelen, C.Y. Hsu, R. Oyen, T. Roskams, H. Van Poppel (Leuven, Belgium)

- 762** **Neoadjuvant chemohormonal therapy in poor prognosis localised prostate cancer** bord-7-0630

A. Zisman, N. Yarom, K. Stav, D. Leibovici, A. Lindner, A. Sella (Ness Ziona, Zeriffin, Israel)

- 763** **Outcome for clinical unilateral T3a prostate cancer: A single-institution experience** bord-7-0640

C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel (Leuven, Belgium)

- 764** **Prognostic factors for patients with locally advanced prostatic cancer who underwent radical prostatectomy** bord-7-0650

K. Tomita, Y. Tsurumaki, H. Kume, S. Takahashi, T. Takeuchi, T. Kitamura (Tokyo, Japan)

- 765** **Neo-adjuvant chemohormonal taxane-based therapy before radical prostatectomy (RRP) in high-risk prostate cancer: 4.4 Years follow-up of a phase II trial** bord-7-0660

T. Prayer-Galetti, P. Sperandio, M. Gardiman, V. De Marco, A. Cisternino, G. Betto, S. Fracalanza, F. Pagano, W. Artibani (Padua, Italy)

Summary

G. Ahlgren, Malmö (SE)

bord-7-0670



Poster Session 46

Chairs: *T.B. Hargreave, Edinburgh (GB)*
V.R. Izard, Le Kremlin Bicêtre (FR)

Study for 30 min. Interactive discussion for 60 min.

- 766 Morphometric analysis of the testis in NFAT1 gene knockout mice**
W. Costa, H. Pazos, J. Viola, F. Sampaio (Rio de Janeiro, Brazil)
- 767 Immunohistochemical changes and expression of connexin 43 and occludin in rat testis and epididymis after epididymal ligation**
B. Turna, K. Ozdedeli, G. Oktem, B. Altay, H. Aktug, B. Semerci, A. Bilir (Izmir, Istanbul, Turkey)
- 768 The effects of acute epididimoorchitis and ciprofloxacin treatment on testicular histomorphology and sperm parameters in rats**
A. Demir, P. Türker, S. Sirvanci, F.F. Önoel, A. Findik, S. Arbak, T. Tarcan (Istanbul, Turkey)
- 769 The antidepressant St. John's Wort (*hypericum perforatum*) inhibits rat and human vas deferens contractility**
V. Altieri, V. Montanaro, R. Capasso, G. Aviello, F. Capasso, G. Napodano, A. Izzo (Naples, Italy)
- 770 Loss of the male gamete y-chromosome during spermatogenesis in men with history of bilateral cryptorchidism**
A. Sylakos, D. Giannakis, D. Baltogiannis, N. Giotitsas, I. Miyagawa, N. Sofikitis (Ioannina, Greece; Yonago, Japan)
- 771 Is Inhibin B a predictor before testicular sperm extraction or just a cost factor?**
F. Reiher, O. Rau, T. Nelius, T. Lindenmeir, I. Nickel, J. Kleinstein, E.P. Allhoff (Magdeburg, Germany)
- 772 Vibratory ejaculation and home insemination in 136 spinal cord injured men and their partners**
J. Sønksen, D. Löchner-Ernst (Herlev, Denmark; Murnau, Germany)
- 773 Comparison between sonographic findings in the scrotum and hormonal and semen profiles in extreme mountain bikers**
L. Pallwein, J. Gradl, L. Nikolai, G. Bartsch, F. Frauscher (Innsbruck, Austria)
- 774 Klinefelter's syndrome and male fertility with assisted reproduction techniques (ART)**
F. Garcia-Belandria, B. Lobel, D. Le Lannou (Rennes, France)
- 775 Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) influences acrosome function in spermatozoa**
M. Ludwig, T. Diemer, H.C. Schuppe, W.B. Schill, W. Weidner, R. Henkel (Giessen, Germany; Belville, South Africa)
- 776 Measurement of steroid hormone concentrations in peripheral and spermatid blood in infertile patients with non-obstructive azoospermia: A prospective comparative study**
L. Sibert, G. Pasquier, N. Rives, B. Mace, C. Pfister, P. Grise (Rouen, France)

- 777 Vas deferens endoscopy (vasoscopy): A new diagnostic tool?**
L. Carmignani, G. Bozzini, F. Gadda, P. Acquati, M. Ferruti, G.M. Colpi, F. Rocco (Milan, Italy)
- 778 Effect of alpha-blockers on sperm parameters in healthy adult men**
W. Hellstrom, S.C. Sikka (New Orleans, Louisiana, United States of America)
- 779 Chronic post-vasectomy testicular pain – a prospective assessment**
R. Illing, T. Leslie, J. Guillebaud, D. Cranston (London, Oxford, United Kingdom)
- 780 Post vasectomy semen analysis: Compliance, outcome and distress symptoms**
M. Mitterberger, N. Leonhartsberger, K. Tosun, H. Strasser, G. Bartsch, G.M. Pinggera (Innsbruck, Austria)

Poster Session 47

Chairs: *S.G. Joniau, Leuven (BE)*
P. Matthews, Cardiff (GB)

Study for 30 min. Interactive discussion for 60 min.

- 781 High-intensity focused ultrasound for the treatment of small renal tumours**
R. Illing, T. Leslie, J. Kennedy, F. Wu, G. Ter Haar, R. Phillips, A. Protheroe, D. Cranston (London, Oxford, United Kingdom; Chongqing, China)
- 782 Percutaneous radiofrequency ablation (PRFA) of small renal tumours under ultrasound (US) in high risk patients: 2 Year follow-up**
M. Brausi, M. Gavioli, G. De Luca, G. Peracchia, G. Verrini, G. Simonini, M. Viola, F. Ferrari (Carpi, Italy)
- 783 Bipolar radiofrequency ablation: A technical advancement in radiofrequency technology**
A. Häcker, F. Risse, K. Peters, S. Vallo, P. Alken, J. Jenne, M.S. Michel (Mannheim, Heidelberg, Germany)
- 784 Percutaneous radiofrequency ablation of small renal tumours – the Cleveland clinic experience**
J. Kaouk, N. Hegarty, A. Fineli, M. Spaliviero, E. Remer, C. O Malley, I. Gill, A. Novick (Cleveland, United States of America)
- 785 Radiofrequency ablation of kidney tumours in surgical risk patients**
M. Salagierski, M. Salagierski, T. Konecki, M. Sosnowski (Lodz, Poland)
- 786 Skipping is still a common problem with radiofrequency ablation of small renal tumours**
H. Klingler, J. Mauermann, M. Remzi, J. Kettenbach, M. Susani, M. Marberger (Vienna, Austria)
- 787 Common features of patients with complications following radiofrequency ablation of renal tumours**
V. Glentzes, S. Martinis, H. Stathis, P. Aggelidis, I. Poulas (Athens, Greece)
- 788 Impact of radiofrequency and cryoablation of small renal tumours on renal function in the solitary kidney and early oncological results**
N. Hegarty, J. Kaouk, E. Remer, C. O Malley, I. Gill, A. Novick (Cleveland, United States of America)
- 789 Percutaneous cryoablation of small kidney tumours under magnetic resonance imaging guidance: Medium term follow up**
A. Caviezel, F. Schmidlin, C. Iselin (Geneva, Switzerland)
- 790 Laparoscopic renal cryoablation (LRC) of small renal masses: Lesson learned after 70 procedures**
A. Cestari, G. Guazzoni, R. Naspro, T. Maga, V. Dell'acqua, P. Rigatti (Milan, Italy)
- 791 Retroperitoneoscopy-assisted cry ablation of small renal tumours: A 21 months follow-up**
B. Weltzien, R. Ruzsat, A. Bachmann, R. Casella, T. Forster, S. Wyler, T. Sulser (Basel, Switzerland)
- 792 Surgical management of isolated renal bed recurrence**
S. Sandhu, V. Khoo, T. Eisen, M. Gore, T. Christmas (London, United Kingdom)

- 793** **The role of metastasectomy in the management of renal cancer**
S. Ramsey, M. Aitchison (Glasgow, United Kingdom)
- 794** **The role of metastasectomy in renal cell carcinoma**
C. Ghysel, S. Joniau, H. Van Poppel (Leuven, Belgium)
- 795** **How should we manage patients with T4 renal tumours?**
S. Ramsey, M. Aitchison (Glasgow, United Kingdom)

Poster Session 48

Chairs: A. Apostolidis, London (GB)
D.J.M.K. De Ridder, Leuven (BE)

Study for 30 min. Interactive discussion for 60 min.

- 810** Activation of the ERK signalling pathway in lumbosacral spinal cord neurones of spinal injured rats by bladder reflex activity contributes to detrusor overactivity
C. Cruz, S. McMahon, F. Cruz (Porto, Portugal; London, United Kingdom)
- 796** The essence of urgency: Vanilloid receptor expression in women's bladders
R.J. Millard, L. Liu, I. Kristiana, K.J. Mansfield, K. Vaux, E. Burcher (Sydney, Australia)
- 797** The effect of bladder sensory input modulation on urgency: Data from a placebo controlled trial with intravesical resiniferatoxin
C. Silva, J. Silva, H. Castro, F. Reis, P. Dinis, A. Avelino, F. Cruz (Porto, Portugal)
- 798** The decline of urgency following intradetrusor botulinum neurotoxin type a (BoNT/A) injections for detrusor overactivity (DO): Preliminary results
V. Kalsi, A. Apostolidis, G. Gonzales, S. Elneil, P. Dasgupta, C. Fowler (London, United Kingdom)
- 799** Intravesical Botulinum A Toxin (Botox™) – does it have a role in the management of interstitial cystitis?
A. Davies, R. Chahal, R. Inman, G. Urwin (Otley, Leeds, Sheffield, York, United Kingdom)
- 800** Daily intravesical instillation of 1 mg nociceptin/orphanin FQ (N/OFQofq) for the control of neurogenic detrusor overactivity - a multicentre, placebo controlled, randomised study
M. Lazzeri, D. Turini, P. Beneforti, M. Spinelli, S. Malaguti, G. Calo, G. Remo, S. Salvadori, D. Regoli (Ferrara, Milan, Italy)
- 801** The effect of botulinum toxin A on sensations evoked by electrical stimulation and bladder filling sensations
G. Karsenty, S. Boy, A. Reitz, P.A. Knapp, B. Schurch (Zurich, Switzerland)
- 802** Brain activation in response to pudendal afferent stimulation, bladder afferent stimulation and neuromodulation - an fMRI-study in healthy female subjects
S. Boy, J. Svensson, A. Reitz, P.A. Knapp, V. Candia, R. Kleiser, A. Curt, S. Kollias, B. Schurch (Zurich, Switzerland)
- 803** Quantifying urge sensation during routine cystometry using a computerised visual analog scale
I. Gruenwald, I. Gertman, Y. Vardi, O. Massarwa (Haifi, Israel)
- 804** The effect of tolterodine on sensations evoked by electrical stimulation and bladder filling sensations
S. Boy, B. Schurch, G. Mehning, P.A. Knapp, G. Karsenty, A. Reitz (Zurich, Switzerland)
- 805** Sensory recovery after decompression of the pudendal nerve at the urogenital diaphragm: A prospective clinical study
S. Hruby, L. Dellon, W. Höftl, J. Ebmer, O. Aszmann (Vienna, Austria; Baltimore, United States of America)

- 806 Percutaneous radiofrequency sacral rhizotomy in the treatment of neurogenic detrusor overactivity in spinal cord injured patients**
R. Ferreira, C.A.L. Dancona, N.R. Netto Jr., V.P. Dantas Filho (Campinas - Sao Paulo, Brazil)
- 807 Sub-sensory threshold: Effective long term setting in patients with a permanent neuromodulator**
K. Sievert, J. Pannek, D. Engeler, M. Horstmann, A.S. Merseburger, L. Hertle, A. Stenzl (Tübingen, Herne, Münster, Germany; St. Gallen, Switzerland)
- 808 The ice water test in patients with idiopathic detrusor overactivity**
S. Al-hayek, N. Gardener, I. Mills, D. Scholfield, P. Abrams (Bristol, Sandwich, United Kingdom)
- 809 Is urine analysis a prerequisite before conducting an ice water test?**
S. De Wachter, T. Van Meel, J.J. Wyndaele (Edegem, Wilrijk, Belgium)

Poster Session 49

Chairs: P. Jichlinski, Lausanne (CH)
G. Lüdecke, Giessen (DE)

Study for 30 min. Interactive discussion for 60 min.

- 811** Expression of cyclooxygenase-2 in patients treated with radical cystectomy
S. Shariat, Y. Lotan, R. Ashfaq, Y. Sagalowsky, J.T. Hsieh (Dallas, United States of America)
- 812** EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology
R. Zigeuner, S. Leibl, G. Hutterer, T. Chromecki, P. Rehak, C. Langner (Graz, Austria)
- 813** Cox-2 expression in urothelial carcinomas of the upper urinary tract correlates with tumour progression
C. Langner, G. Hutterer, T. Chromecki, P. Rehak, R. Zigeuner (Graz, Austria)
- 814** Subdivision of stage pT3 in urothelial carcinoma of the renal pelvis facilitates detection of patients at high risk for failure
C. Langner, G. Hutterer, T. Chromecki, P. Rehak, R. Zigeuner (Graz, Austria)
- 815** The effect of competing mortality on the risk of bladder-cancer recurrence and bladder cancer-specific survival
K.F. Chun, A. Briganti, S.F. Shariat, G.S. Palapattu, L. Yair, R. Craig, P. Bastian, G. Amiel, A. Gupta, A. Vazina, N. Matt, S. Arthur, S. Lerner, M. Schoenberg, P.I. Karakiewicz (Montreal, Canada; Dallas, Baltimore, Huston, United States of America)
- 816** Positive cytology, but negative white light endoscopy: An indication for fluorescence cystoscopy in bladder cancer?
A. Karl, O. Reich, S. Tritschler, R. Knuechel-Clarke, A. Hartmann, C. Stief, D. Zaak (Munich, Aachen, Regensburg, Germany)
- 817** A novel virtual reality endoscopy simulator for endourological procedures: Development and evaluation
O. Reich, M. Noll, B. Schlenker, C. Gratzke, R. Waidelich, M. Seitz, R. Baumgartner, A. Hofstetter, C. Stief (Munich, Germany)
- 818** Changing histological pattern of bladder carcinoma in Egypt in the last 20 years: Shift of squamous to transitional types
M. Abdel-Latif, Y. Osman, A. Mosbah, A. Shaaban (Mansoura, Egypt)
- 819** Loss of heterozygosity (LOH) or fluorescence in-situ hybridization (FISH) analysis compared to routine cytology from voided urine for the detection of bladder cancer
R.T. Strebelt, S. Frigerio, B.C. Padberg, D. Lenggenhager, A. Messthaler, M.T. Abdou, H. Moch, D.R. Zimmermann (Zurich, Switzerland)

- 820** **A prospective study to evaluate CT urography for diagnosis of bladder cancer in patients presenting with macroscopic haematuria**
B. Turney, N. Cowan (Oxford, United Kingdom)
- 821** **Multidetector CT cystoscopy in the evaluation of bladder tumours**
A. Tsili, C. Tsampoulas, D. Giannakis, P. Tzoumis, E. Arkoumani, N. Sofikitis, S. Efremidis (Ioannina, Greece)
- 822** **Urine survivin in non-invasive diagnosis of transitional cell carcinoma of the urinary bladder**
M. Pesl, M. Babjuk, V. Soukup, I. Pavlik, J. Dvoracek (Prague, Czech Republic)
- 823** **A prospective controlled comparison of urine cytology and the NMP22 BladderChek assay in the detection of urinary transitional cell carcinoma**
S. Srirangam, A Crump, G. Thiruendran, D. Neilson (Blackburn, United Kingdom)
- 824** **Comparison of survivin, telomerase subunits, and cytology for the noninvasive detection of bladder cancer**
S. Weikert, F. Christoph, C. Kempkensteffen, M. Schrader, M. Mueller, K. Miller (Berlin, Ludwigshafen, Germany)
- 825** **Prognostic factors of intermediate and high risk superficial bladder cancer: Long term results of a large cohort study**
A. Zitella, G. Casetta, A. Greco, D. Pacchioni, G. Bussolati, A. Tizzani (Torino, Italy)

Poster Session 50

Chairs: *B. Bemelmans, Amsterdam (NL)*
F.C. Burkhard, Berne (CH)

Study for 30 min. Interactive discussion for 60 min.

- 826 Medication use of European women seeking treatment for UI: Findings from the PURE observational study**
C. Chinn, M. Espuna Pons, E. Chartier-Kastler, A. Wagg, G. Samsioe, S. Hunskaar, D. Quail, B. Monz, C. Hampel (Surrey, London, United Kingdom; Barcelona, Spain; Paris, France; Lund, Sweden; Bergen, Norway; Ingelheim, Mainz, Germany)
- 827 Characteristics of European women consulting a physician for the first time: Results from the PURE study on urinary incontinence**
A. Wagg, B. Monz, D. Quail, M. Espuna Pons, C. Hampel, E. Chartier-Kastler, G. Samsioe, S. Hunskaar, C. Cinn (London, Surrey, United Kingdom; Ingelheim, Mainz, Germany; Barcelona, Spain; Paris, France; Lund, Sweden; Bergen, Norway)
- 828 Estimating a preference-based single index from the overactive bladder questionnaire**
Y. Yang, J. Brazier, A. Tsuchiya, T. Young, K. Coyneb (Sheffield, United Kingdom; Maryland, United States of America)
- 829 Usefulness of antibiotic prophylaxis in invasive urodynamics in fertile and in post menopausal female subjects**
S. Siracusano, A. Tiberio, M. Simonazzi, F. Facchini, V. Alfano, A. Giannantoni, S. Ciciliato, R. Knez, G. D'aloia, M. Bernabei (Trieste, Brescia, Perugia, Italy)
- 830 Dynamic MR imaging of the pelvic floor: Technique and feasibility**
A.H. Karantanas, G. Daskalopoulos, N. Chondros, N. Gourtsogiannis, F. Sofras (Heraklion, Greece)
- 831 Urodynamic characterization of a female population with clinical SUI and concomitant symptoms suggestive of bladder outlet obstruction**
A.M. Costa, G.L. Gravina, G. Paradiso Galatioto, P. Ronchi, L. Gualà, C. Vicentini (L'Aquila, Italy)
- 832 The natural history of female urinary incontinence over 5 years**
S. Madersbacher, C. Wehrberger, C. Temml, A. Ponholzer (Vienna, Austria)
- 833 P-Mate: A new device allowing women to urinate in standing position. Urodynamic and user's satisfaction assessment**
G. Karsenty, E. Elzayat, M.C. Lemieux, J. Corcos (Montréal, Canada)
- 834 Comparison of lower urinary tract symptoms reported in voiding diary and its agreement with the physician and nurse assessment**
J. Gajewski, J. Puthenparumpil, S. Weerasinghe (Halifax, Canada)

- 835 Female urinary incontinence in urology and ob&gyn outpatient clinics: Analysis of the risk factors of bothersomeness and help seeking behavior**
B. Cetinel, O. Demirkesen, T. Tarcan, O. Yalcin, T. Kocak, M. Senocak, I. Itil (Istanbul, Izmir, Turkey)
- 836 Urethral and bladder neck functional length following bladder neck suspension in female stress urinary incontinence: Tension free vaginal tape (TVT) vs Stamey procedure**
D. Basic, J. Stoiljkovic, J. Hadzi Djokic, L. Djurasic, B. Basic (Nis, Belgrade, Serbia and Montenegro)
- 837 Age-related rhabdosphincter function in female urinary stress incontinence: Assessment of intraurethral ultrasonography**
F. Frauscher, L. Pallwein, A. Klauser, J. Gradl, S. Hannes, M. Michael (Innsbruck, Austria)
- 838 Does the urodynamic evaluation change the treatment decision for uncomplicated female urinary incontinence?**
O. Yaycioglu, S. Guvel, U. Gul, T. Turunc, H. Ozkardes (Adana, Ankara, Turkey)
- 839 Evaluation of pelvic floor reconstructive surgery using tridimensional helical CT**
P. Palma, M. Dambros, C. Riccetto, R. De Fraga, R. Maia, N. Rodrigues Netto Jr. (Campinas, Brazil)

Poster Session 51

Chairs: *S. Madersbacher, Vienna (AT)*

P. Tenke, Budapest (HU)

Study for 30 min. Interactive discussion for 60 min.

- 841 Photo selective vaporisation of the prostate (PVP): Functional outcome and adverse events after 285 procedures**
R. Ruszat, A. Bachmann, S. Wyler, H.H. Seifert, T. Forster, O. Reich, T. Sulser (Basel, Switzerland)
- 842 Objective evaluation of rotoresection: A prospective study**
S. Soliman, B. Wadie, A. Shehab El-din, A. Ghanem, E.H. Ibrahim (Mansoura, Egypt)
- 843 8 Year multicentre European pooled analysis of clinical and urodynamical outcome and retreatment rates of high energy transurethral microwave thermotherapy:**
M. Harik, M. Waldert, B. Djavan, C. Seitz, S. Alavi, P. Dobronski, V. Ravery, A. Kaisary, S. Marihart, S. Hruby, M. Marberger (Vienna, Austria; Warzaw, Poland; Paris, France; London, United Kingdom)
- 844 A randomised double blind study comparing transurethral enucleative resection with classical transurethral resection for treatment of BPH**
L. Chunxiao, Z. Shaobo, C. Binshen, L. Hulin, X. Yawen, X. Abai, F. Ping (Guangzhou, China)
- 845 Holmium laser enucleation of the prostate (HoLEP) versus open prostatectomy for prostates >70 gr: 2 Year follow-up**
F. Montorsi, R. Naspro, N. Suardi, R. Colombo, A. Salonia, A. Cestari, G. Guazzoni, V. Digirolamo, P. Rigatti (Milan, Italy)
- 846 Transurethral microwave thermotherapy (TUMT) using the TherMatrix TMx-2000™ for treatment of benign prostatic hyperplasia: Five year follow-up of multicentre randomised pivotal trial**
D. Albala, G. Andriole, B. Davis, G. Eure, J. Kabalin, J. Lingeman, J. Nuzarello (Durham, North Carolina, St. Louis, Overland Park, Norfolk, Scottsbluff, Indianapolis, Wheaton, United States of America)
- 847 Outcome of 71 patients with huge prostates >100 mls treated with Green Light PVP**
R. Krishnamoorthy, N. Barber, K. Walsh, P. Thompson, G. Muir (London, United Kingdom)
- 848 Transurethral enucleative resection of prostate for treatment of BPH**
L. Chunxiao, X. Abai, Z. Shaobo, L. Hulin, X. Yawen, C. Binshen, F. Ping (Guangzhou, China)
- 849 Bipolar versus monopolar TURP: A randomised study**
C. Terrone, C. Scoffone, C. Cracco, M. Poggio, R. Tarabuzzi, I. Morra, M. Cossu, F. Ragni, R.M. Scarpa (Orbassano, Orbassano, Italy)
- 850 Incidence and prediction of prostate cancer (PSA) after open adenectomy for benign prostatic hyperplasia (BPH)**
B. Tombal, G. De Buyl, A. Feyaerts, R. Opsomer, F.X. Wese, P. Van Cangh (Brussels, Belgium)

- 851** **Photoselective vaporization of the prostate for benign prostatic hypertrophy: Comparison of short-term treatment outcomes with TURP**
J. Park, S.H. Song, S. Lee, B. Hong, T.Y. Ahn (Seoul, South Korea)
- 852** **Photo-selective vaporization of the prostate utilizing local anaesthesia for the treatment of symptomatic prostatic obstruction. A report of 150 cases**
C. Arum, P. Romundstad, J. Mjønes (Trondheim, Norway)
- 853** **Acute urinary retention (AUR) following a trial without catheter (TWOC): Is a second TWOC worthwhile?**
O. Celhay, J. Irani, B. Merlet, F. Ouaki, C. Pirès, B. Doré (Poitiers, France)
- 854** **Prostatectomy in octogenarians**
A. Muslumanoglu, A. Tefekli, F. Altunrende, M. Barut, M. Baykal, Y. Berberoglu (Istanbul, Turkey)
- 855** **Photoselective vaporization of the prostate (PVP) versus transurethral resection of the prostate (TURP)**
A. Bachmann, R. Ruzsat, U. Straumann, S. Wyler, L. Schürch, T. Forster, O. Reich, K. Lehmann, T. Sulser (Basel, Baden, Switzerland)

Poster Session 52

Chairs: *P.C. Albertsen, Farmington (US)*
G. Aus, Göteborg (SE)

Study for 30 min. Interactive discussion for 60 min.

- 856** Extent of PSA contamination in the Spanish section of the European randomised study of screening for prostate cancer (ERSPC)
M. Lujan, A. Paez, J. Angulo, C. Pascual, E. Miravalles, A. Berenguer (Madrid, Spain)
- 857** Serum prostate-specific antigen is a predictor of the transition zone volume rather than total prostate volume in men with benign prostatic hyperplasia
A. Zlotta, A. Ben Addi, C. Schulman, F. Dehò, A. Saccà, D. Angiolilli, M. Sangalli, P. Rigatti, V. Scattoni, F. Montorsi (Brussels, Belgium; Milan, Italy)
- 858** Prostate cancer detection rate in patients with low serum prostate specific antigen and normal digital rectal examination in a European referral population
S. Ahyai, T. Steuber, J. Walz, K.H. Chun, S. Thorsten, A. Haese, P. Karakiewicz, H. Huland, M. Graefen (Hamburg, Germany; Montreal, Canada)
- 859** Diagnostic yield of a PSA threshold for prostate biopsy of 2.5 ng/ml compared to 4 ng/ml
M. Muntener, U. Kunz, K. Eichler, M. Puhan, D.M. Schmid, P. Jaeger, R.T. Strebel (Zurich, Switzerland)
- 860** Can PSA patterns be used to identify men with prostate cancer?
D. Connolly, A. Black, T. Nambirajan, L.J. Murray, A. Gavin, P.F. Keane (Belfast, United Kingdom)
- 861** Finger-prick PSA testing. Do PSA levels in capillary correlate with PSA levels in venous blood?
R. Vaidyanathan, M. Sharma, M. Partridge, D. Cochrane, M. Emberton, O. Karim, I. Walker, I. Davidson (Slough, Rugby, London, United Kingdom)
- 862** PSAwatch™ - a 10 minute, quantitative PSA assay on stored plasma
R. Vaidyanathan, M. Sharma, M. Partridge, D. Cochrane, M. Emberton, O. Karim, I. Walker, I. Davidson (Slough, Rugby, London, United Kingdom)
- 863** Detection of prostate cancer using (F/T)PSA/PSA-density ratio
M. Müller, G. Kapanadze, A. Obaje, H.H. Seifert, R. Ackermann (Düsseldorf, Germany)
- 864** Calculating PSA velocity – the secret of success? Regress!
D. Connolly, A. Black, G. Napolitano, L.J. Murray, A. Gavin, P.F. Keane (Belfast, United Kingdom)
- 865** PSA velocity and the detection of clinically significant cancers in an early detection setting (ERSPC, Rotterdam)
M.J. Roobol, F.H. Schröder (Rotterdam, The Netherlands)

- 866 Correlation of PSA-velocity with tumour-stage and Gleason score in a screening population**
A.P. Berger, M. Deibl, H. Klocker, H. Steiner, J. Bektic, A.E. Pelzer, N. Leonhartsberger, G. Bartsch, W. Horninger (Innsbruck, Austria)
- 867 Prostate-specific antigen velocity and prostate-specific antigen slope compared for prostate cancer diagnosis in men with 3 or more PSA measurements**
L. Benecchi, M. Potenzoni (Parma, Italy)
- 868 Is a PSA velocity cut-off of 0.75 ng/ml/year appropriate for all men?**
D. Connolly, A. Black, L.J. Murray, A. Gavin, P.F. Keane (Belfast, United Kingdom)
- 869 The prognostic value of PCA3 gene-based analysis of urine sediments after extended digital rectal examination**
D. Hessels, M. Van Gils, F. Witjes, C. Jansen, P. Peelen, O. Van Hooij, S. Jannink, S. Hanssen, P. Mulders, J. Schalken (Nijmegen, The Netherlands)
- 870 Specificity of the APTIMA® PCa3 assay for prostate cancer**
J. Groskopf, S.M.J. Aubin, I.L. Deras, A. Blase, S. Bodrug, S. Brentano, C. Clark, H. Rittenhouse, M.L. Macairan, L.S. Marks (San Diego, Los Angeles, United States of America)

Poster Session 53

Chairs: *S. Egawa, Tokyo (JP)*
U.E. Studer, Berne (CH)

Study for 30 min. Interactive discussion for 60 min.

- 871 Are the volume of high-grade prostatic intraepithelial neoplasia (HG PIN) and the number of biopsies with HG PIN predictive for prostate cancer?**
A. Govorov, D. Pushkar, J. Kosko, M. Kovylyna (Moscow, Russia; Emporia Ks, United States of America)
- 872 A new PSA sensitive probe to be used for preoperative assessment of extraprostatic extension of tumours**
D.R. Hjelm, R. Ellingsen, B. Falch, A. Bjørkøy, D. Østling, O. Aune, E. Paus, H. Wæhre (Trondheim, Oslo, Norway)
- 873 Predictors of seminal vesicle invasion before radical prostatectomy**
Y. Tsurumaki, K. Tomita, H. Kume, S. Takahashi, T. Takeuchi, T. Kitamura (Tokyo, Japan)
- 874 The significance of negative AMACR staining in prostate cancer: Sorting neuroendocrine prostatic cancer in challenging diagnostic cases**
E. Fridman, J. Pinthus, M. Laufer, Y. Mor, J. Ramon, J. Kopolovic (Tel-Hashomer, Israel; Hamilton Ontario, Canada)
- 875 Pathological and biochemical features of cancers detected in men with PSA levels 1.5 - 4 ng/ml: A multi-institutional European pooled analysis**
B. Djavan, B. Rocco, V. Ravery, A. Zlotta, R. Herwig, T. Anagnostou, P. Dobronski, A. Borkowski, L. Boccon Gibod, C. Schulman, M. Marberger (Vienna, Austria; Milan, Italy; Paris, France; Brussels, Belgium; Athens, Greece; Warsaw, Poland)
- 876 Histopathological features of prostate cancer treated by radical prostatectomy in the PSA era**
C. Terrone, S. Grande, E. Bollito, M. Papotti, R. Tarabuzzi, M. Poggio, C. Cracco, C. Scoffone, F. Porpiglia, S. Guercio, M. Bellina, R.M. Scarpa (Orbassano, Rivoli, Italy)
- 877 Is lymph node density a prognostic factor?**
D. Echte, E. Mueller, D. Frohneberg (Essen, Karlsruhe, Germany)
- 878 Should we replace the Gleason score with the amount of high-grade cancer?**
A.N. Vis, S. Roemeling, R. Kranse, F.H. Schröder, T.H. Van Der Kwast (Rotterdam, The Netherlands; Toronto, Canada)
- 879 The prognostic significance of tumour angiogenesis and matrix metalloproteinase expression in prostate cancer after radical prostatectomy: A multivariate analysis study**
M. Abdel-Khalek, M. Abdel-Hamid, E. Ibrahim (El-Mansoura, Egypt)
- 880 Up-regulation of hypoxia-inducible factor 1 alpha (HIF-1a) is an early event in prostate cancer development**
C. Pipinikas, S. Nair, R. Kirby, N. Carter, C. Fenske (London, United Kingdom)

- 881 PSA-velocity depends on pathologic stage and Gleason score even after biochemical failure after radical prostatectomy**
A.P. Berger, M. Deibl, H. Klocker, H. Steiner, A. Tewari, J. Bektic, A.E. Pelzer, N. Leonhartsberger, A. Lunacek, G. Bartsch, W. Horninger (Innsbruck, Austria; New York, United States of America)
- 882 Atheromatous disease, and latent prostate cancer observations on autopsy study material**
K. Stamatiou, E. Agapitos, G. Dilernia, I. Heretis, V. Papadimitriou, F. Sofras (Peiraias, Athens, Heraklion, Greece)
- 883 Ability of serum markers to detect bone metastases in patients with prostate cancer**
E. Sánchez Sánchez, C. Ponce, A. Ortiz Gamiz, J.M. Arribas, J.L. Alvarez Ossorio, J.L. Moyano Calvo, J. Castiñeiras Fernández (Sevilla, Spain)
- 884 Detection of bone metastases in prostate cancer by 18-F sodium fluoride PET**
A.J. Breeuwmsma, J. Pruim, E.J. Van Der Jagt, P.L. Jager, R.J. Nijman, R.A. Dierckx, I.J. De Jong (Groningen, The Netherlands)
- 885 Detection of prostate cancer (PCa) bone metastases using MRI of the axial-skeleton (as-MRI): Efficiency and cost/benefit ratio over Tc-99m bone scan**
B. Tombal, A. Stainier, P.J. Van Cangh, F. Jamart, B. Vande Bergh, F. Lecouvet (Brussels, Belgium)

Poster Session 54

Chairs: *J.L. Descotes, Grenoble (FR)*
F. Schmidlin, Chêne-Bougeries (CH)

Study for 30 min. Interactive discussion for 60 min.

- 886 A comprehensive renal injury concept based upon impact tests on porcine kidneys and a validated (fresh human cadaver) finite element model of the human abdomen**
F. Schmidlin, J. Snedeker, P. Niederer, M. Farshad, P. Iazzio (Geneva, Zurich, Switzerland; Minneapolis, United States of America)
- 887 Renal trauma: A ten-year experience in the diagnosis and treatment of renal injuries**
A. Lekas, I. Fokitis, G. Lefakis, V. Charalampidis, S. Tsalavoutas, S. Koritsiadis (Piraeus, Greece)
- 888 Features and outcomes of patients with grade 4 renal injury**
S. Shariat, G. Dhami, K. Stage (Dallas, United States of America)
- 889 Traumatic dissection of the renal pedicle. Modalities of management in adults and children**
J. Long, A. Manel, J. Descotes, B. Boillot, C. Sengel, J. Rambeaud (Grenoble, France)
- 890 Selective and super selective embolization as a minimally invasive management of active renovascular bleeding in high grade renal injuries- experience in 13 patients**
H. Khairy Salem, A. Nassef (Cairo, Egypt)
- 891 Long-term results of internal urethrotomy for recurrence stenosis after urethroplasty for post-traumatic urethral stricture**
T. Culty, L. Boccon-Gibod (Paris, France)
- 892 End to end anastomosis vs. patch urethroplasty in the treatment of incomplete bulbar urethral strictures**
M. Tunc, O. Gokce, O. Acar, O. Sanli, N. Aras, C. Ozsoy (Istanbul, Turkey)
- 893 Anastomotic urethroplasty for post-traumatic urethral strictures: Previous urethral manipulations have a negative impact on the final outcome**
T. Culty, L. Boccon-Gibod (Paris, France)
- 894 The use of tubularized penile circular fasciocutaneous flap in the reconstruction of urethral injuries**
P. Tsakiris, K. Souras, V. Moutzouris, A. Arhontakis (Athens, Greece)
- 895 Can we prevent the recurrence of urethral strictures with direct visual dilatation of urethra?**
M. Tunc, O. Gokce, O. Acar, O. Sanli, N. Aras, C. Ozsoy (Istanbul, Turkey)
- 896 Endoscopic and surgical realignment for post-traumatic rupture of the posterior urethra**
M.M. Gargouri, Y. Noura, N. El Fekih, F. Ben Jeddou, K. Belhadj, M. Chtourou, A. Horchani (Tunis, Tunisia)
- 897 When perform surgical exploration in patients with "presumed penile fracture"?**
A. Cavalcanti, L. Koifman, L. Favorito, C. Manes, D. Rachid Filho, J. Carvalho, P. Rabelo (Rio de Janeiro, Brazil)

- 898 Accuracy of ultrasonography in diagnosis of testicular rupture after testicular trauma**
J. El Ammari, G. Guichard, H. Wallerand, E. Chabannes, S. Bernardini, H. Bittard, F. Kleinclauss (Besançon, France)
- 899 Genital burns in pediatric patients**
A. Cavalcanti, R. Reis, A. Beatriz, M.L. Neurauper, I. Afcer, L. Favorito (Rio de Janeiro, Brazil)
- 900 Management of penile urethral lesion in penile blunt trauma**
L. Favorito, A. Cavalcante, R. Krambeck, A. Alexandre (Rio de Janeiro, Brazil)

Friday, 7 April - EAU Programme

Abstract Session

14:00 - 15:30

Laparoscopic surgery: Difficult cases

eURO Auditorium Level 1

Video Session 7

Chairs: *H.P. Beerlage, Amsterdam (NL)*
R.J.A. van Moorselaar, Amsterdam (NL)

All presentations are 14 minutes in length

- V37** **Laparoscopic radical prostatectomy: Technical aspects and pitfalls during the apical dissection** eURO-7-0680
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet, A. Volant (Brest, Nancy, France)
- V38** **Bladder neck dissection during laparoscopic radical prostatectomy: Difficult cases** eURO-7-0690
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet, A. Volant (Brest, Nancy, France)
- V39** **Dealing with a difficult urethrovesical anastomosis in laparoscopic radical prostatectomy** eURO-7-0700
F. Secin, N. Karanikolas, A.J. Stephenson, F. Bianco, K. Touijer, B. Guillonneau (New York, United States of America)
- V40** **Laparoscopic repair of an inferior vena cava injury during a right partial nephrectomy** eURO-7-0710
F. Secin, Z. Dotan, B. Shayegan, S. Olgac, B. Guillonneau, K. Touijer (New York, United States of America)
- V41** **Technical difficulties in retroperitoneoscopic radical nephrectomy. Is tumour location important?** eURO-7-0720
M. Lucan, V. Lucan, F. Elec, G. Iacob, C. Burghielea, A. Barbos (Cluj-Napoca, Romania)
- V42** **Laparoscopic repair of rectourethral fistulae** eURO-7-0730
R. Sotelo, A.J. Garcia, M. Mariano, G. Trujillo, E. Rodriguez, R. De Andrade, L. Sánchez, C. Andrade, A. Finelli (Caracas, Venezuela; Porto Alegre, Brazil; Toronto, Canada)

Abstract Session

14:00 - 15:30

Prostatitis and prostatodynia

Room Blue Level 2

Oral Session 12

Chairs: W. Aulitzky, Vienna (AT)
W. Weidner, Giessen (DE)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

W. Weidner, Giessen (DE) blue-7-0740

901 Heat/burning sensation induced by topical application of capsaicin on the perineal cutaneous area: A new approach in the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)? blue-7-0750

D. Turini, M. Lazzeri, P. Beneforti, M. Spinelli, S. Malaguti (Florence, Milan, Italy)

902 Significance of pyuria in patients with chronic pelvic pain syndrome blue-7-0760

W.C. Moon, T.H. Kim, M.R. Oh, C.H. Noh, J.H. Cho (Seoul, South Korea)

903 MnSOD and IL-10 polymorphisms in chronic pelvic pain syndrome patients blue-7-0770

S. Arisan, E.D. Buyuktuncer, M.C. Kiremit, T. Caskurlu, N. Palavan Unsal, E. Ergenekon (Istanbul, Turkey)

904 Changes in some components of the kallikrein-kinin system in the ejaculate of patients with chronic pelvic pain syndrome blue-7-0780

M. Kogan, A. Shangichev, Z. Mikashinovich, E. Chernogubova, I. Belousov, A. Afoko (Rostov on Don, Russia)

905 Transrectal colour Doppler-ultrasonographical imaging of prostate blue-7-0790

M. Kogan, I. Belousov, A. Shangichev, A. Afoko, A. Paleniy (Rostov on Don, Russia)

906 Serum and prostatic tissue concentrations of moxifloxacin (400 mg) after a single intravenous infusion in patients with benign prostatic hyperplasia undergoing transurethral resection of the prostate blue-7-0800

F. Wagenlehner, J. Lutz, F. Kees, W. Wieland, K.G. Naber (Straubing, Regensburg, Germany)

907 Antiviral treatment with valacyclovir: Does it improve symptoms of chronic pelvic pain syndrome? blue-7-0810

M. Hwuyler, E. Dobry, H. Danuser (Lucerne, Switzerland)

908 Intraprostatic injection of botulinum toxin A for men with chronic pelvic pain syndrome blue-7-0820

D.S. Park, S.M. Shin (Sungnam, Seoul, South Korea)

Summary

W. Aulitzky, Vienna (AT) blue-7-0830

Friday, 7 April - EAU Programme

Abstract Session

14:00 - 15:30

Prostate cancer: Hormonal treatment

Room **Bordeaux Level 3**

Oral Session 13

Chairs: *W. Albrecht, Vienna (AT)*

L. Klotz, Toronto (CA)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

L. Klotz, Toronto (CA)

bord-7-0840

909 Endocrine treatment and LUTS in men with prostate cancer

bord-7-0850

L. Klarskov, S. Mommsen, P. Klarskov, N. Svoldgaard (Herlev, Middelfart, Odense, Denmark)

910 Improving patient choice in the treatment of prostate cancer – self-injection of leuprorelin acetate (Prostap® SR)

bord-7-0860

B. Patel, R. Hamm, T. Whittlestone, R. Persad (Bristol, Exeter, United Kingdom)

911 Natural progression in men treated with hormonal therapy after radical prostatectomy failure

bord-7-0870

C. Porter, A. Briganti, K.F. Chun, K. Kodama, R. Gibbons, R.J. Correa, P. Perrotte, P.I. Karakiewicz (Montreal, Canada; Seattle, United States of America)

912 Bicalutamide monotherapy in high-grade prostatic intraepithelial neoplasia

bord-7-0880

A.V. Bono, A.V. Bono, R. Montironi, L. Mazzucchelli, I. Ferrari (Buguggiate, Varese, Ancona, Italy)

913 Adjuvant therapy with bicalutamide 150 mg versus standard care alone: Third analysis results from trial 24 of the early prostate cancer programme

bord-7-0890

M. Wirth, C. Tyrrell, K. Delaere, M. Sanchez-Chapado, J. Ramon, D. Wallace, J. Hetherington, F. Pina, C. Heyns, T. Borchers, S. Navani, J. Armstrong (Dresden, Germany; Plymouth, Birmingham, Hull, Macclesfield, United Kingdom; Heerlen, The Netherlands; Madrid, Spain; Tel-Hashomer, Israel; Porto, Portugal; Cape Town, South Africa)

914 Efficacy and tolerability of bicalutamide in early non-metastatic prostate cancer: Latest findings from the Scandinavian Prostatic Cancer Group Study No 6 (SPCG-6) of the early prostate cancer programme

bord-7-0900

P. Iversen, J. Johansson, P. Lodding, O. Lukkarinen, P.I. Lundmo, P. Klarskov, T. Tammela, I. Tasdemir, J. Armstrong, T. Morris (Copenhagen, Herlev, Denmark; Örebro, Goteborg, Sweden; Oulu, Tampere, Finland; Trondheim, Stavanger, Norway; Macclesfield, United Kingdom)

915 A one-year, multicentre, randomised study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients

bord-7-0910

H. Van Poppel, J. De La Rosette, B. Persson, J.K. Jensen, T.K. Olesen (Leuven, Belgium; Amsterdam, The Netherlands; Copenhagen, Denmark)

- 916** **Efficacy and safety of teverelix, a new gonadotrophin releasing hormone antagonist in patients with advanced prostate cancer. Results from a phase 2 multicentre, open-label, pilot study investigating an initial intramuscular** bord-7-0920
- C. Maclean, A. Ulys, F. Jankevicius, D. Kaniušas, J. Drewe, [F. Larsen](#) (Edinburgh, United Kingdom; Vilnius, Kaunas, Lithuania; Basel, Switzerland)

Summary

W. Albrecht, Vienna (AT)

bord-7-0930

Poster Session 55

Chairs: *H. Steiner, Innsbruck (AT)*
J.A. Witjes, Nijmegen (NL)

Study for 30 min. Interactive discussion for 60 min.

- 917 UCyt+/immunocytä in the detection of recurrent urothelial carcinoma: An update on 1,991 analyses**
C. Mian, K. Maier, E. Comploj, M. Lodde, L. Berner, S. Palermo, F. Vittadello, A. Pycha (Bolzano, Italy)
- 918 Fiberoptic infrared (FT-IR) spectroscopy as a tool for discrimination between normal urothelium and transitional carcinoma cells (TCC) of different grade: Pilot study**
S. Kravchick, Y. Raichlin, Y. Kravchenko, D. Ben Dor, A. Katzir, S. Cytron (Ashkelon, Ariel, Tel-Aviv, Israel)
- 919 Fluorescence in situ hybridization (FISH) for diagnosis of upper urinary tract tumours - a pilot study**
T. Akkad, A. Brunner, I. Verdorfer, T. Mueller, C. Gozzi, G. Bartsch, H. Steiner (Innsbruck, Austria)
- 920 Survivin expression is associated with bladder cancer presence, stage, progression and mortality**
S. Shariat, R. Ashfaq, A. Sagalowsky, Y. Lotan (Dallas, United States of America)
- 921 Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in the abdomen and pelvis**
L. Vaucher, M.E. Kamel, S. Schmidt, J. Prior, H.J. Leisinger, A. Bischof Delaloye, J. Patrice (Lausanne, Switzerland)
- 922 Evaluation of five potential tumour markers for urinary bladder cancer – endostatin, midkine, survivin, livin and E-FABP**
R. Fiala, D. Stejskal, A. Vidlar, M. Grepl (Olomouc, Czech Republic)
- 923 Soluble fas is a new sensitive and specific urine marker for bladder cancer presence and staging**
S. Shariat, R. Svatek, Y. Lotan, A. Sagalowsky, R. Casella (Dallas, United States of America; Biel, Switzerland)
- 924 Genetic signature of the early recurrence of superficial bladder cancer by combining the expression profile of 3 genes**
F. Dubosq, P. Mongiat Artus, H. Soliman, E. Turpin, H. De Thé, A. Latil, P. Teillac (Paris, Evry, France)
- 925 Multicolour-FISH for the risk-stratification of superficial bladder cancer**
A. Pycha, M. Lodde, E. Comploj, L. Lusuardi, S. Palermo, M. Mian, K. Maier, C. Mian (Bolzano, Italy)
- 926 RisikoCheck®, an internet-based instrument to identify risk populations for bladder cancer: Experiences of two years online risk check in four languages**
G. Lüdecke, W. Weidner (Giessen, Germany)
- 927 The new CST-2000 flexible cystoscope with slide-on™ Endosheath® System**
E. Mayer, S. Undre, N. Sevdalis, A. Patel (London, United Kingdom)

- 928 Can we estimate upper tract transitional cell cancer grade based on metachronous or synchronous bladder tumour grade?**
A. Beri, Y. Bar Yosef, I. Kaver, H. Matzkin (Tel Aviv, Israel)
- 929 Evaluation of the diagnostic value of NMP-22 bladder tumour test by means of fluorescence cystoscopy**
S. Tritschler, S. Scharf, A. Karl, D. Zaak, C. Stief (Munich, Germany)
- 930 Cellular autofluorescence imaging for the diagnosis of urothelial carcinoma in urine**
P. Eschwège, K. Steenkeste, A. Deniset, S. Lécart, S. Lévêque-Fort, M. Fontaine-Aupart, S. Ferlicot (Le Kremlin Bicêtre, Orsay, France)
- 931 Multiplex polymerase chain reaction in microsatellite analysis urine sediment cells. A fast and cheap method in diagnosing and monitoring of superficial transitional bladder cell carcinoma**
R. Bartoletti, T. Cai, M. Dal Canto, G. Nesi, V. Boddi, M. Piazzini (Florence, Italy)

Poster Session 56

Chairs: *V. Ficarra, Verona (IT)*
H. Klingler, Vienna (AT)

Study for 30 min. Interactive discussion for 60 min.

- 932** **Is there an obvious learning curve effect for laparoscopic nephrectomies performed by newly appointed UK consultant surgeons trained in laparoscopy?**
M. Nuttall, N. Barber, R. Hindley, J. Poulsen, P. Rimington, W. Choi (Canterbury, Frimley, Basingstoke, London, Eastbourne, United Kingdom)
- 933** **Complications of laparoscopic partial nephrectomy**
E. Barret, S. Lorin, X. Cathelineau, F. Rozet, N. Cathala, A. Mombet, D. Prapotnich, G. Vallancien (Paris, France)
- 934** **The use of tissue glues and/or sealants in laparoscopic nephron-sparing surgery : A European survey**
A. Celia, G. Guazzoni, V. Pansadoro, V. Disanto, F. Porpiglia, P. Fornara, C. Abbou, G. Janetschek, N. Soomro, C. Milani, A. Breda, P. Schulam, J. De La Rosette, M. Laguna, G. Breda (Bassano del Grappa (VI), Milan, Rome, Acquaviva Delle Fonti, San Luig Hospital, Padua, Italy; Halle, Germany; Creteil, France; Linz, Austria; Newcastle, United Kingdom; Los Angeles, United States of America; Amsterdam, The Netherlands)
- 935** **Autologous fibrin glue for haemostasis in laparoscopic partial nephrectomy for renal cell carcinoma**
L. Schips, K. Lipsky, O. Dalpiaz, S. Gidaro, P. Petritsch, R. Zigeuner (Graz, Austria)
- 937** **Is there still a role for hand assisted laparoscopic nephrectomy (HAL)?**
T. Appanna, A. Martindale, J. Goad, C. Temelcos, A. Clarke, R. Asopa, L. Cleeve, O. Niall (Melbourne, Australia)
- 938** **Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: A consecutive study**
A. Bex, M. Kerst, H. Mallo, W. Meinhardt, S. Horenblas, G. De Gast (Amsterdam, The Netherlands)
- 939** **Radical nephrectomy and metastectomy combined with immunotherapy for metastatic renal cell carcinoma**
Y.H. Park, C.W. Jeong, S.K. Hong, H. Jeong, C. Kwak, E. Lee, S.E. Lee (Seoul, Gyeonggi, South Korea)
- 940** **With increasing tumour size histopathological features are more aggressive in clear cell RCC, but not in papillary RCC**
M. Remzi, C. Seitz, M. Özsoy, E. Tanovic, H.C. Klingler, M. Susani, M. Dobrovits, H. Faikovic, M. Marberger (Vienna, Austria)
- 941** **Combination immunochemotherapy as an adjuvant therapy for stage T3 renal cell carcinoma**
S.K. Hong, I.H. Chang, M.C. Gil, Y.J. Kim, S.B. Lee, H. Jeong, J.S. Jeong, J.B. Lee, S.S. Byun, C. Kwak, S.E. Lee (Sunghnam, Daejun, Seoul, Koyang, Incheon, South Korea)
- 942** **Renal cell carcinoma with venous tumour thrombus: Prognostic significance of the level of the tumour thrombus and of associated metastases on long-term survival**
S. Klaver, S. Joniau, H. Goethuys, R. Suy, H. Van Poppel (Leuven, Genk, Belgium)

- 943 Follow-up after radical nephrectomy-modified protocol based on pathological stage**
J. Cherian, S. Madan, S. King, A. Lawson, M. Stower, R. Sundaram, R. Puri (Bradford, Wakefield, York, Harrogate, United Kingdom)
- 944 The impact of hospital provider volume on the outcome of radical nephrectomy**
P. Cathcart, M. Nuttall, M. Emberton (London, United Kingdom)
- 945 Outcome analysis of 28 cases of Wilm's tumour in adults**
D. Roschin, V. Matveev, M. Volkova, T. Sharoev (Moscow, Russia)
- 946 Surgical strategies for urological malignancies of the retrocrural area**
D. Sahi, C. Ohlmann, E. Özgür, U. Engelmann, A. Heidenreich (Cologne, Germany)

Poster Session 57

Chairs: *J.L.H.R. Bosch, Utrecht (NL)*
J.L. Ruiz-Cerdá, Valencia (ES)

Study for 30 min. Interactive discussion for 60 min.

- 947 Deep brain stimulation in Parkinson's disease and urodynamic and positron emission computed tomography (PET) changes**
C. Seif, B. Wefer, C. Van Der Horst, P. Braun, K.P. Junemann, J. Herzog, P. Weiss Blankenhorn (Kiel, Jülich, Germany)
- 948 Long latency somatosensory evoked potentials: Modifications after percutaneous tibial nerve stimulation**
E. Finazzi Agro, F. Petta, C. Pachatz, R. Miano, F. Sciobica, G.A. Marfia (Rome, Italy)
- 949 Impact of electrostimulation of the periprostatic urethral branch of the pelvic nerves on the pudendal nerve on the membranous urethra in the male rabbit**
C. Van Der Horst, C. Seif, C. Naumann, G. Böhrer, P. Braun, K. Jünemann (Kiel, Germany)
- 950 Detrusor contractility test: A reliable patient selection method for sacral neuromodulation**
M.P. Bertapelle, M.C. Dalle Ore, G. Bodo, A. Giannò, R. Carone (Torino, Italy)
- 952 Are there any programming algorithms associated with successful and effective InterStim therapy in patients with urinary voiding dysfunction?**
E. Kocjancic, J. Smith, S. Crivellaro, P. Gontero, G. Marchioro, B. Frea (Novara, Italy; Burlington, Massachusetts, United States of America)
- 953 Long-term clinical efficacy of sacral neuromodulation (SNM) for patients with neurogenic low urinary tract symptoms (LUTS)**
G. Lombardi, A. Macchiarella, N. Mondaini, G. del Popolo (Florence, Italy)
- 954 Simultaneous registration of intraabdominal and intravesical pressures during cystometries in awake rats – effects of outflow obstruction and intravesical PGE2**
T. Lee, K.E. Andersson, T. Streng, P. Hedlund (Lund, Sweden)
- 955 Heart rate variability during urodynamic examination to assess autonomic nervous system function - initial results from a feasibility study**
P.A. Knapp, A. Reitz, M. Sax, S. Boy, B. Schurch (Zurich, Switzerland)
- 956 The outcome of urodynamic findings in patients with tethered cord**
A. El-Hefnawy, B. Wadie (Mansoura, Egypt)
- 957 Clinical and urodynamic abnormalities of patients in different phases after cerebrovascular accidents**
A. Abdel Hafez, D. Rohrmann, R. Toepper, J. Noth, G. Jakse (Sohag, Egypt; Aachen, Germany)

- 958 Urodynamically demonstrated rectal contraction: Do they represent neuropathy?**
A. Abdel Hafez, D. Rohrmann, G. Jakse (Sohag, Egypt; Aachen, Germany)
- 959 Guarding response of the bladder and bowel: Are they both aberrant following spinal cord injury?**
A.V. Balasubramaniam, E.A.L. Chung, J.B. Woodhouse, M.D. Craggs, S.L. Knight, J.A. Bycroft, A. Gall, F.R.I. Middleton (Stanmore, United Kingdom)
- 960 Micturition and defecation: Which act has predominance?**
S. De Wachter, J.J. Wyndaele (Wilrijk, Belgium)
- 961 Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients**
G. Lombardi, N. Mondaini, A. Cilotti, G. Giubilei, G. Del Popolo (Florence, Italy)

Poster Session 58

Chairs: *R. Kocvara, Prague (CZ)*
J.M. Nijman, Groningen (NL)

Study for 30 min. Interactive discussion for 60 min.

- 962 Diagnostic accuracy of colour Doppler sonography of the ureteral jets in children with hydronephrosis: Evolution of a novel concept to evaluate obstruction**
J. Bessa Junior, M.C. Chammas, L. Cerri, F.T. Denes, G. Cerri, M. Srougi (Sao Paulo, Brazil)
- 963 Optimization of the pyeloplasty technology on the base of hydrodynamic analysis**
M. Kogan, V. Sizonov, S. Konovalov, V. Antonenko, A. Afoko (Rostov on Don, Russia)
- 964 Detection of viruses in bladder, renal pelvis urine and kidney biopsies in children with obstruction of upper urinary tract**
M. Kogan, U. Naboka, I. Kluka, I. Suchkov, A. Afoko (Rostov on Don, Russia)
- 965 Isolating viral and bacterial pathogens in biopsy material from kidneys of children with obstructive uropathy**
M. Kogan, U. Naboka, I. Kluka, L. Bragina, I. Suchkov (Rostov on Don, Russia)
- 966 The expression of interleukin-6 and its receptors in the developing rat kidney**
U.S. Ha, J.H. Cha, J.Y. Choi, D.H. Cho, C.B. Lee (Suwon, Seoul, South Korea)
- 967 A shift in presentation and treatment in children with a primary non-refluxing megaureter**
R. Beetz, R. Stein, A. Schröder, S. Wölflé, J. Thüroff (Mainz, Germany)
- 969 A histological study of urethral plate with light and transmission electron microscopy in hypospadias**
H.S. Chang, C.H. Park, C.I. Kim, K.S. Kim (Daegu, South Korea)
- 970 The effect of VEGF on the angiogenic activity after urethral reconstruction using free penile graft: Preliminary results**
K. Kambouri, S. Gardikis, A. Giatromanolaki, P. Ipsilantis, C. Kalaitzis, M. Pitiakoudis, A. Polychronidis, S. Touloupidis, E. Sivridis, C. Simopoulos (Alexandroupolis, Greece)
- 971 Modified Snodgrass and Mathieu techniques for treatment hypospadias**
T. Ali (Nyíregyháza, Hungary)
- 972 Microsurgical four-layer two overlapping dorsal subcutaneous flaps for urethrocutaneous fistula after hypospadias repair**
A.F. Hussein (El-Minia, Egypt)
- 973 The value of the uroflowmetric parameters and urinary flow patterns of children with hypospadias operation**
C. Kaya, E.V. Kucuk, M.I. Ozturk, H. Kanberoglu, M.I. Karaman (Istanbul, Turkey)

- 974** **Uncommon manifestations of ventral urethral duplications**
J. Miller, J. Steiß, G. Alzen, W. Weidner (Giessen, Germany)
- 975** **Comparative genomic hybridisation reveals clonal origin of blastemal, epithelial and stromal cells in Wilms' tumours**
E. Currlin, A.M. Luebke, B. Gunawan, H.J. Schulten, N. Graf, I. Leuschner, L. Füzesi, T. Schlomm (Hamburg, Göttingen, Homburg Saar, Kiel, Germany)
- 976** **Laparoscopic nephrectomy for Wilms tumour in children: A new paradigm?**
F. Dénes, R. Duarte, C. Lillian, V. Odone Filho, M. Srougi (Sao Paulo, Brazil)

Poster Session 59

Chairs: J. Grall, Dijon (FR)
D. Pushkar, Moscow (RU)

Study for 30 min. Interactive discussion for 60 min.

- 977 Comparison of transobturator and transabdominal tapes for surgical treatment of female stress urinary incontinence**
H. Sender, J. Green (Toronto, Canada)
- 978 Prospective multicentre trial of Monarc Transobturator Sling for stress incontinence: 24 Month functional data**
D. Deridder, B. Jacquetin, A. Fischer, P. Debodinance, A. Marques Queimadelos, C. Courtieu, M. Cervigni, J. Rassler, A. Rane, S. Herschorn, G. Urwin, W. Goetze, S. Ouellet, M. Schrader, G. Mellier (Leuven, Belgium; Clermont Ferrand, St. Pol Sur Mer, Montpellier, Lyon, France; Ruedesheim Am Rhein, Leipzig, Strausberg, Berlin, Germany; Santiago De Compostela, Spain; Roma, Italy; Townsville, Australia; Toronto, Montreal, Canada; York, United Kingdom)
- 979 Audit of clinical outcome of TVT vs. TOT sub urethral sling procedures**
E. Dickerson, T. Tang, R. Jeavons, G. Urwin, A. Evans (York, United Kingdom)
- 981 Transvaginal bone-anchored sling (bas) for treatment of stress urinary incontinence: Intermediate-term follow-up**
C. Giberti, S. Siracusano, S. Ciciliato, M. Lavagna, P. Cortese (Savona, Trieste, Italy)
- 982 Prospective, multicentre, randomised study comparing retropubic and transobturator routes in female stress incontinence cure. Functional outcomes at three months**
E. David-Montefiore, E. Daraï, M. Grisard-Anaf, K. Bonnet, J. Frobert, J. Lienhard (Paris, Lyon, Bourg en Bresse, Sainte Colombe, France)
- 983 Periurethral prolene mesh supported vaginal wall sling: New periurethral fibrosis procedure for the treatment of stress urinary incontinence**
C. Kaya, N. Pirincci, H. Kanberoglu, M. Ozturk, M.I. Karaman (Istanbul, Turkey)
- 984 Transvaginal endosonography in the evaluation of tension free vaginal tape (TVT) implantation**
A. Loch, M. Stöckle, T. Loch (Flensburg, Homburg, Germany)
- 985 Sexuality after transobturator vaginal tape for stress urinary incontinence. Results at 14 months of a mailed questionnaire**
M. Geraud (Compiègne, France)
- 986 SPARC-Sling System in stress incontinent women with intrinsic sphincter deficiency: 1-Year follow-up**
G. Primus (Graz, Austria)
- 987 Transobturator tape as a day surgery procedure**
M. Abdel-Fattah, K. Sivanesan, I. Ramsay (Glasgow, United Kingdom)

- 988 Remeex system: A therapeutic option in selected cases of stress urinary incontinence with intrinsic sphincter deficiency (ISD)**
J.L. Campos-Fernandes, P. Paparel, A. Leriche, B. Leriche, M. Devonec, A. Ruffion (Pierre Bénite, Lyon, France)
- 989 5 Years experience with a cost-effective modification of the tension-free vaginal sling: Technique and results**
S. Subotic, M. Schulze, D. Teber, J. Rassweiler (Heilbronn, Germany)
- 990 Stamey bladder neck suspension and nonoperative management for the treatment of mixed urinary incontinence in women - a prospective comparison and long-term results**
C. Topuzovic, S. Micic (Beograd, Serbia and Montenegro)
- 991 The tension-free vaginal tape for managing female stress urinary incontinence in 95 cases**
V. Argyropoulos, A. Kostakopoulos, P. Tekerlekis, V. Protogerou, M. Melekos (Athens, Larissa, Greece)

Poster Session 60

Chairs: *M. Emberton, London (GB)*

A. Tubaro, Rome (IT)

Study for 30 min. Interactive discussion for 60 min.

- 992** Questionnaire-based evaluation of erectile function after photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP)
A. Bachmann, R. Ruzsat, U. Straumann, L. Schürch, S. Wyler, T. Forster, O. Reich, K. Lehmann, T. Sulser (Basel, Baden, Switzerland)
- 993** Photoselective vaporisation of the prostate in men over 80 years
R. Ruzsat, A. Bachmann, S. Wyler, H.H. Seifert, T. Forster, T. Leippold, T. Sulser (Basel, Switzerland)
- 994** The comparison of PK tissue management system TURP with conventional monopolar TURP
S.H. Choi, J.H. Lee, J.H. Seo, C.J. Yoon, K.H. Moon, Y.I. Park, S.R. Cho (Daegu, Gumi, South Korea)
- 995** Bipolar transurethral resection of the prostate with the ACMI Vista CTR system: Experience on 74 cases
A. Meneghini, M. Pizzarella, V. Pegoraro (Rovigo, Italy)
- 996** Photoselective vaporization (PVP) vs. transurethral electroresection of the prostate (TURP): A comparing cost analysis
R. Ruzsat, T. Sulser, H.H. Seifert, S. Wyler, T. Forster, T. Leippold, A. Bachmann (Basel, Switzerland)
- 997** Erectile functions in BPH patients after photoselective vaporization of the prostate laser surgery
O.F. Karatas, A. Tasçi, V. Tugcu (Istanbul, Turkey)
- 998** The “learning curve” with holmium laser enucleation of the prostate
T. Aho, H. Fernando, L. Suraparaju (Cambridge, United Kingdom)
- 999** Safety and efficacy of holmium laser enucleation of the prostate for urinary retention
T. Aho, H. Fernando, L. Suraparaju (Cambridge, United Kingdom)
- 1000** Noise levels during holmium laser enucleation of the prostate (HoLEP)
T. Aho, Z. Maan, R. Pillai (Cambridge, London, United Kingdom)
- 1001** Transurethral incision of the prostate (TUIP): Long-term results
D. Argirovic (Belgrade, Serbia and Montenegro)
- 1002** Preliminary clinical experience on molecular quantac resonance electrosurgical unit – vesalius u 20 - in transurethral resection of the prostate
A. Meneghini, V. Pegoraro (Rovigo, Italy)
- 1003** Is intensity of the prostatic vascularization important for TUMT efficacy?
M. Lucan, S. Dudea, F. Elec, V. Lucan, G. Iacob, C. Burghilea, A. Barbos (Cluj Napoca, Romania)

- 1004 Prediction factors in TUMT efficacy**
M. Lucan, [F. Elec](#), V. Lucan, C. Burghelea, G. Iacob, A. Barbos (Cluj Napoca, Romania)
- 1005 The morbidity of laparoscopic versus open simple prostatectomy**
[E. Barret](#), A. Bracq, G. Braud, J. Harmon, D. Almeida, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)
- 1006 Preliminary results of the EAU Real-Life Data Registry on TUNA® therapy**
[A. Tubaro](#), K. Höfner, H. Villavicencio, J. De La Rosette, C. Chapple (Rome, Italy; Oberhausen, Germany; Barcelona, Spain; Amsterdam, The Netherlands; Sheffield, United Kingdom)

Poster Session 61

Chairs: *U.H. Stenman, Helsinki (FI)*
C. Wülfing, Münster (DE)

Study for 30 min. Interactive discussion for 60 min.

- 1007 Preliminary study on plasma nucleic acid based detection of prostate cancer**
W.C. Moon, T.H. Kim, M.R. Oh, C.H. Noh, T.H. Uhm (Seoul, South Korea)
- 1008 Diagnostic performance of serum ribonuclease activity in men with PSA levels between 2,5 and 20 ng/ml**
S. Eskicorapci, H.A. Ozkara, E. Onder, I. Erkan, G. Ciliv, H. Ozen (Ankara, Turkey)
- 1009 Differentiation enhancement of circulating immune cells containing intracellular PSA: A new method for discrimination between benign and malignant prostatic disease**
R. Herwig, G. Kramer, B. Djavan, P. Rehder, R. Ramoner, M. Marberger (Vienna, Innsbruck, Austria)
- 1010 Soluble receptor of human cytokine IL-6 (sIL-6R) on 123 patients with untreated prostate cancer (PC)**
F. Pina, G. Figueiredo, N. Lunet, N. Tomada, A. Silva, F. Cruz, H. Barros (Porto, Portugal)
- 1011 Serum soluble urokinase-type plasminogen activator receptor (SUPAR) is a useful marker of prostate cancer**
G. Milanese, L. Gasparri, M. Dellabella, N. Sidenius, A.B. Galosi, D. Minardi, F. Blasi, F. Fazioli, G. Muzzonigro (Ancona, Milan, Italy)
- 1012 Aptima® PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer**
Y. Fradet, J. Groskopf, S.M.J. Aubin, I.L. Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, M. Desaulniers, H. Rittenhouse (Quebec, Canada; San Diego, United States of America)
- 1013 The usefulness of human glandular kallikrein 2 (hK2) and [-5,-7]proPSA serum measurement for PCA prediction in the re-screening biopsy**
M. Kwiatkowski, D. Seiler, B. Arndt, A. Huber, F. Recker (Aarau, Switzerland)
- 1014 Clinical usefulness of hK2 and free-to-total PSA ratio to improve early diagnosis of prostate cancer in a population based screening**
M. Kwiatkowski, D. Seiler, B. Arndt, A. Huber, F. Recker (Aarau, Switzerland)
- 1015 Comparative assessment of free and total forms of serum human glandular kallikrein 2 and prostate specific antigen for prediction of locally advanced and recurrent prostate cancer**
T. Steuber, A. Vickers, A. Haese, K.F. Chun, T. Schlomm, H. Huland, V. Vaisanen, K. Petterson, J. Eastham, P. Scardino, H. Lilja (Hamburg, Germany; New York, United States of America; Turku, Finland)
- 1016 Glutathione-S-transferase (GSTP1): A serum molecular marker to define the risk of prostate cancer**
R. Gunelli, M. Fiori, L. Valmorri, H. Hanitzsch, P. Lilli, C. Saltutti, C. Vivacqua, T. Zenico, E. Bercovich (Forlì, Italy)

- 1017 Serum levels of pro-matrix metalloproteinases 2, pro-matrix metalloproteinases 9 and gelatinase activity in patients with prostate cancer and benign prostatic hyperplasia**
A. Zitella, G. Casetta, G. Mengozzi, G. Aimo, A. Greco, D. Rosso, A. De Libero, G. Ghignone, A. Tizzani (Torino, Italy)
- 1018 Role of neopterin in diagnosis of prostate cancer: 47114 Analyzed samples**
G. Pinggera, W. Horninger, H. Schennach, J. Bektic, P. Rehder, M. Mitterberger, K. Tosun, G. Walder, H. Strasser, G. Bartsch (Innsbruck, Austria)
- 1019 Quantitative real-time RT-PCR of CD24 m-RNA**
M. Schostak, H. Krause, K. Miller, F. Christoph, C. Kempkensteffen, J. Koellermann, M. Schrader (Berlin, Fulda, Germany)
- 1020 Early diagnosis of prostate cancer: Trimprob versus PSA, DRE, TRUS: A toss-up control study**
A. Tubaro, C. De Nunzio, A. Trucchi, L. Miano (Roma, Italy)
- 1021 Transforming growth factor alfa (TGF-) level is associated both to serum androgen and primary androgen insensitivity prostate cancer (pc) status**
F. Pina, G. Figueiredo, N. Lunet, A. Silva, P. Silva, F. Cruz (Matosinhos, Porto, Portugal)

Poster Session 62

Chairs: L. Cecchini, Barcelona (ES)
C. Terrone, Orbassano (IT)

Study for 30 min. Interactive discussion for 60 min.

- 1022 The discussion of life expectancy with urology patients**
M. Clarke, K. Kennedy, P. Ewings, R. Macdonagh (Taunton, United Kingdom)
- 1023 Sexual, urinary and bowel function in elderly men without prostate cancer**
I. Korfage, M-L. Essink - Bot, M. Roobol, F. Schröder, H. De Koning (Rotterdam, The Netherlands)
- 1024 A prospective study evaluating psychological responses to rapid PSA testing**
S. Wilkinson, K. Warren, A. Ramsden, A. Matthews, G. Chodak (Chicago, United States of America)
- 1025 BMI and its ability to improve prediction of biochemical recurrence (BCR) after radical prostatectomy (RP): Does a statistically significant marker always improve predictive accuracy in multivariate models?**
F.K.H. Chun, A. Briganti, M. Graefen, F. Montorsi, A. Haese, T. Steuber, U. Michl, V. Scattoni, M.G. Friedrich, L. Valiquette, P. Rigatti, H. Huland, P.I. Karakiewicz (Hamburg, Germany; Milan, Italy; Montreal, Canada)
- 1027 Is 11-C choline positron emission tomography an applicable tool in the evaluation of biochemical failure after treatment for localised prostate cancer?**
S. Corvin, D. Schilling, J. Hennenlotter, A. Anastasiadis, A. Stenzl (Tübingen, Germany)
- 1028 Integrated 11C-choline PET/CT scan in the evaluation of patients with biochemical failure after radical retro-pubic prostatectomy: Hystologic correlations after pelvic and retroperitoneal lympho-node dissection**
V. Scattoni, N. Suardi, M. Picchio, C. Messa, M. Freschi, M. Roscigno, L. Da Pozzo, F. Fazio, F. Montorsi, P. Rigatti (Milan, Italy)
- 1029 Introducing a new and simple scoring system to evaluate oncological and functional outcome after radical prostatectomy**
L. Salomon, A. De La Taille, D. Vordos, A. Hoznek, R. Yiou, C. Abbou (Creteil, France)
- 1030 Nomograms and consequent patients risk stratification for clinically localised prostate cancer cannot be safely used for treatment planning in clinical practice**
P. Puppò, C. Introini, A. Naselli, R. Andreatta (Genoa, Italy)
- 1031 Prediction of insignificant cancers: How good are current nomograms?**
E. Currlin, C. Eichelberg, K.H.F. Chun, A. Haese, T. Steuber, M. Graefen, H. Huland (Hamburg, Germany)
- 1032 Partin tables do not adequately predict the risk of lymph node involvement in patients undergoing radical prostatectomy for clinically localised prostate cancer**
A. Heidenreich, C. Ohlmann, U. Engelmann, M. Schuhmacher, U. Studer (Cologne, Germany; Berne, Switzerland)

- 1033 Individual prognostic significance of the nineteen single conditions contributing to the Charlson comorbidity score in patients undergoing radical prostatectomy**
M. Froehner, R. Koch, R.J. Litz, S. Oehlschlaeger, O.W. Hakenberg, M.P. Wirth (Dresden, Germany)
- 1034 Impact of treatment on the long term survival of patients with localised prostate cancer**
F. Schmidlin, G. Fioreta, H.M. Verkooijen, R. Zanetti, E. Rapiti, D. James, R. Miralbell, C. Bouchardy (Geneva, Switzerland)
- 1035 Preliminary results from a 12 month follow-up study of patients receiving different types of treatment for prostate cancer in conditions of usual clinical practice**
J.L. Rodríguez-Miñón, J.M. Cuesta, J. Rodríguez-Molina, E. Cavada, R. Ibarz, C. Casimiro (Madrid, Calahorra, Barcelona, Spain)
- 1036 Prostate cancer treatment costs: What influences them?**
S. Thueroff, C. Chaussy (Munich, Germany)

Poster Session 63

Chairs: *T.J. Greenwell, London (GB)*

K-D. Sievert, Tübingen (DE)

Study for 30 min. Interactive discussion for 60 min.

- 1037** Routine autologous human myoblast and fibroblast cell cultures for reconstruction of the lower urinary tract
H. Strasser, M. Mitterberger, G.M. Pinggera, G. Bartsch, E. Margreiter, R. Marksteiner (Innsbruck, Austria)
- 1038** The effect of diabetes mellitus on urinary continence after radical cystoprostatectomy and ileal orthotopic bladder substitution
T.M. Kessler, U.E. Studer, G.N. Thalmann (Berne, Switzerland)
- 1039** Improved gastrointestinal recovery and metabolic compensation in the early postoperative period after cystectomy and ileal bladder substitution/ileal conduit by intraoperative stenting of the uretero-ileal anastomosis
A. Mattei, C. Baermann, S. Warncke, U.E. Studer (Berne, Switzerland)
- 1040** Management of sphincter weakness incontinence after radical prostatectomy complicated by anastomotic stricture
J. Taylor, T. Dudderidge, D. Wood, T. Greenwell, D. Andrich, A. Mundy (London, United Kingdom)
- 1041** Who responds in mailed questionnaire surveys in a cystectomy population?
B. Volkmer, K. Herkommer, R. Kuefer, G. Bartsch, C. Braun, R. Hautmann (Ulm, Germany)
- 1042** Reconfiguration of the severely fibrotic penis with a penile implant: 3-Year follow-up
F. Montorsi, F. Dehò, A. Briganti, A. Salonia, G. Zanni, L. Barbieri, P. Rigatti (Milan, Italy)
- 1043** Ten-year outcome of patients receiving three-piece penile implant for Peyronie's disease and their partners: Results of a prospective study
F. Montorsi, F. Dehò, A. Salonia, A. Briganti, L. Barbieri, G. Zanni, V. Scattoni, M. Roscigno, P. Rigatti (Milan, Italy)
- 1044** Congenital penile curvature: Dermal grafting procedure to prevent penile shortening in adults
A. Simonato, A. Gregori, P. Traverso, C. Ambruosi, A. Romagnoli, G. Carmignani (Genoa, Milan, Italy)
- 1045** Modified Thiersch-Duplay technique reduces fistula formation after primary distal hypospadias repair
F.J. Murat, M. Kulisa, A. Valmalle, P. Wolf, H. Dodat (Lyons, France)
- 1046** Clinical safety and effectiveness of penile re-augmentation
J.Y. Kim, H.S. Jeon (Seoul, South Korea)
- 1047** A bioactive double layer defined biomatrix for bladder wall regeneration
J. Nuininga, H. Van Moerkerk, E. Oosterwijk, C. Hulsbergen-Van De Kaa, T. Van Kuppevelt, W. Feitz (Nijmegen, The Netherlands)

- 1048 Tissue biocompatibility of new bioactive biodegradable stent materials**
A. Kotsar, T. Isotalo, I. Uurto, J. Mikkonen, M. Kellomäki, M. Talja, J-P. Salenius, T.L.J. Tammela (Tampere, Lahti, Finland)
- 1049 The bulbourethral composite suspension – indication, technique and results. An alternative to the artificial sphincter?**
N. Blick, H. John (Zurich, Switzerland)
- 1050 The York Mason approach to repair of iatrogenic rectourinary fistulas: A 15-year experience**
F. Dal Moro, M. Mancini, F. Pinto, N. Zanovello, P. Bassi, A. Cisternino, F. Pagano (Padua, Italy)
- 1051 Nephrovesical subcutaneous ureteric bypass: Long-term results in patients with advanced metastatic disease – improvement of renal function and quality of life**
J. Schmidbauer, C. Kratzik, H.C. Klingler, M. Remzi, M. Marberger (Vienna, Austria)

Friday, 7 April - EAU Programme

Abstract Session

15:45 - 17:15

Video award session

eURO Auditorium Level 1

Video Session 8

Chairs: *R.J.A. Van Moorselaar, Amsterdam (NL)*

M. Zerbib, Paris (FR)

All presentations are 14 minutes in length

- V8 Third video prize:**
Laparoscopic radical cystectomy in female eURO-5-1830
F. Gaboardi, A. Bozzola, S. Galli, A. Gregori, F. Scieri, S. Stener, B. Rocco (Milan, Italy)
Supported by an unrestricted educational grant from ASTELLAS
- V11 Second video prize:**
Transvesical laparoscopic diverticulectomy eURO-5-1860
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)
Supported by an unrestricted educational grant from ASTELLAS
- V20 First video prize:**
Open retropubic nerve-sparing radical prostatectomy – how I do it eURO-6-0630
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland)
Supported by an unrestricted educational grant from ASTELLAS
- Prize for the best video published in the EUVJ 2005:**
Laparoscopic radical cystectomy with orthotopic ileal neobladder eURO-7-0935
A. Hoznek, D. Vordos, G. Matthew, L. Salomon, A. De La Taille, R. Yiou, C.C. Abbou
Supported by an unrestricted educational grant from ASTELLAS



Abstract Session

15:45 - 17:15

Kidney tumours: Systemic treatment

Room **Blue Level 2**

Oral Session 14

Chairs: *M.O. Grimm, Düsseldorf (DE)*

P.F.A. Mulders, Nijmegen (NL)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

M.O. Grimm, Düsseldorf (DE)

blue-7-0940

- 1052** **Monotherapy with interferon- γ or combination therapy with interferon- γ , interleukin-2 and 5-fluorouracil for metastatic renal cell carcinoma** blue-7-0950
Y.H. Park, C.W. Jeong, S.K. Hong, H. Jeong, C. Kwak, E. Lee, S.E. Lee (Seoul, Gyeonggi, South Korea)
- 1053** **Low-dose interleukin-2 (IL-2) in combination with interferon- α (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma (MRCC)** blue-7-0960
G. Kharkevich, I. Tsimafeyeu, L. Demidov (Moscow, Russia)
- 1054** **An adjuvant vaccination with Reniale® prolongs survival in patients with renal cell carcinoma following radical nephrectomy: Secondary analysis of a multicentre phase-III trial** blue-7-0970
C. Doehn, A. Richter, R.A. Theodor, W. Lehmacher, D. Jocham (Lübeck, Leipzig, Ulm, Cologne, Germany)
- 1055** **Phase 1 study of carbonic anhydrase 9 peptide vaccines in patients with metastatic renal cell carcinoma** blue-7-0980
H. Uemura, M. Tanaka, S. Uejima, K. Fujimoto, Y. Hirao, K. Itoh (Osaka-Sayama, Nara, Fukuoka, Japan)
- 1056** **Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide** blue-7-0990
N. Leonhartsberger, L. Hörtl, R. Ramoner, C. Zelle Rieser, H. Gander, C. Papesh, W. Nussbaumer, G. Bartsch (Innsbruck, Kufstein, Austria)
- 1057** **Sunitinib malate (SU11248) – efficacy in renal cell carcinoma (RCC)** blue-7-1000
R. Motzer, B. Rini, D. Michaelson, B. Redman, G. Hudes, G. Wilding, R. Bukowski, D. George, S. Kim, C. Baum (New York, San Francisco, Boston, Ann Arbor, Philadelphia, Madison, Cleveland, Durham, San Diego, United States of America)
- 1058** **Randomised Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)** blue-7-1010
B. Escudier, C. Szczylik, T. Eisen, S. Oudard, W.M. Stadler, B. Schwartz, M. Shan, R.M. Bukowski (Paris, France; Warsaw, Poland; London, United Kingdom; Chicago, Connecticut, Cleveland, United States of America)

1059 **Bevacizumab treatment for multimetastatic renal cancer: Results after 6 months** blue-7-1020
S. Larré, Y. Schoepen, A. De La Taille, B. Paule, L. Salomon, D. Vordos, A. Hoznek, C.C. Abbou
(Paris, France)

Summary

P.F.A. Mulders, Nijmegen (NL) blue-7-1030

Abstract Session

15:45 - 17:15

Prostate cancer: Intermittent hormonal treatment

Room **Bordeaux Level 3**

Oral Session 15

Chairs: *B. Tombal, Brussels (BE)*

P. Whelan, Leeds (GB)

All presentations are 7 minutes in length, followed by 2 minutes of discussion

Overview presentation

B. Tombal, Brussels (BE)

bord-7-1040

- 1060** **Analysis of body temperature changes during hot flushes in men after bilateral orchidectomy for prostate cancer** bord-7-1050
C. Heyns, N. Aziz (Tygerberg, South Africa)
- 1061** **Men with poor-prognosis non-metastatic prostate cancer can be cured with adjuvant androgen deprivation therapy** bord-7-1060
P. Mulders, T. Keane, N. Fleshner, C. Lawton, H. Payne, S. Taneja (Nijmegen, The Netherlands; Charleston,, Milwaukee,, New York, United States of America; Toronto, Canada; London, United Kingdom)
- 1062** **Is the degree of PSA decline after immediate androgen deprivation a prognostic factor for outcome in patients with T0-4 N0 M0 prostate cancer not suitable for local treatment with curative intent? (Results from the EORTC 30891 trial)** bord-7-1070
L. Collette, U.E. Studer, P. Whelan, W. Albrecht, J. Casselman, T.M. De Reijke, D. Hauri, W. Loidl, S. Isorna, S.K. Sundaram, M. Debois (Brussels, Oostende, Belgium; Berne, Zurich, Switzerland; Leeds, Wakefields, United Kingdom; Vienna, Linz, Austria; Amsterdam, The Netherlands; Las Palmas, Spain)
- 1063** **Rise of serum PSA and testosterone following androgen ablation: Preliminary data in patients with intermittent androgen deprivation therapy for metastatic prostate cancer** bord-7-1080
D.H. Han, S.H. Choo, B.J. Jung, S.S. Jeon, H.M. Lee, H.Y. Choi (Seoul, South Korea)
- 1064** **Intermittent hormone therapy for advanced and non-localised prostate cancer** bord-7-1090
D. Prapotnich, N. Cathala, A. Mombet, X. Cathelineau, F. Rozet, E. Barret, G. Vallancien (Paris, France)
- 1065** **Finnish multicentre study to compare intermittent IAD and continuous androgen deprivation CAD in patients with advanced prostate cancer – what kind of patients are candidates for IAD?** bord-7-1100
A. Salonen, J. Viitanen, M. Ala-Opas, K. Taari, T. Tammela (Kuopio, Joensuu, Helsinki, Tampere, Finland)
- 1066** **Phase III Study of intermittent MAB versus continuous MAB: An international cooperative study - quality of life** bord-7-1110
F. Calais Da Silva, A. Bono, P. Whelan, M. Brausi, A. Queimadelos, J. Portillo, Z. Kirkali, F.M. Calais Da Silva Junior (Lisbon, Portugal; Varese, Modena, Italy; Leeds, United Kingdom; Santiago de Compostela, Santander, Spain; Izmir, Turkey)

1067 Intermittent hormone therapy for biological recurrence after radical prostatectomy bord-7-1130
D. Prapotnich, A. Mombet, N. Cathala, X. Cathelineau, F. Rozet, E. Barret, G. Vallancien
(Paris, France)

Summary

P. Whelan, Leeds (GB)

bord-7-1140

Poster Session 64

Chairs: *H. Abol-Enein, Mansoura (EG)*
D.M.A. Wallace, Birmingham (GB)

Study for 30 min. Interactive discussion for 60 min.

- 1068** **Laparoscopic radical nephroureterectomy: The incidence of local recurrence and port site metastasis**
M. Muntener, E. Schaeffer, F. Romero, M. Allaf, F.A. Brito, C. Pavlovich, L. Kavoussi, T. Jarrett (Baltimore, United States of America)
- 1069** **Radical cystectomy in octogenarians**
R. Kuefer, J.E. Gschwend, G.J. Bartsch, R. Hautmann, B.G. Volkmer (Ulm, Germany)
- 1070** **The impact of age and co-morbid disease on the outcome of radical cystectomy**
P. Cathcart, M. Nuttall, J. Armitage, J. Van Der Meulen, M. Emberton (London, United Kingdom)
- 1071** **Radical cystectomy and orthotopic bladder substitution in women: A report on 192 cases**
B. Ali-el-Dein, A.A. Shaaban, R. Abu-Eideh, A. Mosbah, M. Abdel-Latif, H. Abol-Enein, M.A. Ghoneim (Mansoura, Mansourae, Egypt)
- 1072** **Tumor recurrence in the remnant urothelium after radical cystectomy for transitional cell carcinoma of the bladder in females: Long term results of a single centre**
T. Akkad, C. Gozzi, M. Deibl, T. Mueller, A. Pelzer, G. Pinggera, G. Bartsch, H. Steiner (Innsbruck, Austria)
- 1073** **Combined intra-arterial chemotherapy and concurrent radiotherapy in compromised patients with muscle-invasive bladder cancer**
H. Kubo, N. Harada, K. Nishiyama, M. Kawahara, M. Nakagawa (Kagoshima, Satsuma-Sendai, Japan)
- 1074** **The impact of hospital provider volume on the outcome of cystectomy in the UK**
P. Cathcart, M. Nuttall, J. Armitage, J. Van Der Meulen, M. Emberton (London, United Kingdom)
- 1075** **A single institution cost comparison of laparoscopic versus open radical cystoprostatectomy and orthotopic ileal neobladder**
A. Gregori, A. Bozzola, A. Simonato, A. Lissiani, S. Galli, C. Paoletti, B. Rocco, F. Scieri, S. Stener, F. Gaboardi (Milan, Italy)
- 1076** **Combination chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy; advanced report**
N. Shinohara, T. Harabayashi, S. Suzuki, K. Nagao, H. Seki, M. Murakumo, K. Mitsuhashi, T. Demura, S. Nagamori, H. Matsuyama, K. Naito, K. Nonomura (Sapporo, Ube, Kushiro, Japan)
- 1077** **Evaluation of chemotherapy with magnetic resonance imaging in patients with advanced carcinoma of the bladder**
B. Schrier, A. Witjes, M. Peters, J. Barentsz (Nijmegen, The Netherlands)

- 1078** **Is preservation of prostate and seminal vesicles in patients with infiltrative bladder cancer justified?**
D. Gotsadze, V. Chakvetadze, E. Danelia (Tbilisi, Georgia)
- 1079** **Perioperative complications according to comorbidity and age in patients after radical cystectomy**
V. Novotny, D. Wiessner, O.W. Hakenberg, U. Heberling, S. Oehlschlaeger, R.J. Litz, M.P. Wirth (Dresden, Germany)
- 1080** **Survival and prognostic stratification of patients with metastatic urothelial cancer who underwent systemic chemotherapy**
T. Abe, N. Shinohara, T. Harabayashi, A. Sazawa, Y. Toyoda, T. Akino, S. Maruyama, S. Suzuki, K. Nonomura (Sapporo, Japan)
- 1081** **Long term results of surgical treatment for upper urinary tract transitional cell cancer**
V. Vukotic- Maletic, M. Lazic, D. Kojic (Belgrade, Serbia and Montenegro)
- 1082** **Complications of modified sigma rectum pouch (Mainz pouch 2) urinary diversion: Experience at 238 patients**
J. Hadzi Djokic, D. Basic, V. Colovic (Belgrade, Nis, Serbia and Montenegro)

Poster Session 65

Chairs: P.J. Conort, Paris (FR)
L. Cormio, Bari-Carbonara (IT)

Study for 30 min. Interactive discussion for 60 min.

- 1083 Shock wave lithotripsy (SWL) for all location large (> 10 mm) ureteral stones using HM3 lithotripter**
S. Halachmi, M. Nagar, S. Golan, O. Goldin, Z. Kaufman, Y. Ofer, S. Meretyk (Haifa, Israel)
- 1084 Clinical result of ultrasound based real-time tracking for urolithiasis in extracorporeal shock wave lithotripsy**
C. Chang, C.R. Chen (Hsinchu, Hua-Lien, Taiwan)
- 1085 Efficacy of extracorporeal shock wave lithotripsy for lower calyceal stones**
K. Sarica, E. Alkan, O.F. Karatas (Istanbul, Turkey)
- 1086 Impact of air bubbles in the coupling medium in efficacy of extracorporeal shock wave lithotripsy**
A. Jain, T. Shah (Bradford, United Kingdom)
- 1087 Long term follow-up of effect of extracorporeal shock wave**
W. Eassa, K. Shier, M. Dawaba, M. El-Kenawey (Mansoura, Egypt)
- 1088 In-situ ESWL for ureteric stones – still up to date?**
C. Chaussy, T. Bergsdorf, S. Thueroff (Munich, Germany)
- 1089 The new CST-2000 flexible cystoscope with slide-on™ Endosheath® System: Use as a cysto-nephroscope**
E. Mayer, S. Undre, N. Sevdalis, A. Patel (London, United Kingdom)
- 1090 Ultrasound-guided percutaneous nephrostomy performed by an urologist. Ten-years experience**
A. Skolarikos, G. Alivizatos, I. Varkarakis, D. Staios, C. Liakouras, A. Papatsoris, C. Constantinides, C. Deliveliotis (Athens, Greece)
- 1091 Supracostal approach for percutaneous renal surgery: Experience with 67 cases**
M.R. El Halaby, A. Abdelmaksoud, M. Shoeb, K. Fawaz, A. Elrobeigi (Cairo, Egypt)
- 1092 Antegrade approach for large ureteric stones according to the Chinese minimally invasive percutaneous nephrolithotomy (MPCNL) technique: An effective method with minimal morbidity**
S.K. Li, C. Tai, H. Chau, T. Fung, C. Fan, S. Hou (Hong Kong, Hong Kong)
- 1093 A simple cost effective model for remote teleconsultation (telerounding) for the post operative management of urological patients**
S.S. Kommu, I.J. Persad, J. Groom, J. Mc Gurk, S.J. Kodamala, N.A. Watkin, J.B. Emtage (Surrey, United Kingdom)
- 1094 Dissolve your stones with herbal tablets – a survey of remedies available over the internet**
M. Harris, J. Hindmarsh (Northallerton, Middlesbrough, United Kingdom)

- 1095** **The effect of papaverine hydrochloride on ureteral colic resistant to conventional treatment**
E. Alkan, F. Karatas, *K. Sarica* (Istanbul, Turkey)
- 1096** **Do weather conditions influence the ureterocolic onset?**
F. Dal Moro, A. Abate, R. Boscolo, G. Arandjelovic, F. Tosato, A. Cisternino, T. Prayer Galetti, P. Bassi (Padua, Italy; Berkeley, United States of America)
- 1097** **Predictive factors for abscondes of renal stone clinic - a multi-centre study**
S.S. Kommu, Z.R. Zaman, M.F. Lynch, E. Siddiqui, P. Hadway, D.H. Lau, F.H. Mumtaz, N.A. Watkin, K. Anson, J.B. Emtage (London, Surrey, Barbados, United Kingdom)

Poster Session 66

Chairs: *M.D. Craggs, London (GB)*

A. Reitz, Zurich (CH)

Study for 30 min. Interactive discussion for 60 min.

- 1098** **Influence of mechanical stretch on gene expression and contraction in pig detrusor tissue**
M. Wuest, G. Ram Liebig, E.M. Graf, C. Werner, O.W. Hakenberg, M.P. Wirth, U. Ravens (Dresden, Germany)
- 1099** **Gene expression and functional role of prostaglandin E2 receptor subtypes in the rat urinary bladder mucosa and detrusor: How do these changes in association with bladder outlet obstruction?**
B. Masanori, D. Shuqi, Z. Hidenori, A. Isao, T. Masayuki (Tamaho, Japan)
- 1100** **Therapeutic effects of connexin inhibitors on detrusor overactivity associated with bladder outlet obstruction in rats**
J.C. Kim, E.Y. Park, D. Kim, J.H. Kim, T. Hwang (Seoul, Daegu, South Korea)
- 1101** **The presence and the functional role of muscarinic receptor subtypes in human bladder smooth muscle in patients with normal and detrusor overactivity**
T. Yamanishi, T. Mizuno, H. Abe, T. Kamai, K. Arai, K. Yoshida (Tochigi, Japan)
- 1102** **Juvenile pig detrusor differs in contractile mechanisms from mature tissue**
M. Wuest, K. Schlobach Da Costa, J. Hecht, T. Christ, M. Braeter, U. Ravens (Dresden, Germany)
- 1103** **Solifenacin in multiple sclerosis patients with overactive bladder – a prospective study**
F. Van Rey, J. Heesakkers (Nijmegen, The Netherlands)
- 1104** **Are efficacy and tolerability of propiverine and oxybutynin comparable in children with neurogenic detrusor overactivity (NDO)? A multicenter observational cohort study**
H. Madersbacher, G. Muertz, S. Alloussi, M. Beute, M. Buerst, B. Domurath, T. Henne, I. Koerner, A. Niedeggen, J. Nounla, J. Pannek, M. Schuldt, H. Schulte-Baukloh, D. Schultz-Lampel, S. Siemer, T. Stuckert, B. Willer, P. Bock, J. Hanisch (Innsbruck, Austria; Dresden, Neunkirchen, Hamburg, Deggendorf, Bad Wildungen, Essen, Berlin, Leipzig, Herne, Greifswald, Villingen-Schwenningen, Homburg/Saar, Zwickau, Germany; Basel, Switzerland)
- 1105** **Compliance and long-term efficacy of anticholinergic therapy in paediatric patients with detrusor hyperreflexia**
F. Christoph, A. Moschkowitsch, C. Kempkensteffen, M. Schrader, K. Miller (Berlin, Germany)
- 1106** **Botulinum toxin injections into the bladder wall – a morphological evaluation of the injection technique using magnetic resonance imaging**
S. Boy, M. Schmid, A. Reitz, A. Von Hessling, J. Hodler, B. Schurch (Zurich, Switzerland)

- 1107** **Detrusor injections of botulinum toxin A in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections**
X. Gamé, Y. Bentaleb, I. Thiry-Escudie, X. De Boissezon, C. Roques, B. Malavaud, P. Marque, P. Rischmann (Toulouse, France)
- 1108** **Treatment with Botulinumtoxin A in neurogenic bladder dysfunction - a randomised double-blind study with Dysport**
I. Ehren, D. Volz, E. Farrelly, L. Berglund, L. Brundin, P. Lafolie (Stockholm, Sweden)
- 1109** **Effects of phosphodiesterase 5 inhibition on the NO/ cGMP pathway in the human and pig urethra**
V. Werkström, K.E. Andersson, P. Hedlund (Lund, Sweden)
- 1110** **Increasing by specific phosphodiesterase V inhibitor of neuronal nitric oxide synthase smooth muscle relaxation in the female mice urethra**
X. Gamé, J. Allard, F. Praddaude, J.F. Arnal, G. Escourrou, I. Tack, P. Rischmann, J.L. Ader, J.P. Sarramon, B. Malavaud (Toulouse, France)
- 1111** **Cyclo-oxygenase-2 is expressed in interstitial cells of the mouse bladder**
P. Hedlund, K.E. Andersson (Lund, Sweden)
- 1112** **A facilitatory neuromodulative effect of duloxetine and pelvic floor training on the excitability of urethral sphincter motor neurones**
S. Boy, A. Reitz, S. Simitovic, P.A. Knapp, B. Schurch (Zurich, Switzerland)

Poster Session 67

Chairs: *H.B. Lottmann, Paris (FR)*

S. Tekgül, Ankara (TR)

Study for 30 min. Interactive discussion for 60 min.

- 1113 Inflammation of the testis and epididymis in otherwise healthy child, is it a true bacterial urinary tract infection?**
S. Halachmi, A. Toubi, S. Meretyk (Haifa, Israel)
- 1114 Acute scrotal pain in children: Results of 298 surgical explorations**
M. Waldert, M. Dobrovits, M. Remzi, C. Seitz, M. Marberger (Vienna, Austria)
- 1115 The diagnostic value of C-reactive protein and erythrocyte sedimentation rate for patients with an acute scrotum**
S.A. Asgari (Rasht, Iran)
- 1116 Protective effect of ADL on reperfusion injury following testicular torsion**
C. Yoon, D. Yoon, M.M. Oh, S. Kang, Y. Shim, B. Min, D. Yoon (Seoul, South Korea)
- 1117 Protective effects of sildenafil administration on testicular torsion/detorsion damage in rats**
A. Hassanzadeh Salmasi, S. Payabvash, A. Beheshtian, B. Ghazi Nezami, S. Rahimpour, S. Kiumehr, R. Rabbani, S.M. Tavangar, A.R. Dehpour (Tehran, Iran)
- 1118 Natural history of vanishing testis**
P. Hegarty, I. Mushtaq, R. Rub, N. Sebire (London, United Kingdom; Hadera, Israel)
- 1119 Neurofibromatosis type 1 and its urological manifestation**
A. Schröder, R. Stein, J. Thüroff, P. Gutjahr (Mainz, Germany)
- 1120 Perineal ultrasonography for non invasive evaluation of the sacral reflexes in children**
L. De Kort, T. De Jong, A. Klijn, M. Vijverberg (Utrecht, The Netherlands)
- 1121 Loss of interstitial cells of Cajal and gap junction protein Cx 43 at the ureterovesical junction in children with vesicoureteral reflux**
C. Schwentner, J. Oswald, A. Lunacek, B. Schlenck, H. Fritsch, G. Bartsch, C. Radmayr (Innsbruck, Austria)
- 1122 A new oral MELT formulation of desmopressin in primary nocturnal enuresis (PNE). A randomised comparison to the tablet formulation**
H. Lottmann, F. Froeling, S. Allousi, A.S. El-Rhadi, S. Rittig, A. Riis, B. Persson (Paris, France; Den Haag, The Netherlands; Neunkirchen, Germany; Sidcup, United Kingdom; Aarhus, Copenhagen, Denmark)
- 1123 Parental awareness of paediatric constipation**
I. Akyol, C. Adayener, T. Senkul, K. Karademir, K. Baykal, C. Iseri (Istanbul, Turkey)

- 1124** **What is the bladder wall thickness in normal primary school children ?**
H.S. Dogan, B. Akpinar, S. Gurocak, D. Akata, M. Bakkaloglu, S. Tekgul (Ankara, Turkey)
- 1125** **The effect of bladder filling technique on uroflowmetry parameters in children**
J. Khastgir, S. Al-Hayek, L. Swithinbank, P. Abrams (Bristol, United Kingdom)
- 1126** **Propiverine compared to oxybutynin in children with idiopathic detrusor overactivity – are efficacy and tolerability comparable ?**
S. Alloussi, G. Muertz, R. Braun, U. Gerhardt, M. Heinrich, E. Hellmis, W. Horn, A. Hossfeld, A. Marschall-Kehrel, K. Niklas, M. Raabe, T. Rössler, D. Schultz-Lampel, B. Seibt, S. Siemer, H. Walter, B. Wiedeking, B. Willer, P. Bock, J. Hanisch (Neunkirchen, Dresden, Leipzig, Munich, Duisburg, Mönchengladbach, Stadtlengsfeld, Oberursel, Saarlouis, Freiburg, Rottweil, Villingen-Schwenningen, Zwickau, Homburg/Saar, Grimmen, Essen, Germany; Basel, Switzerland)
- 1127** **Percutaneous renal surgery in children with complex stone**
E. Özden, A. ahin, H.S. Do an, B. Tan, S. Tekgül, H. Özen (Ankara, Turkey)

Poster Session 68

Chairs: *D. Castro Diaz, Santa Cruz De Tenerife (ES)*
F. Haab, Paris (FR)

Study for 30 min. Interactive discussion for 60 min.

- 1128 Does sling incision or removal relieve symptoms after placement of suburethral slings for stress incontinence?**
F.C. Burkhard, T.M. Kessler, D. Thomann, A. Kuhn, U.E. Studer (Berne, Switzerland)
- 1129 Incontinence after colposuspension during sacropexy: Preliminary results of a randomised study**
E. Costantini, A. Giannantoni, L. Mearini, A. Zucchi, M. Saccomanni, V. Bini, A. Vianello, M. Porena (Perugia, Italy)
- 1130 Female sexual functions after surgery for stress urinary incontinence: Vaginal sling versus Burch colposuspension**
F. Çayan, S. Ülger, S. Dilek, E. Akbay, S. Çayan (Mersin, Turkey)
- 1131 Mesh erosions with the transobturator approach for tension free vaginal tapes in management of urodynamic stress incontinence**
M. Abdel-Fattah, K. Sivanesan, I. Ramsay (Glasgow, United Kingdom)
- 1132 Surgical management of acute urinary retention after sling procedure**
V. Landreat, A. Manunta, J.P. Harlicot, P.L. Broux, J. Dugast, J.J. Patard, B. Lobel, F. Guillé (Rennes, France)
- 1133 Pre- and postoperative complications of TVT (tension-free vaginal tape): Our experience**
S. Charalambous, A. Fotas, A. Papathanasiou, G. Fatles, S. Touloupidis, V. Rombis (Thessalonica, Alexandroupolis, Greece)
- 1134 Significant complications following urethral tape implantation: A neglected problem**
H. Klingler, M. Tinzl, M. Marberger (Vienna, Austria)
- 1135 Voiding dysfunction following Transobturator tape procedure**
K. Sivanesan, M. Abdel Fattah, I. Ramsay (Glasgow, United Kingdom)
- 1136 Monofilament versus multifilament polypropylene mesh for female incontinence: Safety evaluation**
J.M. Martinez Sagarra, C. Garcia-Tuñon, F. Castroviejo Royo, A. Rodriguez-Toves, J.H. Amon Sesmero, C. Conde Redondo (Valladolid, Spain)
- 1137 Is the tissular rehabilitation of synthetic suburethral tapes satisfactory?**
V. Boubilil, J. Hermieu, M. Toub Blanc, V. Ravery, V. Delmas, S. Dominique, L. Boccon-Gibod (Paris, France)
- 1138 Urethrolisis after tension-free vaginal tape procedure: Simple incision technique**
A. Cavalcanti, J. Carvalho, R. Krambeck, D. Rachid Filho, M. Rubinstein, I. Rubinstein, L. Favorito (Rio de Janeiro, Brazil)

- 1139 Urethrolisis: A versatile operation for bladder outlet obstruction in women following stress incontinence surgery**
G. Wirth, J.P. Spinosa, C. Iselin (Geneva, Switzerland)
- 1140 Clinical and urodynamic results of sections of sub-urethral tapes**
V. Boubliil, J. Hermieu, V. Ravery, V. Delmas, S. Dominique, L. Boccon-Gibod (Paris, France)
- 1141 Reduced risk of intraoperative complications when the tension-free vaginal tape procedure is used on a full bladder**
T. Lee, S. Yoon (Incheon, South Korea)
- 1142 Unilateral transvaginal urethrolisis for urinary obstruction after antiincontinence surgery**
F. Villacampa, F. Cabrera, M. . Sanchis, S. De La Rosa, J. Romero, N. Felip, O. Leiva (Madrid, Spain)

Poster Session 69

Chairs: *J. Ramon, Ramat-Gan (IL)*
M.H. Vanden Bossche, Brussels (BE)

Study for 30 min. Interactive discussion for 60 min.

- 1143** A prospective randomised controlled trial comparing bipolar transurethral resection in saline (TURIS) system and conventional monopolar transurethral resection of prostate in men with benign prostate hyperplasia: A 1 year's clinical efficacy and safety
H. Ho, S. Yip, K.B. Lim, K.T. Foo, C. Cheng (Singapore, Singapore)
- 1144** A safer way of transurethral resection of the prostate: "Coagulating intermittent cutting" reduces haemostatic complications
A.P. Berger, A.E. Pelzer, J. Bektic, H. Steiner, A. Lunacek, G. Bartsch, W. Horninger (Innsbruck, Austria)
- 1145** Transurethral resection of prostate in patients with chronic urinary retention and a hypocontractile detrusor: A prospective urodynamic based outcome analysis
M. Abdus Salam, P. Jasim, P. Saha, R. Abedin, G. Chowdhury, K. Alam (Dhaka, Bangladesh)
- 1146** Comparative morbidity of transurethral or suprapubic bladder catheterisation for acute urinary retention: Results of a prospective survey in 2635 men with BPH
F. Desgrandchamps, A. De La Taille, J. Doublet (Paris, Creteil, France)
- 1147** Does operator's experience influences the incidence and the "patterns" of the urethral strictures post turp?
A. Cumpanas, M. Botoca, V. Bucuras, P. Boiborean, F. Miclea, P. Dragan (Timisoara, Romania)
- 1148** A propective randomised study between transurethral vaporisation using plasmakinetic energy and transurethral resection of prostate - five year results
P. Chandrasekar, F. Kapasi, J. Virdi (Harlow, United Kingdom)
- 1149** CoreTherm treatment vs TURP in patients with BPH: A prospective randomised multicentre study with 5 years follow-up
A. Mattiasson, S. Schelin, B. Magnusson, S. Moddy, H. Ageheim, J. Richthoff, J. Duelund, K. Krøyer, J. Nordlig, E. Boyle, T. Larson (Lund, Kalmar, Kristianstad, Ljungby, Sweden; Fredriksberg, Herlev, Denmark; Toledo, Scottsdale, United States of America)
- 1150** Effects of resectoscope loop manipulation
J.V. Di Trolio (Roseland, United States of America)
- 1151** Laparoscopic simple prostatectomy vs. open simple prostatectomy: The first comparative study
H. Baumert (Paris, France)
- 1152** Thulium laser enucleation of the prostate
S. Gordon, G. Watson (Southwater, Eastbourne, United Kingdom)

- 1153** **Prospective study: BPH: GYRUS loop vs. conventional TURP - 2 years follow up**
A.F. Tan, R. Chen (Mornington, Frankston, Australia)
- 1154** **Efficacy of high-power KTP photoselective laser vaporization prostatectomy for the treatment of BPH**
D.H. Han, J.W. Chung, B.J. Jung, J.H. Hong, S.W. Lee (Seoul, South Korea)
- 1155** **Monopolar vs bipolar TUR: Results of a randomised prospective study**
F. Bertolotto, M. Raggio, G. Vigliercio, F. Germinale, C. Introini (Camogli, Genoa, Vercelli, Italy)
- 1156** **Potentially dangerous elevations in blood pressure during office microwave treatments of the prostate**
B. Larson, L. Mynderse, V. Sommers, M. Jaff, W. Evans, T. Larson (Cleveland, Ohio, Boston, Rochester, Fort Lauderdale, Scottsdale, Arizona, United States of America)
- 1157** **Prospective study of 645 patients with significant benign prostatic enlargement: Complications and immediate outcome after suprapubic prostatectomy**
O. Reich, A. Bachmann, D. Zaak, C.G. Stief, M. Seitz, B. Schlenker, C. Gratzke, P. Hermanek, N. Lack, C. Burmeister (Munich, Germany)

Poster Session 70

Chairs: *Liliane Boccon-Gibod, Paris (FR)*
F. Frauscher, Innsbruck (AT)

Study for 30 min. Interactive discussion for 60 min.

- 1158** **Definitive histologic diagnosis on prostate biopsies in 3 hours: The first year experience**
L.D. Nava, M. Freschi, C. Doglioni, A. Losa, E. Scapatucci, T. Maga, P. Rigatti, G. Guazzoni (Milan, Italy)
- 1159** **Evaluation of 16 gauge needle for prostate biopsy**
K. Fink, G. Hutarew, R. Szlauer, R. Goetschl, N.T. Schmeller (Salzburg, Austria)
- 1160** **Influence of using sixteen gauge needle on prostate cancer detection rate in transrectal ultrasound-guided prostate biopsy**
G. Inal, K. Onur, M. Tas, V. Oztekin, M. Kosan, B. Ozturk (Ankara, Turkey)
- 1161** **Saturation biopsy versus 8-core biopsy. comparative study in repeated biopsy for the diagnose of prostate cancer**
J.M. De La Morena, C. Capitan, D. Martin, M. Alvarez, P. Dominguez, J. Martinez, C. Carrera, C. Llorente (Madrid, Spain)
- 1162** **Prostate saturation biopsy in the reevaluation of microfocal prostate cancer**
L. Boccon-Gibod, N. Barry Delongchamps, M. Toublanc, L. Boccon-Gibod, V. Ravery (Paris, France)
- 1163** **Improved prediction of the presence of Gleason grade 4/5 component by 3-dimensional 26-core prostate biopsy**
N. Numao, S. Kawakami, Y. Fujii, Y. Kageyama, M. Koike, K. Kihara (Tokyo, Japan)
- 1164** **Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy**
S. Suekane, M. Noguchi, O. Nakashima, K. Matsuoka (Kurume, Japan)
- 1165** **Multifocal prostate cancer: Do needle biopsies detect the largest tumour?**
N. Barry Delongchamps, V. Ravery, M. Toublanc, L. Boccon-Gibod, L. Boccon-Gibod (Paris, France)
- 1166** **Impact of ratio between gland size and number of biopsy cores on repeat prostate biopsy: Development and internal validation of a new repeat biopsy nomogram in men assessed with 10 or more cores**
K.F. Chun, A. Briganti, M. Graefen, M. Otori, A. Haese, T. Steuber, L. Valiquette, J. Walz, Y. Nakagami, T. Schlomm, M. Tachibana, M.G. Friedrich, H. Heinzer, H. Huland, P.I. Karakiewicz (Hamburg, Germany; Montreal, Canada; Tokyo, Japan)
- 1167** **Clinical significance of only one positive biopsy core in a sextant prostate needle biopsy**
C. Poenicke, J. Kamradt, J. Lehmann, U. Zwergel, M. Stoeckle, B. Wullich (Homburg, Germany)

- 1168 Prostate volume at initial biopsy is the most important predictor of repeat biopsy outcome. Validation of a novel predictive tool**
F.K.H. Chun, A. Briganti, S. Ahyai, J. Walz, V. Scattoni, A. Salonia, T. Steuber, A. Haese, J. Kim, Y. Nakagami, K. Latchemsetty, L. Bordon, M. Tachibana, C. Porter, F. Montorsi, M. Ohori, P. Rigatti, M. Graefen, H. Huland, P.I. Karakiewicz (Hamburg, Germany; Milan, Italy; Seattle, United States of America; Shinjuku, Japan; Montreal, Canada)
- 1169 Impact of sampling density on initial 10 or more (+) core prostate biopsy: Development and internal validation of a 10+ cores biopsy nomogram**
A. Briganti, F.K.H. Chun, S.F. Shariat, M. Ohori, C. Porter, M. Graefen, F. Montorsi, A. Haese, Y. Nakagami, V. Scattoni, T. Steuber, A. Salonia, U. Michl, H. Heinzer, M.G. Friedrich, N. Suardi, M. Tachibana, L. Valiquette, L. Borden, K. Latchemsetty, P. Rigatti, C.G. Roehrborn, H. Huland, P.I. Karakiewicz (Milan, Italy; Hamburg, Germany; Dallas, Seattle, United States of America; Tokyo, Japan; Montreal, Canada)
- 1170 Relationship between primary Gleason pattern on needle biopsy and clinicopathological outcomes among men with Gleason 7 adenocarcinoma of the prostate**
P.J. Bastian, M.L. Gonzalgo, L.A. Mangold, J.I. Epstein, P.C. Walsh, A.W. Partin (Baltimore, United States of America)
- 1171 Gleason score upgrading at time of pathological Gleason score occurs more frequently in external-based biopsies than in university-based biopsies**
K.F. Chun, D.J. Lewinshtein, A. Briganti, T. Steuber, H. Isbarn, T. Schlomm, A. Haese, G. Markus, H. Huland, P.I. Karakiewicz (Montreal, Hamburg, Germany; Montreal, Canada)
- 1172 Prostate cancers scored as Gleason 6 in prostate biopsy are frequently Gleason 7 tumours at radical prostatectomy: Implication on outcome**
J. Pinthus, M. Witkos, N. Fleshner, J. Sweet, A. Evans, S. Alibhai, M. Krahn, M. Jewett, J. Trachtenberg (Toronto, Canada)

Friday, 7 April - EAU Programme

Abstract Session

15:45 - 17:15

Prostate cancer: Screening/ early detection

Room **Concorde 2 Level 4**

Poster Session 71

Chairs: *J. Irani, Poitiers (FR)*
D.M. Quinlan, Dublin (IE)

Study for 30 min. Interactive discussion for 60 min.

- 1173 Serum lipid-lowering drugs and prostate cancer risk – a population based case-control study**
T. Murtola, T. Tammela, L. Määttänen, A. Auvinen (Tampere, Helsinki, Finland)
- 1174 Finasteride, alpha-blockers and risk of prostate cancer – a population based case-control study**
T. Murtola, T. Tammela, L. Määttänen, M. Hakama, A. Auvinen (Tampere, Helsinki, Finland)
- 1175 Impact of body mass index on serum PSA levels in Japanese males**
M. Kohno, K. Ito, T. Yamamoto, H. Takechi, M. Ohi, K. Suzuki (Maebashi, Japan)
- 1176 Relationship between prostate specific antigen and obesity in Korea**
N.G. Choi, H.J. Kim, T.S. Shin (Seoul, South Korea)
- 1177 Obesity, insulin resistance and risk of prostate cancer. A prospective study**
P. Stattin, T. Stocks, S. Rinaldi, B. Lindahl, G. Hallmans, R. Kaaks (Umeå, Sweden; Lyon, France)
- 1178 A critical appraisal of the ability of body mass index (BMI) to predict high grade prostate cancer (PCa)**
F.K.H. Chun, A. Briganti, J. Walz, A. Salonia, T. Schlomm, U. Michl, H. Heinzer, L. Da Pozzo, A. Gallina, G. Zanni, F. Bernard, P. Perrotte, F. Montorsi, M. Graefen, P. Rigatti, H. Huland, P.I. Karakiewicz (Montreal, Canada; Milan, Italy; Hamburg, Germany)
- 1179 The evaluation of patient information booklets for localised prostate cancer**
T. Yap, J. Armitage, M. Emberton, J. Van Der Meulen (London, United Kingdom)
- 1180 Pathways to the diagnosis of prostate cancer in the control arm of a large randomised screening trial**
S. Roemeling, M.J. Roobol, C. Gosselaar, F.H. Schröder (Rotterdam, The Netherlands)
- 1181 Incidence of prostate cancers detected in men who refused biopsy at initial screening (1993-1999)**
M.J. Roobol, F.H. Schröder (Rotterdam, The Netherlands)
- 1182 Prostate cancer detection in men aged 45-49 years in the UK ProtecT (prostate testing for cancer and treatment) trial**
A. Lane, J. Howson, M. Mason, D. Neal, J. Donovan, F. Hamdy (Bristol, Sheffield, Cardiff, Cambridge, United Kingdom)
- 1183 Differences in knowledge of prostate cancer among brothers of men with prostate cancer and controls**
K. Herkommer, K. Hohl, J.E. Gschwend, T. Paiss, M. Kron (Ulm, Germany)
- 1184 Is a negative prostate biopsy result a positive outcome?**
M. Harris, M. Speakman (Taunton, United Kingdom)

- 1185** **Is dihydrotestosteron a prognostic factor among men with screening-detected prostate cancer?**
A. Kjellman, O. Akre, U. Norming, M. Tornblom, O. Gustafsson (Stockholm, Sweden)
- 1186** **Attitudes and perception to prostate cancer screening with PSA**
H. Malmi, L. Määttänen, M. Ruutu, T. Tammela, A. Auvinen (Helsinki, Tampere, Finland)
- 1187** **Updated follow-up of active surveillance with selected delayed intervention for localised prostate cancer**
L. Klotz, A. Loblaw, R. Nam (Toronto, Canada)

Poster Session 72

Chairs: *M. Colombel, Lyon (FR)*
P. Hammerer, Braunschweig (DE)

Study for 30 min. Interactive discussion for 60 min.

- 1188 Visible quality - benchmarking in prostate cancer therapy**
M. Schostak, M. Schrader, P. Albers, M. Beer, P. Althaus, W. Diederichs, M. Siegmund, G. Fabricius, K. Miller (Berlin, Kassel, Germany)
- 1189 Incontinence after radical prostatectomy: Subjective and objective outcome is not always the same**
M. Kwiatkowski, D. Seiler, B. Arndt, J. Gregorin, P. Bueschel, H. Gretener, F. Recker (Aarau, Switzerland)
- 1190 Incidence by definition, risk factors and temporal trend of urinary incontinence after radical prostatectomy in a single institution over a 20-year period**
T. Prayer-Galetti, A. Cisternino, E. Sacco, G. Betto, S. Fracalanza, F. Pagano (Padua, Italy)
- 1191 Cystogram after radical prostatectomy is reliable when performed by trans rectal ultrasound**
J. Walz, T. Steuber, S. Ahyai, F. Scharlau, C. Eichelberg, E. Currlin, M. Graefen, H. Huland (Hamburg, Germany)
- 1192 Urinary continence after standard and nerve sparing radical retropubic prostatectomy**
D. Pushkar, V. Diyakov, A. Bernikov, A. Bormotin (Moscow, Russia)
- 1193 Severe vesicourethral anastomotic strictures after radical prostatectomy**
U. Zwergel, J. Lehmann, B. Wullich, J. Kamradt, M. Hack, M. Stoeckle (Homburg, Germany)
- 1194 Nerve sparing radical prostatectomy: A new method of intraoperative frozen section analysis**
K. Bothe, P.M. Braun, S. Hautmann, A. Bannowsky, K.P. Jünemann (Kiel, Germany)
- 1195 Lack or reliability of recollected international index of erectile function domains in candidates to radical prostatectomy**
A. Salonia, G. Zanni, A. Gallina, A. Saccà, A. Briganti, L. Bua, M. Raber, E. Farina, R. Colombo, P. Rigatti, F. Montorsi (Milan, Italy)
- 1196 Quality of life after radical prostatectomy - the influence of the nerve sparing technique**
D. Seiler, M. Kwiatkowski, J. Gregorin, B. Arndt, P. Bueschel, H. Gretener, F. Recker (Aarau, Switzerland)
- 1197 The common spared neurovascular bundle might not be sufficient for all types of nerve distributions in a nerve sparing radical prostatectomy**
J. Hennenlotter, I. Laible, A.S. Merseburger, U. Kühs, A.G. Anastasiadis, S. Corvin, U. Nagele, M. Kuczyk, A. Stenzl, K. Sievert (Tübingen, Germany)
- 1198 Extraperitoneal radical prostatectomy and previous history of hernia repair: Evaluation of results**
S. Keskin, G. Guichard, A. Hoznek, A. De La Taille, R. You, D. Vordos, C. Abbou, L. Salomon (Creteil, France)

- 1199** **The incidence of inguinal hernia in radical retropubic prostatectomy. Do you warn your patients?**
J. Hicks, A. Grey, S. Holmes (Portsmouth, United Kingdom)
- 1200** **Risk adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy**
K. Touijer, K. Kuroiwa, J. Eastham, A. Vickers, V. Reuter, P. Scardino, B. Guillonneau (New York, United States of America)
- 1201** **How significant are surgical case load and patient's age in clinical outcome from radical prostatectomy?**
V.S. Hanchanale, J.E. McCabe, S. Willmott, P.M. Javle (Crewe, United Kingdom)
- 1202** **PSA tracker – remote follow-up of prostate cancer patients**
J. McFarlane, J. McFarlane, K. Warren (Bath, United Kingdom)

Friday, 7 April - EAU Programme

Symposium

17:30 - 19:00

Frontiers in prostate cancer: Advancing our ability towards improved cancer detection

Room **Ternes Level 1**

Chair: L. Boccon-Gibod, Paris (FR)

Introduction

L. Boccon-Gibod, Paris (FR)

tern-7-1150

Global prevalence and outcomes: How well are we managing prostate cancer?

L. Boccon-Gibod, Paris (FR)

tern-7-1160

Prostate cancer detection: Understanding and addressing the clinical limitations of prostate specific antigen

R. Kirby, London (GB)

tern-7-1170

Strategic considerations to address ambiguous biopsy results and the need for repeat procedures

A. De La Taille, Creteil (FR)

tern-7-1180

PCA3 - Performance overview of an emerging molecular clinical marker

P.F.A. Mulders, Nijmegen (NL)

tern-7-1190

PCA3 - Can a novel molecular clinical marker improve prostate cancer management?

M. Droller, New York (US)

tern-7-1200

Questions and answers

tern-7-1210

Conclusion

L. Boccon-Gibod, Paris (FR)

tern-7-1220

Aims and objectives

Prostate cancer is the third most common malignancy in the world and ranks 6th in cancer-related mortality. While the use of the Prostate Specific Antigen test has resulted in earlier diagnoses, it is associated with limitations including the inability to differentiate between aggressive and non-aggressive tumours as well as non-cancerous more common conditions such as benign prostatic hyperplasia and prostatitis. These false-positive results can often lead to biopsy, which might produce equivocal findings, and unnecessary patient anxiety. Thus, despite advances over recent decades, the optimal diagnostic approach for prostate cancer remains elusive. The aim of this programme is to discuss new biological molecular markers (PCA3) along with biopsy strategies as emerging potential approaches to this dilemma.

Objectives

Following completion of this programme, participants should be better able to:

- Describe the current global status of diagnosis, treatment, and survival of prostate cancer.
- List limitations to prostate-specific antigen as a tool for diagnosing prostate cancer, guiding treatment, and monitoring patient response to therapy.
- Discuss the challenges of using biopsy to diagnose prostate cancer.
- Describe PCA3 and the possible implications of its use to improve the clinical management of prostate cancer.

Symposium

17:30 - 19:00

Improving management of prostate cancer: Are all LHRH agonists equal?

Room **Blue** Level 2

Chair: C.C. Schulman, Brussels (BE)

Introduction

C.C. Schulman, Brussels (BE)

blue-7-1230

Management of prostate cancer: Global strategies

A. Alcaraz, Barcelona (ES)

blue-7-1240

Importance of optimal testosterone suppression

B. Tombal, Brussels (BE)

blue-7-1250

Eligard®: Advantages for optimal testosterone control

R. Berges, Cologne (DE)

blue-7-1260

Eligard® 6 - the new treatment paradigm in prostate cancer

O. Sartor, Boston (US)

blue-7-1270

Discussion and take home messages

C.C. Schulman, Brussels (BE)

blue-7-1280

Aims and objectives

The management of prostate cancer remains a key challenge for physicians. Luteinising hormone-releasing hormone (LHRH) agonists have become the treatment of choice for patients diagnosed with advanced prostate cancer. Treatment with LHRH agonists aims to achieve a rapid and sustained suppression of serum testosterone levels with minimal breakthrough responses. During the symposium, global strategies for managing prostate cancer as well as the role of LHRH agonists will be discussed. Additionally, the importance of optimal testosterone suppression and the potential advantages of a new LHRH agonist formulation Eligard® will be reviewed.

Symposium

17:30 - 19:00

Targeting patient and partner satisfaction: Insights into the functional and emotional benefits of Viagra®

eURO Auditorium Level 1

Chair: A. Martin-Morales, Malaga (ES)

Introduction

A. Martin-Morales, Malaga (ES)

eURO-7-1290

Optimising treatment in patients with ED: The importance of establishing treatment goals

R. King, Victoria (AU)

eURO-7-1300

The science of sex: The mechanisms underlying hard erections

A.L. Burnett, Baltimore (US)

eURO-7-1310

Mutual satisfaction: The emotional benefits of hard erections

J. Buvat, Lille (FR)

eURO-7-1320

Conclusion

A. Martin-Morales, Malaga (ES)

eURO-7-1330

Aims and objectives

Erectile dysfunction (ED) is an emotional and a physical burden for patients and their partners and has a significant impact on their quality of life. Because ED continues to be bothersome if treatment is suboptimal, treatment should be targeted to patients based on their therapeutic goals. Many patients report that what they want from their ED medication are hard erections, improved sexual relations, and partner satisfaction.

In this symposium, information will be presented that highlights the ability of Viagra® to deliver hard erections. In addition, preliminary data on the mechanisms underlying the physiology of erection hardness will be shared. Preclinical findings suggest a possible relationship between these mechanisms and the distinct attributes of Viagra. Data on Viagra® will be presented that support the correlation between erection hardness and patient-partner satisfaction.

Participants in this symposium will have a better understanding of the significant relationship between improved function and emotional benefits when treating patients with ED and of the importance of having a treatment goal and optimising therapy to meet that goal.

Symposium

17:30 - 19:00

Exploring the limits of 5 α -reductase inhibitors in prostate cancer prevention, detection and treatment

Room **Concorde 2 Level 4**

Chair: I. Thompson, San Antonio (US)

Introduction

I. Thompson, San Antonio (US) con2-7-1340

How can we change the lifecycle of prostate cancer?

I. Thompson, San Antonio (US) con2-7-1350

Part 1: Research on 5 α -reductase inhibitors in prostate cancer chemoprevention and treatment: From bench to bedside

How does the latest basic science research inform future clinical practice?

J.A. Schalken, Nijmegen (NL) con2-7-1360

How will recent clinical studies with 5 α -reductase inhibitors in prostate cancer change clinical practice?

I. Thompson, San Antonio (US) con2-7-1370

Part 2: The impact of 5 α -reductase inhibitor-based chemoprevention on public health and clinical practice strategies

What are the potential public health effects of prostate cancer chemoprevention?

F.H. Schröder, Rotterdam (NL) con2-7-1380

What are the potential effects of prostate cancer chemoprevention on clinical practice?

N. Fleshner, Toronto (CA) con2-7-1390

Discussion

con2-7-1400

Conclusion

I. Thompson, San Antonio (US) con2-7-1410

Aims and objectives

The introduction of the 5 α -reductase inhibitors (5ARIs) heralded a new era of medical therapy for the treatment of benign prostatic hyperplasia. The 5ARIs were designed to limit the androgen drive that fuels continued prostate growth in ageing men. It was also evident from early in vitro studies that the 5ARIs had an inhibitory effect on the growth of prostate cancer cells, as well as inducing their apoptosis. Coupled with their ability to inhibit the synthesis of dihydrotestosterone, whilst maintaining testosterone levels, the 5ARIs had the potential to impact prostate cancer lifecycle coupled with a more favourable adverse event profile than androgen ablation. During this symposium we will explore what is known concerning the effects of 5ARIs on prostate cancer prevention, detection and treatment. The symposium will begin with a 'view from the bench' of what is known at a cellular and molecular level concerning 5ARI action on the prostate. We will then examine what the Prostate Cancer Prevention Study has taught us concerning the potential of 5ARIs as a chemopreventive strategy, and how they impact prostate cancer detection. These findings will then be placed into a population context, examining the implications of 5ARI-based chemoprevention on screening, detection and management of prostate cancer. Finally, the practical implications of the chemoprevention for daily practice will be considered, including the impact of 5ARIs on the use of PSA, and how men suitable for chemoprevention might be identified.

Sponsored by GLAXOSMITHKLINE

Symposium

17:30 - 19:00

Molecular diagnostics in bladder cancer management: The UroVysion experience

Room **Havana** Level **3**

Chair: *J.J.M.C.H. De La Rosette, Amsterdam (NL)*

Introduction

J.J.M.C.H. De La Rosette, Amsterdam (NL)

[hava-7-1420](#)

Current challenges in bladder cancer management: Where do we go from here?

J.J.M.C.H. De La Rosette, Amsterdam (NL)

[hava-7-1430](#)

Understanding bladder cancer - implications for the use of UroVysion FISH

G. Sauter, Hamburg (DE)

[hava-7-1440](#)

Approaches to bladder cancer diagnosis and management: The non-invasive way

A. Pycha, Bolzano (IT)

[hava-7-1450](#)

Conclusion

J.J.M.C.H. De La Rosette, Amsterdam (NL)

[hava-7-1460](#)

Aims and objectives

Modern molecular diagnostic methods such as fluorescence-in-situ hybridisation (FISH) can significantly improve the management of urological cancer. Based on genetic profiling by comparative genomic hybridisation and FISH, it has recently been shown that there appear to exist two fundamentally different entities of bladder neoplasia, pTaG1/G2 and pTaG3, pT1-4, with the first conferring an extremely low risk of progression, and the latter with high aggressive growth potential. Regular monitoring for bladder tumour recurrence and progression is important and can be managed with unprecedented diagnostic accuracy by employing FISH. FISH uses DNA probes to identify chromosomal abnormalities (chromosomal change is the earliest event associated with cancer). FISH is a non-invasive method based on urine specimen testing and offers higher sensitivity than cytology at comparable specificity, independent of tumour stage and grade. The technique is not affected by ongoing BCG immunotherapy and allows for clear decision-making in the case of atypical or equivocal cytology results. FISH detects signs of malignancy at the molecular level with the capability of tumour detection long before clinical symptoms develop, thereby providing the advantages of earlier diagnosis and therapeutic intervention. The combination of FISH and cystoscopy offers the best available sensitivity and specificity. The sessions will address current issues in management of bladder cancer with a special emphasis on FISH. Both clinical and technical aspects will be presented and discussed.

Symposium

17:30 - 19:00

OAB: What matters to the patient?

Room **Maillot Level 2**

Chair: U. Jonas, Hanover (DE)

Introduction

U. Jonas, Hanover (DE)

mail-7-1470

Efficacy/safety measures

P. Toozs-Hobson, Birmingham (GB)

mail-7-1480

Treatment persistence, long term management

C. Hampel, Mainz (DE)

mail-7-1490

QoL, patient satisfaction/preference, patient-oriented goals

P. Sand, Winnetka (US)

mail-7-1500

Conclusion

U. Jonas, Hanover (DE)

mail-7-1510

Aims and objectives

The latest systematic review and meta-analysis have confirmed that antimuscarinics are safe and efficacious in treating overactive bladder (OAB). Yet, significant differences exist between the antimuscarinics in terms of adverse event profile, withdrawal rate, efficacy outcome and quality of life (QoL). The main challenge of the physician remains fulfilment of the patient's expectations and treatment. Treatment persistence has indeed been found low with each antimuscarinic in daily practice. The symposium will discuss how objective measures of QoL and long-term treatment persistence matter to the patient. What can we expect from patient satisfaction and patient-oriented goals? The symposium will propose the best clinical data mix for selecting a treatment in OAB.

Friday, 7 April - EAU Programme

Symposium

17:30 - 19:00

Prostate cancer: Optimising treatment strategy to meet our patients' needs - working together to improve standard of care

Room **Bordeaux Level 3**

Chair: *J.M. Fitzpatrick, Dublin (IE)*

Introduction

J.M. Fitzpatrick, Dublin (IE)

[bord-7-1520](#)

The need for improved therapeutic strategies for patients with metastatic hormone-refractory prostate cancer

J.B. Anderson, Sheffield (GB)

[bord-7-1530](#)

New hope for patients with metastatic hormone-refractory prostate cancer

R. De Wit, Rotterdam (NL)

[bord-7-1540](#)

Treatment of prostate cancer in the 21st century - future directions

M. Eisenberger, Baltimore (US)

[bord-7-1550](#)

A multidisciplinary team approach for the optimal clinical management of metastatic hormone-refractory prostate cancer - case studies

J.M. Fitzpatrick, Dublin (IE)

[bord-7-1560](#)

Conclusion

J.M. Fitzpatrick, Dublin (IE)

[bord-7-1570](#)

Aims and objectives

Metastatic hormone-refractory prostate cancer (mHRPC) is no longer considered a chemoresistant disease. The recent publications of the TAX 327 and SWOG 99-16 trials demonstrate that three-weekly docetaxel in combination with prednisone is the first and only chemotherapy to exhibit significant improvements in overall survival in patients with mHRPC. Furthermore, this survival benefit is accompanied by a significant improvement in the quality of life of patients with mHRPC. These findings represent a tremendous advance in the treatment of mHRPC and firmly establish docetaxel as the new standard of care for these patients. As such, they also question traditionally held perceptions regarding the use of chemotherapy in patients with mHRPC. This symposium aims to facilitate discussion of the precise definition of mHRPC and to address the optimal time at which patients should be considered eligible for chemotherapy. In addition, while addressing the manageability of docetaxel, this symposium aims to demonstrate that docetaxel therapy can benefit all mHRPC patient groups, including asymptomatic, symptomatic and elderly patients. The potential for the future use of docetaxel in the adjuvant setting will also be discussed. Participants will be encouraged to address the need for a multi-disciplinary team approach, through consultation/partnership of urologists and oncologists, to achieve a practical method to facilitate the identification of the most appropriate treatment strategy for patients with mHRPC.

Symposium

17:30 - 19:00

Targeted agents in the management of renal cell carcinoma (RCC): The role of the urologist

Room **Concorde 1 Level 4**

Chair: J.-J. Patard, Rennes (FR)

Welcome and introduction

J.-J. Patard, Rennes (FR)

con1-7-1580

RCC: Prognostic factors and patient selection

A. Belldegrun, Los Angeles (US)

con1-7-1590

Current treatment in advanced RCC: Impact of targeted therapies in the management of RCC

J. Bellmunt, Barcelona (ES)

con1-7-1600

New perspectives: An oral multikinase inhibitor in patients with advanced RCC

B. Escudier, Paris (FR)

con1-7-1610

Advanced therapy in RCC: Where are we?

T. Eisen, London (GB)

con1-7-1620

Looking ahead: Integrating new agents in the armamentarium of the urologist

J.-J. Patard, Rennes (FR)

con1-7-1630

Conclusion

J.-J. Patard, Rennes (FR)

con1-7-1640

Aims and objectives

In recent years, targeted therapies have come to the forefront of attention in the increasingly sophisticated field of cancer therapeutics. In light of these new developments, this satellite symposium will focus on the role of the urologist in applying these therapies to the management of RCC. The programme will be driven by a panel of international experts who will lead discussions of prognostic factors, patient selection and the impact of targeted treatments on outcomes for patients with advanced RCC. The potential of targeted therapeutics as adjuvant RCC therapy will be reviewed and associated trials will be described.



Sub-plenary session

07:45 - 08:45

Sub-plenary session 15

Room 252 Level 2

Moderator: U. Jonas, Hanover (DE)

07:45 - 08:00

Section highlights of the European Society of Uro-Technology (ESUT)

Speaker: J.J.M.C.H. De La Rosette, Amsterdam (NL)

252-8-0000

08:00 - 08:15

Section highlights of the European Organisation for Research and Treatment of Cancer Genito-Urinary Group (EORTC-GU)

Speaker: Z. Kirkali, Izmir (TR)

252-8-0010

08:15 - 08:30

Section highlights of the European Society of Oncological Urology (ESOU)

Speaker: A. Govorov, Moscow (RU)

252-8-0020

08:30 - 08:45

Section highlights of the European Society of Andrological Urology (ESAU)

Speaker: P. Verze, Naples (IT)

252-8-0030

Sub-plenary session

07:45 - 08:45

Sub-plenary session 16

eURO Auditorium Level 1

Moderator: P.F.A. Mulders, Nijmegen (NL)

07:45 - 08:15 **State-of-the-art lecture** [Nomograms in prostate cancer](#)

Speaker: M. Kattan, Cleveland (US)

eURO-8-0040

Aims and objectives

The ability to make predictions is an essential part of any medical decision. It is particularly crucial when considering treatment of clinically localised prostate cancer. Nomograms and prediction model software typically provide the most accurate predictions. Many nomograms have been developed for all prostate cancer clinical states. Some of these are discussed in this review, as is their utility in facilitating decision-making and informed consent.

08:15 - 08:45 **State-of-the-art lecture** [Imaging strategies in prostate cancer](#)

Speaker: J.L. Descotes, Grenoble (FR)

eURO-8-0050

Aims and objectives

The aim of this lecture is firstly to evaluate the usual place and limitations of imaging techniques in different clinical situations, and then to give an overview of the prospects of transrectal ultrasonography (TRUS) in the detection of prostate cancer and of magnetic resonance imaging (MRI) for local evaluation of the tumour. Concerning prostate cancer detection, it is commonly held that the evolution of TRUS technology (high-frequency transducers) allows visualisation of the prostate's internal architecture and that transrectal random biopsies are now the gold standard method of diagnosis of prostate cancer. However, it has also been well established that TRUS is an imperfect tool due to the low specificity and sensitivity of hypoechoic lesions. New imaging strategies involve: 1. The use of Doppler ultrasound with targeted biopsy is assessed by the neovascularity of prostate cancer. The positive predictive value seems higher than gray-scale TRUS in some studies. 2. Contrast enhanced ultrasound is a different way of visualising small neovessels in the tumour. After intravenous administration of contrast, microbubbles are extremely reflective and their presence in small blood vessels could improve cancer detection. Accurate evaluation of these new technologies is essential to determine their real place in different clinical situations. Concerning local staging, MRI can be helpful if the examination is performed within 4 weeks after the biopsy and if the radiologist has a good expertise in prostate cancer. The variability of sensitivity and specificity in literature is a limitation for the current use of MRI. Intermediate- and poor-prognosis tumours are good indications especially for evaluation of the seminal vesicle. Dynamic MRI and metabolic evaluation of citrates and choline by spectro-MRI is under evaluation by expert centres. These techniques could add information on tumour volume and tumour aggressiveness before radical prostatectomy or for diagnosis of local recurrence after radiotherapy.

Sub-plenary session

07:45 - 08:45

Sub-plenary session 17

Room **Ternes Level 1**

Moderator: J-J. Rambeaud, Grenoble (FR)

07:45 - 08:15

State-of-the-art lecture **Small renal tumours: Pre- and postoperative evaluation**

Speaker: M. Marberger, Vienna (AT)

tern-8-0060

Aims and objectives

Small renal tumours, usually detected by chance in asymptomatic patients, represent a major proportion of kidney tumours today. About 20% of these are benign, some of the malignant lesions have a low potential for progression and some tend to spread early in spite of their size. Therapy therefore ranges from watchful waiting, minimally invasive energy ablation, partial nephrectomy to radical nephrectomy. A safe treatment decision cannot be based on tumour size at diagnosis only, but should follow advanced imaging and biopsy algorithms at diagnosis and, if treatment dependent, at follow-up.

08:15 - 08:45

Urological Research Society lecture **Management of BCG failures in superficial bladder cancer**

Speaker: M. Droller, New York (US)

tern-8-0070

Aims and objectives

Because BCG failure in treatment of “superficial” bladder cancer may indicate impending progression, it is important to understand the biologic potential of the cancer diathesis both from the outset (i.e. when it presented initially) and at treatment failure. The objectives of this presentation are to describe the several features of “superficial” bladder cancer that may be used in characterizing the intrinsic biologic potential, risk for aggressive behavior, and expression of treatment failure of the different cancer diatheses, use these as the context for evaluating results of various treatment approaches with BCG, and describe alternative approaches to consider in patients who have failed BCG therapy.

Saturday, 8 April - EAU Programme

Sub-plenary session

07:45 - 08:45

Sub-plenary session 18

Room 243 Level 2

Moderator: C.C. Abbou, Creteil (FR)

07:45 - 08:15

State-of-the-art lecture **The evolution of urological training in Europe**

Speaker: E. Kiely, Cork (IE)

243-8-0080

Aims and objectives

In the latter years of the 19th century urology evolved mainly from general surgery, but also from dermatology and venereology. The major urological advances in the 20th century were surgical but it appears now that the evolution of urological practice is, and will be, toward a "more medical" speciality.

Urological training has largely run parallel to that of surgery; adopting the apprenticeship model that was best suited to learning the "craft" of urological surgery. There is however an increasing trend toward trainees learning surgery in a simulated environment, which demands less from the trainer. Further challenges to the older approach is the increased non-surgical diagnostic and therapeutic workload resulting both from alterations in clinical practice and changes in population demographics, the feminisation of medical graduates, the efforts at harmonisation of training and accreditation in Europe, and the limitations placed by the European working-time directive.

It is vital that the further evolution of urological training be directed from within the speciality.

08:15 - 08:45

European Urological Scholarship Programme (EUSP)

Introduction on the EUSP

C.C. Abbou, Creteil (FR)

243-8-0090

Prize for the Best EUSP Scholar 2005

243-8-0100

Second Prize for the Best EUSP Scholar 2005

Sub-plenary session

07:45 - 08:45

Sub-plenary session 19

Room **Blue Level 2**

Moderator: J.A. Schalken, Nijmegen (NL)

07:45 - 08:15

State-of-the-art lecture **The long term outcome of medical treatment for BPH**

Speaker: J.M. Fitzpatrick, Dublin (IE)

blue-8-0110

08:15 - 08:45

State-of-the-art lecture **How to handle high-risk infections in urology**

Speaker: M. Lafaurie, Paris (FR)

blue-8-0120

Aims and objectives

The objective of this talk is to present and discuss three clinical cases that will each focus on a specific infectious issue frequently met in urology. Using these cases, the following points will be addressed:

1. Onset of fever in a patient receiving intravesical BCG therapy - the diagnostic procedures and therapeutic options will be discussed.
2. Antibiotic prophylaxis before prostate biopsy - the factors contributing to the choice and duration of antibiotics will be discussed.
3. Febrile complications following insertion of double-J ureteral stents - diagnostic and treatment strategies will be presented.

Saturday, 8 April - EAU Programme

Plenary session

08:45 - 13:00

Plenary session 3

eURO Auditorium Level 1

Chairs: L. Boccon-Gibod, Paris (FR)
M.P. Wirth, Dresden (DE)

08:45 - 09:10

Award session 3

Prize of the Congress President for the best presentation on clinical urology	eURO-8-0130
Prize of the French Urological Society	eURO-8-0140
Prize for the Best Paper published on Fundamental Research Supported by an unrestricted educational grant from SANOFI-AVENTIS	eURO-8-0150
Prize for the Best Paper published on Clinical Research Supported by an unrestricted educational grant from SANOFI-AVENTIS	eURO-8-0160
Prize for the Best Scientific Paper published in European Urology in the year 2005 Supported by an unrestricted educational grant from ELSEVIER	eURO-8-0170
Third prize for the Best Abstract (oncology)	eURO-8-0180
Third prize for the Best Abstract (non-oncology)	eURO-8-0190
Second prize for the Best Abstract (oncology)	eURO-8-0200
Second prize for the Best Abstract (non-oncology)	eURO-8-0210
First prize for the Best Abstract (oncology) Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG	eURO-8-0220
First prize for the Best Abstract (non-oncology) Supported by an unrestricted educational grant from KARL STORZ GMBH & CO.KG	eURO-8-0230
2006 Award for the Best Booth	eURO-8-0240

09:10 - 09:25

State-of-the-art lecture **History of urology in France**

Speaker: P. Teillac, Paris (FR) eURO-8-0250

09:25 - 09:45

EAU Guidelines **What's new in 2006?**

Chair: G. Aus, Göteborg (SE)
Speakers: B. Lobel, Rennes (FR) eURO-8-0260
T. Loch, Flensburg (DE) eURO-8-0270
A.P.M. Van Der Meijden, 's-Hertogenbosch (NL) eURO-8-0280

Aims and objectives

The frontline of knowledge in urology is moving forward rapidly. In order to keep up with the latest, high-quality information in the field, the EAU Guidelines are updated frequently. The aim of this presentation is to show how the EAU guidelines may provide you with the latest information in a readily accessible way. The hot news from selected guidelines updated this year will be presented in this session.

09:45 - 10:05 State-of-the-art lecture **The dilemma of over detection and over treatment of prostate cancer**

Speaker: P.C. Albertsen, Farmington (US)

eURO-8-0290

Aims and objectives

This presentation will review the epidemiology of prostate cancer, including the impact of screening on the changing incidence of this disease. The lecture will discuss the following:

1. The concept of lead time and how it impacts survival statistics.
2. The concept of length time and how it influences the type of cancers identified.
3. The impact of altering the prostate-specific antigen threshold on the incidence of prostate cancer.
4. How finding more cancers may or may not impact mortality from this disease.
5. The relative efficacy of aggressive intervention.

10:05 - 10:40 Round table discussion **Radical prostatectomy: To do or not to do**

Chair: U.E. Studer, Berne (CH)

Introduction

eURO-8-0300

Panel: P.C. Albertsen, Farmington (US)
A. Bill-Axelsson, Uppsala (SE)
L. Boccon-Gibod, Paris (FR)
F. Hamdy, Sheffield (GB)

eURO-8-0310

eURO-8-0320

eURO-8-0330

eURO-8-0340

Conclusion

eURO-8-0350

Aims and objectives

Prostate cancer is a major cause of death in men, thus justifying its prevention and treatment. On the other hand, the number of diagnosed prostate cancers exceeds its death toll several-fold. Over-treatment is possible. Furthermore, despite a rapidly increasing number of radical prostatectomies performed, mortality from prostate cancer has only slowly decreased. These and other issues will be discussed, including results from SPCG-4 and the UK ProtecT study.

10:40 - 11:00 State-of-the-art lecture **The role of PSA kinetics in the management of prostate cancer**

Speaker: P-A. Abrahamsson, Malmö (SE)

eURO-8-0360

Aims and objectives

For more than a decade, the prostate-specific-antigen (PSA) test has been a way for doctors to gauge prostate cancer risk. Men whose PSA levels, measured by a simple blood test, rose above a specific level were considered likely to harbour cancer cells within their prostate gland. Currently, PSA testing helps provide evidence that the disease is present and also indicates how aggressive it is. However, the value of PSA in identifying patients increased risk of prostate cancer is controversial. PSA screening has resulted in a dramatic stage migration towards small volume cancer. Stamey and others have, therefore, questioned the utility of an isolated PSA rea-

ding in the context of prostate cancer diagnosis. The ongoing debate over PSA measurement has only recently begun to incorporate the additional value derived from using PSA kinetics for patient decision-making.

11:00 - 11:35 **Round table discussion [The optimal management of the patient with hormone resistant prostate cancer](#)**

Chair: N.W. Clarke, Manchester (GB)

Introduction	eURO-8-0370
<i>Oncologist:</i> J. Bellmunt, Barcelona (ES)	eURO-8-0380
<i>Radiotherapist:</i> S. Nilsson, Malmö (SE)	eURO-8-0390
<i>Urologist:</i> V. Ravery, Paris (FR)	eURO-8-0400
Conclusion	eURO-8-0410

Aims and objectives

The aims of this discussion are to highlight the spectrum of clinical morbidity associated with hormone-refractory prostate cancer (HRPC), to emphasise the existing therapeutic options and to provide state-of-the-art information about developments in cytotoxic chemotherapy and new agents used alone or in combination in the treatment of HRPC. The main objectives are to provide an up-to-date overview of the nature of the disease and its treatment, and most importantly, to emphasise that HRPC is best managed by a coordinated multi-disciplinary team involving surgeons, oncologists and nursing/palliative care. Individual objectives: Dr Bellmunt - To focus on the use of chemotherapy, the development of novel agents alone or in combination, and to speak about clinical trials and their importance in this disease. Dr Nilsson - To provide an overview of the use of radiotherapy and bone-directed treatments in HRPC. The overview should include the diagnosis and management of pathological fracture and cord compression. Dr Ravery - To provide an overview of the urological complications associated with the disease, including the management of lower urinary tract symptoms and obstructive uropathy. In addition, attention should be focussed on the holistic care of the patient and the general supportive management of problems such as marrow failure. Particular emphasis should be placed on the role of the urologist in coordinating the general management of the spectrum of problems engendered by the disease.

11:35 - 13:00 **[Souvenir Session from the EAU Scientific Committee](#)**

Oncology	
X. Cathelineau, Paris (FR)	eURO-8-0420
Prostate disease	
C. Selli, Pisa (IT)	eURO-8-0430
Minimally invasive therapies	
G. Janetschek, Linz (AT)	eURO-8-0440
Paediatrics	
G.A. Bogaert, Leuven (BE)	eURO-8-0450
Stones disease	
C. Llorente, Madrid (ES)	eURO-8-0460
Reconstruction andrology	
I. Eardley, Leeds (GB)	eURO-8-0470

ESU Course 1

09:00 - 12:00

Paediatric urology for the adult urologist: A practical update

Room **341** Level **3**

Chair: J.M. Nijman, Groningen (NL)

Obstructive uropathy: What to do when, from neonate till puberty

G.A. Bogaert, Leuven (BE)

341-6-1670

How to deal with congenital malformations of the external genitalia, when is surgery indicated and how to do it

S. Tekgül, Ankara (TR)

341-6-1680

Urinary infection, reflux and voiding dysfunction: New insights in pathology, diagnostic work-up and management

J.M. Nijman, Groningen (NL)

341-6-1690

Aims and objectives

During this course an update is provided on common problems of the genito-urinary tract in children by means of state-of-the-art lectures, cases and interactive participation. Also the interaction between paediatric urologist, adult urologist, gynaecologist and paediatrician will be discussed. Corrections of congenital malformations of the urogenital tract have major implication for the quality of life, but also on long-term follow-up and future interventions and treatment of complications. The course is in particular for general urologists and those in training. Participants are encouraged to participate in the course as much as possible: there will be ample time for discussion and presentation of cases.

Registration fee excluding VAT

EAU members, residents	€ 40
Non-EAU member	€ 60

ESU Course 2

09:00 - 12:00

Prostate cancer - screening, diagnosis and staging

Room **342a Level 3**

Chair: P-A. Abrahamsson, Malmö (SE)

Screening

F. Hamdy, Sheffield (GB)

342a-6-1700

Diagnosis and staging

P-A. Abrahamsson, Malmö (SE)

342a-6-1710

Aims and objectives

The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is now the commonest cancer in males in developed countries. The increase is mainly caused by the increasing use of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in serum. With this approach, prostate cancer is detected 5-10 years before giving rise to symptoms and on average 17 years before causing the death of the patient. While this has led to detection of prostate cancer at a potentially curable stage, it has also led to substantial over diagnosis, i.e. detection of cancers that would not surface clinically in the absence of screening. A major challenge is thus to identify the cases that need to be treated while avoiding to diagnose patients who will not benefit from being diagnosed and who will only suffer from the stigma of being a cancer patient. Therefore, prognostic markers that could predict which patients need to be diagnosed and which do not, is of major importance. The aim of this course is therefore designed for urological trainees and established urologists, who wish to update themselves on latest information regarding screening, diagnosis and staging in prostate cancer. The course will stimulate interaction with the audience and in part be based on a number of case-scenarios for discussion with the delegates, followed by brief state-of-the-art presentations. In addition, emphasis will be placed on controversial issues and recent progress in terms of diagnostic tools, staging procedures and prognostic factors.

At the conclusion of this course, the participants should get better insights in terms of:

- What are the best approaches towards screening and early detection of prostate?
- How can the subgroup of patients who will benefit the most from early therapy be identified?
- For which patients is an approach of “watchful waiting” more appropriate than active therapy?

Registration fee excluding VAT

EAU members, residents	€ 40
Non-EAU member	€ 60

ESU Course 3

09:00 - 12:00

Evaluation and management of female pelvic floor disorders

Room **342b** Level **3**

Chair: W. Artibani, Padua (IT)

Female pelvic floor disorders: The clinical picture

W. Artibani, Padua (IT)

342b-6-1720

How to evaluate female pelvic floor disorders

E.J. Messelink, Amsterdam (NL)

342b-6-1730

Female pelvic floor disorders conservative management

E.J. Messelink, Amsterdam (NL)

342b-6-1740

Pelvic floor surgical reconstruction

W. Artibani, Padua (IT)

342b-6-1750

Pelvic floor laparoscopic reconstruction

R. Gaston, Bordeaux (FR)

342b-6-1760

Aims and objectives

The evaluation and management of female pelvic floor disorders request a multi-dimensional and trans-disciplinary approach. Urologists should know how to appropriately assess the anterior, middle and posterior vaginal/pelvic floor's compartments by means of physical examination, imaging and functional assessment, bearing in mind the anatomic-functional unity of pelvic floor. Conservative management is the first line approach to the majority of pelvic floor disorders. Its role and outcome will be presented based on ICI recommendations. Surgical reconstruction (vaginal / supra-pubic) of pelvic floor disorders can be carried out by a team of surgeons (urologists, gynaecologists and colo-rectal surgeons) or by a fully trained pelvic floor surgeon. Careful planning and intra-operative flexibility are the key to success. Laparoscopic reconstruction of female pelvic floor is the forefront approach and yields an appealing alternative to conventional surgery. Participants will be updated by means of balanced reviews of the literature, existing guidelines, personal experience of lecturers and real life clinical cases.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 4

09:00 - 12:00

Update on benign penile and scrotal disorders

Room **343** Level **3**

Chair: *I. Romics, Budapest (HU)*

Scrotal disorders

I. Romics, Budapest (HU)

343-6-1770

Penile disorders: Peyronie's disease, BXO

M.M. Fisch, Hamburg (DE)

343-6-1780

Penile prosthesis

D. Ralph, London (GB)

343-6-1790

Aims and objectives

The most serious benign scrotal disease is the Fournier gangrene. It is a bacterial infection necrotising the skin and the fascia of the scrotum from different ethiology. Its therapy involves the intensive care in case of shock and septicaemia and urgent surgical intervention. It is usually performed in more steps and involves reconstruction and plastic surgery of the scrotum and penis, sometimes the groin and lower part of the abdominal skin. Trauma, benign tumours and different skin diseases will also be discussed. The aim of the session is to provide an update on the ethiology and treatment options of the Peyronie's diseases. Indication and the decision of conservative and operative treatment modalities will be discussed. BXO is a frequent disease, its treatment is controversial. Management of BXO will be introduced. The penile prosthesis is widely used in primary organic erectile dysfunction and after radical prostatectomy, cystectomy as well. Technique, types of prosthesis, follow up, management of complication are the most important issues of penile prosthesis.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 5

09:00 - 12:00

Lower urinary tract dysfunction and urodynamics

Room **351** Level **3**

Chair: P. Abrams, Bristol (GB)

The scientific basics of urodynamics

P. Abrams, Bristol (GB)

351-6-1800

Urodynamics - getting philosophy and technique correct

P. Abrams, Bristol (GB)

351-6-1810

Urodynamics in female urology and neurourology

J.R. Shah, London (GB)

351-6-1820

Urodynamics in the child and in men

S. Madersbacher, Vienna (AT)

351-6-1830

Aims and objectives

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics
- Be able to assess the quality of a urodynamic trace
- Recognise common artefacts and know how to correct them
- Know the indications for urodynamic studies in children, men, women and neurological patients

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 6

09:00 - 11:00

Laparoscopy for beginners

Room **353** Level **3**

Chair: A.D. Joyce, Leeds (GB)

Indications for laparoscopy

A.D. Joyce, Leeds (GB)

353-6-1840

Instrumentation and techniques of haemostasis

X. Cathelineau, Paris (FR)

353-6-1850

Access and pneumoperitoneum

A.D. Joyce, Leeds (GB)

353-6-1860

Avoiding complications

X. Cathelineau, Paris (FR)

353-6-1870

Aims and objectives

Training in urological laparoscopic surgery in Europe is presently inadequate because of several factors:

- A shortage of designated training centres
- A shortage of recognised trainers
- Lack of appropriate facilities, either equipment, expertise or support. Urologists interested in laparoscopy must be properly trained in order to minimise the risk of potential complications and to ensure patient safety. This course aims to provide the delegate with the core knowledge over the correct use of the imaging system, the specialised instrumentation and the important protocols for accessing and exiting the abdomen, including how to recognise and avoid potential complications. The highlight of this revised course will be the use of video clips to illustrate many of the essential points and to promote discussion amongst the delegates.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 7

12:30 - 15:30

Retropubic radical prostatectomy - tips, tricks and pitfalls

Room **341** Level **3**

Chair: H. Van Poppel, Leuven (BE)

Surgical anatomy

B. Djavan, Vienna (AT)

341-6-1880

Step by step radical retropubic prostatectomy

H. Van Poppel, Leuven (BE)

341-6-1890

Tips, tricks and pitfalls

B. Djavan, Vienna (AT)

341-6-1900

Treatment of complications

H. Van Poppel, Leuven (BE)

341-6-1910

Discussion and interaction

341-6-1920

Aims and objectives

In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. Although laparoscopic radical prostatectomy is getting more popular in selected centers, the open surgical approach will still be the most often performed operative procedure in many countries throughout Europe in the coming years. Localised prostate cancer is more and more detected in its earlier stages and surgery offers undoubtedly the best local control. The urologist's surgical skill must be outstanding and the urological community is responsible to guarantee optimal surgical quality through adequate training. The competition with external beam radiotherapy, brachytherapy and novel minimally invasive techniques, like cryosurgery and HIFU should encourage young urologists to optimally perform the surgical resection with the best possible tumour control and the least impact on continence and potency. This course aims at bringing to the modern urologist the different technical steps of the classical "retropubic prostatectomy" with emphasis on the preservation of continence and potency and discusses the special tips and tricks that must enable every contemporary urologist to obtain good results with a minimum of complications. Also, the prevention and treatment of complications are discussed. This teaching course is a must for the elder resident and the younger urologist who begins his career but also the well trained urologists that are not treating many patients with localised prostate cancer, will benefit. The participants will get inside in the detailed surgical anatomy, the pre-operative measures, the intra-operative steps of a very systematic and safe operation. Also the experienced uro-oncological surgeon will enjoy the tricks and pitfalls and will learn how to solve intra- and postoperative complications.

Registration fee excluding VAT

EAU members, residents	€ 40
Non-EAU member	€ 60

ESU Course 8

12:30 - 15:30

Chronic pelvic pain syndromes (CPPS) with special focus on chronic prostatitis (CP) and painful bladder syndrome / interstitial cystitis (PBS/IC)

Room **342a** Level **3**

Chair: J. Nordling, Copenhagen (DK)

CPPS: Definitions, terminology and classification

M. Fall, Göteborg (SE) 342a-6-1930

CP: Definition, classification and etiology

J. Nordling, Copenhagen (DK) 342a-6-1940

CP: Diagnostic work up

J.-J. Wyndaele, Antwerp (BE) 342a-6-1950

CP: Treatment

M. Fall, Göteborg (SE) 342a-6-1960

PBS/IC: Definition, classification and etiology

M. Fall, Göteborg (SE) 342a-6-1970

PBS/IC: Diagnostic work up

J. Nordling, Copenhagen (DK) 342a-6-1980

PBS/IC: Treatment

J.-J. Wyndaele, Antwerp (BE) 342a-6-1990

Scrotal pain

J. Nordling, Copenhagen (DK) 342a-6-2000

Urethral syndrome

M. Fall, Göteborg (SE) 342a-6-2010

Neurological aspects of CPPS

J.-J. Wyndaele, Antwerp (BE) 342a-6-2020

Aims and objectives

Painful diseases of the pelvis are not rare, but are poorly understood and constitutes one of the largest clinical challenges in urological practice. Definitions are often “soft” and consequently evaluation, classification and selection of proper treatment difficult. There have been a lot of activity within these areas during the last few years, and it is the scope of the course to bring the participants up to date, so after the course they can perform a relevant evaluation of patients with chronic pain syndromes in the pelvis and offer these patients the best treatment available today.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 9

12:30 - 15:30

Renal cell carcinoma - surgical aspects

Room **342b** Level **3**

Chair: Z. Kirkali, Izmir (TR)

Radical nephrectomy

Z. Kirkali, Izmir (TR) 342b-6-2030

Surgery for renal vein and vena cava invasion

G.H.J. Mickisch, Bremen (DE) 342b-6-2040

Laparoscopic surgery

D. Jacqmin, Strasbourg (FR) 342b-6-2050

Nephron sparing surgery

Z. Kirkali, Izmir (TR) 342b-6-2060

Surgery for difficult cases

G.H.J. Mickisch, Bremen (DE) 342b-6-2070

Surgery for local recurrence

D. Jacqmin, Strasbourg (FR) 342b-6-2080

Metastasectomy

G.H.J. Mickisch, Bremen (DE) 342b-6-2090

Other minimally invasive techniques

D. Jacqmin, Strasbourg (FR) 342b-6-2100

Aims and objectives

Renal cell carcinoma is a common and killer urologic malignancy in Europe. Despite the recent progress and developments in the therapy of advanced disease, surgery remains the mainstay of treatment in most cases. The aim of this course on surgery for RCC is to highlight the indications and show the surgical techniques for various clinical presentation types of RCC. Attendees for this course on RCC will be able to learn how to do open and minimally invasive surgery for localised and respectable RCC. Indications and techniques of open radical and nephron-sparing surgery will be shown with example cases and video presentations step by step. Similarly the laparoscopic surgical techniques will be presented using video clips. Despite earlier diagnosis, still a substantial number of patients are seen where difficult and more sophisticated surgery is needed. This will be addressed by real life cases and surgery for recurrences and metastases will also be addressed. The course also will deal with new minimally invasive techniques to destruct renal masses. This course is an excellent opportunity to learn the role and techniques of surgery in RCC for residents as well as for the practicing urologist. Don't miss it if you see patients with RCC in you daily practice! At the end of the course the attendees will be able to understand the comprehensive role of surgery in RCC and learn how to perform:

- Open and laparoscopic radical nephrectomy
- Laparoscopic and open nephron-sparing surgery
- Surgery for venous invasion, metastases, local recurrences and difficult cases

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU courses are EU-ACME accredited with 1,5 credits per hour

ESU Course 10

12:30 - 14:30

Management and outcome in invasive and locally advanced bladder cancer

Room **343** Level **3**

Chair: *G.N. Thalmann, Berne (CH)*

Defining the problem - staging, grading, prognosticators of outcome

G.N. Thalmann, Berne (CH)

343-6-2110

Is cystectomy the safest?

G.N. Thalmann, Berne (CH)

343-6-2120

Update on neoadjuvant and adjuvant chemotherapy

C.N. Sternberg, Rome (IT)

343-6-2130

Cases - a practical approach

343-6-2140

Aims and objectives

This course will provide urologists with practical information to treat and counsel patients with invasive and locally advanced bladder cancer and focuses on the relevant principles involved in the management of this disease. Major themes covered in this session include treatment options for invasive bladder cancer and proper patient selection, management strategies for invasive and locally advanced disease and the current role of chemotherapy in both the neoadjuvant/adjuvant and metastatic disease settings. The course is very clinically oriented with lectures highlighted by case studies with audience participation. Objectives: After attending this course, the participants should be able to:

- Explain the rationale, patient selection and controversies regarding radical surgery for invasive and locally advanced bladder cancer
- Understand the rationale and limitations of nonsurgical approaches to the management of invasive and locally advanced bladder cancer
- Define the current role and results of neoadjuvant/adjuvant chemotherapy for invasive bladder cancer as well as chemotherapy used in the management of metastatic bladder cancer.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 11

12:30 - 14:30

Minimally invasive treatment for localised prostate cancer

Room **351** Level **3**

Chair: G. Morgia, Sassari (IT)

Cryotherapy

G. Morgia, Sassari (IT)

351-6-2150

Brachytherapy

S. Machtens, Hanover (DE)

351-6-2160

HIFU

S. Thüroff, Munich (DE)

351-6-2170

Aims and objectives

The challenge of modern medicine is to increasingly use mini-invasive techniques.

Nowadays, while surgery and radio therapy must be considered the standard forms of treatment for prostatic cancer, nonetheless mini-invasive techniques are greeted with ever more enthusiasm by patients. In addition the first long term results, indispensable for correct oncological evaluation of the technique, are also being reported.

Brachytherapy, cryotherapy and HIFU must be recognised by urology and proposed for patients with prostate cancer, albeit only in cases where the indications are correct.

This course will demonstrate the techniques, the results and the complications of this procedure, highlighting those essential aspects which may sometimes make the use of these procedures preferable to conventional techniques.

Finally clinical cases will be discussed. Practical examples of the use of mini-invasive therapy will be examined, and there will be time for an exchange of opinions with the audience on the practical applications of the techniques.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 12

12:30 - 14:30

Advanced course on laparoscopic prostatectomy

Room 353 Level 3

Chair: C.C. Abbou, Creteil (FR)

Introduction

C.C. Abbou, Creteil (FR) 353-6-2180

Laparoscopic anatomy of the prostate including the fascia and the bundles

J-U. Stolzenburg, Leipzig (DE) 353-6-2190

Instruments

C.C. Abbou, Creteil (FR) 353-6-2200

J-U. Stolzenburg, Leipzig (DE) 353-6-2210

P. Dubernard, Lyon (FR) 353-6-2215

Trocar position and technique of placement: Extra versus transperitoneal approach

C.C. Abbou, Creteil (FR) 353-6-2220

J-U. Stolzenburg, Leipzig (DE) 353-6-2230

P. Dubernard, Lyon (FR) 353-6-2235

Steps of the procedure: Anterograde approach

C.C. Abbou, Creteil (FR) 353-6-2240

J-U. Stolzenburg, Leipzig (DE) 353-6-2250

P. Dubernard, Lyon (FR) 353-6-2260

Steps of the procedure: Retrograde technique (video)

P. Dubernard, Lyon (FR)

Complications

C.C. Abbou, Creteil (FR) 353-6-2270

J-U. Stolzenburg, Leipzig (DE) 353-6-2280

P. Dubernard, Lyon (FR) 353-6-2285

Conclusion

C.C. Abbou, Creteil (FR) 353-6-2290

Aims and objectives

Laparoscopic radical prostatectomy needs to be well standardised to be reproduced. For that we will give first precise information on the anatomy of the fascias and the bundles in order to have a better vision of the operative laparoscopic anatomy. The experts must then go through each step of the surgery. For that, short selected video clips will be presented and discussed successively: eg the best way to perform the space for the extraperitoneal approach, how to spare the bladder neck, to make easy the dorsal vein complex control, the anastomosis... Different aspects of the nerve sparing surgery will be addressed including the retrograde and the antegrade technique. The participants must understand the role of the surgeon and of the first assistant in order to have the best exposure. They will be aware of the risk of complications or difficulties for each part of the procedure. The tricks to shorten the operative time will be also discussed. Finally the results and the complications will be addressed. At the end of the session, the participant, if they are beginners, should have a better comprehension of each step of the technique and the way to start. If they are experienced, should improve their technique by picking some important tricks. This course will be presented by experts having more

than 1000 procedures in their own hand. The participants must be ready to be active by asking questions or giving their own opinions.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 13

15:00 - 17:00

Interventional therapies for BPH

Room **343** Level **3**

Chair: M. Emberton, London (GB)

Introduction

M. Emberton, London (GB)

343-6-2300

The role of open surgery

R.M. Kuntz, Berlin (DE)

343-6-2310

TURP: Still the 'gold standard'?

K.M. Anson, London (GB)

343-6-2320

TUMT / TUNA - still up-to-date?

R.M. Kuntz, Berlin (DE)

343-6-2330

Laser technology

K.M. Anson, London (GB)

343-6-2340

Other treatment alternatives- update

K.M. Anson, London (GB)

343-6-2350

Patient selection for invasive and instrumental management

M. Emberton, London (GB)

343-6-2360

Case discussion

343-6-2370

Aims and objectives

To update delegates on the relative harms and benefits of both established and novel interventions for BPH

- To create a classification of BPH interventions
- To create a reporting standard (for both harms and benefits) for these interventions
- To summarise the evidence base for each of these interventions
- To debate with the delegates a hierarchy of interventions
- To speculate on future trends

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 14

15:00 - 17:00

The infertile couple - urological aspects

Room **351** Level **3**

Chair: *W. Aulitzky, Vienna (AT)*

Diagnostic work-up, medical treatment

W. Weidner, Giessen (DE)

351-6-2380

Pathophysiology, diagnosis and treatment of varicocele

W. Aulitzky, Vienna (AT)

351-6-2390

Microsurgical refertilization

W. Aulitzky, Vienna (AT)

351-6-2400

Sperm retrieval techniques, sperm preparation and genetic aspects of IVF/ICSI

W. Weidner, Giessen (DE)

351-6-2410

Aims and objectives

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focussing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also inform about genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

Registration fee excluding VAT

EAU members, residents

€ 25

Non-EAU member

€ 40

ESU Course 15

15:00 - 17:00

Advanced course on laparoscopic cystectomy

Room **353** Level **3**

Chair: R.F. Van Velthoven, Brussels (BE)

Faculty: P.T. Piechaud, Bordeaux (FR)

Surgical anatomy (laparoscopic point of view) 353-6-2420

Material: Laparoscopic set 353-6-2430

Oncological prerequisites 353-6-2440

Technical protocol 353-6-2450

Results 353-6-2460

Aims and objectives

Illustrate from the surgical and anatomical point of view, the step by step protocol of the radical cystectomy done by laparoscopic approach:

- Stressing the respect of fundamental rules of oncologic surgery when treating transitional cell carcinoma of the bladder
- Describing the protocol in both sexes: - nerve sparing cystectomy
- uterus sparing cystectomy

Discuss the cost/benefit ratio of a whole laparoscopic approach versus a combined (laparoscopy + open) procedure for urinary diversion in ileal conduit, orthotopic reservoirs, diversion to the recto-sigmoid. With respect to the actual state of the art regarding the staging of lymph nodes involvement in TCC, discuss the feasibility of laparoscopic extended lymph node dissection. Review the literature with respect to oncological results (port metastases, local recurrences and distant metastases), follow up and functional outcome

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40



ESU Course 16

09:00 - 12:00

Advanced course on urethral stricture surgery

Room **341** Level **3**

Chair: C.R. Chapple, Sheffield (GB)

Anatomy of the urethra and nature of stricture disease

C.R. Chapple, Sheffield (GB)

341-7-1650

Which type of urethroplasty - a critical overview of results and complications

A.R. Mundy, London (GB)

341-7-1660

Anastomotic urethroplasty - principles and practice

L. Boccon-Gibod, Paris (FR)

341-7-1670

Substitution urethroplasty - when, what, how?

C.R. Chapple, Sheffield (GB)

341-7-1680

Aims and objectives

- To review the treatments available for urethral stricture disease
- To detail the role of the treatments which are available for specific patient scenarios?
- To provide a clearer understanding of the role of anastomotic and substitution urethroplasty in the management of urethral stricture disease
- To outline the principles of the surgical management of patients with urethras that have been injured by trauma

Participants of the course will obtain a clear view on the current role of surgery for the management of urethral stenosis affecting both the anterior and posterior urethra in contemporary clinical practice.

Registration fee excluding VAT

EAU members, residents	€ 40
Non-EAU member	€ 60

ESU Course 17

09:00 - 12:00

Diagnosis and management of superficial bladder cancer

Room **342a** Level **3**

Chair: J.A. Witjes, Nijmegen (NL)

Diagnosis of superficial bladder cancer, including urinary markers and PDD

J.A. Witjes, Nijmegen (NL) 342a-7-1690

Cases on diagnosis

J.A. Witjes, Nijmegen (NL) 342a-7-1700

Optimal initial therapy in superficial bladder cancer

M. Babjuk, Prague (CZ) 342a-7-1710

Demonstration of TUR with blue light

M. Babjuk, Prague (CZ) 342a-7-1720

An efficient prognostic factor score system: The 2006 version

W. Oosterlinck, Ghent (BE) 342a-7-1730

Case where decisions can be made based on prognostic factors in the patients' history

W. Oosterlinck, Ghent (BE) 342a-7-1740

EAU guidelines on papillary Ta, T1 lesions: What is new in therapy in the 2006 version?

W. Oosterlinck, Ghent (BE) 342a-7-1750

Intermediate risk cases

W. Oosterlinck, Ghent (BE) 342a-7-1760

Evidence based therapy of CIS and high risk superficial bladder cancers

M. Babjuk, Prague (CZ) 342a-7-1770

High risk cases

M. Babjuk, Prague (CZ) 342a-7-1780

BCG failures, the therapeutic advice and their prognosis

J.A. Witjes, Nijmegen (NL) 342a-7-1790

Case discussion and closure

J.A. Witjes, Nijmegen (NL) 342a-7-1800

Aims and objectives

In Paris there is again a course on diagnosis and management of superficial bladder cancer. Since many years this course is very well attended and received. The course again has been updated, especially since new guidelines have been developed in 2005. The aim is to discuss several problems into more detail, rather than giving an overview of everything that is published. After most presentations some cases will be discussed in an interactive way. In the first presentation Prof. Fred Witjes from Nijmegen will discuss the diagnosis of superficial bladder cancer, including the expanding field of urinary markers and the use of fluorescence cystoscopy. The second lecture will be given by Dr. Marko Babjuk from Prague, where he will discuss the optimal initial therapy in superficial bladder cancer. This will include the TUR technique, the biopsy policy (where, when and how), blue light resection, one immediate instillation and what we should expect from the pathologist. Third,

Prof. Wim Oosterlinck from Ghent will discuss the 2006 view on an efficient prognostic factor score system. His second lecture will deal with therapeutic news according to the new EAU guidelines on papillary Ta, T1 lesions. Dr. Babjuk will then discuss the evidence based therapy of CIS and high risk superficial bladder cancers. This will include BCG versus chemotherapy and the role of primary cystectomy. Finally Prof. Witjes will give an overview on the therapeutic possibilities for patients failing BCG, like new intravesical drugs, new treatment modalities (hyperthermia) and the role of p53. In between the lectures short practical presentations and case discussions are planned. After the course attendees should have clear practical guidelines for some common daily practical problems in patients with superficial bladder cancer.

Registration fee excluding VAT

EAU members, residents	€ 40
Non-EAU member	€ 60

ESU Course 18

09:00 - 12:00

Advanced prostate cancer - new perspectives

Room **342b** Level **3**

Chair: M.P. Wirth, Dresden (DE)

Endocrine therapy - timing and modalities

M.P. Wirth, Dresden (DE)

342b-7-1810

Therapy of hormone refractory prostate cancer

K. Pummer, Graz (AT)

342b-7-1820

New targets for treatment of hormone refractory prostate cancer

P. Teillac, Paris (FR)

342b-7-1830

Aims and objectives

This course aims at delivering up to date information about the role and optimal timing of androgen deprivation therapy in patients with advanced prostate cancer. Once androgen independence develops, new second line hormonal therapies and chemotherapy are available that may improve the quality of life, delay further progression and possibly prolong survival. The role of experimental drugs is critically discussed. Those drugs which are close to clinical application and their mechanisms of action will be explained. There will be room for discussions about the management of patients, and the conduct of clinical trials.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 19

09:00 - 12:00

Update on stone disease

Room **343** Level **3**

Chair: P. Alken, Mannheim (DE)

Principles of case selection

P. Alken, Mannheim (DE)

343-7-1840

ESWL: Prevention of calcium oxalate/phosphate stones

P.J. Conort, Paris (FR)

343-7-1850

URS: Prevention of uric acid stones

A. Patel, London (GB)

343-7-1860

PNL and surgery: Prevention of struvite and cystine stones

P. Alken, Mannheim (DE)

343-7-1870

Aims and objectives

Which are the necessary diagnostic steps to select the right procedure for stone removal? What are the expert's tricks to guarantee success? How to avoid complications? Which diagnostic and therapeutic steps are mandatory to prevent stone recurrence? Based on case reports these questions will be answered for ESWL, URS, PCNL and surgery and the most frequently met stone types. If you want a special case of your own practice to be discussed during the course, send the case report to peter.alken@uro.ma.uni-heidelberg.de

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 20

09:00 - 12:00

Radical cystectomy and orthotopic bladder substitution - surgical tricks and management of complications

Room **351** Level **3**

Chair: U.E. Studer, Berne (CH)

Preoperative investigations and selection of patients for orthotopic bladder substitution

J.E. Gschwend, Ulm (DE)

351-7-1880

Arguments for nerve sparing cystectomy with orthotopic bladder substitution

A. Stenzl, Tübingen (DE)

351-7-1890

How to do a nerve sparing cystectomy in male and female patients, surgical tricks to avoid complications with orthotopic bladder substitution

U.E. Studer, Berne (CH)

351-7-1900

Tips on how to obtain good functional results in female patients

A. Stenzl, Tübingen (DE)

351-7-1910

Active post-operative management is the most important step

U.E. Studer, Berne (CH)

351-7-1920

How to treat complications during follow-up

J.E. Gschwend, Ulm (DE)

351-7-1930

Aims and objectives

In this course special emphasis is on patient selection and on practical surgical steps: on how to do meticulous pelvic lymph node dissection, nerve sparing cystectomy in male and female patients as well as how to do various types of orthotopic bladder substitutes with good long-term functional results. The course is aimed to be interactive with 50% of the time reserved for questions and discussions with the audience. At the end of the course, the participant should know all the essential and practical steps in order to achieve good results with cystectomy and orthotopic bladder substitution.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 21

09:00 - 12:00

Vaginal surgery for urologists

Room **353** Level **3**

Chair: D. Pushkar, Moscow (RU)

Vaginal surgery nowadays - what is new?

D.J.M.K. De Ridder, Leuven (BE)

353-7-1940

Surgery of SUI - 10 years of Prolene

D. Pushkar, Moscow (RU)

353-7-1950

Prolapse surgery for urologists - mesh? When mesh? Which mesh?

D.J.M.K. De Ridder, Leuven (BE)

353-7-1960

Complications of vaginal surgery

D.J.M.K. De Ridder, Leuven (BE)

353-7-1970

Complications of vaginal surgery

D. Pushkar, Moscow (RU)

353-7-1980

Periurethral cysts, fistulas and rare conditions

D. Pushkar, Moscow (RU)

353-7-1990

Video session

353-7-2000

Aims and objectives

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current clinical practice. Special attention will be given to new techniques that use synthetic tapes in stress urinary incontinence alone or those cases associated with prolapse. This course will also cover the management of complications of surgery for stress incontinence. Vaginal approach to prolapse and use of different meshes will be covered in critical view based upon personal experience. Management of periurethral cysts, fistulas and other rare conditions will be shown both during podium and video presentations. Carefully prepared clinical cases and video demonstration of various surgical techniques and tricks will provide a clear understanding of the most common procedures to all participants. Interactive course means active participation by the audience. Participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course participants should know how to apply newest technique in patients with stress incontinence, prolapse and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers.

Registration fee excluding VAT

EAU members, residents € 40

Non-EAU member € 60

ESU Course 22

12:30 - 14:30

Penile and testicular cancer

Room **341** Level **3**

Chairs: P. Albers, Kassel (DE)
 N.W. Clarke, Manchester (GB)

Penile cancer - early stages

N.W. Clarke, Manchester (GB)

341-7-2010

Penile cancer - advanced stages

P. Albers, Kassel (DE)

341-7-2020

Testis cancer - early stages

N.W. Clarke, Manchester (GB)

341-7-2030

Testis cancer - advanced stages

P. Albers, Kassel (DE)

341-7-2040

Aims and objectives

Organ-sparing approaches in penile cancer have proven to be effective. Up to date management of superficial lesions will be presented including laser surgery and several techniques of surgical reconstructions after partial penectomy or glansctomy. The different indications and extensions of lymph node dissection in the groin will be discussed and demonstrated as surgical step by step procedures. In cases of advanced disease, different chemotherapy regimens will be presented and the current favourite of out-patient based chemotherapy will be shown in detail. In the August 2005 issue of European Urology the latest update of the guidelines for diagnosis and treatment of testicular cancer has been published. Based on this European consensus, this ESU course will provide the auditorium with the latest information on diagnostic tools, staging and treatment of testis cancer stage by stage. In early stages, organ sparing surgery, current histopathological prognostic factors for surveillance and individualised treatment options will be discussed with the auditorium following case presentations. The role of conventional as well as laparoscopic RPLND in early stages will be clarified. In advances stages, the course participants will learn about stage by stage treatment according to IGCCCG classification. Detailed information on chemotherapy regimens and the handling of side effects will be provided. In this section of the course, tips and tricks of residual tumor resection will be presented using case reports and intraoperative pictures and movies. Participants will have enough time to ask questions and discuss their own cases.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 23

12:30 - 14:30

Urological management of renal failure and renal transplantation - treatment of urological complications

Room 342a Level 3

Chair: G. Karam, Nantes (FR)

Urological and vascular aspects of recipient preparation

G. Karam, Nantes (FR)

342a-7-2050

Surgical aspects of nephrectomy in living and cadaveric donors

K. Dreikorn, Bremen (DE)

342a-7-2060

Laparoscopic living donor nephrectomy

G. Karam, Nantes (FR)

342a-7-2070

Technical aspects of renal transplantation

K. Dreikorn, Bremen (DE)

342a-7-2080

Surgical complications

A. Alcaraz, Barcelona (ES)

342a-7-2090

Aims and objectives

Given the dramatic improvement in short and long term graft survival, renal transplantation is nowadays the most effective treatment of end stage renal failure. Recipients considered for transplant are older and pose more problems than in the past, in some cases requiring specific urological preparation. We would like to share our experience concerning the selected items with the audience. These include how to prepare transplant recipients with surgical or urological problems, how to choose the most safe technique for performing living donor nephrectomy, how to deal with unusual situations of renal procurement or transplantation and finally for urologists, how to diagnose and manage urological complications.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

Chair: F.M.J. Debruyne, Nijmegen (NL)

Clinical research in urology: What are the dead ends and how to avoid them?

F.M.J. Debruyne, Nijmegen (NL)

342b-7-2100

Clinical research in urology: Demands and expectations from the professionals and patients

B. Malavaud, Toulouse (FR)

342b-7-2110

Statistical power and outcome of clinical trials: What a urological investigator should know

R. Sylvester, Brussels (BE)

342b-7-2120

How to manage a clinical urological trial: Practical aspects

F.M.J. Debruyne, Nijmegen (NL)

342b-7-2130

Case scenarios

342b-7-2140

Aims and objectives

Clinical research is essential for any progress in medicine. It is the most appropriate way to evaluate new diagnostic and/or therapeutic approaches. Also in urology, clinical research has played an important role in defining new treatment strategies for many urological diseases. Where for many years this form of research was limited to selected centres, it has now spread to a larger participation of urological departments and urologists. The academic or academically oriented urological departments are no longer the only more or less exclusive participants in urological clinical research. As a matter of fact, today many non-academic, private and office urologists contribute significantly to current urological clinical protocols. It is therefore important to be informed about all essential aspects of clinical urological research and in this course participants will be able to learn about all issues involved. Hence, the course is a must for all those actually involved in clinical urological research and is thus intended not only for urologists, but also for epidemiologists, statisticians and clinical research nurses.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 25

12:30 - 14:30

Office management of male sexual dysfunction

Room **343** Level **3**

Chair: C. Stief, Munich (DE)

Background on function and dysfunction of erection and ejaculation

C. Stief, Munich (DE)

343-7-2150

Assessment - what is necessary?

I. Eardley, Leeds (GB)

343-7-2160

Testosterone replacement

C. Stief, Munich (DE)

343-7-2170

Medical therapy of ED and premature ejaculation

I. Eardley, Leeds (GB)

343-7-2180

Therapy of ED when pills fail

C. Stief, Munich (DE)

343-7-2190

Management of ED in the patient with cardiovascular disease

I. Eardley, Leeds (GB)

343-7-2200

What to do after radical prostatectomy?

C. Stief, Munich (DE)

343-7-2210

Aims and objectives

The course is aimed at providing practical advice on how to diagnose and treat a patient with premature ejaculation or erectile dysfunction. It will allow an up-to-date understanding of the underlying mechanisms of the erectile process and the etiology of erectile dysfunction. The recent development of various orally available drugs with different modes of action and distinctly different side effect profiles enables individually tailored therapies. However, this individually adopted regimen requires an adequate work up that will be comprehensively presented. Although present and future orally available drugs will be covered in depth, alternative options such as local pharmacotherapy or various devices will be presented with special emphasis since their adequate indication and appropriate use by the urologist makes the distinctive difference in comparison to other specialists in the field. Then, specific topics with high practical importance as the cardiovascular patient with ED or the post-prostatectomy case will be covered. The course will be very interactive allowing in depth information on the various aspects of the cutting edge of erectile dysfunction.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 26

12:30 - 14:30

Update on neurourology

Room **351** Level **3**

Chair: P.E. Van Kerrebroeck, Maastricht (NL)

Introduction

P.E. Van Kerrebroeck, Maastricht (NL)

351-7-2220

History, investigations and diagnostic classifications

P.E. Van Kerrebroeck, Maastricht (NL)

351-7-2230

Conservative and surgical treatments

F.R. Cruz, Porto (PT)

351-7-2240

Case discussion

351-7-2250

Aims and objectives

In this course various aspects of neurourology will be discussed as well theoretical as practical. As an introduction the neural control of the lower urinary and genital tract will be reviewed focusing on those elements relevant to the practising urologist. Furthermore the elements of neuro-urological history and physical examination will be presented and correlated with the different neurological conditions. The role of additional investigations as f.e. urodynamics will be discussed. Finally the different therapeutic options classical as well as more experimental, conservative as well as surgical will be summarised. At the end of this course, the application of practical algorithms in neurourology will be rehearsed with the participants in the form of case discussions.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 27

12:30 - 14:30

Advanced course on laparoscopic nephrectomy

Room **353** Level **3**

Chair: R. Bollens, Brussels (BE)

Extraperitoneal nephrectomy

T. Sulser, Basel (CH)

353-7-2260

Transperitoneal nephrectomy

R. Bollens, Brussels (BE)

353-7-2270

Live donor nephrectomy

T. Sulser, Basel (CH)

353-7-2280

Partial nephrectomy

R. Bollens, Brussels (BE)

353-7-2290

Aims and objectives

Practical tips and tricks in advanced laparoscopic kidney surgeries.

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

Chair: P. Hammerer, Braunschweig (DE)

Indications for TRUS and biopsy

P. Hammerer, Braunschweig (DE)

341-7-2300

Practical aspects of TRUS and TRUS guided biopsies

P. Hammerer, Braunschweig (DE)

341-7-2310

Indications for rebiopsy

A.R. Zlotta, Brussels (BE)

341-7-2320

Update on new technical developments

A.R. Zlotta, Brussels (BE)

341-7-2330

Aims and objectives

The purpose of this ESU Course is to define the optimal transrectal ultrasound, to discuss new ultrasound techniques for prostate cancer detection as well as defining a new standard for transrectal ultrasound-guided prostate biopsies. In addition, techniques to reduce morbidity and to increase patient acceptance will be discussed. Transrectal ultrasound is performed for more than 15 years, and this technique is now an important part of prostate cancer diagnosis and staging. Anatomic studies of prostatectomy specimens that defined the zonal anatomy of the prostate and a detailed mapping of the tumor location has increased our understanding of transrectal ultrasound images as well as optimal placement of the biopsy needles. The stage migration seen by prostate specific antigen based screening has resulted in most tumors being non-palpable at diagnosis. Therefore in the PSA area with tumors at early stage, non-palpable and sometimes ultrasonographically isoechoic, transrectal ultrasound is needed to enable sampling of all relevant areas of the prostate including those that appear normal. The systematic sampling of the prostate by the sextant biopsy technique improved the detection rate of prostate cancer over sampling hypoechoic or palpable suspicious lesions. However, in men with initially negative biopsies a second set of sextant biopsies will be positive in about 20-30%. Several groups demonstrated that the sextant technique is inadequate for sampling of larger prostates and they advocated additional samples. Will an increase of prostate biopsies result in patient discomfort? Although some studies report no additional morbidity from the more extensive biopsy protocols, it seems likely that discomfort for the patient would be increased. What can be done to reduce pain and discomfort and improve tolerance for additional biopsies? Simple and efficacious methods are now available to provide anesthesia in men undergoing prostate biopsies.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 29

15:00 - 17:00

How to write a paper for publication

Room **342a** Level **3**

Chair: F. Montorsi, Milan (IT)

Faculty: C.A. McKillop, Bucks (GB)

Assessing the type of publication	342a-7-2340
Choosing a journal	342a-7-2350
Deciding on authorship	342a-7-2360
Writing: how to do it	342a-7-2370
Submission	342a-7-2380
Reviewer's comments	342a-7-2390
Editor's comments	342a-7-2400
Checking proofs and waiting for publication	342a-7-2410

Aims and objectives

Why should I invest a lot of my time in writing scientific papers? There are a lot of good reasons for this and the course will start by describing them all. All most important aspects of scientific writing will then be discussed: what are the available publication types, how to choose the target journal, how to identify authors. The "How to do it" for a scientific paper will represent the core of the course. A publication type will be taken as a case study and the whole writing process will be described. Mechanics and tips including referencing options, journal style, do's and don'ts will be covered. All details regarding how to submit a paper will also be discussed. In addition, how to deal with reviewers' comments will be considered. The post acceptance for publication phase will be discussed including checking proofs. In summary attendees are expected to leave the course with the knowledge of the fundamental requirements to be successful in having a scientific paper accepted from a major journal

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 30

15:00 - 17:00

Upper urinary tract trauma

Room **342b** Level **3**

Chair: *L. Martínez-Piñero, Madrid (ES)*

Blunt and penetrating renal trauma

L. Martínez-Piñero, Madrid (ES)

342b-7-2420

External ureteral trauma - etiology, diagnosis and treatment

W. Månsson, Lund (SE)

342b-7-2430

Iatrogenic ureteral lesions - etiology, classification, diagnostic algorithm and therapeutic options

J-J. Rambeaud, Grenoble (FR)

342b-7-2440

Ureterointestinal anastomotic strictures - prevention and management

W. Månsson, Lund (SE)

342b-7-2450

Aims and objectives

- To review the current classifications of renal/ureteral trauma
- To outline the principles of diagnosis and management of renal and ureteral trauma
- To provide a clearer understanding of the role of the treatments which are available for specific patient scenarios
- To interact with the audience and discuss together management and treatment of real cases

Participants of the course will obtain a clear view on the current management of blunt and penetrating injuries affecting the ureter and/or kidney in contemporary clinical practice. Iatrogenic injuries of the ureter due to urologic and non-urologic surgery or instrumentation will be covered also. More than 50% of the time of the course will be spent with the discussion of real clinical cases.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 31

15:00 - 17:00

Ageing male

Room **343** Level **3**

Chair: C.C. Schulman, Brussels (BE)

Physiopathology of male hormonal deficiency

M.L. Ruutu, Helsinki (FI)

343-7-2460

Hormonal supplementation

M.L. Ruutu, Helsinki (FI)

343-7-2470

Risks of hormonal substitution (prostate and others)

C.C. Schulman, Brussels (BE)

343-7-2480

Testosterone and erectile dysfunction

C.C. Schulman, Brussels (BE)

343-7-2490

Aims and objectives

The aim of this course is to outline for practising urologists the increasing place and importance of male hormone endocrinology, the basic concept and the clinical implications. The various aspects of hormonal supplementation in men will consider the potential benefits and risks associated. Special attention will focus on testosterone and the prostate and the place of testosterone in erectile dysfunction.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 32

15:00 - 17:00

The molecular basis of prostate cancer; science in practice

Room **351** Level **3**

Chair: *J.A. Schalken, Nijmegen (NL)*

What genetics can tell us

R.W.G. Watson, Dublin (IE)

351-7-2500

From genetics to proteomics and new therapy: Choosing targets suitable for diagnosis, prognosis, therapy

J.A. Schalken, Nijmegen (NL)

351-7-2510

Aims and objectives

Molecular techniques have been introduced in research in life sciences almost two decades ago. Our insight in the genetic code, the complex signalling networks and the interaction with the architecture of cells has increased exponentially. The new 'high throughput' technology platforms now enable the identification of many new potential targets for diagnosis and therapy. In this course we will provide an integral overview of the molecular- and cellular tools we have nowadays in our laboratories. The information presented will be sufficient to understand the principles of molecular- and cell biological methods, so that one can understand the potential use of them for research aimed at solving clinical unmet needs. 'Real life' examples of successes, particular in the diagnosis and therapy of prostate cancer will be presented, i.e. results from basic research that were translated into clinical applicability. Finally, several practical case scenario's will be discussed how molecular techniques are currently implemented in clinical practise.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU Course 33

15:00 - 17:00

Advanced course on upper tract laparoscopy (UPJ) and adrenal

Room **353** Level **3**

Chair: C. Eden, Basingstoke (GB)

Pyeloplasty: Which approach and why?

C. Eden, Basingstoke (GB)

353-7-2520

Pyeloplasty: Technique (video) and results

C. Eden, Basingstoke (GB)

353-7-2530

Pyeloplasty: Intra-operative problems and complications

C. Eden, Basingstoke (GB)

353-7-2540

Adrenalectomy: Which approach and why?

G. Guazzoni, Milan (IT)

353-7-2550

Adrenalectomy: Technique (video) and results

G. Guazzoni, Milan (IT)

353-7-2560

Adrenalectomy: Intra-operative problems and complications

G. Guazzoni, Milan (IT)

353-7-2570

Questions

C. Eden, Basingstoke (GB)

353-7-2580

G. Guazzoni, Milan (IT)

Aims and objectives

Within the next 10 years almost all urology will be subdivided into office urology, endoluminal urology, penoscrotal surgery and laparoscopy. If you want to operate on the adrenal, kidney, bladder or prostate you will need to learn laparoscopy. The well-documented learning curve for advanced laparoscopy can be considerably shortened by expert instruction and learning from the mistakes of others. Two acknowledged experts in laparoscopic pyeloplasty and adrenalectomy will instruct delegates using didactic lectures and video on the laparoscopic management of UPJ obstruction and on laparoscopic adrenalectomy. This course will not deal with the aetiology of the disease processes or with their diagnosis. It will include advice on which laparoscopic route to use, suturing technique, troubleshooting intra-operative problems and how to manage post-operative complications. Be there or be left behind!

Registration fee excluding VAT

EAU members, residents € 25

Non-EAU member € 40

ESU Course 34

09:00 - 11:00

Multi Media Course

Room **242 Level 2**

Chair: *F. Gomez Sancha, Madrid (ES)*

Multimedia applications in urological practice

F. Gomez Sancha, Madrid (ES)

242-7-2590

On-line video surgical learning system

A. Messas, Nanterre (FR)

242-7-2600

Aims and objectives

This course is structured in two parts:

- The first part will explain how to make good use of the internet to keep updated in urology, focusing in the utility of urological surgery video learning systems. The available online video learning systems will be discussed, and the new EAU video learning system Urozoom will be presented.
- The second part of the course will cover how to enhance your powerpoint presentations with the addition of digital photographs, home-made surgical videos, flash animations and animated graphics to produce truly multimedia presentations.

Participants in this course should gain insight in how to use the internet to keep updated and expand their urological knowledge, and make good use of the growing body of surgical video footage available in the Internet. They will also get to know the new EAU project Urozoom - surgical video learning system. Also, they will have a better understanding of how Powerpoint can become a powerful tool to communicate by integrating multimedia elements. It will be relatively easy for the attendants to significantly enhance his presentations with the use of the tips and tricks presented at this course. Although this course is open to everyone and its contents have been designed to make it attractive to a wide range of urologists with different levels of experience with computers, it is not a basic course on how to use a computer from scratch. Those with previous experience in using the internet and creating powerpoint presentations will make the most of it."

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU/ESUT Hands-on Courses, 6 April

10:00 - 12:30

ESU/ESUT Course 1 - Hands-on course on Laparoscopy

Room **352a Level 3**

Chair: *J. Rassweiler, Heilbronn (DE)*

A. Cestari, Milan (IT)	352a-6-2470
A. Hoznek, Creteil (FR)	352a-6-2480
J. Klein, Heilbronn (DE)	352a-6-2490

Aims and objectives

Laparoscopic procedures are continuously evolving in Urology based on the increasing expertise of urologic surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) have both, ablative and reconstructive steps. Since the number of centers with laparoscopic expertise is still limited in Europe, laparoscopic training programs have become very important. Hands-on training courses at the pelvi-trainer represent one of the main steps of such courses.

The European School of Urology (ESU) and the European Society of Uro-technology (ESUT) offer an intensive hands-on-course with different models focussing on both ablative as well as reconstructive laparoscopic techniques. For this purpose standardized models for endoscopic suturing techniques (i.e. vesico-urethral anastomosis) are provided, which allow a step-wise approach to this technically difficult task. Perfused pulsating models of porcine aorta and kidney (P.O.P.-trainer) enable the training of retroperitoneal lymph node dissection, partial and simple nephrectomy as well as the management of vascular complications. The extent of the exercises depends on the educational level of the trainee.

European experts will serve as trainers after a short introduction. According to the flexibility and variety of models, this course is not only directed to beginners, but may also serve for experienced surgeon to extend their technical capabilities.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

Chair: B. Guillonneau, New York (US)

T. Erdogru, Antalya (TR)	352a-6-2500
F. Keeley, Bristol (GB)	352a-6-2510
M.P. Laguna, Amsterdam (NL)	352a-6-2520

Aims and objectives

Laparoscopic procedures are continuously evolving in Urology based on the increasing expertise of urologic surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) have both, ablative and reconstructive steps. Since the number of centers with laparoscopic expertise is still limited in Europe, laparoscopic training programs have become very important. Hands-on training courses at the pelvi-trainer represent one of the main steps of such courses.

The European School of Urology (ESU) and the European Society of Uro-technology (ESUT) offer an intensive hands-on-course with different models focussing on both ablative as well as reconstructive laparoscopic techniques. For this purpose standardized models for endoscopic suturing techniques (i.e. vesico-urethral anastomosis) are provided, which allow a step-wise approach to this technically difficult task. Perfused pulsating models of porcine aorta and kidney (P.O.P.-trainer) enable the training of retroperitoneal lymph node dissection, partial and simple nephrectomy as well as the management of vascular complications. The extent of the exercises depends on the educational level of the trainee.

European experts will serve as trainers after a short introduction. According to the flexibility and variety of models, this course is not only directed to beginners, but may also serve for experienced surgeon to extend their technical capabilities.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

ESU/ESUT Hands-on Courses, 7 April

10:00 - 12:30

ESU/ESUT Course 3 - Hands-on course on Laparoscopy

Room **352a** Level **3**

Chair: *J.J.M.C.H. De La Rosette, Amsterdam (NL)*

G. Breda, Bassano Del Grappa (IT)

352a-7-2610

P. Fornara, Halle/Saale (DE)

352a-7-2620

H.C. Klingler, Vienna (AT)

352a-7-2630

Aims and objectives

Laparoscopic procedures are continuously evolving in Urology based on the increasing expertise of urologic surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) have both, ablative and reconstructive steps. Since the number of centers with laparoscopic expertise is still limited in Europe, laparoscopic training programs have become very important. Hands-on training courses at the pelvi-trainer represent one of the main steps of such courses.

The European School of Urology (ESU) and the European Society of Uro-technology (ESUT) offer an intensive hands-on-course with different models focussing on both ablative as well as reconstructive laparoscopic techniques. For this purpose standardized models for endoscopic suturing techniques (i.e. vesico-urethral anastomosis) are provided, which allow a step-wise approach to this technically difficult task. Perfused pulsating models of porcine aorta and kidney (P.O.P.-trainer) enable the training of retroperitoneal lymph node dissection, partial and simple nephrectomy as well as the management of vascular complications. The extent of the exercises depends on the educational level of the trainee.

European experts will serve as trainers after a short introduction. According to the flexibility and variety of models, this course is not only directed to beginners, but may also serve for experienced surgeon to extend their technical capabilities.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

Chair: G. Janetschek, Linz (AT)

S. Deger, Berlin (DE)	352a-7-2640
P. Rischmann, Toulouse (FR)	352a-7-2650
N. Soomro, Newcastle upon Tyne (GB)	352a-7-2660

Aims and objectives

Laparoscopic procedures are continuously evolving in Urology based on the increasing expertise of urologic surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive techniques, such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) have both, ablative and reconstructive steps. Since the number of centers with laparoscopic expertise is still limited in Europe, laparoscopic training programs have become very important. Hands-on training courses at the pelvi-trainer represent one of the main steps of such courses.

The European School of Urology (ESU) and the European Society of Uro-technology (ESUT) offer an intensive hands-on-course with different models focussing on both ablative as well as reconstructive laparoscopic techniques. For this purpose standardized models for endoscopic suturing techniques (i.e. vesico-urethral anastomosis) are provided, which allow a step-wise approach to this technically difficult task. Perfused pulsating models of porcine aorta and kidney (P.O.P.-trainer) enable the training of retroperitoneal lymph node dissection, partial and simple nephrectomy as well as the management of vascular complications. The extent of the exercises depends on the educational level of the trainee.

European experts will serve as trainers after a short introduction. According to the flexibility and variety of models, this course is not only directed to beginners, but may also serve for experienced surgeon to extend their technical capabilities.

Registration fee excluding VAT

EAU members, residents	€ 25
Non-EAU member	€ 40

Thursday, 6 April - Hands-on Training Sessions

Hands-on training session

10:00 - 12:00

Endourology masterclass training course

Room **352b** Level **3**

10:00 - 11:00

Session 1- Performing PCNL successfully, exploring different access techniques

Chair: J.J.M.C.H. De La Rosette, Amsterdam (NL)

X-ray access

J.J.M.C.H. De La Rosette, Amsterdam (NL)

352b-6-2530

Ultrasound access

A. Gross, Hamburg (DE)

352b-6-2540

Hands-on PCNL training

11:00 - 12:00

Session 2- Ureterscopy. The journey further into inner space continues with the aid of new technology

Chair: D.A. Tolley, Edinburgh (GB)

Ureterscopy. The journey further into inner space continues with the aid of new technology

D.A. Tolley, Edinburgh (GB)

352b-6-2550

G. Preminger, Durham (US)

352b-6-2560

Hands-on ureterscopy training

Aims and objectives

The Endourology training course at the 21st Annual EAU Congress in Paris, (FR) will offer 2 sessions in advanced endourology training. The 1st session will focus on advanced techniques in performing PCNL, focusing on access techniques, x-ray, and ultrasound.

The 2nd session will focus on utilizing new technology when performing rigid and flexible ureterscopy. Both sessions will offer didactic as well as hands on training.

For a free registration please go to the Boston Scientific booth, PA06, Level 1

Hands-on training session

09:00 - 17:00

Holmium laser workshop

Room **352b** Level **3**

09:00 - 10:00

HoLAP workshop

S.M. Kumar, Westland (US)

352b-7-2570

11:00 - 12:00

HoLEP workshop

T. Aho, Cambridge (UK)

352b-7-2580

14:00 - 15:00

HoLAP workshop

S.M. Kumar, Westland (US)

352b-7-2590

16:00 - 17:00

HoLEP workshop

T. Aho, Cambridge (UK)

352b-7-2600

Aims and objectives

The Holmium Laser has been a valuable instrument for Urologists for over 10 years. It is well accepted for endoscopic and percutaneous lithotripsy, is increasingly used for the palliative treatment of recurrent bladder tumours, and is now becoming established as a cost -saving device for treating BPH in prostates up to and over 200 gm.

Experienced practitioners of Holmium Laser Ablation of the Prostate (HoLAP™) and Holmium Laser Enucleation of the Prostate (HoLEP™) will present the techniques in four sessions (2 x HoLAP and 2 x HoLEP). Participants will have the opportunity to discuss the techniques, see the equipment used and work on a simulator.

Limited places are available. For a free registration please go to the Lumenis booth, PA05, Level 1



Meeting of the European Society of Female Urology (ESFU)

08:30 - 12:30

Update on female urology

Room Ternes Level 1

Chairs: D. Castro Diaz, Santa Cruz De Tenerife (ES)
J. Heesakkers, Nijmegen (NL)

08:30 - 08:35 **Welcome and introduction**

08:35 - 08:55 **Indications, technique and outcome of urethrolisis after surgery for SUI**

D. Pushkar, Moscow (RU)

tern-5-0250

08:55 - 09:05 **Discussion**

09:05 - 09:25 **Complications of meshes for lower urinary tract reconstruction**

F. Haab, Paris (FR)

tern-5-0260

09:25 - 09:35 **Discussion**

09:35 - 10:00 **Debate: Are injectables justified as first option for SUI**

Pro: P.E. Van Kerrebroeck, Maastricht (NL)

tern-5-0270

Con: J. Corcos, Montreal (CA)

tern-5-0280

10:00 - 10:20 **New therapies for painful bladder syndrome**

J.J. Wyndaele, Antwerp (BE)

tern-5-0290

10:20 - 10:30 **Discussion**

10:30 - 11:00 **Break**

11:00 - 11:20 **Botox for OAB. How evident is the evidence?**

A. Giannantoni, Perugia (IT)

tern-5-0300

11:20 - 11:30 **Discussion**

11:30 - 11:50 **State of the art of pelvic floor laparoscopic reconstruction**

R. Gaston, Bordeaux (FR)

tern-5-0310

11:50 - 12:00 **Discussion**

12:00 - 12:20 **Recent developments in pelvic floor imaging**

P. Rehder, Innsbruck (AT)

tern-5-0320

12:20 - 12:30 **Discussion and conclusion**

Aims and objectives

This meeting aims to provide an update on the recent developments in the field of female urology. Well-known experts in this subspecialty of urology will cover some of the hottest and most controversial issues related to pelvic floor imaging, surgery for stress urinary incontinence, painful bladder syndrome and overactive bladder. Live interactive discussion will be promoted.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Oncological Urology (ESOU) and the meeting of the European Organisation for Research and Treatment of Cancer Genito-Urinary Group (EORTC GU-Group)

08:30 - 10:30

ESOU - Uro-oncological surgery: Tricks and techniques

eURO Auditorium Level 1

Chair: V. Ravery, Paris (FR)

08:30 - 09:15

Face-to-face on the OR - mini-invasive procedures: Organ-sparing treatment of kidney cancer. Technique and results

Chair: G.H.J. Mickisch, Bremen (DE)

Laparoscopic organ-sparing surgery (+ video)

F. Rozet, Paris (FR)

eURO-5-0000

RFA/Cryosurgery (+video)

P. Whelan, Leeds (GB)

eURO-5-0010

09:15 - 09:45

State-of-the-art and clinical cases

Chair: H. Van Poppel, Leuven (BE)

Penile cancer: Surgical strategy for lymph node dissection

O. Bouchot, Nantes (FR)

eURO-5-0020

09:45 - 10:30

Debate

Chair: A.R. Zlotta, Brussels (BE)

Should ASAP patients be submitted to radical treatment?

Pro: M. Brausi, Modena (IT)

eURO-5-0030

Con: P. Hammerer, Braunschweig (DE)

eURO-5-0040

Aims and objectives

The main goal of the ESOU meeting in Paris 2006, is to provide the audience with very practical points of surgical techniques in penile, renal and prostate cancers.

The first part of the meeting will be dedicated to an update on the strategy for lymph node dissection in penile cancer. Then, minimally invasive techniques for kidney cancers will be discussed by two debaters, defender of laparoscopy or RFA/cryosurgery.

Finally, the relevance of radical prostatectomy for ASAP patients will be debated during a pro and con session.

At the end of the meeting, the delegates attending should be able to apply in the OR the tricks and techniques which will be discussed and described during the meeting.

Chair: Z. Kirkali, Izmir (TR)

10:30 - 10:35	Welcome and introduction Z. Kirkali, Izmir (TR)	eURO-5-0050
10:35 - 10:55	Superficial bladder cancer W. Oosterlinck, Ghent (BE)	eURO-5-0060
10:55 - 11:15	Advanced bladder cancer J. Bellmunt, Barcelona (ES)	eURO-5-0070
11:15 - 11:35	Renal cell cancer M. Aitchison, Glasgow (GB)	eURO-5-0080
11:35 - 11:55	Testis tumors R. De Wit, Rotterdam (NL)	eURO-5-0090
11:55 - 12:15	Prostate cancer T.M. De Reijke, Amsterdam (NL)	eURO-5-0100
12:15 - 12:30	Conclusion Z. Kirkali, Izmir (TR)	eURO-5-0110

Aims and objectives

This 2 hour meeting of the EORTC GU Group is entitled "From clinical trials to patient care". Five experts will review superficial and advanced bladder cancer, prostate, testis and kidney cancer. Each presenter will give a 10-min. highlight of the latest developments and conclusions from the clinical trials conducted by the EORTC GU-Group in the light of the general urological oncologic knowledge. Presentations will be followed by clinical case discussions. At the end of this session the delegates attending will learn the results of the latest EORTC trials and will be able to incorporate this knowledge into their clinical patient care questions and to be part of the interactive discussions.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Andrological Urology (ESAU)

08:30 - 12:30

What's new in andrology? An old head on young shoulders

Room 353 Level 3

Chair: V. Mirone, Naples (IT)

08:30 - 09:40

Gender reassignment surgery

Chair: D. Ralph, London (GB)

08:30 - 08:45

Male to female transsexualism: State of the art

V. Mirone, Naples (IT)

353-5-0120

08:45 - 09:00

The corpus cavernosum tissue from male-to-female gender reassignment: A valuable pharmacological model

F. Fusco, Naples (IT)

353-5-0130

09:00 - 09:15

Female to male transsexualism: State of the art

C. Bettocchi, Bari (IT)

353-5-0140

09:15 - 09:30

Female-to-male transsexualism: What's new?

F. Palumbo, Bari (IT)

353-5-0150

09:30 - 09:40

Discussion

09:40 - 10:50

Andrological surgery

Chair: E.J.H. Meuleman, Amsterdam (NL)

09:40 - 09:55

Peyronie's disease: State of the art

W. Weidner, Giessen (DE)

353-5-0160

09:55 - 10:10

Basic data in Peyronie's disease

E.W. Hauck, Giessen (DE)

353-5-0170

10:10 - 10:25

Male infertility: State of the art

N. Sofikitis, Ioannina (GR)

353-5-0180

10:25 - 10:40

Experimental models of left varicocele in animals: What have we learned

A. Sylakos, Ioannina (GR)

353-5-0190

10:40 - 10:50

Discussion

10:50 - 11:20

ESSM Lecture: Endothelial function, the metabolic syndrome and erectile dysfunction

I. Eardley, Leeds (GB)

353-5-0200

11:20 - 12:30

Medical andrology

Chair: C. Stief, Munich (DE)

11:20 - 11:35

Late Onset Hypogonadism (LOH): State of the art

C.C. Schulman, Brussels (BE)

353-5-0210

11:35 - 11:50	The role of testosterone in PDE5-I non responders T. Roumeguere, Brussels (BE)	353-5-0220
11:50 - 12:05	Prostatic disease and sexuality: State of the art G.R. Dohle, Zoetermeer (NL)	353-5-0230
12:05 - 12:20	Sexual dysfunction after radical prostatectomy: Self-reported questionnaires and haemodynamic profiles Y. Dubbelman, Rotterdam (NL)	353-5-0240
12:20 - 12:30	Discussion	

Aims and objectives

Aims and objectives Three main sessions will focus on the andrological topics of gender reassignment surgery, surgical andrology and medical andrology. Each one of these will include four lectures. Our aim is to introduce an expert speaker to lecture on each topic, which will be followed by a lecture on basic research given by a young research assistant. We hope to deliver and communicate joint ideas and up-to-date information, given the worldwide experience of the lecturing experts. The session offers unprecedented scope to our young researchers and a chance for them to present their hard work to an international forum. This should produce a great effect in an interactive environment. We hope to make it a productive and valid session. Our main goal is to share and provide the quality science to which our society is dedicated to pursue.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Transplantation Urology (ESTU)

08:30 - 12:30

Controversies in immunosuppression and hot topics in renal transplantation

Room 343 Level 3

Chair: J. Burgos Revilla, Madrid (ES)

08:30 - 08:35

Welcome and introduction

J. Burgos Revilla, Madrid (ES)

343-5-0330

08:30 - 10:30

Immunosuppression and renal transplant

Chairs: A.B. Chkhotua, Tbilisi (GE)
A.J. De Castro Figueiredo, Coimbra (PT)

08:30 - 09:00

Immunosuppression in renal transplant: An update

A. Alcaraz, Barna Barcelona (ES)

343-5-0340

09:00 - 09:30

Calcineurin-sparing or steroid sparing immunosuppression in renal transplant

M. Giessing, Berlin (DE)

343-5-0350

09:30 - 10:00

Are surgical complications more common with modern immunosuppression?

G. Karam, Nantes (FR)

343-5-0360

10:00 - 10:30

Post-transplant cytokine responses in living and cadaveric donor renal allografts: Functional implications

E. Lledó Garcia, Madrid (ES)

343-5-0370

Discussion

10:30 - 12:30

Hot topics in clinical transplant

Chairs: R. Vela Navarrete, Madrid (ES)
G. Nicita, Florence (IT)

10:30 - 11:00

Cardiovascular disease after renal transplantation. Current controversies

R. Marcen, Madrid (ES)

343-5-0380

11:00 - 11:30

Management of prostate and bladder cancer after renal transplant

P. Ditonno, Bari (IT)

343-5-0390

11:30 - 12:00

Guidelines for renal transplant in patients with a prior history of neoplasia

K. Dreikorn, Bremen (DE)

343-5-0400

12:00 - 12:30

Transferred pathology associated with renal transplant: Medical, ethical and legal problems

Y. Neuzillet, Marseille (FR)

343-5-0410

Discussion and conclusion

343-5-0415

Aims and objectives

The development of the new immunosuppressive drugs and advances in patient management have decreased acute rejection and improved early graft survival after kidney transplantation. However, the use of these new agents commonly results in the development of complications that present new challenges for the urologist involved in renal transplant. Higher incidences of wound complications and lymphoceles have been reported with the use of sirolimus and mycophenolate mofetil. Knowledge of the mechanisms of action of the different immunosuppressive regimens is beginning to be mandatory for urologists involved in kidney transplant programmes. Cardiovascular diseases, infections and malignancies are the main causes of mortality after renal transplant. However, the management of these situations in the transplant recipient is not clearly established. Finally, the risk of transference of infections and neoplasias from the donor to the recipient represents medical, legal and ethical dilemmas that frequently are a matter of controversy. The discussion of all these issues is the aim of this ESTU session.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Genito-Urinary Reconstructive Surgeons (ESGURS)

08:30 - 12:30

Reconstructive surgery of the pelvis

Room Blue Level 2

Chairs: E.A. Austoni, Milan (IT)
W. Stackl, Vienna (AT)

08:30 - 08:45	Pelvic floor reconstruction in females W. Artibani, Padua (IT)	blue-5-0420
08:50 - 09:05	Urethral hypermobility and anterior vaginal wall prolapse: Transobturator vesico-urethral suspension with different devices E.A. Austoni, Milan (IT)	blue-5-0430
09:10 - 09:25	Vesico-vaginal fistula repair A.R. Mundy, London (GB)	blue-5-0440
09:30 - 09:45	Reconstruction of neovagina S. Perovic, Belgrade (CS)	blue-5-0450
09:50 - 10:05	Laparoscopic mobilisation of neo-vagina to assist secondary ileal vaginoplasty in male-to-female transsexuals E. Belgrano, Trieste (IT) G. Liguori, Trieste (IT)	blue-5-0460 blue-5-0470
10:10 - 10:25	Recurrent bladder neck stenosis: Treatment options and results R. Ollianas, Buchholz (DE) M.M. Fisch, Hamburg (DE)	blue-5-0480 blue-5-0490
10:30 - 11:00	Break <i>Chairs:</i> J-P. Sarramon, Toulouse (FR) S.A. Loening, Berlin (DE)	
11:00 - 11:15	The role of laparoscopy for reconstructive surgery in the pelvis V. Pansadoro, Rome (IT)	blue-5-0500
11:20 - 11:35	Optimal results after orthotopic bladder substitution: Surgical precautions W. Månsson, Lund (SE)	blue-5-0510
11:40 - 12:05	Laparoscopic urinary diversion: What is feasible? S. Deger, Berlin (DE)	blue-5-0520
12:10 - 12:25	Laparoscopic cystectomy with uretero-ileal diversion X. Gamé, Toulouse (FR) R. Mallet, Toulouse (FR) J-P. Sarramon, Toulouse (FR) P. Rischmann, Toulouse (FR)	blue-5-0530 blue-5-0540 blue-5-0550 blue-5-0560

Aims and objectives

Reconstruction of the inner female genitalia is one aspect of pelvic surgery. Beside pelvic floor reconstruction, vesico-vaginal fistula repair as well as surgical techniques for creation of a neovagina will be discussed. The treatment of recurrent bladder neck stenosis in males, who have had endoscopic intervention for benign prostatic disease, remains a challenge. Options and postoperative results will be presented. The second part of the meeting focuses on the role of laparoscopy during reconstructive pelvic surgery. What types of urinary diversion after laparoscopic cystectomy are feasible? What are the results that can be obtained and the complications to be expected compared to open surgery?

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Infection in Urology (ESIU)

08:30 - 12:30

Difficult infections in urology

Room Havana Level 3

Chair: K.G. Naber, Straubing (DE)

08:30 - 08:35	Welcome and introduction K.G. Naber, Straubing (DE)	hava-5-0580
08:35 - 10:20	Neurogenic bladder and urinary tract infection (UTI) <i>Chairs:</i> T.E. Bjerklund Johansen, Porsgrunn (NO) M.C. Bishop, Nottingham (GB)	
08:35 - 08:50	UTI in patients with neurological bladder (overview) C. Hultling, Stockholm (SE)	hava-5-0590
08:50 - 09:00	Discussion	
09:00 - 09:15	Bladder drainage by means of intermittent catheterisation T.E. Bjerklund Johansen, Porsgrunn (NO)	hava-5-0600
09:15 - 09:20	Discussion	
09:20 - 09:35	When to use antibiotic therapy in neurogenic bladder? P. Denys, Garches (FR)	hava-5-0610
09:35 - 09:40	Discussion	
09:40 - 09:55	How to prevent recurrent UTI in neurogenic bladder? M. Stöhrer, Murnau (DE)	hava-5-0620
09:55 - 10:00	Discussion	
10:00 - 10:15	Is cranberry an alternative for prevention in UTI? H. Botto, Suresnes (FR)	hava-5-0630
10:15 - 10:20	Discussion	
10:20 - 10:40	Break	
10:40 - 12:30	Chronic prostatitis/chronic pelvic pain syndrome <i>Chairs:</i> B. Lobel, Rennes (FR) M. Grabe, Malmö (SE)	
10:40 - 10:55	Chronic bacterial prostatitis: A European treatment study K.G. Naber, Straubing (DE)	hava-5-0640

10:55 - 11:00	Discussion	
11:00 - 11:20	From prostatitis to prostate cancer: The morphological view F. Algaba, Barcelona (ES)	hava-5-0650
11:20 - 11:25	Discussion	
11:25 - 11:45	Chronic bacterial prostatitis: Setting the stage for prostatic neoplasia J. Elkahwaji, Madison (US)	hava-5-0660
11:45 - 11:50	Discussion	
11:50 - 12:10	Role of proteomics in prostatitis to cancer G.P.H. Hemstreet, Omaha, Nebraska (US)	hava-5-0670
12:10 - 12:15	Discussion	
12:15 - 12:30	Poster discussion	

Aims and objectives

The section meeting of ESIU will mainly deal with two difficult problems in urology: 1) Urinary tract infections (UTI) in patients with neurogenic bladder disturbances. 2) Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urologists treating UTI in patients with neurogenic bladder should be aware of the peculiarities at all levels: diagnostic parameters, epidemiology, when to treat with what antimicrobials and how to deal with the deteriorated bladder function. CP/CPPS is still an enigma concerning treatment but may also play a role in the development of prostate cancer. Therapeutic, histomorphological and experimental aspects will be discussed in this respect.

Wednesday, 5 April - EAU Section Meetings

Meeting of the eUrolithiasis Society (EULIS)

08:30 - 12:30

Difficult cases of urolithiasis: Medical and surgical solutions

Room Concorde 3 Level 4

Chair: P.N. Rao, Manchester (GB)

- 08:30 - 08:40 **Welcome and introduction**
P.N. Rao, Manchester (GB) con3-5-0720
- 08:40 - 10:00 **Medical solutions**
Chair: H-G. Tiselius, Stockholm (SE)
- 08:40 - 08:55 **Does crystalluria cause recurrent renal colic?**
A. Trinchieri, Saronno (VA) (IT) con3-5-0730
- 08:55 - 09:10 **Who is a recurrent and problematic stoneformer?**
K. Sarica, Gaziantep (TR) con3-5-0740
- 09:10 - 09:25 **Do metabolic investigations help?**
B. Hess, Zurich (CH) con3-5-0750
- 09:25 - 09:40 **Novel medical solutions**
H-G. Tiselius, Stockholm (SE) con3-5-0760
- 09:40 - 10:00 **Discussion**
- 10:00 - 11:20 **Surgical solutions**
Chair: P. Alken, Mannheim (DE)
- 10:00 - 10:10 **The limits of ESWL and endoscopic surgery**
F. Keeley, Bristol (GB) con3-5-0770
- 10:10 - 10:20 **Partial and/or total nephrectomy - when and in whom?**
W.L. Strohmaier, Coburg (DE) con3-5-0780
- 10:20 - 10:30 **Ileal replacement of ureter and renal auto-transplantation - when and in whom?**
P. Alken, Mannheim (DE) con3-5-0790
- 10:30 - 10:40 **Chronic renal pain in stoneformers - what is it?**
B. Hess, Zurich (CH) con3-5-0800
- 10:40 - 10:50 **Renal sympathectomy - has it got a role?**
P.N. Rao, Manchester (GB) con3-5-0810
- 10:50 - 11:20 **Discussion**
M. Daudon, Paris (FR) con3-5-0820
L.J.G. Grenabo, Göteborg (SE) con3-5-0830
- 11:20 - 12:20 **Scientific poster session (selected best papers presented at the eULIS Congress in Coburg, Germany, 2005)**
Chair: W.L. Strohmaier, Coburg (DE)

The influence of variations of calcium and oxalate concentrations on stone growth in vitro N.K. Saw, Wrexham (GB)	con3-5-0840
Stabilisation of calcium oxalate suspension by urinary macromolecules, probably an efficient protection from stone formation J. Baumann, Biel (CH)	con3-5-0850
Do antioxidants protect against renal injury in patients receiving lithotripsy for renal calculi? K. Al-Awadi, Rawda (KW)	con3-5-0860
Extending the application of tubeless percutaneous nephrolithotomy A. Beri, Holon (IL)	con3-5-0870
Role of mutations in the sodium dicarboxylate cotransporter-1 in the etiology of hypocitraturia in calcium-oxalate stone disease S. Lahme, Pforzheim (DE)	con3-5-0880
A new knock-out cell culture model for investigation of cystinuria T. Knoll, Mannheim (DE)	con3-5-0890
Are the new generation biphosphonates effective for inhibition of calcium oxalate urolithiasis? A rat model N. Atsu, Istanbul (TR)	con3-5-0900

12:20 - 12:30

Conclusion

Aims and objectives

The management of most stones is straightforward. As in all clinical situations, difficult problems appear from time to time. What can an urologist offer to such a patient? Sometimes, the solution is medical and sometimes it is surgical. The aim of the meeting is to highlight some not-so-commonly known presentations of urolithiasis and medical and surgical solutions for these problems.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Neurourology (ESNU)

08:30 - 12:30

Introducing the second European masterclass on Botulinum toxin for the overactive bladder

Room 242 Level 2

Chairs: C.J. Fowler, London (GB)
P. Dasgupta, London (GB)

08:30 - 09:00 **Business meeting**

09:00 - 09:20 **Botulinum toxin for adult OAB: The 'magnificent 7' first years**
B. Schürch, Zurich (CH) 242-5-0910

09:20 - 09:40 **Botulinum toxin for adult OAB: The 'bad and the ugly' cases**
P. Radziszewski, Warsaw (PL) 242-5-0920

09:40 - 10:00 **'La cite des enfants perdus': Botulinum toxin for children with neurogenic bladder**
H. Schulte-Baukloh, Berlin (DE) 242-5-0930

10:00 - 10:20 **Delivering Botulinum toxin to the bladder: Design your own technique!**
P. Dasgupta, London (GB) 242-5-0940

10:20 - 10:40 **Break**

10:40 - 11:00 **'Honey, I blew up the kids': Botulinum toxin makes the bladder more compliant**
E. Chartier-Kastler, Paris (FR) 242-5-0950

11:00 - 11:20 **'Innerspace': Electron microscopy views of the overactive detrusor**
A. Haferkamp, Heidelberg (DE) 242-5-0960

11:20 - 11:40 **'Love me tender': The 'sensational' urothelium flirts with Botulinum toxin**
A. Apostolidis, London (GB) 242-5-0970

11:40 - 12:00 **'The colour of money': A cost-consequence model for Botulinum toxin**
V. Kalsi, London (GB) 242-5-0980

12:00 - 12:30 **Discussion and conclusion**
C.J. Fowler, London (GB) 242-5-0990

Aims and objectives

In the past 7 years, Botulinum neurotoxin type A (BoNT/A) has revolutionised the treatment of neurogenic or non-neurogenic LUTS resistant to first line treatments. Worldwide reports of BoNT/A injected into the wall of the overactive bladder (OAB) confirm its exceptional efficacy in improving urgency, frequency and urgency incontinence as well as urodynamic parameters. However, its mode of action in the human bladder is largely unknown and studies are needed to explore whether its effects on detrusor function are the result of modulation of afferent pathways. With a mean duration of action of up to 11 months and reproducibility of its clinical effect in repeat treatments, the challenge for established second line treatments of the OAB is becoming apparent. BoNT/A, however, remains an unlicensed treatment in the OAB and comparative studies with established treatments are needed to examine its cost-effectiveness and its potential integration in the therapeutics of patients with OAB.

This workshop aims to provide a review of the current knowledge on the use of BoNT/A in the OAB, looking at clinical efficacy and safety, mechanism of action, as well as issues related to its application in clinical practice, such as injection techniques and costings.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society for Urological Imaging (ESUI)

08:30 - 12:30

Innovative imaging in and around urology

Room 252 Level 2

Chairs: T. Loch, Flensburg (DE)
H. Strasser, Innsbruck (AT)

08:30 - 09:30	Business meeting	
09:30 - 09:45	Welcome and introduction T. Loch, Flensburg (DE)	252-5-1060
09:45 - 10:00	State of the art: Imaging in Europe: Who, where, what, how many? M. Colombel, Lyon (FR) P. Fornara, Halle/Saale (DE) M. Coelho, Lisbon (PT)	252-5-1070 252-5-1080 252-5-1090
10:00 - 10:15	ESUI guest lecture: Modern radiology: What is doable? G. Schneider, Homburg/Saar (DE)	252-5-1100
10:15 - 10:25	Intralaparoscopic ultrasound in urology C. Trombetta, Trieste (IT) G. Liguori, Trieste (IT)	252-5-1110 252-5-1120
10:25 - 10:35	Intraoperative ultrasound in the evaluation of tumor thrombus of the IVC (inferior vena cava) E. Belgrano, Trieste (IT) C. Trombetta, Trieste (IT)	252-5-1130 252-5-1140
10:35 - 10:45	The use of 3D Ultrasonography in complex kidney cysts M. Coelho, Lisbon (PT)	252-5-1150
10:45 - 11:00	Modern imaging of the prostate: Standards and future T. Loch, Flensburg (DE)	252-5-1160
11:00 - 11:15	4D-ultrasound of the infant bladder - virtual cystoscopy? C. Schwentner, Innsbruck (AT)	252-5-1170
11:15 - 11:30	Ultrasound guided transurethral application of stem cells in treatment of incontinence H. Strasser, Innsbruck (AT)	252-5-1180
11:30 - 11:45	Contrast specific imaging of the prostate and the kidney H. Wijkstra, Amsterdam (NL)	252-5-1190
11:45 - 12:00	PET in urology: Useful tool or waste of money? S. Machtens, Hanover (DE)	252-5-1200
12:00 - 12:15	Sono-elastography of the testis and prostate L. Pallwein, Innsbruck (AT)	252-5-1210

12:15 - 12:30

Discussion and conclusion

H. Wijkstra, Amsterdam (NL)

252-5-1220

T. Loch, Flensburg (DE)

252-5-1230

H. Strasser, Innsbruck (AT)

252-5-1240

Aims and objectives

The role of imaging in urology varies from country to country. In some countries, imaging (even conventional X-ray or fluoroscopy) is considered to be routine work in day-to-day practice. In other countries, on the other hand, all imaging is done by the radiologist. However, due partly to the common use of ultrasound, it seems quite natural that the urologist should utilise imaging modalities in order to evaluate urological organs. Modern imaging technologies, especially 3D- and even 4D-reconstruction, give magnificent anatomical perspectives, which can be displayed and stored digitally in order to evaluate them with or without the patient being present. Increasingly, we are in contact with other specialties to perform more complex imaging. It seems very important to communicate with each other and other fields and to investigate the perspectives of innovative imaging techniques in and around urology. In the name of the ESUI, we want to create or extend your interests in the field of imaging and hope that you will benefit from the experience of the presenters. Furthermore, it seems important that different countries exchange their experiences and discuss the advantages and disadvantages of the different systems. I want to cordially invite you to visit the annual meeting of our society at the EAU and the many special courses offered by the presenters in their field of excellence.

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society for Urological Research (ESUR)

08:30 - 12:30

'...omics in urological disease'

Room 351 Level 3

Chair: G.N. Thalmann, Berne (CH)

08:30 - 08:35 **Welcome and introduction**

08:35 - 08:55 **Why is translational research important in urology?**

J.A. Schalken, Nijmegen (NL)

351-5-1000

08:55 - 09:20 **Genomics in urological research**

T. Visakorpi, Tampere (FI)

351-5-1010

09:20 - 09:45 **Proteomics in urological research I**

U.H. Stenman, Helsinki (FI)

351-5-1020

09:45 - 10:00 **Break**

10:00 - 10:25 **Proteomics in urological research II**

R. Banks, Leeds (GB)

351-5-1030

10:25 - 10:50 **Pharmacogenomics in urological research**

J. Reichardt, Camperdown (AU)

351-5-1040

10:50 - 11:15 **Bio-informatics**

O. Poch, Illkirch Strasbourg (FR)

351-5-1050

11:15 - 11:45 **Discussion**

11:45 - 12:30 **Business meeting**

Aims and objectives

In recent years we have been increasingly confronted with new technologies that are termed "...omics" such as genomics and proteomics. Do these technologies concern us as urologists? What do they tell us? When are they used? In this symposium, very distinguished speakers and experts in the field will discuss the concept of translational research. They will introduce the interested urologist to the concepts, techniques, principles and limitations of these novel technologies in a comprehensive manner. In addition, the problem of how to analyse this large amount of data will be addressed. A round table discussion will enable interactive discussion of these technologies and whether and how they will find their way into clinical practice. This symposium is for all those who are interested in new developments or those just wanting to learn more about "...omics".

Meeting of the European Society for Uro-Pathology (ESUP)

08:30 - 12:30

Morphological changes in prostate tissue following the various forms of treatment

Room 341 Level 3

Chair: *Liliane Boccon-Gibod, Paris (FR)*

08:30 - 09:10	Changes following 5-alpha-reductase treatment Liliane Boccon-Gibod, Paris (FR)	341-5-1250
09:10 - 09:50	Changes induced by cryotherapy R. Montironi, Ancona (IT)	341-5-1260
09:50 - 10:30	Changes induced by androgen blockade A. Lopez-Beltran, Cordoba (ES)	341-5-1270
10:30 - 11:10	Changes induced by radiation therapy F. Algaba, Barcelona (ES)	341-5-1280
11:10 - 11:50	Neo adjuvant hormone therapy before radical prostatectomy, pitfalls in specimen evaluation L. Egevad, Stockholm (SE)	341-5-1290
11:50 - 12:30	Effects of hormonal therapies on surgical margin status G. Mikuz, Innsbruck (AT)	341-5-1300

Wednesday, 5 April - EAU Section Meetings

Meeting of the European Society of Uro-Technology (ESUT)

08:30 - 13:45

What's new in uro-technology?

Room Bordeaux Level 3

Chairs: A.D. Joyce, Leeds (GB)
G.J. Alivizatos, Athens (GR)

08:30 - 08:35	Welcome and introduction J.J.M.C.H. De La Rosette, Amsterdam (NL)	bord-5-1310
08:35 - 09:00	What's new in endourology? D.A. Tolley, Edinburgh (GB)	bord-5-1320
09:00 - 09:30	PDD - live surgery R. Muschter, Rotenburg (DE)	bord-5-1330
09:30 - 10:00	Flexible URS - live surgery R.C. Swartz, Örebro (SE)	bord-5-1340
10:00 - 10:30	Bipolar TURP - live surgery J. Rassweiler, Heilbronn (DE)	bord-5-1350
	<i>Chairs:</i> G. Breda, Bassano Del Grappa (IT) R.F. Van Velthoven, Brussels (BE)	
10:30 - 11:00	What's new in laparoscopy? G. Janetschek, Linz (AT)	bord-5-1360
11:00 - 12:30	Laparoscopic cystectomy - live surgery C.C. Abbou, Creteil (FR)	bord-5-1370
12:30 - 13:00	Training in laparoscopy I.S. Gill, Cleveland (US)	bord-5-1380
13:00 - 13:30	What's new in urologic imaging? J.J.M.C.H. De La Rosette, Amsterdam (NL)	bord-5-1390
13:30 - 13:45	Conclusion J.J.M.C.H. De La Rosette, Amsterdam (NL)	bord-5-1400

Aims and objectives

In the section meeting of the ESUT, we intend to present and demonstrate "What's new in urotechnology?" Special attention will be given to recent achievements in the field of endourology and laparoscopy. LIVEsurgery will include improvements in diagnostics (photodynamics diagnostics), stone management (flexible ureteroscopy) and electrosurgery (bipolar transurethral resection of the prostate). The LIVE surgery demonstrations will conclude with a cystectomy. In addition, two presentations will address training in laparoscopy and recent advances in urological imaging. Attending delegates will receive a full update on recent advances in urotechnology enabling them to judge the value of these technologies.



ESRU Meeting

12:30 - 18:00

13th Meeting of the European Society of Residents in Urology (ESRU)

Room 342a/b Level 3

Chairs: M.S. Keskin, Ankara (TR)
L. Martínez-Piñero, Madrid (ES)

12:30 - 13:00	Lunch	
13:00 - 13:10	Welcome and introduction	
13:10 - 13:35	State-of-the-art lecture Essentials of paediatric urology J.M. Nijman, Groningen (NL)	342-5-1570
13:35 - 14:00	State-of-the-art lecture Ureterorenoscopy: Techniques, indications and results O. Traxer, Paris (FR)	342-5-1580
14:00 - 14:25	State-of-the-art lecture Learning laparoscopy C.C. Abbou, Creteil (FR)	342-5-1590
14:25 - 15:00	Campbell's challenge An interactive quiz, testing the European residents on their urological knowledge: the winner will receive the urological bible: the new Campbell's Urology <i>Chair:</i> M.S. Keskin, Ankara (TR)	
15:00 - 15:20	EAU Guidelines, their use in daily clinical practice <i>Chair:</i> K.F. Parsons, Liverpool (GB) <i>Speakers:</i> T. Hanus, Prague (CZ) D.N. Mitropoulos, Athens (GR)	342-5-1600 342-5-1610
15:20 - 15:45	Break	
15:45 - 16:45	Nightmare session A presentation of clinical problems that have startled and perplexed residents all over Europe <i>Chair:</i> A.R. Mundy, London (GB) <i>Panel:</i> H.C. Klingler, Vienna (AT) L. Martínez-Piñero, Madrid (ES) I.C. Sinescu, Bucharest (RO)	342-5-1620 342-5-1630 342-5-1640
16:45 - 17:00	Prize and conclusion M.S. Keskin, Ankara (TR)	342-5-1650
17:00 - 18:00	Drinks reception	



Wednesday, 5 April

EAUN Programme

12:30 - 18:00

7th International Meeting of the European Association of Urology Nurses (EAUN)

12:30 - 16:00

Workshop Presentations in English: Reading and comprehension

Speaker: A. Hagan, Coleraine (UK)

Room Passy Level 1

pass-5-5010

17:00 - 18:00

EAUN Opening Ceremony

Guest speaker: J. Mattelaer, Kortrijk (BE)

Room Passy Level 1

pass-5-5010

18:15 - 19:30

EAU Congress Opening Ceremony

eURO Auditorium Level 1

19:30 - 21:00

EAU Congress Welcome Cocktail

Exhibition Area Level 1

Thursday, 6 April – EAUN Programme

08:30 – 10:00 Breakfast symposium Intermittent catheterisation

Room 243 Level 2

Chair: *J.T. Marley, Belfast (IE)*

Welcome and introduction

J.T. Marley, Belfast (IE)

243-6-5150

State of the art

M. Beynon (Coloplast GB)

243-6-5160

Best practice – adult

T. Schwennesen, Skejby (DK)

243-6-5170

Introduction to case studies

J. T. Marley, Belfast (IE)

243-6-5180

M. Beynon (Coloplast GB)

243-6-5190

Group discussions

243-6-5200

Plenum discussion

M. Beynon (Coloplast GB)

243-6-5210

Questions

Closing

Aims and objectives

This state of the art symposium will address the implications of intermittent catheterization on the neurogenic and non-neurogenic bladder. Key areas of focus will be, indications, best practice and future challenges. The symposium will be a combination of short presentations, small group workshops / discussions and questions and answers.

Sponsored by COLOPLAST A/S

10:30 – 12:00 ESU Course **Anatomy and pathophysiology of the urinary tract – Part 1**

Room Passy Level 1

Chair: *P. Rischmann, Toulouse (FR)*

Introduction and anatomy of the upper urinary tract

P. Rischmann, Toulouse (FR)

pass-6-5020

Adrenal gland: physiology and main disorders

F. Mantero, Padua (IT)

pass-6-5030

Mechanisms of kidney function and failure

D. Chauveau, Toulouse (FR)

pass-6-5040

12:00 – 13:00 **Break**

Simultaneous translation from English to French will be provided

13:00 - 14:30 ESU Course Anatomy and physiopathology of the urinary tract - Part 2

Room Passy Level 1

Chair: P. Rischmann, Toulouse (FR)

Pyelonephritis: Mechanisms and consequences

B. Lobel, Rennes (FR)

pass-6-5050

Obstruction of the upper urinary tract: Causes and main treatments

P. Van Cangh, Brussels (BE)

pass-6-5060

Videos and discussion

pass-6-5070

14:30 - 15:00 Break

15:00 - 16:30 Abstract session I

Room Passy Level 1

Chairs: K. Jensen, Zürich (CH)

J.T. Marley, Belfast (IE)

P1 Nurses as key figures in clinical trials

S. Skou (Aarhus, Denmark)

P2 Information pass for female patients with a continent catheterisable pouch

K. Ochsner, R. Willener, F.C. Burkhard (Berne, Switzerland)

P3 Validation of the Overactive Bladder Family Impact Measure (OAB-FIM)

K.S. Coyne, L. Matza, J. Brewster-Jordan, E. Goldfischer (New Albany, OH, United States of America)

P4 Identifying own practice with telephone nursing

B. Thoft (Aarhus, Denmark)

01 A way how to put evidence into clinical practice on a urology ward

R. Willener, V. Hantikainen (Berne, Switzerland)

pass-6-5080

02 The urological patient at the nurse reception

E. Bonns (Korsholm, Finland)

pass-6-5090

03 Is it reasonable for a man in acute urinary retention to be catheterised and immediately discharged for nurse-led care in the community?

J. Lee, J. Green, P. Rouse (London, United Kingdom)

pass-6-5100

04 Assessment of sexual dysfunction in women with urinary incontinence

C. Dondar, U. Boylu, H. Aslan, S. Silay, C. Miroglu (Istanbul, Turkey)

pass-6-5110

05 Macroscopic hematuria - an accurate and reliable tool in data collecting and documentation? an inter-disciplinary project.

L. Breindahl Kristensen, A-M. Skovsgaard (Aarhus, Denmark)

pass-6-5120

06 Stress urinary incontinence treatment using synthetic tape. About 60 cases.

A. Bouzouita, M. Sfaxi, M. Cherif, M.R. Ben Slama, M. Hajri, L. Ben Hassine, M. Chebil, M. Ayed (Tunis, Tunisia)

pass-6-5130

Thursday, 6 April – EAUN Programme

16:30 – 18:00 **Workshop Blocked catheters**

Speaker: M. Lauritzen, Stockholm (SE)

Room Passy Level 1

pass-6-5140

16:30 – 18:00 **State-of-the-art lecture Suprapubic catheterisation**

Speaker: O. Ziylan, Istanbul (TR)

Room 243 Level 2

243-6-5220

20.00 – 01.00 **Nurses Dance Evening**

For more information see page 25

Simultaneous translation from English to French will be provided

Friday, 7 April

08:30 - 09:30 **Finding information on the internet and PubMed**

Speaker: J. Marley, Belfast (IE)

Room Passy Level 1

pass-7-5230

09:30 - 10:00 **Break**

10:00 - 11:00 **Workshop Writing for publication**

Speaker: R. Priestley (Blackwell Publishing GB)

Room 243 Level 2

243-7-5350

10:00 - 11:00 **Uro stomas Post indications and technique**

Speaker: C. Simeone, Brescia (IT)

Room Passy Level 1

pass-7-5240

11:00 - 11:30 **Uro stomas Post operative care**

Speaker: R. Pieters, Ghent (BE)

Room Passy Level 1

pass-7-5250

11:30 - 12:00 **Uro stomas Stoma care and patient education**

Speaker: F. Degarat, Lyon (FR)

Room Passy Level 1

pass-7-5260

12:00 - 13:00 **Lunch**

13:00 - 14:00 **Uro stomas Complications**

Speaker: L. Van Vooren, Ghent (BE)

Room Passy Level 1

pass-7-5270

14:30 - 15:00 **Break**

13:00 - 13:45 **State-of-the-art lecture Cystoscopy**

Speaker: A. Gross, Gladbach (DE)

Room 243 Level 2

243-7-5360

13:45 - 14:35 **State-of-the-art lecture Stone management**

Speaker: F. Gaudez, Courbevoie (FR)

Room 243 Level 2

243-7-5370

Simultaneous translation from English to French will be provided

Friday, 7 April – EAUN Programme

15:00 - 15:15 **Presentation of BAUN Journal**

Room Passy Level 1

[pass-7-5280](#)

Speaker: J.T. Marley, Belfast (IE)

15:15 - 16:45 **Abstract session II**

Room Passy Level 1

Chairs: K. Jensen, Zürich (CH)
J.T. Marley, Belfast (IE)

P5 PVP -photoselective vaporisation of the prostate

M. Middtun, M. Bindslev (Herlev, Denmark)

P6 Standardized documentation of Zometa® therapy and nursing care at an urology outpatient clinic

U. Ramseier, R. Willener (Berne, Switzerland)

P7 The artificial urinary sphincter. An overview about the system and a view on nurses' responsibilities

S. Hieronymi, U. Witzsch (Oberursel, Frankfurt, Germany)

P8 Oral oxycodone hydrochloride vs epidural anaesthesia for pain control after radical retropubic prostatectomy

L. Hohwü, O. Akre, B. Lennart, M. Törnblom, O. Gustafsson (Stockholm, Sweden)

P9 Individual quality of life following radical prostatectomy in men with prostate cancer

A. Ghabeli Juibary (Babol, Iran)

07 Prostate biopsy techniques and results. About 350 cases

M. Sfaxi, A. Bouzouita, M.R. Ben Slama, M. Blah, L. Ben Hassine, M. Hajri, M. Chebil, M. Ayed, K. Hamza (Tunis, Tunisia)

[pass-7-5290](#)

08 Transurethral ethanol ablation of prostate (TEAP): An alternative treatment option for patients with BPH

K. Wilkinson, N. Buchholz, N. Bafaloukas, C. Cannaby (London, United Kingdom)

[pass-7-5300](#)

09 Nursing information for prostate cancer patients and its relationship on patients' health related quality of life

L. Kuivalainen (Joensuu, Finland)

[pass-7-5310](#)

010 Tips and tricks in robotic urology - lessons learned in the past three years

M. Nightingale, P. Seagers, S. O'Neil (London, United Kingdom)

[pass-7-5320](#)

011 Percutaneous cystolithotripsy using video-monitoring cystoscope

M.R. Razaghi, A. Tabibi, B. Abadpoor, A. Kavyani, A. Moradi, H. Karami (Tehran, Iran)

[pass-7-5330](#)

17:15 - 18:00 **EAUN General Assembly and Awards**

[pass-7-5340](#)

Room 243 Level 2

Chair: A. Grundal, Aarhus (DK)

Sponsored by HOLLISTER EUROPE Ltd.

EAU Membership

What are your benefits of being a member of the European Association of Urology?

As a member of the EAU you will have many advantages which include the membership fees:

- **Publications**

- European Urology, the official scientific journal of the EAU (12 issues per year, plus all published supplements).
- European Urology Today, the official newsletter of the EAU (5 issues each year). This publication aims at distributing information about the Association and about European urology in the broadest sense.
- European Urology Video Journal, an annually published DVD aiming to distribute the best information on urological diseases and techniques.
- The EAU Urology Updates, a quarterly published educational publication, published as a supplement of European urology.
- EAU Guidelines, an extensive series of guidelines on many urological diseases produced by the EAU Health Care Office.
- Historia Urologiae Europaeae (one volume each year on European historical subjects).
- Uroweb, the official EAU website, to which you as a member have access to all different activities and programmes on the web, such as slide library, European Urology on-line, webcasts of the congress, on-line ESU courses etc.

- **EAU Congress and Meetings**

As an EAU member you will receive regular information on the annual EAU Congress, as well as the (Fall) meetings organised by the different EAU Sections.

Moreover, as a member you will be able to receive a considerable discount on the registration fees in all these events.

- **EAU Education Programme**

Being an EAU member you will receive regular information on all the activities organised by the European School of Urology, the EAU Office of Education. You will be able to participate in the post-graduate teaching activities at reduced registration fees. As an EAU member you are also entitled to apply for the European Urological Scholarship Programme, which provides grants and organises clinical fellowships, short term visits and scholarship programmes.

- **EU-ACME**

Being an EAU Active member you will be automatically participating in the European Urology - Accredited Continuing Medical Education (EU-ACME) Programme. The EU-ACME Programme is based on the EBU/UEMS rules and its primary task is the implementation, promotion and organization of Continual Medical Education (CME) among European Urologists. It provides the urologists with the system which helps them to keep track of their educational activities, irrespective of the country they practice in or where they have participated in CME and / or CPD activities.

So if you are not yet an EAU member, make certain to become one in Paris and visit the EAU booth PA27 on level 1.

EAU Offices

EAU Board

Executive Committee

Secretary General

P. Teillac, Paris (FR)

Adjunct Secretary General

Executive Member related to science

P-A. Abrahamsson, Malmö (SE)

Adjunct Secretary General

Executive Member related to education

C. Chapple, Sheffield (GB)

Treasurer and Executive Member related to Communication

M. Wirth, Dresden (DE)

Board Members

C. Abbou, Creteil (FR)

P. Abrams, Bristol (GB)

W. Artibani, Padua (IT)

G. Aus, Göteborg (SE)

T. Esen, Istanbul (TR)

F. Hamdy, Sheffield (GB)

D. Jacqmin, Strasbourg (FR)

U. Jonas, Hanover (DE)

H. Madersbacher, Innsbruck (AT)

M. Marberger, Vienna (AT)

L. Martínez Piñeiro, Madrid (ES)

H. Van Der Poel, Amsterdam (NL)

H. Van Poppel, Leuven (BE)

D. Schultheiss, Giessen (DE)

I. Sinescu, Bucharest (RO)

C. Stief, Munich (DE)

A. Tubaro, Rome (IT)

Offices related to education

EAU Education Office (ESU)

Chairman

H. Van Poppel, Leuven (BE)

Members

A. Alcaraz, Barcelona (ES)

W. Aulitzky, Vienna (AT)

B. Djavan, Vienna (AT)

P. Hammerer, Braunschweig (DE)

Z. Kirkali, Izmir (TR)

G. Morgia, Sassari (IT)

R. Nijman, Groningen (NL)

D. Pushkar, Moscow (RU)

J. Rassweiler, Heilbronn (DE)

P. Rischmann, Toulouse (FR)

I. Romics, Budapest (HU)

European Urological Scholarship

Programme Office

Chairman

C. Abbou, Creteil (FR)

Members

J. Dvoraček, Prague (CZ)

G. Jakse, Aachen (DE)

R. Scarpa, Torino (IT)

M. Sedelaar, Nijmegen (NL)

N. Sofikitis, Athens (GR)

D. Tolley, Edinburgh (GB)

Guidelines Office

Chairman

G. Aus, Göteborg (SE)

Members

T. Hanus, Prague (CZ)

J. Irani, Poitiers (FR)

B. Lobel, Rennes (FR)

T. Loch, Flensburg (DE)

D. Mitropoulos, Athens (GR)

K. Parsons, Liverpool (GB)

H-P. Schmid, St. Gallen (CH)

EU-ACME Office

Chairman

H. Madersbacher, Innsbruck (AT)

Members

W. Artibani, Padua (IT)

T. De Reijke, Amsterdam (NL)

F. Hamdy, Sheffield (GB)

R. Nijman, Groningen (NL)

P. Teillac, Paris (FR)

H. Van Poppel, Leuven (BE)

Residents Office

Chairman

L. Martínez Piñeiro, Madrid (ES)

Members

M. Emberton, London (GB)

J. Heesakkers, Nijmegen (NL)

J. Manuel Bastos, Lisbon (PT)

J. Palou, Barcelona (ES)

J-J. Patard, Rennes (FR)

T. Prayer-Galetti, Padua (IT)

E. Serafetinides, Athens (GR)

O. Reich, München (DE)

Offices related to science

Scientific Office

Chairman

F. Hamdy, Sheffield (GB)

Members

G. Bogaert, Leuven (BE)

X. Cathelineau, Paris (FR)

F. Cruz, Porto (PT)

P. Dobronski, Warsaw (PL)

I. Eardley, Leeds (GB)

G. Janetschek, Linz (AT)

C. Llorente, Madrid (ES)

P. Mulders, Nijmegen (NL)

J-J. Rambeaud, Grenoble (FR)

J. Schalken, Nijmegen (NL)

C. Sellì, Pisa (IT)

A. Stenzl, Tübingen (DE)

G. Thalmann, Berne (CH)

A. Zlotta, Brussels (BE)

Ex-Officio Members

U. Jonas, Hanover (DE)

H. Van Poppel, Leuven (BE)

Representative Paris

L. Boccon-Gibod, Paris (FR)

Section Office

Chairman

U. Jonas, Hanover (DE)

Chairmen Sections

ESTU: J. Burgos Revilla, Madrid (ES)

ESFU: D. Castro Diaz, Santa Cruz de Tenerife (ES)

ESUT: J. De La Rosette, Amsterdam (NL)

ESNU: D. De Ridder, Leuven (BE)

ESPU: E. Jaurequizar, Madrid (ES)

EORTC: Z. Kirkali, Izmir (TR)

ESUR: G. Thalmann, Berne (CH)



ESIU: K. Naber, Straubing (DE)
EULIS: P. Rao, Manchester (GB)
ESOU: V. Ravery, Paris (FR)
ESAU: V. Mirone, Napels (IT)
ESGURS: M. Fisch, Hamburg (DE)
ESUI: T. Loch, Flensburg (DE)
ESUP: G. Mikuz, Innsbruck (AT)

Regional Office

Chairman

M. Marberger, Vienna (AT)

Research Office

Chairman

A. Tubaro, Rome (IT)

Members

F. Giuliano, Paris (FR)
J. Irani, Poitiers (FR)
K. Miller, Berlin (DE)
P-U. Malmstrom, Uppsala (SE)
G. Pappagallo, Noale (IT)
A. Patel, London (GB)
W. Witjes, Arnhem (NL)
A. Van Der Meijden,
's Hertogenbosch (NL)

Offices related to communication

Professions Allied to Urology Office

Chairman

T. Esen, Istanbul (TR)

Members

K. Bø, Bergen (NO)
F. Burkhard, Berne (CH)
J. Wardle, London (GB)

History Office

Chairman

D. Schultheiss, Hanover (DE)

Members

C. Alamanis, Athens (GR)
J. Elo, Helsinki (FI)
R. Engel, Baltimore (US)
L. Fariña, Vigo (ES)
J. Felderhof, The Hague (NL)
P. Figdor, Vienna (AT)
A. Jardin, Paris (FR)
P. Marandola, Pavia (IT)
J. Mattelaer, Kortrijk (BE)
R. Musitelli, Pavia (IT)
P. Rathert, Düren (DE)

I. Romics, Budapest (HU)
M. Skopec, Vienna (AT)
R. Sosnowski, Warsaw (PL)
A. Verit, San Liurfa (TR)

Publication Office

Chairman

C. Stief, Munich (DE)

Members

European Urology:
F. Montorsi, Milan (IT)
EAU-EBU Update Series:
F. Schröder, Rotterdam (NL)
European Urology Today:
M. Wirth, Dresden (DE)
Historical Publications:
D. Schultheiss, Giessen (DE)

Multimedia Office

Chairman

H. Van Der Poel, Amsterdam (NL)

Members

F. Gomez Sancha, Madrid (ES)
P. Laguna, Amsterdam (NL)
A. Salonia, Milan (IT)
Ex-officio Member
J. Van Moorselaar, Amsterdam (NL)

Video Committee

Chairman

J. Van Moorselaar, Amsterdam (NL)

Members

P. Albers, Kassel (DE)
A. Alcaraz, Barcelona (ES)
I. De Jong, Groningen (NL)
P. Geavlete, Bucharest (RO)
M. Zerbib, Paris (FR)

Offices related to the executive

Strategy Planning Office

Chairman

P. Abrams, Bristol (GB)

Members

M. Brausi, Modena (IT)
G. Carmignani, Genoa (IT)
S. Müller, Bonn (DE)
P. Radziszewski, Warsaw (PL)
J. Shah, London (GB)
J-J. Wyndaele, Antwerp (BE)

Regulatory Office

Chairman

W. Artibani, Padua (IT)

Members

F. Haab, Paris (FR)
D. Hatzichristou, Thessaloniki (GR)
E. Solsona, Valencia (ES)
U. Stolzenburg, Leipzig (DE)
P. Van Kerrebroeck, Maastricht (NL)

International Relations Office (IRO)

Chairman

D. Jacqmin, Strasbourg (FR)

Membership Office

Chairman

I. Sinescu, Bucharest (RO)

Financial Affairs

Chairman

M. Wirth, Dresden (DE)

Auditors

T. Sulser, Zurich (CH)
J-J. Wyndaele, Edegem (BE)

Academy of Urology

Chairman

A. Le Duc, Paris (FR)

Members

R. Ackermann, Düsseldorf (DE)
P. Ekman, Stockholm (SE)
B. Hendry, London (GB)
H-J. Leisinger, Lausanne (CH)
A. Mundy, London (GB)
F. Pagano, Padua (IT)
R. Vela-Navarrete, Madrid (ES)

European Urology – Accredited Continuing Medical Education

Continuing Medical Education

EU-ACME is an initiative resulting from a close collaboration between the European Association of Urology (EAU) and the Accreditation Committee of the European Board of Urology (EBU).

EU-ACME stands for European Urology – Accredited Continuing Medical Education. It is based on the EBU/UEMS rules and its primary task is the implementation, promotion and organization of Continual Medical Education (CME) among European Urologists. It provides urologists with the system which helps them to keep track of their educational activities, irrespective of the country they practice in or where they have participated in CME and/or CPD activities.

It is expected that national CME systems for specialists will become obligatory in European countries in the near future. Participation in the EU-ACME Programme will give certified European urologists the opportunity to start gathering the required points.

At the moment the following associations/countries participate in the EU-ACME Programme:

- EAU
- ESPU
- ICS
- Austria
- Greece
- Italy
- Poland
- Romania
- Spain
- Sweden
- The Netherlands
- Turkey

This means that participants of the EU-ACME Programme can gain credits for participation in all urological activities that are organised by the affiliated associations, for more information, please visit the website: <http://rtweb.rtol.it/ebu>

Accreditation of the 21st Annual EAU congress

Many countries within Europe have a national CME accreditation system. The EAU has requested all European National Urological Societies to give CME accreditation points for attending the EAU Congress. The number of credits granted to the congress by the different National Urological Associations is listed in the programme book. Information on national accreditation can be found as well by contacting the National Urological Associations.

The 21st Annual EAU Congress is accredited with 1 credit per hour with a maximum of 6 credits per day and a maximum of 18 credits for the whole meeting. ESU courses are granted 1.5 credits per hour, irrespective of the 18 credits for the whole congress.

Attendance control will take place at all entrances to sessions, symposia and courses by scanning of the congress badge. Credit points will automatically be attributed to members of the EU-ACME Programme.

Information about the EU-ACME programme, your acquired CME credit points and membership cards can be obtained at the EU-ACME corner at the EAU booth PA27 on level 1.

Continuing Medical Education Accreditation points national urological associations/ societies

The participants of the countries who already joined the EU-ACME programme will receive automatically credits following the rules of the EBU/UEMS system.

The 21st Annual EAU Congress is therefore accredited with 1 credit per hour, 6 credits per day with 18 credits for the whole meeting.

Countries participating in this Programme are: **Austria, Greece, Italy, Poland, Romania, Spain, Sweden, The Netherlands and Turkey** as well as the following international societies: **EAU, ESPU** and **ICS**.

Please find below the CME accreditation points given by other National Urological Societies for participation in the 21st Annual EAU Congress in Paris on 5-8 April 2006 which are given according to European or national regulations.

A Certificate of Attendance has been inserted in the congress bag.

Armenia		
Armenia Association of Urology	entire congress per day	20 points 5 points
Belgium		
Belgische Vereniging voor Urologie	entire congress	100 points
Germany		
Deutsche Gesellschaft für Urologie	entire congress	15 points
Portugal		
Portuguese Association of Urology	entire congress	18 points
Russia		
Federov Urological Society St. Petersburg	entire congress per day	40 points 10 points
Slovakia		
Slovakia Association of Urology	entire congress	18 points
Ukraine		
Ukrainian Urology Association	entire congress per day	10 points 5 points

(countries who responded to our inquire)

Historical Overview EAU Congresses

1974	12-14 September	Padua, Italy
1976	24-26 September	Prague, Czech Republic
1978	14-16 June	Monte Carlo, Monaco
1980	21-30 May	Athens, Greece
1982	12-15 May	Vienna, Austria
1984	23-26 May	Copenhagen, Denmark
1986	26-28 June	Budapest, Hungary
1988	18-21 May	London, Great Britain
1990	10-16 June	Amsterdam, The Netherlands
1992	22-25 July	Genoa, Italy
1994	13-16 July	Berlin, Germany
1996	1-4 September	Paris, France
1998	21-25 March	Barcelona, Spain
1999	7-10 April	Stockholm, Sweden
2000	12-15 April	Brussels, Belgium
2001	7-10 April	Geneva, Switzerland
2002	23-26 February	Birmingham, Great Britain
2003	12-15 March	Madrid, Spain
2004	24-27 March	Vienna, Austria
2005	16-19 March	Istanbul, Turkey

The EAU Digital Video Library is supported by
an unrestricted educational grant from ASTELLAS

Laparoscopic right radical and left partial nephrectomy for bilateral RCC

G. Janetschek, R. Peschel, D. Strohmayer, G. Bartsch (Innsbruck, Austria)

Water jet technology in renal surgery

R. Basting, N. Djakovic, P. Widmann (Altötting, Germany)

Nephron sparing surgery for multiple renal cell carcinoma in a solitary kidney

G. Nicita, M. Paoletti, D. Villari, E. Dattelo, V. Li Marzi, M. Marzocco (Florence, Italy)

Partial nephrectomy and subtotal pancreatectomy for renal adenocarcinoma lumbotomy approach for both procedures

O. Leiva, M. Martin, F. Villacampa, J. Duarte, A. Rodriguez, F. De la Rossa (Madrid, Spain)

Surgical approach in renal cell carcinoma with intravenous neoplastic extension

C. Stief, H. Schäfer, M. Kucyk, U. Jonas (Hannover, Germany)

Surgical management of renal cell carcinoma with intra-atrial extension: Combined cardiopulmonary bypass, hypospermia and temporary cardiac arrest

F. Martins, J. Freeman, J. Alves, J. Lencastre (Lisbon, Portugal)

Radical nephrocapsulectomy under ECC and deep hypothermic arrested circulation in RCC with thrombosis of the inferior v. cava or into the atrium. Surgical techniques and personal series

R. Bertini, M. Rsocigno, L. Da Pozzo, R. Colombo, P. Stefano, O. Alfieri, P. Rigatti (Milan, Italy)

New strategy and minimal access approach for cardiopulmonary bypass (CPB) in renal cell carcinoma (RCC) with suprahepatic caval thrombi

A. Sorcini, J.A. Libertino (Burlington, Massachusetts, United States of America)

Refinement in rectosigmoid vaginoplasty

S. Perovic, D. Stanojevic, M. Djordjevic (Belgrade, Yugoslavia)

Penile disassembly technique in epispadias repair: Our variant

S. Perovic, M. Djordjevic, N. Djakovic (Belgrade, Yugoslavia)

Percutaneous extraction of staghorn calculus

S. Zeren, Y. Bayazi, I. Aridogan, R. Turkyilmaz (Adana, Turkey)

Cold retrograde endoureterotomy

P. Geavlete, V. Mirciulescu, G. Nita, V. Cauni, D. Georgescu (Bucharest, Romania)

Endoscopic retrograde endopyelotomy in ureteropelvic junction obstruction

P. Geavlete, V. Mirciulescu, V. Cauni, G. Nita, D. Georgescu (Bucharest, Romania)

Uroplasty with free appendix mucosal graft

T. Leuret, P. Grise, J. Hervé, P. Mitrofanoff, H. Botto (Rouen, Suresnes, France)

Laparoscopic promontory sacral colposuspension

P. Antiphon, A. Hoznek, L. Salomon, D. Chopin, C. Abbou (Créteil, France)

Full-length buccal mucosa dorsal onlay graft for balanitis xerotica obliterans

S. Kulkarni, J. Kulkarni, D. Kiperkar (Pune, India; Ashford-Middlesex, United Kingdom)

Urethroplasty with free graft of buccal mucosa

A. Mendes Leal, T. Aires (Povoia, Portugal)

Gastrocystoplasty

J. Dvoracek, R. Kocvara, Z. Dite (Prague, Czech Republic)

Cytocele repair using a marlex graft

G. Martorana, E. Brunocilla, S. Concetti, L. Bisceglie, G. Vignoli (Bologna, Italy)

Female cystectomy with orthotopic ileal afferent limb reconstruction

R. Mills, U. Studer (Bern, Austria)

'Y' neobladder: Preliminary results

D. Fontana, M. Bellina, C. Scoffone, M. Poggio, S. Guercio (Torino, Italy)

Duplex Doppler Ultrasound evaluation in single-system ureteroceles

P. Geavlete, D. Georgescu, G. Nita (Bucharest, Romania)

Nephro-ureterectomy performed by transurethral excision of a bladder cuff and retroperitoneal laparoscopy

J. Rozenman, J. Shental, D. Almog, G. Chaimovitch (Afula, Israel)

Percutaneous nephrolithotomy of transplanted kidney

F. Francesca, R. Felipetto, F. Mosca, U. Boggi, G. Rizzo, R. Puccini (Pisa, Italy)

Inlay-onlay flap urethroplasty in the absence of the urethral plate

R. Kocvara, J. Dvoracek (Prague, Czech Republic)

Inverted 'Y' incision-variant of transurethral incision of the prostate

P. Geavlete (Bucharest, Romania)

Volume 8, NUMBER 2

OCTOBER 2001

01 EAU 25

First Prize EAU 2001 Geneva**Simultaneous flap vaginoplasty and introitoplasty in urogenital sinus malformation**

L. Martínez-Piñeiro, J. García-Mediero, P. Cárcamo, M. Gacía-Matres, J. De la Peña (Madrid, Spain)

Second Prize EAU 2001 Geneva**Laparoscopic retroperitoneal lymphnode dissection for testicular cancer**

R. Peschel, G. Janetschek, D. Strohmeier, G. Bartsch, A. Hobisch (Innsbruck, Austria)

Third Prize EAU 2001 Geneva**Robotically assisted laparoscopic radical prostatectomy**

G. Vallancien, G. Pasticier, J. Rietbergen, B. Guillonnet (Paris, France)

Telesurgical laparoscopic radical prostatectomy

J. Rassweiler, T. Frede, O. Seemann, C. Stock, L. Sentker (Heilbronn, Germany)

Volume 8, NUMBER 3

NOVEMBER 2001

01 EAU 26

Use of pedicled flap labia minora for the repair of female urethral strictures

M. Tanello, E. Frego, C. Simeone, S. Cosciani Cunico (Brescia, Italy)

Female urethral sticture and diverticula

V. Pansadoro, F. De Paula, M. Pizzo, P. Emiliozzi, P. Scarpone, G. Federico (Rome, Italy)

Hadera continent reservoir - 5 year follow-up

D. Yachia, N. Erlich (Hadera, Israel)

Retroperitoneal lymph node dissection with caval thrombectomy for advanced nonseminomatous germ cell tumour of the left testicle

F. Martins, M. Alves, J. Freeman, J. Lencastre, J. Varela (Lisbon, Portugal)

Dorsal onlay preputial graft urethroplasty for repair of distal bulbar urethral stricture

L. Martínez-Piñeiro, J. Cisneros, J. Ramón de Fata, J. De la Peña (Madrid, Spain)

Volume 8, NUMBER 4

DECEMBER 2001

01 EAU 27

Nerve and seminal vesicle sparing cystectomy with orthotopic urinary diversion for selected bladder cancer

R. Colombo, R. Bertini, A. Salonia, L. Da Pozzo, M. Roscigno, P. Rìgatti (Milan, Italy)

Seminal vesicle sparing cystectomy and ileocapsuloplasty

G. Muto, F. Bardari, L. D'Urso, P. Coppola (Torino, Italy)

The Ghoneim antireflux ureteroileal implantation technique on GIA stapler detubularised ileal neobladder

G. Muto, F. Bardari, L. D'Urso, P. Coppola (Torino, Italy)

Cost effective hand assisted laparoscopic radical nephrectomy (Hungarian technique)

G. Kovacs, E. Holman, B.S. Dénes, J. Kalman, A. Karsza, J. Rozsahegy (Budapest, Hungary)

Local tumour excision in renal cell carcinoma

L. Martínez-Piñeiro, A. Aguilera, D. Rendon, E. Rios, J. De la Peña (Madrid, Spain)

V.I.P. (Vescica Ileale Padovana) Ileal neobladder: The evolution

P. Bassi, F. Pagano, W. Battenello, D. Battaglia (Padua, Italy)

Seminal vesicle and prostatic capsule sparing cystectomy

M. Carini, A. Lapini, U. Locuntom, L. Maseiri, S. Serni (Padua, Italy)

Total penectomy with perineal urethrostomy for locally advanced neoplasms of the penis

A. Simonato, A. Gregori, A. Lissiani, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)

Radical ilioinguinal node dissection with transposition of the sartorius muscle

A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)

News in urosonography

H. Heynemann, M. Zacharias, A. Wicht, K-V. Jenderka, P. Formara (Halle-Wittenberg, Germany)

Excision and end-to-end anastomosis for repair of bulbar urethral stricture

L. Martínez-Piñeiro, N. Cruz, F. Torrubia, R. Medina, P. Montañes (Madrid, Sevilla, Spain)

Ventral onlay preputial graft urethroplasty for repair of bulbar urethral stricture

L. Martínez-Piñeiro, F. Torrubia, N. Cruz, J.B. García Ramos, P. Montañes (Madrid, Sevilla, Spain)

Endoscopic ureteral stripping in the treatment of renal pelvis tumours

T. Maghiar, G. Bumbu, V. Coltoiu (Oradea, Romania)

Lithiasis on the vesical-urethral anastomosis after radical prostatectomy

G. Bumbu, V. Coltoiu, T. Maghiar, L. Szilagyi (Oradea, Romania)

Dorsal onlay graft urethroplasty with oral mucosa

J. Martínez-Piñeiro, E. Ríos, J. García Mediero, L. Martínez-Piñeiro (Madrid, Spain)

Educational Video Prize 2002 Birmingham**Nerve sparing laparoscopic radical retropubic prostatectomy**

C. Abbou, A. Hoznek, L. Salomon, R. Quintela, F. Saint, E. Olsson, D. Chopin (Créteil, France)

Innovational Video Prize 2002 Birmingham**Resection of RCC with extended vena caval involvement performed with cardiopulmonary bypass, hypothermia and cardiac arrest with heartport device**

P. Graziotti, M. Maffezzini, G. Giusti, M. Seveso, G. Taverna, D. Lavelli, R. Gallotti, A. Bandera, A. Benetti (Milan, Italy)

Research Video Prize 2002 Birmingham**The risk of bladder denervation during antireflux surgery: A reliable neurophysiological model**

C. Seif, P. Braun, F. Martinez Porillo, B. Herberger, G. Boehler, J. Leissner, K-P. Juenemann, R. Hohenfellner (Mannheim, Magdeburg, Kiel, Mainz, Germany)

Best Video published in EUJ in 2001

Inlay-onlay flap urethroplasty in the absence of the urethral plate

R. Kocvara, J. Dvoracek

Volume 9, NUMBER 4

DECEMBER 2002

02 EAU 31

Penile curvature and Peyronie: New problems, new solutions

F. Mantovani, E. Patelli, C. Castelnuovo, E. Pisani (Milan, Italy)

Total urethral reconstruction with S.I.S. (porcine small intestinal sub-mucosa)

D. Mauro (Rome, Italy)

Seminal vesicle sparing sigmoid neobladder reconstruction

G. Nicita, D. Villari, E. Dattolo, V. Li Marzi, M. Paoletti, M. Marzocco (Florence, Italy)

Conversion of a conduit to continent cutaneous diversion

D. Melloni, M. Caramia, C. Magno, V. Serretta, W. Mansson (Messina, Palermo, Italy; Lund, Sweden)

Retroperitoneoscopic partial nephrectomy

S. Sato (Sapporo, Japan)

Volume 10, NUMBER 1

JANUARY 2004

04 EAU 32

Penile duplication with long distance: joining with successful outcome

S. Perovic, M. Djordevic, R. Brdar, (Belgrade, Serbia and Montenegro)

Re-do end to end urethroplasty in traumatic disruption of the membranous urethra

L. Martínez-Piñeiro, J. Madrid, A.J. Garcia (Madrid, Spain)

Reconstructive phalloplasty after amputation for penile cancer, using dermal-epidermal grafts, prosthesis implantation and glanduloplasty with oral mucosa

E. Austoni, F. Colombo (Milan, Italy)

Primary malignant melanoma of the urethra: reconstructive solution in a rare case

G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genova, Italy)

One stage primary reconstruction of bladder extrophy with modified penile disassembly

A. Hafez, M. Eisherbny, M. Baazed, M. Ghoneim (Mansoura, Egypt)

Management of rectoprostatic fistulas with skin or buccal graft patch onlay and gracilis muscle interpretation

A. Sorcini, J. Latini, L. Zinman (Burlington, United States of America)

Conservative vaginal surgery for total genitourinary prolapse

G. Nicita (Florence, Italy)

ACT: Adjustable continence therapy: A minimally invasive post-operative adjustable therapy for female stress urinary incontinence.

E. Kocjancic, T. Sauter, D. Minocci, G. Monesi, M. Favro, G. Ceratti, M. Sala, P. Gontero, S. Guglielmetti, S. Crivellaro, B. Frea (Novara, Italy; Berlin, Germany)

Laparoscopic repair of recurrent prolapse

H. Baumert, H. Widmer, R. Gupta, R. Adorna Rosa, B. Guilloneau, G. Vallencien (Paris, France)

Innovational Video Prize Madrid 2003

Video-assisted nerve and prostate-sparing cystectomy

X. Cathelineau (Paris, France)

Research Video Prize Madrid 2003

Extraperitoneal laparoscopic radical prostatectomy

C. Abbou, A. Hoznek, P. Antiphon, L. Salomon, A. De la Taille, R. Katz, D. Borkowski, D. Chopin (Paris, France)

Retroperitoneoscopic nephroureterectomy without a positioning change

Saito Seichi (Sapporo, Japan)

The new lithoclast

P. van Cangh, A. Feyaerts, B. Tombal, R. Opsomer, F. Wese (Brussel, Belgium)

Bilateral partial obstructive lithiasis on pyeloplasty sutures. Retrograde ureteroscopic treatment

P. Geavlete, V. Mirciulescu, D. Georgescu (Bucharest, Romania)

Endoscopic classification and endourological treatment of incomplete urethral duplication pathology

P. Geavlete, G. Nita, V. Mirciulescu D. Georgescu (Bucharest, Romania)

Multiple lithiasis on sutures points after orthotopic ileal bladder replacement. Endourological treatment

P. Geavlete, D. Georgescu, V. Mirciulesc (Bucharest, Romania)

Volume 10, NUMBER 4

SEPTEMBER 2004

04 EAU 35

Clitoroplasty in intersex repair using disassembly technique

M.L.J. Djordjevic, S.V. Perovic (Belgrade, Serbia and Montenegro)

Complex repair in failed male transsexual surgery

S. Perovic, M.L.J. Djordjevic, A. Kolas (Belgrade, Serbia and Montenegro)

Perugia orthotopic neo-bladder vesicle. Prostate sparing cystectomy: a complete after seminal- recovery of sexual function and body image

E. Mearini, A. Zucchi, L. Mearini, E.Costantini, M. Porena (Perugia, Italy)

Primary malignant melanoma of the urethra. Reconstructive solution in a rare case

G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genova, Italy)

Volume 11, NUMBER 1

DECEMBER 2005

05 EAU 36

Prize for the Best Video published in EUVJ 2003**One stage primary reconstruction of bladder exstrophy with modified penile disassembly**

A.T. Hafez, M.T. El-Sherbiny, M.A. Ghoneim (Mansoura, Egypt)

Educational – laparoscopy video prize**Transobturator tape – perineal hammock**

V. Delmas (Paris, France)

Educational – surgery video prize**Endoscopic extraperitoneal radical prostatectomy (EERPE)**

U. Stolzenburg, R. Rabenalt, M. Do, M. H. Pfeiffer, M. Truss, W. Dorschner (Hannover, Leipzig, Germany)

Innovational video prize**Robotic-assisted (Da Vinci®) laparoscopic conduit urinary diversion in neurogenic bladder**

J. Hubert, J. Beis, B. Feuillu, A. Coissard, P. Mangin, J. Andre (Nancy, France)

Endourologic treatment of renal pelvic and urethral transitional cell carcinoma

P. Geavlete, D. Georgescu, G. Nita, V. Mirciuleascu (Bucharest, Romania)

Pyelocaliceal diverticulum particularities: experiences on 5 cases

P. Geavlete, D. Georgescu, G. Nita, V. Cauni (Bucharest, Romania)

Endoscopic treatment of superficial transitional cell carcinoma in the intramural ureter

P. Geavlete, D. Georgescu, G. Nita (Bucharest, Romania)

Sigma- Rectum pouch, modified technique

J. Hadzi-Djokic, D. Basic, M. Petrovic, D. Jovanovic, Z. Dzamic, N. Prokopiv (Belgrade, Serbia and Montenegro)

Laparoscopic radical cystectomy with mainz rectal pouch urinary diversion

A. Loualalen (Toulouse, France)

Genital organ preservation during radical cystectomy and orthotopic bladder substitution in selected women

B. Ali-El-Dein, A. Mosbah, Y. Osman, M. Abdel-Latif, I. Eraky, A. Shaaban, M. Ghoneim (Mansoura, Egypt)

Laparoscopic cystoprostatectomy for bladder cancer, description step by step

C. Vaessen, M. Mouzin, X. Game, N. Berrogain, B. Malavaud, P. Rischmann (Toulouse, France)

Laparoscopic cystoprostatectomy

X. Cathalineau, F. Rozet, S. Lorin, W. Duncan, C. Arroyo, E. Barret (Paris, France)

Laparoscopic radical cystectomy and ileal conduit in women

H. Baumert, F. Khan, R. Morgan, H. Patel, M.Al-Akraa, A. Kaisary (London, United Kingdom)

Laparoscopic radical cystectomy

A. Hoznek, C-C. Abbou (Creteil, France)

Surgical treatment of total uterine prolapse associated with stress urinary incontinence and bilateral hydronephrosis

J. Hadzi-Djokic, D. Basic, Z. Dzamic, M. Acimovic, V. Stamenkovic, S. Velikovic (Belgrade, Serbia and Montenegro)

Female laparoscopic artificial urinary sphincter in women for type III incontinence: Preliminary results.

B. Nijinou (Le Havre, France)

Treatment of male urinary incontinence with submucosal bulking agents

J. Seibold, A. Merseberger, K. Sievert, A. Stenzl (Tübingen, Germany)

The tunica-albuginea- patch- technique: A new technique of an autologous grafting procedure for patients with Peyronie's disease

J.U. Schwarzer, J. Mayerhofer, O. Schukai, B. Mühlen (Freising, Germany)

Treatment of Peyronie's disease with plaque incision and application of bovine pericardium graft

L. Martinez-Pineiro, S. Alonso, J. Cruz, E. Cuervo, J. De la Pena (Madrid, Spain)

Early ligation of the renal artery during laparoscopy radical nephrectomy

F. Porpiglia, C. Terrone, R. Tarabuzzi, C. Fiori, M. Cossu, C. Cracco, C. Scoffone, R. Scarpa (Orbassano, Italy)

Laparoscopic radical nephrectomy

A. Shoma, E. Ibrahim, H. El Kappany (Mansoura, Egypt)

Laparoscopic partial nephrectomy for renal tumours after renal artery clamping the Quebec City experience.

T. Dujardin, R. Sabbagh, B. Inman (Québec, Canada)

Laparoscopic nephron-sparing surgery techniques of haemostasis

F. Gaboardi, A. Simonata, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)

Laparoscopic radical nephrectomy with lymph node dissection for advanced renal cell carcinoma pT3aN2.

H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; London, United Kingdom)



- 2006-1 Anatomical features and dissection of the accessory pudendal arteries during laparoscopic radical prostatectomy**
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, X. Taccoen, C. Deruelle, L. Doucet, A. Volant, O. Cussenot (Brest, Paris, France)
- 2006-2 Laparoscopic radical prostatectomy, preservation of accessory pudendal arteries**
L. Martínez-Piñeiro, J.R. Cansino, F. Cáceres, A. Tabernero, J. Cisneros, J.J. De La Peña (Madrid, Spain)
- 2006-3 Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy**
F. Secin, N. Karanikolas, J.I. Martínez Salamanca, F. Bianco, K. Touijer, B. Guillonneau (New York, United States of America)
- 2006-4 Neurovascular bundle dissection: interfascial, extrafascial and full resection techniques**
F. Secin, A.J. Stephenson, N. Karanikolas, Z. Dotan, K. Touijer, B. Guillonneau (New York, United States of America)
- 2006-5 Description of the surgical anatomy of the fascias surrounding the prostate during laparoscopic radical prostatectomy**
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, D. John, X. Taccoen, C. Deruelle, L. Doucet, A. Volant, O. Cussenot (Brest, Paris, France)
- 2006-6 How to prevent iatrogenic capsular incision during laparoscopic nerve sparing radical prostatectomy**
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, C. Deruelle, L. Cormier, X. Taccoen, L. Doucet, A. Volant (Brest, Nancy, France)
- 2006-7 Laparoscopic partial cystectomy for bladder müllerianosis**
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)
- 2006-8 Laparoscopic radical cystectomy in female**
F. Gaborardi, A. Bozzola, S. Galli, A. Gregori, F. Scieri, S. Stener, B. Rocco (Milan, Italy)
- 2006-9 Laparoscopic radical cystectomy with neobladder acc. to Studer**
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)
- 2006-10 Laparoscopic radical cystectomy with bladder replacement**
L. Cecchini, A. Orsola, C. Raventos, E. Trilla, J. Planas, C. Salvador, J. Morote (Barcelona, Spain)
- 2006-11 Transvesical laparoscopic diverticulectomy**
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)
- 2006-12 Endoscopic lymphadenectomy for penile carcinoma**
R. Sotelo, A.J. Garcia, R. Sánchez Salas, O. Carmona, R. Dubois, F. Cornejo, M. Mariano, G. Neiva, A. Finelli (Caracas, Venezuela; Quito, Ecuador; Porto Alegre, Goiania, Brazil; Toronto, Canada)
- 2006-13 Laparoscopic partial nephrectomy with clamping of the renal parenchyma**
A. Manunta, K. Bensalah, S. Vincendeau, G. Verhoest, N. Rioux-Leclercq, B. Lobel, F. Guillé, J.J. Patard (Rennes, France)
- 2006-14 Laparoscopic partial nephrectomy for RCC in warm ischemia**
A. Häcker, K. Leeb, N. Albquami, A. Al Badour, S. Jeschke, G. Janetschek (Mannheim, Germany; Linz, Austria)
- 2006-15 Laparoscopic upper pole heminephroureterectomy in complete duplication of the ureter**
P. Casale, M. Simone, R. Marzano, C. Casarosa, G. Pomara, F. Francesca (Pisa, Italy)

- 2006-16 Tachosil® is an effective haemostatic aid during laparoscopic partial nephrectomy in a porcine model**
D. Murphy, R. Puri, P. Rimington, A. Rane (London, Bradford, Eastbourne, Redhill, United Kingdom)
- 2006-17 A refined technique of laparoscopic nephroureterectomy**
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)
- 2006-18 Laparoscopic removal of local recurrence of renal cell carcinoma (RCC)**
A. Tsivian, S. Benjamin, A. Kheifets, A.A. Sidi (Holon, Israel)
- 2006-19 Urachal sparing laparoscopic radical prostatectomy**
F. Secin, F. Bianco, N. Karanikolas, K. Touijer, B. Guillonneau (New York, United States of America)
- 2006-20 Open retropubic nerve sparing radical prostatectomy? How I do it**
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Bern, Switzerland)
- 2006-21 Selective dissection of the apex during radical prostatectomy allows better tumour control and continence**
J. Walz, M. Graefen, A. Haese, H. Heinzer, H. Huland (Hamburg, Germany)
- 2006-22 Nerve sparing radical prostatectomy - the surgeons view through the varioscope M5**
R. Götschl, N. Schmeller (Salzburg, Austria)
- 2006-23 The radical perineal prostatectomy with simultaneous extended pelvic lymphadenectomy via the same incision**
J. Beier, H. Keller (Hof, Germany)
- 2006-24 Laparoscopic radical prostatectomy. Differences between the inter-fascial and intra-fascial technique**
L. Martínez-Piñero, J.R. Cansino, C. Sanchez, A. Tabernero, J. Cisneros, J.J. De La Peña (Madrid, Spain)
- 2006-25 Combined obturator - pre pubic cystocele and incontinence repair: Rationale & technique**
P. Palma, C. Ricetto, M. Dambros, R. De Fraga, N. Rodrigues Netto Jr. (Campinas, Brazil)
- 2006-26 A new surgical technique for implantation of a permanent electro stimulation system for treatment of female overactive bladder and interstitial cystitis**
I. Nissenkorn, R. De Jong, P. Radziszewski, M. Cervigni, M. Parsons, L. Cardozo, B. Farnsworth, J. Nordling (Tel- Aviv, Israel; Cape Town, South Africa; Warsaw, Poland; Rome, Italy; London, United Kingdom; Sydney, Australia; Herley, Denmark)
- 2006-27 Bulbo-urethral sling with invance device for the treatment of post-prostatectomy incontinence**
I. Morra, R. Tarabuzzi, F. Porpiglia, M. Cossu, M. Billia, J. Renard, R. Scarpa (Turin, Italy)
- 2006-28 Laparoscopic sacral colpopexy using a double polyester mesh**
J.P. Giolitto (Reims, France)
- 2006-29 Simultaneous implantation of the artificial urinary sphincter and inflatable penile prosthesis**
L. Jones (San Antonio, Texas, United States of America)
- 2006-30 Dorsal graft urethroplasty for urethral stricture in the female**
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)
- 2006-31 Ureterosopic laser approach in recurrent ureteropelvic junction stenosis**
V. Mirciulescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)

- 2006-32 One day stay for robotic pyeloplasty**
D. Murphy, S. Khan, B. Challacombe, J. Olsburgh, P. Dasgupta (London, United Kingdom)
- 2006-33 The thulium laser vaporesction of the prostate**
R. Götschl, N. Schmeller (Salzburg, Austria)
- 2006-34 Magnetic resonance image-guided robot for prostate brachytherapy**
M. Muntener, H. Bagga, A. Patriciu, D. Mazilu, D. Petrisor, N. Patel, L. Kavoussi, D. Stoianovici (Baltimore, United States of America)
- 2006-35 Retrograde flexible ureteroscopic approach in symptomatic caliceal calculi**
D.R. Multescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)
- 2006-36 Extending the application of tubeless percutaneous nephrolithotomy (PNL)**
M. Sofer, I. Kaver, J. Ben Chaim, A. Friedman, E. Metlitzky, H. Matzkin (Tel Aviv, Israel)
- 2006-37 Laparoscopic radical prostatectomy: Technical aspects and pitfalls during the apical dissection**
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet, A. Volant (Brest, Nancy, France)
- 2006-38 Bladder neck dissection during laparoscopic radical prostatectomy: Difficult cases**
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet, A. Volant (Brest, Nancy, France)
- 2006-39 Dealing with a difficult urethrovesical anastomosis in laparoscopic radical prostatectomy**
F. Secin, N. Karanikolas, A.J. Stephenson, F. Bianco, K. Touijer, B. Guillonneau (New York, United States of America)
- 2006-40 Laparoscopic repair of an inferior vena cava injury during a right partial nephrectomy**
F. Secin, Z. Dotan, B. Shayegan, S. Olgac, B. Guillonneau, K. Touijer (New York, United States of America)
- 2006-41 Technical difficulties in retroperitoneoscopic radical nephrectomy. Is tumour location important?**
M. Lucan, V. Lucan, F. Elec, G. Iacob, C. Burghilea, A. Barbos (Cluj - Napoca, Romania)
- 2006-42 Laparoscopic repair of rectourethral fistulae**
R. Sotelo, A.J. Garcia, M. Mariano, G. Trujillo, E. Rodriguez, R. De Andrade, L. Sánchez, C. Andrade, A. Finelli (Caracas, Venezuela; Porto Alegre, Brazil; Toronto, Canada)

**The following videos were presented during the 20th Annual EAU Congress
in Istanbul, Turkey, 16-19 March 2005**

- 2005-1 Laparoscopic nerve sparing radical prostatectomy using clips for haemostasis during postero-lateral dissection: an unusual "point of view" of the surgical anatomy**
G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)
- 2005-2 Technique of nerve-sparing endoscopic extraperitoneal radical prostatectomy (NSEERPE)**
J.U. Stolzenburg, R. Rabenalt, M. Do, K. Ho, J. Mondry, M. Truß (Leipzig, Hannover, Germany)
- 2005-3 Extraperitoneal laparoscopic radical intrafascial prostatectomy**
F. Porpiglia, C. Terrone, R. Rarabuzzi, F. Ragni, C. Fiori, C. Cracco, M. Cossu, C. Scoffone, R. Scarpa (Orbassano, Italy)
- 2005-4 Nerve-sparing extraperitoneal laparoscopic radical prostatectomy**
V. Poulakis, W. Dillenburg, U. Witzsch, E. Becht (Frankfurt am Main, Germany)
- 2005-5 Robotic-assisted laparoscopic transperitoneal radical prostatectomy**
F. Gaboardi, A. Lissiani, A. Simonato, A. Gregori, S. Galli, A. Bozzola. (Milan, Italy)
- 2005-6 Robot assisted endoscopic extraperitoneal seminal vesical tip and nerve sparing radical prostatectomy**
M. Muentener, D. Schmid, R. Strebel, D. Hauri, H. John (Zürich, Switzerland)
- 2005-7 Laparoscopic cystectomy for bladder cancer: description step by step**
C. Vaessen, M. Mouzin, X. Game, N. Berrogain, B. Malavaud, P. Rischmann (Toulouse, France)
- 2005-8 Laparoscopic cystoprostatectomy**
X. Cathelineau, F. Rozet, S. Lorin, W. Duncan, C. Arroyo, E. Barret (Paris, France)
- 2005-9 Genital organ preservation during radical cystectomy and orthotopic bladder substitution in selected women**
B. Ali-El-Dein, A. Mosbah, Y. Osman, M. Abdel-Latif, I. Eraky, A. Shaaban, M. Ghoneim (Mansoura, Egypt)
- 2005-10 Laparoscopic radical cystectomy + ileal conduit in women**
H. Baumert, F. Khan, R. Morgan, H. Patel, M. Al-Akraa, A. Kaisary (Paris, France; London, United Kingdom)
- 2005-11 Laparoscopic radical cystectomy with mainz rectal pouch urinary diversion**
A. Ioualalen, M. Ziani. (Toulouse, France)
- 2005-12 Laparoscopic radical cystectomy with orthotopic ileal neobladder**
A. Hoznek, D. Vordos, G. Matthew, L. Salomon, A. De la Taille, R. Yiou, C. Abbou. (Créteil, France; Rochester, United States of America)
- 2005-13 Early ligation of the renal artery during laparoscopic radical nephrectomy**
F. Porpiglia, C. Terrone, R. Tarabuzzi, C. Fiori, M. Cossu, C. Cracco, C. Scoffone, R. Scarpa (Orbassano, Italy)
- 2005-14 Laparoscopic radical nephrectomy could duplicate the open technique**
A. Shoma, E. Ibrahim, H. El Kappany (Mansoura, Egypt)
- 2005-15 Laparoscopic partial nephrectomy for renal tumours after renal artery clamping: the Québec City experience**
T. Dujardin, R. Sabbagh, B. Inman (Québec, Canada)
- 2005-16 Laparoscopic nephron-sparing surgery: techniques of haemostasis**
F. Gaboardi, A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)
- 2005-17 Laparoscopic radical nephrectomy with lymph node dissection for advanced renal cell carcinoma (pt3a n2)**
H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; Cambridge, United Kingdom)

- 2005-18 Donor nephrectomy and renal transplantation in horseshoe kidney**
J. Palou Redorta, A. Alcaraz, J. Huguet, C. Baez, H. Villavicencio (Barcelona, Spain)
- 2005-19 Total glans resurfacing for pre-invasive carcinoma of the penis: a new approach**
P. Hadway, R. Singh, C. Corbishley, N. Watkin (London, United Kingdom)
- 2005-20 Dorsal dartos flap for fistula prevention in Snodgrass hypospadias repair**
M. Djordjevic, S. Perovic (Belgrade, Serbia and Montenegro)
- 2005-21 Lingual mucosa graft in the management of short anterior urethral strictures**
A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)
- 2005-22 Phalloplasty penile prosthesis insertion for transexualism**
D. Ralph, N. Christopher, S. Minhas, C. Bettocchi (London, United Kingdom)
- 2005-23 Treatment of Peyronie's disease with plaque incision and application of bovine pericardium graft**
L. Martínez-Piñero, S. Alonso, J. Cruz, E. Cuervo, J. De la Peña (Madrid, Spain)
- 2005-24 The tunica-albuginea-patch-technique: a new technique of an autologous grafting procedure for patients with Peyronie's disease**
J.U. Schwarzer, J. Mayerhofer, O. Schukai, B. Mühlen (Freising, Germany)
- 2005-25 Laparoscopic retroperitoneal lymph node dissection (RPLND) for a large residual mass post chemotherapy**
H. Baumert, F. Khan, T. Aho, N. Shah, W. Turner (Paris, France; Cambridge, United Kingdom)
- 2005-26 Laparoscopic adrenalectomy: an established approach for management of adrenal pheochromocytoma**
A. Shoma, I. Eraky, H. El Kappany (Mansoura, Egypt)
- 2005-27 Endourological treatment of ureteral and bladder pathology after renal transplant**
F.J. Burgos, R. Marcen, J. Pascual, D. Garcia Ortells, I. Gomez Garcia, V. Gomez Dosantos, (Madrid, Spain)
- 2005-28 Robot assisted dismembered pyeloplasty: a new approach for management of primary ureteropelvic junction obstruction with secondary renal stones**
A. Shoma, A. Hemal, N. El Tabey (Mansoura, Egypt; Detroit, United States of America)
- 2005-29 Retroperitoneoscopic dismembered double-V pyeloplasty**
M. Kiliñç (Konya, Turkey)
- 2005-30 Transmesocolic approach in laparoscopic pyeloplasty**
R. Kocvara, J. Dvoráček, J. Sedláček, Z. Díte (Prague, Czech Republic)
- 2005-31 Extra peritoneoscopic millin transcapsular prostatic adenomectomy**
F. Porpiglia, C. Terrone, R. Tarabuzzi, F. Vacca, M. Cossu, C. Cracco, C. Scoffone, F. Ragni, R.M. Scarpa (Orbassano, Italy)
- 2005-32 Laparoscopic simple prostatectomy without the requirement of post operative irrigation: the technique**
H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; Cambridge, United Kingdom)
- 2005-33 Laparoscopic transvesical ureteral advancement**
P. de Kuyper, W. Oosterlinck (Ghent, Belgium)
- 2005-34 Laparoscopic Lich Gregoir ureteral implantation**
C. Vaessen, M. Mouzin, N. Berrogain, X. Game, P. Rischmann (Toulouse, France)

2005-35 Laparoscopic treatment of urachal diverticulum

A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)

2005-36 Laparoscopic partial cystectomy and en-bloc removal of the urachus for urachal adenocarcinoma

F. Porpiglia, C. Terrone, R. Tarabuzzi, F. Ragni, M. Cossu, C. Cracco, C. Scoffone, R.M. Scarpa (Orbassano, Italy)

2005-37 Technique for vesico-uretral anastomosis in laparoscopic radical prostatectomy: an educational video

G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)

2005-38 Bladder neck - urethral anastomosis after laparoscopic extraperitoneal radical prostatectomy: technical details after 200 procedures

G. Martina, J. Lovisolo, P. Giumelli, S. Scuzzarella, M. Remotti, C. Giacomo (Sondalo, Tradate, Italy)

2005-39 Laparoscopic radical prostatectomy: preservation of a left accessory pudendal artery

G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)

2005-40 Bladder neck dissection in laparoscopic radical prostatectomy. Technical details after more than 250 cases


L. Martínez-Piñeiro, J. Cisneros, C. Núñez, A. Tabernero, J. Pacios, S. Alonso, J. de la Peña (Madrid, Spain)

2005-41 Female laparoscopic artificial urinary sphincter in women for type III incontinence: preliminary results

B.Njinou (Yvoir, Belgium)

2005-42 Bulking agents for the treatment male postoperative stress urinary incontinence

J. Seibold, A. Merseburger, K. Sievert, A. Stenzl (Tuebingen, Germany)



**The following videos were presented during the 19th Annual EAU Congress
in Vienna, Austria, 24-27 March 2004**

- 2004-1 Animal model for laparoscopic radical prostatectomy**
L. Martínez Piñero, C. Núñez, S. Alonso, J. Pacios, J. De La Peña (Madrid, Spain)
- 2004-2 Retrograde extraperitoneal laparoscopic prostatectomy (REL P) the Lyon technique-a 204 cases experience. Access to and exposure of the operative field**
P. Dubernard, S. Benchetrit, P. Chaffange, B. Cuzin, T. Hamza, C. Rochat, C.L.U.B. (Lyon, France)
- 2004-3 Creation of the working space for extraperitoneal laparoscopic radical prostatectomy**
L. Ruiz, A. Hoznek, L. Salomon, A. De La Taille, D. Vordos, R. Yyou, P. Antiphon, D. Chopin, C. Abbou (Créteil, France)
- 2004-4 The role of surgical assistants during extraperitoneal laparoscopic radical prostatectomy**
J. Audet, L. Ruiz, V. Destéfano, S. Stener, A. De La Taille, L. Salomon, A. Hoznek, C. Abbou (Créteil, France)
- 2004-5 Complete solo laparoscopic radical prostatectomy**
P. Antiphon, L. Ruiz, J. Audet, R. Yyou, D. Vordos, A. De La Taille, L. Salomon, A. Hoznek, D. Chopin, C. Abbou (Créteil, France)
- 2004-6 Holmium laser enucleation of prostate combined with mechanical morcellation Italian experience**
I. Vavassori, R. Hurle, S. Valenti, A. Manzetti, A. Vismara, O. Fenice (Bergamo, Italy)
- 2004-7 Laparoscopic transperitoneal left partial nephrectomy: the value of isolated arterial cross-clamping**
W. Hassen, E. Trabulsi, A. Toujier, J. Saranchuk, S. Savage, B. Guillonneau (New York, United States of America)
- 2004-8 The use of synthetic glue to enhance hemostatic control during laparoscopic partial nephrectomies**
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)
- 2004-9 Laparoscopic excision of renal cell carcinoma under intracorporeal vascular control**
X. Krah, O. Lux, U. Hanschmann, N. Benken, G. Eschholz, H. Weber (Blankenhain, Bad Berka, Germany)
- 2004-10 Hand-assisted laparoscopy with the LAP DISC®**
N. Kreutzer, F. Redwig, H. Schulze (Dortmund, Germany)
- 2004-11 Radical nephrectomy by transperitoneal, extraperitoneal and hand-assisted laparoscopy: comparative description of surgical steps**
J. Audet, L. Ruiz, S. Laurent, F. Desgrandchamps, T. Piechaud, R. Gaston, A. Hoznek, C. Abbou (Créteil, Paris, Bordeaux, France)
- 2004-12 Laparoscopic robotic-assisted (Da Vinci®) live-donor nephrectomy**
J. Hubert, B. Feuillu, N. Billaut, L. Frimat, L. Cormier, L. Prevot, D. Hestin, P. Mangin, M. Kesler (Nancy, France)
- 2004-13 Retrograde extraperitoneal laparoscopic prostatectomy (REL P): the Lyon technique - a 204 cases experience**
P. Dubernard, S. Benchetrit, P. Chaffange, B. Cuzin, T. Hamza, P. Van Box Som, C.L.U.B. (Lyon, France)
- 2004-14 Endoscopic extraperitoneal radical prostatectomy (EERPE)**
J-U. Stolzenburg, R. Rabenalt, M. Do, H. Pfeiffer, M. Truss, W. Dorschner (Leipzig, Hannover, Germany)
- 2004-15 Laparoscopic radical prostatectomy. Preservation of neurovascular bundles with the combined retrograde and descending technique**
L. Martínez Piñero, C. Núñez, A. Tabernero, J. Pacios, S. Alonso, J. De la Peña (Madrid, Spain)
- 2004-16 Laparoscopic cysto-prostatectomy and orthotopic neo-bladder in man**
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)

- 2004-17 Laparoscopic radical cystectomy with open construction of an orthotopic ileal neobladder**
F. Porpiglia, R. Tarabuzzi, M. Cossu, C. Scoffone, C. Terrone, S. Guercio, R. Scarpa (Orbassano, Italy)
- 2004-19 Robotic assisted laparoscopic dismembered pyeloplasty**
J. Hubert, A. Hoznek, B. Feuillu, A. Lobontiu, C. Abbou (Nancy, Créteil, France)
- 2004-20 Laparoscopic pyeloplasty for uretero-pelvic stenosis treatment failures**
H. Baumert, H. Widmer, F. Dugardin, F. Combes, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)
- 2004-21 Laparoscopic pyeloplasty for an ureteropelvic junction syndrome on a horseshoe kidney**
F. Rozet, H. Widmer, F. Dugardin, F. Combes, X. Cathelineau, H. Baumert, G. Vallancien (Paris, France)
- 2004-22 Robotic-assisted (Da Vinci®) laparoscopic conduit urinary diversion in neurogenic bladder**
J. Hubert, J. Beis, B. Feuillu, A. Coissard, P. Mangin, J. Andre (Nancy, France)
- 2004-23 Retroperitoneal venous hemangioma: laparoscopic approach**
J. Estebanez Zarranz, M. Conde Redondo, J. Amon Sesmero, R. Perez Martin, A. Rodriguez Toves, A. Robles Samaniego, N. Del Valle Gonzalez, F. Castroviejo Royo, J. Martinez Sagarra (Valladolid, Spain)
- 2004-24 Sequential trans-urethral resection of prostate and laparoscopic bladder diverticulectomy under US guidance**
F. Porpiglia, M. Cossu, R. Tarabuzzi, C. Terrone, C. Cracco, R. Scarpa (Orbassano, Italy)
- 2004-25 Transobturator tape - perineal hammock**
V. Delmas (Paris, France)
- 2004-26 Trans-obturator sling procedure for urinary stress incontinence**
L. Ruiz, A. Cicco, R. Yiou, D. Vordos, A. De la Taille, L. Salomon, A. Hoznek, D. Chopin, C. Abbou (Créteil, France)
- 2004-27 Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal tape inside-out**
J. De Leval, P. Bonnet, O. Reul, D. Waltregny (Liege, Belgium)
- 2004-28 Bulbourethral composite suspension for post-prostatectomy urinary incontinence: step by step**
H. John (Zurich, Switzerland)
- 2004-29 Laparoscopic artificial urinary sphincter insertion**
M. Abi Moussa, A. Manunta, Y. Barbé, J. Patard, B. Lobel, F. Guillé (Rennes, France)
- 2004-30 Laparoscopic urethrolisis, treatment of genital prolapse and artificial urinary sphincter insertion**
A. Manunta, Y. Barbé, S. Vincendeau, M. Abi Moussa, J. Patard, B. Lobel, F. Guillé (Rennes, France)
- 2004-31 Renal autotransplantation: an alternative after metallic ureteral stent incrustation**
J. Burgos Revilla, P. Perez, F. Arias, R. Rodriguez Patron, I. Gomez, E. Fernandez (Madrid, Spain)
- 2004-32 Organ-sparing therapy with ureteroscopic and percutaneous approach in upper urinary tract tumours (UUTT)**
A. De Lisa, P. Usai, R. Scarpa, E. Usai (Cagliari, Italy)
- 2004-33 Dorsal free graft urethroplasty by ventral approach**
F. Gomez-Sancha, L.M. Herranz Fernández, M. Jiménez Gálvez, R. Arellano Gañán, I. Pereira Sanz (Madrid, Spain)

2004-34 Complex epispadias repair: new advances
S. Perovic (Belgrade, Serbia and Montenegro)

2004-35 Distal urethra transposition in female patients with chronic uti associated with sexual intercourse
V. Diakov, D. Pushkar (Moscow, Russia)

2004-36 Sex reassignment surgery for male-to-female transsexuals: an urological job
G. Liguori, C. Trombetta, L. Salamè, S. Bucci, G. Garaffa, E. Belgrano (Trieste, Italy)

2004-37 Difficulties, mishaps and errors encountered during the first laparoscopic radical prostatectomies
A. Messas, D. Bohin, S. Beley, J. Ghossein, B. Lhoest, V. Boublil, S. Dominique, O. Dumonceau, V. Delmas, V. Ravery, L. Boccon Gibod (Paris, Argenteuil, France)

2004-38 Laparoscopic correction of surgical complications that can occur during laparoscopic radical prostatectomy
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)

**The following videos were presented during the 18th Annual EAU Congress
in Madrid, Spain, 12-15 March 2003**

- 2003-1 Laparoscopic training in urology**
R. Katz, A. Hoznek, P. Antiphon, L. Salomon (Créteil, France)
- 2003-2 Using fresh cadavers to teach laparoscopic radical prostatectomy**
H. Baumert, H. Widmer, S. Gholami, R. Gupta, J. Adorno Rosa, G. Fournier, X. Cathelineau, B. Guillonneau, G. Vallancien (Paris, France)
- 2003-3 Laparoscopic anatomical radical prostatectomy - experience after 350 cases**
J. Rassweiler, O. Seemann, M. Hatzinger, L. Sentker, T. Frede (Heilbronn, Germany)
- 2003-4 Step by step teaching of the assistant's technique in laparoscopic prostatectomy**
H. Baumert, H. Widmer, R. Gupta, V. Cardot, R. Adorno, B. Guillonneau, G. Vallancien (Paris, France)
- 2003-5 Prostate brachytherapy: a real-time, ultrasound-guided, original technique**
L. Nava, A. Losa, A. Cestari, M. Riva, P. Mangili, N. Di Muzio, G. Guazzoni, L. Rigatti (Milan, Italy)
- 2003-6 Urethral reconstruction with buccal mucosa graft**
H. Keller, F. Lamadé (Hof, Offenburg, Germany)
- 2003-7 Extraperitoneal laparoscopic radical prostatectomy**
C. Abbou, A. Hoznek, P. Antiphon, L. Salomon, A. De la Taille, R. Katz, T. Borkowski, D. Chopin (Créteil, France)
- 2003-8 Laparoscopic extraperitoneal radical prostatectomy: the Montsouris technique 2**
X. Cathelineau, H. Bermudez, S. Gholami, H. Baumert, S. Elard, F. Bruyere, G. Vallancien (Paris, France)
- 2003-9 Modifications of laparoscopic radical prostatectomy: extraperitoneal approach and identification of dissection plane at the bladder neck using simultaneous bi-planar transrectal ultrasonography**
M. Komuro, T. Tsuchida, I. Araki, Y. Takihana, K. Matsushita, M. Takeda (Yamanishi, Japan)
- 2003-10 Laparoscopic salvage prostatectomy compared with normal laparoscopic prostatectomy**
B. Guillonneau, H. Baumert, H. Bermudez, S. Gholami, G. Loison, X. Cathelineau, G. Vallancien (Paris, France)
- 2003-11 Extraperitoneal laparoscopic robot assisted radical prostatectomy**
P. Antiphon, A. Hoznek, M. Gettman, A. De la Taille, L. Salomon, R. Katz, T. Borkowski, C. Abbou (Créteil, France)
- 2003-12 Radical perineal prostatectomy**
H. Villavicencio (Barcelona, Spain)
- 2003-13 The nerve-sparing radical perineal prostatectomy**
H. Keller, M. Linder, F. Lamadé (Hof, Offenburg, Germany)
- 2003-14 Continent vesicostomy after female urethrectomy**
B. Frea, E. Kocjancic, P. Gontero, D. Minocci, G. Monesi, M. Sala, S. Crivellaro, M. Favro, S. Baietto (Novara, Italy)
- 2003-15 Act: adjustable continence therapy: a minimally invasive post operatively adjustable therapy for female stress urinary incontinence**
E. Kocjancic, T. Sauter, D. Minocci, G. Monesi, M. Favro, G. Ceratti, M. Sala, P. Gontero, S. Guglielmetti, S. Crivellaro, B. Frea (Novara, Italy; Berlin, Germany)
- 2003-16 Safyre: a versatile self-anchoring readjustable sling**
P. Palma, C. Riccetto, M. Dambros, M. Thiel, R. Fraga, C. Vilas-Boas, N. Netto Jr. (Campinas, Brazil)

- 2003-17 Intravaginal slingplasty (IVS): building safety in the management of female stress urinary incontinence**
P. Palma, C. Riccetto, M. Dambros, M. Thiel, R. Fraga, C. Villas-Boas, N. Netto Jr. (Campinas, Brazil)
- 2003-18 Laparoscopic repair of recurrent prolapse**
H. Baumert, H. Widmer, R. Gupta, R. Adorno, V. Joulin, B. Guillonneau, G. Vallancien (Paris, France)
- 2003-19 Robot assisted laparoscopic prolapse repair**
H. Baumert, H. Widmer, S. Gholami, R. Gupta, R. Adorno, F. Rozet, B. Guillonneau, G. Vallancien (Paris, France)
- 2003-20 Redo end to end urethroplasty in traumatic disruption of the membranous urethra**
L. Martínez-Piñero, J. Madrid, A. García (Madrid, León, Spain)
- 2003-21 Penile duplication with long distance: joining with successful outcome**
S. Perovic, M. Djordjevic, R. Brdar, S. Ducic (Belgrade, Serbia and Montenegro)
- 2003-22 Primary malignant melanoma of the urethra: reconstructive solution in a rare case**
G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genoa, Italy)
- 2003-23 One stage primary reconstruction of bladder exstrophy with modified penile disassembly**
A. Hafez, M. Elsherbiny, M. Bazeed, M. Ghoneim (Mansoura, Egypt)
- 2003-24 Carcinoma of the penis: video-algorithm for inguinal lymphadenectomy**
A. Simonato, A. Lissiani, A. Gregori, A. Bozzola, S. Galli, F. Gaboardi (Milan, Italy)
- 2003-25 Management of radiation recto-prostatic fistula with skin or buccal graft patch onlay and gracilis muscle interposition**
A. Sorcini, J. Latini, L. Zinman (Burlington, United States of America)
- 2003-26 Laparoscopic retroperitoneal lymphadenectomy in stage I NSGCT**
G. Schön (Würzburg, Germany)
- 2003-27 Bilateral laparoscopic retroperitoneal lymph node dissection (RPLND) in a patient with metachronous bilateral NSGCT**
C. Trombetta, G. Liguori, S. Bucci, F. Scieri, E. Belgrano (Trieste, Italy)
- 2003-28 Laparoscopic retroperitoneal lymph node dissection for residual masses**
H. Baumert, H. Widmer, S. Gholami, R. Adorno, R. Gupta, B. Guillonneau, G. Vallancien (Paris, France)
- 2003-29 Technique of laparoscopic adrenalectomy in large adrenal tumours**
G. Schön (Würzburg, Germany)
- 2003-30 Limitation of retroperitoneoscopic surgery for adrenal and retroperitoneal tumours**
T. Yagisawa, F. Ito, N. Ishikawa, Y. Hashimoto, N. Goya, H. Toma (Tokyo, Japan)
- 2003-31 Substitution of inferior vena cava with reimplantation of hepatic and renal veins**
A. Sorcini, D. Lewis, R. Jenkins (Burlington, United States of America)
- 2003-32 Laparoscopic nephro-ureterectomy with endoscopic laser excision of the distal ureter**
G. Schön (Würzburg, Germany)
- 2003-33 Robot assisted kidney transplantation**
A. Hoznek, M. Gettman, P. Antiphon, A. De la Taille, L. Salomon, F. Saint, A. Lobontiu, C. Abbou (Créteil, France)

2003-34 Retroperitoneal laparoscopic pyeloplasty

R. Katz, A. Hoznek, P. Antiphon, T. Borkowski, A. De la Taille, L. Salomon, C. Abbou (Créteil, France)

2003-35 Retroperitoneal endoscopic nephrectomy: new technique for access and management of vessels

G. Schön (Würzburg, Germany)

2003-36 Hand-assisted retroperitoneoscopic radical nephrectomy

P. Dekuyper, W. Oosterlinck (Gent, Belgium)

2003-37 Is there still a role for open conservative surgery?

F. Francesca, R. Felipetto, A. Barsali, M. Cosci, P. Casale (Pisa, Italy)

2003-38 Video-assisted nerve and prostate-sparing cystectomy

X. Cathelineau, A. Renda, H. Bermudez, D. Cahill, H. Widmer, G. Loison, B. Guillonnet, H. Baumert, G. Vallancien (Paris, France)

2003-39 Laparoscopic prostate, nerve and seminal sparing cystectomy and orthotopic ileal neobladder: technical aspects

A. Cestari, G. Guazzoni, R. Colombo, M. Riva, L. Nava, A. Losa, P. Bellinzoni, P. Rigatti (Milan, Italy)

2003-40 Laparoscopic radical cystectomy with external ileal neobladder: our technique step by step

P. Paulhac, M. Hubert, G. Philippe, C. Pierre (Limoges, France)

2003-41 Minimally invasive laparoscopic neobladder (MILAN)

F. Gaboardi, A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)

2003-42 Bipolar transurethral prostate resection (TURP): a new approach with co-ablation technology

A. Patel, J. Adshead, M. Swinn (London, United Kingdom)

2003-43 Laparoscopic retropubic adenomectomy

H. Baumert, S. Gholami, H. Bermudez, H. Widmer, X. Cathelineau, G. Vallancien (Paris, France; San Francisco, United States of America)



**The following videos were presented during the 17th Annual EAU Congress
in Birmingham, United Kingdom, 23-26 February 2002**

- 2002-1 Laparoscopic nerve-sparing retroperitoneal lymph node dissection: the surgical technique**
R. Peschel, M. Gettman, A. Hobisch, R. Neururer, G. Bartsch (Innsbruck, Austria)
- 2002-2 Laparoscopic left partial nephrectomy for cancer**
C. Gerard, H. Bermudez, D. Rey, G. Vallancien, B. Guillonnet (Paris, France)
- 2002-3 The vascular steps of right lumboscopic nephrectomy for cancer**
P. Paulhac, F. Dargent, J. Dumas, P. Colombeau (Limoges, France)
- 2002-5 Retroperitoneal laparoscopic renal surgery in children without clips**
S. Micali, P. Caione, L. Storti, N. Capozza, M. Scarfini, F. Micali (Rome, Italy)
- 2002-6 Lymphatic-sparing laparoscopic varicocele: a microsurgical repair**
R. Kocvara, J. Dvoracek, J. Kriz, Z. Dite, K. Novak (Prague, Czech Republic)
- 2002-7 Nerve sparing laparoscopic radical retropubic prostatectomy**
C. Abbou, A. Hoznek, L. Salomon, R. Quintela, F. Saint, E. Olsson, D. Chopin (Créteil, France)
- 2002-8 Radical prostatectomy by simplified extra peritoneal laparoscopic technique**
P. Dubernard, P. Van Box Som, T. Hamza, S. Benchetrit (Lyon, France)
- 2002-9 Telerobotic laparoscopic radical prostatectomy**
C. Abbou, A. Hoznek, E. Olsson, D. Samadi, A. Nadu, R. Quintela, L. Salomon (Créteil, France)
- 2002-10 Laparoscopic radical prostatectomy: nerve sparing technique**
J. Davis, M. Fabrizio, S. Deger, S. Loening, I. Türk (Norfolk, United States of America; Berlin, Germany)
- 2002-11 Cavernous nerve sparing during radical prostatectomy**
L. Martínez-Piñeiro, M. García-Matres, J. García Mediero, J. Cruz, J. De la Peña (Madrid, Spain)
- 2002-12 Prostate brachytherapy technique**
F. Aguilo, J. Suarez, N. Serrallach, S. Arbeláez (Barcelona, Spain)
- 2002-13 Resection of RCC with extended vena caval involvement performed with cardiopulmonary bypass, hypothermia and cardiac arrest with heartport device**
P. Graziotti, M. Maffezzini, G. Giusti, M. Seveso, G. Taverna, D. Lavelli, R. Gallotti, A. Bandera, A. Benetti (Milan, Italy)
- 2002-15 Is disseminated angiomylipomatosis a contra-indication to renal transplantation?**
M. Lucan, P. Rotariu, G. Iacob, L. Ghervan, M. Neculoiu, V. Lucan, D. Sarb, C. Burghilea (Cluj-Napoca, Romania)
- 2002-16 Surgical management of RCC with intrapericardiac IVC extension: diaphragmatic approach to the intrapericardiac IVC**
M. Davydov, V. Matveev, B. Matveev, K. Figurin (Moscow, Russia)
- 2002-17 Surgical management in the growing teratoma syndrome**
R. Miano, T. Christmas, C. Vicentini, A. Tubaro, F. Forte, L. Miano (Rome, L'Aquila, Italy)
- 2002-18 Tumorectomy for carcinoma in a single kidney. Classic hemostasis procedures**
L. Martin, A. Diego, A. Diest, A. Santiberi, J. Sanz, J. Godoy, R. Bermudez (Segovia, Spain)
- 2002-19 Incisionless suprapubic pubovaginal sling using the porcine small intestine submucosa (SIS): technical refinements**
P. Palma, C. Riccetto, V. Herrmann, M. Dambros, M. Thiel, N. Netto Jr. (Campinas, Brazil)

- 2002-20 Urethral restoration with simultaneous fascial sling procedure in patients with urethral loss**
O. Loran, D. Pushkar (Moscow, Russia)
- 2002-21 The Sling Plus: a new concept for minimally invasive treatment of female urinary stress incontinence**
P. Palma, C. Riccetto, V. Herrmann, M. Dambros, M. Thiel, L. Paz, N. Netto Jr. (Campinas, Americana, Brazil)
- 2002-23 Radical cystectomy and orthotopic neobladder in women: rationale and nerve-sparing technique**
G. Martorana, S. Concetti, E. Vece, A. Bertaccini (Bologna, Italy)
- 2002-24 Laparoscopic supratrigonal cystectomy with substitute bladder ileoplasty**
H. Bermudez, C. Gerard, D. Rey, J. Adorno Rosa, G. Vallancien, B. Guillonneau (Paris, France)
- 2002-25 Waterjet technology in penile disassembly for M. Peyronie - the ideal tool for worst cases of Induratio Penis Plastica (IPP)**
F. Basting, N. Perovic (Altötting, Germany)
- 2002-26 Clitoroplasty in intersex repair using disassembly technique**
S. Perovic, M. Djordjevic, V. Vukadinovic (Belgrade, Yugoslavia)
- 2002-28 Penile revascularization with epigastric artery by-pass**
L. Martínez-Piñeiro, A. Aguilera, J. Cruz, J. De la Peña (Madrid, Spain)
- 2002-29 Complex repair in failed male transsexual surgery**
S. Perovic, M. Djordjevic, A. Kollias (Belgrade, Yugoslavia; Westerstede, Germany)
- 2002-30 Total penectomy with perineal urethrostomy for carcinoma of the penis**
A. Simonato, A. Lissiani, S. Galli, A. Bozzola, A. Gregori, F. Gaboardi (Milan, Italy)
- 2002-31 The Tyrolean iceman: urethroscopy in a 5200-year old man**
A. Pycha, L. Lusuardi, M. Marberger, E. Egarter Vigl (Bolzano, Italy)
- 2002-32 News in urosonography**
M. Zacharias, K. Jenderka, H. Heynemann (Halle/Saal, Germany)
- 2002-33 Robotic remote laparoscopy (Da Vinci®): results in experimental surgery**
J. Hubert, B. Feuillu, M. Artis, P. Mangin (Vandoeuvre Les Nancy, France)
- 2002-34 Percutaneous access to the kidney using PAKY: our experience in telesurgery**
S. Micali, D. Stoianovici, A. De Carolis, N. Grassi, A. Patriciu, G. Vespasiani, L. Kavoussi (Rome, Italy; Baltimore, United States of America)
- 2002-35 The risk of bladder denervation during antireflux surgery: a reliable neurophysiological model**
C. Seif, P. Braun, F. Martinez Porillo, B. Herberger, G. Boehler, J. Leissner, K-P. Juenemann, R. Hohenfellner (Mannheim, Maddeburg, Mainz, Germany)
- 2002-36 Adjuvant "Miniperc" in percutaneous nephrolithotomy**
A. Frattini, P. Salsi, S. Ferretti, M. Ziveri, P. Cortellini (Parma, Italy)

**The following videos were presented during the 16th Annual EAU Congress
in Geneva, Switzerland, 7-10 April 2001**

- 2001-1 Laparoscopic radical prostatectomy - the Berlin experience**
I. Tuerk, S. Deger, B. Winkelmann, S. Loening (Berlin, Germany)
- 2001-2 Nerve sparing laparoscopic radical prostatectomy**
C. Abbou, A. Hoznek, L. Salomon, P. Antiphon, F. Saint, D. Chopin (Créteil, France)
- 2001-4 Advances in laparoscopic radical prostatectomy: separation of the bladder from the prostate associated with endoscopic access**
J. Cosson, C. Leleu, G. Kouri, Y. Bottine (Perigueux, France)
- 2001-5 Telesurgical laparoscopic radical prostatectomy**
J. Rassweiler, T. Frede, O. Seemann, C. Stock, L. Sentker (Heilbronn, Germany)
- 2001-7 Initial pitfalls in laparoscopic radical prostatectomy**
M. Dubs, M. Largo, F. Recker (Aarau, Switzerland)
- 2001-8 Nerve and seminal-sparing cystectomy with orthotopic urinary diversion for select bladder cancer**
R. Colombo, R. Bertini, A. Salonia, L. Da Pozzo, M. Roscigno, P. Rigatti (San Raffaele, Milan, Italy)
- 2001-9 The Ghoneim antireflux ureteroileal implantation technique on GIA stapler detubularized ileal neobladder**
G. Muto, F. Bardari, L. D'Urso, R. Leggero (Turin, Italy)
- 2001-11 How to minimise urinary incontinence following radical prostatectomy**
N. Blick, J. Crew, U. Studer (Berne, Switzerland)
- 2001-12 The extended radical perineal prostatectomy**
G. Jakse (Aachen, Germany)
- 2001-13 The radical perineal prostatectomy using a self-retaining system**
H. Keller, F. Lamadé, R. Horsch (Offenburg, Germany)
- 2001-14 Percutaneous treatment of a pyelogenic cyst containing stones**
A. Tasca, A. Cacciola, E. Scremin (Vicenza, Italy)
- 2001-15 Laparoscopic renal cryoablation: technical notes**
A. Cestari, G. Guazzoni, L. Nava, F. Montorsi, T. Maga, V. Scattoni, A. Addis, P. Rigatti (Milan, Italy)
- 2001-17 Laparoscopic donor nephrectomy - first experience**
I. Tuerk, S. Deger, B. Schoenberger, S. Loening (Berlin, Germany)
- 2001-18 Retroperitoneal laparoscopic nephrectomy for polycystic kidney disease**
A. Hoznek, L. Salomon, F. Saint, A. Cicco, W. Alamé, D. Chopin, C. Abbou (Créteil, France)
- 2001-19 Cost effective hand assisted laparoscopic radical nephrectomy (Hungarian technique)**
G. Kovács, E. Holman, B.S. Dénes, J. Kálmán, A. Karsza, J. Rózsahégyi (Budapest, Hungary)
- 2001-20 Percutaneous nephrolitholapaxy (PCNL) by a new lithoclast plus ultrasonic handpiece combination - a novel and highly effective technique in the therapy of renal calculi**
R. Hofmann, P. Olbert, Z. Varga, S. Wille, A. Heidenreich (Marburg, Germany)
- 2001-21 Percutaneous nephrolithotomy in the childhood: our experience with 65 children**
C. Tóth, A. Nagy, I. Kocsis (Debrecen, Hungary)

- 2001-22 Ureteroscopic management of lower pole renal calculi**
P. Dahm, B. Auge, N. Wu, G. Preminger (Durham, United States of America)
- 2001-23 Retroperitoneal lymph node dissection with caval thrombectomy for advanced nonseminomatous germ cell tumour of the left testicle**
F. Martins, J. Alves, J. Freeman, J. Lencastre, J. Varela (Lisboa, Portugal)
- 2001-25 Laparoscopic approach to large para-aortic lymphocyst after radical nephrectomy and regional lymphadenectomy**
P. Cortellini, N. Sebastio, G. Incarbone, A. Barbieri, M. Simonazzi, C. Pavlidis, L. Sarli (Parma, Italy)
- 2001-26 Left sided kidney tumour with caval thrombus into right atrium**
H. Weber, M. Torke, N. Benken, E. Gey, M. Günnewig, X. Krah, G. Eschholz (Blankenheim, Bad Berka, Germany)
- 2001-27 Retroperitoneoscopic adrenalectomy: lateral approach vs. posterior approach**
T. Yagisawa, F. Ito, H. Amano, N. Goya, H. Toma (Tokyo, Japan)
- 2001-28 Reconstruction of distal urethra with buccal mucosa onlay patch graft**
M. Fisch, F. Martins, J. Lencastre, J. Varela, J. Alves (Hamburg, Germany; Lisbon, Portugal)
- 2001-29 Local tumour excision in renal cell carcinoma**
L. Martinez-Piñero, A. Aguilera, D. Rendon, E. Rios, J. De la Peña (Madrid, Spain)
- 2001-30 Tailored laminectomy for neuromodulator implantation**
P. Braun, C. Seif, S. Bross, J. Boschert, P. Alken, K-P. Jünemann (Mannheim, Germany)
- 2001-31 Multi-obstruction of the seminal duct**
J. Pomerol, J. Vicente, J. Sarquella, N. Ribé (Barcelona, Spain)
- 2001-33 Tendinous vaginal support (T.V.S.) using the porcine small intestine submucosa (SIS): a promising anatomical approach for urinary stress incontinence**
P. Palma, C. Riccetto, V. Herrmann, M. Dambrós, R. Mesquita, N. Netto jr. (Campinas, Brazil)
- 2001-34 Megameatus intact prepuce: a rare hypospadias presentation**
A. Mendes Leal, T. Aires (Clipóvoa, Portugal)
- 2001-35 Genital prolapse repair - pubovaginal sling sacrospinous ligament suspension with cadaveric fascia**
M. Kozminski (St. Joseph, United States of America)
- 2001-36 Complete penile disassembling and tunica albuginea autograft in the treatment of severe penile deformities due to la Peyronie's disease**
G. Carmignani, C. Corbu, A. De Rose, P. Traverso (Genoa, Italy)
- 2001-37 Correction of the curvature in Peyronie's disease by transplantation of saphenous vein patches**
F. Boeminghaus, M. Schermesser, J. Witt, M. König (Neuss, Germany)
- 2001-38 TURP: state of the art**
V. Pansadoro (Rome, Italy)

**The following videos were presented during the 15th Annual EAU Congress
in Brussels, Belgium, 12-15 April 2000**

- 2000-1 Malignant dysgerminoma in a true hermaphrodite**
V. Bucuras, R. Bardan, J. Corcan, P. Dragan (Timisoara, Romania)
- 2000-7 Surgical treatment of morbus Peyronie using penile disassembly technique accomplished by water jet device and laser beam**
R. Basting, N. Djakovic, P. Widmann, S. Perovic (Belgrade, Yugoslavia; Altoetting, Germany)
- 2000-8 Tension-free vaginal tape (TVT): rationale, technique & complications**
P. Palma, C. Riccetto, G. Ribeiro, A. Das Fo, N. Rodrigues Netto Jr. (São Paulo, Brazil)
- 2000-9 Our experience on tension free vaginal tape for stress urinary incontinence**
M. Naudin, D. Pamart, A. Corbusier (Brussels, Mons, Belgium)
- 2000-20 New strategy and minimal access approach for cardiopulmonary bypass (CPB) in renal cell carcinoma (RCC) with suprahepatic caval thrombi**
A. Sorcini, J. Libertino (Burlington, United States of America)
- 2000-21 Use of the ultrasonic scalpel to facilitate radical prostatectomy**
W. Young, J. Pow-Sang, D. Cuthbertson (Tampa, United States of America)
- 2000-22 Radical perineal prostatectomy, an interesting surgical approach in some selected patients**
A. Mendes Leal, T. Aires (Povoa de Varzim, Portugal)
- 2000-23 Video assisted minilaparotomy for RRP**
P. Puppo, G. Conzi, C. Introini, G. Vigliercio (Genova, Italy)
- 2000-24 Advances in laparoscopic radical prostatectomy: a pure extraperitoneal approach**
R. Bollens, M. Vanden Bossche, T. Roumequere, A. Damoun, A. Zlotta, C. Schulman (Brussels, Belgium)
- 2000-25 Vesicourethral reconstruction during laparoscopic radical prostatectomy**
C. Abbou, A. Hoznek, L. Salomon, P. Antiphon, M. Ben Slama, F. Saint, D. Chopin (Créteil, France)
- 2000-26 Brachytherapy for prostate cancer: technique of transperineal seed implantation**
G. Guazzoni, L. Nava, A. Losa, R. Matteo, A. Cestari, P. Bellinzoni, F. Montorsi, P. Rigatti (Milan, Italy)
- 2000-27 Laparoscopic radical prostatectomy - the Heilbronn technique**
J. Rassweiler, O. Seemann, M. El-Quaran, L. Sentker (Heilbronn, Germany)
- 2000-28 The anatomical approach to radical cystectomy**
M. Gallucci, A. Vincenzoni, M. Mauro, P. Fortunato (Rome, Italy)
- 2000-29 Continent urinary diversion with parietal stoma of Indiana type**
G. Glück (Bucharest, Romania)
- 2000-30 Acucise RP: an experimental and clinical demonstration**
E. Cirillo Marucco, A. Pagliarulo, G. Cardo, V. Pagliarulo, G. Ludovico, G. Giocoli Nacci (Bari, Italy)
- 2000-31 Systematic processing of radical prostatectomy specimens**
H. Schmid, A. Semjonow, A. Terpe, L. Hertle (Münster, Germany)
- 2000-32 Extra-peritoneal radical cystectomy and sigmoid neo-bladder with tenomyotomy**
K. Krajka, A. Mikszewicz, M. Markuszewski, M. Matuszewski (Gdansk, Poland)

2000-34 Retroperitoneoscopy 2000 - the technique

J. Rassweiler, T. Frede, O. Seemann, M. Hatzinger (Heilbronn, Germany)

2000-35 Single stage retrograde endopyelotomy with the Rite-Cut® electrode

A. Patel, J. Webster (London, United Kingdom)

2000-36 Posterior retroperitoneoscopic adrenalectomy for large adrenal tumour

T. Yagisawa, F. Ito, T. Shimizu, H. Amano, H. Toma (Tokyo, Japan)

2000-38 Laparoscopic bilateral partial adrenalectomy in a boy with familial pheochromocytoma

G. Janetschek, R. Peschel, C. Radmayr, G. Bartsch, H. Neumann (Innsbruck, Austria; Freiburg, Germany)

2000-39 Laparoscopic surgery of bilateral multiple renal cysts with the ultracision scalpel

W. Kozak, W. Feil, U. Maier (Vienna, Austria)

2000-40 Retroperitoneoscopy in child: the Visiport technique

S. Micali, P. Bove, R. Miano, G. Maturo, E. Matarazzo, N. Capozza, P. Caione (Rome, Italy)

2000-42 Ileal T pouch with split-cuff ureteral anastomosis

G. Marino, R. Cevoli, G. Del Noce, M. Laudi (Turin, Italy)





Abstract Author's Index

A

- Abad C., 188
Abadías M., 680
Abai X., 844, 848
Abascal J.M., 131, 133, 134
Abatangelo G., 91, 506
Abate A., 1096
Abbona A., 624
Abbou C.C., 122, 177, 180, 183, 269,
336, 447, 714, 715, 934, 1029,
1059, 1198
Abd-alsamad I., 161
Abdel Hafez A., 96, 235, 957, 958
Abdel Khalik Z., 288
Abdel Wahab A., 96
Abdel-Fattah M., 987, 1131, 1135
Abdel-Hamid M., 879
Abdel-Khalek M., 390, 879
Abdel-Latif M., 7, 505, 674, 818, 1071
Abdelmaksoud A., 1091
Abdou M.T., 819
Abdus Salam M., 89, 1145
Abe H., 1101
Abe T., 337, 1080
Abedi A.R., 754
Abedin R., 1145
Abedin S.A., 55
Aben K.A., 216
Abend M., 252
Abo-Elghar M., 655
Abol-Enein H., 505, 1071
Abouel Fetouh H., 519
Aboujeili Z., 429
Abourjeily Z., 203
Abraham L., 166, 170
Abrahamsson P. A., 160
Abrams P., 372, 373, 537, 689, 808,
1125
Abu-Eideh R., 669, 1071
Abuzeid A.M., 96
Acar C., 651
Acar O., 892, 895
Acher P., 591
Ackermann R., 332, 863
Acquati P., 777
Adam C., 148
Adayener C., 1123
Addla S., 30
Ader J.L., 74, 1110
Adler D., 115
Adsan O., 667
Aellen S., 561
Afer I., 899
Afoko A., 904, 905, 963, 964
Afonso A., 112
Agapitos E., 882
Ageheim H., 1149
Aggarwal N., 527, 980
Aggelidis P., 787
Aghajanyan I., 545, 600
Aghamiri S., 666
Agrawal K.C., 9
Aguiló Lúcia F., 307, 724
Ahmed M., 239
Ahmed S., 445
Ahmedov B., 265
Ahn H., 670, 740
Ahn H.S., 752
Ahn S.H., 227
Ahn T.Y., 468, 851
Aho T., 998, 999, 1000
Ahyai S., 431, 716, 858, 1168, 1191
Aimo G., 1017
Aitchison M., 793, 795
Ajayi L., 343
Akao J., 370
Akata D., 1124
Akbay E., 1130
Akcay M., 496
Akdogan B., 261, 298
Akino H., 395
Akino T., 337, 1080
Akkad T., 86, 263, 296, 300, 303, 671,
919, 1072
Akpinar B., 1124
Akre O., 1185
Aktug H., 767
Akyol I., 1123
Al Badour A., V14
Alaev Y., 731
Al-Agha A., 239
Alam K., 1145
Alamanis C., 601
Ala-Opas M., 1065
Alavi S., 843
Albala D., 846
Albanis S., 648
Albers P., 108, 299, 1188
Al-Bodour A., 277, 609
Albouy B., 447, 639
Albqami N., 277, 609, V14
Albrecht K., 22, 38
Albrecht W., 721, 1062
Alcaraz A., 210, 215, 698
Aldo B., 607
Aleksiev B., 114, 746
Alexander V.R., 111
Alexandre A., 900
Alexandre L., 163, 164, 224, 326, 388
Alfano V., 829
Alfaro J., 422
Algaba F., 210, 215
Al-hayek S., 689, 808, 1125
Ali M., 96
Ali T., 971
Alibhai S., 1172
Ali-el-Dein B., 7, 669, 674, 1071
Alivizatos G., 344, 1090
Alkan E., 1085, 1095
Alken P., 44, 45, 65, 90, 195, 217, 362,
603, 783
Allaf M., 1068
Allard J., 74, 1110
Allegro R., 293, 718
Allen C., 192, 201, 244, 433, 434
Allen N., 26
Allepuz C., 422
Allhoff E.P., 23, 62, 176, 287, 771
Allory Y., 122, 715
Alloussi S., 1104, 1122, 1126
Allúe M., 422
Almeida D., 124, 270, 1005
Almeida H., 21
Altay B., 767
Althaus P., 1188
Althof S.E., 702
Altieri V., 290, 293, 769
Altunrende F., 496, 854
Altziebler S., 630
Alvarez M., 421, 1161
Alvarez Ossorio J.L., 883
Alves M.T., 75
Alyaev Y., 580
Alzen G., 974
Amano H., 516
Ambruosi C., 88, 1044
Amend B., 743
Amiel G., 455, 815
Amiel J., 191
Amon Sesmero J.H., 1136
Amarin Da Silva I., 369
Amosov A., 580
Anagnostou T., 426, 427, 531, 875
Anastasiadis A.G., 137, 264, 709, 1027,
1197
Anderson C., 128

Andersson K.E., 10, 11, 14, 954, 1109, 1111
Andorno A., 187
Andrade C., V42
Andre J., 56, 366
Andreatta R., 1030
Andrich D., 1040
Andriole G., 846
Angelozzi G., 659
Angiolilli D., 642, 857
Angulo J., 358, 582, 856
Anna R., 683
Anselmo G., 245
Anson K., 493, 498, 1097
Anstrom K., 142
Antczak A., 726
Antebi E., 423
Antonenko V., 963
Antoniou D., 503
Apaydin E., 657
Apostolidis A., 678, 798
Appanna T., 937
Arabagiou I., 665
Aragona F., 718
Arai K., 1101
Araki I., 211
Arandjelovic G., 1096
Aras N., 892, 895
Aravatinos E., 499
Arbak S., 768
Arbeláez Arango S., 307, 724
Arber S., 550
Arce Y., 215
Argirovic D., 1001
Argyropoulos V., 991
Arhontakis A., 894
Arisan S., 903
Arkoumani E., 297, 821
Armengol S., 374
Armitage J., 6, 543, 544, 1070, 1074, 1179
Armstrong J., 913, 914
Arnal J.F., 1110
Arnal J.L., 74
Arndt B., 1013, 1014, 1189, 1196
Arndt C., 18
Arribas J.M., 883
Arrosagarai P., 692
Ars E., 210, 215
Arslan M., 198
Arthur S., 815
Artibani W., 177, 183, 245, 336, 338,

353, 372, 373, 537, 562, 682, 765
Arum C.J., 852
Arver S., 622
Asakura H., 40
Ascoli R., 718
Asgari S.A., 1115
Ashfaq R., 811, 920
Asimakopoulos K., 51
Askitis A., 12
Aslan Y., 706
Asopa R., 937
Astancolle S., 576
Astesana L., 502
Astobieta A., 350
Aszmann O., 805
Atan A., 706
Ates M., 424
Athanasopoulos A., 51
Athmalingham G., 99
Attisani F., 673, 728
Aubin S.M. J., 870, 1012
Audet J.F., 936
Auerbach S., 696
Augustin H., 719
Aune O., 872
Auprich M., 719
Aurtenetxe J.J., 350
Autorino R., 290
Auvinen A., 386, 1173, 1174, 1186
Avelino A., 797
Aviello G., 769
Avoyan A., 565
Ayder A.R., 198
Aziz N., 1060
Aznaouridis K., 12
Azooz H., 147
Azooz M., 95, 147
Azzouzi A.R., 365

B

Babinski M., 400
Babjuk M., 822
Bachmann A., 791, 841, 855, 992, 993, 996, 1157
Badalyan R., 600
Badawi J.K., 90, 603
Badawy A., 96
Bader P., 760
Badet L., 750
Badran M., 669
Bae J.H., 27
Baermann C., 1039

Bafaloukas N., 648
Baffoe-Bonnie A., 568
Bageti Filho H., 347
Bagga H., V34
Bahar M., 417
Bahary J.P., 583
Bahl A., 734
Bai Y., 547
Bakkaloglu M., 49, 1124
Bal K., 712
Balasubramaniam A.V., 959
Balasubramanian S.P., 571
Baldauf A., 462
Ballanger P., 467
Baltogiannis D., 251, 770
Balzarro M., 738
Bangma C., 364, 593
Bannowsky A., 473, 596, 736, 1194
Bar Yosef Y., 928
Barashkov G., 580
Barbagelata A., 713
Barber N., 847, 932
Barbieri L., 472, 474, 607, 628, 1042, 1043
Barbiroli B., 710, 741
Barbos A., 1003, 1004, V41
Bar-Chama N., 471
Barentsz J., 737, 1077
Bares R., 743
Baretton G., 110, 145
Barghout V., 135, 142
Barmoshe S., 2, 681
Barret E., 118, 124, 270, 272, 933, 1005, 1064, 1067
Barros H., 1010
Barry Delongchamps N., 1162, 1165
Barten E.J., 664
Bartoletti R., 931
Barton Grossman H., 460
Bartsch G., 69, 70, 71, 82, 86, 93, 101, 102, 105, 185, 230, 240, 263, 296, 300, 303, 306, 480, 484, 523, 524, 546, 552, 671, 679, 773, 780, 866, 881, 919, 1018, 1037, 1041, 1056, 1072, 1121, 1144
Bartsch G.J., 4, 1069
Barua J., 602
Barut M., 854
Basic B., 836
Basic D., 836, 1082
Bassi P. F., 1050, 1096
Bastian B., 594

Abstract Author's Index

- Bastian P.J., 61, 111, 455, 815, 1170
Baston C., 512
Batista Miranda J.E., 538
Baum C., 1057
Baumann R., 594
Baumert H., 1151
Baumgartner R., 817
Bavendam T., 376
Bay J.O.B., 286
Baykal K., 1123
Baykal M., 496, 854
Baykara M., 355
Bazeed M., 626
Bazin J.P., 638
Beany R., 591
Beatriz A., 899
Becht E., 276, 280, 302, 446
Beck A., 212
Becker A., 217
Becker A., 41
Becker F., 331, 644, 759
Becker H., 630
Bedir S., 758
Beer M., 1188
Beerenwinkel N., 106
Betz R., 967
Beheshtian A., 1117
Behr-Roussel D., 225, 326
Beier J., V23
Bekavac V., 515
Beketova N., 580
Bektic J., 86, 93, 240, 306, 480, 866,
881, 1018, 1144
Belal M., 689
Belej K., 94
Beley S., 715
Belger M., 622
Belgrano E., 748
Belhadj K., 896
Belldegrün A.S., 447
Bellec L., 447, 639
Bellina M., 876
Belousov I., 904, 905
Belova E., 746
Bemis D., 153, 414
Ben Addi A., 857
Ben Chaim J., V36
Ben Dor D., 918
Ben Jeddou F., 896
Ben Rhouma S., 48, 356
Ben-Abdennebi H., 750
Benard F., 423
Benayoun S., 423
Benchetrit J., 528
Benecchi L., 867
Benedetto G., 91
Beneduce L., 562
Beneforti P., 800, 901
Benetti A., 351
Benjamin S., V17, V18, V30
Benoît G., 161, 162, 262, 429
Bensadoun H., 440
Bensalah I., 48, 356
Bensalah K., 180, 327, 336, 483, V13
Benson M., 153, 414
Bentaleb Y., 1107
Berardi B., 444
Berberoglu Y., 496, 854
Bercovich E., 1016
Berdjis N., 462
Berenguer A., 358, 582, 856
Berger A.P., 86, 306, 866, 881, 1144
Berger M., 294
Berglund L., 1108
Bergsdorf T., 1088
Beri A., 928
Bernabé J., 163, 164, 224, 225, 326,
388
Bernabei M., 829
Bernard F., 1178
Bernardini S., 898
Bernasconi F., 676
Bernat M.M., 510, 515
Berner L., 917
Bernhard J.C., 447, 639
Bernikov A., 1192
Bernsen R.M.D., 312
Bernshausen A., 557
Bernstein J., 528
Bertaccini A., 741, 747
Bertapelle M.P., 84, 950
Bertini R., 308, 607, 612, 642
Bertolotto F., 1155
Bessa Junior J., 962
Betto G., 562, 765, 1190
Bettuzzi S., 576
Beute M., 1104
Bex A., 938
Bezrukov E., 580, 731
Bhanot S., 128, 273
Bhargava S., 92
Bhatt R., 159
Biagi E., 747
Bianchi G., 623
Bianco A.R., 290
Bianco F., 268, V3, V19, V39
Bikhchandani J., 648
Bildosola A., 350
Bilgilişoy U., 656
Bilir A., 767
Bilkenroth U., 109
Billia M., 50, V27
Bini V., 1129
Binshen C., 844, 848
Birzele J., 652
Bisas A., 344
Bischof Delaloye A., 921
Bishop M., 560
Bitker M.O., 425
Bittard H., 898
Bitton A., 622
Bivalacqua T.J., 15
Bjartell A., 155, 160, 256, 406
Bjørkøy A., 872
Black A., 860, 864, 868
Blanchet P., 429
Blase A., 870, 1012
Blasi F., 1011
Blesch A., 18
Blick N., 382, 1049
Blietz C.E., 214
Bluemke K., 109
Bocciardi A., 642
Boccon-Gibod L., 875, 891, 893, 1137,
1140, 1162, 1165
Boccon-Gibod Liliane, 1162, 1165
Bock C., 97, 137, 223, 236
Bock P., 1104, 1126
Bocqueraz F., 328
Boczko J., 120, 123
Boddi V., 931
Boddy A.V., 207
Bodmer W., 154
Bodo G., 84, 950
Bodrug S., 870, 1012
Boehmler A.M., 223
Boeing H., 26
Bogdanos J., 284
Böhler G., 949
Böhm M., 176
Böhmer D., 435
Bohnen A.M., 167, 312, 540, 542
Boiborean P., 354, 500, 1147
Boillot B., 889
Boisson R.C., 366
Boiteux J.P., 286, 578

Bokemeyer C., 301
Bolenz C., 217, 362
Bolinger B., 753
Bolla M., 729
Bollito E., 876
Bolodeoku J., 380
Bolognesi A., 612
Bolukbasi A., 712
Bonde J.P., 575
Bongmo S., 482
Bonhoure E., 581
Bonn G., 101, 102, 105
Bonnet K., 982
Bono A.V., 912, 912, 1066
Bonvini D., 187, 685
Boormans J., 637
Borchers T., 913
Bordon L., 1168, 1169
Borkowski A., 325, 683, 875
Bormotin A., 1192
Borovecki F., 157
Boroyan R., 545
Borque A., 422
Borrè A., 84
Borsato A., 738
Bosch R., 152, 167, 257, 312, 540, 542,
683, 687
Boscolo Berto R., 682, 1096
Bosset J.F., 729
Bothe K., 736, 1194
Botoca M.R., 354, 500, 1147
Botto H., 8, 313, 528
Boublil V., 1137, 1140
Bouchardy C., 1034
Bousquet J.C., 313
Bouvier R., 441, 443
Bouygues V., 483
Bova G., 688
Bown S.G., 433, 434
Boy S., 801, 802, 804, 955, 1106, 1112
Boyd P., 497
Boyle E., 1149
Bozkirli I., 651
Bozzini G., 777
Bozzola A., 127, 1075, V8
Bracq A., 1005
Braeter M., 1102
Bragina L., 965
Braud G., 124, 270, 1005
Braun C., 484, 1041
Braun P.M., 250, 473, 592, 596, 736,
947, 949, 1194

Braun R., 1126
Brausi M., 426, 427, 531, 576, 668,
782, 1066
Brazier J., 828
Breda A., 934
Breda G., 454, 934
Breeuwsma A.J., 884
Brehmer B., 150
Brentano S., 870, 1012
Brewster S., 154
Breza J., 189, 319
Brieger A., 431
Briganti A., 61, 183, 472, 474, 586, 607,
608, 628, 815, 911, 1025, 1026,
1042, 1043, 1166, 1168, 1169,
1171, 1178, 1195
Bringuier P.P., 56
Brito F.A., 1068
Brock G., 465
Broderick G., 174
Brodsky M., 375, 536
Brollo J., 72
Broux P.L., 1132
Brown C., 704
Brown J.E., 130
Brown M., 30, 159, 577
Brugnolaro C., 117
Brundin L., 1108
Brunner A., 919
Brunocilla E., 710, 747
Bruschini H., 75
Brutenic J., 319
Bua L., 586, 1195
Buchholz N., 648
Bucuras V., 354, 500, 1147
Budach V., 435
Buechner F., 26
Buerst M., 1104
Bueschel P., 1189, 1196
Buess G., 121
Bueth D., 125
Buffi N., 271
Buhard O., 364
Buijs J., 157
Bukowski R., 1057, 1058
Bulbul M., 288
Bull S., 174
Bumsik H., 468
Burchardt M., 273
Burcher E., 796
Burdan M., 500
Burden H., 588

Burger M., 368
Burghelea C., 1003, 1004, V41
Burgos F.J., 194, 521
Burkhard F.C., 1128, V20
Burmeister C., 1157
Burmeister Y., 63
Bursat M., 210, 215
Bussolati G., 825
Butnaru D., 580, 731
Butreau M., 8
Büttner M., 660
Buttvan R., 153, 414
Buvat J., 465
Buyuktuncer E.D., 903
Bycroft J.A., 959
Byun S.S., 182, 418, 941

C

Cabeza M.A., 595
Cabezuelo M.A., 188
Cabral C., 76, 77, 233
Cabrera F., 1142
Cabrespine A., 286
Cáceres F., V2
Cafarelli A., 444
Cai T., 931
Calabuig Fariñas S., 219
Calais da Silva F.E.C., 283, 291, 1066
Calais da Silva junior F., 283, 291, 1066
Callea A., 444
Calleary J., 672
Calo G., 800
Calvet C., 467
Camara N.O., 75
Camargo I., 350
Campbell M., 55
Campbell S., 62
Camperat E., 225
Campodonico F., 79
Campos-Fernandes J. L., 56, 366, 988
Camps N., 724
Cancello G., 290
Cancel-Tassin G., 365
Candia V., 802
Canepa G., 79
Cannaby C., 648
Cansino J.R., V2, V24
Cao Y., 44, 45, 217, 362
Capasso F., 769
Capasso R., 769
Capitan C., 421, 1161
Capizzi A., 353

Abstract Author's Index

- Capponi G., 79
Capron F., 229
Carbone A., 688
Carderi A., 175
Cardoso L., 72, 76, 77, 233
Cardozo L., 683, V26
Carini M., 428, 641, 643
Carlino F., 193
Carloni M., 428, 643
Carlsson M., 375, 376
Carmignani G., 88, 1044
Carmignani L., 777
Carmona O., V12
Carone R., 84, 950
Carrera C., 1161
Carrerete F., 400
Carter N., 880
Carvalho J., 897, 1138
Casale P., V15
Casanova J., 181
Casariego J., 627
Casarosa C., V15
Casas P., 713
Casella R., 629, 791, 923
Casetta G., 360, 825, 1017
Casey R., 139
Casimiro C., 1035
Caskurlu T., 903
Casselmann J., 721, 1062
Castagnetti G., 576
Castel L., 142
Castellano S., 84
Castellanos E., 589
Castelo L., 713
Castillón I., 194, 202
Castiñeiras Fernández J., 883
Castro H., 797
Castroviejo Royo F., 1136
Catanese A., 718
Cathala N., 272, 933, 1064, 1067
Cathcart P., 6, 543, 544, 944, 1070, 1074
Cathelineau X., 118, 124, 270, 272, 933, 1005, 1064, 1067
Catto J.W., 57, 365
Cauni V., 85
Cavada E., 1035
Cavalcanti A., 897, 899, 900, 1138
Cavalleri S., 338
Cavaretta L., 91
Caviezel A., 789
Çayan F., 1130
Çayan S., 1130
Cayzergues L., 162, 262
Cecchini L., 131, 133, 134, V10
Cecchini M.G., 156, 157, 566
Celhay O., 714, 853
Celia A., 454, 934
Centemero A., 508
Ceratti G., 187
Cerepei V., 512
Cerri G., 962
Cerri L., 962
Cervigni M., 683, 978, V26
Cestari A., 271, 508, 790, 845
Cetinel B., 835
Cetinkaya M., 667
Cha J.H., 966
Chabannes E., 898
Chae K.Y., 28
Chagas J., 561
Chagas M., 400
Chahal R., 799
Chakvetadze V., 1078
Chalikopoulos D., 344
Challacombe B., V32
Chammas M.C., 962
Chan Y.H., 661
Chancellor M., 531
Chandra S., 9
Chandrasekar P., 672, 1148
Chang C., 1084
Chang C., 126
Chang H.S., 621, 969
Chang I.H., 418, 941
Chang L.S., 20
Chang S.G., 490
Changhee Y., 468
Changug L., 482
Chapelon J.Y., 441, 443
Chaplin B., 593
Chapple C.R., 73, 92, 226, 379, 380, 395, 683, 1006
Charalambous S., 1133
Charalampidis V., 887
Chartier- Kastler E., 83, 229, 388, 528, 826, 827
Chau H., 1092
Chaussy C., 439, 442, 1036, 1088
Chautard D., 177, 336
Chaves J., 466
Chawla S., 664
Chelif M., 48, 356
Chen C.R., 1084
Chen K.C., 413
Chen K.K., 20
Chen R., 1153
Chen Y.M., 130
Cheng C., 1143
Cheon J., 27
Cheon S.H., 329
Cherasse A., 525
Cherian J., 209, 943
Chernogubova E., 904
Chess-Williams R., 73, 226, 395
Chigogidze T., 397
Chihara Y., 333
Chinn C., 83, 826
Chinnaiyan A., 103
Chiong E., 661
Chishti M., 239
Chiu J.H., 20
Cho C.G., 437
Cho D.H., 966
Cho I.R., 34, 329
Cho J.S., 329
Cho J.H., 478, 902
Cho N.H., 402
Cho S.R., 994
Chodak G., 1024
Choe J.H., 491
Choi C.Y., 752
Choi D.H., 17
Choi H.Y., 1063
Choi J.Y., 966
Choi J.B., 752
Choi N.G., 1176
Choi S.H., 994
Choi W., 932
Choi Y.D., 329, 402
Chollet P., 286
Chondros N., 830
Chong C.H., 449
Chong J.H., 315
Choo M.S., 399
Choo S.H., 1063
Choong S., 42, 192, 201
Chopin D., 183
Chowdhury G., 1145
Chowdhury S.D., 342
Chretien Y., 638
Christ G., 471
Christ T., 1102
Christeas N., 371
Christmas T., 792
Christoph F., 58, 208, 253, 255, 824,

1019, 1105
Christopher N., 249
Chromiecki T., 456, 457, 458, 812, 813,
814
Chtourou M., 896
Chun F. K. H., 61, 100, 183, 607, 608,
716, 815, 858, 911, 1015, 1025,
1026, 1031, 1166, 1168, 1169,
1171, 1178
Chung B., 507
Chung B.H., 329
Chung E.A.L., 959
Chung J.W., 1154
Chung L.W.K., 112, 415
Chung M.K., 78, 693
Chung S.K., 66, 511, 518
Chunxiao L., 844, 848
Chyrhai A., 178, 190
Ciammella P., 585
Ciciliato S., 829, 981
Cikili N., 47
Ciliv G., 1008
Cilotti A., 961
Cindolo L., 177, 180, 183, 336
Cinn C., 827
Cisneros J., V2, V24
Cisternino A., 353, 765, 1050, 1096,
1190
Ciuffreda M., 349
Claes H., 320
Claici D., 500
Clark C., 870, 1012
Clarke A., 937
Clarke M., 1022
Clarke N., 30, 159, 577
Claussen C.D., 709
Cleeve L., 937
Clément P., 163, 164
Cloutier S., 361, 561
Coccarelli F., 37
Cochrane D., 861, 862
Coe J., 704
Cohen M., 54
Cohen P., 404
Cohn Cedermark G., 589
Coissard A., 520
Coleman R.E., 130
Collado A., 181
Collette L., 721, 729, 1062
Collin-chavagnac D., 366
Collins O., 619
Collins S., 620

Colombel M., 116, 419, 447, 525, 639,
750
Colombo R., 607, 642, 845, 1195
Colovic V., 1082
Colpi G.M., 777
Compagnie S., 326
Compérat E., 229
Comploj E., 305, 917, 925
Comunale L., 738
Concetti S., 710
Conde Redondo C., 1136
Condom Mundó E., 307, 724
Conford P., 258
Connolly D., 860, 864, 868
Conort P., 191
Constantinides C., 1090
Conti E., 310
Conti M., 429
Cook R., 130
Corbishley C.M., 246
Corcos J., 833
Cormier L., 450, 520, 522, V6, V37, V38
Cornejo F., V12
Cornel E.B., 664
Cornford P., 739
Correa R.J., 911
Cortellini P., 349, 502
Cortese P., 981
Corti A., 576
Corti B., 710
Corvin S., 236, 264, 709, 743, 1027,
1197
Cosciani Cunico S., 245
Coscione M., 659
Cosentino M., 353
Cossu M., 849, V27
Costa A.M., 659, 831
Costa C., 21
Costa P., 528
Costa W., 400, 766
Costantini E., 383, 477, 1129
Coulange C., 328
Cour F., 528
Courtieu C., 978
Cowan N., 820
Coy J.F., 65
Coyne K.S., 375, 536, 828
Cozzarini C., 586, 612, 642
Cracco C., 849, 876
Craggs M.D., 532, 959
Craig R., 815
Cranston D., 779, 781

Crepel M., 447, 639
Crins T., 292
Crivellaro S., 187, 527, 685, 952
Cromwell D., 704
Crook T., 377
Cross N., 408
Cross R., 226
Cross S., 57
Crump A 823
Cruz C., 810
Cruz F., 720, 797, 810, 1010, 1021
Cucherat M., 548, 549
Cuesta J.M., 1035
Culig Z., 406
Culty T., 891, 893
Cumpanas A.A., 354, 500, 1147
Cunliffe H., 412
Curiel L., 441, 443
Curran J., 619
Currlin E., 975, 1031, 1191
Curt A., 802
Cussenot O., 365, 425, V1, V5
Cuvillier O., 581
Cytron S., 918

D

Da Pozzo L.F., 308, 586, 607, 612, 642,
748, 1028, 1178
Dahiya R., 98, 369
Dal Canto M., 931
Dal Moro F., 353, 682, 1050, 1096
Dalla Palma P., 37
Dalle Ore M.C., 950
D'Aloia G., 829
Dalpiaz O., 935
Daly D., 73
Daly P., 755
Damber J.E., 393
Dambros M., 222, 839, V25
Damião R., 693
Danai Y., 115
Dancona C.A.L., 806
Danelia E., 1078
Danilevicius M., 596
Danisman A., 355
Dantas Filho V.P., 806
Danuser H., 907
Dapozza L., 729
Daraï E., 982
Darblade B., 326
Darby S., 104
D'Armiento M., 290

Abstract Author's Index

- Dasgupta P., 343, 381, 675, 798, V32
Daskalopoulos G., 830
Dattolo E., 530
Daudon M., 191
Davenport K., 46
David-Montefiore E., 982
Davidson I., 861, 862
Davies A.M., 799
Davies B.R., 206
Davies J., 445
Davies K., 471
Davis B., 846
Dawaba M., 1087
Dawson J., 550
Dayon A., 581
De Andrade R., V42
De Boissezon X., 1107
De Buyl G., 850
De Carolis A., 673, 728
De Fraga R., 839, V25
De Gast G., 938
De Giorgi G., 345
De Giuli P., 310
De Grande G., 293
De Jong I.J., 884
De Jong P.R., 683, V26
De Jong T., 1120
De Jongh R., 222
De Koning H., 1023
De Kort L., 687, 1120
De La Morena J.M., 421, 1161
De La Peña J.J., V2, V24
De La Rosa S., 595, 1142
De la Rosette J.J., 335, 915, 934, 1006
De La Taille A., 122, 153, 177, 180, 183,
336, 414, 447, 639, 714, 715, 1029,
1059, 1146, 1198
De La Taille F., 694
De Laurentiis M., 290
De Libero A., 1017
De Luca G., 668, 782
De Marco V., 765
De Meerleer G., 584
De Neve W., 584
De Nunzio C., 1020
De Placido S., 290
De Reijke T.M., 664, 721, 729, 1062
De Ridder D., 151, 978
De Stefani S., 623
De Thé H., 924
De Vries R., 276, 280, 302
De Wachter S., 533, 809, 960
De Win G., 151
De Witte P., 361
Dean J., 171
Debie B., 432
Debodinance P., 978
Debois M., 721, 1062
Debre B., 475
Debski R., 398
Decaussin M., 56, 366
Deckers J.W., 312
Deger S., 435, 436, 757
Degirmenci T., 198
Dehò F., 472, 607, 628, 857, 1042, 1043
Dehpour A.R., 1117
Deibl M., 866, 881, 1072
Del Popolo G., 530, 627, 953, 961
Del Zingaro M., 383
Delaere K., 913
Delaporte V., 528
Delcourt A., 229
Deliveliotis C., 1090
Dellabella M., 1011
Dell'Acqua V., 790
Dellon L., 805
Delmas V., 161, 1137, 1140
Demidko Y., 731
Demidov L., 1053
Demir A., 768
Demirkenes O., 835
Demura T., 1076
Denes B., 696
Dênes F.T., 241, 962, 976
Deng W., 15
Deniset A., 930
Denoyette L., 584
Denys P., 164, 224, 225, 229, 388
Deperthes D., 361, 561
Depuy V., 142
Deras I.L., 870, 1012
D'Errico-Grigioni A., 741
Deruelle C., 129, V1, V37, V38, V5, V6
Desai M., 507
Desaulniers M., 1012
Descazeaud A., 475
Descotes F., 56, 366
Descotes J.L., 328, 336, 889
Desgrandchamps F., 501, 694, 1146
Deturmeny J., 197
Devonec M., 56, 366, 988
Dhami G., 888
Di Lorenzo G., 290
Di Stasi S.M., 383, 673, 728
Di Trolio J.V., 1150
Diamandis E., 561
Dickerson E., 979
Dickstein G., 509
Diederichs W., 1188
Diemer T., 19, 775
Dierckx R.A., 884
Dieter M., 389
Dietrich J., 463, 464
Digirolamo V., 845
Dihazi H., 212
Dilek S., 1130
Dilernia G., 882
Dillenburg W., 280, 302, 446
Dimitriadis F., 251
Dimopoulos T., 284
Dinis P., 797
Dinsmore W., 165
Disanto V., 454, 934
Divan C., 37
Divrik R.T., 298
Divrik T., 261
Diyakov V., 686, 1192
Dizeyi N., 256
Djavan B., 426, 427, 531, 843, 875,
1009
Djordjevic M., 242
DJurasic L., 836
Do M., 119, 128, 273
Dobronski P., 426, 427, 843, 875
Dobrovits M., 339, 940, 1114
Dobrowolska B., 564
Dobrowolski Z., 564
Dobry E., 907
Dobson M., 481
Docherty N., 755
Dodat H., 1045
Doehn C., 36, 214, 1054
Dogan H.S., 261, 1124, 1127
Dogliani N., 310
Doglioni C., 1158
Dohle G., 167
Dominguez P., 421, 1161
Dominguez-Escrig J.L., 206
Dominique S., 1137, 1140
Domurath B., 1104
Donohue J., V1, V37, V38, V6
Donovan J., 1182
Dooper I., 517
Doré B., 191, 714, 853
Dotan Z., V4, V40
Douard R., 429

Doublet J.D., 694, 1146
 Doucet L., 328, V1, V37, V38, V5, V6
 Doumanis G., 238
 Doumerc N., 581
 Dragan P., 1147
 Dragicevic S., 52
 Dresser M., 173
 Drevs J., 36
 Drewa T., 398
 Drewe J., 916
 Dristiliaris D., 68
 Droschl N., 334
 Droupy S., 161, 162, 262, 429
 Drüeke T.B., 751
 Duarte R., 976
 Dubois R., V12
 Dubosq F., 313, 501, 924
 Dubravicky J., 319
 Duclos J.M., 501
 Dudderidge T., 1040
 Dudea S., 1003
 Dudu E., 512, 514
 Duelund J., 1149
 Dufour A., 440
 Dufour B., 632, 638
 Dugast J., 1132
 Duggan A., 692, 693
 Dujardin T., 936
 Dumont R., 181
 Durante S., 91
 Dvoracek J., 822
 Dybowski B., 325

E

Eardley I., 321, 322
 Eassa W., 658, 1087
 Eastham J., 1015, 1200
 Eaton C., 408
 Ebara S., 1
 Ebmer J., 805
 Echte D., 610, 877
 Eden C., 126, 279, 597
 Edwards D., 619
 Edwards J., 404
 Efremidis S., 68, 297, 821
 Ehren I., 1108
 Eichelberg C., 100, 613, 1026, 1031,
 1191
 Eichler K., 859
 Eickelberg O., 19
 Eilers T., 38
 Eisen T., 792, 1058

Ekman P., 31
 El Ammari J., 898
 El Fekih N., 896
 El Halaby M.R., 1091
 El Houry E., 634
 Elabbady A., 649
 Elard S., 8
 El-Assmy A., 495, 505, 650, 655, 658
 El-Bahnasawy M., 625, 626
 Elec F., 1003, 1004, V41
 El-Hefnawy A., 956
 Elhilali M., 698
 Elias B., 513
 Eliasson T., 622
 Elinoff V., 376
 El-Kappany H.A., 7, 199, 352, 495, 505,
 658, 674
 El-Kenawy M., 495, 655, 1087
 Ellingsen R., 872
 El-Nahas A., 352, 495, 505, 650, 655,
 658
 Elneil S., 798
 El-Rhadi A.S., 1122
 Elrobeigi A., 1091
 El-Saghir N., 288
 El-Sayed R., 239
 El-Sobky E., 626
 El-Tabey N., 352, 626
 Elzayat E., 833
 Elsevier H.W., 81
 Emberton M., 6, 433, 434, 543, 544,
 698, 704, 861, 862, 944, 1070,
 1074, 1179
 Emery S., 384
 Emiliozzi P., V11, V7, V9
 Emtage J.B., 1093, 1097
 Encabo G., 133, 134
 Engel N., 117
 Engeler D., 363, 753, 807
 Engelmann U., 3, 281, 289, 534, 946,
 1032
 Epstein J.I., 1170
 Eraky I., 352, 495, 505, 655
 Erba P., 282
 Erbersdobler A., 309, 431, 553, 1026
 Erdemir F., 758
 Erdogru T., 274, 355
 Erdt O., 592, 596
 Eren F., 357
 Ergenekon E., 903
 Eric D., 196
 Erkan I., 1008

Erturk E., 120
 Eschwège P., 262, 429, 930
 Escourrou G., 74, 1110
 Escudier B., 1058
 Eskicorapci S., 1008
 Esler A., 696
 Espina P., 138
 Espuna Pons M., 83, 826, 827
 Esser N., 36
 Essink-Bot M.L., 1023
 Esuvaranathan K., 661
 Eure G., 846
 Evangelisti S., 282
 Evans A., 979
 Evans A., 1172
 Evans S., 588
 Evans W., 1156
 Ewings P., 1022
 Eyland N., 376

F

Fabbri F., 628
 Fabre E., 262
 Fabricius G., 1188
 Facchini F., 829
 Faggiano F., 187
 Faisal R., 199
 Fajkovic H., 200, 940
 Falch B., 872
 Fan C.W., 1092
 Fan Y., 31
 Fang X., 31
 Fantini G.V., 470, 612
 Farag K., 95, 147
 Farghal H., 467
 Farina E., 472, 474, 607, 628, 1195
 Farnsworth B., 683, V26
 Farrelly E., 1108
 Farshad M., 741, 886
 Fasolis G., 310
 Fasolo P.P., 310
 Fassi-Fehri H., 525
 Fatles G., 1133
 Fattah O., 361
 Faucon H., 715
 Favorito L., 347, 897, 899, 900, 1138
 Fawaz K., 1091
 Fazio F., 586, 612, 1028
 Fazioli F., 1011
 Federico G., V11, V7, V9
 Fehst K., 452
 Feil G., 32, 97, 137, 223, 236

Abstract Author's Index

Feiner C., 620
Feitz W., 1047
Felber L., 361, 561
Felip N., 1142
Feneley M., 113
Fenske C., 880
Fergelot P., 177, 327, 336
Ferlicot S., 262, 930
Fernandez C., 677
Fernandez M., 362
Fernandez P., 595
Fernandez Micheltorena C., 323
Fernando H., 998, 999
Ferrando U., 585, 624
Ferrarese P., 91, 506
Ferrari F., 782
Ferrari I., 912
Ferreira R., 806
Ferretti S., 349, 502
Ferriere J.M., 447, 639
Ferruelo A., 358, 582
Ferruti M., 777
Feuerstein I., 101, 102, 105
Feuillu B., 450, 520
Feussner A., 436
Feyaerts A., 432, 850
Feyerabend S., 137
Fiala R., 94, 380, 922
Fiandra C., 585
Ficarra V., 177, 180, 183, 245, 336, 338
Figlin R.A., 447
Figueiredo G., 720, 1010, 1021
Filleur S., 23, 62
Filocamo M.T., 530
Filos K., 371
Finazzi Agro E., 948
Findik A., 768
Finelli A., 784, V12, V42
Fink K., 705, 708, 1159
Fioretta G., 1034
Fioretti F., 477
Fiori M., 1016
Fischer A., 978
Fischer T., 757
Fisher W.A., 321, 322
Fitzpatrick J.M., 539, 755
Flad T., 212
Flam T., 475
Flaris N., 371
Fleshner N., 579, 1061, 1172
Floege J., 756
Florence M.L., 419

Flori A.R., 367
Fokitis I., 887
Fontaine E., 632, 638
Fontaine-Aupart M.P., 930
Fontana F., 744
Fonteyne V., 584
Foo K.T., 1143
Fordham M., 258
Fornara P., 109, 934
Forster T., 791, 841, 855, 992, 993, 996
Fotas A., 1133
Fouques Y., 440
Fourcade R.O., 541, 695
Fournier G.H., 129, 269, 328, V1, V37, V38, V5, V6
Fowler C., 684, 798
Fracalanza S., 562, 765, 1190
Fradet V., 1026
Fradet Y., 1012
Francesca F., V15
Franceschelli A., 710, 747
Frank G., 746
Frank M., 605
Franken-Raab C.G.A.M., 727
Frattini A., 349, 502
Frauscher F., 70, 71, 82, 185, 230, 296, 546, 552, 711, 773, 837
Frea B., 187, 527, 676, 685, 744, 952
Frede T., 121, 274
Freeman A., 113, 249, 434
Freschi M., 271, 308, 1028, 1158
Fridman E., 453, 717, 874
Friedman A., V36
Friedrich M.G., 1025, 1166, 1169
Frigerio S., 819
Frimat L., 520
Fritsch H., 69, 1121
Frobert J.L., 982
Fröhner M., 110, 1033
Froeling F., 1122
Frohneberg D., 610, 760, 877
Fromont G., 365, 425
Frumkin L., 465
Fuchsberger C., 101, 102, 105
Fuechsel F., 614
Fuessel S., 63, 110, 220, 295, 409, 559
Fujii Y., 1163
Fujimoto K., 333, 635, 1055
Fujita R., 1
Fukasawa M., 211
Fung T.C., 1092
Fütterer J., 737

Füzesi L., 975

G

Gaboardi F., 127, 1075, V8
Gadaleanu V., 160, 256
Gadda F., 777
Gadet R., 750
Gagliardo C., 259
Gagnon D., 168
Gaillet O., 483
Gajda M., 190
Gajewski J., 385, 834
Gakis G., 743
Gala F., 444
Galatioto Paradiso G., 659
Galchikov I., 686
Galfano A., 338
Gall A., 959
Gallego J.A., 350
Galli S., 127, 1075, V8
Gallina A., 472, 474, 607, 628, 1178, 1195
Gallotta A., 562
Galosi A.B., 1011
Galuffo A., 293, 718
Gam S.C., 315
Gamarra M., 350
Gambra M., 465
Gamé X., 74, 1107, 1110
Gamidov S., 317, 318
Gan M., 167
Gander H., 1056
Gänsbacher B., 18, 557
Garaventa M., 79
Garcia A.J., V12, V42
Garcia J.M., 358
García Cardoso J.V., 401
García Rojo D., 188
García-Belandria F., 774
García-Tuñón C., 1136
Gardener N., 808
Gardikis S., 970
Gardiman M., 765
Gargouri M.M., 896
Garofalo M., 741
Gasparri L., 1011
Gaston R., 2, 681
Gattegno B., 197, 203, 205, 425
Gattuccio F., 259
Gattuccio I., 259
Gaudin A.F., 541, 695
Gauler T., 301

- Gavin A., 860, 864, 868
 Gavioli M., 668, 782
 Gazi E., 577
 Geavlete P., 85, 665, 666, V31, V35
 Gelet A., 116, 441, 443
 Gelet X., 525
 George D., 1057
 Georgescu D.A., 85, 665, 666, V31, V35
 Geraud M., 985
 Gerhardt U., 1126
 Germann M., 566
 Germinale F., 1155
 Gerretsen R., 80
 Gertman I., 618, 803
 Gerullis H., 452
 Ghanem A.A., 842
 Ghani K., 493, 498
 Ghazi Nezami B., 1117
 Ghazzi M., 472
 Ghignone G., 50, 1017
 Ghimenton C., 738
 Ghita E., 500
 Ghoneim M.A., 1071
 Ghysel C., 794
 Giakoumelos A., 707
 Giammò A., 84, 950
 Gianduzzo T., 126
 Giannakis D., 68, 251, 770, 821
 Giannakopoulos S., 503
 Giannakopoulos X., 297
 Giannantoni A., 383, 477, 673, 728, 829, 1129
 Giannarini G., 193
 Giannitsas K., 622
 Giatromanolaki A., 970
 Gibbons R., 911
 Giberti C., 981
 Gidaro S., 935
 Giese A., 348
 Giessing M., 757
 Gigante M., 522
 Gil M.J., 422
 Gil M.C., 418, 941
 Gil P., 422
 Gilad A., 61
 Gill I., 269, 784, 788
 Gillman M., 620
 Gilmore P., 159
 Gimeno Albo F., 677
 Gingu C., 512
 Giolitto J.P., V28
 Giotitsas N., 770
 Giraldi A., 10
 Girshovich A., 197
 Gittelman M., 378
 Giubilei G., 641, 961
 Giuliano F., 162, 163, 164, 168, 171, 224, 225, 272, 326, 388, 469, 627
 Giurlioli A., 673
 Giusti G., 351
 Giwercman A., 256, 575
 Giwercman C., 575
 Giwercman Y., 575
 Glass J., 343
 Glasser D.B., 375, 376
 Gleason D.M., 141
 Glentzes V., 787
 Gnad A., 705
 Gnanapragasam V., 104
 Gnau V., 212
 Gneveckow U., 436
 Goad J., 937
 Goebell P., 630
 Goethuys H., 942
 Goetschl R., 705, 1159, V22, V33
 Goetze W., 978
 Goezen A.S., 424
 Gofrit O., 115
 Gokce O., 892, 895
 Goktas S., 758
 Golan S., 1083
 Goldin O., 1083
 Goldstein I., 470
 Golijanin D., 120
 Gomes C.M., 241
 Gomez Veiga F., 713
 Gonçalves F., 283
 Gontero P., 187, 744, 952
 Gonulalan U., 667
 Gonzales G., 798
 Gonzalez R., 699
 González J.L., 188
 González Enguita C., 401
 Gonzalez Martin M., 713
 Gonzalgo M.L., 1170
 Gordon S., 1152
 Gore M., 792
 Goren M.R., 656
 Goreta N., 510
 Gorilovsky L., 380
 Gortenuiti G., 738
 Gosselaar C., 727, 1180
 Gothe H., 135
 Gotsadze D., 1078
 Gottardo F., 682
 Gourtsoyiannis N., 830
 Gouweloos J., 540
 Govorov A., 871
 Gözen A.S., 267
 Gozzi C., 71, 93, 240, 300, 303, 523, 524, 552, 671, 919, 1072
 Gradl H., 230, 546
 Gradl J., 773, 837
 Graefen M., 100, 309, 553, 613, 608, 716, 858, 1025, 1026, 1031, 1166, 1168, 1169, 1178, 1191, V21
 Graf E.M., 1098
 Graf N., 975
 Graham H., 384
 Granchi S., 747
 Grande S., 50, 451, 876
 Gratzke C., 41, 243, 742, 817, 1157
 Gravina G.L., 659, 831
 Graziotti P., 351
 Greco A., 360, 825, 1017
 Green J., 977
 Greenwell T., 532, 1040
 Greenwood R., 749
 Gregoire M., 936
 Gregori A., 88, 127, 1044, 1075, V8
 Gregorin J., 1189, 1196
 Grenot C., 56
 Grepl M., 94, 922
 Gretener H., 1189, 1196
 Grey A., 1199
 Grimani Justinian M., 562
 Grimm M.O., 332, 367
 Grisard-Anaf M., 982
 Grise P., 528, 776
 Groen J., 683
 Groeneveld F.P.M.J., 540, 542
 Groom J., 1093
 Groskopf J., 870, 1012
 Grosu A.L., 416
 Grover P., 571
 Gruenwald I., 618, 803
 Gschwend J.E., 4, 5, 103, 563, 1069, 1183
 Gualà L., 659, 831
 Guarneri A., 585
 Guazzoni G., 271, 308, 454, 508, 790, 845, 934, 1158
 Gudjonsson S., 461
 Guercio S., 876
 Gugala A., 325
 Guglielmetti S., 187

Abstract Author's Index

Guichard G., 122, 715, 898, 1198
Guillé F., 177, 180, 183, 327, 336, 447,
483, 639, 1132, V13
Guillebaud J., 779
Guillonneau B., 268, 269, 278, 340,
1200, V19, V3, V39, V4, V40
Guimaraes P.E., 98, 369
Guiomord A., 313
Gul U., 838
Gunawan B., 975
Gunelli R., 1016
Gunlusoy B., 198
Gupta A., 61, 455, 815
Gupta M., 342
Gupta S., 173
Gürocak S., 651, 1124
Gurtubay I., 350
Gustafsson O., 1185
Gutjahr P., 1119
Guvel S., 838
Guy L., 286, 578
Gwyther S., 732
Gyftopoulos K., 410
Gygi C., 361, 561

H

Ha U.s., 966
Haab F., 378
Haag S.M., 19
Haase M., 145
Habib F., 394
Hack M., 644, 759, 1193
Häcker A., 195, 277, 609, 745, 783, V14
Hackett G., 619
Hadjadj H., 191
Hadway P., 246, 1097
Hadzi Djokic J., 836, 1082
Haecker A., 44, 45, 90, 603
Haenen G.R., 222
Haese A., 100, 309, 553, 608, 613, 716,
858, 1015, 1025, 1026, 1031, 1166,
1168, 1169, 1171, V21
Hafsia G.H., 48, 356
Hagemann J., 594
Hakama M., 1174
Hakenberg O.W., 63, 220, 295, 462,
559, 1033, 1098, 1079
Halachmi S., 1083, 1113
Hallmans G., 574, 1177
Hamann M., 250
Hamdy F., 57, 365, 408, 1182
Hamelin R., 364

Hamm R., 910
Hammady A., 121, 274
Hammarsten J., 393
Hammerer P., 426, 427
Hammoudi Y., 262, 429
Hampel C., 83, 372, 373, 537, 826, 827
Han D.H., 1063, 1154
Han J.Y., 13
Han J.H., 752
Hanash K., 239
Hanchanale V.S., 1201
Hanecki R., 325
Hanisch J., 1104, 1126
Hanitzsch H., 1016
Hannaoui N., 188
Hannes S., 837
Hanssen S., 304, 869
Hansson J., 160
Harabayashi T., 337, 1076, 1080
Harada N., 1073
Harik M., 843
Harlicot J.P., 1132
Harmon J., 118, 124, 270, 1005
Harris M., 733, 1184
Harris M., 1094
Hart C., 30, 159, 577
Hartmann A., 218, 368, 816
Hartmann F.H., 332
Hartmann J., 301
Hartung R., 18, 416, 557, 698
Harving N., 698
Harza M., 512, 514
Hasan T., 487
Hassanzadeh Salmasi A., 1117
Hatzichristodoulou G., 237
Hatzichristou D., 465, 678, 707
Hatzimouratidis K., 707
Hatzinger M., 90, 603
Hauck E.W., 19, 252
Hauessler B., 135
Hauri D., 117, 382, 721, 1062
Hautmann R.E., 4, 5, 103, 250, 484,
563, 569, 1041, 1069
Hautmann S.H., 250, 473, 592, 596,
736, 1194
Hayama T., 554
Hayashi T., 254, 645
Healy D., 755
Heberling U., 1079
Hecht J., 1102
Hedlund P.O., 723
Hedlund P., 10, 11, 14, 954, 1109, 1111

Heesakkers J.P.F.A., 80, 221, 1103
Hegarty N., 507, 784, 788
Hegarty P., 1118
Hegazy H., 649
Hegele A., 132, 494
Hei Y.J., 130
Heidecke H., 660
Heidenreich A., 3, 281, 289, 299, 534,
946, 1032
Heijmink S., 737
Heinrich M., 1126
Heinzer H., 608, 1166, 1169, 1178, V21
Hekal E., 625
Hellmis E., 1126
Hellstrom W.J.G., 9, 15, 16, 778
Hellström M., 589
Hellwinkel O., 100
Hemadeh K., 288
Henderson A., 597
Henderson J., 343
Hendricksen K., 662
Henkel R., 775
Henkel T., 108
Henne T., 1104
Hennenlötter J., 38, 24, 29, 32, 33, 212,
709, 1027, 1197
Henning A., 730
Henrique B., 720
Henriquez N., 157
Heretis I., 882
Hering S., 70
Herkommer K., 569, 1041, 1183
Herman I., 354, 500
Hermanek P., 1157
Hermieu J.F., 1137, 1140
Herr A., 220
Herschorn S., 372, 373, 526, 537, 978
Hertle L., 807
Herve J.M., 8
Herwig R., 480, 531, 552, 875, 1009
Herzog J., 947
Hesse A., 53
Hessels D., 304, 869
Hetherington J., 913
Heuer R., 608
Heukamp L.C., 111
Hewitt R., 570
Heynemann H., 109
Heyns C., 248, 913, 1060
Hicks J., 1199
Hideki K., 631
Hidenori Z., 631, 1099

- Higashiyama S., 403
 Hill S., 378
 Hindley A.C., 570, 571
 Hindley R., 932
 Hindmarsh J., 1094
 Hirano D., 285
 Hirao Y., 333, 556, 635, 1055
 Hiraoka M 722
 Hirohashi Y., 558
 Hiroshi N., 631
 Hirsch B., 208
 Hirsimäki S., 616
 Hislop J., 550
 Hjelle D.R., 872
 Ho H., 1143
 Hochmuth A., 204
 Hodler J., 1106
 Hoegel J., 569
 Hoepffner J.L., 2, 681
 Hoer A., 135
 Hofer M., 563
 Hofmann R., 132, 494, 534
 Höfner K., 1006
 Hofstetter A., 817
 Höglund M., 461
 Hoh I., 433, 434
 Hohl K., 1183
 Holen I., 408
 Holm P.S., 557
 Holmes S., 1199
 Höhl L., 1056
 Höhl W., 805
 Holzapfel K., 416
 Honda N., 645
 Honeck P., 195
 Hong B., 851
 Hong J.H., 1154
 Hong J.H., 670
 Hong S.J., 329
 Hong S.K., 144, 182, 232, 418, 939, 941, 1052
 Honma I., 558
 Horchani A., 48, 356, 896
 Horenblas S., 247, 938
 Horn L.C., 119, 128, 273
 Horn W., 1126
 Horninger W., 86, 102, 105, 306, 866, 881, 1018, 1144
 Horst C., 592
 Horst J.L., 294
 Horstmann M., 32, 33, 807
 Horvath R., 148
 Hossfeld A., 1126
 Hothersall J., 42
 Hotston M., 438
 Hou S.M., 1092
 Howson J., 1182
 Hoznek A., 122, 715, 1029, 1059, 1198
 Hrachowitz K., 389, 391
 Hricak H., 278
 Hruby S., 805, 843
 Hruza M., 267, 424, 430
 Hsieh J.T., 811
 Hsieh-Li H.M., 413
 Hsu C.Y., 735, 761, 763
 Huang H., 62
 Huber A., 1013, 1014
 Hubert J., 450, 520
 Hudes G., 1057
 Hudolin T., 510, 515
 Huebner W.A., 529
 Huh J.S., 341, 479, 490
 Huhtala H., 616
 Huland H., 100, 309, 431, 553, 608, 716, 858, 1015, 1025, 1026, 1031, 1166, 1168, 1169, 1171, 1178, 1191, V21
 Hulin L., 844, 848
 Hulsbergen-v.d. Kaa C., 304, 662, 737, 1047
 Hummel M., 208
 Hund I., 743
 Hungerhuber E., 243
 Hunskaar S., 83, 372, 373, 537, 826, 827
 Hussein A.F., 972
 Hutarew G., 1159
 Hutterer G., 456, 457, 458, 812, 813, 814
 Huwyler M., 907
 Huyghe E., 587, 634
 Hwang T.K., 1100
 Hwu Y., 179
 Hyland P., 67
 Hyun J.S., 315, 617
 Iacob G., 1003, 1004, V41
 Iasonos A., 340
 Iazzio P., 886
 Ibarluzea G., 350
 Ibarz R., 1035
 Iborra F., 522
 Iborra I., 181
 Ibrahim E.H., 7, 390, 626, 669, 674, 842, 879
 Igawa M., 98
 Iizuka N., 60
 Ijzermans J., 637
 Ikuerowo S.O., 25
 Iles R., 734, 749
 Illing R., 779, 781
 Inadome A., 231
 Inal G., 1160
 Inci K., 49
 Inglese E., 744
 Inman R., 799
 Inoue R., 60
 Inoue T., 405, 722
 Introini C., 1030, 1155
 Ioakeimidis N., 12
 Ioannides E., 678
 Iordache A., 514
 Ipsilantis P., 970
 Irani J., 714, 853
 Iremashvili V., 317, 318
 Irie S., 1
 Irwin D., 372, 373, 537
 Isao A., 631, 1099
 Isbarn H., 553, 608, 1171
 Iselin C., 789, 1139
 Iseri C., 1123
 Ishida H., 516
 Ishii N., 254, 645
 Islamoglu E., 49
 Isorna S., 721, 1062
 Isotalo T., 149, 1048
 Issaq E., 64
 Issaq H.J., 64
 Itil I., 835
 Itkes A., 572
 Ito K., 1175
 Ito M., 213, 359
 Itoh K., 1055
 Itoh N., 558
 Ivanovski O., 751
 Iversen P., 914
 Izard V., 262
 Izquierdo L., 215
 Izzo A., 769
 Jacquelin B., 978
 Jaeger P., 117, 382, 859
 Jaff M., 1156
 Jager P.L., 884

Abstract Author's Index

- Jain A., 1086
Jakse G., 150, 235, 756, 957, 958
Jakubczyk T., 325
Jakubik P., 564
Jamali K., 197
Jamart F., 885
James D., 1034
Jamieson C., 168
Janeiro J., 713
Janetschek G., 269, 277, 609, 745, 934, V14
Janin A., 364
Jankevicius F., 916
Jannini E.A., 728
Jannink S., 304, 869
Jansen C., 304, 869
Jansen F., 593
Jansen P., 593
Jarrett T., 1068
Jasim P., 1145
Javle P.M., 1201
Je J.H., 179
Jean Marie M., 419
Jeanpetit Y., 469
Jeavons R., 979
Jenne J., 783
Jensen J.K., 915
Jentsch B., 368
Jeon H.S., 1046
Jeon S.S., 1063
Jeon S.H., 341, 479, 490
Jeong C.W., 144, 184, 939, 1052
Jeong H., 144, 418, 939, 941, 1052
Jeong H., 182
Jeong I.G., 182
Jeong J.S., 418, 941
Jeschke K., 633
Jeschke S., 277, 609, 745, V14
Jewett M., 1172
Jichlinski P., 361, 561
Jimenez S., 466
Jo M.K., 437
Joan B.W., 568
Jöbsis A., 663
Jocham D., 36, 214, 1054
Johannsen M., 436
Johansson J.E., 914
Johansson R., 723
John B., 493, 498
John D., V5
John H., 117, 652, 1049
Johnell O., 393
Johnston R., 67
Jokonya N., 408
Jonas U., 11, 14, 22, 25, 29, 35, 38, 397, 594
Jones C., 497
Jones D., 384
Jones L., V29
Joniau S., 630, 640, 735, 761, 763, 794, 942
Jonkheijm R., 540
Joo K.J., 752
Jordan A., 436
Jorge A., 350
Joseph J., 120, 123, 266
Jost N., 108
Joulin V., 129, V1, V37, V38, V5, V6
Julia-Guilloteau V., 224, 388
Jumadilova Z., 375
Jun S.y., 555
Jünemann K.P., 250, 473, 592, 596, 736, 947, 949, 1194
Jung B.J., 1063, 1154
Jung H.C., 34, 511, 518, 621
Jung H.T., 485
Jung V., 106, 107
Junker K., 178, 190, 218, 368
- K**
- Kaaks R., 1177
Kabalin J., 846
Kadowitz P.J., 15
Kagadis G., 371
Kageyama Y., 1163
Kai N., 231
Kaipia A., 616
Kaisary A., 426, 427, 531, 843
Kalaitzis C., 503, 970
Kälkner K.M., 589
Kalpinskiy A., 746
Kalsi V., 684, 798
Kamai T., 1101
Kambouri K., 970
Kamel M.E., 921
Kaminetsky J., 696
Kamoto T., 213, 359, 405, 722
Kamp S., 90, 603
Kamradt J., 106, 107, 412, 1167, 1193
Kanberoglu H., 973, 983
Kang S.H., 27
Kang S.G., 1116
Kania I., 218
Kaniusas D., 916
Kantziou M., 707
Kanz L., 301
Kaouk J., 784, 788
Kapanadze G., 863
Kapasi F., 1148
Kaplan S.A., 699
Karademir K., 1123
Karagiotis E., 344
Karakiewicz P.I., 61, 183, 308, 309, 423, 455, 583, 607, 608, 716, 725, 815, 858, 911, 1025, 1026, 1166, 1168, 1169, 1171, 1178
Karam I., 161
Karama Musa A.A., 646
Karaman M.I., 973, 983
Karamanolakis D., 284
Karanikolas N., 268, 269, V19, V3, V39, V4
Karantanas A..H., 830
Karatas O.F., 997, 1085, 1095
Karatzas A., 499
Karim O., 598, 861, 862
Karl A., 816, 929
Karnabatidis D., 371
Karran P., 207
Karsenty G., 801, 804, 833
Karstens J.H., 594
Karzek C., 109
Katsakiori P., 51
Kattan M., 245
Katz R., 115
Katzir A., 918
Kaufman J., 463
Kaufman Z., 1083
Kausch I., 214
Kaver I., 928, V36
Kavoussi L., 1068, V34
Kawahara M., 1073
Kawakami F.T., 378
Kawakami S., 1163
Kawanishi H., 213, 359
Kay G., 377
Kaya C., 973, 983
Kayes O., 244, 249
Keane P.F., 860, 864, 868
Keane T., 1061
Kedia G., 41, 397
Keeley F., 46
Kees F., 906
Kekeeva T., 114
Kelleher C., 372, 373, 537
Keller H., V23

- Kellett M., 192, 201
 Kellomäki M., 149, 1048
 Kelly J.D., 55, 206
 Kemény S., 235
 Kempensteffen C., 58, 253, 255, 824,
 1019, 1105
 Kenawy M., 352
 Kendirci M., 9, 15, 16
 Kennedy J., 781
 Kennedy K., 1022
 Kerasidou O., 707
 Kerst M., 938
 Keskin S., 1198
 Kessler M., 520
 Kessler T.M., 1038, 1128
 Kestler H., 103
 Ketteler M., 756
 Kettenbach J., 786
 Khachatryan G., 565
 Khairy Salem H., 890
 Khaksar S., 597
 Khan A., 602
 Khan S., 381, 675, 684, V32
 Kharkevich G., 1053
 Khastgir J., 1125
 Khattab H., 147
 Khawli R., 288
 Khedis M., 587, 634
 Kheifets A., V18
 Khishdoost H., 653
 Khoo V., 792
 Khoubehi B., 703
 Kia H., 164
 Kiemeney L.A., 216
 Kihara K., 1163
 Kikugawa T., 403
 Kilciler M., 758
 Kim A.R., 179
 Kim B.W., 66, 511, 518
 Kim B.S., 752
 Kim C.G., 28
 Kim C.S., 555, 670, 740
 Kim C.I., 329, 621, 969
 Kim D.G., 34, 621
 Kim D.Y., 66, 392, 518, 621, 1100
 Kim E.H., 28
 Kim H., 399, 555, 740
 Kim H.J., 752
 Kim H.J., 1176
 Kim H.S., 329
 Kim J., 1168
 Kim J.B., 670
 Kim J.C., 399, 1100
 Kim J.H., 1100
 Kim J.H., 17
 Kim J.J., 27
 Kim J.K., 740
 Kim J.I., 479, 490
 Kim J.L., 78
 Kim J.W., 491
 Kim J.W., 392
 Kim J.Y., 617
 Kim J.Y., 1046
 Kim K.H., 437
 Kim K.J., 324
 Kim K.S., 621, 969
 Kim K.T., 184
 Kim S., 1057
 Kim S.C., 227
 Kim S.I., 329
 Kim S.J., 329
 Kim S.S., 752
 Kim S.W., 232
 Kim T. H., 59, 227, 387, 478, 902, 1007
 Kim W.T., 491
 Kim Y.J., 418, 941
 Kim Y.S., 329
 Kim Y.S., 752
 Kim Y.S., 59
 King S., 943
 Kinzig-schippers M., 489
 Kipper R., 450
 Kirby R., 880
 Kirecci S., 146
 Kiremit M.C., 903
 Kirkali Z., 1066
 Kirkels W., 593
 Kisa C., 706
 Kitahara S., 535
 Kitamura H., 558
 Kitamura T., 411, 764, 873
 Kitrey N., 453
 Kiუმehr S., 1117
 Kjellman A., 1185
 Klarskov L., 909
 Klarskov P., 909, 914
 Klatte T., 176, 287
 Klauser A., 82, 837
 Klaver S., 942
 Klein J., 121
 Kleinclaus F., 522, 898
 Kleinmann N., 636
 Kleinstein J., 771
 Kleiser R., 802
 Klevecka V., 311, 611
 Klijn A., 1120
 Klima G., 69
 Klima I., 156
 Kliment J., 513
 Klingler H.C., 339, 786, 940, 1051, 1134
 Klocker H., 101, 102, 105, 866, 881
 Klotz L., 579, 1187
 Kluka I., 964, 965
 Knapp P.A., 801, 802, 804, 955, 1112
 Knauer K., 439, 442
 Knez R., 829
 Knezevic N., 510, 515
 Knight S.L., 532, 959
 Knipscheer B., 304, 517, 737
 Knoll T., 44, 45, 90, 195
 Knuechel-Clarke R., 816
 Knutson T., 393
 Kobayashi T., 405, 722
 Kocak T., 835
 Koch R., 110, 1033
 Kocjancic E., 187, 527, 676, 685, 744,
 952
 Kodama K., 911
 Kodamala S.J., 1093
 Koellermann J., 1019
 Koerner I., 1104
 Koff W.J., 294
 Kofler K., 101, 102, 105, 230
 Kogan M., 904, 905, 963, 964, 965
 Koh J.S., 485
 Köhler Vargas N., 557
 Kohno M., 1175
 Koifman L., 897
 Koike M., 1163
 Koivisto P., 568
 Kojic D., 1081
 Kok E.T., 540
 Kok N., 517
 Kokoszka A., 171
 Koliva L., 132
 Kollias S., 802
 Kommu S.S., 275, 342, 438, 448, 497,
 1093, 1097
 Kondelidis N., 678
 Kondo H., 333
 Konecki T., 785
 Kononov S., 963
 Konstantinidou E., 678
 Kopolovic J., 717, 874
 Kopp Z., 372, 373, 536, 537
 Korfage I., 1023

Abstract Author's Index

Koritsiadis G., 238
Koritsiadis S., 238, 887
Kosan M., 667, 1160
Koskimäki J., 466, 616
Kosko J., 871
Kostakopoulos A., 991
Kotaiche F., 450
Kotsar A., 149, 1048
Kotzsch M., 63
Koutsilieris M., 284
Kovács B., 486
Kovyliina M., 871
Kozomara M., 52
Kraemer K., 63, 220
Krahn M., 1172
Krambeck R., 900, 1138
Kramer G., 200, 389, 391, 1009
Kranse R., 878
Kratzik C., 1051
Krause H., 58, 208, 253, 255, 1019
Krause T., 614
Kravchenko Y., 918
Kravchick S., 918
Kravtsov A., 64
Krebs P., 753
Krege S., 299
Kreutz F., 294
Krhén I., 510, 515
Krishnamoorthy R., 847
Kristensen E., 10
Kristiana I., 796
Kroepfl D., 311, 611
Kron M., 1183
Kroon B., 247
Kröyer K., 1149
Krug J., 97, 223
Kryst P., 325
Ku J.H., 232
Kubo H., 1073
Kucuk E.V., 973
Kucznyk M.A., 24, 25, 29, 32, 33, 35, 38,
212, 301, 709, 1197
Kuefer R., 4, 103, 563, 1041, 1069
Kuettel C., 452
Kuhn A., 1128
Kühs U., 33, 1197
Kuijpers K.A.J., 221
Kuiper R.P., 216
Kulchavenya E., 330
Kulisa M., 1045
Kumagai J., 411
Kumar P., 249

Kume H., 764, 873
Kummer S., 111
Kümmerlin I., 335
Kumon H., 1
Kündig C., 361, 561
Kunz U., 859
Kunze D., 409
Küpeli B., 651
Kuroiwa K., 278, 1200
Kutlu O., 355
Kuukasjärvi P., 616
Kwak C., 144, 182, 184, 418, 939, 941,
1052
Kwart A., 196
Kwias Z., 143, 726
Kwiatkowski M., 1013, 1014, 1189,
1196
Kwon C.H., 752
Kwon O.Y., 315
Kwon S., 617
Kwon T.G., 66, 511, 518, 621
Kynast B., 214

L

La Pera G., 169, 175
Lachat M., 652
Lack N., 1157
Lacour B., 751
Lacquaniti S., 310
Lacroix B., 447, 639
Laczko I., 279
Lafolie P., 1108
Laguna M.P., 335, 934
Lahme S., 204, 237, 346, 504, 630
Laible I., 1197
Laing R., 597
Lakmichi M.A., 205
Lalic N., 52
Lam J.S., 447
Lamb G., 739
Lammintausta R., 700
Landén H., 476
Landreat V., 1132
Lane A., 1182
Langbein S., 65
Langenhuijsen J.F., 292, 737
Langley S., 597
Langner C., 334, 456, 457, 458, 812,
813, 814
Langsteger W., 745
Lanzi F., 643
Lanzós E., 595
Lapini A., 428, 641, 643
Larré S., 197, 1059
Larsen F., 916
Larson B., 1156
Larson T., 1149, 1156
Latchemsetty K., 1168, 1169
Latil A., 924
Lau D.H., 1097
Laufer M., 453, 717, 874
Laurikka J., 616
Lavagna M., 981
Lavallée E., 469
Laville M., 750
Lawler M.P., 573
Lawson A., 943
Lawton C., 1061
Lazar R., 512
Lazarov R., 152
Lazic M., 1081
Lazzeri M., 800, 901
Lazzeri P., 282
Le Lannou D., 774
Lebeau T., 583, 1026
Lebret T., 8, 225, 313, 528
Lécart S., 930
Lechevallier E., 191, 336, 522
Leclers F., 450
Lecouvet F., 885
Lee B.H., 66
Lee C., 437
Lee C.B., 966
Lee D.G., 341
Lee D.H., 329
Lee E.S., 144, 182, 939, 1052
Lee G., 192, 201
Lee H.I., 34
Lee H.L., 752
Lee H.M., 1063
Lee J.B., 418, 941
Lee J.H., 994
Lee J.H., 28, 179
Lee J.S., 402, 491
Lee J.Y., 485
Lee J.Z., 78
Lee K.H., 17, 324
Lee K.S., 34
Lee M.K., 227
Lee M.Y., 227
Lee S.B., 555, 740, 851
Lee S.B., 418, 941
Lee S.E., 144, 182, 184, 418, 939, 941,
1052

Lee S.S., 485
Lee S.W., 1154
Lee S.J., 341, 479, 490
Lee T., 954, 1141
Lee W., 78
Leeb K., 277, 609, 745, V14
Lefakis G., 887
Lehmacher W., 1054
Lehmann J., 331, 759, 1167, 1193
Lehmann K., 629, 855, 992
Lehmer A., 18, 416
Leibl S., 457, 812
Leibovici D., 762
Leippold T., 993, 996
Leisinger H.J., 361, 561, 921
Leissner J., 605
Leite K.R., 75
Leiva O., 595, 1142
Lekas A., 238, 887
Lemieux M.C., 833
Lenaz G., 664
Lenggenhager D., 819
Lentini M., 175
Lenze D., 208
Leonardi E., 37
Leong W.S., 494
Leonhartsberger N., 780, 866, 881,
1056
Leray E., 177, 336
Leriche A., 988
Leriche B., 988
Lerner S., 61, 455, 815
Leslie T., 779, 781
Leung H.Y., 104, 206, 207, 404
Leung S., 394
Leuschner I., 975
Lévêque-Fort S., 930
Lewinshtein D.J., 183, 1171
Lewitt S., 589
Lheritier K., 378
Li G., 560
Li S.K., 1092
Li Marzi V., 530
Liakouras C., 1090
Liang O., 568
Liang S. Y., 465
Liatsikos E., 51, 119, 128, 273, 371
Liberale F., 585
Lichy M.P., 709
Liedberg F., 461
Lienhard J., 982
Lilian C., 976

Lilja H., 1015
Lilli P., 1016
Lim H.K., 329
Lim K.B., 1143
Lima R., 377
Linares A., 194, 202, 521
Lindahl B., 1177
Lindenmeir T., 771
Lindgren D., 461
Lindner A., 417, 762
Lingeman J., 846
Linné C., 559
Liong M.L., 494
Lipczynski W., 564
Lipsky K., 719, 935
Liske P., 204, 237, 346, 504
Lissiani A., 88, 1075
Litz R.J., 1033, 1079
Liu L., 796
Liu M., 526
Liu Z., 31
Livadas K., 344
Ljungberg B., 26
Ljunggren \hat{I} 393
Llombart Bosch A., 219
Llorente C., 421, 1161
Lluell P., 39, 396
Loadman P., 209
Lobel B., 177, 180, 183, 327, 336, 447,
483, 639, 774, 1132, V13
Loblaw A., 1187
Loch A., 984
Loch T., 984
Löchner-Ernst D., 772
Lock M.T.W.T., 152, 257
Lodde M., 305, 917, 925
Lodding P., 914
Lodi R., 710, 741
Loechner Ernst D., 627
Loening S.A., 435, 436, 575
Loewenstein L., 618
Loftus B., 573
Lohse C., 338
Loidl W., 721, 1062
Lombardi G., 953, 961
Long J.A., 889
Longhorn S., 192, 201
Longo M., 738
Lopes D., 447, 639
Lopez A., 595
Lopez Fando L., 521
López Guerrero J.A., 219

Loran O., 572
Lording D., 465, 620
Loric S., 429
Lorin S., 933
Losa A., 508, 1158
Lotan Y., 61, 455, 811, 920, 923
Lotti T., 748
Lottmann H., 1122
Love W., 139
Löwik C.W.G.M., 156, 157
Lozinskiy M., 200
Lucan M., 1003, 1004, V41
Lucan V., 1003, 1004, V41
Lucas M., 384
Luciani L.G., 37, 345
Lucon A.M., 172
Lüdecke G., 926
Ludewig B., 363, 753
Ludwig M., 775
Luebke A.M., 975
Lüftenegger W., 630
Lufuma E., 2
Lugagne P.M., 8
Lujan M., 358, 582, 856
Lukan N., 65
Luke B., 64
Lukkarinen O., 914
Lunacek A., 524, 881, 1121, 1144
Lundell M., 589
Lundmo P.I., 914
Lundwall A., 256
Lunet N., 720, 1010, 1021
Lunz J., 906
Luptak J., 513
Lusuardi L., 305, 925
Lutter I., 189
Lycklama A Nijeholt G.A.B., 81
Lynch M.F., 493, 498, 1097
Lynch T.H., 573

M

Maan Z., 1000
Määttänen L., 1173, 1174, 1186
Macairan M.L., 870
Macchiarella A., 953
Macdonagh R., 1022
Mace B., 776
Mach J.P., 361
Machtens S., 25, 35, 38, 594, 630
Maclean C., 916
MacNeil S., 92
Madan S., 943

Abstract Author's Index

- Madbouly K., 650
Madersbacher H., 1104
Madersbacher S., 316, 420, 615, 730, 832
Maeda Y., 231
Maestroni U., 502
Maffezzini M., 79
Maga T., 508, 790, 1158
Magalhães D., 21
Magatti F., 676
Magnusson B., 1149
Mahmoudi S.A., 492
Mahnken A., 756
Maia R., 839
Maier C., 569
Maier K., 917, 925
Major-Walker K., 692, 693
Makarem J., 288
Malaguti S., 800, 901
Malavaud B., 74, 581, 587, 1107, 1110
Maldonado R., 264, 743
Mallick S., 440
Mallo H., 938
Malmi H., 1186
Malossini G., 37
Mampitya A., 602
Manabe D., 1
Manach C., 578
Managadze L., 397
Manassero F., 193, 282
Mancini M., 682, 1050
Mandras R., 310
Manea I., 514
Manecksha R.P., 573
Manel A., 889
Manes C., 897
Manferrari F., 741, 747, 748
Mangold L.A., 1170
Manikandan R., 739
Manoni L., 643
Mansfield K.J., 796
Mansour O., 199
Månsson W., 461
Mantwill K., 557
Manunta A., 327, 336, 483, 1132, V13
Manzarbeitia F., 401
Marberger M., 200, 339, 389, 391, 426, 427, 531, 691, 786, 843, 875, 940, 1009, 1051, 1114, 1134
Marcen R., 521
Marchand W., 637
Marchiori D., 747
Marchioro G., 187, 744, 952
Marechal J.M., 116
Marekovic Z., 510, 515
Marfia G.A., 948
Margaritondo G., 179
Margreiter E., 70, 1037
Marianantoni Z., 175
Mariani G., 282
Mariani S., 688
Mariano M., V12, V42
Marihart S., 531, 843
Marin M., 215
Marionneau N., 548, 549, 551
Mark D., 563
Marks L.S., 702, 870
Marksteiner R., 70, 1037
Markus G., 1171
Maroclo M., 72, 76, 77
Marque P., 1107
Marques Queimadelos A., 978
Marre R., 484
Marrero R., 274
Marret E., 203
Marschall-Kehrel A.D., 1126
Marszalek M., 316, 615
Martella O., 659
Martenska P., 726
Martignoni G., 338
Martikainen P., 158
Martin C., 569
Martin D., 421, 1161
Martin F.L., 570, 571
Martin K., 467
Martin M., 170
Martin X., 441, 443, 447, 525, 750
Martindale A., 937
Martinez E.M., 323
Martinez J., 1161
Martinez Sagarra J.M., 1136
Martinez Salamanca J.I., V3
Martínez-Piñeiro L., V2, V24
Martini M., V11, V7, V9
Martinis S., 787
Martins J.R., 75
Martirossyan A., 565
Martorana G., 710, 741, 747, 748
Maruyama S., 1080
Marzano R., V15
Marziani F., 305
Marzocco M., 530
Masanori B., 1099
Masayuki T., 631, 1099
Masieri L., 428, 641, 643
Maso G., 187
Mason M., 1182
Masotti L., 747
Massarwa O., 803
Massy Z.A., 751
Masters J., 113
Masumori N., 558
Masunaga K., 231
Matanhelia S., 481, 570, 571
Mathe M., 120
Mathers M., 104, 404
Matiassek K., 18
Matikainen M., 568
Matsui Y., 213, 359
Matsuo N., 407
Matsuoka K., 1164
Matsuyama H., 60, 370, 1076
Matsuyama M., 554
Matsuzaki S., 40
Matt N., 815
Mattei A., 614, 1039
Mattelaer J.J., 599
Matthews A., 1024
Matthias S., 185
Mattiasson A., 1149
Mattos R., 172
Matveev V., 260, 265, 945
Matzkin H., 698, 928, V36
Mauermann J., 786
Maurer S., 97, 223
Maurer T., 18
Mawlawi H., 262
May F., 18
May K., 170
Mayer D., 652
Mayer E., 927, 1089
Mayer F., 301
Mayer J., 756
Mazilu D., V34
Mazo E., 317, 318
Mazzoccoli B., 612, 642, 748
Mazzucchelli L., 912
Mc Culloch T., 560
Mc Gurk J., 1093
Mc Vary K., 696
McCabe J.E., 1201
McCormack M., 423, 725, 1026
McCracken S., 404
McCullough A., 314, 471
McDonald K., 550
McFarlane J., 734, 749, 1202

- McFarlane J., 1202
 McGregor B., 750
 McMahon S., 810
 McNeill A., 394
 McNulty P., 171
 Meadows R., 550
 Mearini L., 477, 1129
 Mecz Y., 54
 Méen M., 396
 Mege Lechevallier F., 116
 Mehnert U., 736
 Mehring G., 804
 Mehra A., 754
 Meinhardt W., 938
 Meisner C., 237
 Meissner P., 705
 Meixl H., 633
 Mejean A., 177, 328, 336, 632, 638
 Melchior A., 109
 Melekos M., 499, 991
 Mellier G., 978
 Melloni D., 293, 718
 Mellström D., 393
 Melman A., 471
 Meltzer P., 107, 412
 Ménard Y., 122
 Mendes A., 75
 Mendive J.M., 374
 Mendoza C., 139
 Meneghini A., 995, 1002
 Mengel M., 29, 32
 Mengozzi G., 1017
 Mengual L., 210, 215
 Merchant S., 169, 171
 Meretyk S., 1083, 1113
 Meria P., 191, 501
 Merlet B., 853
 Merseburger A.S., 24, 29, 32, 33, 212, 709, 807, 1197
 Mesbah A., 625
 Meschia M., 676
 Mesquita J.L.B., 241
 Messa C., 1028
 Messthaler A., 819
 Metlitzky E., V36
 Meuth M., 57
 Mevel K., 224, 388
 Meye A., 63, 110, 220, 295, 409, 462, 559
 Meyer G., 509
 Meyer-Venter R., 711
 Mian C., 305, 917, 925
 Mian M., 305, 925
 Miano L., 1020
 Miano R., 948
 Micali S., 623
 Michael M., 837
 Michaelson D., 1057
 Michalski L., 564
 Michel M., 228
 Michel M.S., 44, 45, 65, 217, 362, 783
 Michl U., 1025, 1169, 1178
 Micic S., 990
 Miclea F., 354, 500, 1147
 Middleton F.R.I., 959
 Migliorini F., 738
 Mikashinovich Z., 904
 Mikisch G., 637
 Mikkonen J., 149, 1048
 Milan G.L., 624
 Milanese G., 1011
 Milani C., 454, 934
 Milathianakis C., 284
 Milcent S., 501
 Milecki P., 143, 726, 726
 Milenkovic-Petronic D., 52
 Milesi C., 193
 Millar J., 590
 Millard R.J., 379, 796
 Miller J., 974
 Miller K., 26, 58, 208, 253, 255, 824, 1019, 1105, 1188
 Mills I., 55, 808
 Miloslavsky M., 174
 Milsom I., 372, 373, 537
 Mimata H., 407
 Min B.H., 28, 1116
 Minardi D., 1011
 Minareci S., 198
 Mincik I., 380
 Minciu R., 500
 Minei S., 285
 Miner M., 701
 Minervini A., 428, 641, 643
 Minhas S., 244, 249
 Miquel C., 364
 Miralbell R., 1034
 Miravalles E., 856
 Mirciulescu V., V31
 Miserez M., 151
 Miskic H., 515
 Misterek B., 398
 Mistry R., 739
 Mitre A., 98
 Mitsiades C., 284
 Mitsios C., 238
 Mitsogiannis I., 499
 Mitsuhashi K., 1076
 Mitsumori M 722
 Mitterberger M., 69, 70, 82, 230, 240, 480, 546, 552, 671, 679, 780, 1018, 1037
 Miyagawa I., 251, 770
 Miyamoto N., 516
 Mizowaki T 722
 Mizuno T., 1101
 Mizuya F., 631
 Mjones J., 852
 Moch H., 819
 Mock K., 316, 615
 Moddy S., 1149
 Modi N., 173
 Moehle R., 223
 Mofferdin A., 623
 Mokhtar A., 239
 Mokhtari G., 654
 Molimard M., 467
 Molinuevo B., 538
 Molkenboer-Kuenen J., 662
 Moll C., 150
 Moll F.H., 605
 Moltzahn F.R., 332
 Mombet A., 272, 933, 1064, 1067
 Mommsen S., 909
 Monaco C., 738
 Mondada-Iribarren I., 323, 466
 Mondaini N., 953, 961
 Monesi G., 744
 Mongiat Artus P., 364, 501, 924
 Monish A., 507
 Monrós J., 181
 Montalto F., 259
 Montanaro V., 769
 Montemezzi S., 738
 Montironi R., 912
 Montorsi F., 271, 308, 472, 474, 586, 607, 612, 628, 693, 845, 857, 1025, 1028, 1042, 1043, 1168, 1169, 1178, 1195
 Monz B., 83, 826, 827
 Moon D., 126, 279
 Moon D.G., 27
 Moon K.H., 315, 617, 994
 Moon W. C., 59, 387, 478, 902, 1007
 Moonen P.M.J., 459, 662, 664
 Moore C., 433, 434

Abstract Author's Index

- Moore K., 936
Moore N., 467
Moosavi S., 754
Moossa F.E., 95, 147
Mor Y., 636, 717, 874
Morgia G., 293
Morin V., 328
Morote J., 131, 133, 134, V10
Morra I., 849, V27
Morrill B., 692, 693
Morris M.F., 166
Morris S., 591
Morris T., 914
Mosbah A., 7, 674, 818, 1071
Moschkowitsch A., 1105
Moskovitz B., 509
Mosse C.A., 433, 434
Mothu N., 751
Motiwala H., 598
Motta M., 293
Motzer R., 1057
Mourad W., 239
Mourey E., 450, 520
Moutereau S., 429
Moutzouris G., 499
Moutzouris V., 894
Moyano Calvo J.L., 883
Moysidis K., 707
Müller E., 610, 877
Müller M., 824
Müller T., 919, 1072
Müntener M., 117
Muertz G., 1104, 1126
Mugnier C., 2, 681
Mühlstädt S., 119
Muir G., 847
Mulders P., 304, 517, 869, 1061
Müller C.A., 212
Müller G., 212
Müller M., 106, 863
Müller R.L., 294
Müller S.C., 111, 416
Müller T., 263, 300, 303, 671
Mullerad M., 64, 509
Multescu D.R., V35
Mumtaz F.H., 275, 448, 1097
Munarriz R., 470
Mundy A., 532, 1040
Mundy T., 704
Munehiro N., 631
Munoz F., 585
Muñoz Segui J., 307
Muntener M., 382, 859, 1068, V34
Muradian A., 565
Murai M., 40
Murakumo M., 1076
Murat F.J., 116, 441, 443, 525, 1045
Murphy D., 732, V16, V32
Murray L.J., 860, 864, 868
Murray R., 141
Murtola T., 1173, 1174
Musch M., 311, 611
Mushtaq I., 1118
Muslumanoglu A., 496, 854
Musso F., 50, 451
Muzzonigro G., 1011
Mynderse L., 1156
Myung S.C., 227
- N**
- Nabeeh A., 7, 669, 674
Naber K.G., 489, 906
Nabi G., 487
Nabieh A., 390
Naboka U., 964, 965
Nader H., 75
Nadorp S., 257
Nadu A., 453, 636
Nagai A., 1
Nagamori S., 1076
Nagao K., 370, 1076
Nagar M., 1083
Nagatsuma K., 40
Nagele U., 97, 709, 1197
Nair S., 880
Naito K., 60, 370, 1076
Nakagami Y., 1166, 1168, 1169
Nakagawa M., 1073
Nakamura E., 405, 722
Nakashima O., 1164
Nakatani T., 554
Näkel E., 100
Nalcacioglu V., 706
Nam R., 1187
Nambirajan T., 99, 860
Napodano G., 290, 769
Napoli M., 293
Napolitano G., 864
Nariculam J., 113, 732
Naselli A., 1030
Naspro R., 271, 508, 790, 845
Nassef A., 890
Nasu Y., 1
Nativ O., 64, 509
Naud A., 936
Naumann C.M., 250, 736, 949
Nava L.D., 1158
Navani S., 913
Nawijn M., 567
Nazli O., 47, 657
N'Dow J., 487
Neal D.E., 55, 206, 1182
Nedergaard P., 10
Nehra A., 646
Neilson D., 823
Neiva G., V12
Nelius T., 23, 62, 287, 771
Nelli F., 641
Nemtsova M., 114
Nergiz N., 198
Nesi G., 428, 931
Netto Jr., N.R., 806
Neuhauser A., 367
Neurauper M.L., 899
Neururer R., 263
Neuzillet Y., 522
Newman S., 704
Neyer J., 71
Neyer M., 303
Nguyen-Khoa T., 751
Niall O., 937
Niang L., 205
Nichol J., 591
Nicholson C.M., 570
Nicita G., 530, 748
Nickel I., 771
Niedeggen A., 1104
Niederer P., 886
Nielson M., 61
Niermeijer M.F., 216
Nieweg O., 247
Nigro F., 91, 506
Nijman R.J., 884
Nikbin B., 754
Nikiforidis G., 371
Niklas K., 1126
Nikolai L., 773
Nilson A., 700
Nilsson J., 589
Nilsson S., 589
Nilsson-Neijber A., 174
Nishiyama H., 213, 359
Nishiyama K., 1073
Nissenkorn I., 683, V26
Nita G., 85, 666, V31, V35
Noble J.G., 606

Nobuharu S., 631
Noguchi M., 1164
Noh C. H., 59, 387, 478, 902, 1007
Nohra J., 587, 634
Noll M., 817
Nomura T., 211
Nonomura K., 337, 1076, 1080
Norat T., 26
Nordling J., 683, 1149, V26
Norming U., 1185
Norrie J., 487
North E., 497
Noth J., 235, 957
Nouira Y., 48, 356, 896
Nounla J., 1104
Novak C., 165
Novara G., 338
Novick A., 784, 788
Novotny V., 1079
Nuckolls J., 701
Nuininga J., 1047
Numao N., 1163
Nüser V., 22
Nussbaumer W., 1056
Nuttall M., 932, 944, 1070, 1074
Nuzarelli J., 846
Nyushko K., 746

O

O' Kane H.F., 67
O Malley C., 784, 788
O'Connell H., 683
O'Connor K., 755
Obaje A., 863
Obereder R., 630
Obwexer S., 711
Öchsle K., 301
Odone Filho V., 976
O'Donoghue J.P., 606
Oehlschläger S., 1033, 1079
Ofer Y., 1083
Ogawa O., 213, 359, 405, 722
Oger S., 224, 225
Ogiste J., 699
Oh C.W., 179
Oh M.M., 1116
Oh M.R., 59, 387, 478, 902, 1007
Oh T.H., 449, 511
Ohi M., 1175
Ohjung K., 482
Ohlmann C.H., 3, 281, 289, 534, 946,
1032

Ohlsson C., 393
Ohmi C., 60, 370
Ohneseit P.A., 24
Ohno R., 254, 645
Ohoi M., 1166, 1168, 1169
Okada T., 645
Oktem G., 767
Olbert P., 132, 494
Olesen T.K., 915
Oleynik D., 123
Olgac S., V40
Oliver T., 283
Olsgurgh J., V32
Omar A., 598
Onder E., 1008
Önol F.F., 357, 768
Onur K., 1160
Ooi J., 126, 279
Ooms B., 663
Oosterlinck W., 584
Oosterwijk E., 1047
Opsomer R., 432, 850
Ordonez M., 340
Oren M., 566
Orestano F., 293
O'Riordan A., 87
Orsola A., 131, 133, 134, V10
Orsoni J.L., 8
Ortega F., 181
Ortiz V., 75
Ortiz Gamiz A., 883
Ortuño J., 521
Osada H., 645
Osaki A., 98
Osman Y., 352, 818
Osmonov D., 736
Østling D., 872
Oswald J., 1121
Özsoy M., 339
Otunctemur A., 146
Ouaki F., 853
Oudard S., 1058
Oudot A., 326, 388
Ouellet S., 978
Overmoyer K., 592, 596
Oyen R., 735, 761, 763
Ozbek E., 146
Ozcan L., 146
Ozdamar Y., 712
Ozdedeli K., 767
Özden E., 49, 1127
Özen H., 49, 261, 298, 1008, 1127

Ozer C., 656
Ozer K., 712
Ozgok Y., 758
Özgür E., 3, 281, 289, 946
Ozkara H.A., 1008
Ozkardes H., 656, 838
Ozsoy C., 892, 895
Özsoy M., 940
Oztekin V., 667, 1160
Ozturk B., 1160
Ozturk M., 973, 983

P

Pacchioni D., 825
Pace G., 659
Pachatz C., 948
Padberg B.C., 819
Padmanabhan P., 314
Paez Borda A., 194, 202, 521, 856
Pagano F., 562, 682, 765, 1050, 1190
Pahira J., 196
Paick J.S., 232
Paiss T., 569, 1183
Pakkanen S., 568
Palapattu G.S., 61, 455, 815
Palavan Unsal N., 903
Palea S., 39, 396
Paleniy A., 905
Palermo S., 305, 917, 925
Palleschi G., 688
Pallwein E., 185
Pallwein L., 71, 86, 185, 230, 240, 296,
523, 546, 552, 773, 837
Palma P., 839, V25
Panek A., 564
Panicucci E., 193
Pannek J., 807, 1104
Pansadoro A., 2, 681, V11, V7, V9
Pansadoro V., 454, 934, V11, V7, V9
Pantazis T., 503
Pantuck A.J., 447
Panzer C., 470
Paoletti M.C., 127, 1075
Papadaki E., 410
Papadimitriou V., 882
Paparel P., 56, 366, 988
Papathanasiou A., 1133
Papatsoris A., 1090
Papesh C., 1056
Papotti M., 876
Paradiso M., 624
Paradiso Galatioto G., 831

Abstract Author's Index

- Paras L., 708
Pardo-Cladellas Y., 538
Park B.S., 490
Park C.H., 66, 518, 621, 969
Park D.S., 908
Park E.Y., 1100
Park H.J., 752
Park H.S., 27
Park J., 555, 670, 740, 851
Park J.K., 752
Park J.S., 34
Park J.Y., 555, 740
Park K., 402
Park K.J., 232, 437
Park M.H., 752
Park T.C., 617
Park Y.H., 939, 1052
Park Y.H., 17, 324
Park Y.I., 994
Park Y.K., 66, 511, 518
Parr N., 136
Parrinello M., 259
Parsons K., 739
Parsons M., 683, V26
Partin A.W., 1170
Partridge M., 861, 862
Pascual C., 856
Pascual J., 521
Pascual-Mateo C., 358, 582
Pasechnikov S., 380
Pasini J., 510, 515
Pasini L., 351
Pasquale G., 624
Pasquier G., 776
Pasta A., 642
Pasta D.J., 702
Pastore A., 688
Patard J.J., 177, 180, 183, 327, 336,
447, 483, 639, 715, 1132, V13
Patel A., 42
Patel A., 703, 927, 1089
Patel B., 910
Patel H., 120, 123, 266
Patel N.I., V34
Patel S., 438, 448
Patel U., 493, 498
Pathak S., 415
Patil N., 126
Patrice J., 921
Patriciu A., V34
Patrick D., 168, 169, 171
Pauels H.G., 36
Paul R., 416, 557
Paule B., 1059
Paus E., 872
Pavel C., 512
Pavlik I., 680, 822
Pavlovich C., 1068
Pavone C., 293, 718
Pavone Macaluso M., 293, 718
Payabvash S., 1117
Payne H., 433, 1061
Pazos H., 766
Peck K.R., 485
Pedersen H.S., 575
Peeker R., 393
Peelen P., 304, 869
Pegoraro V., 995, 1002
Peker A.F., 758
Peleg E., 115
Pelger R.C.M., 81, 157, 604
Pellin A., 219
Peluso G., 623
Pelzer A.E., 86, 93, 101, 102, 105, 306,
866, 881, 1072, 1144
Peña J.A., 188
Peng C.C., 413
Peracchia G., 576, 668, 782
Perdonà S., 290
Pereira S., 76
Pereira-Sampaio M.A., 347
Pereverzeva O., 580
Perimenis P., 51, 371, 410, 622
Peris F., 175
Perovic S., 242
Perrin P., 56, 366, 548, 549, 551
Perrotte P., 183, 423, 583, 725, 911,
1026, 1178
Perry A., 573
Perry M., 246
Persad I.J., 1093
Persad R.A., 438, 448, 588, 734, 749,
910
Persson B.E., 915, 1122
Persson J., 155, 406
Pertega S., 713
Perucchini D., 382
Peschel R., 185, 263, 300
Peskircioglu L., 656
Pesi M., 822
Peter D., 683
Peters I., 38
Peters K., 783
Peters M., 1077
Peterson C., 464
Petit J., 522
Petrisor D., V34
Petritsch P., 719, 935
Petta F., 948
Petterson K., 1015
Peyromaure M., 475
Pfister C., 447, 639, 776
Pfister D., 3
Pfundt R., 216
Philip J., 739
Philips J., 112
Phillips R., 781
Phillips R., 209
Philp T., 192, 201
Phipps S., 394
Pianon R., 738
Piao S., 13
Piazzini M., 931
Picchio M., 1028
Piccinelli A., 351
Piccinni R., 444
Pickard R., 87
Picot M.C., 541, 695
Piechaud T., 2, 269, 681
Pierre P., 587
Pietropaolo F., 748
Pifarotti P., 676
Pillai R., 1000
Pilzecker D., 517
Pimentel L.G., 75
Pimentel M., 294
Pina F., 720, 913, 1010, 1021
Ping F., 844, 848
Pinggera G.M., 69, 70, 71, 82, 93, 230,
240, 480, 546, 552, 679, 780, 1018,
1037, 1072
Pinthus J., 874, 1172
Pinto F., 1050
Pipinikas C., 880
Pirès C., 853
Pirinci N., 983
Pitiakoudis M., 970
Pizzarella M., 995
Pizzo M., V7, V9, V11
Planas J., 131, 133, 134, V10
Plante P., 634
Pode D., 115
Poenicke C., 1167
Poggio M., 451, 849, 876
Pointner J., 711
Poissonnier L., 116, 443

Politis V., 238
Polotskiy B., 265
Polverejan E., 168
Polyakov V., 746
Polychronidis A., 970
Pomara G., V15
Ponce C., 883
Ponce J., 713
Ponholzer A., 316, 615, 730, 832
Pönicke C., 644, 759
Pontes Junior J., 369
Popa J., 65
Popert R., 591
Popken G., 452
Porcaro A.B., 738
Porena M., 383, 477, 1129
Porpiglia F., 50, 451, 454, 876, 934, V27
Porst H., 169
Port M., 252
Porter C., 911, 1168, 1169
Portillo J., 1066
Potenzoni M., 867
Potluri B., 672
Potters L., 591
Poulain J.E., 8
Poulakis V., 276, 280, 302, 446
Poulakou-Rebelakou E., 601
Poulas I., 787
Poulsen J., 932
Pourmand G., 754
Powe D., 560
Pow-Sang J., 125
Praddaude F., 74, 1110
Pradhan L., 9
Praetorius M., 236
Prammer P., 277, 609
Prapotnich D., 272, 933, 1064, 1067
Prats J., 188
Prayer Galetti T., 353, 562, 765, 1096, 1190
Praz F., 364
Prera A., 188
Prezioso D., 748
Pricaz E., 116
Pridgeon S., 207
Prieto D., 64
Prieto N., 350
Primus G., 986
Prior J., 921
Prockop D.J., 16
Protheroe A., 781
Protogerou V., 991

Pruim J., 884
Puccetti L., 310
Puhan M., 859
Pummer K., 719
Pupca G., 500
Puppo P., 1030
Puri R., 209, 664, 943, V16
Pushkar D., 380, 686, 871, 1192
Puthenparumpil J., 834
Pych K., 325
Pycha A., 917, 925

Q

Qazi H., 739
Quail D., 83, 826, 827
Queimadelos A., 1066

R

Raabe M., 1126
Rabbani R., 1117
Rabelo P., 897
Rabenalt R., 119, 128, 273
Raber M., 1195
Rachid Filho D., 897, 1138
Radmayr C., 1121
Radziszewski P., 683, V26
Ragavan N., 570, 571
Raggio M., 1155
Ragni F., 849
Ragona R., 585
Rahimpour S., 1117
Rahnenführer J., 106
Raichlin Y., 918
Rainer M., 101
Ralph D., 244, 249
Ram-Liebig G., 145, 1098
Ramani V., 30, 159
Rambaud B., 750
Rambeaud J.J., 328, 889
Ramirez A., 423
Rammal A., 129, V1, V37, V38, V5, V6
Ramon J., 453, 636, 717, 874, 913
Ramoner R., 671, 1009, 1056
Ramos D., 219
Ramp U., 332
Ramsay I., 987, 1131, 1135
Ramsden A., 1024
Ramsey S., 793, 795
Rane A., V16
Rane A., 978
Ranieri G., 659
Ranzoni S., 685, 744

Rao A., 598, 602
Rapiti E., 1034
Rassler J., 978
Rassweiler J.J., 121, 267, 274, 424, 430, 989
Rastegari M., 653
Rau O., 771
Rauchenwald M., 316, 420, 615
Ravens U., 1098, 1102
Raventós C.X., 131, 133, 134, V10
Ravery V., 426, 427, 843, 875, 1137, 1140, 1162, 1165
Ravichandran S., 99, 258, 481
Recker F., 1013, 1014, 1189, 1196
Redman B., 1057
Redondo E., 194, 202
Rees R., 560
Refai H., 352
Regoli D., 800
Rehak P., 334, 456, 457, 458, 812, 813, 814
Rehder P., 71, 93, 240, 480, 523, 524, 552, 679, 1009, 1018
Rehman I., 57
Reich A., 37
Reich O., 41, 243, 742, 816, 817, 841, 855, 992, 1157
Reichelt O., 178, 186, 190
Reiher F., 23, 287, 771
Reilly K., 372, 373, 537
Reis F., 797
Reis R., 899
Reissigl A., 711
Reitz A., 229, 801, 802, 804, 955, 1106, 1112
Rejas J., 323
Rekeda L., 377
Remer E., 784, 788
Rémésy C., 578
Remo G., 800
Rempelakos A., 601
Remzi M., 200, 339, 711, 786, 940, 1051, 1114
Renard J., 50, 451, V27
Rennert G., 54
Renoult E., 520
Rentsch C.A., 156, 157, 566
Rentschler M., 123
Reuter V., 278, 1200
Reymond D., 139
Rhee H., 415
Ribal M.J., 210, 215

Abstract Author's Index

- Ribeiro-Filho L., 98, 369
Ricardi U., 585
Ricetto C., 839, V25
Richard F., 365, 425
Richards A., 279
Richter A., 1054
Richter K., 22
Richter K., 295, 559
Richthoff J., 1149
Rick O., 301
Rickards D., 192, 201
Ricós J., 181
Rieber E.P., 295, 559
Rigamonti W., 353
Rigatti P., 271, 308, 472, 474, 508, 586,
607, 612, 628, 642, 748, 790, 845,
857, 1025, 1028, 1042, 1043, 1158,
1168, 1169, 1178, 1195
Riis A., 1122
Rimington P., 932, V16
Rinaldi S., 1177
Ringert R.H., 488
Rini B., 1057
Rioja C., 422
Rioja L., 422
Rios E., 194, 202
Rioux-leclercq N., 177, 180, 327, 336,
V13
Rischmann P., 39, 74, 581, 587, 1107,
1110
Risse F., 783
Rittenhouse H., 870, 1012
Rittig S., 1122
Rittmaster R., 691
Riva D., 676
Riva M., 508
Rives N., 776
Rivière P., 197
Rixon L., 704
Rizzi F., 576
Roberts R.G., 376
Robertson W., 42
Robineau P., 39
Robinson D., 723
Robson C., 104, 404
Rocco B., 127, 426, 427, 531, 875,
1075, V8
Rocco F., 777
Rodrigues Netto Jr., N., 839, V25
Rodriguez A., 125
Rodriguez E., V42
Rodriguez R., 54
Rodríguez Rodríguez-Madrid A., 595
Rodriguez-Miñón J.L., 1035
Rodríguez-Molina J., 1035
Rodriguez-Toves A., 1136
Rodriguez-Vela L., 466
Roehrborn C.G., 690, 691, 692, 696,
697, 701, 702, 1169
Roemeling S., 727, 878, 1180
Rogers C., 61, 455
Roggenbuck U., 311, 611
Rohrmann D., 235, 756, 957, 958
Roigas J., 435, 757
Rokkas K., 12
Romagnoli A., 88, 1044
Romano M., 738
Rombis V., 1133
Romero E., 713
Romero F., 1068
Romero I., 582
Romero J., 1142
Romics I., 426, 427
Romundstad P., 852
Roncevic T., 510
Ronchi P., 659, 831
Ronci L., 629
Roobol M.J., 727, 865, 1023, 1180, 1181
Roques C., 1107
Rosado E., 713
Roschin D., 260, 945
Roscigno M., 642, 1028, 1043
Rose L., 465
Rosen R.C., 321, 322, 539, 701
Rosier P., 687
Roskams T., 735, 761, 763
Rosser J., 136
Rössler T., 1126
Rosso D., 1017
Rothman M., 169, 171
Rotman S., 361
Rotter V., 566
Rouach Y., 197
Rouprêt M., 365, 425
Rouviere O., 441
Roux D., 634
Royce P., 590
Rozet F., 118, 124, 270, 272, 933, 1005,
1064, 1067
Rub R., 1118
Rubin M., 103, 563
Rubinstein I., 1138
Rubinstein M., 1138
Rubio J., 181, 219
Rubio Auriolas E., 465
Rudoni M., 744
Rueben R., 394
Ruffion A., 56, 366, 549, 988
Rusakov I., 114, 746
Rüschoff J., 108
Russo P., 340
Ruszat R., 791, 841, 855, 992, 993, 996
Ruutu M., 1186
Ryberg M., 589
Ryu D.S., 449
Ryu J.K., 13

S

- Sa V., 369
Saad F., 130, 140, 141, 142, 423, 583,
725
Saccà A., 472, 474, 857, 1195
Sacco E., 1190
Saccomanni M., 1129
Sáenz J., 202, 521
Sagalowsky A., 61, 455, 920, 923
Sagalowsky Y., 811
Sagi S., 44, 45
Saha P., 1145
Sahadevan K., 104
Sahai A., 381, 675, 684
Sahi D., 946
Sahin A., 49, 1127
Saika T., 1
Sakai M., 411
Sakano S., 60, 370
Sakellaropoulos G., 410
Sala M., 744
Salagierski M., 785
Salagierski M., 785
Salame' L., 259
Saleem M., 96
Salenius J.P., 1048
Salizzoni E., 710
Sallami S., 48, 356
Salomon G., 608
Salomon L., 122, 177, 180, 336, 447,
522, 639, 714, 715, 1029, 1059,
1198
Salonen A., 1065
Salonia A., 271, 308, 472, 474, 586,
607, 612, 628, 845, 1042, 1043,
1168, 1169, 1178, 1195
Salsi P., 349, 502
Saltutti C., 1016
Salvador C., 131, V10

- Salvadori S., 800
 Samman R., 672
 Sampaio F., 72, 76, 77, 233, 347, 400, 766
 Samsioe G., 83, 826, 827
 Samuel J., 159
 Sanchez C., V24
 Sanchez M., 421
 Sánchez L., V42
 Sanchez Ramos A., 627
 Sánchez Salas R., V12
 Sánchez Sánchez E., 883
 Sanchez-Chapado M., 913
 Sanchis M.A., 1142
 Sand C., 228
 Sand M., 321, 322
 Sandblom G., 723
 Sandhu S., 792
 Sangalli M., 642, 857
 Sanjmyatav J., 178
 Sanli A., 355
 Sanli O., 892, 895
 Sansalone S., 242
 Santaniello F., 383
 Santos J., 21
 Santti R., 700
 Saporta F., 8
 Saraiva L., 720
 Saraji A., 754
 Saramäki O., 158
 Sarasa J.L., 401
 Sarica K., 1085, 1095
 Sarkis A., 98, 369
 Sarkissyan T., 565
 Sarramon J.P., 74, 1110
 Sato E., 558
 Sato F., 407
 Sato N., 558
 Satoji Y., 231
 Sauer mann P., 382
 Saussine C., 191
 Sauter G., 553
 Savoca G., 259
 Sax M., 955
 Sayed M.A., 647
 Sazawa A., 337, 1080
 Sblendorio D., 444
 Scaburri A., 127
 Scaillet P., 432
 Scandella E., 363
 Scapaticci E., 1158
 Scardino P., 278, 1015, 1200
 Scarpa R.M., 50, 451, 849, 876, V27
 Scarpone P., V7, V9, V11
 Scattoni V., 308, 586, 607, 857, 1025, 1028, 1043, 1168, 1169
 Scavini M., 308
 Schaaf A., 217
 Schaeffer E., 1068
 Schalken J., 221, 304, 566, 869
 Scharf S., 929
 Scharlau F., 1191
 Schelin S., 1149
 Scheller F., 22, 41
 Schennach H., 1018
 Scher B., 243, 742
 Schiavina R., 710, 741, 747
 Schiffforst G., 135
 Schill W.B., 775
 Schilling D., 264, 743, 1027
 Schink T., 435
 Schips L., 177, 336, 935
 Schlarp O., 529
 Schleicher J., 301
 Schlemmer H.P., 709
 Schlenck B., 1121
 Schlenker B., 41, 243, 742, 817, 1157
 Schleutker J., 568
 Schlieper G., 756
 Schlobach Da Costa K., 1102
 Schlomm T., 100, 309, 431, 553, 613, 716, 975, 1015, 1026, 1166, 1171, 1178
 Schmeller N.T., 630, 705, 708, 1159, V22, V33
 Schmelz H., 252
 Schmid D.M., 117, 382, 859
 Schmid H.P., 363, 708, 753
 Schmid M., 1106
 Schmidbauer J., 339, 1051
 Schmidlin F., 789, 886, 1034
 Schmidt S., 921
 Schmidt U., 110, 220, 409, 462
 Schmitt H., 622
 Schmitz M., 295, 559
 Schneede P., 243
 Schoenberg M.P., 61, 216, 455, 815
 Schoenmakers E.F.P.M., 216
 Schoepen Y., 1059
 Schöffski P., 301
 Scholfield D., 808
 Scholz R., 436
 Schostak M., 1019, 1188
 Schouten B.W.V., 312
 Schrader A.J., 132, 494
 Schrader M., 253, 255, 824, 978, 1019, 1105, 1188
 Schraml J., 680
 Schrier B., 1077
 Schröder A., 967, 1119
 Schröder F.H., 727, 729, 865, 878, 1023, 1180, 1181
 Schubert J., 178, 186, 190, 218, 368
 Schubert P., 65
 Schuhmacher M., 1032
 Schuit S.J., 472, 474
 Schulam P.G., 934
 Schuldts M., 1104
 Schulman C., 269, 692, 857, 875
 Schulman K., 142
 Schulte-Baukloh H., 1104
 Schulten H.J., 975
 Schultheiss D., 11
 Schultz-Lampel D., 1104, 1126
 Schulz W.A., 106, 367
 Schulze H., 473
 Schulze M., 430, 989
 Schuppe H.C., 775
 Schurch B., 382, 801, 802, 804, 955, 1106, 1112
 Schürch L., 855, 992
 Schwaiger M., 416
 Schwanager R., 156, 157, 566
 Schwartz B., 1058
 Schwentner C., 1121
 Schwenk F., 127, 1075, V8
 Sciobica F., 948
 Scoffone C., 50, 849, 876
 Scopa C., 371
 Scremin E., 91, 506
 Sebastiani G., 310
 Sèbe P., 197, 205
 Sebire N., 1118
 Secin F., 268, 269, 340, V3, V4, V19, V39, V40
 Sedigh O., 585, 624
 Seftel A.D., 702
 Segal S., 745
 Segawa T., 405, 722
 Seibt B., 1126
 Seidl C., 416
 Seif C., 250, 473, 947, 949
 Seifert H.H., 841, 863, 993, 996
 Seiler D., 1013, 1014, 1189, 1196
 Seiler T., 488
 Seitz C., 200, 339, 389, 843, 940, 1114

Abstract Author's Index

- Seitz G., 223
Seitz M., 243, 742, 817, 1157
Seki H., 1076
Sella A., 762
Sellars N., 732
Selli C., 193, 282
Semeradt T., 680
Semerci B., 767
Sender H., 977
Senekowitsch Schmidtke R., 416
Sengel C., 889
Sengul F., 712
Senkul T., 1123
Senocak M., 835
Seo J.H., 994
Seo J.T., 491
Seo Y.J., 621
Seol S.K., 179
Seong D.H., 13, 329
Seoung Hun S., 468
Serbanescu B., 512, 514
Serio A., 268, 269
Seriogin, Jr A., 572
Serni S., 428, 641, 643
Serrallach Mila N., 307, 724
Serretta V., 293, 718
Serth J., 25, 29, 32, 35, 38, 594
Servera A., 422
Seseke F., 488
Seseke S., 488
Seth R., 560
Sevdalis N., 927, 1089
Severin E., 580
Seveso M., 351
Sevinc S., 132
Seyam R., 239
Shaaban A.A., 7, 505, 625, 674, 818, 1071
Shabsigh R., 174
Shah T., 209, 1086
Shahbazyan G., 545
Shakeri S., 653
Shamseddine A., 288
Shan M., 1058
Shangichev A., 904, 905
Shaobo Z., 844, 848
Shariat S., 61, 455, 811, 815, 888, 920, 923, 1169
Sharma M., 861, 862
Sharma N.K., 342
Sharoev T., 945
Shayegan B., V40
Shechner C., 509
Shegai P., 114
Shehab El-din A., 842
Shehi E., 688
Sheir K., 650, 655, 658
Shergill I., 602
Shestiperov P., 580
Shier K., 1087
Shiina H., 98, 369
Shim B. S., 59
Shim K.S., 27
Shim Y.J., 28, 1116
Shimizu Y., 405, 722
Shin H.Y., 13
Shin S.M., 908
Shin T.S., 1176
Shin T., 407
Shinohara N., 337, 1076, 1080
Shiomi M., 231
Shittu O.B., 25
Shoeb M., 1091
Shokeir A., 495, 658
Shoma A., 199, 352, 495, 505
Shuqi D., 1099
Siablis D., 371
Sibert L., 776
Siddiqui E., 448, 1097
Sidenius N., 1011
Sides G., 696
Sidi A.A., V17, V18, V30
Siegmund M., 1188
Siemer S., 331, 630, 644, 1104, 1126
Siener R., 53
Sievert K.D., 32, 97, 223, 807, 1197
Sighinolfi M.C., 623
Sikes R.A., 415
Sikka S.C., 778
Silakos A., 297
Silva A., 1010, 1021
Silva C., 797
Silva F.A.Q., 241
Silva J., 797
Silva P., 720, 1021
Simitovic S., 1112
Simms M., 590
Simon P., 24
Simon R., 553
Simonato A., 88, 1044, 1075
Simonazzi M., 829
Simoncini G., 659
Simone M., V15
Simonini G., 668, 782
Simopoulos C., 970
Simsir A., 47, 657
Sinescu I., 512, 514
Singh R., 126
Singla A., 527, 980
Siracusano S., 829, 981
Siragusa A., 293
Sirvanci S., 768
Sivanesan K., 987, 1131, 1135
Sivridis E., 970
Sizonov V., 963
Skok Z., 398
Skolarikos A., 344, 1090
Skriapas K., 302
Slama A., 541, 695
Small E.J., 140
Smit M., 167
Smith J., 952
Smith M.R., 130, 140
Smith R.D., 703
Smith R., 258
Snedeker J., 886
Snow R., 590
Snyder M., 340
So S.M., 399
Sofer M., V36
Sofikitis N., 68, 251, 297, 770, 821
Sofras F., 830, 882
Sohn M., 11, 14
Soler R., 75
Soliman H., 364, 924
Soliman S., 842
Solsona E., 181, 219
Somani B., 487
Somay A., 146
Song C., 670
Song K.H., 329
Song K.W., 752
Song S.H., 851
Song S.U., 13
Song S.Y., 485
Song Y.S., 17, 324, 329
Sønksen J., 772
Soomro N.A., 934
Sooriakumaran P., 597
Sörgel F., 489
Soroiu D., 665
Sosnowski M., 785
Sotelo R., V12, V42
Soukup V., 822
Soulie M., 447, 587, 634, 639
Souras K., 894

- Sourla A., 284
 Spahn M., 760
 Spaliviero M., 784
 Sparwasser C., 252
 Speakman M., 733, 1184
 Spees J.L., 16
 Spera G., 465
 Sperandio P., 765
 Spinelli M., 800, 901
 Spinosa J.P., 1139
 Spirichev V., 580
 Spranger R., 679
 Srirangam S., 823
 Sroka R., 148
 Srougi M., 75, 98, 172, 241, 369, 962, 976
 Stadler W.M., 1058
 Stage K., 888
 Stainier A., 885
 Staios D., 1090
 Stajduhar E., 515
 Stamatiou K., 882
 Stanley N., 550
 Stathis H., 787
 Stattin P., 574, 1177
 Stauch K., 476
 Stav K., 417, 762
 Stecher V., 620
 Steenkeste K., 930
 Stefanadis C., 12
 Stefancik J., 319
 Steghens J.P., 750
 Steidler A., 65
 Stein A., 54
 Stein R., 967, 1119
 Steiner G., 391
 Steiner H., 263, 296, 300, 303, 671, 866, 881, 919, 1072, 1144
 Steiß J., 974
 Stejskal D., 922
 Stelzl U., 409
 Stener S., 127, 1075, V8
 Stenman U.H., 574
 Stenzl A., 24, 29, 32, 33, 97, 137, 223, 236, 237, 264, 709, 743, 807, 1027, 1197
 Stephen R.L., 673
 Stephens T.C., 206
 Stephenson A.J., V4, V39
 Steuber T., 309, 431, 553, 613, 716, 858, 1015, 1025, 1026, 1031, 1166, 1168, 1169, 1171, 1191
 Stief C., 11, 14, 41, 148, 243, 742, 816, 817, 929, 1157
 Stiggelbout A.M., 81
 Stikarovska I., 725
 Stindel E., 328
 Stock C., 267, 430
 Stöckle M., 106, 107, 331, 412, 644, 759, 984, 1167, 1193
 Stocks T., 1177
 Stoerker S., 311
 Stöhr R., 368
 Stoianovici D., V34
 Stoiljkovic J., 836
 Stolzenburg J.U., 51, 119, 128, 273, 371, 630
 Storti L., 673, 728
 Stoss O., 108
 Stower M., 943
 Strach A., 564
 Strasser H., 69, 70, 82, 230, 240, 480, 546, 552, 679, 780, 1018, 1037
 Straub M., 4
 Straumann U., 855, 992
 Strauß A., 488
 Strebel R.T., 117, 382, 819, 859
 Streng T., 700, 954
 Strohmaier W.L., 348, 630, 660
 Struhal G., 730
 Stübinger S.H., 592, 596, 736
 Stuckert T., 1104
 Student V., 94
 Studer U.E., 156, 415, 566, 614, 721, 1032, 1038, 1039, 1062, 1128, V20
 Stummvoll P., 719
 Sturm W., 236
 Suardi N., 612, 628, 845, 1028, 1169
 Suarez Novo J., 307, 724
 Subotic S., 430, 989
 Suchkov I., 964, 965
 Suekane S., 1164
 Sugimoto S., 285
 Sugiyama Y., 231
 Suh J.K., 13
 Sulser T., 629, 791, 841, 855, 992, 993, 996
 Sültmann H., 100
 Sumiyoshi H., 407
 Sundaram R., 943
 Sundaram S.K., 721, 1062
 Sung D.J., 179
 Sung G.T., 511
 Surange R.S., 342
 Suraparaju L., 998, 999
 Susani M., 339, 786, 940
 Susser J., 532
 Suy R., 942
 Suzuki K., 1175
 Suzuki M., 411
 Suzuki S., 1076, 1080
 Suzuki T., 535
 Svatek R., 923
 Svensson J., 802
 Svihra J., 513
 Svoldgaard N., 909
 Swearingen D., 464
 Sweet J., 1172
 Swinn M., 732
 Swithinbank L., 1125
 Syed Ahmed T., 626
 Sylakos A., 251, 770
 Symonds T., 166, 170
 Szardening-kirchner C., 19
 Szczylik C., 1058
 Szlauer R., 705, 1159
 Szumilak D., 751

T

- Taari K., 1065
 Taberner A., V2, V24
 Taccoen X., 129, 328, V1, V37, V38, V5, V6
 Tachibana M., 1166, 1168, 1169
 Tack I., 74, 1110
 Taggi F., 175
 Taher A., 288
 Tai C.K., 1092
 Taieb C., 548, 549, 551
 Tainturier C., 313
 Takada S., 556
 Takahashi A., 558
 Takahashi S., 764, 873
 Takahashi T., 359
 Takayuki T., 631
 Takechi H., 1175
 Takeda M., 211
 Takemoto Y., 554
 Takeuchi T., 411, 764, 873
 Takihana Y., 211
 Talja M., 149, 1048
 Tammela T.L.J., 149, 158, 386, 568, 700, 914, 1048, 1065, 1173, 1174, 1186
 Tan A.F., 1153
 Tan B., 1127

Abstract Author's Index

- Tanabe K., 516
Tanagho E., 98
Tanaka M., 333, 635
Tanaka M., 333, 556, 635, 1055
Tanaka N., 333
Taneja S., 1061
Tang T., 979
Tanjil N., 403
Tanovic E., 200, 339, 940
Tarabuzzi R., 849, 876, V27
Tarcan T., 768, 835
Tas M., 1160
Tasar C., 261
Tasca A., 91, 506
Tasçi A.I., 146, 997
Tascini M.C., 383
Tasdemir I., 914
Tauber V., 334
Taubert H., 109
Tavangar S.M., 1117
Taverna G., 351
Taylor C., 755
Taylor G.A., 207
Taylor J., 1040
Taymoorian K., 435, 436
Tchekmedyan S., 141
Te A.E., 699
Teber D., 121, 267, 274, 424, 430, 989
Teerds K., 256
Tefekli A., 496, 854
Teh M., 661
Teichmann R., 301
Teillac P., 364, 501, 924
Tekdogan U., 706
Tekerek P., 991
Tekgül S., 1124, 1127
Tekin M.I., 656
Telegrafi S., 314
Tellez Martinez- Fornes M., 677
Temelcos C., 937
Temiz Y., 357
Temml C., 316, 615, 832
Tempesta A., 444
ten Dyke P., 157
Ten Kate F., 335
Tenke P., 486
Ter Haar G., 781
Terao T., 254, 645
Terrone C., 451, 849, 876
Terry S., 153, 414
Teruhisa N., 631
Testa C., 710, 741
Tetens V., 630
Tewari A., 881
Texier N., 541, 695
Tezval H., 35
Thalmann G.N., 112, 156, 157, 361, 415, 566, 1038, V20
Thamboo T.P., 661
Theodor R.A., 1054
Theron P., 248
Thevenin A., 203
Thibault F., 8, 205
Thibault P., 203, 205
Thiesen B., 436
Thiounn N., 632, 638
Thiruendran G., 823
Thiry-Escudie I., 1107
Thomaidou E., 707
Thomann D., 1128
Thomas K., 343
Thomas M., 165
Thomas S., 312, 540
Thompson P., 847
Thorsten S., 858
Thueroff S., 439, 442, 1036, 1088
Thurairaja R., 734, 749
Thüroff J., 967, 1119
Thwaini A., 602
Tiberio A., 829
Tigaran D., 354
Tikkinen K.A., 386
Timoney A., 46
Timsit M.O., 632, 638, 750
Tinn G., 608
Tinzl M., 1134
Tiptaft R., 343
Tischmeyer U., 489
Titta M., 91, 506
Tizzani A., 360, 825, 1017
Tjulandin A., 265
Toepper R., 235, 957
Toft G., 575
Tokumoto N., 516
Tolson J., 212
Toma H., 516
Tomada N., 21, 1010
Tomaskin R., 513
Tombal B., 432, 850, 885
Tombul T., 261
Tomioka A., 556
Tomita K., 764, 873
Topuzovic C., 990
Torigoe T., 558
Tornblom M., 1185
Tosato F., 1096
Tosi N., 641
Tostain J., 177, 180, 183, 336, 447, 639
Tosto A., 530
Tosun K., 240, 480, 679, 780, 1018
Toubi A., 1113
Toublanc M., 1137, 1162, 1165
Touijer K., 268, 269, 278, 340, 1200, V3, V4, V19, V39, V40
Touloupidis S., 503, 970, 1133
Toutouza M., 12
Toyoda Y., 337, 1080
Trachtenberg J., 1172
Traficante A., 444
Tran-dang M.A., 703
Traverso P., 88, 1044
Traxer O., 191, 197, 203, 205
Trebaticky B., 319
Treiber U., 416, 557
Triantafyllidis A., 503
Trilla E., 133, 134, V10
Trilla H., 131
Tritschler S., 816, 929
Trojan L., 217, 362
Trost L., 9, 16
Trucchi A., 1020
Trujillo G., V42
Truss M.C., 119, 273, 397
Truzzi J.C., 75
Tsakiris P., 894
Tsalavoutas S., 238, 887
Tsalikis C., 238
Tsampoulas C., 68, 297, 821
Tsiamis C., 601
Tsili A., 68, 297, 821
Tsimafeyeu I., 1053
Tsimtsiou Z., 678
Tsvivan A., V17, V18, V30
Tsuchida K., 554
Tsuchida T., 211
Tsuchiya A., 828
Tsukamoto T., 558
Tsurumaki Y., 764, 873
Tsuchima T., 1
Tubaro A., 379, 688, 1006, 1020
Tugcu V., 146, 997
Tulic C., 52
Tunc M., 892, 895
Tuncel A., 706
Turini D., 800, 901
Turk I., 269

Türker P., 768
Türkeri L., 357
Turna B., 47, 657, 767
Turney B., 820
Turpin E., 924
Turunc T., 838
Tyrrell C., 913
Tzavaras A., 644
Tzortzis V., 499
Tzoumis P., 68, 821

U

Ucar M., 355
Ückert S., 11, 14, 22, 41, 397
Ueda S., 231
Uehara S., 1
Uejima S., 1055
Uemura H., 1055
Ugurlu O., 667
Uhl J.F., 161
Uhm T. H., 387, 1007
Ülger S., 1130
Ulys A., 916
Undre S., 927, 1089
Urwin G., 799, 978, 979
Ustun G., 657
Uurto I., 149, 1048
Uy A., 138

V

Vaahtera K., 700
Vaccino D., 50
Vacherot F., 153, 414
Vaidyanathan R., 861, 862
Vaisanen V., 1015
Vakaet L., 584
Vale J., 703
Valente G., 187
Valenti M., 673, 728
Valeri A., 129, 177, 328, 336, V1, V37, V38, V5, V6
Valiquette L., 423, 607, 1025, 1166, 1169
Vallancien G., 118, 124, 270, 272, 365, 425, 933, 1005, 1064, 1067
Vallejo J., 194, 202
Vallo S., 783
Valmalle A.F., 1045
Valmorri L., 1016
Valot A., 483
Van Ahlen H., 476
Van Baelen A., 761

Van Bezooijen R., 156
Van Boven E., 664
Van Boven H., 247
Van Cangh P.J., 432, 729, 850, 885
Van Cleynenbreugel B., 151
Van de Bergh B., 885
Van Der Aa M., 364
Van Der Heijden A.G., 459, 662, 664
Van Der Horst C., 250, 473, 596, 947, 949
Van Der Horst G., 157
Van Der Jagt E.J., 884
Van Der Kwast T., 364
Van Der Kwast T.H., 663, 727, 729, 878
Van Der Meulen J., 543, 544, 704, 1070, 1074, 1179
Van Der Pluijm G., 156, 157
Van Der Poel H., 567
Van Gils M., 304, 869
Van Hooij O., 304, 869
Van Kerrebroeck P., 222, 379, 536
Van Koeveringe G., 222
Van Kuppevelt T., 1047
Van Leeuwen M.A., 257
Van Meel T., 809
Van Moerkerk H., 1047
Van Moerkerk H., 737
Van Moorselaar J., 698
Van Oers J., 218
Van Overveld P., 157
Van Poppel H., 320, 630, 640, 729, 735, 761, 763, 794, 915, 942
Van Randenborgh H., 416, 557
Van Reijmersdal S., 216
Van Rey F., 1103
Van Rhijn B., 663
Varadaraj H., 573
Varakis I., 410
Vardanyan S., 600
Vardi Y., 618, 803
Varenhorst E., 723
Varkarakis I., 344, 1090
Vashchenko N., 160
Vassiliadi C., 12
Vaucher L., 921
Vaux K., 796
Vazina A., 61, 455, 815
Védrine N., 578
Vedruccio C., 748
Veenstra T.D., 64
Veerakumarasivam A., 55
Vekemans K., 729

Vela Navarrete R., 401
Vendeira P., 21
Venkateswaran V., 579
Venn S., 550
Verdorfer I., 919
Vergunst H., 664
Verhagen P., 637
Verhoest G., V13
Verkooijen H.M., 1034
Verrini G., 668, 782
Vespasiani G., 673, 728
Vessella R., 158
Vianello A., 1129
Vicaut E., 469
Vicente E., 188
Vicente I., 120
Vicentini C., 659, 831
Vicentini F., 241
Vickers A., 269, 278, 1015, 1200
Vidlar A., 94, 922
Vigliercio G., 1155
Vignolini G., 428
Vigués Juliá F., 307
Viitanen J., 1065
Vijverberg M., 1120
Villacampa F., 595, 1142
Villari D., 530, 748
Villavicencio H., 210, 215, 1006
Villeirs G., 584
Vinarov A.Z., 580, 731
Vincendeau S., 327, 336, 483, V13
Viola J., 766
Viola M., 668, 782
Virdi J., 672, 1148
Virgili G., 728
Vis A.N., 878
Visakorpi T., 158
Vittadello F., 917
Vivacqua C., 1016
Vlachopoulos C., 12
Vodovnik A., 209
Vogel W., 569
Voinea S., 512, 514
Volant A., V1, V5, V6, V37, V38
Volkmer B.G., 4, 5, 250, 484, 563, 1041, 1069
Volkova M., 260, 265, 945
Voller M., 566
Volpert O., 23, 62
Volz D., 1108
Von Der Heyde E., 29, 32
Von Hessling A., 1106

Abstract Author's Index

Von Nordenflycht O., 608
Von Wasielewski R., 25
Voorham-Van Der Zalm P.J., 81
Vordos D., 122, 715, 1029, 1059, 1198
Vorobyev N., 746
Voudoukis T., 51, 371
Vourda K., 410
Vozianov A., 219
Vrany M., 513
Vroemen M., 18
Vrtal R., 94
Vseticka J., 513, 680
Vukicevic S., 157
Vukotic-Maletic V., 1081
Vuksanovic A., 52

W

Wachs B., 696
Wadhwa V., 136
Wadie B., 842, 956
Wæhre H., 872
Wagenlehner C., 489
Wagenlehner F., 489, 906
Wagg A., 83, 826, 827
Wahl H.G., 132
Wahlgren T., 589
Waidlich R., 817
Wakonig J., 633
Walder G., 480, 1018
Waldert M., 200, 339, 843, 1114
Waldkirch E., 11, 14
Waldöfner N., 436
Walkay G., 672
Walker B., 107
Walker I., 861, 862
Walker M., 703
Wallace D., 913
Wallerand H., 898
Walsh K., 847
Walsh P.C., 1170
Walter H., 1126
Walton T., 560
Walz J., 100, 613, 716, 858, 1026, 1166,
1168, 1178, 1191, V21
Wang B., 173
Wang J.T., 536
Wareham K., 384
Warncke S., 614, 1039
Warren K., 1024, 1202
Wasilewska A., 564
Watanabe J., 213, 359
Watanabe T., 645

Waterman E., 408
Watkin N.A., 246, 497, 1093, 1097
Watkins A., 384
Watson C., 67
Watson G., 1152
Watson W., 755
Wawroschek F., 462
Wechsel H.W., 630
Weerasinghe S., 834
Wefer B., 473, 736, 947
Wegener G., 32
Wegiel B., 155, 406
Wehrberger C., 832
Wei J.T., 701, 702
Weibl P., 189
Weidlich P., 148
Weidner N., 18
Weidner W., 19, 252, 489, 775, 926,
974
Weikert S., 26, 58, 253, 255, 824
Weinfurt K., 142
Weinseisen A., 71
Weiss C., 65
Weiss Blankenhorn P., 947
Weltzien B., 791
Wendt Nordahl G., 195
Wenzel M., 362
Werkström V., 1109
Werner C., 1098
Werner M., 382
Werther M., 108
Wese F.X., 432, 850
Wester H.J., 416
Wetterwald A., 156, 157, 566
Whelan P., 721, 1062, 1066
Whitney M.J., 16
Whittlestone T., 910
Wiedeking B., 1126
Wieland W., 906
Wiessner D., 1079
Wijkstra H., 335
Wild D., 170
Wildhagen M., 593
Wilding G., 1057
Wilke N., 38
Wilkinson S., 1024
Wille A., 757
Wille S., 289, 534
Willer B., 1104, 1126
Williamson K., 67
Willinger M., 420
Willmott S., 1201

Wilson T., 691
Winkler R., 652
Wirén S., 574
Wirth G., 1139
Wirth M.P., 110, 145, 220, 409, 462,
559, 913, 1033, 1079, 1098
Witherow R., 703
Witjes J.A., 152, 216, 292, 304, 459,
662, 664, 737, 869, 1077
Witkos M., 1172
Witzsch U., 276, 280, 302, 446
Wiunig C., 711
Woehr M., 760
Wolf G., 22
Wolf P.Y., 1045
Wolff I., 332
Wolfgang D., 276
Wölfle S., 967
Wolski Z., 398
Won J.H., 17
Won N.H., 28
Woo J.C., 449
Wood D., 1040
Woodhouse J.B., 959
Woolfenden A., 739
Wright M.P., 380, 448
Wu F., 781
Wuest M., 1098, 1102
Wullich B., 106, 107, 331, 412, 1167,
1193
Wunderlich H., 178, 186, 190
Wust P., 436
Wylser S., 791, 841, 855, 992, 993, 996
Wyllie J., 165
Wyllie M., 165
Wyndaele J.J., 533, 809, 960

X

Xavier M., 116, 419
Xie L.P., 547
Xu C., 162
Xu D., 31
Xu L., 547
Xue Q.S., 162

Y

Yaici E.D., 162
Yair L., 815
Yalcin O., 835
Yamada D., 1
Yamada T., 254, 645
Yamaguchi K., 285

Yamamoto T., 1175
 Yamamoto Y., 60, 370
 Yamanishi T., 535, 1101
 Yang E.K., 392
 Yang J., 394
 Yang J.H., 232
 Yang X., 153, 414
 Yang Y., 828
 Yano S., 60
 Yao K.S., 547
 Yap R., 287
 Yap T., 704, 1179
 Yardy G., 154
 Yarom N., 762
 Yasuda K., 535
 Yates D., 57
 Yawen X., 844, 848
 Yaycioglu O., 838
 Yenokyan H., 600
 Yeznkyan G., 565
 Yi J.W., 479
 Yiu R., 122, 1029, 1198
 Yip S., 1143
 Yokoyama M., 403
 Yonneau L., 8
 Yoo C., 555, 740
 Yoo E.S., 66, 511, 518
 Yoon C.J., 994
 Yoon C.Y., 28, 179, 1116
 Yoon D.H., 28, 179, 1116
 Yoon D.K., 27, 28, 179, 1116
 Yoon S.M., 13, 1141
 Yoshida K.I., 535, 1101
 Yoshida M., 231
 Yoshida S., 254, 645
 Yoshida T., 285
 Yoshikawa T., 285
 Yoshimura R., 554
 Yoshinaga A., 645
 Yoshio T., 631
 Yoshioka H., 407
 Young J., 696
 Young T., 828
 Yuki M., 631
 Yüksel M., 357
 Yurakh A., 219
 Zermans J., 517

Z

Zaak D., 816, 929, 1157
 Zacci F., 417
 Zaitcev A., 686

Zakoji H., 211
 Zaletaev D., 114
 Zaman Z.R., 497, 1097
 Zammit P., 648
 Zampa G., 673, 728
 Zanetti R., 1034
 Zangara F., 259
 Zanin M., 345
 Zanni G., 308, 472, 474, 628, 1042,
 1043, 1178, 1195
 Zanollo N., 1050
 Zanti N., 416, 557
 Zaramella S., 744
 Zarenda M., 139
 Zastrow S., 295, 462, 559
 Zattoni F., 245, 345
 Zât'ura J., 680
 Z'brun S., 614
 Zelle Rieser C., 1056
 Zenico T., 1016
 Zezerov E., 580
 Zhang L.W., 13
 Zhang X.Z., 547
 Zhao S., 31
 Zhao Y., 627
 Zhou H.E., 415
 Zheng X.Y., 547
 Ziegerhofer S., 745
 Zielinsky D., 108
 Zigeuner R., 177, 334, 336, 456, 457,
 458, 812, 813, 814, 935
 Zimmerman R., 589
 Zimmermann D.R., 819
 Zimmermann R., 223, 236
 Zimmermanns V., 204, 346, 504
 Zisman A., 417, 762
 Zitella A., 360, 825, 1017
 Zizzi V., 444
 Zlotta A.R., 426, 427, 857, 875
 Zorlu F., 261, 298
 Zucchi A., 477, 1129
 Zumbé J., 476
 Zur Hausen A., 65
 Zwarthoff E., 218
 Zwergel U., 759, 1167, 1193

Study groups

Alf-Life Study Group, 539
 Alf-One Study Group, 698
 ALTESS Study group, 690, 697
 BPH Registry Investigators, 701, 702
 Degarelix Study Groups, 915

DETECT Study Investigators, 622
 E4018/CL50 Clinical Trial Group, 680
 EAU Real-Life Data Registry on TUNA
 Therapy, 1006
 EORTC Genito-Urinary Group, 721,
 1062
 EPIC working group on kidney cancer,
 26
 European Randomized Study of
 Screening for Prostate Cancer,
 878
 FinnProstate Group, 1065
 German Testicular Cancer Study
 Group, 299
 GKT Botulinum Study Group, 381, 675
 GSTU Foundation, 293
 GUONE Penile Cancer Project
 Members, 245
 Krimpen Study, 312, 540
 NMP22 Clinical Investigation Group,
 460
 Okayama Urogenital Cancer
 Collaboration Group, 1
 Oncologic Committee of the
 Association Française d'Urologie
 (Sub Committee Kidney Tumours),
 328
 Prostate Cancer Symptom Study
 Group, 597
 ProtecT Study Group, 1182
 RetenFrance Study Group, 694, 1146
 Self-management for men with
 uncomplicated LUTS study group,
 704
 Sorafenib TARGETs Clinical Trial
 Group, 1058
 SPCG-6, 914
 Spinal Research Centre, 959
 Surgical Trainees Interested in
 Laparoscopic Urological Surgery
 (STILUS) Group, 275
 Trial 24 Study Group, 913
 Urolithiasis section of the French
 Urological Association, 191
 Vardenafil REALISE Study Group, 476

Abstracts per Topic

Adrenals

508, 509, 510, 511, 512, 513, 514, 515

BPH

Basic research

387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401

Evaluation

538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 842

Intervention therapy

704, 841, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, V33

Medical therapy

690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703

Female urology

Basic research

69, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 225, 826, 827

Diagnosis and treatment

675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 828, 829, 833, 834, 835, 836, 837, 838, 839, 840, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1141, 1142, V7, V25, V26, V28

History of urology

598, 599, 600, 601, 602, 603, 604, 605, 606

Infectious diseases

478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 901, 902, 903, 904, 905, 906, 907, 908

Infertility

766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780

Kidney transplantation

Basic research

38, 750, 751, 752, 753, 754, 755, 756, 757

Clinical

187, 516, 517, 518, 519, 520, 521, 522

Kidney tumours

Basic research

24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37

Diagnosis

176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 188, 189, 190, 327, 328, 329, 330, 333, 334, 335, 336

Treatment

331, 332, 337, 338, 339, 340, 447, 448, 449, 450, 451, 452, 453, 454, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, V13, V14, V15, V16, V17, V18, V40, V41

Neuro-urology

Basic research

229, 796, 802, 810, 947, 948, 949, 954, 955, 959, 960, 1098, 1099, 1100, 1101, 1102, 1109, 1110, 1111

Diagnosis and treatment

797, 798, 800, 801, 803, 804, 805, 806, 807, 808, 809, 950, 951, 952, 953, 956, 957, 958, 961, 1103, 1104, 1105, 1106, 1107, 1108, 1112

Non neurogenic voiding dysfunction

Basic research

221, 222, 223, 224, 226, 227, 228, 230, 231, 232, 233, 234, 372, 373, 375, 536, 537, 830

Diagnosis and treatment

70, 84, 235, 374, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 799, 831, 977, 978, 1139, 1140, V27

Paediatrics

341, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127

Penis/Testis

Penile disorders (excluding urethra)

236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, V12

Testis tumours

251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 296, 297, 298, 299, 300, 301, 302, 303

Prostate cancer

Basic research

100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 135, 153, 154, 155, 156, 157, 158, 159, 160, 268, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 765, 882, 1025, 1035, 1036, 1197

Management of metastatic disease

130, 132, 136, 138, 139, 140, 141, 142, 143, 144, 281, 282, 284, 286, 289, 291, 292, 294, 295, 723, 732, 733, 909, 910, 915, 1060, 1063, 1064, 1065, 1067

Non-surgical management of localised tumours

283, 287, 288, 290, 293, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 445, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 610, 721, 722, 724, 726, 728, 729, 730, 731, 912, 913, 914, 916, 1061, 1062, 1066, 1187, 1202, V34

Screening/Diagnosis

131, 133, 134, 137, 285, 705, 706, 707, 708, 709, 710, 711, 712, 714, 715, 716, 717, 718, 719, 740, 741, 747, 748, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 867, 868, 869, 870, 871, 874, 876, 878, 880, 883, 1007, 1008, 1009, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1022, 1023, 1024, 1158, 1159, 1160, 1161, 1162, 1163, 1165, 1166, 1167, 1169, 1173, 1174, 1175, 1176, 1177, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1190, 1195

Staging

304, 305, 306, 307, 308, 309, 310, 311, 608, 614, 713, 720, 734, 735, 736, 737, 738, 739, 742, 743, 745, 746, 749, 866, 872, 873, 877, 881, 884, 885, 1010, 1021, 1027, 1028, 1029, 1030, 1031, 1168, 1171, 1172, 1178, 1194

Surgical management of localised tumours

115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 267, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 444, 446, 583, 597, 607, 609, 611, 612, 613, 725, 727, 744, 758, 759, 760, 761, 762, 763, 764, 875, 879, 911, 1026, 1032, 1033, 1034, 1164, 1170, 1188, 1189, 1191, 1192, 1193, 1196, 1198, 1199, 1200, 1201, V1, V2, V3, V4, V5, V6, V19, V20, V21, V22, V23, V24, V37, V38, V39

Sexual dysfunction

Basic research

9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 161, 162, 163, 164, 166, 167, 170, 312, 316, 319, 326, 615, 617, 627, 832

Diagnosis and treatment

165, 168, 169, 171, 172, 173, 174, 175, 313, 314, 315, 317, 318, 320, 321, 322, 323, 324, 325, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 616, 618, 619, 620, 621, 622, 623, 624, 625, 626, 628, 629

Stones

Endourology/Open surgery

51, 191, 192, 193, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 266, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 1089, 1090, 1091, 1092, 1093, 1097, V31, V35, V36

ESWL

645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 1083, 1084, 1085, 1086, 1087, 1088

Medical/Research

39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 194, 1094, 1095, 1096

Trauma

886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900

Abstracts per Topic

Uro-genital reconstruction/Urethral strictures

85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 145, 146, 147, 148, 149, 150, 151, 152, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1082, V11, V29, V30, V32, V42

Urothelial tumours

Basic research

54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 918

Diagnosis and staging

455, 456, 457, 458, 459, 460, 461, 462, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 917, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931

Management of infiltrative/advanced tumours

1, 2, 3, 4, 5, 6, 7, 8, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, V8, V9, V10

Management of superficial tumours

660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 1081

List of Sessions sorted by Topic

Ageing male

37, 177

Andrology

81, 97, 168, 171, 175, 181, 184, 256, 270

Benign Prostatic Hyperplasia

35, 84, 91, 95, 166, 169, 267

Bladder - bladder overactivity

82, 167, 172, 177, 259

Bladder cancer

35, 175, 258, 265

Infections

267

Female urology

35, 89, 173,

Kidney cancer

87, 90, 182, 261, 265

Laparoscopy

94

Lithiasis

89, 91, 99, 270

Miscellaneous

89, 98, 176, 266, 268

Miscellaneous-oncology

89, 91, 175, 270

Neurourology

80

Neurourology-voiding dysfunction

35

Paediatric urology

96, 270

Prostate cancer

35, 83, 85, 86, 90, 94, 99, 170, 175, 176, 180, 183, 184, 254, 255, 257, 260, 264, 269, 270

Reconstruction

95

Testis cancer

180

Urinary incontinence

173, 179

List of Speakers (not abstract)

A

Abbou C.C., 94, 146, 147, 266, 282, 334, 335
Abrahamsson P-A., 84, 175, 184, 269, 272
Abrams P., 167, 177, 275
Aho T., 313
Aitchison M., 317
Al-Awadi K., 327
Albers P., 101, 180, 295
Albertsen P.C., 202, 269
Alcaraz A., 58, 255, 296
Algaba F., 325, 333
Alken P., 152, 292, 326
Allona Almagro A., 171
Anderson J.B., 56, 175, 260
Andersson K-E., 48, 177
Anson K.M., 284
Apostolidis A., 194, 328
Artibani W., 156, 179, 185, 273, 322
Atsu N., 327
Aulitzky W., 209, 285
Aus G., 35, 176, 202, 268
Austoni E.A., 148, 322

B

Babjuk M., 289
Baumann J., 327
Behre H., 37
Belgrano E., 322, 330
Belldegrun A., 90, 261
Bellmunt J., 261, 270, 317
Berges R., 158, 255
Beri A., 327
Bettocchi C., 318
Bill-Axelsson A., 269
Bishop M.C., 93, 324
Bjerklund Johansen T.E., 128, 324
Boccon-Gibod L., 88, 254, 268, 269, 288
Boccon-Gibod Liliane, 248, 333
Bogaert G.A., 96, 270, 271
Bollens R., 100, 300
Botto H., 324
Bouchot O., 316
Brausi M., 175, 316
Breda G., 310, 334
Burgos Revilla J., 187, 320
Burnett A.L., 256
Buvat J., 256

C

Carboni F., 89
Castro Diaz D., 177, 244, 315
Cathelineau X., 76, 270, 276
Cestari A., 308
Chapple C.R., 82, 89, 95, 288
Chartier-Kastler E., 80, 177, 328
Clark J., 98
Clarke N.W., 78, 86, 270, 295
Coelho M., 330
Coleman R.E., 183
Collette L., 98
Colombel M., 86, 252, 330
Conort P.J., 91, 238, 292
Corcos J., 315
Costantini E., 178
Cruz F.R., 179, 299
Cuzin B., 81

D

Dasgupta P., 328
Daudon M., 326
Davila Barrios H., 35
De La Rosette J.J.M.C.H., 99, 258, 263, 310, 312, 334
De la Taille A., 164, 254
De Mulder P., 87
De Reijke T.M., 35, 142, 317
De Ridder D.J.M.K., 93, 172, 194, 294
De Wit R., 260, 317
Dean J., 256
Dearnaley D., 120, 180
Debruyne F.M.J., 85, 101, 184, 297
Deger S., 54, 311, 322
Denys P., 324
Descotes J.L., 206, 264
Desgrandchamps F., 136, 169
Ditonno P., 320
Djavan B., 158, 169, 277, 344
Dobs A., 171
Dohle G.R., 319
Dreikorn K., 296, 320
Droller M., 254, 265
Droupy S., 97
Dubbelman Y., 319
Dubernard P., 282

E

Eardley I., 97, 168, 270, 298, 318
Eastham J., 86
Eden C., 306
Egevad L., 102, 333

Eisen T., 261
Eisenberger M., 260
Elkhwaji J., 325
Emberton M., 166, 222, 284
Erdogru T., 309
Escudier B., 261
Espuna Pons M., 172

F

Fall M., 278
Fisch M.M., 50, 274, 322
Fitzpatrick J.M., 260, 267
Fleshner N., 257
Fornara P., 310, 330
Fowler C.J., 328
Fusco F., 318

G

Gamé X., 322
Gaston R., 38, 273, 315
Giannantoni A., 315
Giessing M., 178, 320
Gill I.S., 334
Gomez Sancha F., 307
Govorov A., 263
Graziottin A., 81
Grenabo L.J.G., 326
Gross A., 312
Gschwend J.E., 59, 293
Guazzoni G., 306

H

Haab F., 172, 244, 315
Haferkamp A., 328
Hakenberg O.W., 89, 110
Hamdy F., 175, 183, 269, 272
Hammerer P., 252, 301, 316
Hampel C., 259
Hanus T., 128, 335
Harkaway R., 169
Hauck E.W., 318
Hautmann S., 89
Hedlund P., 40, 90
Hei Y., 99
Hellstrom W., 168
Hemstreet G.P.H., 325
Hess B., 326
Hoznek A., 308
Hultling C., 324
Hunskaar S., 173

J

Jacqmin D., 64, 87, 279
 Janetschek G., 270, 311, 334
 Jaureguizar E., 96
 Jewett M., 123, 182
 Jocham D., 95
 Jonas U., 93, 178, 259, 263
 Joyce A.D., 83, 276, 334
 Jünemann K.P., 70, 173, 181

K

Kadioglu A., 181
 Kalsi V., 328
 Kaplan S.A., 82
 Karam G., 296, 320
 Kattan M., 264
 Kay G., 167
 Keeley F., 91, 108, 309, 326
 Kelleher C., 167
 Keskin M.S., 335
 Kiely E., 266
 Kirby R., 254
 Kirkali Z., 263, 279, 317
 Klein E.A., 90
 Klein J., 308
 Klingler H.C., 310, 335
 Knoll T., 327
 Kumar S.M., 313
 Kuntz R.M., 284

L

Lafaurie M., 267
 Laguna M.P., 309
 Lahme S., 327
 Lee K.H., 176
 Liguori G., 322, 330
 Lippman S., 83
 Lledó Garcia E., 320
 Llorente C., 35, 94, 270
 Lobel B., 74, 268, 324, 338
 Loch T., 160, 268, 330, 331
 Lopez-Beltran A., 333
 Lottmann H.B., 96, 242
 Lunenfeld B., 37

M

Machtens S., 46, 180, 281, 330
 Madersbacher S., 200, 275
 Malavaud B., 297
 Mallet R., 322
 Marberger M., 83, 265
 Marcen R., 320

Martin-Morales A., 126, 256
 Martínez-Piñeiro L., 303, 335
 Messas A., 307
 Messelink E.J., 273
 Mickisch G.H.J., 37, 279, 316
 Mikuz G., 333
 Miller K., 170
 Milsom I., 82
 Mirone V., 91, 104, 169, 318
 Mitropoulos D.N., 335
 Montironi R., 333
 Montorsi F., 37, 89, 171, 302
 Montorsi P., 168, 181
 Moore C., 85
 Morgia G., 281
 Morris T., 184
 Mulders P.F.A., 90, 232, 233, 254, 264
 Mundy A.R., 59, 288, 322, 335
 Murat F.J., 170
 Muschter R., 334
 Månsson W., 303, 322

N

Naber K.G., 324
 Neuzillet Y., 320
 Newling D., 184
 Nijman J.M., 218, 271, 335
 Nilsson S., 270
 Nordling J., 278

O

Okuyama A., 184
 Olianas R., 322
 Oosterlinck W., 289, 317
 Oosterwijk E., 42, 178
 O'Leary M.P., 168

P

Pallwein L., 330
 Palma P., 35
 Palumbo F., 318
 Pansadoro V., 123, 322
 Patard J.J., 90, 106
 Patel A., 44, 292
 Perovic S., 178, 322
 Perrin P., 84
 Preminger G., 312
 Pummer K., 291
 Pushkar D., 220, 294, 315
 Pycha A., 258

R

Radziszewski P., 112, 328
 Ralph D., 62, 274, 318
 Rambeaud J.-J., 265, 303
 Ramon J., 176, 246
 Rao P.N., 93, 326
 Rassweiler J., 308, 334
 Ravery V., 120, 270, 316
 Rehder P., 315
 Rischmann P., 311, 322, 338
 Rixe O., 87
 Robinson D., 172
 Roehrborn C.G., 166
 Romics L., 150, 274
 Rosen R.C., 166
 Roumeguere T., 319
 Rozet F., 316
 Ruiz-Cerdá J.L., 35, 216
 Ruutu M.L., 304

S

Saad F., 86
 Saenz de Tejada I., 81, 148
 Salonia A., 72, 175
 Sand P., 259
 Sarica K., 326
 Sarramon J-P., 322
 Sartor O., 255
 Sauter G., 258
 Saw N.K., 327
 Scardino P., 85
 Schalken J.A., 257, 267, 305, 332
 Schneider G., 330
 Schröder F.H., 257
 Schulman C.C., 99, 162, 177, 255, 304, 318
 Schulte-Baukloh H., 328
 Schwentner C., 330
 Schürch B., 328
 Selli C., 182, 270
 Shah J.R., 173, 179, 275
 Sievert K-D., 95, 228
 Sinescu I.C., 64, 335
 Smith A., 173
 Sofikitis N., 318
 Soomro N., 311
 Sotelo Noguera R., 35
 Speakman M.J., 80
 Stanley N., 80
 Stenman U.H., 91, 224, 332
 Stenzl A., 293
 Sternberg C.N., 78, 280

List of Speakers (not abstract)

Stief C., 171, 298, 318
Stolzenburg J-U., 35, 76, 282
Strasser H., 330, 331
Strohmaier W.L., 326
Studer U.E., 204, 269, 293
Stöckle M., 182
Stöhrer M., 324
Sulser T., 54, 300
Swartz R.C., 334
Sylakos A., 318
Sylvester R., 98, 297

Z

Zlotta A.R., 84, 180, 301, 316

T

Teillac P., 88, 89, 169, 174, 184, 268, 291
Ter Haar G., 170
Thalmann G.N., 39, 99, 280, 332
Thompson I., 257
Thüroff S., 170, 281
Tirelli U., 170
Tiselius H-G., 152, 326
Tolley D.A., 312, 334
Tombal B., 175, 183, 234, 255
Toozs-Hobson P., 259
Trachtenberg J., 85
Traxer O., 335
Trinchieri A., 326
Trombetta C., 330

V

Vallancien G., 94
Van Der Meijden A.P.M., 268
Van Der Pluijm G., 183
Van Der Poel H.G., 100
Van Kerrebroeck P.E., 80, 299, 315
Van Poppel H., 98, 188, 277, 316
Verze P., 263
Vodopija N., 91

W

Watson R.W.G., 116, 305
Weidner W., 97, 171, 209, 285, 318
Wein A., 167
Whelan P., 175, 234, 235, 316
Wijkstra H., 93, 330, 331
Wirth M.P., 84, 99, 174, 175, 268, 291
Witjes J.A., 35, 212, 289
Wyndaele J-., 278, 315

Y

Yassin A., 37